Clustering O 0 5.513077212526696e-06
of O 0 2.400280436631874e-07
missense O 0 2.9038317279628245e-06
mutations O 0 1.4382941060375742e-07
in O 0 3.2243281822275094e-08
the O 0 2.084056723106187e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.6381936802645214e-06
in O 0 1.7417681519305006e-08
a O 0 1.8765236475815072e-08
sporadic B-Disease 0 0.0001200695987790823
T I-Disease 1 0.9999918937683105
- I-Disease 1 0.9998531341552734
cell I-Disease 1 0.6166486740112305
leukaemia I-Disease 1 0.9780136346817017
. O 0 1.832177076721564e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.841056266968735e-08
is O 0 4.6110709694957563e-10
a O 0 9.300594738803625e-10
recessive B-Disease 0 1.7439044768252643e-06
multi I-Disease 0 0.00011929070751648396
- I-Disease 0 0.0003436736005824059
system I-Disease 0 2.0705817860289244e-06
disorder I-Disease 0 1.3286316971061751e-06
caused O 0 2.1132384731004095e-09
by O 0 1.1801599975047594e-10
mutations O 0 4.5199016751595877e-10
in O 0 1.1594398774406045e-09
the O 0 1.1891201801006446e-08
ATM O 0 1.6656141497151111e-06
gene O 0 2.0430171332463942e-08
at O 0 4.6538139031326864e-07
11q22 O 0 2.2877229639561847e-06
- O 0 1.6626353271931293e-06
q23 O 0 1.9493174931994872e-06
( O 0 1.0757137403061279e-08
ref O 0 3.0846200615997077e-07
. O 0 2.1349375600721032e-09
3 O 0 8.54963815299925e-08
) O 0 7.439365568018275e-09
. O 0 1.7283248610056035e-07

The O 0 2.2263671439759491e-07
risk O 0 2.9140446144992893e-07
of O 0 1.8561094350388885e-07
cancer B-Disease 0 2.290408019689494e-06
, O 0 5.351153298249756e-09
especially O 0 6.667818297501071e-08
lymphoid B-Disease 0 0.0008661195752210915
neoplasias I-Disease 0 0.2138880491256714
, O 0 4.372384676543106e-09
is O 0 2.408160060252129e-10
substantially O 0 4.338747583432223e-09
elevated O 0 1.8944587054647855e-07
in O 0 3.3043562552848016e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.0010141099646717e-07
and O 0 8.083579361439774e-10
has O 0 1.1204753097571185e-10
long O 0 1.262382004485474e-10
been O 0 1.6741014130516874e-10
associated O 0 2.47133757902418e-09
with O 0 5.622065035737478e-09
chromosomal O 1 1.0
instability O 1 1.0
. O 0 3.247806671424769e-05

By O 0 2.539673289447819e-07
analysing O 0 8.47261162562063e-06
tumour B-Disease 1 0.9999998807907104
DNA O 0 5.100745070762969e-08
from O 0 5.146514325815588e-10
patients O 0 3.143649784931313e-10
with O 0 1.6904591615407583e-10
sporadic B-Disease 0 2.5777637802093523e-06
T I-Disease 1 0.6068223714828491
- I-Disease 1 0.5171893835067749
cell I-Disease 0 0.36424797773361206
prolymphocytic I-Disease 0 0.018175514414906502
leukaemia I-Disease 1 0.9998145699501038
( O 0 2.5761269739632553e-07
T B-Disease 0 4.9330683395965025e-05
- I-Disease 0 2.889037432396435e-06
PLL I-Disease 0 4.007581082987599e-06
) O 0 1.0593974586470267e-09
, O 0 1.733348603538687e-10
a O 0 9.801414124765984e-10
rare O 0 1.1925590293060395e-08
clonal B-Disease 0 7.238938337650325e-07
malignancy I-Disease 0 5.260101261228556e-07
with O 0 1.2115556335956512e-09
similarities O 0 1.0470016853503239e-08
to O 0 3.3344722538686256e-09
a O 0 2.8336149426877455e-08
mature B-Disease 0 0.00015244238602463156
T I-Disease 0 0.07056926190853119
- I-Disease 0 0.00033647497184574604
cell I-Disease 0 5.553206574404612e-05
leukaemia I-Disease 0 0.014658006839454174
seen O 0 7.057572304347559e-08
in O 0 9.408634760177392e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
, O 0 2.158801803986421e-09
we O 0 3.4060138043301436e-10
demonstrate O 0 2.8429233966953404e-10
a O 0 1.1720999171238589e-10
high O 0 1.8223926812055424e-09
frequency O 0 7.971507010040568e-09
of O 0 8.375925730774725e-09
ATM O 0 7.182659373938804e-07
mutations O 0 3.802093928584327e-08
in O 0 7.374565313966741e-08
T B-Disease 0 0.00015227196854539216
- I-Disease 0 2.2270252884482034e-05
PLL I-Disease 0 5.5843960581114516e-05
. O 0 9.531714226795884e-07

In O 0 1.3582800306721765e-07
marked O 0 8.04930877507104e-08
contrast O 0 3.730480369057432e-09
to O 0 7.625752806994512e-10
the O 0 5.406604497437684e-09
ATM O 0 4.4487879335974867e-07
mutation O 0 1.1681328793144985e-08
pattern O 0 2.868121384835831e-08
in O 0 7.634226584229964e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 2.9196889350657784e-09
the O 0 7.425809411820694e-10
most O 0 3.0242263554525195e-11
frequent O 0 4.7377896744693615e-11
nucleotide O 0 3.927887459731494e-10
changes O 0 2.7763466525776437e-10
in O 0 1.1322201509678109e-10
this O 0 1.8354451292168505e-10
leukaemia B-Disease 0 1.6486852700836607e-06
were O 0 3.861644159997013e-08
missense O 0 3.3333374176436337e-06
mutations O 0 1.8613329757499741e-06
. O 0 2.4286998723255238e-06

These O 0 4.439319667426389e-08
clustered O 0 7.818654523816804e-08
in O 0 1.3960541611623967e-09
the O 0 2.4300410572664077e-09
region O 0 2.375515562036412e-09
corresponding O 0 2.7491313669969486e-09
to O 0 2.3609121324597027e-09
the O 0 1.4304950113341874e-08
kinase O 0 4.6826624355844615e-08
domain O 0 7.544262992098538e-09
, O 0 8.805722817584183e-11
which O 0 2.960809375451845e-11
is O 0 2.609588066471158e-11
highly O 0 3.6208455678199414e-10
conserved O 0 3.9526302231251975e-09
in O 0 1.917516145866216e-09
ATM O 0 2.522210138522496e-07
- O 0 3.42136416975336e-08
related O 0 2.6305495559597603e-09
proteins O 0 8.262922984725307e-11
in O 0 3.392359726461791e-10
mouse O 0 7.1120007660852025e-09
, O 0 4.939263442693687e-10
yeast O 0 3.359113875944786e-08
and O 0 1.271733474084158e-08
Drosophila O 0 8.751641757953621e-07
. O 0 2.534877410198533e-07

The O 0 4.753637483645434e-07
resulting O 0 5.041690087637107e-07
amino O 0 1.9495131198254967e-07
- O 0 1.0048028542541942e-07
acid O 0 1.749319267219107e-08
substitutions O 0 2.4558653777262407e-08
are O 0 1.1856997605974584e-09
predicted O 0 2.7843890748613376e-08
to O 0 2.7586122275380376e-09
interfere O 0 6.633087679119853e-08
with O 0 5.977481620789149e-09
ATP O 0 8.33973717817571e-06
binding O 0 6.830942567148668e-08
or O 0 4.213029480837349e-09
substrate O 0 4.937008313277147e-08
recognition O 0 3.957293870371359e-08
. O 0 3.556435217433318e-07

Two O 0 3.47686125223845e-07
of O 0 3.3880152727761015e-07
seventeen O 0 2.572439825598849e-06
mutated O 0 1.3521322443921235e-06
T B-Disease 0 1.2584241630975157e-05
- I-Disease 0 6.322579224615765e-07
PLL I-Disease 0 1.5851290982027422e-06
samples O 0 1.678866823340286e-09
had O 0 1.0221760105011413e-09
a O 0 6.558505405429571e-10
previously O 0 1.3716481284120619e-08
reported O 0 1.6955799253537407e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
allele O 0 0.00010786220082081854
. O 0 6.176604529173346e-06

In O 0 3.8205293151349906e-08
contrast O 0 1.3292441813916867e-08
, O 0 8.252563077348896e-10
no O 0 1.1242692332658066e-09
mutations O 0 1.559518403304594e-09
were O 0 1.5689224364123788e-09
detected O 0 1.8373514931724344e-09
in O 0 5.860153473591367e-10
the O 0 3.3935523280348434e-09
p53 O 0 4.725592805954193e-09
gene O 0 5.605318875723242e-09
, O 0 8.439972609686208e-10
suggesting O 0 2.279940236604716e-09
that O 0 2.573025126295647e-10
this O 0 9.746419227241176e-10
tumour B-Disease 1 1.0
suppressor O 0 1.1141002005388145e-06
is O 0 2.395059151005796e-10
not O 0 1.6218583420712918e-10
frequently O 0 7.517154676506266e-10
altered O 0 1.0451580934045523e-08
in O 0 2.61347588015326e-09
this O 0 5.792479829125341e-09
leukaemia B-Disease 0 3.377975372131914e-05
. O 0 6.466419222306286e-07

Occasional O 0 9.488289833825547e-07
missense O 0 3.23355902764888e-06
mutations O 0 8.651342398025008e-08
in O 0 1.2946834715421573e-08
ATM O 0 4.3173940866836347e-07
were O 0 1.0948756568041063e-08
also O 0 6.102201521862582e-10
found O 0 6.930426232898412e-10
in O 0 1.634997359722945e-09
tumour B-Disease 1 1.0
DNA O 0 2.392664555372903e-08
from O 0 6.889371850782311e-10
patients O 0 1.4560555539055997e-10
with O 0 6.010415498636235e-10
B B-Disease 0 4.774710305355256e-06
- I-Disease 0 1.048113244905835e-05
cell I-Disease 0 0.00014304542855825275
non I-Disease 0 0.03714064136147499
- I-Disease 0 0.27856162190437317
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 8.411570161115378e-05
( O 0 3.318181285294486e-08
B B-Disease 0 6.388329438777873e-07
- I-Disease 0 1.1200153693380344e-07
NHL I-Disease 0 7.635058523192129e-07
) O 0 3.070393661541715e-10
and O 0 5.582717621521738e-10
a O 0 2.7436468652553003e-09
B B-Disease 0 1.4653187463409267e-06
- I-Disease 0 1.3082701570965583e-06
NHL I-Disease 0 3.1983916414901614e-05
cell O 0 1.3191436210036045e-06
line O 0 4.919224352306628e-07
. O 0 3.6394854419086187e-07

The O 0 4.112220253205123e-08
evidence O 0 2.9921974231683635e-08
of O 0 5.349489740069657e-09
a O 0 7.254385425703447e-10
significant O 0 1.4512874235705908e-09
proportion O 0 3.527309555551028e-09
of O 0 3.434302797700184e-08
loss O 0 3.318802157536993e-07
- O 0 1.4901664258104574e-07
of O 0 1.6149105022122967e-06
- O 0 1.10526798380306e-06
function O 0 6.160539811617127e-08
mutations O 0 9.165977976621775e-10
and O 0 9.350144269948402e-11
a O 0 1.0966259150757551e-10
complete O 0 4.132202358064774e-10
absence O 0 1.3330119230658966e-08
of O 0 6.816675224285973e-09
the O 0 1.6732276675313074e-09
normal O 0 1.7355527015538996e-09
copy O 0 6.027547350129225e-09
of O 0 4.855738922060482e-09
ATM O 0 2.3061479836883336e-08
in O 0 5.665281022082524e-10
the O 0 8.190606526348176e-10
majority O 0 1.4986676344364014e-09
of O 0 7.418199743369769e-08
mutated O 0 3.3355283903802047e-06
tumours B-Disease 1 1.0
establishes O 0 2.3004244553703757e-07
somatic O 0 3.5423201438788965e-07
inactivation O 0 1.8077500385516032e-07
of O 0 9.201979622730505e-09
this O 0 6.790769058184765e-10
gene O 0 7.843277138874782e-10
in O 0 5.026585814249529e-10
the O 0 1.7329527812748324e-09
pathogenesis O 0 3.45510471788657e-07
of O 0 1.9289959141133295e-07
sporadic B-Disease 0 0.00030664654332213104
T I-Disease 1 0.9994543194770813
- I-Disease 0 0.0035250894725322723
PLL I-Disease 0 8.183021236618515e-06
and O 0 9.402979506134557e-10
suggests O 0 2.711106894537352e-10
that O 0 2.6265361413591037e-11
ATM O 0 6.667357776990457e-09
acts O 0 1.392275517098085e-09
as O 0 1.1183706183359732e-09
a O 0 1.551893369367008e-08
tumour B-Disease 1 1.0
suppressor O 0 5.984642120893113e-05
. O 0 1.4576959301848547e-06

As O 0 6.437475974507834e-08
constitutional O 0 3.7132539887352323e-07
DNA O 0 1.9007886820077147e-08
was O 0 3.189023711769323e-09
not O 0 4.767741063060882e-11
available O 0 4.5487011379741205e-10
, O 0 1.7465302815100614e-10
a O 0 7.203218577167547e-10
putative O 0 5.01607530623005e-07
hereditary O 1 0.8681570291519165
predisposition O 0 0.00019126434926874936
to O 0 1.569412779645063e-05
T B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999871253967285
PLL I-Disease 0 0.0004672182258218527
will O 0 6.484709214049644e-09
require O 0 2.37270803005174e-09
further O 0 6.346668968149061e-09
investigation O 0 1.8262490186771174e-08
. O 0 2.736298965189121e-09
. O 0 7.58845573045619e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 2.140334981959313e-05
kinase O 0 3.7379402328951983e-07
is O 0 2.3559221240532224e-10
involved O 0 8.886406194230645e-11
in O 0 1.9661118219604923e-11
the O 0 1.2439964336419251e-10
modulation O 0 2.5161182026778306e-09
of O 0 8.530734452172339e-10
the O 0 1.3891083838757368e-09
Ca2 O 0 2.1922220483361343e-08
+ O 0 2.2957651424349024e-07
homeostasis O 0 9.103669071919285e-07
in O 0 4.185008251056388e-08
skeletal O 0 3.531668698997237e-05
muscle O 0 1.8597891084937146e-06
cells O 0 9.71229837887222e-07
. O 0 5.878221145394491e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999987006187439
DM B-Disease 1 1.0
) O 0 2.8832486620444797e-08
, O 0 3.3954150602255595e-10
the O 0 6.497271609617883e-10
most O 0 6.84486578528265e-10
prevalent O 0 0.0001121041423175484
muscular B-Disease 1 0.9999998807907104
disorder I-Disease 0 0.040756579488515854
in O 0 6.4981673375541504e-09
adults O 0 1.0352914081579456e-08
, O 0 2.6077981440941755e-10
is O 0 9.350856894352333e-11
caused O 0 4.391750518806248e-09
by O 0 4.0330498940477355e-09
( O 0 1.2545150696041674e-08
CTG O 0 2.4647731606819434e-06
) O 0 4.740641657008382e-09
n O 0 3.874983889318173e-08
- O 0 5.880691489323908e-09
repeat O 0 3.1520688281716502e-09
expansion O 0 1.567836527271993e-09
in O 0 1.763024032319649e-10
a O 0 4.22451851278538e-10
gene O 0 3.0933772210417487e-10
encoding O 0 8.810872031972394e-09
a O 0 8.054557021353048e-09
protein O 0 3.8285680403760125e-08
kinase O 0 7.268449166986102e-07
( O 0 9.154017988066698e-08
DM B-Disease 1 0.9999991655349731
protein O 0 6.723601586600125e-08
kinase O 0 4.032882472415622e-08
; O 0 9.457585825600745e-10
DMPK O 0 4.41460514366554e-07
) O 0 2.969543222430815e-10
and O 0 1.2623338485617808e-10
involves O 0 4.3431003238225685e-10
changes O 0 2.21818896584125e-09
in O 0 3.2021711948715392e-09
cytoarchitecture O 0 1.054018525792344e-06
and O 0 8.291999620269053e-08
ion O 0 0.0001668235199758783
homeostasis O 0 0.045433368533849716
. O 0 9.456181942368858e-06

To O 0 2.5552647997528766e-08
obtain O 0 5.6504699585957496e-08
clues O 0 1.2584051489739068e-07
to O 0 8.166240461626728e-10
the O 0 8.686785180067602e-10
normal O 0 1.2776164570738047e-09
biological O 0 3.159707606670281e-09
role O 0 2.5614996790324085e-09
of O 0 1.429169582678469e-08
DMPK O 0 6.5537155023776e-05
in O 0 1.507346638618401e-07
cellular O 0 1.3850581126462203e-06
ion O 0 7.514917524531484e-05
homeostasis O 0 7.215430377982557e-05
, O 0 2.4300410572664077e-09
we O 0 1.1184645432038565e-09
have O 0 7.947208863212651e-11
compared O 0 2.6379243234231353e-10
the O 0 3.1853444881768667e-10
resting O 0 1.3295915479716314e-08
[ O 0 4.138601461534108e-09
Ca2 O 0 2.578760316396256e-09
+ O 0 8.324752442945282e-09
] O 0 9.950150037241201e-09
i O 0 3.2474776201496525e-09
, O 0 7.420340036867756e-11
the O 0 1.7908287353041175e-10
amplitude O 0 1.0699428010241263e-09
and O 0 2.1314615350487287e-10
shape O 0 3.4256672165611235e-08
of O 0 4.433294975569879e-08
depolarization O 0 2.1521350390685257e-07
- O 0 2.7071033059655747e-07
induced O 0 2.0655355115195562e-07
Ca2 O 0 7.809100566191773e-08
+ O 0 1.3234678419848933e-07
transients O 0 8.182025368341783e-08
, O 0 2.0337889705679402e-10
and O 0 1.456608444971863e-10
the O 0 1.979289510067872e-10
content O 0 9.193887873237827e-10
of O 0 5.522649004774394e-09
ATP O 0 1.442602410861582e-06
- O 0 3.283241056806219e-08
driven O 0 3.3227287588033505e-08
ion O 0 2.3038317920054396e-07
pumps O 0 6.65968400426209e-08
in O 0 3.763557998581746e-08
cultured O 0 1.0743440270744031e-06
skeletal O 0 5.424318715085974e-06
muscle O 0 3.76706985605324e-08
cells O 0 2.4623849625982075e-08
of O 0 4.247533169632334e-08
wild O 0 9.309473192331552e-09
- O 0 4.2914072295729966e-09
type O 0 1.0777078784940386e-08
and O 0 1.05168718178561e-08
DMPK O 0 2.0312678316258825e-05
[ O 0 3.9070900470505876e-07
- O 0 3.8253023149081855e-07
/ O 0 1.5934651855786797e-06
- O 0 1.0347524721510126e-06
] O 0 4.736789378512185e-07
knockout O 0 0.0008272675913758576
mice O 0 3.3624330626480514e-06
. O 0 4.5905764523013204e-07

In O 0 9.168265364678518e-07
vitro O 0 2.6871150566876167e-06
- O 0 1.595148432897986e-06
differentiated O 0 2.381538251938764e-06
DMPK O 0 3.9616974390810356e-05
[ O 0 1.4010011000209488e-06
- O 0 8.228772117035987e-07
/ O 0 1.066901745616633e-06
- O 0 2.6301304956177773e-07
] O 0 8.036055021420907e-08
myotubes O 0 1.6416298365129478e-07
exhibit O 0 2.278053745641273e-09
a O 0 2.4608484139321263e-09
higher O 0 2.5182414375990447e-08
resting O 0 2.6537585995356494e-07
[ O 0 5.770450428599361e-08
Ca2 O 0 4.110965079462403e-08
+ O 0 1.0558037644159413e-07
] O 0 3.740914067407175e-08
i O 0 7.0173018507091456e-09
than O 0 2.6094601479620394e-10
do O 0 6.288705667323313e-10
wild O 0 2.218929484598675e-09
- O 0 9.945514412024181e-10
type O 0 1.1253741272199136e-09
myotubes O 0 4.2072823447369956e-08
because O 0 1.989660658452408e-10
of O 0 8.624002623136562e-10
an O 0 7.484789177336637e-11
altered O 0 3.945775706171162e-09
open O 0 1.068305888196619e-08
probability O 0 1.5818590881622185e-08
of O 0 9.79166525638675e-09
voltage O 0 7.380024271697039e-07
- O 0 4.81765084714425e-07
dependent O 0 1.0192313482093596e-07
l O 0 1.4136220727323234e-07
- O 0 7.985477168404032e-09
type O 0 7.056277340211636e-09
Ca2 O 0 9.271162504376207e-09
+ O 0 1.8111041555357588e-08
and O 0 6.203291658124499e-09
Na O 0 3.5262490882814745e-07
+ O 0 4.331737812890424e-08
channels O 0 9.547565582579409e-08
. O 0 7.960252190741812e-08

The O 0 5.783418259852624e-07
mutant O 0 8.355279987881659e-07
myotubes O 0 2.0427735307748662e-06
exhibit O 0 2.0472844752816854e-08
smaller O 0 7.124165257721415e-09
and O 0 6.49899822846578e-09
slower O 0 2.7506066757609915e-08
Ca2 O 0 1.364977464390904e-08
+ O 0 7.236685473088755e-09
responses O 0 2.5472818299121514e-10
upon O 0 6.419335063512221e-10
triggering O 0 3.185570696118134e-09
by O 0 3.038908569230614e-10
acetylcholine O 0 7.344592489744173e-09
or O 0 3.5086957783647676e-09
high O 0 4.205388748346195e-08
external O 0 3.428419859119458e-07
K O 0 5.455796667774848e-07
+ O 0 1.9507182003053458e-07
. O 0 1.3199699822052935e-07

In O 0 7.506559995817952e-08
addition O 0 1.4190920438750254e-08
, O 0 2.1213475420722716e-09
we O 0 1.3731631387514653e-09
observed O 0 1.112976155681622e-09
that O 0 2.779890206916491e-11
these O 0 1.5342008219398906e-10
Ca2 O 0 8.882788726793933e-09
+ O 0 3.74819144610683e-08
transients O 0 3.510290724761944e-08
partially O 0 4.476559567478944e-09
result O 0 3.178953489335612e-10
from O 0 4.2970047658963395e-11
an O 0 2.2010254729920575e-11
influx O 0 1.9089468894506467e-10
of O 0 7.636760557261368e-09
extracellular O 0 1.6368391086984957e-08
Ca2 O 0 2.089284834028149e-08
+ O 0 1.6501175537086965e-08
through O 0 9.161573166771575e-10
the O 0 1.9299806197636826e-09
l O 0 1.0047948251212802e-08
- O 0 1.7272769881060412e-09
type O 0 2.5629365296708784e-09
Ca2 O 0 3.4971922246995746e-08
+ O 0 8.135512530316191e-08
channel O 0 1.436494301287894e-07
. O 0 1.3182187785787391e-07

Neither O 0 5.895894901186693e-07
the O 0 2.5886913945782908e-08
content O 0 1.0086004920140113e-08
nor O 0 1.6024268134628983e-08
the O 0 1.3592091896441616e-09
activity O 0 4.032988165647566e-09
of O 0 1.260347914922022e-08
Na O 0 3.3417072131669556e-07
+ O 0 1.4840736639598617e-07
/ O 0 1.7984471867293905e-07
K O 0 2.3997102971407003e-07
+ O 0 1.275696348557176e-07
ATPase O 0 8.117437459986832e-07
and O 0 4.655154128840877e-08
sarcoplasmic O 0 1.3240401131042745e-06
reticulum O 0 3.265485872816498e-07
Ca2 O 0 5.69202825317916e-07
+ O 0 9.32850127810525e-07
- O 0 1.0674141748268084e-07
ATPase O 0 1.362509465252515e-07
are O 0 2.13878789678823e-10
affected O 0 7.38020089485758e-10
by O 0 6.3501287561607e-10
DMPK O 0 1.3100894648232497e-05
absence O 0 3.169129968227935e-06
. O 0 1.1897053582288208e-06

In O 0 1.4787630675527907e-07
conclusion O 0 4.4841505086878897e-07
, O 0 4.05839095662941e-09
our O 0 4.112312268489404e-09
data O 0 1.3400165421728616e-09
suggest O 0 4.271169806724373e-10
that O 0 1.1290565704591415e-10
DMPK O 0 3.0276680718088755e-07
is O 0 2.1834316299429446e-10
involved O 0 8.51901105214381e-10
in O 0 5.995942631287221e-10
modulating O 0 4.09584437477406e-08
the O 0 3.2048654841076996e-09
initial O 0 5.76745451397187e-09
events O 0 2.692500000733844e-09
of O 0 1.9118566285669658e-08
excitation O 0 0.00045986296026967466
- O 0 0.0005313787260092795
contraction O 0 5.091326897854742e-07
coupling O 0 5.465915933200449e-07
in O 0 6.293270615742586e-08
skeletal O 0 4.197193629806861e-05
muscle O 0 6.290055125646177e-07
. O 0 1.3178291169424483e-07
. O 0 4.2033761360471544e-07

Constitutional O 0 0.0004519122012425214
RB1 O 0 0.08139311522245407
- O 0 4.9609447160037234e-05
gene O 0 1.2837753082806103e-08
mutations O 0 5.0258024408833535e-09
in O 0 5.468017150178639e-10
patients O 0 7.815620373108345e-10
with O 0 6.051400491813297e-10
isolated O 0 1.0733879918234379e-07
unilateral B-Disease 0 1.2288325706322212e-05
retinoblastoma I-Disease 1 0.9999983310699463
. O 0 0.0005221284809522331

In O 0 5.920715651086539e-08
most O 0 7.868120044385307e-10
patients O 0 3.462806430487575e-10
with O 0 1.6098938848685407e-10
isolated O 0 2.1508869352260263e-08
unilateral B-Disease 0 2.3219461127155228e-06
retinoblastoma I-Disease 1 0.9999892711639404
, O 0 2.0068544870355254e-07
tumor B-Disease 0 1.2435300504876068e-06
development O 0 1.0378263937127485e-07
is O 0 3.2343769329479244e-10
initiated O 0 3.0131341866024286e-09
by O 0 1.1984842285261976e-10
somatic O 0 1.1765988183753961e-08
inactivation O 0 2.840887880495302e-08
of O 0 2.674743537767199e-09
both O 0 1.657548653888341e-09
alleles O 0 1.8883579144812757e-08
of O 0 5.03632193726844e-08
the O 0 9.114452836911369e-08
RB1 O 0 1.9262659407104366e-05
gene O 0 2.765653164260584e-07
. O 0 1.6822160660012742e-06

However O 0 2.623671662149718e-07
, O 0 2.104188823182085e-09
some O 0 1.0765480867869215e-10
of O 0 5.031295380319989e-10
these O 0 1.834339347084324e-10
patients O 0 4.112937490585722e-10
can O 0 9.551563984189215e-10
transmit O 0 1.1068443228623437e-07
retinoblastoma B-Disease 0 3.2558821203565458e-06
predisposition O 0 1.7465029600316484e-07
to O 0 9.683072121902114e-09
their O 0 3.868389342187584e-08
offspring O 0 3.1860983540354937e-07
. O 0 6.449052420975931e-07

To O 0 1.2782826352975007e-08
determine O 0 2.446486924156943e-08
the O 0 3.464750486514845e-09
frequency O 0 3.385937930033833e-08
and O 0 9.833096559219712e-10
nature O 0 4.529155273047536e-09
of O 0 1.412142047740872e-08
constitutional O 0 7.195698344730772e-06
RB1 O 0 0.00032263301545754075
- O 0 7.962253789628448e-07
gene O 0 1.8285764014080996e-09
mutations O 0 1.4358465527664066e-09
in O 0 1.8116758093711383e-10
patients O 0 1.1343753020254255e-10
with O 0 1.1116114972953284e-10
isolated O 0 7.619649800005845e-09
unilateral B-Disease 0 1.063918091404048e-07
retinoblastoma I-Disease 0 0.00037265775608830154
, O 0 8.582572874615835e-09
we O 0 3.000316661783131e-09
analyzed O 0 3.1866707050909326e-09
DNA O 0 9.920771981697385e-10
from O 0 2.1954878193231053e-10
peripheral O 0 2.0510757536840174e-08
blood O 0 6.433189092547309e-09
and O 0 8.20364931541917e-09
from O 0 1.1628110918593393e-08
tumor B-Disease 0 1.4455329164775321e-06
tissue O 0 1.911628942252719e-06
. O 0 9.832426712819142e-07

The O 0 3.2417676720797317e-07
analysis O 0 1.2101166646516504e-07
of O 0 2.3825167261293245e-07
tumors B-Disease 1 1.0
from O 0 1.862915155470546e-08
54 O 0 8.683181818014418e-08
( O 0 3.1438731618038673e-09
71 O 0 1.9094295922172932e-08
% O 0 5.368970268371243e-10
) O 0 4.450675661349379e-10
of O 0 1.2283607908614158e-08
76 O 0 1.3763765593921562e-07
informative O 0 5.236686462239959e-08
patients O 0 3.8547538494526634e-09
showed O 0 2.145781330398222e-08
loss O 0 1.7310219391220016e-07
of O 0 5.105456466480973e-07
constitutional O 0 0.0005871818866580725
heterozygosity O 1 0.9686800837516785
( O 0 3.4364898056082893e-06
LOH O 0 0.11486238241195679
) O 0 3.9827519060509076e-08
at O 0 7.060958182592003e-07
intragenic O 0 1.0188276064582169e-05
loci O 0 4.183375494903885e-06
. O 0 2.1193159227550495e-06

Three O 0 3.089168387759855e-07
of O 0 1.6519874179721228e-07
13 O 0 1.1160568647028413e-06
uninformative O 0 0.00010529413702897727
patients O 0 1.762682977357599e-08
had O 0 3.503347656419464e-08
constitutional O 0 2.567185219959356e-06
deletions O 0 4.437924417288741e-06
. O 0 3.1593465337209636e-06

For O 0 3.5908084328184486e-07
39 O 0 1.148043452303682e-06
randomly O 0 2.464076942487736e-07
selected O 0 5.708238859369885e-07
tumors B-Disease 1 1.0
, O 0 1.0350390766689088e-07
SSCP O 0 7.48922029742971e-05
, O 0 7.752853292686268e-08
hetero O 0 3.1587596822646447e-06
- O 0 2.178966127530657e-07
duplex O 0 8.87955735606738e-08
analysis O 0 3.315256957847623e-09
, O 0 2.5779570145267883e-10
sequencing O 0 6.678911312896219e-10
, O 0 1.65911034910593e-10
and O 0 6.012055298043606e-10
Southern O 0 1.9211926272078017e-08
blot O 0 3.391325833490555e-07
analysis O 0 8.718459731937855e-09
were O 0 1.2785648095814395e-09
used O 0 5.006435266352582e-10
to O 0 3.074954957327236e-09
identify O 0 1.221556402697388e-07
mutations O 0 1.6509586657775799e-06
. O 0 3.5379753171582706e-06

Mutations O 0 5.513379051080847e-07
were O 0 2.9077918739517372e-08
detected O 0 6.551907016927316e-09
in O 0 1.9439938547805014e-09
21 O 0 6.528108542624977e-08
( O 0 3.6435428008019244e-09
91 O 0 4.66109781882551e-08
% O 0 1.5199268510457387e-09
) O 0 3.337418119642166e-09
of O 0 3.022933583451959e-07
23 O 0 0.002084909239783883
tumors B-Disease 1 1.0
with O 0 0.00013797909196000546
LOH O 1 1.0
. O 0 6.0858408687636256e-05

In O 0 2.536587260237866e-07
6 O 0 1.7504993365946575e-06
( O 0 5.137787528752824e-09
38 O 0 1.28724728654106e-08
% O 0 4.522212326829589e-10
) O 0 6.027727761370727e-10
of O 0 4.418134125216966e-08
16 O 0 3.335668588988483e-05
tumors B-Disease 1 1.0
without O 0 2.5570827347110026e-05
LOH O 1 0.9986627101898193
, O 0 1.8048683658733466e-09
one O 0 3.435898232595491e-10
mutation O 0 2.813352051322937e-10
was O 0 1.0940733874420516e-09
detected O 0 6.885063075223741e-10
, O 0 1.0457234383975944e-10
and O 0 2.364746176652943e-10
in O 0 1.422158613095803e-09
9 O 0 4.829104227610514e-07
( O 0 8.047309485448295e-09
56 O 0 5.146421244717203e-08
% O 0 1.3219693117960674e-09
) O 0 1.3125350806220126e-09
of O 0 7.193723661202966e-08
the O 0 4.480688858166104e-06
tumors B-Disease 1 1.0
without O 0 0.00018763849220704287
LOH O 1 0.9999783039093018
, O 0 1.4347323329388928e-09
both O 0 1.0772881475773488e-09
mutations O 0 4.210587434272384e-09
were O 0 7.50071738053748e-09
found O 0 1.7437093546845972e-08
. O 0 2.6029019295492617e-07

Thus O 0 4.3979727593068674e-07
, O 0 3.979135243525889e-09
a O 0 6.270093333426985e-10
total O 0 3.086222943871064e-10
of O 0 1.939875149403747e-09
45 O 0 2.7944218050635072e-09
mutations O 0 4.457304303429055e-09
were O 0 5.723991058914635e-09
identified O 0 2.781055918887887e-08
in O 0 3.100433332292596e-08
tumors B-Disease 1 1.0
of O 0 0.008976821787655354
36 O 0 4.804817945114337e-05
patients O 0 4.271353475360229e-07
. O 0 7.429841843986651e-06

Thirty O 0 1.0727656444942113e-05
- O 0 5.048912044003373e-07
nine O 0 2.71762790049479e-08
of O 0 4.4891454997753044e-09
the O 0 2.1980826048206836e-09
mutations O 0 4.943808917801107e-09
- O 0 5.229098487546935e-09
including O 0 5.928495472318218e-10
34 O 0 1.7007389274681373e-08
small O 0 1.9107402327023237e-09
mutations O 0 1.135006222341417e-08
, O 0 3.0716487131599024e-09
2 O 0 1.412641097431333e-07
large O 0 6.837457267039326e-09
structural O 0 0.0007355815614573658
alterations O 0 1.5963574696797878e-05
, O 0 9.577273196725855e-09
and O 0 1.4722543184575443e-08
hypermethylation O 0 5.5938828154467046e-05
in O 0 6.167089168229722e-07
3 O 0 0.42247751355171204
tumors O 1 1.0
- O 0 2.045358314717305e-06
were O 0 2.7074134045790288e-09
not O 0 1.5776570327918904e-10
detected O 0 6.891540671460916e-10
in O 0 1.5804579867051416e-10
the O 0 8.008596008579616e-10
corresponding O 0 8.470682821837272e-09
peripheral O 0 2.847374105385825e-07
blood O 0 1.8128977430365012e-08
DNA O 0 1.3152578048902797e-07
. O 0 1.6705665473182307e-07

In O 0 3.263431267441774e-07
6 O 0 2.8667134301940678e-06
( O 0 3.504148082811298e-09
17 O 0 1.1024950730131877e-08
% O 0 9.434161091226301e-11
) O 0 6.004316488450456e-11
of O 0 7.085310116394794e-10
the O 0 1.42063505403911e-09
36 O 0 1.1004320121799083e-08
patients O 0 4.386357388419526e-10
, O 0 2.2827154055882204e-10
a O 0 8.860921441034009e-10
mutation O 0 2.3016559769217793e-09
was O 0 1.4026420913637594e-08
detected O 0 6.524073725699964e-09
in O 0 6.484890957558775e-10
constitutional O 0 6.485020520585749e-08
DNA O 0 1.0451640441999643e-08
, O 0 1.537643068427741e-10
and O 0 1.767353902115687e-10
1 O 0 5.233049549246971e-09
of O 0 7.470273843956932e-10
these O 0 1.7210342873053008e-10
mutations O 0 7.77928665929295e-10
is O 0 4.1770597397627895e-11
known O 0 1.2918600911238087e-10
to O 0 1.9425917818782779e-10
be O 0 1.5283632137652603e-09
associated O 0 9.026287273172784e-09
with O 0 3.292972783341952e-09
reduced O 0 2.606647967695608e-06
expressivity O 0 0.0015434647211804986
. O 0 4.826783879252616e-06

The O 0 2.907558815934408e-08
presence O 0 3.840692652801181e-09
of O 0 5.083939047523245e-09
a O 0 1.0783961501559247e-09
constitutional O 0 8.487150182645564e-08
mutation O 0 4.083174687252722e-09
was O 0 2.2062984772475147e-09
not O 0 6.473493963099486e-11
associated O 0 5.09673303561442e-10
with O 0 1.428442433781818e-11
an O 0 1.2989705665267248e-11
early O 0 5.9833444865375895e-09
age O 0 2.575925073244889e-08
at O 0 8.434508913524041e-08
treatment O 0 7.414677583028606e-08
. O 0 6.908740601829777e-07

In O 0 2.5515689117128204e-07
1 O 0 1.1976991345363786e-06
patient O 0 5.4493238366148944e-08
, O 0 2.3714954444642444e-09
somatic O 0 6.083822654545656e-07
mosaicism O 0 2.013985977100674e-06
was O 0 2.2177754743779587e-08
demonstrated O 0 3.879389254279886e-09
by O 0 1.0119408089259707e-10
molecular O 0 1.4108921808642094e-09
analysis O 0 3.3080418959663405e-10
of O 0 2.07213052272337e-10
DNA O 0 8.614549074081879e-10
and O 0 3.119304536891576e-10
RNA O 0 2.1055737153830023e-09
from O 0 2.6481541404166364e-09
peripheral O 0 1.783615971362451e-06
blood O 0 2.773955145585205e-07
. O 0 1.0318492513761157e-06

In O 0 1.478897075912755e-07
2 O 0 5.74084197069169e-07
patients O 0 2.475069038609945e-09
without O 0 8.626518943621875e-10
a O 0 1.4552732352512976e-09
detectable O 0 8.417072194788489e-08
mutation O 0 3.363831213576418e-09
in O 0 1.2084215850194369e-09
peripheral O 0 2.2591164849927736e-07
blood O 0 8.881026580809248e-09
, O 0 1.742677890881339e-09
mosaicism O 0 4.921607796859462e-07
was O 0 3.96997812401878e-09
suggested O 0 7.381580902077189e-10
because O 0 1.770410484880358e-10
1 O 0 5.950306025681584e-09
of O 0 6.529796703347301e-10
the O 0 1.3448199220889023e-09
patients O 0 3.815487925606931e-09
showed O 0 7.530018706347619e-07
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 3.407745907679782e-08
the O 0 8.273733698160868e-09
other O 0 3.1325286808936426e-10
later O 0 1.0714444442783133e-08
developed O 0 5.5413917010582736e-08
bilateral B-Disease 0 0.00011272737174294889
retinoblastoma I-Disease 1 0.9763376116752625
. O 0 4.3185241338505875e-06

In O 0 1.2751684153045062e-07
conclusion O 0 7.032953703856037e-07
, O 0 8.354194669379922e-09
our O 0 8.843400678415492e-09
results O 0 5.571699990269963e-09
emphasize O 0 9.661759170498385e-10
that O 0 4.212270116044081e-11
the O 0 2.8330066070836324e-10
manifestation O 0 1.5629915139925288e-08
and O 0 8.366373704937757e-10
transmissibility O 0 2.7207326525058306e-07
of O 0 1.0194312061173605e-08
retinoblastoma B-Disease 0 5.147089154888818e-07
depend O 0 5.286198145881826e-09
on O 0 6.522555828780696e-09
the O 0 9.805340983604083e-10
nature O 0 9.135608380894666e-10
of O 0 1.1945092692755566e-09
the O 0 5.493126509215074e-10
first O 0 8.600709033856901e-10
mutation O 0 1.993466780536579e-10
, O 0 7.051642603173036e-11
its O 0 1.4838252848647926e-10
time O 0 2.095385864819832e-09
in O 0 9.195606498479947e-10
development O 0 7.679030744611737e-09
, O 0 2.16192411195415e-10
and O 0 2.2732435378536309e-10
the O 0 5.633375987912359e-10
number O 0 1.74465580871086e-10
and O 0 8.364614556555239e-11
types O 0 1.8659938039178314e-09
of O 0 8.5387803494541e-09
cells O 0 2.083144101661105e-09
that O 0 1.2627866807779498e-10
are O 0 2.07206335423038e-10
affected O 0 1.478749012129299e-09
. O 0 3.436070095119703e-09
. O 0 1.3533252740671742e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9981430768966675
the I-Disease 0 1.1338721378706396e-05
fifth I-Disease 0 1.1807892406068277e-06
component I-Disease 0 3.0200745015918073e-08
of I-Disease 0 1.5070988013121678e-08
complement I-Disease 0 1.5185889878921444e-08
in O 0 3.30126290748467e-08
man O 0 9.99661278910935e-06
. O 0 2.1681139514839742e-06

I O 0 0.00159373227506876
. O 0 1.0877467502723448e-05

Clinical O 0 5.348571721697226e-05
, O 0 5.893630117270732e-08
immunochemical O 0 1.0143766303372104e-05
, O 0 1.0921141324615746e-08
and O 0 1.1698073620891591e-08
family O 0 1.6857663709402004e-08
studies O 0 6.62004353557677e-08
. O 0 4.374902573545114e-07

The O 0 1.1837732927233446e-07
first O 0 8.630555825561714e-09
recognized O 0 3.819536242843924e-09
human O 0 4.8196262980582105e-08
kindred O 0 4.130536399316043e-05
with O 0 2.2971535429405776e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
of I-Disease 1 0.9991797804832458
the I-Disease 0 7.161740995798027e-06
fifth I-Disease 0 7.123705358935695e-07
component I-Disease 0 2.297306167520219e-08
of I-Disease 0 8.021216046927293e-08
complement I-Disease 0 2.2261505705500895e-07
( O 0 1.979824446607381e-07
C5 O 1 0.996039628982544
) O 0 2.027021395178963e-08
is O 0 5.799997815358893e-09
described O 0 2.0742071171753196e-07
. O 0 6.76723516335187e-07

The O 0 2.701875018829014e-06
proband O 0 3.3116717531811446e-05
, O 0 2.2000298471880342e-08
a O 0 1.6070515584942768e-08
20 O 0 7.42529167041539e-08
- O 0 5.298111815932316e-08
year O 0 5.1901869468906625e-09
- O 0 1.3213831095981732e-07
old O 0 7.150631518015871e-07
black O 0 6.051833167930454e-08
female O 0 1.272500327331727e-08
with O 0 1.2594012055444637e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9966689944267273
age O 0 0.0044366647489368916
11 O 0 1.1626767673078575e-06
, O 0 3.0774542914002723e-09
lacked O 0 4.3967230567432125e-07
serum O 0 1.5146510179420147e-07
hemolytic O 0 5.232157036516583e-06
complement O 0 1.4023664896001264e-08
activity O 0 2.5959003835396288e-08
, O 0 5.244327749842626e-10
even O 0 8.393993833344382e-10
during O 0 1.3410909716071728e-08
remission O 0 6.239534400265256e-08
. O 0 1.0755520918337425e-07

C5 O 1 0.9422065615653992
was O 0 3.84591794500011e-06
undetectable O 0 7.240898867166834e-07
in O 0 1.04317199323134e-09
her O 0 2.676446841931579e-10
serum O 0 4.411679632720933e-10
by O 0 1.1304485819652044e-10
both O 0 1.7348942282779944e-09
immunodiffusion O 0 1.3575913726526778e-06
and O 0 6.159552867757156e-08
hemolytic O 0 0.0003996727173216641
assays O 0 9.128811143455096e-06
. O 0 3.303031689938507e-06

Other O 0 3.643153556609491e-09
complement O 0 2.347204208774656e-09
components O 0 7.285851921778885e-09
were O 0 1.2086381895315412e-09
normal O 0 3.0873963385857905e-09
during O 0 9.412381984930107e-10
remission O 0 4.213511761719246e-09
of O 0 2.627636108698539e-09
lupus O 0 3.319890993225272e-07
, O 0 1.554037121209717e-09
but O 0 6.791912365855524e-09
C1 O 0 0.00026370881823822856
, O 0 3.82265774589996e-08
C4 O 0 0.003952073864638805
, O 0 1.1672553590358348e-08
C2 O 0 6.7360660978010856e-06
, O 0 9.808768908214915e-09
and O 0 3.653175539852782e-08
C3 O 1 0.859345018863678
levels O 0 8.93499054654967e-06
fell O 0 2.42019505094504e-05
during O 0 1.4856510688332492e-07
exacerbations O 0 8.802506636129692e-05
. O 0 8.706247740519757e-07

A O 0 7.872336936998181e-06
younger O 0 4.288359832571587e-06
half O 0 3.710273404067266e-07
- O 0 8.340870181200444e-07
sister O 0 1.4020407945736224e-07
, O 0 1.5526593344361572e-09
who O 0 8.865570499949627e-10
had O 0 4.597742186973619e-09
no O 0 1.4160908001770167e-08
underlying O 1 0.9247843623161316
disease O 0 0.0006659920327365398
, O 0 2.0814043821815176e-09
was O 0 9.360898900467873e-08
also O 0 1.0763228086574372e-09
found O 0 2.209043836742808e-09
to O 0 3.6285074944686357e-09
lack O 0 6.06785761192441e-06
immunochemically O 1 0.9914895296096802
detectable O 1 0.9997566342353821
C5 O 1 0.999963641166687
. O 0 6.597841547772987e-06

By O 0 5.77925050038175e-07
hemolytic O 0 0.0009532005642540753
assay O 0 4.853352038480807e-06
, O 0 9.553791535665823e-09
she O 0 1.3415099031632849e-09
exhibited O 0 7.185863459824304e-09
1 O 0 6.341517178043432e-08
- O 0 1.4488541921764408e-08
2 O 0 7.856232109304528e-09
% O 0 5.3806948480117356e-11
of O 0 2.477902050213032e-10
the O 0 9.553021707020548e-10
normal O 0 2.6985372159060717e-08
serum O 0 2.138406607343768e-08
C5 O 0 3.4430868254275993e-06
level O 0 4.9325844742043046e-08
and O 0 3.2600619426226274e-10
normal O 0 7.985046512892779e-10
concentrations O 0 5.661964785907969e-10
of O 0 1.8804774404301838e-10
other O 0 4.695847530267194e-11
complement O 0 2.975111712544276e-09
components O 0 6.8795166896507e-08
. O 0 8.693356789990503e-08

C5 O 0 0.00022607951541431248
levels O 0 1.0682044404575208e-07
of O 0 9.00772967327157e-09
other O 0 1.662258802825889e-10
family O 0 7.318519401611212e-11
members O 0 4.740880951703552e-11
were O 0 3.3557681633489267e-10
either O 0 1.1789613729717985e-09
normal O 0 1.9734109457658633e-08
or O 0 2.807264642967766e-09
approximately O 0 5.4322604192691415e-09
half O 0 4.082505000724268e-09
- O 0 1.7754915759837786e-08
normal O 0 1.492022860816178e-08
, O 0 2.3021026751557372e-10
consistent O 0 9.193857231082347e-09
with O 0 5.620357512725604e-10
autosomal O 0 8.800479633919167e-08
codominant O 0 4.684056023052108e-07
inheritance O 0 2.012256317129868e-08
of O 0 1.1359699847446336e-08
the O 0 1.1146487288726803e-08
gene O 0 1.6806049529805023e-07
determining O 0 6.002170994179323e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00021101057063788176

Normal O 0 6.380680861184373e-05
hemolytic O 0 0.006323038134723902
titers O 0 2.2543616069015115e-05
were O 0 1.0329836541700388e-08
restored O 0 2.592149961344603e-08
to O 0 8.211096247379146e-10
both O 0 1.1450803860668657e-08
homozygous O 0 2.05826527235331e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 2.277091880387161e-06
C5D B-Disease 1 1.0
) O 0 6.2021556779257025e-09
sera O 0 3.981551444098841e-08
by O 0 6.676768166125058e-11
addition O 0 4.407692544283748e-10
of O 0 7.396439016815748e-09
highly O 0 1.2418099970545882e-07
purified O 0 7.026150115052587e-07
human O 0 3.0461419555649627e-06
C5 O 1 0.9768174290657043
. O 0 5.313775091053685e-06

In O 0 2.1850507891940651e-07
specific O 0 4.936094910590327e-07
C5 O 0 0.03872794285416603
titrations O 0 6.683225819870131e-06
, O 0 2.408418353638808e-09
however O 0 1.8644854549165757e-09
, O 0 2.565595791370612e-10
it O 0 6.454396045407762e-11
was O 0 1.6923763501708322e-09
noted O 0 1.6567386351695745e-10
that O 0 1.2687927097854157e-11
when O 0 7.477368724195799e-11
limited O 0 1.4251774760332125e-10
amounts O 0 4.013403220870515e-10
of O 0 1.2382782799136294e-08
C5 O 0 2.1191917767282575e-05
were O 0 2.318983760574156e-08
assayed O 0 1.0574583342304322e-07
in O 0 4.6036016665418344e-10
the O 0 5.383818946214092e-10
presence O 0 5.148202975036043e-10
of O 0 5.619642085008536e-09
low O 0 1.7443240096781665e-07
dilutions O 0 2.757643642326002e-06
of O 0 1.7869450630314532e-07
either O 0 1.2266795010873466e-06
C5D B-Disease 1 1.0
serum O 0 3.8968715898590744e-07
, O 0 2.297217305269328e-09
curving O 0 2.8068912527601242e-08
rather O 0 1.5441538048222014e-09
than O 0 2.9444172100490107e-10
linear O 0 1.518820624824002e-08
dose O 0 7.486752551244535e-09
- O 0 1.0784805271057962e-09
response O 0 7.366036253175778e-11
plots O 0 2.05217820514747e-09
were O 0 5.887422216410698e-10
consistently O 0 5.894512100645954e-10
obtained O 0 2.528867781848021e-09
, O 0 1.99552110946577e-10
suggesting O 0 2.0922628074515615e-09
some O 0 3.8458661255624804e-10
inhibitory O 0 1.3450622304844728e-07
effect O 0 6.00365581249207e-07
. O 0 5.01126066865254e-07

Further O 0 2.212081255947851e-07
studies O 0 1.4025298256115093e-08
suggested O 0 6.621733383838091e-09
that O 0 3.884333410475449e-10
low O 0 7.463815165920096e-08
dilutions O 0 2.422486659270362e-06
of O 0 8.959598858382378e-07
C5D B-Disease 1 1.0
serum O 0 5.5186301750609346e-08
contain O 0 1.96564897692042e-09
a O 0 7.287502268304991e-10
factor O 0 2.279409994088155e-09
( O 0 1.5286948096271402e-10
or O 0 2.1532532701318274e-10
factors O 0 1.5219169258173793e-09
) O 0 2.7639199262630143e-10
interfering O 0 3.616485111379575e-09
at O 0 8.983416677210698e-09
some O 0 7.561153092527917e-11
step O 0 2.918836949916681e-09
in O 0 5.569593120036131e-10
the O 0 4.87449280939245e-09
hemolytic O 0 6.789010512875393e-05
assay O 0 3.7926963614154374e-06
of O 0 7.911504326330032e-06
C5 O 1 0.9999375343322754
, O 0 4.822271915116971e-09
rather O 0 1.6640171462967146e-09
than O 0 3.105058155039586e-10
a O 0 1.2128457127502656e-09
true O 0 1.553054858050018e-07
C5 O 0 0.0004058414197061211
inhibitor O 0 3.990804088971345e-06
or O 0 1.3172775936709513e-07
inactivator O 0 8.449493179796264e-06
. O 0 6.874577707094431e-07

Of O 0 1.208864546242694e-06
clinical O 0 4.209877715766197e-06
interest O 0 6.108938777060757e-08
are O 0 2.1310602171809023e-09
( O 0 3.9966127629575965e-10
a O 0 4.217015070473451e-10
) O 0 7.019088088533465e-11
the O 0 1.8039966742655622e-10
documentation O 0 1.6983594974817606e-08
of O 0 4.750673454623211e-08
membranous O 1 0.9999998807907104
glomerulonephritis B-Disease 1 1.0
, O 0 0.18345703184604645
vasculitis B-Disease 1 1.0
, O 0 4.1715588849911e-06
and O 0 0.00011352120782248676
arthritis B-Disease 1 1.0
in O 0 5.647398779728974e-07
an O 0 3.6597991304176958e-09
individual O 0 8.90895268668146e-09
lacking O 0 0.04903166741132736
C5 O 1 0.9999980926513672
( O 0 8.729391431927525e-09
and O 0 1.5035550582354062e-09
its O 0 9.161014169478676e-10
biologic O 0 5.955214277264531e-08
functions O 0 4.470671832734752e-09
) O 0 5.517295301182834e-11
, O 0 2.8308284535927264e-11
and O 0 2.2631892193647474e-10
( O 0 2.1546542328110263e-10
b O 0 5.757408771955852e-09
) O 0 1.082432546373191e-10
a O 0 3.1068117523069816e-10
remarkable O 0 3.949397253677489e-09
propensity O 0 5.095882826822162e-08
to O 0 1.0019204133016046e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.0194020738651943e-08
the O 0 3.884307631096817e-08
proband O 0 1.8268990515935002e-06
, O 0 3.6597275210326075e-10
even O 0 2.550884226071304e-10
during O 0 1.7461515566807861e-09
periods O 0 3.7638936412065505e-09
of O 0 1.2898910828340604e-09
low O 0 2.54299283852788e-08
- O 0 1.3830753209376212e-09
dose O 0 3.226559686098085e-09
or O 0 9.92690374346239e-10
alternate O 0 4.759298377621235e-08
- O 0 7.845140004292261e-08
day O 0 1.143622441190928e-08
corticosteroid O 0 3.705672952492023e-06
therapy O 0 1.1217390465390054e-06
. O 0 1.9556021868538664e-07

Other O 0 3.6552386006860615e-08
observations O 0 5.2848498910407216e-08
indicate O 0 4.276030196592728e-09
that O 0 1.3812187504846918e-10
the O 0 5.188315999049564e-09
C5D B-Disease 1 0.9999998807907104
state O 0 2.7186632944875555e-09
is O 0 1.5385936968925762e-10
compatible O 0 3.1135998224129935e-09
with O 0 1.6305337635635908e-10
normal O 0 5.249985335353813e-09
coagulation O 0 8.848091148649928e-09
function O 0 5.983630035899523e-09
and O 0 3.3719235736917597e-10
the O 0 4.920739371527816e-10
capacity O 0 3.009010596244366e-09
to O 0 8.075720647759965e-10
mount O 0 6.613493042095797e-07
a O 0 1.8122102574125165e-07
neutrophilic O 1 0.9950107336044312
leukocytosis O 0 0.34370195865631104
during O 0 9.646108082961291e-06
pyogenic B-Disease 0 0.0004898548359051347
infection I-Disease 0 5.5360210353683215e-06
. O 0 6.73687523544686e-08
. O 0 5.622249545922386e-07

Susceptibility O 0 0.00046344639849849045
to O 0 1.8955926861963235e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 2.4363775082747452e-05
twins O 0 1.472801386626088e-06
: O 0 2.6426730248552133e-10
the O 0 1.0486594925751547e-10
role O 0 3.084192901070537e-10
of O 0 2.469495274937117e-09
genes O 0 1.1862629767378507e-09
, O 0 1.7759547166207312e-09
HLA O 0 2.470879962856998e-07
, O 0 2.2751791561859136e-09
and O 0 1.1756363882398091e-08
the O 0 6.70440556405083e-08
environment O 0 1.8341140730626648e-06
. O 0 1.0215322845397168e-06

OBJECTIVE O 0 3.3441028790548444e-06
To O 0 9.69445590470741e-09
determine O 0 1.9128886918906574e-08
the O 0 9.438592130095458e-10
relative O 0 9.129899503079741e-09
effects O 0 1.425356117579213e-07
of O 0 1.7080273195801965e-08
genetic O 0 2.4542451626530237e-08
and O 0 9.469246498028383e-10
environmental O 0 6.911355487915216e-09
factors O 0 5.608912445609349e-09
in O 0 1.714135944297368e-09
susceptibility O 0 7.0521618908969685e-06
to O 0 7.890405868238304e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0003212297451682389
AS B-Disease 1 1.0
) O 0 1.2692980888573402e-08
. O 0 5.6255110791880725e-08

METHODS O 0 3.2162017305381596e-05
Twins O 0 8.058484127104748e-06
with O 0 2.424439093928754e-09
AS B-Disease 1 0.9985234141349792
were O 0 1.3435994539179319e-09
identified O 0 2.5177201989912135e-10
from O 0 2.856706364517958e-11
the O 0 4.503456774163084e-10
Royal O 0 1.4499785550015076e-07
National O 0 1.1762654139602091e-06
Hospital O 0 1.4571368410543073e-05
for O 0 2.5070558962170253e-08
Rheumatic B-Disease 1 0.9999997615814209
Diseases I-Disease 1 0.9999998807907104
database O 0 7.466048828064231e-07
. O 0 2.629964910738636e-06

Clinical O 0 7.534051746915793e-06
and O 0 1.7871554902626485e-08
radiographic O 0 6.512923391710501e-07
examinations O 0 3.8193130080799165e-07
were O 0 1.0216106849370021e-09
performed O 0 5.6342968485223466e-11
to O 0 6.031473931411568e-11
establish O 0 3.79685971552135e-09
diagnoses O 0 2.1301993911038153e-06
, O 0 3.2815863360013964e-09
and O 0 5.259930446754879e-08
disease O 0 0.0011378044728189707
severity O 0 1.2397324098856188e-05
was O 0 1.2242352909197507e-07
assessed O 0 2.801243326189251e-08
using O 0 8.167315712626078e-10
a O 0 8.849436183844261e-10
combination O 0 8.863140443793327e-09
of O 0 3.242032775574444e-08
validated O 0 8.756634315432166e-07
scoring O 0 3.5083402849522827e-07
systems O 0 7.170367553044343e-07
. O 0 2.2198646831839142e-07

HLA O 0 0.0002035608486039564
typing O 0 6.39701283944305e-06
for O 0 6.023274323752048e-08
HLA O 0 2.512827904865844e-06
- O 0 1.5863419378092658e-07
B27 O 0 5.599534915745608e-07
, O 0 4.681793619454311e-09
HLA O 0 1.6456614559956506e-07
- O 0 1.6146250558790598e-08
B60 O 0 6.105280903057064e-08
, O 0 6.188563550502124e-10
and O 0 2.95929925009375e-09
HLA O 0 5.870691666132188e-07
- O 0 6.341323910419305e-08
DR1 O 0 6.493043201771798e-06
was O 0 6.1810525586736276e-09
performed O 0 3.0763083747054054e-10
by O 0 1.6900755794857503e-10
polymerase O 0 3.69282537882043e-09
chain O 0 3.3789553377516768e-09
reaction O 0 2.5668895897723587e-09
with O 0 1.7910140037713518e-09
sequence O 0 1.127299587011521e-08
- O 0 6.774756755589806e-09
specific O 0 4.4210127225774443e-10
primers O 0 1.8572031024177704e-08
, O 0 3.600034992334855e-10
and O 0 1.3583643099224219e-09
zygosity O 0 4.3301727714606386e-07
was O 0 2.7449882367136524e-08
assessed O 0 1.2441060448509234e-07
using O 0 1.4175311591202444e-08
microsatellite O 0 2.0738546027132543e-06
markers O 0 2.4741605102462927e-06
. O 0 1.6287192465824774e-06

Genetic O 0 9.740961104398593e-07
and O 0 1.0727407406818656e-08
environmental O 0 1.1027264434915196e-08
variance O 0 6.253233042485817e-09
components O 0 1.4127455649770582e-08
were O 0 2.437886559292224e-09
assessed O 0 1.591995690830572e-08
with O 0 8.57206111648523e-11
the O 0 4.728394342734532e-10
program O 0 6.966633936400513e-10
Mx O 0 1.637462787584809e-07
, O 0 6.131108815088382e-11
using O 0 3.610650667340565e-11
data O 0 1.3685891309123122e-10
from O 0 7.378363545140765e-12
this O 0 5.791874358590521e-12
and O 0 2.0972629882765048e-11
previous O 0 3.349194532820121e-10
studies O 0 3.81787379488685e-10
of O 0 9.432185033020346e-10
twins O 0 8.731444722798187e-08
with O 0 1.152729911524375e-09
AS B-Disease 1 0.9999996423721313
. O 0 1.0821022442542017e-06

RESULTS O 0 1.3365145605348516e-05
Six O 0 5.488287797561497e-07
of O 0 2.5951982252081507e-07
8 O 0 2.6994697691407055e-05
monozygotic O 0 0.00038684983155690134
( O 0 2.7578673211792193e-07
MZ O 1 0.9665348529815674
) O 0 1.2500700030670941e-08
twin O 0 1.8451299865773763e-06
pairs O 0 1.7789693274039564e-08
were O 0 2.0737306272167189e-07
disease O 0 3.1042713089846075e-05
concordant O 0 9.001942089525983e-06
, O 0 7.393646139775001e-09
compared O 0 2.72244116139575e-09
with O 0 3.7196010160833737e-10
4 O 0 1.4894700939294125e-07
of O 0 4.5336257414874126e-08
15 O 0 1.314079298708748e-07
B27 O 0 1.0233000011794502e-06
- O 0 3.101939398675313e-07
positive O 0 4.327031177808749e-08
dizygotic O 0 1.2419051017786842e-05
( O 0 2.9427413394955693e-08
DZ O 0 5.846744443260832e-06
) O 0 9.052252281094297e-09
twin O 0 2.7993186790808977e-07
pairs O 0 4.785182916577924e-09
( O 0 2.592094094922004e-09
27 O 0 5.633156163753483e-08
% O 0 8.076244117916076e-10
) O 0 2.816777644465418e-10
and O 0 1.1160246060626378e-09
4 O 0 2.026403649324493e-07
of O 0 5.541115797313978e-07
32 O 0 3.699817170854658e-05
DZ O 0 0.02126624621450901
twin O 0 2.8947246391908266e-05
pairs O 0 9.02762931076495e-09
overall O 0 1.9560461339551694e-07
( O 0 2.8184452549595562e-09
12 O 0 2.3195942944198578e-08
. O 0 1.4078437304831937e-09
5 O 0 2.6112649820220213e-08
% O 0 5.370813793703633e-10
) O 0 2.3547017669045545e-09
. O 0 1.7732671153680712e-07

Nonsignificant O 0 8.830131264403462e-05
increases O 0 5.48111707132648e-08
in O 0 2.0475567907851655e-09
similarity O 0 3.1662108490593255e-09
with O 0 4.735350306317443e-11
regard O 0 4.5033107798353456e-10
to O 0 1.1585771231281683e-10
age O 0 2.5205959985896698e-08
at O 0 1.6230119115334674e-07
disease O 0 1.443783048671321e-07
onset O 0 3.7048348389134844e-08
and O 0 2.8403002172439074e-10
all O 0 9.494308117474759e-11
of O 0 5.434350747179906e-10
the O 0 1.3873661108831925e-09
disease O 0 2.224838269171414e-08
severity O 0 1.8903614673604352e-08
scores O 0 1.4934464331872732e-08
assessed O 0 2.0688585067318854e-08
were O 0 2.471695959016529e-09
noted O 0 4.86415530076556e-09
in O 0 8.315215183074542e-09
disease O 0 0.00019609308219514787
- O 0 7.365178316831589e-05
concordant O 0 0.07038745284080505
MZ O 1 0.9999998807907104
twins O 0 5.849477474839659e-06
compared O 0 1.020108086891014e-08
with O 0 5.120608381758984e-09
concordant O 0 0.00012018300185445696
DZ O 0 0.08768409490585327
twins O 0 0.0002636869321577251
. O 0 4.589081072481349e-06

HLA O 0 0.00025318629923276603
- O 0 2.5966639896068955e-06
B27 O 0 6.680936621705769e-07
and O 0 2.7708568772766284e-09
B60 O 0 1.0590530052922986e-07
were O 0 2.2193908932877093e-09
associated O 0 1.3312225766171082e-09
with O 0 1.2620401945717674e-10
the O 0 4.2421226531530465e-09
disease O 0 5.537545888500972e-08
in O 0 8.246190397187547e-10
probands O 0 2.7339431198925013e-06
, O 0 9.54158640986691e-10
and O 0 7.269357893413542e-10
the O 0 2.431385537349229e-09
rate O 0 1.5289820964881073e-08
of O 0 1.302453167539852e-08
disease O 0 1.556818318704245e-07
concordance O 0 4.7248740031591296e-08
was O 0 1.4720970220594154e-08
significantly O 0 4.012922882878911e-09
increased O 0 9.44495504029419e-09
among O 0 2.49566269872048e-08
DZ O 0 2.5098050173255615e-05
twin O 0 1.3715875866182614e-06
pairs O 0 1.292723483814484e-09
in O 0 1.513106417938559e-09
which O 0 6.981412115081298e-10
the O 0 1.7009725183925184e-08
co O 0 1.1257460528213414e-06
- O 0 2.675056975931511e-07
twin O 0 7.907919439276156e-07
was O 0 1.1526116949767129e-08
positive O 0 4.944598619438523e-10
for O 0 4.028266054056928e-10
both O 0 8.98521612668901e-09
B27 O 0 3.3668611649773084e-06
and O 0 4.681979248744028e-07
DR1 O 0 0.006057980936020613
. O 0 3.811275519183255e-06

Additive O 0 1.751646664160944e-06
genetic O 0 9.253606236825362e-08
effects O 0 5.967243055238214e-08
were O 0 2.2030437474285236e-09
estimated O 0 2.648284092021669e-10
to O 0 8.864822070853151e-11
contribute O 0 3.584385843691251e-10
97 O 0 6.799715457361799e-09
% O 0 4.1254905741583414e-11
of O 0 1.3518888786201444e-10
the O 0 1.5269288611285958e-10
population O 0 5.2321333030014294e-12
variance O 0 1.5299965738790888e-09
. O 0 2.8870459800600656e-08

CONCLUSION O 0 7.726465810264926e-06
Susceptibility O 0 1.552570552121324e-06
to O 0 1.7543380081974647e-08
AS B-Disease 1 0.9999996423721313
is O 0 4.988153778917592e-10
largely O 0 1.0036488307108016e-09
genetically O 0 4.91460483420525e-10
determined O 0 3.996828201735525e-09
, O 0 2.3083637779031108e-10
and O 0 8.203269730167051e-10
the O 0 1.662621151865551e-09
environmental O 0 6.9282752868105035e-09
trigger O 0 4.030390954312679e-08
for O 0 2.5245689982966724e-09
the O 0 1.154363431510319e-07
disease O 0 0.00022494743461720645
is O 0 8.043990473716178e-10
probably O 0 2.5459728547616578e-08
ubiquitous O 0 2.1114027504154365e-07
. O 0 2.558872154168057e-07

HLA O 0 0.0002887327573262155
- O 0 3.420276016186108e-06
B27 O 0 4.950596235175908e-07
accounts O 0 2.9308577786935075e-10
for O 0 3.598715075936454e-11
a O 0 7.025624526590946e-11
minority O 0 1.6458348572889747e-10
of O 0 2.077882088613592e-09
the O 0 1.8321932859777235e-09
overall O 0 1.3726060288377084e-08
genetic O 0 9.163185765714843e-09
susceptibility O 0 2.5700947148266096e-08
to O 0 2.30120065225492e-08
AS B-Disease 1 1.0
. O 0 2.4456843675579876e-05

Cell O 0 6.628320988966152e-05
cycle O 0 2.1004482277930947e-06
- O 0 4.114845353342389e-07
dependent O 0 9.275907331129929e-08
colocalization O 0 1.8878736227634363e-06
of O 0 1.2685532624345797e-07
BARD1 O 0 3.172019569319673e-05
and O 0 2.2633944496419645e-08
BRCA1 O 0 7.903168786072001e-09
proteins O 0 3.353541333517285e-10
in O 0 7.457831019408445e-10
discrete O 0 6.559561427366134e-08
nuclear O 0 7.631069252056477e-07
domains O 0 3.952175575250294e-06
. O 0 9.011236556943913e-07

Germ O 0 0.0002262108027935028
- O 0 1.5344197890954092e-05
line O 0 2.2374395314272988e-07
mutations O 0 1.1427327528679143e-08
of O 0 1.6113764544911646e-08
the O 0 4.2654917820073024e-08
BRCA1 O 0 7.228783971413577e-08
gene O 0 1.1888118045533247e-08
predispose O 0 1.1891795992369225e-07
women O 0 3.803412251812688e-09
to O 0 6.779018457692132e-10
early O 0 8.456801765532873e-07
- O 0 0.3987032175064087
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 6.799322136430419e-07
compromising O 0 7.4470303843554575e-06
the O 0 3.352790045596521e-08
genes O 0 1.986597553127467e-09
presumptive O 0 8.287478436841411e-08
function O 0 1.7972840993252248e-08
as O 0 1.94842608713941e-09
a O 0 3.037067708433483e-09
tumor B-Disease 0 3.265165275934123e-07
suppressor O 0 9.144748219114263e-06
. O 0 4.315671048971126e-06

Although O 0 2.2237908581246302e-07
the O 0 3.7108321748746675e-08
biochemical O 0 1.4420120919567125e-07
properties O 0 2.373393499510712e-07
of O 0 1.1623093598700507e-07
BRCA1 O 0 1.488779322045275e-08
polypeptides O 0 1.1573458635893985e-08
are O 0 9.56413837016612e-11
not O 0 9.395731415118291e-11
understood O 0 1.662773363442227e-09
, O 0 8.50699163890134e-11
their O 0 1.8985438221541528e-10
expression O 0 3.220472777343275e-09
pattern O 0 1.2502702873007365e-08
and O 0 2.1386952209212495e-09
subcellular O 0 5.905202442590962e-07
localization O 0 1.556297434035514e-06
suggest O 0 2.4719188473909526e-08
a O 0 4.9904587129390166e-09
role O 0 2.606885729505848e-08
in O 0 3.747048182844992e-08
cell O 0 8.514701039530337e-05
- O 0 6.636713806074113e-05
cycle O 0 2.8380393359839218e-06
regulation O 0 3.909541646862635e-06
. O 0 4.8525470219829e-07

When O 0 9.002405931823887e-07
resting O 0 2.8648248644458363e-06
cells O 0 1.335714738814886e-08
are O 0 3.212630439453079e-10
induced O 0 9.033693793014663e-09
to O 0 3.2454325338271417e-10
proliferate O 0 2.131935339377833e-08
, O 0 6.211458014604432e-10
the O 0 2.3026394124769922e-09
steady O 0 2.4238579143798233e-08
- O 0 2.65027644275051e-09
state O 0 2.97159435946881e-10
levels O 0 2.957775802059359e-09
of O 0 2.5126267733099894e-09
BRCA1 O 0 1.4257328651012813e-09
increase O 0 1.6243349720834743e-10
in O 0 4.932043662364549e-10
late O 0 1.4642162682321214e-07
G1 O 0 2.82618316305161e-07
and O 0 3.7420874732241316e-10
reach O 0 1.3174886737132852e-09
a O 0 1.9851043031593463e-10
maximum O 0 2.5374889744966822e-08
during O 0 1.7639239402456042e-08
S O 0 1.5528074754911358e-06
phase O 0 6.1031141740386374e-06
. O 0 8.645483831060119e-07

Moreover O 0 7.591813186991203e-07
, O 0 1.3840208090698525e-08
in O 0 5.457725382740364e-09
S O 0 5.796649134026666e-07
phase O 0 1.879226260825817e-06
cells O 0 1.4363019218421869e-08
, O 0 1.3643104423977093e-09
BRCA1 O 0 4.201266001757631e-09
polypeptides O 0 1.713626929245038e-08
are O 0 7.529524226335127e-10
hyperphosphorylated O 0 1.2117207859319024e-07
and O 0 2.1315684772815757e-09
accumulate O 0 3.853871888281901e-09
into O 0 2.740979221371731e-09
discrete O 0 3.371618504388607e-07
subnuclear O 0 3.7060972317704e-06
foci O 0 9.869866516964976e-06
termed O 0 2.9518030260078376e-06
" O 0 1.104050170397386e-06
BRCA1 O 0 1.3475057585310424e-06
nuclear O 0 1.1159100722579751e-05
dots O 0 2.6536888981354423e-05
. O 0 2.3623290417162934e-06

" O 0 1.36008047775249e-05
BRCA1 O 0 4.515151431405684e-06
associates O 0 1.8392515812593047e-06
in O 0 4.846710766059914e-08
vivo O 0 2.1719723974911176e-07
with O 0 1.3307401847129086e-09
a O 0 8.21833978648101e-09
structurally O 0 1.1705169526976533e-06
related O 0 4.119374352740124e-06
protein O 0 1.1591490874707233e-05
termed O 0 2.940796548500657e-05
BARD1 O 0 0.028807276859879494
. O 0 3.5277332699479302e-06

Here O 0 7.046784276099061e-07
we O 0 5.584509743528088e-09
show O 0 3.8005093516702004e-10
that O 0 4.4649579172828524e-11
the O 0 6.451753020719764e-10
steady O 0 8.760866698764858e-09
- O 0 1.5686592025332402e-09
state O 0 1.201246602189343e-10
levels O 0 3.8208405328532535e-09
of O 0 7.353788245012538e-09
BARD1 O 0 2.395709543634439e-06
, O 0 1.1787427978138254e-10
unlike O 0 2.0295534697289952e-10
those O 0 1.1046578235474058e-10
of O 0 1.2700676066401684e-09
BRCA1 O 0 4.2673771183388e-09
, O 0 3.6912181644588316e-10
remain O 0 2.943301380398111e-09
relatively O 0 1.9688308761089957e-09
constant O 0 3.4784591207426274e-08
during O 0 8.815111840476675e-08
cell O 0 2.063563897536369e-06
cycle O 0 7.846754215279361e-07
progression O 0 2.8908452804898843e-06
. O 0 6.223993409548711e-07

However O 0 9.209329050463566e-07
, O 0 3.197400033627673e-08
immunostaining O 0 9.990064882003935e-07
revealed O 0 6.407255881413221e-08
that O 0 1.704345886643921e-09
BARD1 O 0 2.456280981277814e-06
resides O 0 3.864908393325095e-08
within O 0 1.1082719630906013e-08
BRCA1 O 0 1.952243700031886e-08
nuclear O 0 3.349294388499402e-07
dots O 0 9.345610152422523e-08
during O 0 1.8705987869793717e-08
S O 0 1.7768661564332433e-07
phase O 0 4.855509700973926e-07
of O 0 1.8890963460194143e-08
the O 0 7.590465145312919e-09
cell O 0 2.3030095164244813e-08
cycle O 0 1.3457897019009124e-09
, O 0 7.39022662510358e-11
but O 0 8.266232837117471e-11
not O 0 1.4449698382268394e-10
during O 0 3.6520868551548347e-09
the O 0 6.882572289867994e-09
G1 O 0 3.2685629776096903e-06
phase O 0 2.153248942704522e-06
. O 0 3.0496835279336665e-07

Nevertheless O 0 7.187372375483392e-06
, O 0 1.1719729542392088e-07
BARD1 O 0 5.0739431571855675e-06
polypeptides O 0 2.8669290941252257e-08
are O 0 1.0863064614508033e-10
found O 0 1.610618860503621e-10
exclusively O 0 1.5566706257352791e-10
in O 0 9.788742039162912e-11
the O 0 2.4398391640367834e-10
nuclear O 0 3.4031987894422855e-08
fractions O 0 4.012167309497272e-08
of O 0 1.7207867131219245e-08
both O 0 7.673027546672984e-09
G1 O 0 5.934701334808778e-07
- O 0 1.7272251184863308e-08
and O 0 2.9933373557611276e-09
S O 0 3.4612523336363665e-07
- O 0 1.27279207617903e-07
phase O 0 1.1048759915865958e-06
cells O 0 1.5090324723132653e-07
. O 0 8.658242478531974e-08

Therefore O 0 7.261299401761789e-07
, O 0 1.2903002222230953e-08
progression O 0 3.346758603584021e-08
to O 0 1.5415613230373992e-09
S O 0 1.7235646510016522e-07
phase O 0 5.077590117252839e-07
is O 0 1.7399999496792162e-10
accompanied O 0 4.13098083518193e-10
by O 0 3.720173821775141e-11
the O 0 3.180487817555644e-10
aggregation O 0 3.2267750693648622e-09
of O 0 2.2644339736643815e-09
nuclear O 0 5.07146808104153e-07
BARD1 O 0 0.00014417775673791766
polypeptides O 0 4.904333081867662e-07
into O 0 1.1374773123407067e-07
BRCA1 O 0 6.459688961513166e-07
nuclear O 0 8.175696166290436e-06
dots O 0 1.2618601431313436e-05
. O 0 1.655902110542229e-06

This O 0 5.451771016851126e-07
cell O 0 2.0060347196704242e-06
cycle O 0 4.2497293861742946e-07
- O 0 6.68689636995623e-08
dependent O 0 1.5311298895426262e-08
colocalization O 0 6.402308372344123e-07
of O 0 5.415731152424996e-08
BARD1 O 0 6.27056579105556e-05
and O 0 2.0482062268456502e-08
BRCA1 O 0 1.8518337085993153e-08
indicates O 0 2.8059368162303144e-09
a O 0 5.603221220340515e-10
role O 0 1.9608483725619408e-09
for O 0 1.4424700323090178e-09
BARD1 O 0 7.968141289893538e-06
in O 0 8.774651405474287e-08
BRCA1 O 0 2.7501507702254457e-06
- O 0 2.4796576326480135e-05
mediated O 0 2.3750970285618678e-05
tumor B-Disease 0 7.05915999787976e-06
suppression O 0 2.1678471966879442e-05
. O 0 2.1712714897148544e-06

Ethnic O 0 4.825232622351905e-07
differences O 0 1.2103849940103828e-06
in O 0 5.561965821243575e-08
the O 0 1.367127566709314e-07
HFE O 0 7.741081935819238e-05
codon O 0 4.2553483581286855e-06
282 O 0 4.915078534395434e-06
( O 0 2.9680239777007955e-07
Cys O 0 0.3233906924724579
/ O 0 0.00012468833301682025
Tyr O 0 0.00020089454483240843
) O 0 4.876103787410102e-08
polymorphism O 0 1.2133609743614215e-06
. O 0 9.663192486186745e-07

Recent O 0 5.573733119490498e-08
studies O 0 6.090077775411373e-09
have O 0 3.8559730408671555e-10
shown O 0 6.764917070967158e-09
that O 0 5.976286843178968e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 8.772389264777303e-05
HH B-Disease 1 0.9999866485595703
) O 0 1.7011501096675374e-09
is O 0 1.0437983810618334e-10
likely O 0 9.165873060545948e-10
to O 0 2.5549062865337646e-10
be O 0 4.958851107517148e-10
caused O 0 6.386425610571678e-09
by O 0 8.079217850287534e-10
homozygosity O 0 1.3976939783333364e-07
for O 0 5.139764724937379e-10
a O 0 2.581584723770902e-09
Cys282Tyr O 0 4.1629010638644104e-07
mutation O 0 2.7437150329490123e-09
in O 0 9.91891790924626e-10
the O 0 5.617305731675515e-09
HFE O 0 2.1677005861420184e-06
gene O 0 1.238448366081002e-08
located O 0 2.3666165915869897e-08
4 O 0 7.553659884251829e-07
. O 0 7.874648417782737e-07

5 O 0 3.801774073508568e-05
Mb O 0 0.0005089013138785958
telomeric O 0 5.399604560807347e-05
to O 0 2.926325919361261e-07
HLA O 0 7.189570897025988e-05
- O 0 2.4754915557423374e-06
A O 0 2.2254373277519335e-07
. O 0 2.421439262434433e-07

Population O 0 9.97983251593837e-10
studies O 0 7.908547705604008e-10
of O 0 7.521486211636841e-10
this O 0 1.2635865964671922e-10
polymorphism O 0 3.5185743207932774e-09
are O 0 1.0550735979331094e-10
facilitated O 0 1.0260045035792587e-09
by O 0 6.535973845478438e-11
the O 0 1.819279865644674e-10
fact O 0 1.2662089432513568e-10
that O 0 5.463865471178053e-11
the O 0 1.8948691504760973e-09
Cys282Tyr O 0 4.215449735056609e-06
mutation O 0 1.3125212205977732e-07
creates O 0 3.99460482469749e-08
a O 0 3.048932839533336e-08
Rsal O 0 5.657076144416351e-06
restriction O 0 2.4453467517560057e-07
site O 0 7.343698484874039e-07
. O 0 7.216398216769448e-07

We O 0 1.4470596454430051e-07
have O 0 2.584979785780206e-09
studied O 0 4.211730342262854e-08
the O 0 1.1428243240629854e-08
codon O 0 4.2080566231561534e-07
282 O 0 1.7061832977560698e-06
( O 0 2.557308391715196e-07
Cys O 0 0.15427246689796448
/ O 0 4.672084469348192e-05
Tyr O 0 2.7557391149457544e-05
) O 0 2.950495847642287e-09
polymorphism O 0 5.44603784291553e-09
in O 0 7.75139327724439e-11
different O 0 1.1336873800837921e-10
ethnic O 0 1.7740781066422073e-10
groups O 0 1.2187777453931403e-09
. O 0 8.759769087873792e-08

In O 0 1.0984737741637218e-07
agreement O 0 1.214286555750732e-07
with O 0 1.8473453877732027e-09
previous O 0 1.5508044626244555e-08
observations O 0 3.2098530056146046e-08
the O 0 3.1137303846406894e-09
Tyr O 0 1.4024528809386538e-06
allele O 0 2.2772470131826594e-08
appeared O 0 5.614853026969513e-09
to O 0 4.0342942875248866e-10
be O 0 2.967504852957603e-10
rare O 0 9.960777758166728e-10
or O 0 1.2548495575970264e-09
absent O 0 1.8862015949139277e-08
in O 0 1.1054762660833717e-09
Asiatic O 0 2.5721986318671952e-08
( O 0 5.079691112186424e-10
Indian O 0 1.7302247412587235e-09
, O 0 4.218833338232031e-10
Chinese O 0 1.9660950645317143e-09
) O 0 8.37515501395103e-10
populations O 0 2.942756927026835e-09
. O 0 1.35968747372317e-07

The O 0 3.3601142490624625e-07
highest O 0 4.6269869358184224e-07
allele O 0 3.537889980975706e-08
frequency O 0 3.932561654096389e-08
( O 0 5.881742870528228e-10
7 O 0 3.6770606559599628e-09
. O 0 1.4973611239810225e-10
5 O 0 2.035446922121764e-09
% O 0 4.03884981015068e-11
) O 0 5.152503076977233e-11
was O 0 2.349125560741072e-09
found O 0 3.7313824252649397e-10
in O 0 2.6421451693181552e-09
Swedes O 0 6.929038136149757e-06
. O 0 2.1742530407209415e-06

Saamis O 0 0.0002027757145697251
( O 0 8.062415446374871e-08
2 O 0 2.3523377024048386e-07
% O 0 1.0672543959699965e-09
) O 0 5.240697875663614e-10
and O 0 2.3908157675833763e-09
Mordvinians O 0 1.0751045920187607e-06
( O 0 9.144708879027519e-10
1 O 0 7.784931810306261e-09
. O 0 3.7581238121475735e-10
8 O 0 7.009663072210515e-09
% O 0 9.540507273086973e-11
) O 0 3.6943149928081453e-11
had O 0 4.341659531892361e-10
significantly O 0 2.6703648181580775e-09
lower O 0 2.7350271381010316e-08
frequencies O 0 1.0864881971883733e-07
of O 0 9.293860792070063e-09
the O 0 2.207162275169594e-08
Tyr O 0 1.3558584214479197e-05
allele O 0 1.7960252307602786e-06
. O 0 4.368231714124704e-07

Comparisons O 0 2.8823203024330724e-07
with O 0 3.756062127990845e-09
allele O 0 3.659451763837751e-08
frequencies O 0 4.006110643217653e-08
based O 0 7.791597367301506e-10
on O 0 3.7226477456187013e-09
prevalence O 0 1.8420262648533026e-08
estimates O 0 1.7858461376363266e-09
of O 0 7.676453250837767e-09
HH B-Disease 1 0.9930225014686584
showed O 0 4.425210065051033e-08
some O 0 4.799274866407188e-10
disagreements O 0 7.02590199352926e-08
with O 0 3.163734274558294e-10
the O 0 2.941039634052345e-09
RFLP O 0 1.2441370245142025e-07
data O 0 2.6097448646567045e-09
, O 0 2.1402202232678746e-10
particularly O 0 1.1432030877500665e-09
in O 0 4.2282284340444676e-09
Finns O 0 2.142392986570485e-06
. O 0 1.4698084669362288e-06

The O 0 1.107320031223935e-06
newly O 0 7.75115313444985e-06
described O 0 7.253699436660099e-07
HFE O 0 0.0001266856852453202
marker O 0 1.180059712169168e-06
provides O 0 6.056346091298792e-09
a O 0 1.0569713992936158e-09
new O 0 1.401683880075666e-09
approach O 0 1.3815987243148697e-09
to O 0 2.876116567129827e-10
the O 0 4.75417649692389e-10
screening O 0 1.6345920172966544e-09
of O 0 3.0706177600592355e-09
HH B-Disease 0 0.0012345467694103718
as O 0 1.3392907893816641e-09
well O 0 2.1742141420588723e-10
as O 0 1.26076982187584e-10
studies O 0 2.412242350313676e-10
of O 0 2.953828015517246e-10
the O 0 8.188091316085888e-10
relationship O 0 4.590696711659348e-09
between O 0 1.2943328187020597e-08
the O 0 1.8167087389997505e-08
HFE O 0 5.008193329558708e-05
Tyr O 0 1.911061190185137e-05
allele O 0 2.127966922671476e-07
and O 0 2.3420849259991883e-08
different O 0 5.890527745577856e-07
disorders O 1 0.9993509650230408
including O 0 2.3507365654040768e-07
cancer B-Disease 1 0.9496924877166748

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9855301380157471
associated O 0 4.144678769080201e-07
with O 0 4.829912025883232e-09
a O 0 4.922790708405955e-08
missense O 0 1.7155683735836647e-06
mutation O 0 1.1796699794786036e-07
encoding O 0 1.0987206451318343e-06
Gly23 O 0 6.260265945456922e-05
- O 0 2.008451883739326e-05
- O 0 6.977024440857349e-06
> O 0 2.403772214165656e-06
Val O 0 9.287765010412841e-07
in O 0 1.7379122141392145e-08
neurophysin O 0 4.336807705840329e-06
II O 0 0.0018615953158587217
. O 0 4.688418812293094e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 9.318959200754762e-06
ADNDI B-Disease 1 0.999963641166687
) O 0 1.0528211191740411e-08
is O 0 4.657059182733292e-10
an O 0 1.0111618209407425e-09
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 6.214531458681449e-05
by O 0 2.680194022275373e-08
progressive O 1 0.999996542930603
degeneration O 1 1.0
of O 0 1.29478712551645e-05
the O 0 6.578205216101196e-07
magnocellular O 0 2.3897218852653168e-05
neurons O 0 3.2220816592598567e-07
of O 0 1.6174075767594331e-07
the O 0 1.248856307256574e-07
hypothalamus O 0 1.932951505523306e-07
leading O 0 5.3092495733153555e-08
to O 0 3.622387501067692e-09
decreased O 0 1.799774551614064e-08
ability O 0 4.755721150218051e-09
to O 0 2.001644183735607e-09
produce O 0 5.7503221739807486e-08
the O 0 2.7487141096571577e-07
hormone O 0 3.4738757221930427e-06
arginine O 0 1.9167227947036736e-05
vasopressin O 0 2.615422772578313e-06
( O 0 3.3628257511963966e-08
AVP O 0 1.028522638080176e-05
) O 0 1.7039404553997883e-08
. O 0 2.0964468205875164e-07

Affected O 0 7.275467623912846e-07
individuals O 0 8.587611177723886e-10
are O 0 3.019363092882088e-10
not O 0 3.5017408417381546e-10
symptomatic O 0 3.165904871593739e-08
at O 0 1.998090048971335e-08
birth O 0 3.218974420349241e-09
, O 0 3.9017084008108327e-10
but O 0 1.0704714892284528e-09
usually O 0 5.856192331066268e-08
develop O 0 1.0166069841943681e-05
diabetes B-Disease 1 0.9991649389266968
insipidus I-Disease 0 0.05202747881412506
at O 0 0.0002293094148626551
1 O 0 9.548536036163568e-05
- O 0 2.9912964237155393e-05
6 O 0 8.067449925874826e-06
yr O 0 9.50383473536931e-05
of O 0 8.877034218812696e-08
age O 0 6.025572929502232e-07
. O 0 5.542754593079735e-07

The O 0 2.2389124865185295e-07
genetic O 0 4.0865735684292304e-08
locus O 0 1.5431321287451283e-07
of O 0 1.4356479027810565e-07
the O 0 9.02037058381211e-08
disease O 0 2.2261810954660177e-06
is O 0 2.950495847642287e-09
the O 0 5.425656723900829e-08
AVP O 0 3.998472311650403e-05
- O 0 5.4227984946919605e-06
neurophysin O 0 1.0258179827360436e-05
II O 1 0.9999686479568481
( O 0 1.1229073493268515e-07
NPII O 0 3.7578171031782404e-05
) O 0 4.951972165656571e-09
gene O 0 3.5986911228746976e-09
, O 0 8.062422951482517e-10
and O 0 1.5311000245432638e-09
mutations O 0 3.658598757283471e-09
that O 0 2.519535968747988e-10
cause O 0 3.244866064733287e-08
ADNDI B-Disease 0 1.1597760931181256e-05
have O 0 1.125279647240518e-09
been O 0 4.390065255766018e-10
found O 0 1.2074118094229647e-10
in O 0 1.2558018513963987e-10
both O 0 4.298499056698546e-10
the O 0 5.465621732980708e-09
signal O 0 1.3942725729521044e-07
peptide O 0 1.1921496678723997e-08
of O 0 4.9766978094112346e-08
the O 0 6.214354897338126e-08
prepro O 0 4.20119431510102e-05
- O 0 9.93374633253552e-05
AVP O 0 0.00017269911768380553
- O 0 1.7815895034800633e-06
NPII O 0 6.189163741510129e-06
precursor O 0 7.773465426907933e-08
and O 0 1.0558556695627885e-08
within O 0 5.699786242985283e-08
NPII O 0 1.692829027888365e-05
itself O 0 1.2821986672406638e-07
. O 0 8.564455242776603e-07

An O 0 1.3485750116615236e-07
affected O 0 4.148435550632712e-07
girl O 0 4.61868552292799e-07
who O 0 1.1093251650606817e-08
presented O 0 2.0676522183293855e-07
at O 0 2.806720544867858e-07
9 O 0 9.279658996774742e-08
months O 0 2.026058210091719e-09
of O 0 2.1757833312818775e-09
age O 0 8.0213498065973e-09
and O 0 7.653189748602074e-10
her O 0 6.046946832150013e-10
similarly O 0 6.0230420650952965e-09
affected O 0 2.9901777054419654e-08
younger O 0 3.252513351981179e-07
brother O 0 8.296792088913207e-07
and O 0 9.592172389716325e-09
father O 0 5.3215678974538605e-08
were O 0 6.2133098666095066e-09
all O 0 1.9066835610370703e-10
found O 0 6.330341112414928e-11
to O 0 1.6927984014536435e-10
have O 0 2.8652696881792394e-10
a O 0 2.6394251229078236e-09
novel O 0 7.45129753454421e-08
missense O 0 3.886241302097915e-06
mutation O 0 1.4634443346039916e-07
( O 0 3.13407362284579e-08
G1758 O 0 9.194533845402475e-07
- O 0 1.442342295376875e-06
- O 0 7.138918931559601e-07
> O 0 2.390628424109309e-07
T O 0 9.328779526640574e-08
) O 0 4.1696029962068337e-10
encoding O 0 2.9966049641672043e-09
the O 0 3.44616490899341e-09
amino O 0 2.951959343633348e-09
acid O 0 1.1574688985049875e-09
substitution O 0 1.1797088639298181e-08
Gly23 O 0 2.8118320187786594e-06
- O 0 1.618201963538013e-06
- O 0 1.001842065306846e-06
> O 0 1.2377751090753009e-06
Val O 0 1.8126179384125862e-06
within O 0 3.395678334072727e-07
NPII O 0 0.00010142719838768244
. O 0 1.6890674032765673e-06

The O 0 2.826905642905331e-07
mutation O 0 4.3494381429809437e-08
was O 0 1.6207033937121196e-08
confirmed O 0 3.3806317745188608e-09
by O 0 2.6693652843690074e-10
restriction O 0 1.0640760272906391e-08
endonuclease O 0 2.459396228005062e-06
analysis O 0 5.062402692601609e-07
. O 0 8.365502139895398e-07

A O 0 6.111634138505906e-05
T1 O 0 0.0003075588901992887
- O 0 1.1967809996349388e-06
weighted O 0 7.763863152376871e-08
magnetic O 0 1.3763974493485875e-07
resonance O 0 7.763655673898029e-08
imaging O 0 7.619673283443262e-07
of O 0 4.334217251766859e-08
the O 0 1.5843356493405736e-07
fathers O 0 1.4820675460214261e-05
pituitary O 0 6.342273991322145e-05
gland O 0 4.744163106806809e-06
demonstrates O 0 1.5384462415113376e-07
an O 0 2.3510587254804705e-08
attenuated O 0 1.7184556782012805e-05
posterior O 0 0.0028703981079161167
pituitary O 1 0.9998499155044556
bright O 1 0.9999306201934814
spot O 0 0.3572019934654236
. O 0 1.507552860857686e-05

This O 0 1.1267346877730233e-07
mutation O 0 9.144716983655599e-08
may O 0 2.7031838101265748e-08
be O 0 3.1761244745354134e-09
valuable O 0 1.9067872614186854e-08
for O 0 3.323409880628958e-10
developing O 0 5.326509899816756e-09
models O 0 5.077817277765462e-08
of O 0 4.0301912918039307e-08
dominantly B-Disease 0 0.013238497078418732
inherited I-Disease 1 0.9999932050704956
neurodegeneration I-Disease 1 1.0
, O 0 2.6668425245901517e-09
as O 0 2.332266602067534e-10
the O 0 9.441396969789295e-11
early O 0 1.06773290209361e-09
age O 0 1.8240757793108742e-09
of O 0 3.344357679679888e-09
onset O 0 1.6223932107095607e-05
of O 0 6.343778977679904e-07
symptoms O 0 1.848322972364258e-05
suggests O 0 6.047757850069502e-09
that O 0 2.0304440073726227e-10
this O 0 3.550351401759855e-10
mutation O 0 2.1446755482656954e-09
may O 0 2.441739699321488e-09
be O 0 1.966871554515137e-09
particularly O 0 4.109176110489443e-09
deleterious O 0 5.201318913350406e-07
to O 0 1.3496720185912636e-08
the O 0 7.712413463423218e-08
magnocellular O 0 5.968614004814299e-06
neuron O 0 7.049815735626908e-07
. O 0 3.102793755260791e-08
. O 0 2.3826281392302917e-07

Frequent O 0 3.875851689372212e-06
inactivation O 0 8.861105743562803e-05
of O 0 3.5579865652834997e-05
PTEN O 1 0.998615026473999
/ O 1 0.887252688407898
MMAC1 O 1 0.6296831965446472
in O 0 4.80570179206552e-07
primary O 1 0.9999755620956421
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.0673963162116706e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 7.730165521024901e-07
the O 0 1.2740885679818348e-08
most O 0 3.9656014583222543e-10
common O 0 4.285256149927363e-09
male B-Disease 0 1.6449411832653027e-09
cancer I-Disease 0 1.145722183792941e-09
in O 0 4.282688370604859e-10
the O 0 3.3962006540377843e-09
Western O 0 2.04162319050738e-07
world O 0 3.0203164413933337e-08
, O 0 1.8094242770771984e-10
yet O 0 2.993084669000723e-10
many O 0 1.3670023446543667e-11
of O 0 1.155555789944529e-10
the O 0 1.445785852149939e-10
major O 0 1.7774017813110277e-09
genetic O 0 5.387879475904356e-09
events O 0 9.373576359550384e-10
involved O 0 5.579332551519656e-10
in O 0 2.074451860289983e-10
the O 0 1.6353529641577325e-09
progression O 0 9.123758104578883e-08
of O 0 1.98644709570317e-08
this O 0 4.988260471350259e-09
often O 0 2.2388995546407386e-07
fatal O 0 0.2747704088687897
cancer B-Disease 0 2.5463998099439777e-05
remain O 0 9.186225042867591e-07
to O 0 2.4985967073121174e-08
be O 0 1.896881229868086e-07
elucidated O 0 0.00020693465194199234
. O 0 2.438612455080147e-06

Numerous O 0 8.065335350693204e-07
cytogenetic O 0 6.246597331482917e-05
and O 0 1.125610253893683e-07
allelotype O 0 9.137904271483421e-06
studies O 0 3.56386991029467e-08
have O 0 2.206774096791264e-09
reported O 0 3.849456309268362e-09
frequent O 0 3.7883021164475394e-09
loss O 0 1.2244653646575898e-07
of O 0 9.940523568729986e-07
heterozygosity O 1 0.8082534670829773
on O 0 0.00030369465821422637
chromosomal O 0 0.0006027037743479013
arm O 0 4.0285056456923485e-05
10q O 0 2.6521054678596556e-05
in O 0 5.323019536263018e-07
sporadic B-Disease 1 0.9999997615814209
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0008445103885605931

Deletion O 0 1.4911665857653134e-05
mapping O 0 4.6593868319178e-07
studies O 0 2.02992698206117e-08
have O 0 1.765818269383601e-09
unambiguously O 0 5.1749072582651934e-08
identified O 0 1.7823998277322062e-08
a O 0 3.016400240696271e-09
region O 0 1.9315688604137904e-08
of O 0 1.4044040597127605e-07
chromosome O 0 8.225400449646258e-08
10q23 O 0 1.4498043299226993e-07
to O 0 6.1904875670038e-10
be O 0 5.903997291056839e-10
the O 0 1.2158590800837032e-09
minimal O 0 4.5350184052495024e-08
area O 0 7.875600616102929e-09
of O 0 2.0718518456419588e-08
loss O 0 1.2019235100524384e-06
. O 0 1.3869548638467677e-06

A O 0 4.1876717205013847e-07
new O 0 4.181601553909786e-08
tumor B-Disease 0 1.5452128820925282e-07
suppressor O 0 2.542295192142774e-07
gene O 0 1.608925614959844e-08
, O 0 1.6092263521727546e-08
PTEN O 0 1.8267359337187372e-05
/ O 0 9.083073564397637e-06
MMAC1 O 0 9.818971011554822e-05
, O 0 7.370807963980042e-09
was O 0 3.939100068350854e-08
isolated O 0 8.937647955065131e-09
recently O 0 4.506509387880442e-09
at O 0 1.1695954427182187e-08
this O 0 1.4207751641848176e-10
region O 0 1.66106162158286e-09
of O 0 1.9818905627744243e-08
chromosome O 0 6.937402474704868e-08
10q23 O 0 2.974359745167021e-07
and O 0 2.7137108116193076e-09
found O 0 5.563477456504984e-10
to O 0 1.338763960800904e-10
be O 0 2.406631005591464e-10
inactivated O 0 8.618103564117519e-09
by O 0 2.7508137434573143e-10
mutation O 0 9.454778293616073e-09
in O 0 1.5479379555927153e-08
three O 0 2.5557144454069203e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.0001734081597533077
lines O 0 4.7188490270855254e-07
. O 0 8.062689857979422e-07

We O 0 1.2479066526793758e-06
screened O 0 1.2240104751981562e-06
80 O 0 8.988337185655837e-07
prostate B-Disease 0 0.00046009119250811636
tumors I-Disease 1 0.9999998807907104
by O 0 2.75081490919149e-09
microsatellite O 0 8.955449715131181e-08
analysis O 0 4.806367748244611e-09
and O 0 2.6044439938033292e-09
found O 0 5.562207139320208e-09
chromosome O 0 4.393822194970198e-08
10q23 O 0 2.2581880898542295e-07
to O 0 3.948922966401369e-09
be O 0 4.706576905988413e-09
deleted O 0 3.049921559750146e-08
in O 0 2.9735403028752216e-09
23 O 0 9.073413309579337e-08
cases O 0 2.431192136498339e-08
. O 0 2.4326399739038607e-07

We O 0 7.967800996766528e-08
then O 0 3.6046128304434433e-09
proceeded O 0 5.315397011429468e-09
with O 0 3.099329126676764e-11
sequence O 0 1.9992546507197062e-10
analysis O 0 3.494988187746628e-10
of O 0 6.620239911825365e-10
the O 0 2.3640618351805642e-09
entire O 0 2.5860126129373384e-07
PTEN O 0 5.225077620707452e-05
/ O 0 1.7480706446804106e-05
MMAC1 O 0 5.7563811424188316e-05
coding O 0 1.5868320133449743e-06
region O 0 2.316154734671727e-08
and O 0 3.6848608608863742e-09
tested O 0 6.323276569020209e-09
for O 0 9.966022451735057e-10
homozygous O 0 1.415853123631905e-08
deletion O 0 2.077383598475535e-08
with O 0 3.453348162985037e-10
new O 0 9.13488129583584e-09
intragenic O 0 3.300061166555679e-07
markers O 0 7.754358932743344e-09
in O 0 4.428794275757042e-10
these O 0 3.025658612543225e-10
23 O 0 6.491824855459072e-09
cases O 0 4.701720124344888e-10
with O 0 3.797103742542163e-10
10q23 O 0 6.631189535255544e-07
loss O 0 1.7697357179713435e-06
of O 0 3.849569111480378e-06
heterozygosity O 0 0.0038118476513773203
. O 0 1.7854532416095026e-05

The O 0 3.1530749566854865e-08
identification O 0 1.6701898530868675e-08
of O 0 2.129740650502754e-08
the O 0 1.4098975320564477e-08
second O 0 4.806865305795327e-08
mutational O 0 9.178842219625949e-07
event O 0 5.0462066525369664e-08
in O 0 8.631197090380738e-09
10 O 0 6.909908023544631e-08
( O 0 4.769264982940058e-09
43 O 0 7.611330232748514e-08
% O 0 1.9955802343929463e-08
) O 0 2.1819958817559382e-07
tumors B-Disease 1 1.0
establishes O 0 0.0007710716454312205
PTEN O 1 0.8572974801063538
/ O 0 0.0001154334531747736
MMAC1 O 0 4.0474704292137176e-05
as O 0 4.6773132034161335e-09
a O 0 1.1017041723349053e-09
main O 0 4.927936281262646e-09
inactivation O 0 3.232745982018059e-08
target O 0 6.341538405507663e-09
of O 0 8.236401782824032e-09
10q O 0 1.0933845260296948e-06
loss O 0 1.040675442709471e-06
in O 0 1.0274624173689517e-07
sporadic B-Disease 1 0.9999983310699463
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.198442638880806e-06
. O 0 4.682042344938964e-06

Risk O 0 8.654197699797805e-06
reversals O 0 4.701806574303191e-06
in O 0 1.4961578642669338e-08
predictive O 0 1.1931969083889271e-06
testing O 0 1.3701125567422423e-07
for O 0 1.0564563979187369e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.1230331438127905e-05

The O 0 3.138237616440165e-07
first O 0 2.9153889968824842e-08
predictive O 0 5.926494281993655e-07
testing O 0 1.1969872559802752e-07
for O 0 1.5407704268000089e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.349188227806053e-08
HD B-Disease 0 7.5615771493176e-06
) O 0 6.330417301469993e-10
was O 0 1.1154328571905126e-09
based O 0 6.479917297186333e-11
on O 0 9.310108239901638e-10
analysis O 0 1.6906342992228929e-09
of O 0 1.3469119153342035e-09
linked O 0 1.4431891237620675e-08
polymorphic O 0 2.2648064756936037e-08
DNA O 0 5.723379548072671e-09
markers O 0 2.368019558218748e-09
to O 0 4.524938757022312e-10
estimate O 0 2.2336343885598353e-09
the O 0 5.696802474197682e-10
likelihood O 0 1.7825358966661042e-08
of O 0 3.905926959646422e-08
inheriting O 0 4.461942921807349e-07
the O 0 2.6128791574819843e-08
mutation O 0 1.1887211215366733e-08
for O 0 1.664436766191102e-08
HD B-Disease 0 0.0002620418672449887
. O 0 3.221173756173812e-06

Limits O 0 1.1941664013193076e-07
to O 0 2.9185807104425976e-09
accuracy O 0 7.137333568607573e-08
included O 0 2.657834174968343e-09
recombination O 0 2.432007040198414e-09
between O 0 2.3211286226398897e-09
the O 0 1.0179890264083724e-09
DNA O 0 1.5639748385254393e-09
markers O 0 1.5085417359728126e-09
and O 0 3.4851097008292697e-10
the O 0 1.083428680104248e-09
mutation O 0 1.744626776378766e-09
, O 0 4.415846577288107e-10
pedigree O 0 5.408069103651769e-09
structure O 0 1.968640184202286e-08
, O 0 2.9874383522532355e-10
and O 0 1.3106830898390598e-10
whether O 0 1.9522418404083197e-10
DNA O 0 4.4375117469463987e-10
samples O 0 8.234618542601879e-11
were O 0 1.1166265828643773e-10
available O 0 2.6735744174111176e-10
from O 0 3.486559096987918e-10
family O 0 2.189329162405329e-09
members O 0 8.514191129904702e-09
. O 0 3.7615131986967754e-07

With O 0 8.469067225291838e-09
direct O 0 8.115129901398177e-09
tests O 0 4.9580681782401825e-09
for O 0 3.3762156959049605e-10
the O 0 1.833123097760847e-09
HD B-Disease 0 5.955582309979945e-06
mutation O 0 1.9731916101051183e-09
, O 0 8.871350876127337e-11
we O 0 7.554536163301151e-11
have O 0 1.557245998817791e-11
assessed O 0 1.3021419498215892e-09
the O 0 6.351288939221433e-11
accuracy O 0 3.806953863261242e-09
of O 0 8.753998081978409e-10
results O 0 2.8143574137828864e-09
obtained O 0 1.5002319386780982e-09
by O 0 7.677207480849546e-11
linkage O 0 2.9787685651427864e-09
approaches O 0 3.5379419394132583e-09
when O 0 4.4384007580333673e-10
requested O 0 2.981831170867366e-10
to O 0 1.306208335938308e-10
do O 0 1.0386844162546538e-10
so O 0 4.527060323833432e-11
by O 0 3.490496433555812e-11
the O 0 3.251547919802533e-10
test O 0 8.282544428084293e-09
individuals O 0 1.4619475630084366e-09
. O 0 9.274350531995879e-08

For O 0 1.227553241278656e-07
six O 0 6.765407789544042e-09
such O 0 9.470506323605576e-11
individuals O 0 9.595419597774324e-11
, O 0 8.453904937200107e-11
there O 0 9.32263155561941e-11
was O 0 1.070173394346341e-09
significant O 0 1.22219967479964e-09
disparity O 0 2.236884100170755e-08
between O 0 1.1480436157285112e-08
the O 0 1.6017086323927288e-08
tests O 0 5.5372392893104916e-08
. O 0 2.45888685412865e-07

Three O 0 1.6285564186091506e-07
went O 0 1.2291381779050425e-07
from O 0 1.4712485674195364e-09
a O 0 2.1396051597122323e-09
decreased O 0 1.5275800180347687e-08
risk O 0 1.0194676214325682e-09
to O 0 1.4626050370836197e-10
an O 0 4.054023436395049e-11
increased O 0 6.113875516966516e-10
risk O 0 2.311863367410183e-09
, O 0 1.4944508130998457e-10
while O 0 2.9113406130321096e-10
in O 0 1.1595276822040645e-10
another O 0 2.491313266794748e-10
three O 0 7.514742994541024e-11
the O 0 3.380513924344797e-10
risk O 0 4.503192485572072e-09
was O 0 2.9086406172496027e-08
decreased O 0 3.030565665085305e-07
. O 0 2.4509805029993004e-07

Knowledge O 0 1.2813433158953558e-06
of O 0 3.46329223077646e-08
the O 0 7.178517225092662e-10
potential O 0 4.985813428781682e-10
reasons O 0 5.563806637631785e-10
for O 0 4.75978145786371e-11
these O 0 5.5671266208090486e-11
changes O 0 1.4094181377544146e-09
in O 0 5.153409921021535e-10
results O 0 9.72866853743426e-09
and O 0 6.440515343264508e-10
impact O 0 1.1210749661927366e-08
of O 0 1.8323644823681207e-09
these O 0 2.325780679157674e-10
risk O 0 1.3873449056234222e-09
reversals O 0 8.621293012822662e-09
on O 0 5.77646019905842e-09
both O 0 4.2724407345318127e-10
patients O 0 1.9724832878154075e-10
and O 0 2.5121080216017333e-10
the O 0 2.0294692593125774e-09
counseling O 0 1.3316897584658705e-09
team O 0 9.35667876511559e-10
can O 0 1.339359179119981e-10
assist O 0 8.407821661116088e-10
in O 0 2.336732474184089e-10
the O 0 2.2928354770357373e-09
development O 0 1.6241104461300893e-08
of O 0 5.511116452083797e-09
strategies O 0 1.90041156145071e-08
for O 0 3.1957383961334074e-10
the O 0 1.1900589402813466e-09
prevention O 0 7.192801909639002e-09
and O 0 1.179338710022293e-10
, O 0 1.5205757486480564e-10
where O 0 4.4491652029243767e-10
necessary O 0 1.7231776894277573e-08
, O 0 1.6322430074211525e-09
management O 0 1.8883289598647934e-08
of O 0 1.8737116302958157e-09
a O 0 1.444135699912863e-09
risk O 0 6.060101753746494e-09
reversal O 0 4.006554021884767e-08
in O 0 1.0673439909680837e-09
any O 0 1.8810450974626747e-09
predictive O 0 6.596989265972297e-08
testing O 0 1.1677720124225743e-08
program O 0 2.020720701878531e-09
. O 0 3.42045525236756e-09
. O 0 6.383261563769338e-08

A O 0 4.251043037584168e-07
novel O 0 1.6165702731996134e-07
common O 0 1.3806557319639978e-07
missense O 0 1.8329582189835492e-06
mutation O 0 6.08502901400243e-08
G301C O 0 5.163317950973578e-07
in O 0 6.839530719560116e-09
the O 0 1.8646570509872618e-08
N O 0 7.786892979311233e-07
- O 0 2.9555900482591824e-07
acetylgalactosamine O 0 1.708172817416198e-06
- O 0 5.830902978232189e-07
6 O 0 1.5694582771175192e-06
- O 0 1.5573499467791407e-07
sulfate O 0 1.8460507078543742e-07
sulfatase O 0 6.057508016965585e-06
gene O 0 1.0920433446415245e-08
in O 0 2.121316278191898e-08
mucopolysaccharidosis B-Disease 0 4.195708970655687e-05
IVA I-Disease 0 0.12906813621520996
. O 0 1.1478068699943833e-05

Mucopolysaccharidosis B-Disease 1 0.9918417930603027
IVA I-Disease 1 1.0
( O 0 0.00037163900560699403
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.4486070060447673e-07
is O 0 4.839871614592539e-09
an O 0 1.0615886836262689e-08
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 0.9999998807907104
lysosomal I-Disease 1 0.9999998807907104
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 7.044700851110974e-06
by O 0 2.363179518738434e-08
a O 0 1.2247601262060925e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 7.795224519213662e-06
N O 0 0.0013250198680907488
- O 0 0.0029736889991909266
acetylgalactosamine O 0 0.002595034195110202
- O 0 0.0005271017435006797
6 O 0 0.0002531617064960301
- O 0 4.413217538967729e-06
sulfate O 0 1.715756525300094e-06
sulfatase O 0 5.361348303267732e-05
( O 0 6.677640662644535e-09
GALNS O 0 4.161974175076466e-06
) O 0 8.630144598953393e-09
. O 0 1.3903819251481764e-07

In O 0 1.1658807608228017e-07
previous O 0 4.167587164261022e-08
studies O 0 8.046480814982715e-09
, O 0 2.1626334056890073e-10
we O 0 1.401354310370806e-10
have O 0 2.245772838527227e-11
found O 0 6.657883966365574e-11
two O 0 5.250219703434311e-11
common O 0 3.601374198858309e-10
mutations O 0 1.5885310844510059e-09
in O 0 1.2746325106505196e-09
Caucasians O 0 3.3428541712510196e-08
and O 0 5.976421579845237e-09
Japanese O 0 2.1603150912596902e-07
, O 0 2.8063237067499358e-08
respectively O 0 4.788760179508245e-07
. O 0 1.1289142776149674e-06

To O 0 1.4293691208422388e-07
characterize O 0 5.693945013263146e-07
the O 0 2.1925732340832838e-08
mutational O 0 5.804886313853785e-07
spectrum O 0 2.703802692849422e-08
in O 0 2.0550326718105083e-10
various O 0 1.3351073024914228e-10
ethnic O 0 6.742625208167041e-11
groups O 0 3.61773701273993e-11
, O 0 5.077596676450469e-11
mutations O 0 2.3564705742273873e-10
in O 0 1.842597324719364e-10
the O 0 1.4349457178042258e-09
GALNS O 0 6.365607987390831e-07
gene O 0 2.366452811486397e-09
in O 0 4.211005322218853e-09
Colombian O 0 1.5946950497891521e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.4496066569336108e-07
were O 0 2.0691190982802254e-08
investigated O 0 2.1663373672708985e-07
, O 0 1.0265212013749192e-09
and O 0 2.4272430731997474e-09
genetic O 0 1.9094112957418474e-08
backgrounds O 0 7.173171923113841e-08
were O 0 1.180260245092768e-08
extensively O 0 3.5317393454192825e-09
analyzed O 0 2.587455805169725e-09
to O 0 1.1791564946683764e-10
identify O 0 1.3227082762412579e-09
racial O 0 2.3793611525491087e-09
origin O 0 9.459643068865375e-10
, O 0 2.1126489446743335e-10
based O 0 6.920849449087996e-10
on O 0 2.2354086581799493e-08
mitochondrial O 0 3.7161868249313557e-08
DNA O 0 3.14784074362251e-08
( O 0 2.9567153170262372e-09
mtDNA O 0 1.4227889089113432e-08
) O 0 1.2735298149380014e-08
lineages O 0 3.491774123176583e-07
. O 0 9.604136721463874e-07

Three O 0 1.5899163940957806e-07
novel O 0 2.8406395813362906e-07
missense O 0 3.7574220641545253e-06
mutations O 0 8.97781902153838e-08
never O 0 7.6147713912178e-08
identified O 0 3.1211765616490084e-08
previously O 0 6.739893088081317e-09
in O 0 3.560544081793182e-10
other O 0 1.0812337136734129e-10
populations O 0 4.180957316468614e-11
and O 0 7.345300062633342e-11
found O 0 2.318760183861457e-10
in O 0 3.728053143969845e-10
16 O 0 1.0291447694044109e-08
out O 0 5.037643080463283e-10
of O 0 7.390008605057119e-09
19 O 0 3.923844928976905e-07
Colombian O 0 4.909260042040842e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
unrelated O 0 4.764789309774642e-07
alleles O 0 1.179857367361592e-08
account O 0 9.081664309462667e-10
for O 0 2.95087287938145e-09
84 O 0 3.1297881264436e-07
. O 0 8.474102628497349e-07

2 O 0 1.1364746796971303e-06
% O 0 2.1635009339604494e-09
of O 0 4.527496599848746e-09
the O 0 2.145023270117008e-09
alleles O 0 4.326195401915811e-09
in O 0 7.596094864226188e-10
this O 0 5.659934743107442e-10
study O 0 5.133164560078285e-09
. O 0 7.709942195788244e-08

The O 0 3.6280667359278596e-07
G301C O 0 1.0957070344375097e-06
and O 0 1.1874021765834186e-08
S162F O 0 2.3515279679031664e-07
mutations O 0 1.056192022730329e-08
account O 0 9.642538989496074e-10
for O 0 1.35716271554287e-09
68 O 0 3.09454065927639e-07
. O 0 6.348596457428357e-07

4 O 0 4.071534021932166e-06
% O 0 1.6821884329942804e-08
and O 0 1.3748593374884877e-08
10 O 0 1.0099117986328565e-07
. O 0 3.5981307178190036e-07

5 O 0 7.864044277994253e-07
% O 0 4.875180703578508e-09
of O 0 7.852142935860229e-09
mutations O 0 7.592057649219441e-09
, O 0 1.4198927589248456e-09
respectively O 0 8.723117339570763e-09
, O 0 5.348507747804376e-10
whereas O 0 1.7097799842602512e-09
the O 0 3.7104974648372036e-09
remaining O 0 8.36536031556534e-08
F69V O 0 3.8489524740725756e-06
is O 0 2.6891422422181677e-10
limited O 0 6.049623024750872e-10
to O 0 6.114808104307201e-10
a O 0 3.0435913789261804e-09
single O 0 2.2400692856194837e-08
allele O 0 1.5046508679006365e-06
. O 0 1.5422582464452717e-06

The O 0 5.112208896207449e-07
skewed O 0 3.870818261475506e-07
prevalence O 0 1.267355997924824e-07
of O 0 1.1110403264069646e-08
G301C O 0 5.622304044550219e-08
in O 0 6.674581998211693e-10
only O 0 6.088854975772051e-10
Colombian O 0 1.7158050980015105e-08
patients O 0 3.557034666812342e-10
and O 0 4.482008097994594e-10
haplotype O 0 5.181521878228068e-09
analysis O 0 4.342752824015861e-10
by O 0 5.234301880818748e-11
restriction O 0 3.247054569666119e-10
fragment O 0 9.86055948004605e-09
length O 0 2.033258672540228e-09
polymorphisms O 0 2.0220045637842077e-09
in O 0 6.89502455131219e-10
the O 0 4.135066067334492e-09
GALNS O 0 1.7359628827762208e-06
gene O 0 1.4073471277242788e-09
suggest O 0 1.2817047423396843e-09
that O 0 1.1207830497017568e-10
G301C O 0 1.9230331105291043e-08
originated O 0 9.26688004110332e-10
from O 0 2.613624316971652e-10
a O 0 8.637517368015324e-10
common O 0 8.298087550429045e-09
ancestor O 0 1.9778676119130978e-07
. O 0 7.609804129060649e-07

Investigation O 0 1.982723915716633e-06
of O 0 6.199793034511458e-08
the O 0 2.7945445957300308e-09
genetic O 0 1.772803903676845e-09
background O 0 5.552833748367902e-10
by O 0 7.001598606448667e-11
means O 0 2.603058435468597e-09
of O 0 1.1538765498642078e-08
mtDNA O 0 7.534153745325511e-09
lineages O 0 4.398238662162157e-09
indicate O 0 1.2655697601005045e-09
that O 0 1.0485194656961738e-10
all O 0 3.304623796829276e-10
our O 0 5.079323073253761e-10
patients O 0 1.6901232149924006e-11
are O 0 6.385441654599422e-12
probably O 0 2.392666897943485e-10
of O 0 1.1925401777190814e-09
native O 0 3.4902469803199665e-09
American O 0 9.852328730630688e-08
descent O 0 3.5163644497515634e-05

Low O 0 3.424793021622463e-06
frequency O 0 8.43619602619583e-07
of O 0 1.9853644062095555e-07
BRCA1 O 0 4.601328384978842e-07
germline O 0 2.0249790395610034e-06
mutations O 0 8.590368416605543e-09
in O 0 1.794296600188261e-09
45 O 0 4.017665489186584e-08
German O 1 0.9999998807907104
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.858821065070515e-06
. O 0 4.350722520030104e-06

In O 0 5.9362868398693536e-08
this O 0 1.4946568427376405e-09
study O 0 1.0867691191407403e-09
we O 0 1.2552421324585339e-09
investigated O 0 4.13365661700027e-08
45 O 0 1.6268078439907185e-08
German O 1 0.9996607303619385
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.118194116946142e-09
for O 0 5.307687622746471e-09
germline O 0 3.6919828971804236e-07
mutations O 0 4.998346625484373e-09
in O 0 2.735839998990741e-09
the O 0 2.583709424186509e-08
BRCA1 O 0 2.179373552735342e-07
gene O 0 2.30784706900522e-07
. O 0 1.5948882037264411e-06

We O 0 2.7514050771060283e-07
identified O 0 1.3413908561688004e-07
four O 0 2.997189696429814e-08
germline O 0 1.833505507420341e-06
mutations O 0 4.6968761324706065e-08
in O 0 1.0112452208943523e-08
three O 0 5.5143686950032134e-08
breast B-Disease 0 1.1530732990649994e-06
cancer I-Disease 0 1.1320053090457805e-06
families O 0 2.9142532831372137e-09
and O 0 2.2103684216290276e-08
in O 0 5.125228312863328e-07
one O 1 0.9998327493667603
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 8.502933269483037e-06
. O 0 3.997041808645463e-09
among O 0 2.262049991763604e-10
these O 0 1.3124493158933603e-10
were O 0 1.6678968206562672e-09
one O 0 2.051814274039998e-09
frameshift O 0 7.317838139897503e-07
mutation O 0 2.4975388868142545e-08
, O 0 6.156085419206647e-09
one O 0 9.312137727590653e-09
nonsense O 0 2.9263927103784226e-07
mutation O 0 1.15187983595888e-08
, O 0 8.015274555184249e-10
one O 0 5.740475317317362e-10
novel O 0 4.348871929238385e-09
splice O 0 2.03749962679467e-07
site O 0 1.7982717537279314e-08
mutation O 0 6.894410375934967e-09
, O 0 1.6737703445457441e-09
and O 0 4.1050398635889e-09
one O 0 1.55291193237872e-08
missense O 0 3.755802936211694e-06
mutation O 0 1.6537275087102898e-06
. O 0 7.727364391030278e-06

The O 0 4.128528132696374e-07
missense O 0 4.556895873975009e-06
mutation O 0 5.6245777813046516e-08
was O 0 6.773906591206469e-08
also O 0 2.6381368201100486e-09
found O 0 2.351097982966621e-09
in O 0 7.613142116724703e-09
2 O 0 2.98332997772377e-06
. O 0 1.8765382492347271e-06

8 O 0 2.109801698679803e-06
% O 0 3.8743608321567535e-09
of O 0 5.813088232997643e-09
the O 0 3.423216154985198e-09
general O 0 6.60420118592242e-09
population O 0 2.528947364022205e-11
, O 0 1.1291684948178116e-10
suggesting O 0 7.370972721076896e-10
that O 0 5.361373844881001e-11
it O 0 9.719867272162119e-11
is O 0 1.1176280734215283e-10
not O 0 1.0480981638139042e-09
disease O 0 1.403327729576631e-07
associated O 0 9.799703093449352e-08
. O 0 1.052556967806595e-06

The O 0 1.4478906962267502e-07
average O 0 1.5381550255710863e-08
age O 0 1.5867755109866266e-08
of O 0 1.0697434049689036e-08
disease O 0 5.121358981341473e-07
onset O 0 2.550459612393752e-07
in O 0 7.164168702722407e-10
those O 0 4.999240466041499e-10
families O 0 5.591733187593206e-10
harbouring O 0 1.194543415294902e-07
causative O 0 4.690000920959392e-08
mutations O 0 2.6305912115276442e-08
was O 0 9.478796414441604e-08
between O 0 2.1414847140022175e-07
32 O 0 2.8718877729261294e-06
. O 0 1.4677228818982258e-06

3 O 0 1.2888565834145993e-05
and O 0 4.737471783755609e-07
37 O 0 3.3293345040874556e-06
. O 0 1.5936050203890773e-06

4 O 0 3.1990828119887738e-06
years O 0 2.5724782304337168e-08
, O 0 7.100069976395673e-10
whereas O 0 9.921831134462877e-10
the O 0 8.540633200659897e-10
family O 0 7.643400912193954e-10
harbouring O 0 8.18530381252458e-08
the O 0 7.0188272971449805e-09
missense O 0 6.44482213374431e-07
mutation O 0 1.4436323247934979e-08
had O 0 5.806838121458213e-09
an O 0 2.0669081723934113e-10
average O 0 8.536105156053964e-10
age O 0 1.1808389821510445e-08
of O 0 6.658984830210102e-08
onset O 0 0.007876657880842686
of O 0 0.0001699477288639173
51 O 0 1.3486317584465723e-05
. O 0 7.901731805759482e-06

2 O 0 2.489727921783924e-05
years O 0 9.908249012369197e-07
. O 0 1.6683358126101666e-06

These O 0 2.9809243073941616e-08
findings O 0 3.8260715484739194e-08
show O 0 3.646233315279801e-09
that O 0 3.9223174708169495e-10
BRCA1 O 0 2.4449846591778623e-08
is O 0 1.1073523209503833e-09
implicated O 0 1.3040415858256438e-08
in O 0 5.980512196579468e-10
a O 0 4.128499764277649e-10
small O 0 7.164742688026138e-10
fraction O 0 7.258831313805558e-09
of O 0 0.01648310199379921
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.3734878951131577e-08
suggesting O 0 6.210442382581505e-09
the O 0 1.2849750152810202e-09
involvement O 0 3.917773661044066e-09
of O 0 7.159391302025142e-09
another O 0 2.344608951432292e-09
susceptibility O 0 1.3201412230046117e-07
gene O 0 1.4941252857170184e-07
( O 0 1.847908919216934e-07
s O 0 2.301339918631129e-05
) O 0 6.29088026471436e-06

Paternal O 0 9.103838965529576e-05
transmission O 1 0.9999983310699463
of O 1 0.9999997615814209
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999641180038452

We O 0 1.3057335763733136e-06
report O 0 1.3940192999939427e-08
a O 0 5.770422473183601e-10
rare O 0 1.1092018414871063e-09
case O 0 3.435801643192349e-09
of O 0 4.263067765464257e-08
paternally O 1 0.9999998807907104
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9970656037330627
DM B-Disease 1 1.0
) O 0 1.7981797384436504e-07
. O 0 5.485137535288231e-07

The O 0 5.350901233214245e-07
proband O 0 1.5166375305852853e-05
is O 0 1.6502615940439114e-09
a O 0 1.0561290730848327e-09
23 O 0 1.2469718591034962e-08
year O 0 1.2933030202333384e-09
old O 0 1.8038009557130863e-06
, O 0 2.2890270656716893e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 6.581018624274293e-06
who O 0 4.0156129443857935e-07
suffers O 1 0.9994860887527466
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9999997615814209

He O 0 9.726943517307518e-07
presented O 0 2.0798674995603506e-06
with O 0 7.247545852351323e-08
respiratory O 1 0.9903760552406311
and O 0 2.472548885634751e-07
feeding O 0 5.250568619885598e-07
difficulties O 0 9.89056752587203e-06
at O 0 5.0422895583324134e-06
birth O 0 5.301225201037596e-07
. O 0 1.3747566072197515e-06

His O 0 3.373298568476457e-06
two O 0 5.667404820997035e-07
sibs O 0 0.0016951048746705055
suffer O 0 2.2723238544131164e-06
from O 0 1.6465467922444077e-07
childhood O 0 0.10978589951992035
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.0001527317799627781

Their O 0 1.1138202893334892e-07
late O 0 1.7245641856789007e-06
father O 0 6.882233805072246e-08
had O 0 5.843079353695657e-09
the O 0 1.2598425636056731e-09
adult O 0 1.904314927969608e-09
type O 0 1.6716940720584716e-08
of O 0 5.894860919397615e-07
DM B-Disease 1 1.0
, O 0 3.699087613995289e-08
with O 0 3.656422276065996e-09
onset O 0 4.032714423374273e-05
around O 0 1.4748062326930267e-08
30 O 0 1.9633155545761838e-08
years O 0 1.954825989969322e-08
. O 0 9.942829848341717e-08

Only O 0 1.5856743473818824e-08
six O 0 3.911166057690707e-09
other O 0 2.042226977805317e-11
cases O 0 5.222803092785888e-11
of O 0 4.657529917295733e-10
paternal O 0 6.815091069256596e-08
transmission O 1 0.999946117401123
of O 1 0.9999984502792358
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 4.312131932238117e-05
been O 0 7.434460513877639e-08
reported O 0 7.641047261586209e-08
recently O 0 2.589368932603975e-07
. O 0 8.750181450523087e-07

We O 0 1.9928478423025808e-07
review O 0 5.568621830320808e-08
the O 0 1.3000920340289213e-09
sex O 0 1.656796366766855e-09
related O 0 1.5734116232124506e-09
effects O 0 2.897041007088319e-08
on O 0 1.2494793111272884e-07
transmission O 1 0.9387226700782776
of O 1 0.8773801326751709
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.030757803469896317

Decreased O 0 2.0872212189715356e-06
fertility O 0 5.751451936930607e-08
of O 0 4.1627394864462985e-09
males O 0 2.3479833632933378e-09
with O 0 4.0987313543183745e-10
adult O 0 1.5552691934317409e-07
onset O 1 0.9761030077934265
DM B-Disease 1 1.0
and O 0 1.4389458158348134e-07
contraction O 0 5.869701169558539e-08
of O 0 3.780153079446791e-09
the O 0 9.873389883452433e-10
repeat O 0 3.498965339687743e-09
upon O 0 3.5373548534778365e-09
male O 0 2.1973658448359856e-09
transmission O 0 3.892701272434351e-09
contribute O 0 1.8319268324518134e-10
to O 0 1.4720225038900026e-10
the O 0 6.858038026358315e-10
almost O 0 7.410019264852963e-10
absent O 0 7.431933735091434e-09
occurrence O 0 2.3047088681948935e-09
of O 0 1.052597675688105e-09
paternal O 0 5.836600180941787e-08
transmission O 0 0.003671647049486637
of O 0 0.01268148235976696
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0022782115265727043

Also O 0 1.6158642779373622e-07
the O 0 4.251294072332712e-08
fathers O 0 1.001546223733385e-07
of O 0 5.791751078731977e-09
the O 0 7.09787961739039e-09
reported O 0 6.051925538486103e-08
congenitally O 0 4.694360904977657e-05
affected O 0 7.102487131760427e-08
children O 0 7.833921955580081e-09
showed O 0 2.3611791633015855e-08
, O 0 4.35951896804454e-09
on O 0 1.6049602891143877e-07
average O 0 1.1739670568999827e-08
, O 0 3.639805790101036e-09
shorter O 0 2.8464538104344683e-07
CTG O 0 3.8647689507342875e-05
repeat O 0 7.331159395107534e-07
lengths O 0 2.2089936919655884e-06
and O 0 5.7296816180496535e-09
hence O 0 6.335133662105363e-08
less O 0 7.239584931539866e-09
severe O 0 6.998403478064574e-06
clinical O 0 7.607673524034908e-06
symptoms O 0 7.607585672531059e-08
than O 0 1.7913068250940967e-10
the O 0 4.58948629100675e-10
mothers O 0 1.8348501884535295e-10
of O 0 7.156739090241615e-10
children O 0 3.3323870329837746e-09
with O 0 8.073356383420105e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.001614756416529417

We O 0 2.3012647432096855e-07
conclude O 0 3.2252756909656455e-07
that O 0 7.525676748443288e-10
paternal O 0 2.3493247169881215e-07
transmission O 0 0.05306990444660187
of O 1 0.9981012940406799
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 2.4215157168328005e-07
rare O 0 7.654010758528784e-09
and O 0 5.213977583018448e-10
preferentially O 0 1.8713401939152163e-09
occurs O 0 1.4362627753783386e-09
with O 0 2.1266373384509762e-10
onset O 0 1.0255901088385144e-06
of O 0 7.350236046477221e-07
DM B-Disease 1 1.0
past O 0 8.221855551937551e-08
30 O 0 1.851733877344941e-09
years O 0 1.2241564706361174e-10
in O 0 4.035276973679558e-11
the O 0 2.0551110813116225e-10
father O 0 5.931654278867882e-09
. O 0 4.354034466302892e-09
. O 0 9.053256633251294e-08

The O 0 1.0159585599467391e-06
RB1 O 0 3.452298915362917e-05
gene O 0 2.7755447717936477e-08
mutation O 0 1.1319923665098486e-08
in O 0 1.5307087819493859e-09
a O 0 1.3848182156550592e-08
child O 0 9.511228995506826e-07
with O 0 3.1493848950958636e-07
ectopic B-Disease 1 0.9998685121536255
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.01902344636619091

The O 0 2.208380919910269e-06
RB1 O 0 6.407276669051498e-05
gene O 0 4.266337683134225e-08
mutation O 0 3.8339027952360993e-08
was O 0 4.032174771850805e-08
investigated O 0 5.469816954928319e-08
in O 0 1.3486085581604357e-09
a O 0 4.5783496993578865e-09
child O 0 2.0221295926603489e-07
with O 0 3.9462292988901027e-08
ectopic B-Disease 0 0.0003089654492214322
intracranial I-Disease 0 0.26324549317359924
retinoblastoma I-Disease 0 0.0004345745546743274
using O 0 1.7225632475970087e-08
DNA O 0 4.645731799257646e-09
obtained O 0 1.9755868052584447e-09
from O 0 2.591341585755913e-10
both O 0 1.1479445172213332e-09
the O 0 2.1067599220714328e-08
pineal B-Disease 0 2.5982764782384038e-05
and I-Disease 0 8.45715817376913e-08
retinal I-Disease 1 0.9054100513458252
tumours I-Disease 1 1.0
of O 0 2.92783479380887e-05
the O 0 9.249650361198292e-07
patient O 0 5.080016762804007e-07
. O 0 7.295087698366842e-07

A O 0 2.015815198319615e-06
nonsense O 0 2.0897307422274025e-06
mutation O 0 3.848570528930395e-08
in O 0 1.2234457891224793e-08
exon O 0 3.456162858128664e-07
17 O 0 3.3824915135483025e-07
( O 0 1.2269815385934635e-08
codon O 0 7.679327040932549e-08
556 O 0 3.103652090885589e-08
) O 0 4.734846958953653e-10
of O 0 3.860596287097451e-09
the O 0 2.3529159065560634e-08
RB1 O 0 7.14592715667095e-06
gene O 0 5.2828110774783e-09
was O 0 7.226134357551928e-09
found O 0 1.423194478933354e-10
to O 0 5.984217288368399e-11
be O 0 3.9540759555478644e-10
present O 0 1.695827367420577e-09
homozygously O 0 2.941774255305063e-07
in O 0 2.81305867488868e-09
both O 0 1.1792049114944803e-08
the O 0 9.811990508978852e-08
retinal B-Disease 0 3.188342088833451e-05
and I-Disease 0 6.79556876548304e-07
the I-Disease 0 1.250516561412951e-05
pineal I-Disease 1 0.9997379183769226
tumours I-Disease 1 1.0
. O 0 2.176690941269044e-05

The O 0 2.1402348338028787e-08
same O 0 1.8732471129823125e-09
mutation O 0 1.973026186874449e-09
was O 0 1.4318564112159038e-09
present O 0 4.560028465938615e-10
heterozygously O 0 1.526732340551007e-08
in O 0 1.3732802395249877e-10
the O 0 2.0691959257135295e-10
DNA O 0 5.665573010738001e-10
from O 0 4.2982017250947635e-11
the O 0 1.9042993570916877e-10
constitutional O 0 3.401784098855387e-08
cells O 0 3.430085326883159e-09
of O 0 3.4633500511915827e-09
the O 0 1.834305263237468e-09
patient O 0 3.283627592054472e-09
, O 0 3.652544933174795e-10
proving O 0 1.049586995094387e-08
it O 0 1.0882620499197415e-10
to O 0 2.3582150121548295e-10
be O 0 1.0315143184058684e-09
of O 0 1.1627623308640977e-08
germline O 0 2.97057704301551e-06
origin O 0 1.3194312487030402e-07
. O 0 8.048984341257892e-07

The O 0 7.411962599235267e-08
initial O 0 3.5178512547417995e-08
mutation O 0 6.843328570482754e-09
was O 0 5.151643556189356e-09
shown O 0 7.257111578340414e-10
to O 0 3.4005354088151307e-10
have O 0 4.1970829589565994e-10
occurred O 0 2.5214136556428457e-08
in O 0 4.0758429964427023e-10
the O 0 4.033280376347648e-09
paternally O 0 1.003200736704457e-06
derived O 0 1.8806734658483037e-07
RB1 O 0 4.083300518686883e-05
allele O 0 3.5398650197748793e-06
. O 0 1.7576792288309662e-06

The O 0 1.8379033406290546e-07
mutation O 0 1.1456811499499508e-08
is O 0 1.3895529171747967e-10
in O 0 7.467164386820713e-11
an O 0 2.694942879966078e-11
area O 0 6.482775982696865e-10
of O 0 2.035625668028729e-09
the O 0 5.2061688293747466e-09
gene O 0 1.3416275868038952e-09
that O 0 6.451974510213176e-10
encodes O 0 3.8358098919388794e-09
the O 0 5.303387062838283e-09
protein O 0 9.699023806319929e-09
- O 0 1.002310323627853e-08
binding O 0 1.9387071503729203e-08
region O 0 2.2232560681345603e-08
known O 0 3.1440470227295236e-09
as O 0 1.051377762628647e-09
the O 0 2.3580994934491173e-09
pocket O 0 8.401768241128593e-07
region O 0 1.1615166606304683e-08
and O 0 1.6803018976219164e-09
has O 0 2.197234894030231e-10
been O 0 1.8283242975147829e-10
detected O 0 2.9409877311259436e-10
in O 0 4.747613413513818e-11
other O 0 5.90032467329138e-11
cases O 0 3.854546126724756e-10
of O 0 5.364898303383825e-09
retinoblastoma B-Disease 0 8.266879376606084e-06
. O 0 1.1318870463128405e-07
. O 0 8.878487847141514e-07

Low O 0 6.627777111134492e-06
levels O 0 1.4916166435341438e-07
of O 0 4.0036894688455504e-08
beta O 0 8.368246540157998e-07
hexosaminidase O 0 5.496285666595213e-07
A O 0 7.412595870448513e-09
in O 0 7.280042124691022e-10
healthy O 0 1.6769017285866994e-09
individuals O 0 3.294753705973541e-11
with O 0 1.490334800013926e-10
apparent O 0 6.443752909035538e-07
deficiency O 0 0.00021592676057480276
of O 0 1.6698189938324504e-05
this O 0 3.8716148509365667e-08
enzyme O 0 4.994885216547118e-07
. O 0 5.862226544195437e-07

Appreciable O 0 8.006798452697694e-05
beta O 0 2.0029046936542727e-05
hexosaminidase O 0 5.396659980760887e-05
A O 0 1.0746718999143923e-06
( O 0 2.7946578384785425e-08
hex O 0 1.7576456912138383e-06
A O 0 3.8555501902237665e-08
) O 0 5.9153704157211e-10
activity O 0 2.189379344486042e-09
has O 0 1.3519277364260063e-10
been O 0 2.9933588940878053e-10
detected O 0 3.671755344214489e-09
in O 0 4.6313815005305514e-09
cultured O 0 1.4794650269323029e-05
skin O 1 0.5899000763893127
fibroblasts O 0 7.856549018470105e-06
and O 0 1.621161658249548e-07
melanoma B-Disease 0 0.0012222398072481155
tissue O 0 5.918435164176117e-08
from O 0 1.7712288302718093e-09
healthy O 0 1.0191065769049601e-08
individuals O 0 3.250839181179188e-11
previously O 0 1.4424067495966142e-09
reported O 0 1.7927264117645336e-09
as O 0 2.4109740870414953e-09
having O 0 2.256941513678612e-07
deficiency B-Disease 0 0.00035676921834237874
of I-Disease 0 1.6137426428031176e-05
hex I-Disease 0 4.577918298309669e-05
A I-Disease 0 6.074337477457448e-08
activity O 0 1.4949199211855557e-08
indistinguishable O 0 4.169064204972983e-09
from O 0 3.4898705453256795e-11
that O 0 1.5068722311606386e-11
of O 0 3.2296304519618957e-10
patients O 0 5.832743177336397e-10
with O 0 1.3374840790447706e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.666498630787828e-06
TSD B-Disease 0 0.008572409860789776
) O 0 1.0188289678580986e-07
. O 0 1.0817792599482345e-06

Identification O 0 1.0226572157989722e-06
and O 0 1.1867867755199768e-07
quantitation O 0 8.526564488420263e-05
of O 0 9.682974450697657e-06
hex O 0 7.680800626985729e-05
A O 0 1.619128369156897e-07
, O 0 3.162101247511373e-09
amounting O 0 1.540392169374627e-08
to O 0 7.716617567155026e-09
3 O 0 6.17073681041802e-07
. O 0 4.882977009401657e-07

5 O 0 6.981290880503366e-06
% O 0 2.017787466002119e-07
- O 0 1.3209764802013524e-06
6 O 0 2.896033038268797e-06
. O 0 6.470441462624876e-07

9 O 0 1.5534607200606843e-06
% O 0 5.063326646848054e-09
of O 0 9.155342262090471e-09
total O 0 3.789935476561368e-09
beta O 0 1.2528799686606362e-07
hexosaminidase O 0 3.5048458357778145e-07
activity O 0 5.3127622301474275e-09
, O 0 5.697147267835767e-11
has O 0 9.914216149431443e-12
been O 0 4.688026356003405e-11
obtained O 0 1.1613255912479303e-09
by O 0 7.035551030654119e-10
cellulose O 0 3.774471224460285e-07
acetate O 0 1.0491710611404415e-07
gel O 0 1.501851016882938e-07
electrophoresis O 0 5.2772147540736114e-08
, O 0 1.1401681376810302e-08
DEAE O 0 8.236803296313155e-06
- O 0 1.0049789125332609e-06
cellulose O 0 1.6003518794605043e-06
ion O 0 1.7923663108376786e-05
- O 0 1.7132417724496918e-06
exchange O 0 2.41980274040543e-07
chromatography O 0 1.1626956393229193e-06
, O 0 3.311869667399492e-09
radial O 0 4.264019253241713e-07
immunodiffusion O 0 1.8198009001935134e-06
, O 0 1.0360597713088282e-08
and O 0 3.0606091883100817e-08
radioimmunoassay O 0 1.1744409675884526e-05
. O 0 1.7471587625550455e-06

Previous O 0 1.3127783859090414e-05
family O 0 2.974818436030091e-08
studies O 0 5.246761691779511e-09
suggested O 0 1.8782881916479255e-09
that O 0 4.237007966700901e-11
these O 0 4.5022520434034874e-11
individuals O 0 1.107311031062208e-11
may O 0 2.9277233415392345e-10
be O 0 2.457212211481874e-10
compound O 0 4.156313071490558e-09
heterozygotes O 0 3.431642747742103e-09
for O 0 9.125954852917673e-11
the O 0 7.940667012817926e-10
common O 0 6.607628222354833e-09
mutant O 0 3.542961906077835e-07
TSD B-Disease 0 6.304784164967714e-06
gene O 0 8.152517771975454e-09
and O 0 1.9153667540905417e-09
a O 0 3.712904650399196e-09
rare O 0 1.9313404209242435e-08
( O 0 9.321555971553153e-09
allelic O 0 9.621583103580633e-07
) O 0 1.2894441070443463e-08
mutant O 0 7.938711519273056e-07
gene O 0 3.619972517299175e-07
. O 0 1.4295874279923737e-06

Thus O 0 2.409720707419183e-07
, O 0 4.2783958598136e-09
the O 0 2.0129387046097236e-09
postulated O 0 2.7798042978588455e-08
rate O 0 1.5163247324423423e-09
mutant O 0 4.473998949094948e-09
gene O 0 1.983567615715387e-10
appears O 0 2.1356451329612725e-10
to O 0 2.647893709850635e-11
code O 0 4.507089493288596e-11
for O 0 2.227004344823591e-11
the O 0 4.4276939753506994e-11
expression O 0 3.1874594630387776e-10
of O 0 4.2975481506779545e-10
low O 0 2.0481663032256847e-09
amounts O 0 2.975604207478e-10
of O 0 7.306336868850849e-09
hex O 0 2.324405613762792e-06
A O 0 2.7113665623801353e-07
. O 0 3.1234458219842054e-07

Heterozygotes O 0 4.553400867735036e-05
for O 0 7.728272066742647e-08
the O 0 2.3314102648441803e-08
rare O 0 1.4295512329454141e-08
mutant O 0 2.151625544399849e-08
may O 0 2.0336543560262044e-09
be O 0 7.259077228205513e-10
indistinguishable O 0 2.786863628756464e-09
from O 0 1.7860529721858143e-10
heterozygotes O 0 8.49038528372148e-09
for O 0 5.451604723205605e-10
the O 0 6.98162905266031e-09
common O 0 1.31513104406622e-07
TSD B-Disease 0 2.7677329853759147e-05
mutant O 0 3.28834107676812e-06
. O 0 1.1834024462586967e-06

However O 0 2.1159179652840976e-07
, O 0 3.3131266619079724e-09
direct O 0 3.372349510755157e-09
visualization O 0 7.497715870385946e-08
and O 0 6.354966330945899e-09
quantitation O 0 1.9139244614052586e-05
of O 0 1.3345901379580027e-06
hex O 0 7.489949894079473e-06
A O 0 2.0865886796173072e-08
by O 0 2.344259231179535e-10
the O 0 6.815474851151748e-10
methods O 0 1.61010440535847e-08
described O 0 3.289457595201384e-09
may O 0 3.9289536069020414e-09
prevent O 0 8.80522676993678e-09
false O 0 1.9552031460534636e-07
- O 0 1.59560030965622e-07
positive O 0 8.435213416646548e-09
prenatal O 0 8.116263217061714e-08
diagnosis O 0 1.7119779727181594e-07
of O 0 1.5924634055863862e-08
TSD B-Disease 0 3.013963214471005e-05
in O 0 3.185396124649742e-08
fetuses O 0 1.383588426051574e-07
having O 0 1.1731143167992286e-08
the O 0 1.0486505885864972e-08
incomplete O 0 6.611418825741566e-07
hex B-Disease 0 0.00011423954128986225
A I-Disease 0 1.1262228554187459e-06
deficiency I-Disease 0 1.006381990009686e-05
of O 0 4.4536400878314453e-07
the O 0 1.5885348148003686e-08
type O 0 5.534018328035017e-07
described O 0 4.3626901202742374e-08
in O 0 6.119105222524013e-09
the O 0 2.0784864318557084e-07
four O 0 9.71750523603987e-07
healthy O 0 2.6479390271560987e-06
individuals O 0 1.8677096136343607e-07

The O 0 1.3906487765780184e-06
tumor B-Disease 0 1.9830852124869125e-06
suppressor O 0 4.077277026226511e-06
gene O 0 1.5024298249954882e-07
Smad4 O 0 2.8563612431753427e-05
/ O 0 4.6847267185512464e-06
Dpc4 O 0 4.920340415992541e-06
is O 0 8.092249648150585e-10
required O 0 4.66383265340653e-10
for O 0 3.534136039373692e-10
gastrulation O 0 5.194408458919497e-08
and O 0 5.961936500042953e-10
later O 0 1.1054599013959887e-08
for O 0 8.500264936373014e-10
anterior O 0 4.1360826230629755e-07
development O 0 1.8318557692964532e-07
of O 0 1.2964557072336902e-07
the O 0 8.582053112604626e-08
mouse O 0 3.266517012434633e-07
embryo O 0 1.1688722167946253e-07
. O 0 4.589289801515406e-07

Mutations O 0 2.2262065613176674e-06
in O 0 7.562692871943e-08
the O 0 1.687607351641418e-07
SMAD4 O 0 0.0016472246497869492
/ O 0 4.292586527299136e-05
DPC4 O 0 4.3389321945142e-05
tumor B-Disease 0 6.017888836140628e-07
suppressor O 0 4.169091027961258e-07
gene O 0 3.779403456860564e-09
, O 0 7.868224960461134e-10
a O 0 2.5478077425589163e-09
key O 0 1.7188357048780745e-07
signal O 0 3.2189919352276775e-07
transducer O 0 6.001257020216144e-07
in O 0 1.0756502355491193e-08
most O 0 5.520669255076882e-09
TGFbeta O 0 4.228896796121262e-05
- O 0 7.767149554638308e-07
related O 0 5.7287341093115174e-08
pathways O 0 5.592909246843192e-09
, O 0 4.6646218138102213e-11
are O 0 8.735958137440214e-12
involved O 0 3.5418813715271114e-11
in O 0 9.26825421965205e-11
50 O 0 1.6060121010852413e-09
% O 0 3.2410174544139636e-09
of O 0 2.0045333712914726e-06
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.0025184110272675753

Homozygous O 0 1.4649171134806238e-05
Smad4 O 0 0.00010253453365294263
mutant O 0 3.545264007698279e-06
mice O 0 9.234191225004906e-07
die O 0 1.5534266140093678e-06
before O 0 2.7054232987211435e-07
day O 0 1.2292132112179388e-07
7 O 0 8.086499860837648e-07
. O 0 5.649537229146517e-07

5 O 0 1.2695743862423114e-05
of O 0 2.405315399300889e-06
embryogenesis O 0 5.755601523560472e-05
. O 0 3.2366506275138818e-06

Mutant O 0 1.020871877699392e-06
embryos O 0 2.453589864614969e-08
have O 0 3.673212178867402e-09
reduced O 0 6.082578440924635e-09
size O 0 4.400294795203763e-09
, O 0 4.029933609039915e-10
fail O 0 1.846832020646616e-08
to O 0 6.100296712219233e-09
gastrulate O 0 3.220160124328686e-06
or O 0 1.1760311835473658e-08
express O 0 3.4268288207073283e-09
a O 0 2.470069926374663e-09
mesodermal O 0 3.611758643273788e-07
marker O 0 1.0500198754925805e-07
, O 0 1.1928700249796975e-09
and O 0 3.06993852561277e-09
show O 0 4.947773746266648e-08
abnormal O 0 9.204359798786754e-07
visceral O 0 9.976860383176245e-06
endoderm O 0 0.0008877693326212466
development O 0 8.049958523770329e-06
. O 0 1.1022668786608847e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 2.6151212750846753e-06
the O 0 1.2754397005210194e-07
Smad4 O 0 3.322946577100083e-05
- O 0 5.665956450684462e-07
deficient O 0 5.647044076795282e-08
embryos O 0 2.9403275370043502e-09
results O 0 7.8701800632075e-09
from O 0 6.580006539635974e-10
reduced O 0 3.5122596386827354e-08
cell O 0 2.895604822583664e-08
proliferation O 0 9.307591142260208e-09
rather O 0 7.503374033213106e-10
than O 0 1.5848017342889875e-10
increased O 0 2.7009250391785145e-09
apoptosis O 0 2.3622381206678256e-07
. O 0 5.831525839994356e-08

Aggregation O 0 1.456756535844761e-06
of O 0 4.965149855706841e-07
mutant O 0 1.5139145261855447e-06
Smad4 O 0 5.4940486734267324e-05
ES O 0 4.68096332042478e-05
cells O 0 2.256945208500838e-08
with O 0 2.6678803610735713e-09
wild O 0 2.6040680722871912e-08
- O 0 3.07444025793302e-08
type O 0 1.3771800411177537e-07
tetraploid O 0 0.00013676653907168657
morulae O 0 0.00030869958573020995
rescues O 0 2.411691866655019e-06
the O 0 1.568834164800137e-07
gastrulation B-Disease 0 0.00014766813546884805
defect I-Disease 0 2.1087569621158764e-05
. O 0 4.4881735448143445e-06

These O 0 4.762867433782958e-08
results O 0 1.0251837778696427e-07
indicate O 0 8.270215623440436e-09
that O 0 5.901407695851901e-10
Smad4 O 0 2.965245471386879e-07
is O 0 2.144150829108682e-10
initially O 0 1.116639891662885e-09
required O 0 2.474039029198849e-10
for O 0 7.123369949457725e-11
the O 0 3.62243429696818e-10
differentiation O 0 2.064576509752669e-09
of O 0 1.9614880830687298e-09
the O 0 2.8006916785727753e-09
visceral O 0 1.9659992744891497e-07
endoderm O 0 1.4007232493895572e-06
and O 0 9.391185606943964e-10
that O 0 1.290919177110439e-10
the O 0 3.4686915562076592e-09
gastrulation B-Disease 0 7.497444016735244e-07
defect I-Disease 0 5.487958532057746e-08
in O 0 3.0776539095001e-09
the O 0 1.151471273885818e-08
epiblast O 0 5.333677563612582e-06
is O 0 1.4276212434438662e-09
secondary O 0 9.782353060927562e-08
and O 0 8.467678114243427e-09
non O 0 5.957081611995818e-06
- O 0 2.732751272560563e-05
cell O 0 2.5340908905491233e-05
autonomous O 0 3.720641359450383e-07
. O 0 8.958163562056143e-07

Rescued O 0 1.16001947390032e-05
embryos O 0 1.553333248693889e-07
show O 0 2.7647720912682416e-07
severe O 0 3.966845906688832e-05
anterior O 0 0.00442679924890399
truncations O 1 0.6334863305091858
, O 0 6.30663308243129e-08
indicating O 0 1.1482061523793163e-07
a O 0 1.015976014429043e-08
second O 0 3.457543584772793e-08
important O 0 5.622279974915045e-09
role O 0 6.460425527876623e-09
for O 0 3.3417433265015006e-09
Smad4 O 0 4.534613253781572e-06
in O 0 1.2054127296323713e-07
anterior O 0 0.00015389132022392005
patterning O 0 0.00016650916950311512
during O 0 4.9727968871593475e-06
embryogenesis O 0 3.179421401000582e-05
. O 0 1.4267462802308728e-06

Prevalence O 0 6.885141374368686e-06
of O 0 2.941721106708428e-07
p16 O 0 6.167112474031455e-07
and O 0 1.0037378217475634e-07
CDK4 O 0 0.00042495265370234847
germline O 0 3.106770236627199e-05
mutations O 0 8.105278936909599e-08
in O 0 2.2742083771731814e-08
48 O 0 1.5939561990307993e-06
melanoma B-Disease 1 0.9997604489326477
- O 0 0.00021120098244864494
prone O 0 1.3356595445657149e-05
families O 0 1.2274520955202206e-08
in O 0 3.160197437068746e-08
France O 0 4.699691271525808e-05
. O 0 4.601263572112657e-05

The O 0 2.6818695459951414e-06
French O 0 0.00013364182086661458
Familial B-Disease 0 0.3454627990722656
Melanoma I-Disease 1 0.9999806880950928
Study O 0 6.437991260099807e-07
Group O 0 2.2093446716553444e-07
. O 0 1.0304726174581447e-06

Germline O 0 0.00017684746126178652
mutations O 0 2.565557792877371e-07
in O 0 7.690404757454417e-09
the O 0 9.860935179517583e-09
p16 O 0 6.669242225143535e-08
and O 0 1.1084368090052976e-08
CDK4 O 0 4.278208507457748e-06
genes O 0 4.536642617125608e-09
have O 0 6.552240972013124e-10
been O 0 5.828384441741719e-10
reported O 0 8.268192241978056e-10
in O 0 2.053524156275799e-10
a O 0 1.91615612266105e-09
subset O 0 9.724887206630228e-08
of O 0 3.382378679361864e-07
melanoma B-Disease 0 0.040296800434589386
pedigrees O 0 2.3646860825010663e-07
, O 0 1.4666005077046407e-09
but O 0 7.910327948223994e-10
their O 0 9.59560764179912e-10
prevalence O 0 2.0174404369299737e-08
is O 0 1.0770779407254238e-10
not O 0 3.6910349776597684e-10
well O 0 2.9640669918507e-09
known O 0 4.871121461746952e-08
. O 0 7.552716283498739e-07

We O 0 1.347274150020894e-07
searched O 0 3.280092641944066e-08
for O 0 2.866155368597134e-10
such O 0 6.884196546153021e-10
germline O 0 1.540917423881183e-06
mutations O 0 3.7695567556284004e-08
in O 0 1.0809028339053839e-08
48 O 0 4.766212100548728e-07
French O 0 0.03882569074630737
melanoma B-Disease 1 1.0
- O 0 0.012332511134445667
prone O 0 2.39837504523166e-06
families O 0 3.898004419244927e-10
selected O 0 1.088034329299603e-09
according O 0 9.529886602077653e-11
to O 0 5.7461580632578446e-11
two O 0 1.3693254863333948e-10
major O 0 1.1292832224896188e-09
criteria O 0 1.415334782706168e-08
families O 0 5.403485645039119e-11
with O 0 6.173493660721618e-11
at O 0 1.7592972412217023e-08
least O 0 8.596576228647734e-10
three O 0 6.530195273413142e-10
affected O 0 2.9995212980082897e-09
members O 0 1.760981693799124e-09
( O 0 3.979340412740839e-09
n O 0 1.7590564027614164e-07
= O 0 2.2159537138577434e-07
20 O 0 9.178823923150503e-09
) O 0 6.792812146105831e-11
or O 0 6.833839050202073e-11
families O 0 1.0562288023374666e-11
with O 0 1.013974668118145e-11
two O 0 1.718967607144961e-10
affected O 0 6.624180648451272e-10
members O 0 1.993299553193495e-10
, O 0 1.1700249102908344e-10
one O 0 8.647007415651942e-11
of O 0 3.976955709195096e-10
them O 0 9.674976098050792e-11
affected O 0 3.987954688700057e-10
before O 0 7.774703658647297e-10
the O 0 2.447856639609114e-10
age O 0 8.028540054993982e-10
of O 0 1.2764423962252636e-09
50 O 0 1.3577425850286318e-09
( O 0 9.150361024445886e-10
n O 0 8.771037585120212e-08
= O 0 2.767331181985355e-07
28 O 0 8.518937733015264e-08
) O 0 3.4704369933358237e-10
, O 0 1.0538708100638061e-10
and O 0 1.1435732916176278e-10
one O 0 9.961912544875773e-11
additional O 0 3.447109542253912e-10
minor O 0 8.479739221911586e-08
criterion O 0 4.015622835140675e-06
. O 0 8.797682653494121e-07

Sixteen O 0 7.698589797655586e-06
different O 0 8.923173311359278e-08
p16 O 0 7.266328339028405e-07
germline O 0 1.1650754458969459e-06
mutations O 0 2.662623899141181e-09
were O 0 5.507940215032647e-10
found O 0 1.2115919378885565e-10
in O 0 1.5618990822918732e-10
21 O 0 9.166821079986676e-09
families O 0 1.2949882832735682e-10
, O 0 3.0499183734100654e-10
while O 0 1.5888643734029984e-09
one O 0 8.523810102190055e-09
germline O 0 1.6410425587309874e-06
mutation O 0 3.644768042931901e-08
, O 0 1.0789213966688749e-08
Arg24His O 0 5.6749290706648026e-06
, O 0 1.8892080788646126e-08
was O 0 9.689819080449524e-08
detected O 0 1.636932722703932e-08
in O 0 4.880567505693989e-09
the O 0 8.806171791775341e-08
CDK4 O 0 0.00012533871631603688
gene O 0 1.249426190952363e-06
. O 0 2.5791828193177935e-06

The O 0 1.9156898645178444e-07
frequency O 0 1.199487655867415e-07
of O 0 3.093103373430495e-08
p16 O 0 3.245819613084677e-08
gene O 0 9.882471507793866e-10
mutation O 0 7.957147163395462e-10
in O 0 3.272759008243753e-10
our O 0 1.040725505774276e-09
sample O 0 1.7165496801752056e-10
( O 0 1.7145700137444209e-10
44 O 0 7.614154307056253e-10
% O 0 1.9562972075615193e-10
) O 0 2.118689806929197e-10
is O 0 1.1833110880044018e-10
among O 0 2.0037249637283594e-10
the O 0 7.051511041744618e-10
highest O 0 1.0949466222598403e-08
rates O 0 1.5093880589844844e-09
yet O 0 3.420062288927994e-10
reported O 0 5.186492901820827e-10
and O 0 1.8714105265438263e-10
the O 0 2.1861996657435157e-09
CDK4 O 0 1.251548951586301e-06
mutation O 0 1.8629175979612e-09
is O 0 1.833073137724739e-10
the O 0 5.845997574915884e-10
second O 0 4.501560901815083e-09
mutation O 0 1.4307262041768354e-09
detected O 0 2.3430801743273832e-09
in O 0 5.83689430122547e-10
this O 0 1.311821762328691e-09
gene O 0 1.3114446417716863e-08
worldwide O 0 4.615316839817751e-08
. O 0 8.249193683695921e-07

In O 0 2.5204045073223824e-07
summary O 0 6.901188044139417e-06
, O 0 4.599425729168161e-09
our O 0 1.1051310089271738e-08
results O 0 1.4280033155955607e-08
show O 0 1.7337397073546867e-09
frequent O 0 7.452271577612635e-10
involvement O 0 9.012627977256216e-09
of O 0 9.443388293561839e-09
the O 0 8.567493381406166e-09
p16 O 0 4.832900657447681e-08
gene O 0 1.1731769333778175e-08
in O 0 6.90965462624149e-09
familial B-Disease 0 9.039761152962456e-07
melanoma I-Disease 0 1.3983187272970099e-05
and O 0 2.5869919539900366e-09
confirm O 0 9.16906017778274e-09
the O 0 1.4656217350861311e-09
role O 0 3.78451048277384e-09
of O 0 9.370062770130971e-08
the O 0 3.60009039468423e-07
CDK4 O 0 0.44056153297424316
gene O 0 1.0411672235477454e-07
as O 0 3.582947272207093e-08
a O 0 8.661876194082652e-08
melanoma B-Disease 0 0.001571335131302476
- O 0 1.7103904610848986e-05
predisposing O 0 1.0929685458904714e-06
gene O 0 1.775058144914965e-08
. O 0 4.414368959260173e-08
. O 0 5.477782565321831e-07

Progression O 0 3.667239798232913e-05
of O 0 4.745574642583961e-06
somatic O 0 3.2114636269398034e-05
CTG O 0 2.3346479792962782e-05
repeat O 0 7.840158389171847e-08
length O 0 5.30170796153584e-09
heterogeneity O 0 2.5283531712716467e-08
in O 0 5.924505330767715e-10
the O 0 1.4015315574766873e-09
blood O 0 3.677250060007964e-09
cells O 0 1.0311021725328828e-07
of O 0 1.0868601748370565e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.625388126238249e-05
. O 0 2.5582799025869463e-06

The O 0 3.9407684226944184e-08
genetic O 0 1.817693195960146e-08
basis O 0 1.2981580255200242e-07
of O 0 0.00034992131986655295
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9986693859100342
DM B-Disease 1 1.0
) O 0 8.61777493810223e-09
is O 0 1.9273788121054736e-10
the O 0 3.1660402077804406e-10
expansion O 0 3.354016397949522e-09
of O 0 3.130427916886447e-09
an O 0 7.297141224604786e-10
unstable O 0 4.796937105311372e-07
CTG O 0 3.2852317417564336e-06
repeat O 0 2.3699231022078493e-08
in O 0 1.721994102865665e-09
the O 0 8.736937395781297e-09
34 O 0 5.200167763064201e-08
UTR O 0 3.7821637306478806e-06
of O 0 1.2540395744053967e-07
the O 0 6.230573603716039e-07
DM B-Disease 1 1.0
protein O 0 1.2215878086863086e-07
kinase O 0 4.9615426434002075e-08
gene O 0 2.20095208725013e-09
on O 0 4.162193434353867e-08
chromosome O 0 1.3560421052716265e-07
19 O 0 1.0257525673296186e-06
. O 0 1.0590241572572268e-06

One O 0 6.189159051928073e-08
of O 0 3.268582560167488e-08
the O 0 5.891019227988181e-09
principal O 0 5.757192056421445e-08
features O 0 7.750987407462162e-09
of O 0 6.393423745976179e-08
the O 0 9.12681002773752e-07
DM B-Disease 1 1.0
mutation O 0 8.63139959506043e-08
is O 0 6.067661928454982e-10
an O 0 2.20927026672868e-10
extraordinarily O 0 4.243678475290835e-08
high O 0 5.301660053191881e-07
level O 0 1.4201002159097698e-05
of O 0 2.299078687428846e-06
somatic O 0 0.00012708277790807188
mosaicism O 0 1.576563954586163e-05
, O 0 9.601227590749772e-10
due O 0 5.56311974264645e-09
to O 0 1.769735330503508e-10
an O 0 3.571295342785774e-11
extremely O 0 1.1390112186759893e-09
high O 0 7.47580841675699e-09
degree O 0 1.278266097415326e-07
of O 0 1.5827916755029037e-08
somatic O 0 4.7518744850094663e-07
instability O 0 5.265611946470017e-08
both O 0 1.6213396181186113e-09
within O 0 1.6531284119380985e-09
and O 0 3.937841719370283e-10
between O 0 1.4694173655627196e-09
different O 0 2.4299113832171315e-09
tissues O 0 4.5848537411075085e-08
. O 0 4.6245958174040425e-08

This O 0 3.929660152834913e-08
instability O 0 2.011285999969914e-07
appears O 0 5.4197379917297894e-09
to O 0 1.4526768676859092e-10
be O 0 2.2832638557623852e-10
biased O 0 7.170911864307072e-09
towards O 0 4.604253422968441e-09
further O 0 5.715860007526885e-10
expansion O 0 1.4964454120303117e-09
and O 0 2.6474203385085104e-10
continuous O 0 5.092848365251257e-09
throughout O 0 4.4009557109703223e-10
the O 0 7.242564881160263e-10
life O 0 3.8496972276647057e-10
of O 0 2.2150550837984895e-10
an O 0 1.863715605454619e-11
individual O 0 1.7383969264095356e-11
, O 0 2.9091520858948172e-11
features O 0 8.067864432081961e-11
that O 0 5.75680692352365e-12
could O 0 4.0513873506009546e-11
be O 0 1.1958879719831117e-10
associated O 0 1.2465836141117848e-09
with O 0 8.57641180296298e-11
the O 0 3.242105695022701e-09
progressive O 0 4.2830753955058753e-05
nature O 0 1.4623365984789416e-07
of O 0 3.009265014952689e-07
the O 0 8.250727319136786e-07
disease O 0 8.19731576484628e-05
. O 0 1.2108109785913257e-06

Although O 0 5.812525927240131e-08
increasing O 0 2.621185224427336e-08
measured O 0 3.092047506925155e-08
allele O 0 2.2536672972250926e-08
size O 0 7.756193021180025e-09
between O 0 3.757058220088538e-09
patients O 0 1.916580227856457e-09
clearly O 0 2.8766447002226414e-09
correlates O 0 3.889376820609414e-09
with O 0 1.1691832398075253e-11
an O 0 3.9956098325799605e-12
increased O 0 7.188913353495252e-11
severity O 0 3.6655013246900126e-08
of O 0 1.4346318799596247e-08
symptoms O 0 4.769203343357731e-08
and O 0 1.175186892243829e-10
an O 0 1.0684835828611572e-11
earlier O 0 1.744785704804741e-10
age O 0 9.981355741928155e-10
of O 0 6.273323527317132e-10
onset O 0 1.235838631430397e-08
, O 0 1.8363512099828228e-11
this O 0 6.538763454300156e-12
correlation O 0 1.7751443370794817e-10
is O 0 1.0747421182177863e-11
not O 0 3.015407715190044e-11
precise O 0 4.41250636029622e-09
and O 0 4.66090666062513e-10
measured O 0 3.575933993360536e-09
allele O 0 5.768070465705932e-09
length O 0 9.254092492305688e-10
cannot O 0 4.711172563176547e-10
be O 0 5.965550275988107e-11
used O 0 4.492379038212313e-11
as O 0 5.410312475806478e-11
an O 0 9.022779919043433e-12
accurate O 0 3.410137061621299e-09
predictor O 0 8.56138768767778e-08
of O 0 9.280433310721037e-09
age O 0 2.9853458727302495e-07
of O 0 3.4924735814456653e-07
onset O 0 0.0007138922228477895
. O 0 1.7795161966205342e-06

In O 0 8.152910169201277e-08
order O 0 3.1760293950355845e-08
to O 0 1.7196669643837481e-09
further O 0 6.728474222228442e-09
characterize O 0 1.1987785342171264e-07
the O 0 2.3333589282970024e-08
dynamics O 0 1.5855539459153078e-06
of O 0 2.183220885854098e-06
DM B-Disease 1 1.0
CTG O 0 0.0014217286370694637
repeat O 0 2.7891496756637935e-07
somatic O 0 3.585203671718773e-07
instability O 0 2.8593385437147845e-08
, O 0 2.1347407175298372e-10
we O 0 2.0597769323504878e-10
have O 0 6.202351132689188e-11
studied O 0 2.882015737171173e-09
repeat O 0 1.8049716166146368e-09
length O 0 3.259489622653433e-10
changes O 0 5.412410519767263e-10
over O 0 3.5036851198100294e-10
time O 0 4.3334111299309086e-10
in O 0 5.203009689758176e-10
111 O 0 1.6286880963889416e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.5177260337395637e-08
with O 0 3.1330307792565293e-10
varying O 0 2.8440977573040982e-08
clinical O 0 1.5524344121331524e-07
severity O 0 6.066505306989711e-07
and O 0 2.7015653714101973e-08
CTG O 0 2.583239393061376e-06
repeat O 0 2.5180348472986225e-08
size O 0 3.5442504486837834e-09
over O 0 9.018848445840888e-10
time O 0 1.0541165718080947e-09
intervals O 0 2.6318545121029047e-09
of O 0 1.0041658615733695e-09
1 O 0 2.0003628975473475e-08
- O 0 8.765247194730819e-09
7 O 0 1.776236580042223e-08
years O 0 7.65831931204275e-09
. O 0 5.736125174848894e-08

We O 0 7.962908910030819e-08
have O 0 5.728422181050519e-10
found O 0 1.590540338325397e-10
a O 0 1.7852219702518823e-10
direct O 0 8.217504454677282e-10
progression O 0 1.7511752048449125e-08
of O 0 5.523513202376762e-09
the O 0 2.2115735909267187e-09
size O 0 4.454261848252372e-09
heterogeneity O 0 3.333691722673393e-08
over O 0 4.5200936327205454e-09
time O 0 6.9989622986099675e-09
related O 0 5.962200955167418e-09
to O 0 1.6605359309807e-09
initial O 0 3.2376085812302335e-08
CTG O 0 1.5614338053637766e-06
repeat O 0 1.599092591675344e-08
size O 0 3.138115767242766e-09
and O 0 5.682217474323181e-10
the O 0 1.106843394715895e-09
time O 0 3.872720810704777e-09
interval O 0 6.0955742675616875e-09
and O 0 2.293162465472065e-10
always O 0 6.560306742287025e-10
biased O 0 1.0342690259790288e-08
towards O 0 9.564457670308002e-09
further O 0 9.672587175657554e-09
expansion O 0 1.1543789213419586e-07
. O 0 3.5325365388416685e-07

Attempts O 0 5.90053559790249e-07
to O 0 1.873876875890801e-08
mathematically O 0 5.532161253540835e-07
model O 0 7.385869338349949e-08
the O 0 1.0753711698896495e-08
dynamics O 0 4.6285049393191e-07
have O 0 6.347174452692173e-10
proved O 0 4.4097657081465513e-08
only O 0 4.026729505390847e-10
partially O 0 3.530082448577332e-09
successful O 0 8.337031620619939e-10
suggesting O 0 7.384340916516408e-10
that O 0 2.5668427452996134e-11
individual O 0 2.4182251687210332e-11
specific O 0 1.4322626418206141e-10
genetic O 0 2.7520010714709997e-09
and O 0 9.784938415080546e-10
/ O 0 9.261728450837836e-08
or O 0 8.205037760333767e-10
environmental O 0 1.8135781765238335e-09
factors O 0 3.884298216405568e-09
also O 0 6.497246629599829e-10
play O 0 1.0757774226988204e-08
a O 0 1.6339343211768664e-09
role O 0 9.330734407342334e-09
in O 0 1.0280382767291485e-08
somatic O 0 3.7152271943341475e-06
mosaicism O 0 9.091236279346049e-06
. O 0 1.1490441664818718e-07
. O 0 9.057175134330464e-07

Aspartylglucosaminuria B-Disease 1 0.9999998807907104
among O 0 2.922348869560665e-07
Palestinian O 0 7.013917638687417e-06
Arabs O 0 5.659655471390579e-06
. O 0 9.795288633540622e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9012423753738403
AGU B-Disease 1 1.0
) O 0 2.126177101047233e-08
is O 0 4.895341909616491e-10
a O 0 1.9605566059510693e-09
rare O 0 3.5688023558577697e-07
disorder B-Disease 1 0.9968520998954773
of I-Disease 0 0.0006985721993260086
glycoprotein I-Disease 0 0.006771979387849569
metabolism I-Disease 1 0.8904504776000977
caused O 0 2.4444676682833233e-07
by O 0 2.5326329922137347e-09
the O 0 1.3131786147368985e-07
deficiency B-Disease 0 0.12664897739887238
of I-Disease 0 4.6507473598467186e-05
the I-Disease 0 3.2482957976753823e-06
lysosomal I-Disease 0 8.386989065911621e-05
enzyme I-Disease 0 3.296491115634126e-07
aspartylglucosaminidase I-Disease 0 1.2703520042123273e-05
( O 0 1.6568414196171943e-08
AGA O 0 3.856172043015249e-06
) O 0 3.639002699173943e-08
. O 0 5.951886805632967e-07

AGU B-Disease 1 1.0
is O 0 1.1648954796328326e-06
inherited O 0 4.525556869339198e-05
as O 0 2.374402541249765e-08
an O 0 3.6782810131086308e-09
autosomal O 0 5.207391495787306e-06
recessive O 0 3.493597205306287e-06
trait O 0 3.000204173986276e-07
and O 0 9.198698691648133e-09
occurs O 0 2.1409440886799302e-09
with O 0 4.161846214878473e-11
a O 0 5.327269736454809e-10
high O 0 4.48043984135893e-08
frequency O 0 1.3577360391536786e-07
in O 0 4.7748258680258004e-09
Finland O 0 4.599866798571384e-08
because O 0 3.4635545542727186e-09
of O 0 1.8887757136099026e-08
a O 0 5.894762455938007e-09
founder O 0 8.739508672306329e-08
effect O 0 4.2283156176381453e-07
. O 0 2.6221735538456414e-07

While O 0 9.510974905424519e-07
very O 0 4.3132537541623606e-08
few O 0 1.1649510689437648e-08
patients O 0 3.3981901736979125e-09
with O 0 4.3465004928577855e-09
AGU B-Disease 1 1.0
have O 0 8.560208542007786e-09
been O 0 2.072973570577119e-09
reported O 0 1.196833188110702e-09
from O 0 3.22835563837387e-10
non O 0 5.348880449673743e-08
- O 0 4.901924910427624e-08
Finnish O 0 7.380080546681711e-07
origin O 0 2.4378135066172035e-08
, O 0 2.812656108019951e-09
we O 0 1.3460882186677736e-08
diagnosed O 0 2.4477060378558235e-06
the O 0 2.145224797800438e-08
disorder O 0 3.8416109759964456e-07
in O 0 1.7918273531591922e-09
8 O 0 7.138831392694556e-08
patients O 0 4.1850123366771186e-10
originating O 0 4.092404193301036e-10
from O 0 5.371653677421762e-10
3 O 0 9.732681149898781e-08
unrelated O 0 1.7308328992271527e-08
families O 0 1.0279275347579997e-10
, O 0 4.2836342112329007e-11
all O 0 9.581849896855843e-11
Palestinian O 0 2.2403769506240678e-08
Arabs O 0 6.75836542285424e-09
from O 0 2.8901339654829883e-10
the O 0 1.469050214808476e-09
region O 0 6.707613575684945e-09
of O 0 3.694180250590762e-08
Jerusalem O 0 7.495409136026865e-06
. O 0 4.2571546146064065e-06

The O 0 3.496746217024338e-07
clinical O 0 4.823581093660323e-06
diagnosis O 0 0.25102880597114563
of O 0 0.029427828267216682
AGU B-Disease 1 1.0
is O 0 4.432940059473367e-08
often O 0 8.923744521105448e-10
difficult O 0 3.0991251787071405e-09
, O 0 1.072698804782668e-10
in O 0 4.0863729067197596e-11
particular O 0 9.693281594058689e-11
early O 0 3.134837500695653e-09
in O 0 1.420818601660656e-10
the O 0 3.4567090856363336e-10
course O 0 2.1459520826994094e-09
of O 0 1.3451173508371994e-09
the O 0 4.3267482929820744e-09
disease O 0 4.917779250490639e-08
, O 0 5.493123317323878e-11
and O 0 1.6333695507242396e-10
most O 0 7.1615421926019e-11
of O 0 1.1787950615627096e-09
the O 0 2.4655890662472757e-09
patients O 0 6.64844568287748e-10
are O 0 2.7750549080884923e-10
diagnosed O 0 2.6365084337953704e-08
after O 0 3.8310057348667215e-09
the O 0 1.453170805909565e-09
age O 0 5.675688807826873e-09
of O 0 5.299797045665855e-09
5 O 0 7.831161497051653e-08
years O 0 2.271845644941095e-08
. O 0 1.7559791842813866e-07

However O 0 3.7679325259887264e-07
, O 0 6.1161413711374735e-09
since O 0 2.491086448230817e-09
these O 0 2.4650892438415895e-10
patients O 0 1.4664738867686822e-10
excrete O 0 2.072040761191829e-09
early O 0 1.0767046143556058e-09
large O 0 7.72102659585272e-11
amounts O 0 3.457711339471814e-10
of O 0 3.5986911228746976e-09
aspartylglucosamine O 0 1.4769744893783354e-07
in O 0 1.1984390146935198e-09
urine O 0 3.318572305843759e-09
, O 0 8.865989192807788e-11
biochemical O 0 1.686257689037518e-09
screening O 0 1.606263122511109e-09
is O 0 1.4401904668837062e-10
easy O 0 1.700163898554763e-09
by O 0 7.044373417919303e-10
urine O 0 1.267577953711907e-08
chromatography O 0 9.887155272281234e-08
. O 0 2.876020843700644e-08
. O 0 2.057388570619878e-07

Detection O 0 2.4894809484976577e-06
of O 0 1.125001745094778e-07
heterozygous O 0 1.952675710015228e-08
carriers O 0 3.761611022667921e-09
of O 0 1.6004908331979095e-07
the O 0 0.0006004917668178678
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.893204535008408e-05
ATM O 0 6.101408871472813e-06
) O 0 1.87790472061522e-09
gene O 0 1.0156810947847816e-09
by O 0 9.429415026573906e-10
G2 O 0 3.056274181290064e-06
phase O 0 1.3788321666652337e-06
chromosomal O 0 9.321253742200497e-07
radiosensitivity O 0 1.5755168760733795e-06
of O 0 2.9710656690440373e-07
peripheral O 0 3.039797957171686e-05
blood O 0 1.415597353116027e-06
lymphocytes O 0 1.962973101399257e-06
. O 0 1.3486525176631403e-06

In O 0 0.004849908873438835
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.359128169539872e-09
patients O 0 2.7212662678799404e-10
, O 0 2.1098170085998014e-11
mutations O 0 5.670997352269502e-11
in O 0 4.4185658604201095e-11
a O 0 1.6859770524124684e-10
single O 0 4.1150088891939163e-10
gene O 0 1.4513096280310833e-09
, O 0 1.1928313892184406e-09
ATM O 0 3.039286013972742e-07
, O 0 7.44651673656449e-10
result O 0 6.464185187127214e-09
in O 0 9.781734533476083e-09
an O 0 7.849966095818672e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 9.439012274015113e-07
embraces O 0 1.6835340943543997e-07
a O 0 4.756083527013288e-09
variety O 0 1.1646089426164963e-08
of O 0 2.7013696168864954e-08
clinical O 0 2.8658419637395127e-07
features O 0 4.0558859382144874e-08
and O 0 6.912673544690051e-09
manifests O 0 2.6012036968836583e-08
extreme O 0 1.7952477264771005e-06
radiosensitivity O 0 3.180206840625033e-05
and O 0 2.2842506552933628e-08
a O 0 1.3694576139755554e-08
strong O 0 1.7231850790722092e-07
pre O 0 0.00012335892824921757
- O 0 4.9277414291282184e-06
disposition O 0 1.2917679669044446e-05
to O 0 4.813728082808666e-08
malignancy B-Disease 0 4.302963861846365e-05
. O 0 1.6662273765177815e-06

Heterozygotes O 0 2.1182652290008264e-06
for O 0 1.3805354193152652e-08
the O 0 1.4421160265953858e-08
ATM O 0 2.3178698427273048e-07
gene O 0 7.548808245161354e-10
have O 0 8.085981190175673e-11
no O 0 2.0595176952742378e-10
clinical O 0 5.80281911410907e-09
expression O 0 2.85593038107379e-09
of O 0 1.5472906511604378e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.5626090998921427e-07
may O 0 2.143820267974661e-07
be O 0 2.8483539082913012e-08
cancer B-Disease 0 1.4318685259695485e-07
prone O 0 2.333274373711447e-08
with O 0 2.328510440019471e-10
a O 0 1.8883963281979277e-09
moderate O 0 2.233031182186096e-07
increase O 0 2.916210384285023e-09
in O 0 6.422057552413207e-09
in O 0 2.5334895070727725e-08
vitro O 0 1.1266976116530714e-06
radiosensitivity O 0 1.1636935596470721e-05
. O 0 9.529360340820858e-07

We O 0 3.3390122666787647e-07
performed O 0 4.309520207357309e-08
a O 0 2.2724220727354805e-08
blind O 0 3.965772350511543e-07
chromosomal O 0 1.361908289254643e-06
analysis O 0 1.386584358442633e-07
on O 0 5.902703037463652e-07
G2 O 0 9.649761523178313e-06
- O 0 9.03050931810867e-08
phase O 0 2.691311067337665e-07
lymphocytes O 0 5.0743289570220895e-09
from O 0 5.163110494699197e-10
7 O 0 1.3156090972188395e-07
unrelated O 0 5.880452818018966e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.626461028081394e-07
, O 0 2.8369770976865993e-09
13 O 0 4.724540758616058e-08
obligate O 0 3.735495397449995e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 3.0082430839684093e-06
( O 0 7.914931487995602e-10
parents O 0 1.7085860504195693e-10
of O 0 3.5814609611328763e-10
the O 0 2.104155599758073e-10
patients O 0 1.722609901944061e-11
) O 0 3.833911660366951e-11
, O 0 1.245770153701642e-10
and O 0 1.003289118450823e-09
14 O 0 7.370304899723124e-08
normal O 0 2.3407361382510317e-08
controls O 0 1.4104945655901702e-08
following O 0 1.1908315222797228e-08
X O 0 8.807412541500526e-07
- O 0 1.1929548016098579e-08
irradiation O 0 3.862776321028605e-09
with O 0 2.2229952600927305e-10
1 O 0 5.4141402472396294e-08
Gy O 0 4.926045562569925e-07
in O 0 1.1986922565654368e-10
order O 0 4.034724776502685e-10
to O 0 1.3534860732189458e-10
evaluate O 0 4.143474452433793e-09
this O 0 2.500567808372267e-10
cytogenetic O 0 2.273606298786035e-07
method O 0 1.8227899190037533e-08
as O 0 1.0451994825189104e-09
a O 0 5.617356579890043e-10
tool O 0 1.936474802732846e-08
for O 0 8.346099922285077e-10
detection O 0 7.40889518624499e-08
of O 0 5.6665083292273266e-08
ATM O 0 1.958035227289656e-06
carriers O 0 7.009679592329121e-08
. O 0 1.010813434731972e-06

Both O 0 6.152277364890324e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 3.6260695196688175e-05
and O 0 1.2968929041790034e-08
heterozygotes O 0 1.0570087027872432e-07
showed O 0 7.170720905946837e-09
significantly O 0 1.4819452331948924e-09
increased O 0 3.559844363731912e-10
levels O 0 2.1563326679796546e-09
of O 0 1.4755314747816328e-09
radiation O 0 6.4963078330038115e-06
- O 0 4.5768854306516005e-07
induced O 0 6.179192837407754e-07
chromatid O 0 9.324143093181192e-07
damage O 0 1.2785854153207765e-07
relative O 0 2.2648151798421168e-08
to O 0 4.168139999816134e-10
that O 0 1.25775070913825e-10
of O 0 5.5674500565316976e-09
normal O 0 6.75117846071771e-08
controls O 0 3.4517060498728824e-07
. O 0 4.5430738282448146e-07

These O 0 1.6508794331571153e-08
results O 0 4.057247338096204e-08
show O 0 2.440738722242486e-09
that O 0 2.2987241277139248e-10
the O 0 3.64906505012641e-09
G2 O 0 9.69613893175847e-07
- O 0 7.493484588394494e-08
phase O 0 5.910380309614993e-07
chromosomal O 0 2.259754410260939e-07
radiosensitivity O 0 3.819218363787513e-07
assay O 0 2.748765837168321e-08
can O 0 2.422598233131623e-10
be O 0 8.536687329252501e-11
used O 0 5.6268007614379556e-11
for O 0 4.3375185387883874e-11
the O 0 1.7438805954839154e-10
detection O 0 6.494031623560659e-08
of O 0 5.895574872738507e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.008694509975612164
. O 0 5.068854989076499e-06

In O 0 1.2932105164509267e-07
combination O 0 1.6992271412163973e-07
with O 0 4.920009732956032e-09
molecular O 0 1.3648912045027828e-06
genetic O 0 2.4516625174442197e-08
analyses O 0 8.295002018599007e-09
, O 0 1.8213318353499375e-10
this O 0 2.935225673628139e-11
test O 0 1.006190464281076e-09
may O 0 1.0695402896665485e-10
be O 0 4.9805836538352466e-11
of O 0 3.6638882899842073e-11
value O 0 5.965743871128026e-11
in O 0 1.0640540532014242e-11
studies O 0 5.388623575131035e-11
of O 0 1.9349852276029367e-10
familial B-Disease 0 9.888283081238569e-09
and I-Disease 0 4.28298463361898e-09
sporadic I-Disease 0 2.7620837954600574e-06
cancers I-Disease 0 8.49376228870824e-05
aimed O 0 1.955253082996933e-06
at O 0 5.6719522945059e-07
determination O 0 3.283704330669934e-08
of O 0 2.383722907950414e-08
the O 0 1.2673331273305166e-09
potential O 0 3.5876024373493465e-09
involvement O 0 2.2732978166573048e-08
of O 0 1.5574806866425206e-07
ATM O 0 3.7667505239369348e-06
mutations O 0 2.2601804872124376e-08
in O 0 3.866801101537476e-09
tumor B-Disease 0 1.4528080782838515e-06
risk O 0 1.532688145289285e-07
or O 0 3.339846088579179e-08
development O 0 1.7758428327852016e-07
. O 0 2.6901913585675175e-08
. O 0 2.2790335663103178e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.8821136791302706e-06
identification O 0 9.349657403845413e-08
and O 0 1.9800534545311166e-09
detection O 0 6.894821069636237e-08
of O 0 6.105490513164114e-08
founder O 0 9.704770036478294e-07
- O 0 1.7651430539444846e-07
effect O 0 7.587616579485257e-08
mutations O 0 1.8927632794429883e-09
in O 0 3.396600778415859e-10
the O 0 1.8231087750564257e-09
ATM O 0 2.9773387311138322e-08
gene O 0 3.599623099592719e-10
in O 0 2.8218596903606397e-10
ethnic O 0 1.1415993705909955e-09
populations O 0 9.705797054948562e-09
. O 0 1.8147977698390605e-07

To O 0 7.247684408184796e-08
facilitate O 0 3.368333523212641e-08
the O 0 7.025283021988571e-09
evaluation O 0 4.652136098570736e-08
of O 0 4.335573322578057e-08
ATM O 0 2.0713837329822127e-06
heterozygotes O 0 3.0169056230988645e-07
for O 0 2.1848074460706357e-09
susceptibility O 0 1.9252540539582697e-07
to O 0 3.2342120093176163e-09
other O 0 2.025788425896735e-08
diseases O 1 0.9074192047119141
, O 0 1.3941003906836613e-10
such O 0 4.211573589874007e-10
as O 0 6.873470681512117e-08
breast B-Disease 0 3.129754304609378e-06
cancer I-Disease 0 1.6288142035136843e-07
, O 0 8.77820871547641e-10
we O 0 1.455689790930137e-09
have O 0 1.396154580834974e-10
attempted O 0 2.1805608430014445e-09
to O 0 1.1274468858513131e-10
define O 0 2.4528867825779344e-09
the O 0 3.0132762951495806e-10
most O 0 5.157448773607243e-11
common O 0 3.658945646467515e-10
mutations O 0 9.814133949959114e-10
and O 0 1.288415207856275e-10
their O 0 7.140540936312334e-10
frequencies O 0 1.8368905330135021e-07
in O 0 4.344612989370944e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999667406082153
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.4337147852548924e-09
homozygotes O 0 2.4010809340779815e-08
from O 0 2.0878128392798345e-10
10 O 0 1.0049514553855943e-09
ethnic O 0 3.337957688032134e-10
populations O 0 3.095385725515598e-09
. O 0 7.691435399692637e-08

Both O 0 2.0435692249520798e-07
genomic O 0 3.2378991932091594e-07
mutations O 0 1.3273795396173682e-08
and O 0 1.1284349010765027e-09
their O 0 4.0159758851743277e-10
effects O 0 1.0202734657127621e-08
on O 0 1.3750167227044585e-08
cDNA O 0 4.257217511849376e-08
were O 0 2.6553223619885102e-08
characterized O 0 2.5176657914016687e-07
. O 0 9.598084034223575e-07

Protein O 0 2.6023906229966087e-06
- O 0 3.603350080538803e-07
truncation O 0 3.5134095810462895e-07
testing O 0 1.522289316824299e-08
of O 0 3.800496806150022e-09
the O 0 1.7547052699740107e-09
entire O 0 6.3216125667509004e-09
ATM O 0 4.234573935946173e-08
cDNA O 0 9.777779474973158e-09
detected O 0 6.4558309809115144e-09
92 O 0 3.5663450859146906e-08
( O 0 7.025655057724123e-10
66 O 0 8.89153550787114e-09
% O 0 3.7508340877678847e-10
) O 0 7.267084156659109e-10
truncating O 0 5.210304721003922e-08
mutations O 0 5.703306715787448e-09
in O 0 5.429152682978611e-09
140 O 0 3.2675849581664806e-08
mutant O 0 2.1791990434394393e-07
alleles O 0 4.522333654222166e-07
screened O 0 9.234931326318474e-07
. O 0 1.3088080095258192e-06

The O 0 1.6376485518776462e-06
haplotyping O 0 3.060076414840296e-05
of O 0 3.0744260470783047e-07
patients O 0 5.6030957651387325e-09
with O 0 5.145866510680719e-10
identical O 0 3.397647958536254e-07
mutations O 0 2.91493300608181e-08
indicates O 0 5.100022626436385e-09
that O 0 1.8739107487952822e-10
almost O 0 5.086021603872837e-10
all O 0 5.648899056853729e-11
of O 0 6.736082525105047e-11
these O 0 1.2668412326111156e-11
represent O 0 6.827206855408718e-11
common O 0 3.4219935218793296e-10
ancestry O 0 2.88813362114837e-10
and O 0 3.8348346720340487e-10
that O 0 2.617255856485201e-10
very O 0 2.731204817862931e-09
few O 0 1.221133150153264e-08
spontaneously O 0 4.1876994316680793e-08
recurring O 0 1.0977113618082512e-07
ATM O 0 8.812622240839119e-07
mutations O 0 8.919293748022028e-08
exist O 0 1.361709252023502e-07
. O 0 4.90069112402125e-07

Assays O 0 9.035425705405942e-07
requiring O 0 3.2666257254732045e-08
minimal O 0 8.151371133635621e-08
amounts O 0 3.95783539275385e-09
of O 0 3.1488602836304835e-09
genomic O 0 3.352538691103746e-09
DNA O 0 5.9106257666030615e-09
were O 0 3.8764139120850416e-10
designed O 0 1.7185292078281122e-09
to O 0 1.9871991552289359e-10
allow O 0 6.263232710246314e-10
rapid O 0 3.352641275711221e-09
screening O 0 1.2619106870559449e-09
for O 0 1.5423133603587047e-10
common O 0 6.759499626696197e-09
ethnic O 0 8.384429150964934e-09
mutations O 0 9.895985186858525e-08
. O 0 1.9382493121611333e-07

These O 0 7.47678043921951e-08
rapid O 0 7.792645106974305e-08
assays O 0 1.4093483002852736e-07
detected O 0 2.3010512606447264e-08
mutations O 0 1.3258555364714653e-09
in O 0 5.097646749163687e-10
76 O 0 8.691645625447109e-09
% O 0 4.6512887985628026e-10
of O 0 8.391692674081241e-09
Costa O 0 1.2647952871702728e-06
Rican O 0 3.3046813996406854e-07
patients O 0 3.974160112107938e-09
( O 0 7.886149511193707e-10
3 O 0 4.1224527791428045e-08
) O 0 2.78605416514921e-10
, O 0 1.0632533048449133e-10
50 O 0 3.074630827715197e-10
% O 0 7.984220229406702e-11
of O 0 2.2902437724070523e-09
Norwegian O 0 2.7624108156487637e-07
patients O 0 9.984649773642218e-10
( O 0 4.88095619477491e-10
1 O 0 1.6756429133124584e-08
) O 0 1.8324963768634461e-10
, O 0 8.549136398805501e-11
25 O 0 3.833810768849588e-10
% O 0 4.4657499920219834e-11
of O 0 9.860855465504414e-10
Polish O 0 1.3726055385632208e-06
patients O 0 5.981701356461144e-09
( O 0 7.826017056622447e-10
4 O 0 4.850178569881791e-08
) O 0 2.0429213876127506e-10
, O 0 1.385403319842382e-10
and O 0 3.633450207374267e-10
14 O 0 5.651889622981798e-09
% O 0 8.656314554045252e-11
of O 0 2.9829532177672036e-09
Italian O 0 1.1891359008586733e-06
patients O 0 6.7941665626847225e-09
( O 0 9.039927695297933e-10
1 O 0 1.6000207381239306e-07
) O 0 8.47691750127666e-10
, O 0 2.645613172980177e-10
as O 0 1.8809759305682405e-10
well O 0 1.1989940984502567e-10
as O 0 6.277892788952855e-11
in O 0 1.0652607962402527e-10
patients O 0 8.853077992920788e-11
of O 0 3.5862821601284622e-09
Amish O 0 7.228348977150745e-07
/ O 0 1.0452816923134378e-06
Mennonite O 0 1.5610719401593087e-06
and O 0 2.015759648088533e-08
Irish O 0 1.8614984753639874e-07
English O 0 2.751646206888836e-06
backgrounds O 0 6.8373169597180095e-06
. O 0 2.2878732579556527e-06

Additional O 0 7.631987841705268e-08
mutations O 0 4.464538960746722e-08
were O 0 6.42770681125171e-09
observed O 0 3.3711600178065737e-09
in O 0 7.042559313497065e-10
Japanese O 0 2.25156622235545e-08
, O 0 2.5318407370633622e-09
Utah O 0 3.040778651097753e-08
Mormon O 0 7.123893919214197e-09
, O 0 5.500444544281891e-10
and O 0 2.0547514800739464e-09
African O 0 4.4479815386466726e-08
American O 0 2.8565036558347856e-08
patients O 0 2.7186752404873005e-08
. O 0 7.830233812455845e-07

These O 0 5.539447300861866e-08
assays O 0 1.0208364642494416e-07
should O 0 5.85773163308545e-09
facilitate O 0 4.531332198354221e-09
screening O 0 3.69719499460075e-09
for O 0 5.074058062604081e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 3.3414744393667206e-07
in O 0 7.446431804503106e-10
the O 0 1.6773424316163243e-10
populations O 0 2.5011772167293778e-11
studied O 0 2.138364818549121e-09
. O 0 1.4151666505313187e-09
. O 0 4.7431225169702884e-08

The O 0 8.047425581025891e-06
von B-Disease 1 0.9999909400939941
Hippel I-Disease 1 0.9999947547912598
- I-Disease 1 0.9997139573097229
Lindau I-Disease 0 0.2961295247077942
tumor I-Disease 0 6.767294507881161e-06
suppressor O 0 6.579974183296144e-07
gene O 0 1.4561672978530282e-09
is O 0 1.0190375626661918e-10
required O 0 6.539742636313406e-10
for O 0 5.087952836824172e-10
cell O 0 4.863276714672793e-08
cycle O 0 2.7343700637061374e-08
exit O 0 4.812241272134088e-08
upon O 0 2.2617156147930473e-08
serum O 0 7.744754526584074e-08
withdrawal O 0 1.5079837112352834e-07
. O 0 9.882251106319018e-07

The O 0 5.385065833252156e-07
inactivation O 0 3.0975013487477554e-06
of O 0 1.912313081220418e-07
the O 0 2.1163297958537441e-07
von B-Disease 1 0.9999994039535522
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 1.3464470612234436e-05
VHL I-Disease 1 0.878411054611206
) I-Disease 0 8.748414614956346e-08
tumor I-Disease 0 3.3621895454416517e-06
suppressor O 0 1.0337274034100119e-05
gene O 0 1.773519215930719e-07
predisposes O 0 5.915399015066214e-07
affected O 0 1.5321234059229027e-08
individuals O 0 1.8161942783034846e-10
to O 0 1.0329554989141343e-09
the O 0 7.076929620097872e-08
human O 1 0.9999547004699707
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
and O 0 2.65811941346783e-08
is O 0 1.0462127830734858e-09
associated O 0 1.0112239934301215e-08
with O 0 2.5329711661470355e-09
sporadic B-Disease 1 0.7905389666557312
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 8.472784975310788e-05
RCC B-Disease 1 0.999962568283081
) O 0 6.668886243232919e-08
and O 0 9.702358738650219e-08
brain B-Disease 0 0.13553132116794586
hemangioblastomas I-Disease 0 0.0002489240141585469
. O 0 4.313239060138585e-06

VHL O 0 0.005153322126716375
- O 0 3.059393566218205e-05
negative O 0 7.90475326084561e-07
786 O 0 5.87390650252928e-06
- O 0 1.6799732520667021e-06
0 O 0 5.090127501716779e-07
RCC B-Disease 0 6.142803158581955e-06
cells O 0 2.708804558437805e-08
are O 0 1.123728998742024e-09
tumorigenic O 0 1.0575022315606475e-06
in O 0 1.889453038472766e-08
nude O 0 4.649759262065345e-07
mice O 0 4.248203566703523e-09
which O 0 2.2506281560641384e-10
is O 0 1.1880421646459638e-10
suppressed O 0 2.883775218620599e-09
by O 0 1.0171539305270372e-10
the O 0 1.3896436223959086e-09
reintroduction O 0 6.987306733208243e-08
of O 0 7.531010481898193e-08
VHL B-Disease 0 0.0003400315181352198
. O 0 6.241395112738246e-06

Remarkably O 0 9.432115803065244e-06
, O 0 1.8977808213804792e-09
this O 0 1.7228078685871395e-10
occurs O 0 1.1969016888713213e-09
without O 0 7.208688646009875e-10
affecting O 0 2.5895838806633265e-09
the O 0 5.702227023896e-10
growth O 0 9.580903848060984e-10
rate O 0 7.692307901763229e-10
and O 0 2.527159870258089e-10
cell O 0 7.758827358372855e-09
cycle O 0 1.3394824138757144e-09
profile O 0 6.707252531157337e-10
of O 0 5.720015572308057e-10
these O 0 1.9750545643404394e-10
cells O 0 8.632839443301066e-10
in O 0 7.234253751597919e-10
culture O 0 6.48701288241682e-08
. O 0 1.4718506236022222e-07

The O 0 1.3514259080693591e-06
786 O 0 5.1485503718140535e-06
- O 0 6.132772796263453e-07
0 O 0 2.2879576988543704e-07
cell O 0 8.28245276807138e-08
line O 0 1.2791996795158411e-08
, O 0 7.130686596745761e-10
like O 0 3.135721127200952e-10
many O 0 2.35476332877127e-10
cancer B-Disease 0 3.1704168179658154e-09
cells O 0 1.2527833215258966e-09
, O 0 3.2602856525620894e-10
fails O 0 5.1580539839335415e-09
to O 0 1.8332908524598679e-09
exit O 0 7.592799278199891e-08
the O 0 1.7816045527752067e-08
cell O 0 8.669562134855369e-08
cycle O 0 1.0902784453037384e-08
upon O 0 1.1583971115669556e-08
serum O 0 2.5707910467076545e-08
withdrawal O 0 2.300920272091389e-07
. O 0 1.1059216831199592e-06

Here O 0 4.2550988155198866e-07
, O 0 8.003526730249177e-10
it O 0 5.461760557712303e-11
is O 0 8.890453477572446e-12
shown O 0 2.6754296694742052e-11
that O 0 1.2578580538269435e-11
reintroduction O 0 1.7794368201151656e-09
of O 0 9.431142533600223e-10
the O 0 2.0399866240694564e-09
wild O 0 2.0131162514758216e-08
- O 0 5.3720995651929115e-08
type O 0 6.141299877526762e-07
VHL B-Disease 0 0.0001295989495702088
gene O 0 6.25514431362717e-08
restores O 0 4.0435045889353205e-07
the O 0 9.982008108977425e-09
ability O 0 2.7363004306835137e-08
of O 0 3.5178217672182654e-07
VHL O 1 0.6902449727058411
- O 0 0.00018817794625647366
negative O 0 2.6562929633655585e-06
RCC B-Disease 0 0.0007221485720947385
cancer I-Disease 0 2.7869395680113485e-08
cells O 0 5.255372248491597e-10
to O 0 2.95726637622451e-10
exit O 0 1.9189807076713805e-08
the O 0 8.29090573972735e-09
cell O 0 4.350989613044476e-08
cycle O 0 6.662222329367751e-09
and O 0 2.370066587431552e-09
enter O 0 1.1032317814851922e-07
G0 O 0 0.0005518081597983837
/ O 0 6.966241471673129e-06
quiescence O 0 6.501271400338737e-06
in O 0 5.456999829789311e-08
low O 0 1.9375077044969657e-06
serum O 0 1.2290647646295838e-06
. O 0 6.359092026286817e-07

Both O 0 6.548438705067383e-06
VHL O 0 0.014162681996822357
- O 0 1.1080605872848537e-05
positive O 0 3.498973910609493e-08
and O 0 3.653280344906307e-08
VHL O 0 2.5195415219059214e-05
- O 0 2.867454895749688e-07
negative O 0 6.126850138343798e-08
RCC B-Disease 0 3.2360765089833876e-06
cells O 0 8.605751666834749e-09
exit O 0 1.7920742223509478e-08
the O 0 1.7468609891935216e-09
cell O 0 1.3009286981002788e-08
cycle O 0 6.614967684726025e-09
by O 0 1.4037787599008311e-09
contact O 0 2.844532502876973e-07
inhibition O 0 1.0913656296906993e-05
. O 0 2.234804696854553e-06

The O 0 6.847626991657307e-06
cyclin O 0 1.8417738829157315e-05
- O 0 1.47709999964718e-06
dependent O 0 2.8973212806704396e-07
kinase O 0 4.4804400545217504e-07
inhibitor O 0 1.716208402058328e-07
, O 0 1.3533369980223142e-09
p27 O 0 4.5723133723640785e-08
, O 0 3.2806524163930817e-10
accumulates O 0 2.47792675267533e-09
upon O 0 1.6405576896971752e-09
serum O 0 7.45089268061605e-10
withdrawal O 0 8.288166264414087e-10
, O 0 1.0713778475501812e-10
only O 0 3.970170719957977e-11
in O 0 2.5077502574522015e-11
the O 0 8.9570600936284e-11
presence O 0 3.2914515557536106e-10
of O 0 9.338728901298055e-09
VHL B-Disease 0 1.2151328519394156e-05
, O 0 7.703951365733985e-10
as O 0 2.8073274260798087e-10
a O 0 3.0335695067051915e-10
result O 0 1.27032917518477e-09
of O 0 4.992620095123357e-09
the O 0 2.23487894857044e-09
stabilization O 0 2.7766354548930394e-08
of O 0 3.180781860123716e-08
the O 0 5.1670369316525466e-08
protein O 0 1.8375371269030438e-07
. O 0 2.3718683905826765e-07

We O 0 1.7634368987273774e-07
propose O 0 4.900363492765791e-08
that O 0 4.735903891273097e-10
the O 0 2.490212258621227e-09
loss O 0 3.679370763620682e-08
of O 0 3.298304918075701e-08
wild O 0 4.892098814934798e-08
- O 0 6.067089231009959e-08
type O 0 1.028646238410147e-06
VHL B-Disease 0 0.0023181878495961428
gene O 0 3.219786393060531e-08
results O 0 1.1010412492851174e-07
in O 0 2.0779533649317727e-09
a O 0 2.655047515176534e-09
specific O 0 2.2728338322508534e-08
cellular O 0 5.649090439874271e-07
defect O 0 1.4777987189518171e-07
in O 0 7.54600382180115e-09
serum O 0 1.0649616655200589e-07
- O 0 2.0643947209464386e-06
dependent O 0 3.792186120676888e-08
growth O 0 5.3783817399732925e-09
control O 0 1.1627180107609547e-08
, O 0 2.749575567229101e-10
which O 0 1.8325836681487573e-10
may O 0 3.1850302395497465e-09
initiate O 0 3.815868510059772e-08
tumor B-Disease 0 2.0199458106162638e-07
formation O 0 4.1751303569981246e-07
. O 0 6.425466381188016e-07

This O 0 4.871019143593003e-08
is O 0 3.2003393268809077e-09
corrected O 0 3.723664931953863e-08
by O 0 1.010262984380006e-10
the O 0 4.772874873104627e-10
reintroduction O 0 5.4114122072235205e-09
of O 0 3.205018250795888e-09
wild O 0 2.294696166416088e-08
- O 0 1.60180562147616e-07
type O 0 1.776574026735034e-05
VHL B-Disease 1 0.9999856948852539
, O 0 2.3099302381979214e-07
implicating O 0 0.0012573201674968004
VHL B-Disease 0 0.00011598346463870257
as O 0 3.981245555451096e-09
the O 0 2.5829884897632382e-09
first O 0 2.3867925413867397e-09
tumor B-Disease 0 7.552483083372863e-09
suppressor O 0 2.8041567290415514e-08
involved O 0 1.8381892674668165e-09
in O 0 1.208891875492668e-09
the O 0 5.48501510877486e-09
regulation O 0 6.401184293736151e-08
of O 0 1.2616111177976563e-07
cell O 0 2.0881938667116628e-07
cycle O 0 1.339245425668878e-08
exit O 0 8.577041299417942e-09
, O 0 7.538487195590804e-11
which O 0 3.919570917831905e-11
is O 0 7.123723139157434e-11
consistent O 0 1.058028331613059e-09
with O 0 5.603389280350868e-11
its O 0 7.42670147602098e-10
gatekeeper O 0 3.176138108074156e-08
function O 0 5.30209209870236e-09
in O 0 1.3765537598686706e-09
the O 0 7.061178308731542e-09
kidney O 0 3.7552192111434124e-07
. O 0 5.1417902824368866e-08
. O 0 5.846214889970724e-07

Piebaldism B-Disease 1 1.0
with O 0 0.22336198389530182
deafness B-Disease 1 1.0
: O 0 6.64971935293579e-08
molecular O 0 6.903900384713779e-08
evidence O 0 8.889042391047042e-09
for O 0 4.1139103235110497e-10
an O 0 7.780325828043999e-10
expanded O 0 3.9556041997457214e-07
syndrome O 1 0.5655452013015747
. O 0 1.3304586900630966e-05

In O 0 7.023222536872709e-08
a O 0 1.0324005650375057e-08
South O 0 1.2100774426926364e-07
African O 0 6.119212798694207e-07
girl O 0 3.3484255368421145e-07
of O 0 9.833667036218685e-08
Xhosa O 0 2.2905171590537066e-06
stock O 0 1.4387751434696838e-08
with O 0 5.213808274007192e-10
severe O 0 2.9552168143709423e-06
piebaldism B-Disease 0 0.0009135084110312164
and O 0 1.444328631805547e-06
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.4696305470351945e-06
identified O 0 4.644332030068199e-09
a O 0 3.233198986318797e-10
novel O 0 2.402637422349585e-09
missense O 0 8.502153292511139e-08
substitution O 0 2.1627840851579094e-08
at O 0 1.3058864567483397e-07
a O 0 3.028668205118379e-09
highly O 0 9.592208805031532e-09
conserved O 0 3.044075214120312e-08
residue O 0 1.6847771178163384e-07
in O 0 4.831533839677604e-09
the O 0 1.902043500479067e-08
intracellular O 0 1.7506785354726162e-07
kinase O 0 1.5678081410896993e-07
domain O 0 4.455861457586252e-08
of O 0 2.034772528247686e-08
the O 0 1.5458873292573116e-08
KIT O 0 1.8626773453433998e-05
proto O 0 0.00010212168126599863
- O 0 4.91217315357062e-06
oncogene O 0 7.791218195052352e-06
, O 0 2.6915309092601092e-08
R796G O 0 4.206891389912926e-06
. O 0 1.3118095694153453e-06

Though O 0 3.2411307415713964e-07
auditory B-Disease 0 7.21840187907219e-05
anomalies I-Disease 0 2.9932616598671302e-06
have O 0 6.832538979040237e-10
been O 0 4.435777023470422e-10
observed O 0 2.246640429248714e-09
in O 0 1.0287125595809243e-09
mice O 0 2.136087218218563e-08
with O 0 4.946902887326132e-09
dominant O 0 0.35069510340690613
white O 0 7.232111329358304e-06
spotting O 0 1.8902925148722716e-05
( O 0 9.107049692147484e-08
W O 0 6.452288653235883e-05
) O 0 3.286835914551034e-09
due O 0 5.976833961085504e-08
to O 0 1.1395419718951416e-08
KIT O 1 0.9993744492530823
mutations O 0 5.570344001171179e-05
, O 0 6.093066531320801e-07
deafness B-Disease 1 1.0
is O 0 1.9006680673783194e-09
not O 0 3.046558005870281e-10
typical O 0 1.6056138640863082e-09
in O 0 8.537962004062649e-10
human O 0 3.089871825068258e-08
piebaldism B-Disease 0 5.332385171641363e-06
. O 0 1.2390482879709452e-06

Thus O 0 1.4411115500934102e-07
, O 0 2.144732835773766e-09
the O 0 2.064505899568303e-09
occurrence O 0 1.3422200595414324e-07
of O 0 4.389668902149424e-06
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 5.828144935549062e-07
this O 0 3.98082056207727e-09
patient O 0 5.722615270542519e-09
extends O 0 2.1029931129845636e-09
considerably O 0 3.3387232978299153e-09
the O 0 1.2067585819508508e-09
phenotypic O 0 2.1183652165746025e-07
range O 0 3.954728455823897e-08
of O 0 2.4519525965160938e-08
piebaldism B-Disease 0 6.262354190766928e-07
due O 0 7.169588656097403e-08
to O 0 6.122736095903747e-09
KIT O 0 1.7615606111576199e-06
gene O 0 3.785868063488351e-09
mutation O 0 2.067319204712703e-09
in O 0 3.235061940554118e-10
humans O 0 1.5315090307055357e-09
and O 0 6.180471689987144e-10
tightens O 0 7.584632477630748e-09
the O 0 7.898583453957997e-10
clinical O 0 5.847427875238509e-09
similarity O 0 4.16024681371141e-09
between O 0 1.4657874025658657e-08
piebaldism B-Disease 0 2.9579786087197135e-07
and O 0 8.342853075049561e-10
the O 0 7.970985538285902e-10
various O 0 8.508488358316413e-10
forms O 0 2.420476086228973e-08
of O 0 1.5314913071051706e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9998781681060791
. O 0 2.2976881552949635e-07
. O 0 1.3168722716727643e-06

Cycloheximide O 0 8.226055069826543e-05
facilitates O 0 9.063347050641823e-08
the O 0 3.940541226654659e-09
identification O 0 1.0829953822621974e-08
of O 0 2.584783942438662e-08
aberrant O 0 1.7145301001164626e-07
transcripts O 0 3.7479347270164e-07
resulting O 0 1.442468100520955e-08
from O 0 4.3227230683839934e-09
a O 0 5.9299578580862544e-09
novel O 0 8.847487009688848e-08
splice O 0 9.158065950032324e-06
- O 0 9.29642283153953e-07
site O 0 3.6589355545402213e-08
mutation O 0 7.826662873355872e-09
in O 0 6.264406771094855e-09
COL17A1 O 0 5.645699638989754e-05
in O 0 1.3352766892182899e-08
a O 0 1.1810101341325208e-08
patient O 0 1.0916480874811896e-07
with O 0 4.538487985428219e-08
generalized O 1 0.999994158744812
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9997058510780334
. O 0 3.017221752088517e-05

Patients O 0 3.32917261403054e-06
with O 0 9.742822015823549e-08
generalized O 1 0.9738474488258362
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9856745600700378
often O 0 2.198599347025265e-08
show O 0 1.601491739222638e-08
decreased O 0 1.0352716017791863e-08
expression O 0 3.06154146478832e-09
of O 0 6.90618939813703e-09
type O 0 8.216211710987409e-08
XVII O 0 4.54228138551116e-05
collagen O 0 2.0278032764053933e-07
, O 0 3.7165392985372137e-09
a O 0 1.1880818107101732e-08
transmembrane O 0 2.2241260921873618e-07
hemidesmosomal O 0 4.2403615907460335e-07
protein O 0 7.838704796370166e-09
encoded O 0 2.11000816818796e-09
by O 0 3.451875008053662e-09
COL17A1 O 0 1.2937304745719302e-05
. O 0 8.102223887362925e-07

This O 0 1.3544304522383754e-07
report O 0 4.679269594021207e-08
documents O 0 5.150535642428622e-08
a O 0 8.861247735580946e-09
novel O 0 3.1887029905419695e-08
splice O 0 1.7745591094353586e-06
- O 0 1.590336466961162e-07
site O 0 2.335210957937761e-08
mutation O 0 6.7017307259220615e-09
in O 0 4.100578987475956e-09
COL17A1 O 0 3.1206105632008985e-05
in O 0 5.4073265864929e-09
a O 0 8.61895887993569e-09
patient O 0 8.287604202905641e-08
with O 0 2.9576643356676868e-08
generalized O 1 0.9999994039535522
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999958276748657
, O 0 3.103296819517709e-08
and O 0 2.830329082215144e-09
applies O 0 3.018760130757414e-09
a O 0 3.0220423385962647e-10
new O 0 4.037388479094517e-10
methodology O 0 9.621632379719358e-10
to O 0 1.1339296862589165e-10
define O 0 3.619949451305615e-09
and O 0 7.753171993307717e-10
characterize O 0 1.044078157264039e-08
the O 0 4.2379819653604045e-09
resulting O 0 1.756661838214768e-08
mRNA O 0 2.255915063642533e-07
splice O 0 2.687668711587321e-06
variants O 0 9.857307077254518e-07
. O 0 7.101158985278744e-07

Mutational O 0 0.00011462887050583959
analysis O 0 7.925707450340269e-07
of O 0 5.307923061081965e-07
COL17A1 O 0 0.0009428985067643225
identified O 0 6.081676247049472e-07
a O 0 7.375690813660185e-08
maternally O 0 1.6377001657019719e-06
inherited O 0 2.1822694179718383e-05
G O 0 4.1668954509077594e-05
- O 0 2.6933881599688902e-05
to O 0 2.2424659107400657e-07
- O 0 0.010175390169024467
T O 0 4.441767305252142e-05
transversion O 0 4.202969648758881e-06
at O 0 4.661178110154651e-08
the O 0 6.997863954971706e-10
- O 0 1.4684814475529606e-09
1 O 0 2.58671573050151e-09
position O 0 1.8059401085679383e-08
of O 0 1.8148663016859246e-08
exon O 0 4.5259622538651456e-07
32 O 0 9.79451328930736e-07
. O 0 8.73575629611878e-07

This O 0 1.1799253485378358e-07
acceptor O 0 9.788718102754501e-08
splice O 0 3.2330533485946944e-06
- O 0 9.585646409959736e-08
site O 0 9.205596285255524e-09
mutation O 0 9.721836669029926e-10
led O 0 9.75188596541443e-10
to O 0 6.082632730830539e-10
the O 0 2.8712781041662083e-09
formation O 0 4.73615244800385e-08
of O 0 2.701030155094486e-07
aberrant O 0 3.222050963813672e-07
transcripts O 0 4.7671392167103477e-07
present O 0 3.2125786475489804e-08
at O 0 5.303855346028286e-07
extremely O 0 2.858368475244788e-07
low O 0 2.189795304730069e-05
levels O 0 1.362792681902647e-05
. O 0 1.993337491512648e-06

Based O 0 3.2573245789535576e-07
on O 0 2.3138238702813396e-07
our O 0 1.805144655975255e-08
recent O 0 9.530308764382767e-10
finding O 0 4.999090474910872e-09
that O 0 3.237629886410076e-10
cycloheximide O 0 1.7863740708889964e-07
stabilized O 0 3.5900447414860537e-07
mutant O 0 1.8379138566615438e-07
COL17A1 O 0 3.0566063742298866e-06
transcripts O 0 1.0295261176906934e-07
in O 0 1.7676344832295854e-09
keratinocytes O 0 9.547292023626142e-08
homozygous O 0 1.6208456798949555e-08
for O 0 1.8595806006160842e-09
a O 0 1.4581692298065718e-08
frameshift O 0 1.3072636875222088e-06
mutation O 0 2.0604312922500867e-08
, O 0 3.57972806952489e-09
the O 0 5.712516681910529e-09
effects O 0 1.438621950455854e-07
of O 0 2.5829513106145896e-07
the O 0 1.1718456249809606e-07
splice O 0 1.0260674798701075e-06
- O 0 2.6882627679469806e-08
site O 0 4.606361514447599e-09
mutation O 0 3.4806851845203823e-10
on O 0 6.237461214197992e-09
splicing O 0 2.1610688349937845e-08
of O 0 2.195075587962947e-08
COL17A1 O 0 3.888476840074873e-06
transcripts O 0 1.5987426138508454e-07
were O 0 1.1612014683137772e-09
determined O 0 2.163546453104459e-09
using O 0 1.2643874836015812e-09
reverse O 0 5.253734158827683e-08
transcriptase O 0 6.417394615709782e-08
polymerase O 0 1.7233880100775423e-08
chain O 0 7.363637477553198e-10
reaction O 0 4.92603569046679e-10
of O 0 1.1997799198582015e-08
total O 0 1.3921002128824966e-09
RNA O 0 2.254599174023042e-09
from O 0 8.352597502536696e-10
keratinocytes O 0 7.430575976741238e-08
incubated O 0 2.1097115165957803e-08
for O 0 1.2581520270060764e-09
2 O 0 1.2722387054964202e-07
. O 0 1.3675943932867085e-07

5 O 0 3.2151519917533733e-06
h O 0 1.8178739935592603e-07
in O 0 2.169277646402179e-09
the O 0 4.085915217277858e-10
presence O 0 4.509679851771864e-10
or O 0 5.039699768616401e-10
absence O 0 1.2538548865848043e-08
of O 0 1.5177867851434712e-08
10 O 0 6.780071970524659e-08
microg O 0 2.0689772100013215e-06
cycloheximide O 0 6.70463759888662e-06
per O 0 1.7513900729682064e-07
ml O 0 7.012412424955983e-06
. O 0 1.0059186479338678e-06

Using O 0 3.568685968957652e-08
this O 0 1.0344342049606325e-09
approach O 0 7.145203984038062e-09
, O 0 4.953963350651236e-10
an O 0 4.1313194532044406e-10
abnormally O 0 6.586968481769873e-08
spliced O 0 3.0201729828149837e-07
transcript O 0 5.962510840618052e-07
was O 0 2.280976829638348e-08
identified O 0 2.4919228902575696e-09
that O 0 6.655839074332093e-11
contains O 0 1.0186761156827373e-10
an O 0 3.5669044107233816e-11
extra O 0 2.884083416532235e-09
264 O 0 7.1218693165064906e-09
bases O 0 1.0238970782339152e-09
upstream O 0 4.295501732087814e-09
from O 0 1.5160124267055153e-09
exon O 0 9.002425827020488e-08
32 O 0 3.729052622247764e-08
, O 0 2.05649913764816e-10
resulting O 0 2.0470647399406516e-09
in O 0 8.735167589257742e-10
a O 0 4.5093981881905165e-09
premature O 0 3.8849006500640826e-07
termination O 0 9.1377137323434e-07
codon O 0 1.6126419950523996e-06
27 O 0 2.006836439250037e-06
bp O 0 8.299491014440719e-07
downstream O 0 1.2534704296740529e-07
from O 0 5.150955662003298e-09
the O 0 6.344009051417743e-08
cryptic O 0 1.9141828033752972e-06
splice O 0 6.345543170027668e-06
site O 0 5.246714636086836e-07
. O 0 9.403289027432038e-07

Three O 0 5.040252304411297e-08
other O 0 2.0979371573304206e-09
splice O 0 1.2821338657431625e-07
variants O 0 8.01758748281145e-09
, O 0 1.3060863501834774e-10
including O 0 3.4206738136477455e-11
one O 0 6.28472135444369e-11
derived O 0 1.556094836319133e-10
from O 0 2.09262093764373e-10
the O 0 1.162007934318865e-09
skipping O 0 1.4373762624586561e-08
of O 0 1.4993803532092898e-08
exon O 0 1.3183370128899696e-07
32 O 0 6.264372842679222e-08
, O 0 3.0125364425259704e-09
were O 0 1.075354827406727e-08
also O 0 9.146161161766031e-09
identified O 0 2.8056902579010057e-07
. O 0 1.1761690075218212e-06

These O 0 5.354943510837984e-08
results O 0 9.199333561582534e-08
indicate O 0 4.7822630300231594e-09
the O 0 9.34453292522619e-10
usefulness O 0 2.6115092310874388e-08
of O 0 3.303617157612848e-09
cycloheximide O 0 1.4476228216153686e-07
treatment O 0 1.320686449091113e-09
in O 0 9.421865510006455e-10
evaluating O 0 2.932532616739536e-08
the O 0 7.968618653819703e-09
abnormal O 0 1.6265007118931862e-08
processing O 0 3.417900629187898e-08
of O 0 2.09713011400936e-08
mRNA O 0 3.2223912427298274e-08
due O 0 1.4214330690265342e-07
to O 0 1.0361013380588702e-08
splice O 0 1.316979023613385e-06
- O 0 5.7421242871669165e-08
site O 0 7.028419624077742e-09
mutations O 0 1.2989915809669128e-09
, O 0 2.1037463437956205e-10
because O 0 7.856422734597857e-10
( O 0 2.0997865668448412e-09
i O 0 4.9768495102853194e-08
) O 0 2.141258503840504e-09
aberrant O 0 4.1179653464951116e-08
splicing O 0 7.681509828216804e-08
often O 0 2.2578268144002323e-09
generates O 0 4.483788895726093e-09
a O 0 3.844650375839365e-09
premature O 0 1.4876388831908116e-07
termination O 0 3.2622926937619923e-07
codon O 0 2.953065632027574e-07
, O 0 1.0878398626346097e-08
( O 0 2.9730695683127806e-09
ii O 0 4.272341811883962e-06
) O 0 1.3060279080434611e-08
transcripts O 0 2.596123920284299e-07
with O 0 8.39181613088158e-10
premature O 0 9.576472592698337e-08
termination O 0 9.917184939922663e-08
codons O 0 2.9581947558199317e-08
can O 0 2.7445470340836664e-09
occur O 0 1.6380603540255834e-08
at O 0 9.133177059084119e-08
low O 0 2.4518081431779137e-07
or O 0 3.2253044679464438e-09
undetectable O 0 2.7784684775156165e-08
levels O 0 2.032607193669378e-09
due O 0 4.721106172667078e-09
to O 0 5.957457305250102e-10
nonsense O 0 3.1843754300098226e-08
- O 0 1.0565225139202994e-08
mediated O 0 4.9458865447604694e-08
mRNA O 0 3.0080753443684216e-09
decay O 0 2.0547799906012187e-08
, O 0 9.32339552783823e-11
and O 0 1.783329872662165e-10
( O 0 9.399674788523882e-11
iii O 0 6.500847860024805e-08
) O 0 3.0954372398639407e-10
the O 0 5.02656694045811e-10
levels O 0 4.799680652922689e-09
of O 0 1.341044275626757e-09
these O 0 7.158978410082284e-10
transcripts O 0 7.411323110773083e-09
can O 0 9.406794787558681e-11
be O 0 6.640749755648656e-11
increased O 0 2.4562843425890435e-10
by O 0 7.634222143337865e-10
cycloheximide O 0 3.720254653671873e-06
. O 0 4.397872146455484e-07

A O 0 1.0084525001730071e-06
deletion O 0 7.02844829447713e-07
mutation O 0 4.5445258223253404e-08
in O 0 8.569944753844538e-09
COL17A1 O 0 7.4006366048706695e-06
in O 0 7.771119747701505e-09
five O 0 9.647548537827788e-09
Austrian O 0 1.1221751350376508e-07
families O 0 2.3855957209661938e-09
with O 0 1.0309012310472099e-08
generalized O 1 0.9985299110412598
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9982123374938965
represents O 0 2.415025903701462e-07
propagation O 0 1.3623682662000647e-06
of O 0 6.649478478948367e-08
an O 0 4.357881167038613e-09
ancestral O 0 4.5605290210914973e-07
allele O 0 3.520681502777734e-06
. O 0 3.0056592095206724e-06

Patients O 0 9.567930646880995e-06
with O 0 2.1442373565605521e-07
generalized O 1 0.9999080896377563
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999932050704956
, O 0 1.634892221602513e-08
a O 0 2.020323686124925e-09
usually O 0 2.329515691457118e-09
nonlethal O 0 1.506189846622874e-06
form O 0 3.608267320487357e-07
of O 0 2.0666067939600907e-05
junctional B-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9999524354934692
, O 0 4.204602888080444e-08
have O 0 6.358689130792072e-09
generalized O 0 2.465041234245291e-06
blistering B-Disease 0 2.4341434254893102e-05
, O 0 8.011703016563843e-07
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 5.169626456336118e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 2.2223036921786843e-06
and O 0 0.00013409035454969853
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.00022193252516444772

Skin B-Disease 1 0.9999872446060181
fragility I-Disease 0 5.568638880504295e-05
in O 0 6.794452112046656e-09
most O 0 1.8213838770542168e-10
cases O 0 1.2817726047220646e-10
is O 0 1.1547466975680987e-11
due O 0 8.425914965748404e-10
to O 0 1.4367772249723743e-10
mutations O 0 3.7798486562934386e-10
in O 0 3.1935082356326916e-10
the O 0 1.9157906372413436e-09
gene O 0 2.093803797009741e-09
encoding O 0 5.529324198505492e-08
type O 0 6.938579417692381e-07
XVII O 0 0.0006614801241084933
collagen O 0 1.048832473315997e-06
( O 0 1.2472169075294914e-08
COL17A1 O 0 6.31762213743059e-06
) O 0 1.910587954512266e-08
. O 0 1.4481807397714874e-07

Recently O 0 1.1568732816158445e-06
, O 0 8.900222780994227e-09
we O 0 7.504437959937604e-09
reported O 0 4.197197256416985e-09
five O 0 1.6388626011831775e-09
Austrian O 0 5.661776469878532e-08
families O 0 2.8451812017493694e-09
with O 0 8.940888029940197e-09
generalized O 1 0.9963017702102661
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999855756759644
who O 0 2.69170101319105e-07
share O 0 2.4950059795969537e-08
the O 0 3.1637316766364165e-08
same O 0 3.3848142066972287e-08
COL17A1 O 0 5.547226101043634e-05
mutation O 0 9.842024155659601e-07
. O 0 1.1631525467237225e-06

Affected O 0 3.470321985332703e-07
individuals O 0 7.264728263400855e-10
in O 0 9.752499918747048e-10
three O 0 6.265921115300443e-10
families O 0 4.6391040314786025e-11
are O 0 3.8286790404740145e-11
homozygous O 0 1.0254292970302004e-09
for O 0 5.81574677305241e-10
4003delTC O 0 2.1562931351581938e-07
, O 0 5.988228246600613e-10
whereas O 0 1.5744984205312562e-09
those O 0 2.3004785576485887e-10
in O 0 2.1781822179267607e-10
two O 0 2.421997602475301e-10
others O 0 9.274572221329436e-10
are O 0 5.346141307427388e-10
compound O 0 1.0882635592679435e-07
heterozygotes O 0 2.996855073433835e-06
. O 0 2.10777648135263e-06

To O 0 2.3931574943958367e-08
determine O 0 4.5727755804136905e-08
if O 0 1.3191306935667058e-09
the O 0 5.516898049506835e-10
occurrence O 0 2.4458837177832038e-09
of O 0 1.6651664491718066e-09
4003delTC O 0 4.9594987672207935e-08
in O 0 4.5791331837463645e-10
these O 0 3.2695704477170295e-10
unrelated O 0 5.0656834282847285e-09
families O 0 2.2621189643690087e-10
signifies O 0 1.5950890608351642e-09
propagation O 0 1.67172284903927e-08
of O 0 3.720951102792469e-09
an O 0 5.170304739898768e-10
ancestral O 0 6.986907408190746e-08
allele O 0 2.399534366759326e-07
or O 0 3.6817294102320375e-08
a O 0 2.7851751127627722e-08
mutational O 0 4.139679731451906e-06
hot O 0 2.0172201402601786e-05
spot O 0 8.572319529775996e-06
, O 0 7.702354309913062e-09
haplotypes O 0 2.7688402681746993e-08
were O 0 1.7744411495712598e-09
determined O 0 8.496361836307642e-09
for O 0 1.6705490324397942e-09
polymorphisms O 0 1.8216082864341843e-08
both O 0 8.831769982009519e-09
within O 0 6.070608549180179e-08
and O 0 5.609043896015464e-08
flanking O 0 8.426824933849275e-06
COL17A1 O 0 0.013137099333107471
. O 0 5.013850113755325e-06

Five O 0 3.1727615805721143e-06
intragenic O 0 1.3390214007813483e-05
polymorphisms O 0 2.6462879532118677e-07
were O 0 1.4056336539169934e-08
chosen O 0 6.706666777489545e-09
based O 0 2.898554063435199e-09
on O 0 3.5982534285494694e-08
their O 0 1.6358528753812607e-08
informativeness O 0 1.2062402674928308e-05
. O 0 1.370748123008525e-06

One O 0 7.957261516366998e-08
of O 0 9.551678559205357e-09
these O 0 4.5408821147674416e-10
, O 0 1.284758688324672e-10
not O 0 1.519317449627522e-10
previously O 0 4.416480958724378e-09
reported O 0 4.196957004154456e-09
, O 0 1.2996210774218753e-09
was O 0 5.645492962003118e-08
2988 O 0 1.3586055729319924e-06
A O 0 1.1866148241779229e-07
or O 0 2.875395566093175e-08
C O 0 1.1585814263526117e-06
that O 0 6.262205198837023e-10
introduces O 0 5.042394057852562e-09
a O 0 3.22611493075442e-10
new O 0 4.951167253963717e-10
restriction O 0 1.2788233805238747e-09
site O 0 1.6785913770078764e-09
for O 0 4.982856904867106e-10
Eco0109 O 0 2.2257748355514195e-07
I O 0 1.5884188542258926e-06
. O 0 4.1852879917314567e-07

All O 0 8.634724935063787e-08
the O 0 1.5599001201849205e-08
4003delTC O 0 1.4928333769148594e-07
alleles O 0 9.47543021823094e-09
showed O 0 3.173423968050315e-09
the O 0 2.7459803875196087e-10
same O 0 4.5718201446831586e-10
haplotype O 0 8.664813755387968e-09
for O 0 3.5573058387861067e-10
these O 0 1.3756717986979083e-09
five O 0 1.0580329501408414e-08
polymorphic O 0 3.1921723575578653e-07
markers O 0 1.1698908792823204e-06
. O 0 2.3329287159867818e-06

Fourteen O 0 8.181764314940665e-06
microsatellite O 0 6.2335548136616126e-06
polymorphisms O 0 1.6175788175587513e-07
were O 0 1.3686062061424309e-08
selected O 0 5.967639271631242e-09
based O 0 9.365355158053035e-10
on O 0 1.0495089242112954e-08
their O 0 3.5561207312184706e-09
high O 0 3.8673644553455233e-07
heterozygosity O 0 1.0501917131477967e-06
and O 0 2.7713749073399185e-09
their O 0 1.5160644961653702e-09
location O 0 1.031715601840233e-08
within O 0 1.763900492335324e-08
10q23 O 0 1.2448638244677568e-06
- O 0 1.1471886409708532e-06
q25 O 0 3.5409793781582266e-06
near O 0 2.9405475743260467e-06
COL17A1 O 0 0.0003457449784036726
. O 0 4.645447006623726e-06

Three O 0 2.0119190935474762e-07
families O 0 4.403560627253e-09
shared O 0 2.856514491611506e-08
microsatellite O 0 3.7300596886780113e-06
polymorphisms O 0 1.1141532922920305e-06
covering O 0 1.4427770338443224e-06
at O 0 7.344482924054319e-07
most O 0 3.238199708377465e-09
19 O 0 1.2510376734553574e-07
cM O 0 3.229141611882369e-07
, O 0 1.4052816688092662e-09
whereas O 0 4.233166706058e-09
the O 0 2.4026007849897724e-09
others O 0 8.690033137526143e-10
shared O 0 1.2959426864966872e-09
smaller O 0 1.0112737314216247e-09
regions O 0 2.740205617968172e-09
consistent O 0 2.429931100778049e-08
with O 0 8.538824647352783e-10
cross O 0 2.6210450698727072e-08
- O 0 1.4283526184044604e-07
over O 0 3.1425420043973418e-09
events O 0 5.217618559427706e-10
during O 0 1.2384329672876504e-10
passage O 0 5.751037146506377e-11
of O 0 8.039691828942708e-11
this O 0 3.0792479677188567e-11
mutation O 0 2.897878048635505e-10
through O 0 5.600421792983923e-10
several O 0 4.9325818984868874e-09
generations O 0 1.4286931104834366e-07
. O 0 5.236497031546605e-07

These O 0 1.0811877615424237e-07
results O 0 7.802371726484125e-08
indicate O 0 7.69128494226834e-09
that O 0 2.574134516653004e-10
4003delTC O 0 5.8231009347764484e-08
occurs O 0 1.8719470418204764e-09
on O 0 3.6724698837531378e-09
a O 0 8.800286610544106e-10
single O 0 1.4603227516118977e-09
ancestral O 0 5.988496099007534e-08
allele O 0 1.601776631332541e-07
. O 0 4.4513257080325275e-08
. O 0 3.357897355726891e-07

The O 0 1.4639651908510132e-06
haptoglobin O 0 9.082612086785957e-05
- O 0 1.9874021290888777e-06
gene O 0 1.4354858635101664e-08
deletion O 0 4.4366700535647396e-08
responsible O 0 1.2775489111049865e-08
for O 0 1.1707693481355363e-08
anhaptoglobinemia B-Disease 0 3.3945314498851076e-05
. O 0 5.131442776473705e-06

We O 0 2.0760140273523575e-07
have O 0 1.0530876171088721e-09
found O 0 4.1943140627331843e-10
an O 0 9.341623308234404e-11
allelic O 0 8.96520830906411e-08
deletion O 0 8.526513539663938e-08
of O 0 1.601034398390766e-07
the O 0 2.861213204141677e-07
haptoglobin O 0 3.133726568194106e-05
( O 0 4.9447546501824036e-08
Hp O 0 3.423457656026585e-06
) O 0 1.7048563671906436e-09
gene O 0 8.283124741659265e-10
from O 0 3.962063177542774e-10
an O 0 1.450705389149931e-10
individual O 0 3.89046544979621e-10
with O 0 2.9440703208649666e-09
anhaptoglobinemia B-Disease 0 1.870491905719973e-05
. O 0 2.3487830276280874e-06

The O 0 1.9779872673098e-06
Hp O 0 6.405852673196932e-06
gene O 0 6.211864356231445e-09
cluster O 0 2.7904341948215006e-08
consists O 0 5.709793970964938e-09
of O 0 1.2487808120908994e-08
coding O 0 1.2331052801073383e-07
regions O 0 8.642251358992326e-09
of O 0 6.272479424751509e-08
the O 0 1.3234963347485973e-08
alpha O 0 6.122633067207062e-08
chain O 0 1.5140706466354459e-09
and O 0 4.1347328338936506e-10
beta O 0 1.0485066148646638e-08
chain O 0 7.674985091910003e-10
of O 0 3.0118698646219855e-09
the O 0 8.039516607993846e-09
haptoglobin O 0 7.070668175401806e-07
gene O 0 6.59881171927168e-09
( O 0 1.8231853804451248e-09
Hp O 0 1.9259151429196208e-07
) O 0 3.567123818548623e-10
and O 0 7.909951027507134e-10
of O 0 8.985508337389092e-09
the O 0 1.5020996002590437e-08
alpha O 0 1.5912466722056706e-07
chain O 0 3.6150229476561435e-09
and O 0 1.7025166831885485e-09
beta O 0 8.111371840868742e-08
chain O 0 1.6194581675677e-08
of O 0 2.90800254987289e-08
the O 0 6.123730855733811e-08
haptoglobin O 0 3.392473445273936e-05
- O 0 1.4701575992148719e-06
related O 0 3.0986484489403665e-07
gene O 0 2.0525002142335325e-08
( O 0 6.954357534283417e-09
Hpr O 0 5.04032925618958e-07
) O 0 3.4150837713298188e-09
, O 0 1.2267515892006031e-09
in O 0 1.9205836920832553e-09
tandem O 0 6.59914221046165e-08
from O 0 3.919462532309126e-09
the O 0 4.984164192478602e-08
5 O 0 1.55621580688603e-06
side O 0 1.605775105417706e-05
. O 0 5.464166861202102e-06

Southern O 0 5.058236183685949e-06
blot O 0 6.9933721533743665e-06
and O 0 2.0660037236552853e-08
PCR O 0 3.735879872124315e-08
analyses O 0 5.399823255203273e-09
have O 0 2.056181336307361e-10
indicated O 0 9.010732160419366e-10
that O 0 2.6175341408252173e-11
the O 0 1.5279311149640762e-10
individual O 0 1.9121235844687945e-11
with O 0 3.4140513333058564e-11
anhaptoglobinemia B-Disease 0 3.9541856011737764e-08
was O 0 3.0579876408864948e-09
homozygous O 0 3.8841332927752603e-10
for O 0 4.113657331439313e-11
the O 0 4.737538694676857e-10
gene O 0 2.5966007122235624e-10
deletion O 0 1.2640306579214666e-09
and O 0 2.7729385454478006e-10
that O 0 6.457573364926361e-11
the O 0 7.114411837427781e-10
gene O 0 4.6427001132443024e-10
deletion O 0 6.243221939428167e-09
was O 0 8.354513525432594e-09
included O 0 2.2670225696685975e-09
at O 0 1.3166528312069659e-08
least O 0 5.981869444227073e-10
from O 0 3.9699754594835213e-10
the O 0 4.097983286044382e-09
promoter O 0 5.707531158805068e-07
region O 0 1.1502688579412279e-07
of O 0 4.797422661795281e-06
Hp O 0 0.0005331228603608906
to O 0 1.07985641761843e-07
Hpr O 0 3.411454144952586e-06
alpha O 0 3.401690946702729e-07
but O 0 1.2612995092808887e-09
not O 0 4.289653354749845e-10
to O 0 1.3981512614336111e-09
Hpr O 0 4.782763198818429e-07
beta O 0 9.988941656047245e-07
( O 0 2.7594030171940176e-08
Hpdel O 0 5.577493084274465e-06
) O 0 3.081261823467685e-08
. O 0 3.0574761922252947e-07

In O 0 4.175711509901703e-08
addition O 0 5.699892113852911e-09
, O 0 4.746638082586685e-10
we O 0 7.787897549071943e-10
found O 0 2.061549680965058e-10
seven O 0 2.26345692189156e-10
individuals O 0 8.208238776175047e-12
with O 0 4.671210293571981e-11
hypohaptoglobinemia B-Disease 0 5.467220276500484e-08
in O 0 7.438255011926742e-10
three O 0 7.122856748864592e-10
families O 0 1.0028063796019282e-10
, O 0 9.291706987157866e-11
and O 0 2.3126295323194768e-10
the O 0 2.557369871425408e-09
genotypes O 0 4.1551825802343956e-07
of O 0 4.2580012404869194e-07
six O 0 7.157673564961442e-08
of O 0 2.985795077847797e-08
the O 0 1.7338926738830196e-08
seven O 0 9.795027011705315e-09
individuals O 0 9.558904362494403e-11
were O 0 1.9207226920059384e-09
found O 0 1.1275592681769808e-09
to O 0 1.4657195457346006e-09
be O 0 7.969624959969224e-08
Hp2 O 0 0.35433223843574524
/ O 0 0.22347860038280487
Hpdel O 0 0.05136184021830559
. O 0 1.2131181392760482e-05

The O 0 4.465284462185082e-07
phenotypes O 0 5.401421958595165e-07
and O 0 5.590136353816888e-09
genotypes O 0 7.551550851303546e-08
in O 0 7.90352672197514e-10
one O 0 2.150359751373898e-10
of O 0 7.463352158509906e-10
these O 0 2.7427141113811615e-10
three O 0 4.693880284456498e-10
families O 0 1.452577086391571e-10
showed O 0 1.8448347294253153e-09
the O 0 2.3683492944570617e-09
father O 0 1.3596377357316669e-08
to O 0 2.2123411991259445e-09
be O 0 1.6613222797445815e-08
hypohaptoglobinemic B-Disease 0 4.265937150194077e-06
( O 0 5.4244356562094254e-08
Hp2 O 0 2.4622482669656165e-05
) O 0 2.8617280989351457e-08
and O 0 5.7038750611582145e-08
Hp2 O 0 0.0004985725390724838
/ O 0 2.8788783311028965e-05
Hpdel O 0 6.54421019135043e-05
, O 0 7.308956995188964e-09
the O 0 8.654391869811207e-09
mother O 0 3.1175573234065723e-09
to O 0 6.894458892681143e-10
be O 0 3.595644892939731e-09
Hp2 O 0 1.4907178638168261e-06
- O 0 1.708624353113919e-07
1 O 0 2.417339430849097e-07
and O 0 2.1840586228449865e-08
Hp1 O 0 2.531687823648099e-05
/ O 0 9.080267204808479e-07
Hp2 O 0 3.31983869727992e-06
, O 0 6.351945636140499e-10
one O 0 1.6043212591743128e-10
of O 0 5.395198177104987e-10
the O 0 5.878647013624061e-10
two O 0 2.123115294683231e-10
children O 0 3.9339583673969614e-11
to O 0 1.5985787693573172e-10
be O 0 8.294464670655088e-09
hypohaptoglobinemic B-Disease 0 5.006176706956467e-06
( O 0 3.512554513918076e-08
Hp2 O 0 1.185852124763187e-05
) O 0 1.0942994066454048e-08
and O 0 2.5744073539613055e-08
Hp2 O 0 0.0003864358877763152
/ O 0 2.1712197849410586e-05
Hpdel O 0 9.854944801190868e-05
, O 0 2.3208188704160193e-09
and O 0 6.59916066236832e-10
the O 0 1.0872377442794345e-09
other O 0 1.0137335415549842e-10
child O 0 6.448603873110414e-10
to O 0 1.9388088356997457e-10
be O 0 4.1404724093752066e-09
Hp1 O 0 6.792271960875951e-06
and O 0 1.7137681140866334e-07
Hp1 O 1 0.7045446038246155
/ O 0 0.0009341923287138343
Hpdel O 0 0.00085146987112239
, O 0 1.0752152945769922e-08
showing O 0 1.5820249998910185e-08
an O 0 9.278553481095742e-10
anomalous O 0 3.2684206985322817e-07
inheritance O 0 3.5567879308473493e-07
of O 0 7.081134754116647e-07
Hp O 0 0.00010643231507856399
phenotypes O 0 1.0052473271571216e-06
in O 0 1.033910113079628e-08
the O 0 2.3520275505006794e-08
child O 0 8.944029161739309e-08
with O 0 1.2701118379254694e-08
Hp1 O 0 0.000334675278281793
. O 0 1.248843182111159e-05

The O 0 3.0020698886801256e-06
Hp2 O 0 0.0008913248893804848
/ O 0 3.237947021261789e-05
Hpdel O 0 3.240282603655942e-05
individuals O 0 2.9182969374375034e-09
had O 0 7.207757946048332e-09
an O 0 3.092115175018506e-10
extremely O 0 2.0817031654019047e-08
low O 0 3.8533340784852044e-07
level O 0 1.6313590094796382e-05
of O 0 1.2631235222215764e-06
Hp O 0 0.00016184983542189002
( O 0 2.4655606445378453e-09
mean O 0 1.3325060166380354e-08
+ O 0 2.7776154709613365e-08
/ O 0 2.1964661200968294e-08
- O 0 1.2925269743391254e-08
SD O 0 1.8702782256241335e-07
= O 0 2.8037769439492877e-08
0 O 0 6.885171544013247e-09
. O 0 8.068669066219059e-10
049 O 0 1.2987450759283092e-07
+ O 0 1.8606707286039637e-08
/ O 0 2.64386041948228e-08
- O 0 1.0091854463212258e-08
0 O 0 1.119811976479923e-08
. O 0 2.965311107772095e-09
043 O 0 1.2808301335098804e-06
mg O 0 2.851656290658866e-06
/ O 0 2.4098494577629026e-07
ml O 0 1.3369769646942586e-07
; O 0 1.973891938789052e-09
n O 0 3.709919127459216e-08
= O 0 5.319893148225674e-08
6 O 0 4.772898165583683e-08
) O 0 1.3910485263668448e-10
, O 0 6.614708086827292e-11
compared O 0 1.2248362046829442e-10
with O 0 1.3914086029187533e-11
the O 0 6.67720490010737e-10
level O 0 8.256112948856753e-08
( O 0 1.018524570239876e-10
1 O 0 1.839294050398621e-09
. O 0 3.1089991692212493e-10
64 O 0 2.2130670629394444e-09
+ O 0 8.946960505795687e-09
/ O 0 1.4524899505374833e-08
- O 0 4.368558403911038e-09
1 O 0 6.695151544278133e-09
. O 0 1.0191624211230987e-09
07 O 0 1.2079743783033337e-07
mg O 0 5.49965193386015e-07
/ O 0 2.814761579372771e-08
ml O 0 8.914834204176714e-09
) O 0 1.970887689162204e-11
obtained O 0 4.6042514245669963e-10
from O 0 2.2975317481854773e-10
52 O 0 1.542788652386662e-08
healthy O 0 5.788636237014089e-09
volunteers O 0 2.316515645972572e-09
having O 0 1.0506966852119604e-08
phenotype O 0 1.7628617854370532e-07
Hp2 O 0 3.165770976920612e-06
, O 0 3.6046332585470964e-09
whereas O 0 5.9392846196715254e-09
the O 0 4.277220799764336e-09
serum O 0 1.7455528578125268e-08
Hp O 0 2.998905586082401e-07
level O 0 1.671892420063159e-07
of O 0 1.952942918492795e-09
an O 0 4.735693781565686e-11
individual O 0 1.0827092000731398e-10
with O 0 5.228936172940735e-10
Hp1 O 0 6.66127971271635e-06
/ O 0 1.3029348338022828e-06
Hpdel O 0 6.458336429204792e-06
was O 0 1.2209473254642944e-07
0 O 0 2.743188645126793e-07
. O 0 1.360751156198603e-07

50 O 0 1.8549021660874132e-06
mg O 0 0.00011106437887065113
/ O 0 4.485451427171938e-06
ml O 0 7.780390660627745e-07
, O 0 2.7360469445625313e-10
which O 0 7.598249807116986e-11
was O 0 1.8196486539778789e-09
approximately O 0 2.560096579173887e-10
half O 0 2.715044855605697e-10
the O 0 4.6005116383085465e-10
level O 0 3.638627532609462e-08
of O 0 5.109876077824538e-09
Hp O 0 2.6527919771979214e-07
in O 0 1.081917111456221e-09
control O 0 4.460053304455869e-08
sera O 0 6.842142852292454e-07
from O 0 1.4063462616675793e-09
the O 0 6.823439147041199e-09
Hp1 O 0 9.746155456014094e-07
phenotype O 0 1.8445682314904843e-08
( O 0 3.7447867029527515e-10
1 O 0 6.561661436421673e-09
. O 0 1.1533390908979868e-09
26 O 0 3.5762699468477877e-08
+ O 0 3.4407019455784393e-08
/ O 0 3.6409602444109623e-08
- O 0 1.1689887280397215e-08
0 O 0 6.204261993048021e-09
. O 0 7.023484016599468e-10
33 O 0 1.6900223442917195e-08
mg O 0 3.1738130701342016e-07
/ O 0 8.956952513017313e-08
ml O 0 6.199840640874754e-08
; O 0 7.796220335976045e-10
n O 0 1.7665266582866934e-08
= O 0 4.143682019730477e-08
9 O 0 7.912312582902814e-08
) O 0 8.834528109069595e-10
, O 0 4.941431153149267e-10
showing O 0 9.365145992035195e-09
a O 0 2.168066792762602e-08
gene O 0 8.921166028130756e-08
- O 0 4.731132889901346e-07
dosage O 0 4.743375939142425e-06
effect O 0 5.514323220268125e-06
. O 0 1.5580170611428912e-06

The O 0 2.0147723489571945e-07
other O 0 1.095987212096361e-08
allele O 0 1.1252099341163557e-07
( O 0 6.389191398170624e-09
Hp2 O 0 1.8044979697151575e-06
) O 0 8.813590413048189e-10
of O 0 3.522079072837414e-09
individuals O 0 2.963867762328931e-10
with O 0 2.0804478140235005e-09
Hp2 O 0 0.00045641837641596794
/ O 0 3.4072581911459565e-05
Hpdel O 0 6.973105337237939e-05
was O 0 5.200941899374811e-08
found O 0 3.2606711775073904e-10
to O 0 1.3069635651508094e-10
have O 0 1.739528798783141e-10
, O 0 7.277955321738361e-11
in O 0 1.5056091096088409e-10
all O 0 5.531670677072498e-10
exons O 0 1.9501149139955487e-08
, O 0 1.855565423536376e-10
no O 0 1.6337746433503497e-10
mutation O 0 1.423471479577998e-10
, O 0 5.3585524906196724e-11
by O 0 1.7630981397065426e-10
DNA O 0 2.1719365861372353e-08
sequencing O 0 7.868217721807014e-08
. O 0 7.373833454948908e-07

On O 0 1.9900637937553256e-07
the O 0 1.7783851058439382e-09
basis O 0 2.10731343486259e-09
of O 0 4.622871530024497e-10
the O 0 2.0024489011394309e-10
present O 0 1.7472899516146612e-10
study O 0 2.255527153938175e-10
, O 0 4.785543489260746e-11
the O 0 2.6150703824612265e-10
mechanism O 0 1.1664185173287933e-08
of O 0 1.3035940327199569e-08
anhaptoglobinemia B-Disease 0 2.0973116079403553e-06
and O 0 8.212698965337495e-09
the O 0 1.1303462166267764e-08
mechanism O 0 4.242917839292204e-07
of O 0 4.5852207364305286e-08
anomalous O 0 1.0345452210458461e-06
inheritance O 0 1.4382996482709132e-07
of O 0 1.4274796455993055e-07
Hp O 0 2.5838387955445796e-05
phenotypes O 0 1.3873093394067837e-06
were O 0 3.7049055379156925e-08
well O 0 3.848467855505078e-08
explained O 0 6.000501571179484e-07
. O 0 7.788407856423873e-07

However O 0 2.6786281637214415e-07
, O 0 2.9246998156651216e-09
the O 0 1.0964005259239684e-09
mechanism O 0 2.153464784271364e-08
of O 0 6.347516290361455e-09
hypohaptoglobinemia B-Disease 0 9.216964826919138e-07
remains O 0 5.247635499472381e-07
unknown O 0 9.201716238749214e-06

ATM O 0 2.402263635303825e-05
mutations O 0 1.2106701205993886e-06
and O 0 6.692230414273581e-08
phenotypes O 0 1.3307987501320895e-05
in O 0 1.1754067600122653e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 3.342114496263093e-08
in O 0 1.644580471804602e-09
the O 0 1.0636249658801944e-09
British O 0 2.725663783564869e-08
Isles O 0 9.442676969229069e-07
: O 0 1.810440020122428e-09
expression O 0 2.585216485329056e-09
of O 0 7.719119565763322e-09
mutant O 0 1.9436537712635982e-08
ATM O 0 7.583247452203068e-08
and O 0 3.768474421406154e-10
the O 0 3.4461367093285844e-10
risk O 0 2.5318407370633622e-09
of O 0 6.081339876118363e-08
leukemia B-Disease 1 1.0
, O 1 0.5671249628067017
lymphoma B-Disease 1 1.0
, O 1 0.9999984502792358
and O 1 0.9999985694885254
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999352693557739
. O 0 0.47151046991348267

We O 0 1.4558244743057003e-07
report O 0 1.1427502499827824e-08
the O 0 2.381694841346871e-09
spectrum O 0 1.9693651154284453e-08
of O 0 7.658610634564411e-09
59 O 0 2.6931587626677356e-08
ATM O 0 1.6907326028103853e-07
mutations O 0 3.2382569514766146e-08
observed O 0 1.3792093511710846e-07
in O 0 1.4462058288700064e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3587277969406841e-08
patients O 0 9.30165944268424e-10
in O 0 4.5015419170013615e-10
the O 0 4.005711318200156e-09
British O 0 2.2484556438939762e-07
Isles O 0 2.276479972351808e-05
. O 0 1.696043909760192e-06

Of O 0 3.3682067623885814e-06
51 O 0 2.370923539274372e-06
ATM O 0 1.862877979874611e-06
mutations O 0 2.7998758866942808e-08
identified O 0 1.4426056793581665e-08
in O 0 1.1004377409307153e-09
families O 0 3.9597214396280833e-10
native O 0 3.468544340634594e-10
to O 0 2.5790589108787287e-10
the O 0 1.960235085363138e-09
British O 0 8.332333578664475e-08
Isles O 0 1.2045780749758705e-05
, O 0 8.454816402547749e-09
11 O 0 5.851112305776951e-08
were O 0 1.6803156199785008e-08
founder O 0 1.1575394154306196e-07
mutations O 0 9.050870275473244e-09
, O 0 1.0314041842818256e-09
and O 0 2.0531727429329294e-09
2 O 0 1.1389893472824042e-07
of O 0 8.601583445511096e-09
these O 0 1.604135380084415e-09
11 O 0 1.607821076277105e-08
conferred O 0 7.07962968249376e-08
a O 0 2.758407058323087e-09
milder O 0 1.7323331746865733e-07
clinical O 0 2.4602348602797974e-08
phenotype O 0 3.988025465417877e-09
with O 0 2.801329827828436e-11
respect O 0 1.086760903490358e-09
to O 0 8.895296721433965e-10
both O 0 4.092010286171899e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 4.7609237299184315e-06
cellular O 0 2.886286210923572e-06
features O 0 2.0577692794176983e-07
. O 0 3.675204709452373e-07

We O 0 5.298097107697686e-07
report O 0 2.5078019660895734e-08
, O 0 7.21789294999553e-10
in O 0 7.317811356877257e-10
two O 0 4.1306362774662375e-09
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
families O 0 4.342373571830649e-09
, O 0 5.700084848569986e-10
an O 0 3.7814928965929084e-10
ATM O 0 1.8237849985780485e-07
mutation O 0 1.0494469293576003e-08
( O 0 3.7809892994289385e-09
7271T O 0 3.6225523558641726e-07
- O 0 1.718796056593419e-06
- O 0 2.4007047159102513e-06
> O 0 4.4359680373418087e-07
G O 0 1.2541113392217085e-07
) O 0 9.05013702867663e-11
that O 0 1.0713609686907599e-11
may O 0 4.0310635385232274e-10
be O 0 2.4459897995932067e-10
associated O 0 6.0036331461788e-10
with O 0 2.8422278419704128e-11
an O 0 2.4198169509825895e-11
increased O 0 9.055096672483387e-10
risk O 0 3.1766717256687116e-08
of O 0 7.835695214453153e-06
breast B-Disease 0 0.040744710713624954
cancer I-Disease 0 3.625891849878826e-06
in O 0 5.45271312546447e-08
both O 0 1.7007575081606774e-07
homozygotes O 0 6.0460579334176145e-06
and O 0 1.5716990731107217e-07
heterozygotes O 0 6.627914217460784e-07
( O 0 3.1929556776333357e-09
relative O 0 8.67454090780484e-08
risk O 0 9.831695457762635e-09
12 O 0 1.0423491403344087e-08
. O 0 9.233129261154716e-10
7 O 0 2.6064483904519875e-08
; O 0 3.2027573926285413e-09
P O 0 2.621871090013883e-06
= O 0 1.6649774181587418e-07
. O 0 5.891671150948241e-09
0025 O 0 5.271515988169995e-07
) O 0 1.383802933352385e-10
, O 0 2.0725208008109952e-11
although O 0 1.2259721016150138e-10
there O 0 1.6815514258805564e-10
is O 0 9.367673303728452e-11
a O 0 3.6800548719462256e-10
less O 0 7.818307778961753e-09
severe O 1 0.9980525970458984
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 2.6141708531213226e-07
in O 0 2.6656107876554813e-10
terms O 0 3.736474740723139e-10
of O 0 1.4506833234673167e-10
the O 0 6.559127546656995e-11
degree O 0 2.489771944169661e-08
of O 0 4.1068116019005174e-08
cerebellar B-Disease 1 0.9999998807907104
degeneration I-Disease 1 1.0
. O 0 7.842587365303189e-06

This O 0 3.031629205452191e-07
mutation O 0 8.765618275674569e-08
( O 0 1.2726531828377574e-08
7271T O 0 5.387768169384799e-07
- O 0 2.806817178679921e-07
- O 0 1.2824443729186896e-07
> O 0 7.229156295807115e-08
G O 0 3.55570186627574e-08
) O 0 2.0332731331951237e-10
also O 0 4.072530507270855e-11
allows O 0 5.00396946101489e-11
expression O 0 3.6373334899586496e-10
of O 0 1.2434774321334885e-09
full O 0 4.689014510006473e-09
- O 0 5.000291736223517e-09
length O 0 1.6168432148688794e-09
ATM O 0 5.99727485450785e-08
protein O 0 9.418456237142436e-09
at O 0 7.710997174115164e-09
a O 0 4.5009324045608423e-10
level O 0 1.2312365349487209e-08
comparable O 0 1.3348177008154494e-09
with O 0 9.020009565652298e-12
that O 0 1.2757718492739656e-11
in O 0 1.4212631072041404e-10
unaffected O 0 1.5028561506369442e-08
individuals O 0 6.082574999233259e-10
. O 0 6.394692775302246e-08

In O 0 5.83711248225427e-08
addition O 0 8.755088209966289e-09
, O 0 8.197357792560922e-10
we O 0 6.220966519698834e-10
have O 0 1.4447272544959588e-10
studied O 0 1.9112476934424194e-08
18 O 0 5.9028209875577886e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 9.071264628346398e-09
, O 0 2.3643581537058367e-10
in O 0 2.6520197149437763e-10
15 O 0 2.107402030659955e-09
families O 0 6.847734879134038e-11
, O 0 9.802437334061054e-11
who O 0 3.9552905395368043e-10
developed O 0 7.47253864119557e-07
leukemia B-Disease 1 1.0
, O 0 3.4679032978601754e-05
lymphoma B-Disease 1 1.0
, O 0 0.030979355797171593
preleukemic O 1 0.9999960660934448
T O 1 0.999940037727356
- O 0 0.00041088691796176136
cell O 0 7.427536274917657e-07
proliferation O 0 4.4423944700611173e-07
, O 0 2.4789621466680956e-09
or O 0 5.05916872839407e-08
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.8471811813469685e-07
mostly O 0 1.9575674414795685e-09
in O 0 5.533340896590744e-09
childhood O 0 1.3753651728620753e-06
. O 0 1.8193254618381616e-06

A O 0 1.8512776023271726e-06
wide O 0 2.761870803169586e-07
variety O 0 3.676206716818342e-08
of O 0 7.952770175734258e-08
ATM O 0 4.924847871734528e-07
mutation O 0 2.5081452470487875e-09
types O 0 5.226425958682057e-09
, O 0 6.230395088735463e-10
including O 0 9.724248073439412e-10
missense O 0 2.979685973514279e-07
mutations O 0 5.28797556853533e-08
and O 0 9.6902219581807e-09
in O 0 1.565032015093948e-08
- O 0 7.296980584214907e-07
frame O 0 7.3484875429130625e-06
deletions O 0 2.4179660940149006e-08
, O 0 9.641362153089972e-10
were O 0 4.203349668330247e-09
seen O 0 8.232192705293073e-09
in O 0 2.421767675286901e-09
these O 0 7.897321907535115e-09
patients O 0 2.3397852544349007e-08
. O 0 4.42078999185469e-07

We O 0 2.4043265511863865e-07
also O 0 2.5611381904155905e-09
show O 0 4.4862674686285686e-10
that O 0 3.557792602193466e-11
25 O 0 6.216850922946549e-10
% O 0 9.747194718023877e-11
of O 0 2.142259258874901e-09
all O 0 1.5235384509537653e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.762171977925391e-08
carried O 0 1.1956474033070208e-08
in O 0 4.348523763297862e-09
- O 0 6.656711803998405e-08
frame O 0 9.520049957245647e-07
deletions O 0 4.920959995047269e-08
or O 0 4.779263207410622e-09
missense O 0 8.454384925471459e-08
mutations O 0 1.946598660040877e-09
, O 0 2.2719257031234008e-10
many O 0 4.645709511530427e-11
of O 0 1.9488116675958622e-10
which O 0 3.24855212174846e-11
were O 0 4.329213931786313e-10
also O 0 5.692563434522846e-11
associated O 0 5.89162330033588e-10
with O 0 2.0943378975513127e-10
expression O 0 8.72022276610096e-09
of O 0 3.404105655135936e-07
mutant O 0 9.051614142663311e-07
ATM O 0 4.16370494349394e-06
protein O 0 3.4389574921078747e-07
. O 0 4.980861945114157e-07

The O 0 4.7562861027472536e-07
DMPK O 0 6.506097997771576e-05
gene O 0 3.2162631669052644e-08
of O 0 7.430335102753816e-08
severely O 1 0.9999724626541138
affected O 1 0.9999959468841553
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00015174162399489433
is O 0 9.441550652411479e-09
hypermethylated O 0 6.861714041406231e-07
proximal O 0 7.245548090395459e-07
to O 0 3.066836784526572e-09
the O 0 9.92986315395683e-09
largely O 0 4.7216129672733587e-08
expanded O 0 1.7911419547544938e-07
CTG O 0 2.69070515059866e-05
repeat O 0 2.680187208170537e-06
. O 0 1.1470825711512589e-06

Using O 0 4.819805781153264e-07
methylation O 0 1.6180446209546062e-06
- O 0 5.39241511887667e-07
sensitive O 0 4.711177936655986e-08
restriction O 0 3.5478893156692948e-09
enzymes O 0 2.2016490852649895e-09
, O 0 1.4829454331177772e-10
we O 0 2.373929108845374e-10
characterized O 0 2.2453200410055274e-10
the O 0 3.8607711472238293e-10
methylation O 0 4.763373695482187e-09
pattern O 0 6.913253969287325e-09
on O 0 9.552844737470423e-09
the O 0 1.7292086651465866e-09
5 O 0 1.6142372771810187e-08
side O 0 5.0917922322923914e-08
of O 0 4.355133143008061e-08
the O 0 4.5766583411932515e-08
CTG O 0 3.127707486783038e-06
repeat O 0 2.2706499791524948e-08
in O 0 1.416646577823144e-09
the O 0 4.979980872121814e-09
DMPK O 0 1.65217318226496e-06
gene O 0 1.6936486657570526e-09
of O 0 2.3431023787878758e-09
normal O 0 6.01287242218973e-09
individuals O 0 2.1927706178592743e-11
and O 0 5.2463963728932583e-11
of O 0 5.143904191484694e-10
patients O 0 4.1739872669310785e-10
affected O 0 8.869211143291977e-09
with O 0 3.61780917046417e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.4847701379494538e-07
showing O 0 3.1262587185665325e-08
expansions O 0 3.28414913042252e-08
of O 0 9.785074972512575e-09
the O 0 7.065529938898862e-09
repetitive O 0 3.2469995403516805e-07
sequence O 0 3.3377570929360445e-08
. O 0 1.8160442039061309e-07

The O 0 1.550595243315911e-06
gene O 0 5.973802075232015e-08
segment O 0 2.944335975030299e-08
analyzed O 0 2.0431027536460533e-08
corresponds O 0 2.9818212343712958e-09
to O 0 6.347440906218083e-10
the O 0 5.7202362846453525e-09
genomic O 0 8.249754301914436e-08
SacI O 0 5.84279860049719e-06
- O 0 2.1864349264433258e-07
HindIII O 0 1.5665079899918055e-06
fragment O 0 7.146815050873556e-08
carrying O 0 1.1186767778781359e-07
exons O 0 2.1531502625293797e-06
11 O 0 1.2804027846868848e-06
- O 0 5.666999527420558e-07
15 O 0 4.451368056379579e-07
. O 0 9.613301017452613e-07

There O 0 1.6650488987579593e-07
is O 0 5.423667293058543e-09
constitutive O 0 9.782611414266285e-07
methylation O 0 1.0508573922152209e-07
in O 0 1.8321033579127288e-08
intron O 0 2.103050888990765e-07
12 O 0 2.265465894879526e-07
at O 0 3.86036269617307e-08
restriction O 0 1.4993910557592471e-09
sites O 0 2.8610824820418657e-09
of O 0 7.05816249890745e-09
SacII O 0 1.0030677231043228e-06
and O 0 1.2483425848586194e-08
HhaI O 0 2.031677922786912e-06
, O 0 3.0037694553897154e-09
localized O 0 5.758202092920328e-08
1 O 0 1.7391697326729627e-07
, O 0 2.4032698053844115e-09
159 O 0 7.529916246085122e-09
- O 0 2.2938735355637618e-08
1 O 0 7.814762881253046e-08
, O 0 3.4752010158456415e-09
232 O 0 4.316191493103361e-08
bp O 0 6.876079794437828e-08
upstream O 0 2.08179447014345e-08
of O 0 2.3009020466702168e-08
the O 0 4.5649063196151474e-08
CTG O 0 2.5372879463247955e-05
repeat O 0 1.3589641412181663e-07
, O 0 8.643681326248043e-10
whereas O 0 5.945538505969239e-10
most O 0 7.136452540024152e-11
, O 0 1.7598516394157215e-11
if O 0 1.466820068185548e-11
not O 0 2.239741378473603e-11
all O 0 6.232032251363151e-11
, O 0 4.464762240474762e-11
of O 0 2.2485428796681362e-10
the O 0 1.580563457892481e-10
other O 0 4.41938326212199e-11
sites O 0 1.0082095158736593e-09
of O 0 1.1408229028120331e-08
SacII O 0 5.603553745459067e-06
, O 0 9.433702707895009e-09
HhaI O 0 4.708519554696977e-06
, O 0 8.114757754640323e-09
and O 0 6.459193624408499e-09
HpaII O 0 1.654289008001797e-06
in O 0 1.2607872523773267e-09
this O 0 6.084164838604522e-10
region O 0 5.479379616701863e-09
are O 0 1.472629906906775e-09
unmethylated O 0 1.886828329134005e-07
, O 0 5.240577971576954e-10
in O 0 2.417041289337618e-10
normal O 0 5.268080638387573e-09
individuals O 0 4.543478787644162e-11
and O 0 1.6494111632070485e-10
most O 0 6.524887574688165e-11
of O 0 2.953147504314302e-09
the O 0 8.057538636307982e-09
patients O 0 1.102452973356094e-08
. O 0 2.5777245582503383e-07

In O 0 1.185994324970352e-08
a O 0 1.5556562704688304e-09
number O 0 9.767112674197165e-10
of O 0 6.5474847765756294e-09
young O 0 6.295216081753097e-08
and O 0 2.2419415657282116e-08
severely O 0 0.00010991103772539645
affected O 0 2.5597525876719374e-08
patients O 0 1.430952689673859e-09
, O 0 2.221465095209041e-10
however O 0 1.9493182623619987e-09
, O 0 3.304296003481255e-10
complete O 0 1.7528186679882651e-09
methylation O 0 2.9461320050216955e-09
of O 0 6.935993446255395e-10
these O 0 3.498120890177425e-11
restriction O 0 1.4802324643792275e-10
sites O 0 4.3352543777075425e-10
was O 0 2.0020336499726454e-09
found O 0 1.9185322774895042e-10
in O 0 4.1729444899551993e-10
the O 0 2.430736278924428e-09
mutated O 0 4.075388559954263e-08
allele O 0 4.3041853814429487e-07
. O 0 8.23949903860921e-07

In O 0 5.1087486241385704e-08
most O 0 7.867894669111308e-10
of O 0 1.8854524608258316e-09
these O 0 1.6856233076012472e-10
patients O 0 1.2471798593871597e-10
, O 0 3.332078363227353e-11
the O 0 1.4427638250769093e-10
onset O 0 1.9559566055704636e-07
of O 0 1.3394624964746527e-08
the O 0 1.325573606436592e-07
disease O 1 0.9668611288070679
was O 0 2.439190211589448e-05
congenital O 1 1.0
. O 0 0.00015081367746461183

Preliminary O 0 6.259348538151244e-06
in O 0 1.2519245728981332e-07
vivo O 0 9.60385250436957e-07
footprinting O 0 2.864141833924805e-06
data O 0 2.8406496710431384e-08
gave O 0 3.909457646500414e-09
evidence O 0 5.250194945460862e-09
for O 0 6.344088032683715e-10
protein O 0 4.914251228171906e-09
- O 0 9.176722493009493e-09
DNA O 0 5.217700937976133e-09
contact O 0 3.4167257911832394e-09
in O 0 1.7173724664587553e-09
normal O 0 3.71297019796657e-08
genes O 0 8.40665581591793e-09
at O 0 2.4080982541363483e-08
an O 0 3.698970574284033e-10
Sp1 O 0 3.0436137876677094e-07
consensus O 0 8.823825226045301e-08
binding O 0 2.8187800538148622e-08
site O 0 3.8488710885076216e-08
upstream O 0 4.535439579456124e-09
of O 0 4.6383830110130475e-09
the O 0 1.0618984802590603e-08
CTG O 0 3.564214466678095e-06
repeat O 0 9.730245942307647e-09
and O 0 2.1258424187653446e-10
for O 0 4.1659762445300785e-11
a O 0 5.539861624992426e-11
significant O 0 2.8567950782765195e-10
reduction O 0 2.1220232238050585e-09
of O 0 4.133449582610638e-09
this O 0 3.3236188801133437e-10
interaction O 0 2.3904600521262864e-09
in O 0 1.7179646594200904e-10
cells O 0 1.0679686301973135e-10
with O 0 3.483140859072975e-11
a O 0 9.066312700589663e-10
hypermethylated O 0 2.532866858473426e-07
DMPK O 0 2.216064558524522e-06
gene O 0 9.102253173409736e-09
. O 0 1.0827021057480124e-08
. O 0 1.3492375217083463e-07

The O 0 6.426865002140403e-05
hemochromatosis B-Disease 1 1.0
gene O 0 4.852787682807502e-08
product O 0 6.09852834898561e-09
complexes O 0 4.592965119343262e-09
with O 0 6.171401167875956e-10
the O 0 5.7987810109239035e-09
transferrin O 0 1.6111034994992224e-07
receptor O 0 6.188828649555944e-08
and O 0 4.872680037237842e-09
lowers O 0 1.6093306243192274e-08
its O 0 2.7948948710943e-10
affinity O 0 6.912524441737844e-10
for O 0 2.1370304137402485e-10
ligand O 0 2.0956827384566168e-08
binding O 0 2.0912709430831455e-07
. O 0 1.5452040713626047e-07

We O 0 2.852783040907525e-07
recently O 0 6.355308812544536e-08
reported O 0 4.428864386341047e-09
the O 0 7.717231853554551e-10
positional O 0 8.463064204988768e-08
cloning O 0 8.796767758667556e-09
of O 0 1.6829738713752818e-09
a O 0 6.966341392633524e-10
candidate O 0 4.297880451531455e-08
gene O 0 1.4915484314315108e-07
for O 0 4.943217390973587e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.7173662781715393
HFE O 1 0.8497905731201172
. O 0 9.02773354027886e-06

The O 0 2.045799902816725e-07
gene O 0 3.997986830484024e-09
product O 0 2.0977570791558264e-09
, O 0 3.953050387028867e-10
a O 0 8.026274089800722e-10
member O 0 5.198588226562606e-09
of O 0 2.5002224290915365e-08
the O 0 3.011400551145016e-08
major O 0 1.581250330673356e-07
histocompatibility O 0 8.776398317422718e-05
complex O 0 8.2838159869425e-06
class O 0 1.8831970294286293e-07
I O 0 4.782302767125657e-06
- O 0 8.011018337583664e-08
like O 0 6.523696582938499e-10
family O 0 3.425977557203197e-10
, O 0 9.109242526950112e-11
was O 0 1.1803339416971426e-09
found O 0 2.0639141784517534e-10
to O 0 1.5807082032193165e-10
have O 0 7.389976963700917e-10
a O 0 1.0562725805129958e-08
mutation O 0 5.042964090762325e-08
, O 0 1.01250208217607e-07
Cys O 1 0.8564394116401672
- O 0 0.0022862842306494713
282 O 0 8.998527846415527e-06
- O 0 0.00040928798262029886
- O 0 0.0004042003129143268
> O 0 8.514675755577628e-06
Tyr O 0 6.365505396388471e-05
( O 0 2.4693069811121404e-09
C282Y O 0 8.053301314703276e-08
) O 0 1.401894433872286e-10
, O 0 3.389673958187345e-11
in O 0 9.451234933566255e-11
85 O 0 2.0692523250431805e-09
% O 0 2.5546967319378666e-10
of O 0 9.828769798048143e-09
patient O 0 5.110775802563694e-08
chromosomes O 0 5.045004058956692e-07
. O 0 1.2983205124328379e-06

This O 0 1.4347281762638886e-07
mutation O 0 7.433553150804073e-08
eliminates O 0 2.6109569262189325e-07
the O 0 6.7079208854181616e-09
ability O 0 7.1777268573214315e-09
of O 0 1.9515661975333387e-08
HFE O 0 5.348571448848816e-06
to O 0 1.0032589869979347e-08
associate O 0 1.1633051855142185e-07
with O 0 1.1405829614119511e-09
beta2 O 0 4.245659965818049e-06
- O 0 1.1187721611349843e-05
microglobulin O 0 2.872587356250733e-05
( O 0 2.334079951538115e-08
beta2m O 0 1.7985413478527335e-06
) O 0 3.621454913727007e-09
and O 0 7.120184886133529e-09
prevents O 0 1.9404904350039942e-08
cell O 0 1.3415294688456925e-06
- O 0 4.327695819483779e-07
surface O 0 8.597721148362325e-07
expression O 0 9.26672555578989e-07
. O 0 1.2309286603340297e-06

A O 0 1.3284098940857803e-06
second O 0 6.47421956045946e-08
mutation O 0 5.088431009880878e-09
that O 0 8.759488273613059e-11
has O 0 3.922046368232124e-11
no O 0 1.1943515620949086e-10
effect O 0 8.127583939199212e-09
on O 0 5.272807968026427e-08
beta2m O 0 3.474226787147927e-06
association O 0 2.0875839723544232e-08
, O 0 2.133581755714431e-09
H63D O 0 1.2435300504876068e-06
, O 0 8.322763589418969e-10
was O 0 3.85781406819774e-09
found O 0 2.3903040657913266e-10
in O 0 2.3233288903856675e-10
eight O 0 8.811170126854506e-10
out O 0 3.3234606733323346e-10
of O 0 5.287871918113751e-09
nine O 0 5.179587958537013e-08
patients O 0 9.035032721982361e-10
heterozygous O 0 6.412595787708142e-09
for O 0 2.164962209505461e-09
the O 0 3.859479136281152e-08
C282Y O 0 3.7864404021092923e-06
mutant O 0 5.595842594630085e-06
. O 0 3.097873559454456e-06

In O 0 6.64618156065444e-08
this O 0 2.438430790618895e-09
report O 0 2.2935309207383625e-09
, O 0 2.0554129231964424e-10
we O 0 6.575565092425961e-10
demonstrate O 0 3.838627637975378e-09
in O 0 4.7419077553456646e-09
cultured O 0 2.0007831835755496e-07
293 O 0 5.680001891050779e-08
cells O 0 5.074399211935088e-08
overexpressing O 0 1.6784374565759208e-06
wild O 0 3.884203891857396e-08
- O 0 2.8887148673106822e-08
type O 0 2.752270056305406e-08
or O 0 8.451929822683724e-09
mutant O 0 5.446964834732171e-08
HFE O 0 4.500190016187844e-07
proteins O 0 8.33089153218225e-11
that O 0 1.7830263307483385e-11
both O 0 1.0120662641277534e-10
the O 0 6.124426521481041e-10
wild O 0 2.846592739302878e-09
- O 0 2.506997276441325e-09
type O 0 9.403055223344836e-09
and O 0 1.1837524738211869e-08
H63D O 0 9.741201938595623e-05
HFE O 0 9.505493835604284e-06
proteins O 0 3.0883915425050645e-09
form O 0 5.00833818861679e-09
stable O 0 6.035394761738644e-08
complexes O 0 2.9445421656504323e-09
with O 0 3.080706523217458e-10
the O 0 8.498663994771505e-09
transferrin O 0 3.2149424100680335e-07
receptor O 0 2.603512427867827e-07
( O 0 4.332082692570793e-09
TfR O 0 7.796300565132697e-07
) O 0 5.712212036712572e-09
. O 0 1.1172225100608557e-07

The O 0 5.789588612969965e-07
C282Y O 0 3.1298409339797217e-06
mutation O 0 2.502078011445974e-08
nearly O 0 5.106816747257881e-09
completely O 0 8.469390522236608e-09
prevents O 0 6.010025810354591e-10
the O 0 1.3343950389099746e-09
association O 0 2.239162633088654e-09
of O 0 5.7847953094380955e-09
the O 0 7.26039672827028e-09
mutant O 0 1.3743303384217143e-07
HFE O 0 6.402444796549389e-06
protein O 0 2.6295777999507663e-08
with O 0 2.082508387957205e-09
the O 0 3.398852754799009e-08
TfR O 0 9.836733624979388e-06
. O 0 9.27842563669401e-07

Studies O 0 1.944360292327474e-06
on O 0 9.855577900452772e-07
cell O 0 9.842577810559305e-07
- O 0 6.397010565706296e-08
associated O 0 7.79512365767232e-09
transferrin O 0 8.715670674064313e-08
at O 0 9.499284914227246e-08
37 O 0 5.8047788797921385e-09
degrees O 0 4.635396066987596e-08
C O 0 4.0653038269056196e-08
suggest O 0 1.2307733721073078e-09
that O 0 9.957278057637353e-11
the O 0 2.727544856639952e-09
overexpressed O 0 2.2010839018093975e-07
wild O 0 3.1752055207334706e-08
- O 0 5.126064195337676e-08
type O 0 1.422404096729224e-07
HFE O 0 4.37394874097663e-06
protein O 0 9.04845443017166e-09
decreases O 0 2.1941701788819046e-09
the O 0 2.757232775429941e-10
affinity O 0 1.1331561244887212e-09
of O 0 5.754378751277045e-09
the O 0 8.229759096423095e-09
TfR O 0 2.749256680090184e-07
for O 0 2.0443879922282804e-09
transferrin O 0 1.7880577161122346e-06
. O 0 6.443089546337433e-07

The O 0 1.1173912753292825e-05
overexpressed O 0 7.67729216022417e-05
H63D O 0 0.00011210499360458925
protein O 0 2.167888979442978e-08
does O 0 2.1000419458960806e-10
not O 0 6.848244193946584e-11
have O 0 2.6450317630599685e-11
this O 0 7.788826007770755e-12
effect O 0 5.342695730270464e-10
, O 0 1.6179460549103908e-11
providing O 0 2.2764269635988654e-11
the O 0 4.154953464619027e-11
first O 0 2.915473765185972e-11
direct O 0 5.306457356857308e-11
evidence O 0 6.013786690850509e-10
for O 0 7.082699010618754e-11
a O 0 3.09877484783172e-10
functional O 0 4.354302518549957e-08
consequence O 0 7.802907475706888e-08
of O 0 2.9367249965162046e-08
the O 0 4.8334168667452104e-08
H63D O 0 2.2255793737713248e-05
mutation O 0 3.2930850579759863e-07
. O 0 4.97468590765493e-07

Addition O 0 4.0507569565306767e-07
of O 0 1.8798589280777378e-06
soluble O 0 6.303094778559171e-06
wild O 0 1.385550518762102e-07
- O 0 1.7832202559020516e-07
type O 0 1.1019673138434882e-06
HFE O 1 0.9945648908615112
/ O 0 0.00013888343528378755
beta2m O 0 7.695712156419177e-06
heterodimers O 0 1.0606049727357458e-06
to O 0 7.331296458801262e-09
cultured O 0 1.9982158150355644e-08
cells O 0 1.4507919310347006e-09
also O 0 1.2138634541969395e-10
decreased O 0 8.079880098321723e-10
the O 0 1.3239823126731665e-10
apparent O 0 1.2204316446329244e-09
affinity O 0 1.7454655498738703e-09
of O 0 9.915668286453183e-09
the O 0 2.3430890561115802e-09
TfR O 0 1.5879139780849982e-08
for O 0 5.649879869507046e-11
its O 0 5.931104912759722e-11
ligand O 0 3.46883721746849e-09
under O 0 5.163467875490824e-09
steady O 0 6.066649405056523e-08
- O 0 5.120276647119226e-09
state O 0 1.0599103539288279e-10
conditions O 0 3.064977160960325e-09
, O 0 3.71792527320558e-11
both O 0 1.019369935684189e-10
in O 0 2.3068320864627623e-10
293 O 0 1.0864914523622815e-09
cells O 0 2.569023604959142e-10
and O 0 9.5760444018822e-10
in O 0 5.713562956088936e-09
HeLa O 0 1.556959432491567e-06
cells O 0 3.759978142170439e-07
. O 0 8.445953199043288e-07

Furthermore O 0 1.9637356274415652e-07
, O 0 7.055819928325491e-09
at O 0 2.639441731844272e-08
4 O 0 1.7819035136312777e-08
degrees O 0 8.85268676142914e-08
C O 0 9.963560643200253e-08
, O 0 3.697940842428693e-10
the O 0 8.622242364531019e-10
added O 0 1.1796278620579415e-08
soluble O 0 6.149478704031708e-09
complex O 0 5.72752956173872e-09
of O 0 4.225922722866926e-09
HFE O 0 1.2403982509567868e-05
/ O 0 4.080791313754162e-07
beta2m O 0 7.901926437625661e-07
inhibited O 0 1.838758301175858e-08
binding O 0 1.1461643190102677e-08
of O 0 1.7480717318107963e-08
transferrin O 0 2.419576503598364e-07
to O 0 4.714692636298423e-08
HeLa O 0 6.861720521555981e-06
cell O 0 9.640779126129928e-07
TfR O 0 7.595542683702661e-07
in O 0 1.982592978677644e-09
a O 0 3.9562051412644905e-09
concentration O 0 3.6541831605063635e-07
- O 0 3.688769538712222e-07
dependent O 0 6.490390802582624e-08
manner O 0 8.047994128901337e-07
. O 0 3.635568930349109e-07

Scatchard O 0 1.7471073078922927e-05
plots O 0 5.736573598369432e-07
of O 0 5.672087866059883e-08
these O 0 2.9430036185829067e-09
data O 0 6.529837559554608e-09
indicate O 0 6.901857307894943e-09
that O 0 7.509960986418207e-10
the O 0 4.788917262743553e-09
added O 0 2.3402451532206214e-08
heterodimer O 0 1.176457828933053e-07
substantially O 0 7.378938349233977e-09
reduced O 0 5.1735029593658055e-09
the O 0 1.3789556163601446e-09
affinity O 0 3.330575815141401e-09
of O 0 1.035743668609257e-08
TfR O 0 3.133309292024933e-07
for O 0 3.8376906097425945e-09
transferrin O 0 1.6342800108759548e-06
. O 0 6.436984563151782e-07

These O 0 5.64566526861654e-08
results O 0 1.9833697706417297e-07
establish O 0 1.3471310289503435e-08
a O 0 3.450018493111884e-09
molecular O 0 5.205675535080445e-08
link O 0 8.234378867655323e-08
between O 0 7.769641285904072e-08
HFE O 0 9.848021727520972e-05
and O 0 1.4679978121989734e-08
a O 0 1.119903902946362e-08
key O 0 2.9909423915341904e-07
protein O 0 2.466775583798153e-08
involved O 0 1.9742609769224373e-09
in O 0 9.804929090861947e-10
iron O 0 2.547846634115558e-06
transport O 0 6.509191621262289e-07
, O 0 3.224713829297343e-09
the O 0 5.070749153901488e-09
TfR O 0 2.822622491294169e-07
, O 0 3.4082495159459825e-10
and O 0 1.6466197849673847e-10
raise O 0 6.008375463828486e-10
the O 0 8.261130113318416e-10
possibility O 0 3.445770557775063e-09
that O 0 9.616857310490445e-11
alterations O 0 6.3746941059150686e-09
in O 0 1.0356636381825268e-10
this O 0 7.141654628783911e-11
regulatory O 0 3.2063880439636705e-09
mechanism O 0 7.654846712057406e-08
may O 0 4.850481349905067e-09
play O 0 3.758570343848078e-09
a O 0 3.710700913206466e-10
role O 0 6.242004690903968e-10
in O 0 3.0935309869306593e-10
the O 0 2.150902345121608e-09
pathogenesis O 0 3.981300687883049e-05
of O 0 9.370111365569755e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 6.5676508711476345e-06
. O 0 1.2658307468882413e-06

Genomic O 0 2.782048568406026e-06
organization O 0 2.0797374133962876e-07
of O 0 1.245840763886008e-07
the O 0 1.8932612988464825e-07
UBE3A O 0 0.0005997350672259927
/ O 0 0.0004391650145407766
E6 O 0 0.0002663658815436065
- O 0 1.6023792341002263e-05
AP O 0 3.8583792047575116e-05
gene O 0 1.76176868649236e-08
and O 0 7.385246192370687e-09
related O 0 1.3412552846148174e-07
pseudogenes O 0 3.1605761705577606e-06
. O 0 1.431599798706884e-06

The O 0 3.1642316571378615e-06
UBE3A O 0 3.362935967743397e-05
gene O 0 3.192244690808366e-08
encodes O 0 2.0813578416323253e-08
the O 0 2.483208128012393e-08
E6 O 0 1.1772465768444818e-05
- O 0 5.75348212805693e-06
AP O 0 0.0003299563832115382
ubiquitin O 0 5.754958692705259e-06
- O 0 3.5532793845050037e-06
protein O 0 5.1846093640506297e-08
ligase O 0 3.0384192939436616e-08
and O 0 1.6299096516902978e-09
has O 0 5.199299324409878e-10
recently O 0 2.360763584619008e-09
been O 0 4.2189621241028874e-10
shown O 0 1.948477212909694e-10
to O 0 7.305270971480482e-11
be O 0 6.847359346195958e-10
mutated O 0 1.490689527372524e-07
in O 0 4.2215103235321294e-07
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 3.823124927748722e-07
who O 0 1.0852700071950494e-08
lack O 0 3.824868315405183e-07
15q11 O 0 6.127930191723863e-06
- O 0 2.003728695854079e-06
q13 O 0 1.2288444395380793e-06
deletions O 0 1.031141536600444e-07
or O 0 1.885759104425233e-08
chromosome O 0 9.982582582779287e-08
15 O 0 2.583133777989133e-07
paternal O 0 7.265196472872049e-06
uniparental B-Disease 0 0.004656568635255098
disomy I-Disease 0 0.003648592857643962
. O 0 4.931257353746332e-05

Previous O 0 3.874171397910686e-06
UBE3A O 0 2.9273071049829014e-05
cDNA O 0 1.720167261964889e-07
analysis O 0 1.316637732173831e-08
has O 0 1.7117174344605246e-10
shown O 0 6.20736018142054e-10
a O 0 1.688159501078701e-09
coding O 0 3.4172877860783046e-08
region O 0 6.524869977653225e-09
of O 0 1.1982728587156544e-08
approximately O 0 4.81848427824616e-09
2 O 0 2.3013328132037714e-07
. O 0 2.138582573252279e-07

6 O 0 5.458604573504999e-05
kb O 0 0.0001064275493263267
and O 0 3.6273053893864926e-08
a O 0 3.716193930358713e-08
3 O 0 1.0634114460117416e-06
- O 0 1.8942162114399252e-06
untranslated O 0 0.00027599575696513057
region O 0 4.82814641600271e-08
( O 0 8.504614790183496e-09
UTR O 0 9.21719129109988e-06
) O 0 2.905977458667053e-09
of O 0 1.5868815594899388e-08
< O 0 2.598001174192177e-07
50 O 0 1.7514425465492423e-08
bp O 0 2.361719531052131e-08
, O 0 3.572727946821175e-10
whereas O 0 1.872407784375696e-09
Northern O 0 3.4109564062134723e-09
analysis O 0 4.040672685334812e-09
has O 0 4.828141220158955e-10
indicated O 0 4.147665322307148e-09
mRNA O 0 3.994549579999784e-09
sizes O 0 1.3064763493275677e-08
of O 0 2.2245115971486484e-08
5 O 0 2.3676601301758637e-07
- O 0 2.1873817956929997e-07
8 O 0 4.4591735104404506e-07
kb O 0 3.5897533962270245e-05
. O 0 1.0722088745751535e-06

We O 0 1.6329107666024356e-07
have O 0 1.3338556925646117e-09
analyzed O 0 3.4035478879701486e-09
additional O 0 2.154613015781237e-10
cDNA O 0 5.405614622588928e-09
clones O 0 1.2109186542375028e-08
and O 0 3.103956813799158e-10
provide O 0 2.1763715829514751e-10
evidence O 0 1.21923804385915e-09
for O 0 3.873145207333728e-11
an O 0 1.9020295755067806e-11
additional O 0 5.965326010937133e-10
0 O 0 2.1525106319586484e-07
. O 0 2.2552073630777159e-07

5 O 0 6.671496066701366e-06
kb O 0 1.6492498616571538e-05
of O 0 4.509753352976986e-07
5 O 0 1.1535748853930272e-06
- O 0 6.094199420658697e-07
UTR O 0 8.125531167024747e-06
and O 0 1.1249799314327902e-08
> O 0 1.6689358517396613e-07
2 O 0 1.5396659591715434e-07
kb O 0 2.009232048294507e-06
of O 0 1.3691656874925684e-07
3 O 0 4.000722583441529e-06
- O 0 3.2832208489708137e-06
UTR O 0 0.00018395850202068686
. O 0 1.4488107353827218e-06

We O 0 8.049600097592702e-08
have O 0 9.35946320446135e-10
established O 0 1.7043556566065377e-09
the O 0 5.719993367847565e-10
genomic O 0 5.1352211372091006e-09
organization O 0 2.1493602453404037e-09
of O 0 8.504907000883577e-09
UBE3A O 0 1.268773644369503e-06
and O 0 2.8353650538548436e-09
the O 0 3.770784573475794e-09
sequence O 0 3.863903863532414e-09
of O 0 2.595826131823742e-08
intron O 0 7.960089760672417e-07
- O 0 8.452298061456531e-06
exon O 0 1.0354473261031671e-06
borders O 0 1.1675921030018799e-07
. O 0 2.2001615889166715e-06

We O 0 3.4019149097730406e-07
have O 0 6.4429022117451495e-09
also O 0 3.1869138439333256e-09
mapped O 0 1.1488957341043715e-08
two O 0 4.89492169020167e-10
highly O 0 3.109350554808543e-09
homologous O 0 8.782701677034765e-09
processed O 0 1.909768165830883e-08
pseudogenes O 0 1.4168099937705847e-07
, O 0 4.009495402357288e-09
UBE3AP1 O 0 1.6344608866347698e-06
and O 0 1.91421385409285e-08
UBE3AP2 O 0 1.7064013491108199e-06
, O 0 4.457114954892205e-10
to O 0 1.9403699480502468e-10
chromosomes O 0 8.928273120822894e-10
2 O 0 1.0162047203721158e-08
and O 0 5.581695106116058e-10
21 O 0 1.0774529712875847e-08
, O 0 2.1412165096545976e-10
respectively O 0 3.183779018200994e-09
, O 0 1.2253222048119738e-10
and O 0 1.6170889627353802e-10
determined O 0 3.5240144136139406e-09
their O 0 2.7765811871915957e-09
genomic O 0 3.8925847434256866e-08
organization O 0 8.028854381336714e-08
. O 0 4.509185771439661e-07

These O 0 4.151181443035057e-08
results O 0 4.876159565014859e-08
will O 0 3.4746494570470077e-10
form O 0 8.920931354738926e-11
the O 0 7.040286409409902e-11
basis O 0 9.225924191280654e-11
for O 0 3.315568089176657e-12
studies O 0 6.146365361114903e-11
of O 0 1.9911336468503293e-10
mutation O 0 1.659870796366647e-09
and O 0 5.142120951262541e-09
imprinting O 0 1.6116979395519593e-06
of O 0 1.7750924143911107e-06
UBE3A O 0 0.0010047235991805792
. O 0 8.692362825968303e-06

Mutation O 0 4.955167241860181e-06
spectrum O 0 2.0119050532230176e-06
and O 0 9.916258392195232e-08
genotype O 0 3.811184342339402e-06
- O 0 1.5939166360112722e-06
phenotype O 0 4.5537490223068744e-07
analyses O 0 4.9121453571387974e-08
in O 0 1.4522130165062208e-08
Cowden B-Disease 1 0.7155200242996216
disease I-Disease 0 0.011947570368647575
and O 0 1.2156995126133552e-06
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.3773685948499406e-08
two O 0 1.682635115685116e-07
hamartoma B-Disease 1 0.9874469637870789
syndromes I-Disease 0 0.0002375754847889766
with O 0 7.982972647369024e-07
germline O 0 0.17264105379581451
PTEN O 0 0.0008967679459601641
mutation O 0 4.958580575475935e-06
. O 0 4.0695854295336176e-06

The O 0 1.5107996659935452e-05
tumour B-Disease 1 1.0
suppressor O 0 0.00019669228640850633
gene O 0 3.7418777765196864e-07
PTEN O 0 4.908276878268225e-06
, O 0 3.841952977978735e-09
which O 0 9.476727180768307e-10
maps O 0 1.5202466840946727e-08
to O 0 1.0734223288011435e-08
10q23 O 0 4.416261617734563e-06
. O 0 1.7957408999791369e-06

3 O 0 1.782369622560509e-06
and O 0 2.386998687597952e-08
encodes O 0 8.444163590581866e-09
a O 0 3.8050953499180196e-09
403 O 0 7.0789112349700645e-09
amino O 0 2.1850294018577188e-08
acid O 0 3.073385101970416e-08
dual O 0 1.1459301276772749e-06
specificity O 0 3.0379924282897264e-05
phosphatase O 1 0.6445683240890503
( O 0 3.0978742415754823e-07
protein O 0 5.576836770160298e-07
tyrosine O 0 1.0182718597206986e-06
phosphatase O 0 3.44667995477721e-07
; O 0 5.133455882599947e-10
PTPase O 0 1.6001672520360444e-07
) O 0 1.3151003896982871e-10
, O 0 5.678530562436279e-11
was O 0 6.054136636457486e-10
shown O 0 2.6131455332922826e-10
recently O 0 1.4316815510895253e-09
to O 0 4.652699614471345e-10
play O 0 9.453858140773264e-09
a O 0 1.0798925087485145e-09
broad O 0 1.4963006833568215e-08
role O 0 1.8579543237251528e-08
in O 0 1.4697151939913056e-08
human O 0 5.192551384425315e-07
malignancy B-Disease 0 4.073922900715843e-05
. O 0 1.7245411072508432e-06

Somatic O 0 0.0002936669625341892
PTEN O 0 6.282866524998099e-05
deletions O 0 2.3417884165155556e-07
and O 0 5.304863659461034e-09
mutations O 0 2.7721571704830694e-09
were O 0 1.329314436304685e-09
observed O 0 2.122513054203523e-09
in O 0 7.217741959664181e-10
sporadic B-Disease 0 1.3732313846048783e-06
breast I-Disease 1 0.9950180053710938
, I-Disease 0 1.919045826070942e-05
brain I-Disease 1 1.0
, I-Disease 0 0.001728226663544774
prostate I-Disease 1 1.0
and I-Disease 1 0.9971127510070801
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9989116191864014
cell O 0 0.00030671435524709523
lines O 0 1.120162735901431e-07
and O 0 6.792819640111247e-09
in O 0 1.252702053200494e-09
several O 0 2.3898583112469396e-09
primary O 0 5.8456149417907e-05
tumours B-Disease 1 1.0
such O 0 8.982906507526423e-08
as O 0 4.950302354700398e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999889135360718
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.8509438037872314

In O 0 8.036514742570944e-08
addition O 0 2.324306258572051e-08
, O 0 8.289403830019637e-09
PTEN O 0 2.0134270926064346e-06
was O 0 3.1300352532070974e-08
identified O 0 2.725844217010831e-09
as O 0 3.716154606259181e-10
the O 0 4.690425825515376e-10
susceptibility O 0 1.5961550303700278e-08
gene O 0 7.134364210514832e-09
for O 0 6.5275838068146186e-09
two O 0 9.061650416697375e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9996896982192993
( O 0 4.0196891148980285e-08
CD B-Disease 0 8.555453860026319e-06
; O 0 1.3617665217680042e-07
MIM O 0 3.391674181330018e-05
158350 O 0 1.7006826737997471e-06
) O 0 3.2328368870793156e-09
and O 0 1.0273757844458942e-08
Bannayan B-Disease 0 0.0002875079517252743
- I-Disease 0 0.015486043877899647
Zonana I-Disease 1 0.9990419745445251
( I-Disease 0 2.6565388111521315e-07
BZS I-Disease 0 0.00014692023978568614
) I-Disease 0 8.064491652248762e-08
or I-Disease 0 1.0570691699740564e-07
Ruvalcaba I-Disease 0 0.00010620633111102507
- I-Disease 0 5.240800965111703e-05
Riley I-Disease 0 0.01058423612266779
- I-Disease 1 0.9999532699584961
Smith I-Disease 1 0.998171329498291
syndrome I-Disease 1 0.999996542930603
( O 0 4.864617721977993e-07
MIM O 0 0.00018841960991267115
153480 O 0 8.564164090785198e-06
) O 0 7.813123659161647e-08
. O 0 9.400598628417356e-07

Constitutive O 0 3.290896347607486e-05
DNA O 0 2.621735859520413e-07
from O 0 1.083292833214955e-08
37 O 0 8.721091404595427e-08
CD B-Disease 0 3.230767902095977e-07
families O 0 1.8683157243515325e-09
and O 0 3.1005975564823984e-09
seven O 0 3.6696569338801055e-08
BZS B-Disease 0 7.2621969593456015e-06
families O 0 3.192389241846172e-09
was O 0 3.0404191164734584e-08
screened O 0 6.950540409889072e-08
for O 0 4.123970498426388e-08
germline O 0 0.0001853480061981827
PTEN O 0 0.00017577993276063353
mutations O 0 1.1334007467667107e-05
. O 0 4.550238827505382e-06

PTEN O 0 0.00018297639326192439
mutations O 0 3.1658720445193467e-07
were O 0 2.3358259326755615e-08
identified O 0 8.882009794319856e-09
in O 0 1.2333606358438942e-09
30 O 0 5.3954685164114835e-09
of O 0 1.726862741691093e-08
37 O 0 9.60568726782185e-08
( O 0 4.1882883827781825e-09
81 O 0 4.231740291515962e-08
% O 0 8.710044907545011e-10
) O 0 7.239443489126529e-10
CD B-Disease 0 1.5186967061708856e-07
families O 0 4.50722931200076e-10
, O 0 1.47493420254996e-10
including O 0 5.972748962079777e-10
missense O 0 2.759861956747045e-07
and O 0 3.4075377186582045e-08
nonsense O 0 4.770795840158826e-06
point O 0 6.513644166261656e-07
mutations O 0 1.783345204842135e-08
, O 0 2.195015724737459e-09
deletions O 0 1.569473973006552e-08
, O 0 1.165186058749157e-09
insertions O 0 2.233567464315911e-08
, O 0 3.2335458755028412e-09
a O 0 9.270774370406798e-09
deletion O 0 7.556506034234189e-07
/ O 0 3.216869799871347e-06
insertion O 0 1.4357271993503673e-07
and O 0 2.2799943621976126e-07
splice O 0 2.9559940230683424e-05
site O 0 8.856137583279633e-07
mutations O 0 1.246415195055306e-06
. O 0 2.110987225023564e-06

These O 0 3.7379681572247137e-08
mutations O 0 5.387502000075983e-08
were O 0 1.0169221908995496e-08
scattered O 0 1.5051913493380198e-08
over O 0 3.190709030320704e-09
the O 0 2.7887459008724136e-09
entire O 0 1.2167947538443968e-08
length O 0 2.7080540032642375e-09
of O 0 9.667699529813945e-09
PTEN O 0 4.7294093974414864e-07
, O 0 4.834960765087715e-10
with O 0 4.677933040930782e-11
the O 0 3.8126782286873606e-10
exception O 0 2.833849821470835e-10
of O 0 1.3866016113084356e-09
the O 0 6.802488017321195e-10
first O 0 2.977371238443993e-09
, O 0 1.0039896691793615e-09
fourth O 0 5.62577966434219e-08
and O 0 1.8432563919645872e-08
last O 0 7.733173674751015e-07
exons O 0 2.8550157367135398e-05
. O 0 9.513737495581154e-06

A O 0 3.574508127712761e-06
hot O 0 2.2938793335924856e-06
spot O 0 1.1983548802163568e-06
for O 0 7.326375950356123e-09
PTEN O 0 1.5648475937268813e-06
mutation O 0 8.36963298667115e-09
in O 0 1.4668830594644078e-09
CD B-Disease 0 1.3379515451106272e-07
was O 0 2.7643970668123075e-08
identified O 0 5.364161559384684e-09
in O 0 1.6761086962802096e-09
exon O 0 1.8249744826448477e-08
5 O 0 8.375414140004978e-09
that O 0 1.1245990944042106e-10
contains O 0 2.337459115153706e-10
the O 0 3.1123112975706135e-09
PTPase O 0 3.8484827769025287e-07
core O 0 1.366899340382588e-07
motif O 0 7.0402532692526165e-09
, O 0 1.040068170476971e-10
with O 0 3.1544114542647606e-11
13 O 0 3.445323359940744e-09
of O 0 2.7500963728499528e-09
30 O 0 1.051630960091643e-08
( O 0 1.003204852523254e-09
43 O 0 7.82346987193705e-09
% O 0 3.817626215152359e-10
) O 0 6.146895770164917e-10
CD B-Disease 0 1.1963778945300874e-07
mutations O 0 2.0892530372407236e-08
identified O 0 1.6817551795611507e-08
in O 0 2.5050375107582568e-09
this O 0 5.43463363200658e-09
exon O 0 1.0515126405152841e-06
. O 0 7.803054131727549e-07

Seven O 0 9.225793746736599e-07
of O 0 1.0485709367458185e-07
30 O 0 9.308801907081943e-08
( O 0 2.354575867613562e-09
23 O 0 2.5352248300691826e-08
% O 0 1.6424855919794368e-10
) O 0 1.0338420397548731e-10
were O 0 8.389896000160491e-10
within O 0 1.9102663895154137e-09
the O 0 7.240382737805362e-10
core O 0 3.0767516534524475e-08
motif O 0 2.8433475574018985e-09
, O 0 5.227696747711619e-11
the O 0 7.748052893719048e-11
majority O 0 4.45063950971214e-11
( O 0 1.5427664701306298e-10
five O 0 8.962157682645966e-10
of O 0 1.4358957356463975e-09
seven O 0 1.988413433906544e-09
) O 0 7.027380066748634e-11
of O 0 4.1606257328297147e-10
which O 0 4.470789294330757e-10
were O 0 3.1414650436545344e-08
missense O 0 3.87427098758053e-06
mutations O 0 2.6871944669437653e-07
, O 0 7.03861502415748e-09
possibly O 0 9.681986767873241e-08
pointing O 0 8.647779026205171e-08
to O 0 1.9276849005933627e-09
the O 0 3.4994191988602097e-09
functional O 0 8.621198333003122e-08
significance O 0 7.454055150901695e-08
of O 0 2.4136207699143597e-08
this O 0 2.370021290332147e-09
region O 0 4.2946684430944515e-08
. O 0 4.4470911575444916e-07

Germline O 0 0.0022230695467442274
PTEN O 0 8.974212687462568e-05
mutations O 0 1.753194851517037e-07
were O 0 1.4493792832581676e-08
identified O 0 6.413244157954523e-09
in O 0 1.324334086838519e-09
four O 0 3.6137408621073064e-09
of O 0 2.504541818382222e-08
seven O 0 5.308925565827849e-08
( O 0 7.153139858218083e-09
57 O 0 9.759895647221128e-08
% O 0 7.856456818444713e-09
) O 0 3.487147637315502e-08
BZS B-Disease 0 0.00011242026084801182
families O 0 1.223377523729141e-07
studied O 0 4.92427443532506e-06
. O 0 2.8314971132203937e-06

Interestingly O 0 1.1807577493527788e-06
, O 0 4.741374404204635e-09
none O 0 4.382002316560829e-09
of O 0 9.982764614946404e-10
these O 0 2.1584713183475657e-10
mutations O 0 1.9324188915703644e-09
was O 0 3.736376985585821e-09
observed O 0 2.2049606585028414e-09
in O 0 8.410211971288106e-10
the O 0 1.7995754220123672e-08
PTPase O 0 1.0839566130016465e-05
core O 0 1.5067853382788599e-05
motif O 0 2.787397079373477e-06
. O 0 1.1794116971941548e-06

It O 0 1.847818609235219e-08
is O 0 3.7420874732241316e-10
also O 0 6.950743453026931e-11
worthy O 0 2.9457050132464246e-09
of O 0 1.3805134813082987e-09
note O 0 8.490833591778824e-10
that O 0 2.8820898792525362e-11
a O 0 2.1762262825131273e-10
single O 0 1.1823166889968206e-09
nonsense O 0 7.693488868198983e-08
point O 0 5.096952548910849e-08
mutation O 0 2.622974282218138e-09
, O 0 6.724262813229132e-10
R233X O 0 4.8031079558086276e-08
, O 0 6.845818911749291e-10
was O 0 4.140125131613104e-09
observed O 0 1.641280666930811e-09
in O 0 3.334184317527189e-10
the O 0 2.305566404459114e-09
germline O 0 7.963000570043732e-08
DNA O 0 6.070489444454097e-09
from O 0 6.553003140119529e-10
two O 0 1.0020957397216534e-09
unrelated O 0 1.3139635157699558e-08
CD B-Disease 0 2.5355399202453555e-07
families O 0 1.6890098208932613e-09
and O 0 5.049670015466745e-09
one O 0 4.769185224517969e-08
BZS B-Disease 0 0.00015732926840428263
family O 0 9.463402648179908e-07
. O 0 4.012893441540655e-06

Genotype O 0 2.790616053971462e-05
- O 0 2.8926158393005608e-06
phenotype O 0 2.8275570329583388e-08
studies O 0 1.4665754166642841e-09
were O 0 2.583287750379526e-10
not O 0 2.3102212851067172e-11
performed O 0 6.531637036788496e-11
on O 0 9.744263174127354e-10
this O 0 1.0856084087240703e-10
small O 0 6.242051875382515e-10
group O 0 2.0079842233400313e-09
of O 0 9.329456673867753e-08
BZS B-Disease 0 0.0003853027301374823
families O 0 1.9477754165109218e-07
. O 0 1.5651908142899629e-06

However O 0 4.6178971047083905e-07
, O 0 3.606079346241131e-08
genotype O 0 2.752924785909272e-07
- O 0 1.5421480270561005e-07
phenotype O 0 5.056245910850521e-08
analysis O 0 6.172275579530151e-09
inthe O 0 1.8097543375006353e-07
group O 0 7.010261260376183e-10
of O 0 6.948126074490801e-09
CD B-Disease 0 6.033727117937815e-07
families O 0 1.7507804095373558e-09
revealed O 0 2.0551327750695236e-08
two O 0 3.8327727103215636e-10
possible O 0 4.611530712850254e-09
associations O 0 2.9428408598874967e-09
worthy O 0 5.227585120337608e-08
of O 0 4.1051670507386007e-08
follow O 0 2.1551988638179864e-08
- O 0 5.29308188390587e-08
up O 0 2.5855320107126545e-09
in O 0 1.0440797115762734e-09
independent O 0 1.0014618467835135e-08
analyses O 0 2.6420715926178673e-07
. O 0 1.005199351311603e-06

The O 0 3.273043489571137e-07
first O 0 3.3341940763875755e-08
was O 0 2.433511703259228e-08
an O 0 3.953729288408425e-10
association O 0 1.2732789267388966e-09
noted O 0 9.719834936916527e-10
in O 0 4.300680367386178e-10
the O 0 2.7246229716837433e-09
group O 0 3.944268522904082e-10
of O 0 5.568214778151059e-09
CD B-Disease 0 6.246597331482917e-05
families O 0 1.3913126650777485e-08
with O 0 1.6570474770105648e-07
breast B-Disease 1 0.999983549118042
disease I-Disease 1 0.9999836683273315
. O 0 0.00022774799435865134

A O 0 3.3102958241215674e-07
correlation O 0 4.907828099476319e-08
was O 0 2.262604503755483e-08
observed O 0 2.0371015985176655e-09
between O 0 6.491870929714594e-10
the O 0 4.6373546669364885e-10
presence O 0 2.2051624970487183e-09
/ O 0 1.9649888827188988e-07
absence O 0 4.3160351737014935e-08
of O 0 2.4641611418019238e-08
a O 0 1.0566131081191088e-08
PTEN O 0 1.0081158734465134e-06
mutation O 0 8.562885511764762e-09
and O 0 1.32817401521379e-09
the O 0 1.543408845172678e-09
type O 0 1.713531219138531e-07
of O 0 3.619983544922434e-06
breast O 0 0.0005146952462382615
involvement O 0 0.00021070557704661041
( O 0 2.779762326099444e-06
unaffected O 0 0.0005717866588383913
versus O 1 0.9999563694000244
benign O 1 0.9999797344207764
versus O 1 0.9939543604850769
malignant O 0 0.07524056732654572
) O 0 1.780205849399863e-07
. O 0 1.0141444590772153e-06

Specifically O 0 9.115304777651545e-08
and O 0 6.7818541893416295e-09
more O 0 2.1657954596410178e-10
directly O 0 5.701270011648774e-10
, O 0 1.5579716683422618e-10
an O 0 1.4733708697534098e-10
association O 0 1.659687165478374e-09
was O 0 2.1765563573694635e-08
also O 0 7.049386629986998e-10
observed O 0 1.5853104384788708e-09
between O 0 6.646201922144712e-10
the O 0 3.6571595751766495e-10
presence O 0 3.807271442557436e-10
of O 0 5.373398170860355e-09
a O 0 1.8703206094983216e-08
PTEN O 0 0.0008560368441976607
mutation O 0 3.62873324775137e-05
and O 0 1.5811394405318424e-05
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9997301697731018
. O 0 1.9718363546417095e-05

Secondly O 0 1.3967713130114134e-05
, O 0 1.3237640317242949e-08
there O 0 1.6929834201206972e-09
appeared O 0 3.040951046529017e-09
to O 0 2.113092201216915e-10
be O 0 4.735208336548169e-10
an O 0 3.9700590037661243e-10
interdependent O 0 1.2289874575799331e-06
association O 0 1.0737192468468493e-08
between O 0 6.245237216262467e-08
mutations O 0 2.0872416683914707e-08
upstream O 0 1.39774138929738e-08
and O 0 8.010002106040304e-10
within O 0 5.573464356700697e-09
the O 0 6.676367458879895e-09
PTPase O 0 1.5967906392688747e-06
core O 0 4.2017009604933264e-07
motif O 0 1.5002786568629745e-08
, O 0 3.5255590113969504e-10
the O 0 4.002364273336667e-10
core O 0 7.316293793024897e-09
motif O 0 6.685118014715385e-10
containing O 0 7.646780431080913e-11
the O 0 5.7220637950106124e-11
majority O 0 1.0570233577311683e-10
of O 0 2.8972937382576447e-09
missense O 0 1.4983946527991066e-07
mutations O 0 1.0857668542030297e-08
, O 0 5.92507043428725e-10
and O 0 4.001898812333593e-10
the O 0 1.165288310289725e-09
involvement O 0 7.623109254950577e-09
of O 0 2.871581017416247e-08
all O 0 3.042250673601643e-09
major O 0 3.980215268484244e-08
organ O 0 0.0001384647621307522
systems O 1 0.9999902248382568
( O 0 7.447884127032012e-05
central O 1 0.9999994039535522
nervous O 1 0.999996542930603
system O 1 0.9999998807907104
, O 0 0.0014993615914136171
thyroid O 1 1.0
, O 0 0.0008122613653540611
breast O 1 0.9999998807907104
, O 0 0.0002972029324155301
skin O 1 1.0
and O 1 0.9969115853309631
gastrointestinal O 1 0.9999998807907104
tract O 0 0.0023820921778678894
) O 0 1.1599622666835785e-06
. O 0 2.582944398454856e-05

However O 0 4.741087309412251e-07
, O 0 4.123590802151966e-09
these O 0 1.676817851237189e-10
observations O 0 1.087067658112062e-09
would O 0 2.5468918640747518e-11
need O 0 7.002719931703538e-11
to O 0 2.9265048717697084e-11
be O 0 1.1705404701078947e-10
confirmed O 0 9.215939678064444e-10
by O 0 5.231886451850798e-11
studying O 0 1.0615880396969146e-09
a O 0 6.1137553353241e-11
larger O 0 3.332397691124811e-10
number O 0 1.1629214258235265e-09
of O 0 1.1886485573597838e-08
CD B-Disease 0 1.1908427950402256e-06
families O 0 1.5251462315291064e-08
. O 0 1.1901587271267999e-07

Molecular O 1 0.999065101146698
defects O 1 0.9999513626098633
leading O 0 9.319795708506717e-07
to O 0 5.0035353638122615e-09
human O 0 4.737345093985823e-08
complement B-Disease 0 4.166628514212789e-06
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.4471722487030547e-08
an O 0 3.611657917179656e-10
African O 0 1.2851693043103296e-08
- O 0 8.089506842168248e-09
American O 0 1.2147535199957815e-09
family O 0 1.2427099349565651e-08
. O 0 1.2178632857740013e-07

Complement B-Disease 0 1.822309241106268e-05
component I-Disease 1 0.9998961687088013
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 7.202675078588072e-08
C6D B-Disease 0 1.636087654333096e-05
) O 0 2.5988218244066275e-09
was O 0 2.285968037085695e-08
diagnosed O 0 4.738239667290145e-08
in O 0 1.7922100470357805e-09
a O 0 5.077795073304969e-09
16 O 0 1.583551636485936e-07
- O 0 6.314962774922606e-08
year O 0 7.582130479022453e-09
- O 0 4.566282285622947e-08
old O 0 7.640004469067208e-07
African O 0 2.0604829842341132e-07
- O 0 6.638603444741875e-09
American O 0 1.0016294460513109e-09
male O 0 1.2198435150878595e-08
with O 0 5.208238107456964e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.00017845106776803732

The O 0 2.1330342292458226e-07
patients O 0 1.4460382224967816e-08
father O 0 5.2852531240432654e-08
and O 0 4.37524638741138e-09
two O 0 1.202831967361817e-08
brothers O 0 7.887270214723685e-08
also O 0 3.4524147984882347e-09
had O 0 3.8653357847806546e-08
C6D B-Disease 0 5.530883208848536e-05
, O 0 8.439876020283066e-10
but O 0 3.482524824072186e-10
gave O 0 1.4074168497302253e-09
no O 0 2.4850771440654285e-10
history O 0 2.2549559997031565e-09
of O 0 8.724315492258938e-09
meningitis B-Disease 1 1.0
or O 0 2.679284172302232e-08
other O 0 1.0574196629420385e-08
neisserial B-Disease 0 2.47120169660775e-05
infection I-Disease 0 5.178152787266299e-05
. O 0 2.9274051485117525e-06

By O 0 5.104297429170401e-08
using O 0 5.241282963197591e-08
exon O 0 3.030530706382706e-07
- O 0 3.9968149678770715e-08
specific O 0 2.6698556698789844e-09
polymerase O 0 6.247236505885212e-09
chain O 0 4.390887653471509e-09
reaction O 0 3.1278732937067844e-09
( O 0 1.0157295005086553e-09
PCR O 0 9.249226273766453e-09
) O 0 8.462410772125395e-10
/ O 0 6.379632377928601e-09
single O 0 1.1409724276489897e-09
- O 0 5.344115372452052e-09
strand O 0 2.77713185781181e-09
conformation O 0 4.275522436092416e-10
polymorphism O 0 4.32062691180235e-10
as O 0 2.1186928947369843e-11
a O 0 1.8471708537748377e-11
screening O 0 5.851081424923521e-11
step O 0 1.0471750133689284e-09
and O 0 5.265686775501877e-10
nucleotide O 0 1.2951963945795342e-09
sequencing O 0 9.150291635506846e-10
of O 0 1.7059297308108512e-09
target O 0 1.5370524408808706e-08
exons O 0 2.91298874799395e-07
, O 0 1.3807189835901568e-09
we O 0 9.346725615699825e-10
determined O 0 2.2453123804666575e-09
that O 0 9.711546844481944e-11
the O 0 1.129901616714335e-09
proband O 0 2.5404605707990413e-07
was O 0 8.803917594946142e-09
a O 0 1.0310244880074038e-09
compound O 0 1.819399741975758e-08
heterozygote O 0 2.7896234655599983e-07
for O 0 9.074656581731233e-09
two O 0 1.3143788635261444e-07
C6 O 0 0.0035127918235957623
gene O 0 8.251530516645289e-07
mutations O 0 2.3680267986492254e-06
. O 0 2.5034635200427147e-06

The O 0 2.8930773510182917e-07
first O 0 5.5714689750629987e-08
, O 0 2.1578467901406384e-09
1195delC O 0 1.563372222790349e-07
located O 0 8.752749636187218e-09
in O 0 1.6555391502137695e-09
exon O 0 6.520580342339599e-08
7 O 0 3.282352452060877e-07
, O 0 1.0553959928216727e-09
is O 0 8.773701209996432e-11
a O 0 1.885483852381853e-10
novel O 0 1.1092928797751256e-09
mutation O 0 6.590443746290475e-10
, O 0 3.098538370327475e-10
while O 0 3.560360617438363e-10
the O 0 1.3663311593248295e-09
second O 0 5.984873929776313e-09
, O 0 1.4775844991987697e-09
1936delG O 0 7.957427783367166e-08
in O 0 6.061708024418522e-09
exon O 0 1.1958621826124727e-07
12 O 0 1.6212126752179756e-07
, O 0 1.7796202289588336e-09
has O 0 4.438299172626614e-10
been O 0 1.5406059761247093e-09
described O 0 4.00477961903789e-09
before O 0 6.654525819271839e-09
to O 0 9.540584988698697e-10
cause O 0 4.368094153051061e-08
C6D B-Disease 0 4.7974783228710294e-05
in O 0 8.582998312078871e-09
an O 0 1.2376637492650389e-09
unrelated O 0 1.844241666049129e-07
African O 0 7.576538223474927e-07
- O 0 3.645536708063446e-07
American O 0 2.895041362194206e-08
individual O 0 5.361014387972318e-08
. O 0 1.1187177051397157e-06

Both O 0 3.748235144485079e-07
mutations O 0 4.21633586711323e-07
result O 0 6.740062019616744e-08
in O 0 1.4964603778366836e-08
premature O 0 4.4410222699298174e-07
termination O 0 8.553125780963455e-07
codons O 0 4.3672739025168994e-07
and O 0 2.473674101111101e-07
C6 O 0 0.0004955992917530239
null O 0 4.296752013033256e-05
alleles O 0 2.5745921448105946e-06
. O 0 2.4789644612610573e-06

Allele O 0 4.675189302361105e-06
- O 0 2.0855031834798865e-07
specific O 0 2.5027162564583705e-09
PCR O 0 5.247882572945173e-09
indicated O 0 2.088746064998759e-09
that O 0 9.459530381228376e-11
the O 0 9.681128121385996e-10
probands O 0 4.229836179092672e-07
two O 0 4.167784339870195e-09
brothers O 0 1.8920134792210774e-08
also O 0 1.9442756293841512e-09
inherited O 0 7.98063766183077e-08
the O 0 1.1582159231693367e-08
1195delC O 0 9.357524533015749e-08
mutation O 0 1.3204622950624412e-09
from O 0 3.5463584846517904e-10
their O 0 2.445216473745404e-09
heterozygous O 0 8.504031256961753e-09
mother O 0 2.3202257892762645e-09
and O 0 9.140662671214272e-10
the O 0 3.208578291946651e-09
1936delG O 0 4.2241676823095986e-08
mutation O 0 5.114144663309617e-10
from O 0 1.0682314754983935e-10
their O 0 1.1710458158731285e-09
homozygous O 0 9.031626113653601e-09
father O 0 8.011415530972954e-08
. O 0 4.5779678714552574e-08
. O 0 9.072934972209623e-07

PAX6 O 0 0.0076730018481612206
mutations O 0 5.306819366523996e-05
reviewed O 0 3.9112037484301254e-05
. O 0 5.522227183973882e-06

Mutations O 0 1.05068454558932e-06
in O 0 7.922762534917638e-08
PAX6 O 0 0.00013463078357744962
are O 0 3.998223530032874e-09
responsible O 0 7.072149976750097e-09
for O 0 1.1615580719492868e-09
human O 0 4.578605796723423e-07
aniridia B-Disease 1 1.0
and O 0 5.7627950411642814e-08
have O 0 1.270828442478944e-09
also O 0 3.339861998075122e-10
been O 0 2.9906652154743085e-10
found O 0 1.9621566871297347e-10
in O 0 1.7431224519359745e-10
patients O 0 3.928546654652365e-10
with O 0 3.086224609205601e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.1047212612756994e-06
with O 1 0.9057565331459045
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 8.74159286468057e-06
with O 0 2.6622096811479423e-06
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 7.092036469202867e-08
and O 0 3.3547344457929285e-08
with O 0 9.747133589144141e-08
isolated B-Disease 0 0.06618189066648483
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.048241596668958664

No O 0 1.9446574128778593e-07
locus O 0 1.4366352729666687e-07
other O 0 1.5682612986012145e-09
than O 0 1.3339065407791395e-09
chromosome O 0 2.896422302001156e-08
11p13 O 0 1.3440261170671874e-07
has O 0 1.9316193089480294e-09
been O 0 4.465669167785791e-09
implicated O 0 7.000673463153362e-08
in O 0 9.968612602051508e-09
aniridia B-Disease 1 1.0
, O 0 8.875134405172957e-09
and O 0 1.5320063440071863e-08
PAX6 O 0 0.0001514939940534532
is O 0 3.652142588350671e-09
clearly O 0 6.302638411170847e-09
the O 0 2.5684074866916262e-09
major O 0 7.508790922372555e-09
, O 0 2.981040414518077e-10
if O 0 1.1916642672638034e-10
not O 0 1.1807566036026174e-10
only O 0 2.5254059954349373e-10
, O 0 9.949878698733983e-10
gene O 0 1.7014787800917475e-08
responsible O 0 1.4458319697041588e-07
. O 0 1.4476934211415937e-06

Twenty O 0 1.2491696907090954e-05
- O 0 7.127945877982711e-07
eight O 0 2.4196269876597398e-08
percent O 0 2.371224105957026e-09
of O 0 8.073814505848986e-09
identified O 0 1.3185758973577322e-07
PAX6 O 0 1.9181454263161868e-05
mutations O 0 1.4189559749411274e-07
are O 0 9.961086178122969e-09
C O 0 1.6373520338675007e-05
- O 0 4.403052116686013e-06
T O 0 3.176169229845982e-07
changes O 0 1.0867323929630857e-08
at O 0 4.3403638017025514e-08
CpG O 0 6.170747468559057e-08
dinucleotides O 0 3.087379951693947e-08
, O 0 1.633453650118355e-10
20 O 0 6.881781255962949e-10
% O 0 1.0761005975190585e-10
are O 0 1.9133540585247744e-10
splicing O 0 3.581464369517562e-08
errors O 0 6.069803362152015e-07
, O 0 6.356430382048472e-10
and O 0 1.3120488029372268e-10
more O 0 9.486049099005633e-12
than O 0 2.9028501824512887e-11
30 O 0 5.252005497169421e-10
% O 0 6.664223339836184e-11
are O 0 1.2657791481629488e-10
deletion O 0 1.6233084210171e-08
or O 0 7.367560783677618e-09
insertion O 0 6.20921269955943e-08
events O 0 2.930028699665854e-07
. O 0 8.339820851688273e-07

There O 0 2.52666183087058e-07
is O 0 3.3910938501691135e-09
a O 0 6.552693943007171e-09
noticeably O 0 2.3576966157179413e-07
elevated O 0 3.1785964438313385e-07
level O 0 1.5536592457010556e-07
of O 0 3.6861753649475304e-09
mutation O 0 6.623511183967423e-10
in O 0 2.2308233038614844e-10
the O 0 6.532661633862347e-10
paired O 0 1.5144634435415583e-09
domain O 0 6.817113540336095e-10
compared O 0 1.2398605753194403e-10
with O 0 1.5764259689299287e-11
the O 0 1.1514306175186562e-10
rest O 0 4.77102746199165e-10
of O 0 7.986569183771053e-10
the O 0 3.35172689602814e-09
gene O 0 1.4884698806838514e-08
. O 0 1.8400464796286542e-07

Increased O 0 1.2590305686899228e-07
mutation O 0 2.1952597961671927e-08
in O 0 4.0711447546470936e-09
the O 0 7.901510556962421e-09
homeodomain O 0 6.391113629433676e-07
is O 0 7.271909741035643e-10
accounted O 0 5.245358036809478e-10
for O 0 9.779373838503247e-11
by O 0 2.765886963906894e-10
the O 0 8.99315466540429e-09
hypermutable O 0 3.7456409245351097e-06
CpG O 0 2.8256515633984236e-06
dinucleotide O 0 2.0630209291994106e-06
in O 0 3.998172104502373e-08
codon O 0 9.891189165500691e-07
240 O 0 4.309989094508637e-07
. O 0 5.740300252909947e-07

Very O 0 1.3707987989164394e-07
nearly O 0 6.4084382245255256e-09
all O 0 3.9494180148480496e-10
mutations O 0 1.1057335047581773e-09
appear O 0 1.346719291639431e-09
to O 0 4.0835934633776105e-10
cause O 0 1.1981175163100488e-08
loss O 0 2.7536092517266297e-08
of O 0 1.4013451732353133e-08
function O 0 8.188173694634315e-09
of O 0 4.280583887350531e-09
the O 0 3.248592728155586e-09
mutant O 0 1.0453674370580757e-08
allele O 0 5.811148451329018e-09
, O 0 1.5660037155917905e-10
and O 0 4.813206777587453e-11
more O 0 3.8840107345616826e-12
than O 0 6.631759377762059e-12
80 O 0 8.426842557085479e-11
% O 0 1.5932571234555937e-11
of O 0 3.9615494218381286e-10
exonic O 0 1.0940034655959607e-07
substitutions O 0 1.2400887428043461e-08
result O 0 4.308022383270327e-09
in O 0 2.5028976669005942e-09
nonsense O 0 2.1393820759385562e-07
codons O 0 4.47181719209766e-07
. O 0 3.2971954055938113e-07

In O 0 1.1619513884397747e-07
a O 0 2.4509098750513658e-08
gene O 0 1.1965409774106206e-09
with O 0 1.3438704316026673e-10
such O 0 4.558741439897318e-10
extraordinarily O 0 9.750331741997798e-08
high O 0 2.3270905558092636e-07
sequence O 0 4.836531175556047e-09
conservation O 0 5.165337046975083e-10
throughout O 0 4.7082598236825035e-11
evolution O 0 1.0114280524220476e-09
, O 0 2.8781563937707588e-11
there O 0 3.4793428554946715e-11
are O 0 4.6203128128974313e-11
presumed O 0 5.468940855735127e-08
undiscovered O 0 8.446501169601106e-07
missense O 0 8.170327987500059e-07
mutations O 0 6.06648740131277e-08
, O 0 1.1804960342587378e-09
these O 0 4.976939416145854e-10
are O 0 2.697392031958401e-10
hypothesized O 0 5.963918248141908e-09
to O 0 4.3465064880621185e-10
exist O 0 4.662936259336448e-09
in O 0 1.6270986780142493e-09
as O 0 5.504519062782265e-09
- O 0 6.789661455286478e-08
yet O 0 1.4067815357066138e-08
unidentified O 0 2.967950365473371e-07
phenotypes O 0 3.0293000463643693e-07
. O 0 2.1654919635238912e-08
. O 0 3.7056551605019195e-07

Genetic O 0 1.4095231790633989e-06
heterogeneity O 0 8.355368095180893e-07
and O 0 1.7359509385528327e-08
penetrance O 0 1.1321748161208234e-06
analysis O 0 1.777297420346713e-08
of O 0 2.5371887701908236e-08
the O 0 2.3170560581320387e-08
BRCA1 O 0 8.406707507901956e-08
and O 0 9.477422224790644e-08
BRCA2 O 0 2.657385209658969e-07
genes O 0 6.431167776099755e-08
in O 0 1.0047548926195304e-07
breast B-Disease 0 3.334319990244694e-05
cancer I-Disease 0 2.758924665613449e-06
families O 0 6.06419661153268e-08
. O 0 2.2863900994707365e-06

The O 0 0.02095932699739933
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 8.557223191019148e-05
Consortium O 0 2.9889058623666642e-06
. O 0 2.3254428924701642e-06

The O 0 9.583708759919318e-08
contribution O 0 4.735348824169705e-08
of O 0 9.164448044884921e-08
BRCA1 O 0 8.080041880020872e-08
and O 0 3.452041141827067e-08
BRCA2 O 0 2.362671466471511e-06
to O 0 1.0524435083425487e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.008593493141233921
assessed O 0 9.704659760245704e-07
by O 0 1.4265978398597667e-09
linkage O 0 2.0448414517204583e-08
and O 0 2.356112416279643e-09
mutation O 0 1.3140655230614584e-09
analysis O 0 1.4371451806383106e-09
in O 0 2.407397614589968e-10
237 O 0 1.0965344188207382e-09
families O 0 2.8624606157601207e-11
, O 0 3.753251182070372e-11
each O 0 4.6043013152141654e-11
with O 0 6.880097880301861e-11
at O 0 3.013894200876166e-08
least O 0 1.4210225218747041e-09
four O 0 1.1116799703003721e-09
cases O 0 2.977433632977977e-09
of O 0 1.9586484256706171e-07
breast B-Disease 0 7.226591696962714e-05
cancer I-Disease 0 3.750284122361336e-06
, O 0 5.7983164936104e-09
collected O 0 5.260148761010441e-09
by O 0 2.2887327588705375e-09
the O 0 5.04439640280907e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 3.447433846304193e-05
Consortium O 0 1.3368282907322282e-06
. O 0 1.5316929875552887e-06

Families O 0 3.263063419467471e-08
were O 0 5.710686590276737e-09
included O 0 7.35539740226443e-10
without O 0 7.282041636358372e-10
regard O 0 1.9785961757889936e-09
to O 0 2.3799678894320664e-10
the O 0 1.2888532463506408e-09
occurrence O 0 1.1072877725837316e-07
of O 0 7.204185294540366e-06
ovarian B-Disease 1 0.9999992847442627
or I-Disease 0 0.0223845224827528
other I-Disease 0 2.6151085421588505e-06
cancers I-Disease 1 0.9995455145835876
. O 0 1.9906508896383457e-05

Overall O 0 0.00014080494293011725
, O 0 2.163741896765714e-07
disease O 0 8.471331238979474e-05
was O 0 3.464700171207369e-07
linked O 0 1.0180830400940977e-07
to O 0 3.4663900638776113e-09
BRCA1 O 0 8.052821520720954e-09
in O 0 6.353835790839923e-10
an O 0 6.830776222432888e-11
estimated O 0 1.4694810646087575e-10
52 O 0 1.4808545500955006e-09
% O 0 1.312459307900582e-10
of O 0 1.7013934705545353e-09
families O 0 1.6090220822384538e-10
, O 0 1.8241236299232355e-10
to O 0 4.841383405285171e-10
BRCA2 O 0 1.2783118563675089e-08
in O 0 2.9687743374751108e-09
32 O 0 2.084679273650636e-08
% O 0 1.9303626752620318e-10
of O 0 1.15234510822404e-09
families O 0 8.538852958039911e-11
, O 0 7.473006241598412e-11
and O 0 1.0753331558532864e-10
to O 0 1.8526938316831831e-10
neither O 0 2.695408340969152e-09
gene O 0 7.074061891820804e-10
in O 0 1.0088154756004997e-09
16 O 0 1.192936682770096e-08
% O 0 3.4001851334508615e-10
( O 0 3.0603022893593845e-10
95 O 0 1.5704770817137614e-08
% O 0 1.6371132227632756e-09
confidence O 0 1.9390850525269343e-07
interval O 0 5.217634111431835e-07
[ O 0 3.503221819300961e-07
CI O 0 3.823573479166953e-06
] O 0 9.325862748710279e-08
6 O 0 6.209070591012278e-08
% O 0 6.462935742135301e-10
- O 0 3.694206274218459e-09
28 O 0 6.336774660553601e-09
% O 0 2.2684357170454916e-10
) O 0 1.9545629004191767e-10
, O 0 1.8182323702209402e-10
suggesting O 0 5.8230087418564835e-09
other O 0 2.763509865388869e-09
predisposition O 0 2.3688527051035635e-07
genes O 0 3.0370523518286063e-07
. O 0 9.313585564996174e-07

The O 0 3.2263525895359635e-07
majority O 0 1.685329209522024e-08
( O 0 5.426751048531742e-09
81 O 0 2.1238749425833703e-08
% O 0 6.846967437468265e-10
) O 0 3.968295136935751e-10
of O 0 1.668648685893004e-08
the O 0 9.95046939351596e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.925095638455332e-08
were O 0 4.972851908036091e-09
due O 0 7.590844575133815e-08
to O 0 5.813664660792028e-09
BRCA1 O 0 1.4407852688691491e-08
, O 0 8.400528050955813e-10
with O 0 9.588357885448318e-11
most O 0 2.935428289330133e-10
others O 0 1.8626370446028773e-09
( O 0 7.395334900017758e-10
14 O 0 1.4428010786105006e-08
% O 0 2.9588179129014236e-10
) O 0 3.208148191546911e-10
due O 0 8.52706634191236e-08
to O 0 1.0236480108005708e-07
BRCA2 O 0 1.7200167349074036e-05
. O 0 5.154720838618232e-06

Conversely O 0 1.5194427760434337e-06
, O 0 5.310350825737942e-09
the O 0 8.049930722009435e-10
majority O 0 5.949077341860232e-10
of O 0 3.275639537392294e-09
families O 0 9.794830918563591e-11
with O 0 3.627149691709519e-10
male B-Disease 0 2.391675195667631e-07
and I-Disease 0 2.7475791739561828e-06
female I-Disease 0 0.0135166822001338
breast I-Disease 0 0.2131945788860321
cancer I-Disease 0 0.050246935337781906
were O 0 9.3550934252562e-06
due O 0 0.4382036328315735
to O 0 2.267163608848932e-06
BRCA2 O 0 2.837536158040166e-06
( O 0 5.6904223555420685e-08
76 O 0 3.6379793755259016e-07
% O 0 4.731454783524214e-09
) O 0 8.431898734784227e-09
. O 0 3.6650584434028133e-07

The O 0 3.11726523705147e-07
largest O 0 1.6245161660322083e-08
proportion O 0 7.070005469955731e-09
( O 0 1.0718792520236775e-09
67 O 0 1.2108863245430257e-08
% O 0 1.3910166074548869e-10
) O 0 7.483275804576195e-11
of O 0 7.808602098258177e-10
families O 0 4.7645408451924e-11
due O 0 2.1088817359071754e-09
to O 0 2.347426975024547e-10
other O 0 1.9585037758229618e-10
genes O 0 7.122530898406865e-10
was O 0 2.2175121738854386e-09
found O 0 1.854687931013288e-10
in O 0 1.5486864568536873e-10
families O 0 5.1695227959447365e-11
with O 0 6.945548303161075e-11
four O 0 1.3977833335232503e-09
or O 0 1.48192258464519e-09
five O 0 2.0511843334958257e-09
cases O 0 2.7665583157698848e-09
of O 0 1.0916007795458427e-06
female O 0 0.4777015745639801
breast B-Disease 1 0.9957745671272278
cancer I-Disease 0 0.006504901684820652
only O 0 3.684357352540246e-06
. O 0 3.14768694806844e-05

These O 0 5.9028774757052815e-08
estimates O 0 3.4213314847875154e-08
were O 0 3.3349174533015002e-09
not O 0 3.7727682089538916e-10
substantially O 0 8.657528915989587e-09
affected O 0 1.4886821775306203e-09
either O 0 7.650694522354229e-10
by O 0 3.676869642088576e-10
changing O 0 6.181818612560619e-09
the O 0 6.463798940536947e-10
assumed O 0 1.102663294005879e-08
penetrance O 0 7.36181888782994e-08
model O 0 3.220657074365363e-09
for O 0 2.537921817147293e-10
BRCA1 O 0 1.2862328979679205e-09
or O 0 1.1454287518475326e-10
by O 0 4.422646623924997e-11
including O 0 2.0055029859022966e-10
or O 0 6.221871906575416e-09
excluding O 0 6.131818963694968e-08
BRCA1 O 0 1.5094096283974068e-07
mutation O 0 8.868911294257487e-08
data O 0 1.833928990890854e-07
. O 0 5.805079581477912e-07

Among O 0 1.0766050451138653e-07
those O 0 8.693286979166714e-09
families O 0 7.960138104223802e-10
with O 0 3.561678452168593e-10
disease O 0 3.338457332802136e-08
due O 0 5.055898810724102e-08
to O 0 3.588930264086798e-09
BRCA1 O 0 6.947410202684523e-09
that O 0 2.3767199319735255e-10
were O 0 6.961387577497646e-10
tested O 0 3.7039410427652797e-10
by O 0 3.683845242741235e-11
one O 0 6.086169762609117e-11
of O 0 2.605411719702744e-10
the O 0 1.6044129913517224e-10
standard O 0 4.6325099312127804e-10
screening O 0 8.107354371178488e-11
methods O 0 8.566998221937183e-10
, O 0 3.9444773836105895e-11
mutations O 0 2.1384656545553327e-10
were O 0 2.1850772580211952e-10
detected O 0 3.524187608405782e-10
in O 0 9.880543605511605e-11
the O 0 1.3415661914706334e-09
coding O 0 2.0730812622105077e-08
sequence O 0 1.4696891481591479e-09
or O 0 8.187638345091841e-10
splice O 0 1.7852782363547703e-08
sites O 0 1.1517826692397648e-09
in O 0 1.480091327277222e-10
an O 0 3.4841376311822714e-11
estimated O 0 3.329526099271618e-10
63 O 0 7.904013443749136e-09
% O 0 9.607987738746715e-10
( O 0 1.0917969861523602e-09
95 O 0 7.385869338349949e-08
% O 0 1.4123899383378102e-08
CI O 0 5.147986030351603e-06
51 O 0 1.318374671654965e-07
% O 0 4.143672072132176e-09
- O 0 7.028690163224383e-08
77 O 0 1.1448140213587976e-08
% O 0 8.048425814699556e-10
) O 0 2.6940616404402817e-09
. O 0 1.5664825525618653e-07

The O 0 2.2834367996438232e-07
estimated O 0 1.0099268088481494e-08
sensitivity O 0 2.311617741668215e-08
was O 0 7.21229564959458e-09
identical O 0 1.2091408985170915e-09
for O 0 4.296136710268961e-11
direct O 0 1.4802946368686065e-10
sequencing O 0 6.86000034555434e-10
and O 0 4.1234235470533065e-10
other O 0 4.44876635530278e-10
techniques O 0 2.6699390787143784e-07
. O 0 1.0367343605821588e-07

The O 0 8.985457498056348e-07
penetrance O 0 6.834617670392618e-05
of O 0 1.1823206023109378e-06
BRCA2 O 0 4.893652771897905e-07
was O 0 5.307184025582501e-08
estimated O 0 9.549669943709205e-10
by O 0 2.810380816953284e-10
maximizing O 0 4.4118856123986916e-08
the O 0 7.0119767769938335e-09
LOD O 0 3.856580406136345e-06
score O 0 1.5773161976539996e-07
in O 0 1.66274869428662e-08
BRCA2 O 0 5.638917173200753e-07
- O 0 7.930818810564233e-07
mutation O 0 3.3358462658839017e-09
families O 0 2.8637017757127126e-10
, O 0 2.2942429900307815e-10
over O 0 8.715662080938102e-10
all O 0 7.972202342720891e-10
possible O 0 2.8643711402764893e-08
penetrance O 0 6.403727184078889e-06
functions O 0 5.670680707225983e-07
. O 0 4.784455427397916e-07

The O 0 1.0261540950295966e-07
estimated O 0 9.569038006418396e-09
cumulative O 0 6.045360834150415e-08
risk O 0 1.3246934216226691e-08
of O 0 1.4158902672534168e-07
breast B-Disease 0 6.444803943850275e-07
cancer I-Disease 0 1.769140567375871e-07
reached O 0 1.6432759366580285e-06
28 O 0 6.450282512560079e-07
% O 0 1.1822806067485203e-09
( O 0 5.161299165834521e-10
95 O 0 1.625322276765928e-08
% O 0 1.6263075330869015e-09
CI O 0 4.2093691376976494e-07
9 O 0 9.4920395099507e-08
% O 0 8.232486914394599e-10
- O 0 2.1480488499037165e-09
44 O 0 2.625655803889515e-10
% O 0 1.4915029281081793e-11
) O 0 6.24526125259095e-12
by O 0 1.4733868639038583e-11
age O 0 3.8802605573096116e-10
50 O 0 1.6979076478129684e-10
years O 0 7.811682550817878e-11
and O 0 8.008348151289368e-11
84 O 0 1.0515059933879911e-09
% O 0 6.566538285346368e-11
( O 0 9.970885228582915e-11
95 O 0 1.1019400503187171e-08
% O 0 2.659771514146314e-09
CI O 0 8.174318395504088e-07
43 O 0 4.981142254223414e-08
% O 0 8.877550361496844e-10
- O 0 5.175595507722619e-09
95 O 0 2.912163843404869e-09
% O 0 3.6695112226592386e-11
) O 0 1.0624114435420218e-11
by O 0 3.526687275545726e-11
age O 0 4.697661815100673e-09
70 O 0 5.5963131906366925e-09
years O 0 8.458735933913886e-09
. O 0 1.3757177441675594e-07

The O 0 4.963855644746218e-06
corresponding O 1 0.9999241828918457
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 3.731824790520477e-06
were O 0 2.5119865654232854e-07
0 O 0 1.26111694953579e-06
. O 0 5.207016329222824e-07

4 O 0 2.6981103928847006e-06
% O 0 1.0242296788476324e-08
( O 0 2.1316497456069783e-09
95 O 0 2.932180187542599e-08
% O 0 3.869885301099885e-09
CI O 0 6.635262934651109e-07
0 O 0 6.188970758103096e-08
% O 0 4.755011384638408e-10
- O 0 1.928365245262853e-09
1 O 0 3.262912606771806e-09
% O 0 2.4757699362831787e-11
) O 0 5.189446528747199e-12
by O 0 6.5942221301462656e-12
age O 0 4.287747656928076e-10
50 O 0 1.4730842934351784e-10
years O 0 9.021527969110821e-11
and O 0 1.0711326964285561e-10
27 O 0 3.832007156034933e-09
% O 0 1.359670015466108e-10
( O 0 1.2643242008891775e-10
95 O 0 5.757979870679719e-09
% O 0 1.3405482279793546e-09
CI O 0 5.266014113658457e-07
0 O 0 5.413438586288066e-08
% O 0 1.1035253821845004e-09
- O 0 4.911739903690204e-09
47 O 0 3.3124631926284565e-09
% O 0 9.269066764128198e-11
) O 0 3.1979439929497033e-11
by O 0 6.274947228490646e-11
age O 0 1.479804900839099e-08
70 O 0 1.1269405852942782e-08
years O 0 1.8964501080631635e-08
. O 0 2.2812450595210976e-07

The O 0 3.684620537569572e-07
lifetime O 0 2.905130941144307e-06
risk O 0 5.832643637404544e-06
of O 0 0.0002590258955024183
breast B-Disease 1 0.639828085899353
cancer I-Disease 0 4.722306584881153e-06
appears O 0 3.275959770121517e-08
similar O 0 3.5862273151110458e-09
to O 0 1.4669894188301669e-09
the O 0 6.55204424049316e-09
risk O 0 8.452671451664173e-09
in O 0 4.014660603957054e-09
BRCA1 O 0 5.471964215075786e-09
carriers O 0 3.468980935839028e-10
, O 0 1.7960076481582377e-10
but O 0 1.0456575882944463e-10
there O 0 9.894876584759515e-11
was O 0 3.62331886716305e-10
some O 0 1.091577262607446e-11
suggestion O 0 1.7537583607563079e-09
of O 0 2.001151910846488e-09
a O 0 2.1223673929426923e-09
lower O 0 5.3144471934274407e-08
risk O 0 9.812679557796855e-09
in O 0 1.0713789855287814e-08
BRCA2 O 0 1.5061225155932334e-07
carriers O 0 1.50558179257132e-08
< O 0 2.930112827925768e-07
50 O 0 9.465749073456209e-09
years O 0 1.5822112509056296e-09
of O 0 2.1009085582335274e-09
age O 0 6.693468179719275e-08
. O 0 1.1721965620381525e-07

Eye B-Disease 1 0.9999704360961914
movement I-Disease 0 3.472845128271729e-05
abnormalities I-Disease 0 0.0003020594303961843
correlate O 0 1.2684492389780644e-07
with O 0 9.556155866619065e-10
genotype O 0 2.904583311647002e-07
in O 0 2.5165753925193712e-08
autosomal O 1 0.9998669624328613
dominant O 1 0.9999998807907104
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999998807907104
. O 0 5.075578883406706e-06

We O 0 4.049632877922704e-07
compared O 0 9.688267255114624e-08
horizontal O 0 5.831703219882911e-06
eye O 0 0.00024428474716842175
movements O 0 3.172581557464582e-07
( O 0 1.7455397127719152e-08
visually O 0 2.485956684949997e-08
guided O 0 1.1334598326584455e-07
saccades O 0 2.0510465219558682e-06
, O 0 7.126421230907454e-09
antisaccades O 0 4.7100141387090844e-07
, O 0 1.663376103522296e-09
and O 0 2.0578851955832533e-09
smooth O 0 2.520076769485513e-08
pursuit O 0 2.5591033292471366e-08
) O 0 6.572718480590822e-10
in O 0 4.974519129952171e-10
control O 0 3.4422708239389976e-08
subjects O 0 1.1824661214632215e-06
( O 0 7.3221988472482735e-09
n O 0 1.4209614107585367e-07
= O 0 2.7589248929871246e-07
14 O 0 3.047857077831395e-08
) O 0 1.848218383893041e-10
and O 0 1.5179386914088155e-10
patients O 0 4.7582018186664854e-11
with O 0 1.000959905239629e-11
three O 0 7.256083234263855e-11
forms O 0 2.0553199142625544e-09
of O 0 7.970749749119932e-08
autosomal O 0 0.03260412812232971
dominant O 1 0.9990330934524536
cerebellar B-Disease 1 1.0
ataxias I-Disease 1 0.8866645097732544
type I-Disease 0 0.00014526033191941679
I I-Disease 0 0.00013978421338833869
spinocerebellar B-Disease 0 7.89992991485633e-05
ataxias I-Disease 0 1.133737987402128e-05
1 I-Disease 0 1.2213962463647476e-06
and I-Disease 0 2.37984316697748e-08
2 I-Disease 0 8.588010587118333e-07
( O 0 7.693897075000677e-09
SCA1 B-Disease 0 2.644784217409324e-06
, O 0 5.535874425532938e-09
n O 0 6.532580698603851e-08
= O 0 7.448142724797435e-08
11 O 0 1.500072599469604e-08
; O 0 8.043499755139294e-10
SCA2 B-Disease 0 6.185696292959619e-07
, O 0 3.389412306376016e-09
n O 0 3.1216647045084756e-08
= O 0 1.1390567777880278e-07
10 O 0 1.7575096933342138e-08
) O 0 1.2414844707819839e-09
and O 0 3.105322221585993e-08
SCA3 B-Disease 1 1.0
/ O 0 0.0004095745098311454
Machado B-Disease 0 1.0906448551395442e-05
- I-Disease 0 2.397051048319554e-06
Joseph I-Disease 0 7.476247992599383e-05
disease I-Disease 0 0.00012572486593853682
( O 0 6.272132679896458e-08
MJD B-Disease 1 1.0
) O 0 5.043204964749748e-08
( O 0 9.155708191599388e-09
n O 0 4.2918188114526856e-07
= O 0 6.645979055974749e-07
16 O 0 3.325338013837609e-07
) O 0 2.131236165325845e-08
. O 0 2.2089359674737352e-07

In O 0 9.788332135940436e-07
SCA1 B-Disease 0 7.028080290183425e-05
, O 0 3.685797622665632e-08
saccade O 0 1.1841588047900586e-06
amplitude O 0 1.9551994512312376e-07
was O 0 1.2846595787152637e-08
significantly O 0 1.9726873468073336e-09
increased O 0 1.8325357897808203e-09
, O 0 4.438485412538995e-10
resulting O 0 3.1913420794893455e-09
in O 0 7.366506959982644e-09
hypermetria B-Disease 0 4.892172910331283e-06
. O 0 5.182963604966062e-07

The O 0 1.264467300643446e-06
smooth O 0 1.5354252127508516e-06
pursuit O 0 6.340676463878481e-07
gain O 0 6.636079206145951e-07
was O 0 7.392372936010361e-07
decreased O 0 6.815753295086324e-07
. O 0 4.5544223326032807e-07

In O 0 1.2762868664140115e-06
SCA2 B-Disease 0 7.760045991744846e-05
, O 0 5.465895824841027e-08
saccade O 0 2.081315869872924e-06
velocity O 0 8.02958709300583e-07
was O 0 3.9690149833404575e-07
markedly O 0 2.1187581751291873e-06
decreased O 0 9.468042208027327e-07
. O 0 3.950529787744017e-07

The O 0 1.7435139909594e-07
percentage O 0 5.244363165957111e-08
of O 0 1.7197201884755486e-08
errors O 0 1.3695929510504357e-06
in O 0 7.501776089213763e-09
antisaccades O 0 1.3117895605319063e-06
was O 0 2.8905171589599377e-08
greatly O 0 3.81620113287795e-09
increased O 0 5.760360521911423e-10
and O 0 5.686988102659996e-10
was O 0 4.2370280617376466e-09
significantly O 0 5.40567424156535e-10
correlated O 0 2.2251809284057344e-09
with O 0 6.68059010888733e-11
age O 0 6.921568029838454e-08
at O 0 4.517570744155819e-07
disease O 0 1.446338274035952e-06
onset O 0 1.6608254327366012e-06
. O 0 2.2985166481248598e-07

In O 0 3.117981250966295e-08
addition O 0 7.495254195077905e-09
, O 0 6.1092941816554e-10
a O 0 8.190887412773407e-10
correlation O 0 6.466490898304755e-09
between O 0 1.0094530544790814e-08
smooth O 0 2.4791807717861047e-08
pursuit O 0 1.0027156882586041e-08
gain O 0 1.6412846193247788e-08
and O 0 4.1449743637400616e-10
the O 0 4.212449000728924e-10
number O 0 9.415864754558356e-10
of O 0 1.555769912897631e-08
trinucleotide O 0 1.240994720319577e-06
repeats O 0 1.045631066176611e-07
was O 0 6.066822777484049e-08
found O 0 2.366571649758953e-08
. O 0 2.486379457877774e-07

In O 0 7.987466233316809e-06
SCA3 B-Disease 1 1.0
, O 0 4.6538093556591775e-07
gaze B-Disease 0 0.053076572716236115
- I-Disease 0 6.027920244378038e-05
evoked I-Disease 0 2.143778601748636e-06
nystagmus I-Disease 0 1.9918588805012405e-05
was O 0 2.5498410494151358e-08
often O 0 3.667064429890843e-10
present O 0 3.486559096987918e-10
as O 0 6.536737262585746e-10
was O 0 1.3475910165539062e-08
saccade O 0 2.905320002355438e-07
hypometria O 0 1.2593407063832274e-06
and O 0 2.530828346891667e-08
smooth O 0 4.044869967856357e-07
pursuit O 0 3.6491718446995947e-07
gain O 0 1.9348892692505615e-06
was O 0 1.8256067733091186e-06
markedly O 0 2.5719491532072425e-06
decreased O 0 4.663098707169411e-07
. O 0 2.7320979256728606e-07

Three O 0 1.8631465081853094e-07
major O 0 4.0423085323482155e-08
criteria O 0 1.0496915336943857e-07
, O 0 5.940281599947639e-09
saccade O 0 1.898209660566863e-07
amplitude O 0 5.959736881777644e-08
, O 0 2.0210868534320525e-09
saccade O 0 4.9959091086293483e-08
velocity O 0 5.866332131176932e-08
, O 0 9.558636104856078e-10
and O 0 6.347961045705119e-10
presence O 0 3.248245672438088e-09
of O 0 7.479112014152633e-07
gaze B-Disease 1 0.9998230338096619
- I-Disease 0 0.0926627442240715
evoked I-Disease 0 5.4518568504136056e-06
nystagmus I-Disease 0 2.058229711110471e-06
, O 0 7.989525152574117e-10
permitted O 0 1.6603616259658338e-09
the O 0 8.752612523643677e-10
correct O 0 1.4154804439669988e-08
assignment O 0 1.0068437639176864e-08
of O 0 3.5776599460746183e-09
90 O 0 1.176051434015335e-08
% O 0 5.617045717443148e-10
of O 0 6.598296131699044e-09
the O 0 2.3642614976893128e-08
SCA1 B-Disease 0 7.793380973453168e-06
, O 0 2.4906112727762775e-09
90 O 0 4.060915159698197e-09
% O 0 2.0391026367416742e-10
of O 0 1.3936570786299285e-09
the O 0 5.159175309188413e-09
SCA2 B-Disease 0 2.459401002852246e-06
, O 0 4.518763696559347e-10
and O 0 3.935161363433082e-10
93 O 0 3.661823955170007e-09
% O 0 7.728408191187697e-11
of O 0 9.111106868964214e-10
the O 0 1.4861173402991312e-09
patients O 0 9.90931114941418e-10
with O 0 8.913792481912708e-10
SCA3 B-Disease 1 1.0
to O 0 2.8758984083054884e-09
their O 0 2.6509892059323192e-09
genetically O 0 6.379291761504646e-09
confirmed O 0 1.0048062826228943e-08
patient O 0 9.318728899643247e-09
group O 0 1.2216170297563167e-09
and O 0 2.3434196805283136e-09
, O 0 4.751601889729784e-10
therefore O 0 3.49352391459945e-09
, O 0 6.623372406089345e-10
may O 0 4.954513688204543e-09
help O 0 6.536915453381198e-09
orient O 0 3.424332817303366e-06
diagnoses O 0 2.182085410140644e-07
of O 0 3.4902353007737474e-08
SCA1 B-Disease 0 1.1651371096377261e-05
, O 0 7.49808481970149e-09
SCA2 B-Disease 0 2.0680440684373025e-06
, O 0 1.918467384953715e-09
and O 0 1.1841544633739431e-08
SCA3 B-Disease 1 1.0
at O 0 1.6577082817548217e-07
early O 0 1.690835027545745e-08
clinical O 0 2.633331952495155e-08
stages O 0 3.2899233559646746e-08
of O 0 1.4245213009189683e-08
the O 0 5.201606256832747e-08
diseases O 0 4.729527063318528e-06
. O 0 2.013592315108781e-08
. O 0 5.25804523476836e-07

Genetic O 0 1.6065204988535697e-07
basis O 0 2.9564798609271747e-08
and O 0 1.7198603652346378e-09
molecular O 0 1.1246176967460997e-07
mechanism O 0 1.8630715885592508e-06
for O 0 2.798680611704185e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.32786497473716736

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9982185959815979
causes O 0 3.668705858217436e-06
more O 0 2.339538784923434e-09
than O 0 6.04509053925284e-10
300 O 0 1.4147023552624205e-09
, O 0 3.773912571336524e-10
000 O 0 9.643556175831236e-09
sudden O 0 7.383190059329081e-09
deaths O 0 1.5622456661645856e-09
each O 0 2.1786931980738444e-10
year O 0 6.223127013704755e-10
in O 0 9.359569785871713e-10
the O 0 7.292637160816184e-09
USA O 0 7.134747193049407e-08
alone O 0 3.4469749721210974e-08
. O 0 2.1838799568740797e-07

In O 0 3.728878823494597e-07
approximately O 0 4.4434024459860666e-08
5 O 0 1.484162766018926e-07
- O 0 2.843837343391442e-08
12 O 0 4.151115895467683e-09
% O 0 6.808507924116469e-11
of O 0 1.0901318042710884e-10
these O 0 3.062858647262523e-11
cases O 0 8.040704213563288e-11
, O 0 5.751176878482367e-12
there O 0 1.6921714030004864e-11
are O 0 2.0997606431372162e-11
no O 0 7.75033315303375e-10
demonstrable O 0 3.62757382390555e-05
cardiac O 0 0.025426845997571945
or O 0 1.830097176025447e-06
non O 1 0.9999608993530273
- O 1 0.9732743501663208
cardiac O 0 0.47956809401512146
causes O 0 2.0098593722650548e-07
to O 0 1.9482551127936176e-09
account O 0 8.240703119888337e-10
for O 0 4.0469796958042537e-10
the O 0 4.4369725671344895e-09
episode O 0 1.0255999605135457e-08
, O 0 5.6216736127323585e-11
which O 0 1.5891779212018342e-11
is O 0 1.3368113040146401e-11
therefore O 0 3.2346669787131077e-10
classified O 0 4.124157015894525e-09
as O 0 2.357803907671041e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.0011210094671696424
IVF B-Disease 1 1.0
) O 0 4.262783477315679e-07
. O 0 3.5752823350776453e-06

A O 0 1.0235382887913147e-06
distinct O 0 1.0635893943344854e-07
group O 0 1.1580303826974614e-08
of O 0 7.101294841049821e-07
IVF B-Disease 1 1.0
patients O 0 8.186408884114371e-09
has O 0 7.674044733008145e-11
been O 0 1.4028467276716583e-10
found O 0 1.2829025342053768e-10
to O 0 5.233323496778297e-11
present O 0 9.6057474474609e-11
with O 0 5.3491169826891394e-11
a O 0 1.3298724343968615e-09
characteristic O 0 2.6678619633457856e-06
electrocardiographic O 0 3.835677489405498e-05
pattern O 0 6.042022960173199e-06
. O 0 6.430112762245699e-07

Because O 0 7.408019797594534e-08
of O 0 7.925967082655916e-08
the O 0 4.518507346062961e-09
small O 0 4.076737281089038e-10
size O 0 1.2379280933672021e-09
of O 0 2.0249222298929226e-09
most O 0 1.8086926401039705e-10
pedigrees O 0 1.2226947454507808e-08
and O 0 4.052317092995139e-10
the O 0 1.2017031814082202e-09
high O 0 3.182676096002979e-07
incidence O 0 4.297331486213807e-07
of O 0 1.0250348125850905e-08
sudden B-Disease 0 1.5049680257561704e-07
death I-Disease 0 1.6308595149894245e-06
, O 0 6.770464189287395e-10
however O 0 2.036969481977735e-09
, O 0 4.004701015247747e-10
molecular O 0 5.983926687491703e-09
genetic O 0 8.632444203904299e-10
studies O 0 1.0670834216242042e-09
of O 0 1.607483923748987e-08
IVF B-Disease 1 0.9989846348762512
have O 0 8.969374132306029e-10
not O 0 3.2713109998638856e-10
yet O 0 2.778318686225134e-09
been O 0 3.2236440183908144e-09
done O 0 1.94708977829805e-08
. O 0 1.4723251240411628e-07

Because O 0 2.7940350832977856e-07
IVF B-Disease 1 0.9999996423721313
causes O 0 7.396508863166673e-06
cardiac O 1 0.9889652729034424
rhythm O 1 0.9860775470733643
disturbance O 0 0.1608886867761612
, O 0 4.283327914578194e-09
we O 0 4.312856738408755e-09
investigated O 0 3.007806981258909e-08
whether O 0 3.1671349987050235e-09
malfunction O 0 7.073298888826685e-07
of O 0 2.3528173187514767e-08
ion O 0 5.938896265433868e-06
channels O 0 2.8406694241311925e-07
could O 0 1.3024457068411266e-08
cause O 0 1.4559159922100662e-07
the O 0 1.2058250398183645e-08
disorder O 0 1.630034773825173e-08
by O 0 8.186322453251904e-11
studying O 0 2.5982966889159798e-09
mutations O 0 3.898011635694587e-10
in O 0 2.6677365871918823e-10
the O 0 4.4963779366469225e-09
cardiac O 0 5.176714807930693e-07
sodium O 0 2.607749252092617e-07
channel O 0 8.054589670791756e-07
gene O 0 2.4365078843402443e-07
SCN5A O 0 6.58217613818124e-05
. O 0 2.389332166785607e-06

We O 0 2.6343175818510645e-07
have O 0 3.4306872898071106e-09
now O 0 1.833095009118324e-09
identified O 0 6.334672342234171e-09
a O 0 3.010997007280025e-09
missense O 0 6.388091833287035e-07
mutation O 0 6.295528010014095e-08
, O 0 6.544488506676771e-09
a O 0 1.3094001438673786e-08
splice O 0 6.533658165608358e-07
- O 0 1.2438522389857098e-07
donor O 0 1.7497989723835872e-09
mutation O 0 5.136484571011124e-09
, O 0 5.628692512082978e-10
and O 0 1.1918899200935584e-09
a O 0 4.964749056313167e-09
frameshift O 0 3.444179412781523e-07
mutation O 0 7.917290822945233e-09
in O 0 1.7956248710149225e-09
the O 0 9.25065624102217e-09
coding O 0 1.1832020874180671e-07
region O 0 8.428314046682317e-09
of O 0 2.004973254088327e-08
SCN5A O 0 1.4718714737682603e-05
in O 0 6.077197411968882e-09
three O 0 2.1544016348684636e-08
IVF B-Disease 0 0.056106679141521454
families O 0 5.1486770402675575e-09
. O 0 2.0119689736475266e-07

We O 0 8.398838247103413e-08
show O 0 4.037860712458041e-09
that O 0 1.2014068906385234e-10
sodium O 0 7.732717799413535e-10
channels O 0 1.4503188650039078e-09
with O 0 4.859273053381408e-11
the O 0 1.0102905179110167e-09
missense O 0 1.5206271086753986e-07
mutation O 0 1.420630280080104e-08
recover O 0 3.5433462386436076e-08
from O 0 1.7045310718444284e-09
inactivation O 0 8.109778804055168e-08
more O 0 1.9233685477626494e-10
rapidly O 0 1.6721174445066822e-09
than O 0 2.7642450828313514e-11
normal O 0 3.2272842731551066e-10
and O 0 3.5908574724796694e-11
that O 0 1.7278288175215373e-11
the O 0 3.7550287879106747e-10
frameshift O 0 6.444994227194911e-08
mutation O 0 2.65070609906104e-09
causes O 0 2.0517241239303985e-09
the O 0 1.2443862607014466e-09
sodium O 0 2.403315768617631e-09
channel O 0 6.177151234965095e-09
to O 0 4.732734204537792e-10
be O 0 1.820502748550723e-09
non O 0 8.926340200332561e-08
- O 0 9.644221421467591e-08
functional O 0 4.4779199015465565e-07
. O 0 1.7395048246271472e-07

Our O 0 3.8434467342085554e-07
results O 0 9.57400700940525e-08
indicate O 0 5.492207133528382e-09
that O 0 2.3153218231541928e-10
mutations O 0 4.083782201291797e-09
in O 0 1.7860403156433335e-09
cardiac O 0 1.7125918816418562e-07
ion O 0 2.082127502944786e-05
- O 0 0.24641038477420807
channel O 0 4.0691983826945943e-07
genes O 0 1.6080718978628283e-09
contribute O 0 2.1270511740834053e-10
to O 0 7.787181316443181e-11
the O 0 2.472284044152673e-10
risk O 0 1.1395587806717344e-09
of O 0 8.069504175978182e-09
developing O 0 1.66573795468139e-06
IVF B-Disease 1 0.9999721050262451
. O 0 2.0541529366369105e-08
. O 0 1.231988733252365e-07

Molecular O 0 7.334946076298365e-06
heterogeneity O 0 1.9638794128695736e-06
in O 0 1.02680409952427e-07
mucopolysaccharidosis B-Disease 0 2.1728706997237168e-05
IVA I-Disease 0 0.0009846648899838328
in O 0 3.9560866582633025e-08
Australia O 0 3.835482687009062e-08
and O 0 2.2568451552018587e-09
Northern O 0 4.2997417182277786e-08
Ireland O 0 1.4480853849363484e-07
: O 0 4.472668013733028e-09
nine O 0 5.6151208127630525e-09
novel O 0 1.6580926631704074e-09
mutations O 0 2.997399661808231e-09
including O 0 7.498253129512022e-10
T312S O 0 1.21839875077967e-07
, O 0 1.1045909742435356e-09
a O 0 1.2813186067717197e-09
common O 0 2.1941326533436722e-09
allele O 0 2.6054939539221778e-08
that O 0 5.262956181972811e-10
confers O 0 2.2504872276840615e-07
a O 0 3.836023765302343e-08
mild O 0 1.494051957706688e-05
phenotype O 0 1.7911104805534706e-05
. O 0 2.103260612784652e-06

Mucopolysaccharidosis B-Disease 1 0.9948241710662842
IVA I-Disease 1 1.0
( O 0 9.284539555665106e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 5.5843738522298736e-08
is O 0 1.8236583354536151e-09
an O 0 7.502577226148333e-09
autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 0.9999998807907104
lysosomal I-Disease 1 0.9999973773956299
storage I-Disease 1 1.0
disorder I-Disease 1 0.9999996423721313
caused O 0 2.6137174700124888e-06
by O 0 1.327827625630107e-08
a O 0 6.264761509555683e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.4047856186371064e-06
N O 0 0.0008292924612760544
- O 0 0.010731587186455727
acetylgalactosamine O 0 0.005306735634803772
- O 0 0.00022225883731152862
6 O 0 0.00013793306425213814
- O 0 4.31012267654296e-06
sulfate O 0 1.4150547258395818e-06
sulfatase O 0 0.00016173985204659402
( O 0 2.534045151492137e-08
GALNS O 0 1.3538660823542159e-05
) O 0 1.7866749857375908e-08
. O 0 2.6552066856311285e-07

Previous O 0 1.102326791624364e-06
studies O 0 2.6934822372481904e-08
of O 0 1.0770215830291363e-08
patients O 0 3.067069098694475e-10
from O 0 1.5975301637105588e-10
a O 0 6.354562986921053e-10
British O 0 2.1446275866310316e-08
- O 0 3.5742723980547453e-07
Irish O 0 1.761939927291678e-08
population O 0 4.807903380976697e-11
showed O 0 4.2373252129301875e-10
that O 0 9.303890297074346e-11
the O 0 1.0579315201653117e-09
I113F O 0 6.911634642392528e-08
mutation O 0 2.5887838539517816e-09
is O 0 8.536883006060592e-11
the O 0 1.0273160100382484e-10
most O 0 3.522908700870353e-11
common O 0 2.45770931384115e-10
single O 0 3.8568115368065037e-10
mutation O 0 1.1327808024930164e-08
among O 0 2.534257959041497e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.479538923376822e-06
and O 0 1.861394949287387e-08
produces O 0 2.4268878462407883e-08
a O 0 9.894773000951318e-09
severe O 0 7.771998934913427e-05
clinical O 0 8.54829340823926e-05
phenotype O 0 6.802118605264695e-06
. O 0 1.0429694157210179e-06

We O 0 1.5536103603608353e-07
studied O 0 1.4913207735389733e-07
mutations O 0 2.737677196051891e-09
in O 0 7.306416582864017e-10
the O 0 3.6082585808117074e-09
GALNS O 0 7.887704214226687e-07
gene O 0 1.6187811091583626e-09
from O 0 1.1662133481138426e-09
23 O 0 3.664208492182297e-08
additional O 0 7.059416873289592e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 3.673802595471898e-08
( O 0 1.6196273211477319e-09
15 O 0 6.687085551959626e-09
from O 0 4.042906009971148e-10
Australia O 0 2.2696919899090062e-09
, O 0 1.6616026610183354e-10
8 O 0 3.833183992441036e-09
from O 0 1.4982295959420355e-10
Northern O 0 3.9628664794122415e-09
Ireland O 0 2.030744283842978e-08
) O 0 4.95865237759574e-10
, O 0 5.391810956045795e-11
with O 0 2.1785592427270295e-11
various O 0 1.9779544668807603e-09
clinical O 0 1.1114112794530229e-06
phenotypes O 0 3.982227553933626e-06
( O 0 5.5566720114086365e-09
severe O 0 6.9447755777218845e-06
, O 0 6.975346522608561e-09
16 O 0 7.652773348354458e-08
cases O 0 1.6892578447169626e-09
; O 0 3.7288352960906934e-10
intermediate O 0 2.2391814979982883e-07
, O 0 1.025859619474545e-09
4 O 0 2.859218461992441e-08
cases O 0 4.47652331869719e-10
; O 0 1.1243529440818634e-09
mild O 0 4.5231661260913825e-07
, O 0 3.7049745493789032e-09
3 O 0 2.0894408692129218e-07
cases O 0 1.7518567929641904e-08
) O 0 4.6494901262406074e-09
. O 0 1.5146828502565768e-07

We O 0 7.309769500807306e-08
found O 0 2.9931090939072647e-09
two O 0 3.8717290484768796e-10
common O 0 5.444341644178508e-10
mutations O 0 1.126548965224572e-09
that O 0 8.493551001409472e-11
together O 0 1.2800770166077058e-10
accounted O 0 5.776986111705185e-10
for O 0 8.059097833523765e-11
32 O 0 4.6807580034169405e-09
% O 0 1.1160260909859332e-10
of O 0 1.581831110541998e-09
the O 0 3.6634169031657393e-09
44 O 0 1.1117398557303204e-08
unrelated O 0 1.1214599915376766e-08
alleles O 0 1.1607104610789065e-08
in O 0 2.2745805239310357e-09
these O 0 5.375448530742233e-09
patients O 0 6.946720976230836e-09
. O 0 8.813867680146359e-08

One O 0 1.9886368818333722e-07
is O 0 1.976276475801342e-09
the O 0 3.182224483921914e-09
T312S O 0 3.479570978015545e-07
mutation O 0 6.026535714909187e-09
, O 0 5.373815836762219e-10
a O 0 3.9151568098638734e-10
novel O 0 1.5547693132944573e-09
mutation O 0 3.0856126542744278e-09
found O 0 1.7504665494882943e-09
exclusively O 0 4.35119540398432e-09
in O 0 7.2507506665431265e-09
milder O 0 1.474439341109246e-05
patients O 0 2.5005996917570883e-07
. O 0 1.0271032806485891e-06

The O 0 2.344485636740501e-07
other O 0 2.360304396376023e-09
is O 0 2.525492592830858e-10
the O 0 5.914987388777604e-10
previously O 0 5.636000999231783e-09
described O 0 9.134933698362602e-09
I113F O 0 1.0458744270636089e-07
that O 0 6.329076707167758e-10
produces O 0 7.472557683740888e-09
a O 0 8.855147726194446e-09
severe O 0 3.475302582955919e-05
phenotype O 0 0.0001444327353965491
. O 0 4.408997938298853e-06

The O 0 3.803116896961001e-07
I113F O 0 1.4712429674546001e-06
and O 0 1.56894728320367e-08
T312S O 0 2.323369585610635e-07
mutations O 0 1.1076633832374227e-08
accounted O 0 2.7732891538789772e-09
for O 0 6.21164730763013e-10
8 O 0 3.431369677286966e-08
( O 0 5.691664917151229e-10
18 O 0 7.2902168746225016e-09
% O 0 1.3936032883243854e-10
) O 0 1.519143699724168e-10
and O 0 1.0436774777744517e-09
6 O 0 1.0274428063894447e-07
( O 0 3.583818519725668e-10
14 O 0 5.0243453841858354e-09
% O 0 5.319813686788244e-11
) O 0 6.603539243199563e-11
of O 0 1.2742265020904142e-09
44 O 0 4.19282830677048e-09
unrelated O 0 1.769217483627017e-08
alleles O 0 2.7644919242675314e-08
, O 0 1.2876991029031615e-08
respectively O 0 4.7574019390594913e-07
. O 0 1.322468847320124e-06

The O 0 2.1381032411227352e-07
relatively O 0 5.068527997309502e-08
high O 0 1.5405839803861454e-07
residual O 0 1.517290911579039e-06
GALNS O 0 1.485013126512058e-05
activity O 0 1.0899915636741753e-08
seen O 0 1.3663050690837508e-09
when O 0 3.401365578081794e-10
the O 0 3.010610927223212e-10
T312S O 0 8.094523273882714e-09
mutant O 0 9.803999390101126e-09
cDNA O 0 2.293532297414913e-08
is O 0 2.468431015145711e-09
overexpressed O 0 2.2881651773332123e-07
in O 0 5.714543949153494e-09
mutant O 0 9.414382162731272e-08
cells O 0 5.697218252720404e-09
provides O 0 3.751463584222847e-10
an O 0 1.894993884032914e-11
explanation O 0 6.571528321508424e-10
for O 0 1.538916494236986e-10
the O 0 2.5614996790324085e-09
mild O 0 9.055671625901596e-07
phenotype O 0 9.56385974859586e-08
in O 0 1.8639092491667952e-09
patients O 0 2.762138573420003e-10
with O 0 1.1400604071898357e-10
this O 0 1.1067420313537468e-09
mutation O 0 4.562416933140412e-08
. O 0 2.180498199777503e-07

The O 0 2.4667379250331578e-08
distribution O 0 1.0739358291544931e-09
and O 0 3.81740805632802e-10
relative O 0 9.815899204568268e-09
frequencies O 0 2.5772322942430037e-08
of O 0 1.9552164332026223e-09
the O 0 1.0762694069299528e-09
I113F O 0 2.1377093872843034e-08
and O 0 1.426102680390784e-09
T312S O 0 9.806901601905338e-08
mutations O 0 5.395170088462464e-09
in O 0 7.978971927613543e-10
Australia O 0 2.16638729177987e-09
corresponded O 0 7.366587895241139e-10
to O 0 2.4627111461228424e-10
those O 0 1.8931956002887773e-10
observed O 0 1.940570815150977e-09
in O 0 4.2062270333431684e-10
Northern O 0 1.0084465706938772e-08
Ireland O 0 4.9531369228361655e-08
and O 0 1.8979040561362126e-09
are O 0 7.862924894519452e-11
unique O 0 8.057775974235071e-11
to O 0 2.4423430292075388e-11
these O 0 2.8285993339260962e-11
two O 0 5.278032177979952e-11
populations O 0 3.0226633696006644e-11
, O 0 2.691706406376948e-11
suggesting O 0 3.1300922964661027e-10
that O 0 4.8166966942764233e-11
both O 0 3.0771946102348124e-10
mutations O 0 4.75557548895722e-09
were O 0 7.700117210518442e-10
probably O 0 6.400837082587429e-10
introduced O 0 6.60029364496495e-10
to O 0 1.8438946203236384e-10
Australia O 0 5.48337042438618e-10
by O 0 1.0558606766686296e-10
Irish O 0 9.408473111705007e-09
migrants O 0 1.8132393364567179e-09
during O 0 1.849665198783157e-09
the O 0 2.7679305514283215e-09
19th O 0 8.799187867225555e-08
century O 0 3.863099777845491e-07
. O 0 7.653809461771743e-07

Haplotype O 0 9.584852705302183e-06
analysis O 0 1.7197555735037895e-07
using O 0 4.4583181590951426e-08
6 O 0 1.6884924889382091e-06
RFLPs O 0 3.683450813696254e-06
provides O 0 3.4116722780197506e-09
additional O 0 1.9832888664694792e-09
data O 0 7.451091410537458e-10
that O 0 1.053723514693461e-11
the O 0 1.1015312273432443e-10
I113F O 0 3.5458458391701697e-09
mutation O 0 2.2655387288406104e-10
originated O 0 1.292140977549039e-10
from O 0 3.7671647051817914e-11
a O 0 3.5069744330762376e-10
common O 0 2.774019014495366e-09
ancestor O 0 1.0014430529281526e-07
. O 0 3.822042344836518e-07

The O 0 1.0255181592810914e-07
other O 0 1.7765000581704271e-09
9 O 0 8.1786240002657e-08
novel O 0 6.2985039406271426e-09
mutations O 0 3.8933847257283105e-09
identified O 0 2.8952058528375346e-09
in O 0 2.3561244621994604e-10
these O 0 2.5984836504733266e-10
23 O 0 1.0267998007407186e-08
patients O 0 2.926305309181032e-10
were O 0 9.428732239413762e-10
each O 0 1.028347129672369e-10
limited O 0 3.30186433750157e-10
to O 0 4.097371608668965e-10
a O 0 3.734253350984318e-09
single O 0 2.830805634346234e-08
family O 0 7.056953421624712e-08
. O 0 6.80862058288767e-07

These O 0 4.1755523483288925e-08
data O 0 2.49409239927445e-08
provide O 0 4.698448297091318e-10
further O 0 4.943260245582337e-10
evidence O 0 4.254609109466401e-09
for O 0 2.1570967234652016e-10
extensive O 0 5.046165263422608e-09
allelic O 0 4.338853614171967e-07
heterogeneity O 0 5.402426381806436e-07
in O 0 6.749337444489356e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
in O 0 3.2518428838557156e-08
British O 0 2.1402881600351975e-07
- O 0 9.17956072044035e-07
Irish O 0 1.2436844443186601e-08
patients O 0 3.547657445590602e-10
and O 0 6.762253257353024e-11
provide O 0 5.838305533467647e-11
evidence O 0 9.84722969832319e-10
for O 0 5.310588427342999e-11
their O 0 3.6307623574316494e-10
transmission O 0 2.594039472114673e-08
to O 0 2.096591927847058e-10
Australia O 0 8.864776135375507e-10
by O 0 1.5134114794701503e-10
British O 0 3.600684195248505e-08
- O 0 1.2413529759669473e-07
Irish O 0 3.11085308624115e-08
migrants O 0 9.273390944031235e-09
. O 0 4.1743795087256785e-09
. O 0 8.273185159168861e-08

Identification O 0 1.4470419955614489e-06
of O 0 5.652124173138873e-07
constitutional O 0 3.7845413316972554e-05
WT1 O 0 0.0016040634363889694
mutations O 0 1.522249419849686e-07
, O 0 9.216009622114996e-10
in O 0 1.5437466582834958e-10
patients O 0 1.5005519049537952e-10
with O 0 3.165913364799877e-10
isolated O 0 6.522582793877518e-07
diffuse B-Disease 1 0.9999984502792358
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.092525346914954e-08
and O 0 2.729970471904153e-09
analysis O 0 6.697360888097137e-09
of O 0 2.3696609119383538e-08
genotype O 0 1.170678842754569e-06
/ O 0 1.7796705833461601e-06
phenotype O 0 2.2304467606204526e-08
correlations O 0 7.547098057614221e-09
by O 0 7.840281895932222e-11
use O 0 2.916387131790543e-10
of O 0 3.662857794850538e-09
a O 0 2.2556314593913385e-09
computerized O 0 7.331327367410267e-08
mutation O 0 2.174469315718852e-08
database O 0 4.6505835626931e-08
. O 0 3.657624461084197e-07

Constitutional O 0 7.5245011430524755e-06
mutations O 0 1.902281638876957e-07
of O 0 7.302104876316662e-08
the O 0 3.3723125625328976e-08
WT1 O 0 3.519728352330276e-06
gene O 0 6.633059879135317e-09
, O 0 1.8044415961426807e-09
encoding O 0 2.9639556586857907e-08
a O 0 1.8736267648478133e-08
zinc O 0 5.952635433459363e-07
- O 0 5.603228146355832e-06
finger O 0 2.0636191493395017e-06
transcription O 0 2.5411608817194065e-07
factor O 0 1.3249339758658607e-07
involved O 0 1.911677927068922e-08
in O 0 1.6524356993841138e-08
renal O 1 0.9999992847442627
and O 0 1.2664099813264329e-05
gonadal O 1 0.9999996423721313
development O 0 0.007764502894133329
, O 0 2.538286247855126e-09
are O 0 1.1686399070676146e-10
found O 0 4.716009804894838e-10
in O 0 4.87494544731959e-10
most O 0 5.512680312236284e-10
patients O 0 1.2186265330171864e-09
with O 0 7.678297997415484e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.002151166321709752
DDS B-Disease 1 1.0
) O 0 2.144741984011489e-08
, O 0 2.39778019661685e-09
or O 0 9.45514244676815e-08
diffuse B-Disease 1 0.9997038245201111
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.1597938282648101e-05
DMS B-Disease 0 0.05621090158820152
) O 0 3.424169614518746e-09
associated O 0 1.1058689963761026e-08
with O 0 7.459456163871891e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.02975350059568882
/ O 1 0.9999171495437622
or O 0 1.6132502423715778e-05
Wilms B-Disease 1 0.9999648332595825
tumor I-Disease 0 5.170765507500619e-05
( O 0 4.4910362362315936e-07
WT B-Disease 1 1.0
) O 0 3.1118682386477303e-07
. O 0 1.527736458228901e-06

Most O 0 3.205415168849868e-07
mutations O 0 5.823411584060523e-07
in O 0 1.0946985185000813e-07
DDS B-Disease 1 1.0
patients O 0 8.836120457544894e-08
lie O 0 1.1821069989537136e-07
in O 0 9.861575556158186e-09
exon O 0 2.076522918059709e-07
8 O 0 3.5988099966743903e-07
or O 0 1.6436155547694398e-08
exon O 0 1.0613238288215143e-07
9 O 0 2.1796188320877263e-07
, O 0 6.497052229548217e-09
encoding O 0 2.563696455126774e-07
zinc O 0 1.020944978336047e-06
finger O 0 8.889994205674157e-06
2 O 0 2.0276291252230294e-05
or O 0 1.2582060548993468e-07
zinc O 0 6.375547627612832e-07
finger O 0 9.159122782875784e-06
3 O 0 5.340538791642757e-06
, O 0 2.596513004604617e-09
respectively O 0 1.5879805914664757e-08
, O 0 3.4648017788185825e-10
with O 0 7.45922143496891e-11
a O 0 1.7271847285726949e-09
hot O 0 1.8781427968406206e-07
spot O 0 6.462394139816752e-07
( O 0 2.362646522868772e-09
R394W O 0 1.5071023540258466e-07
) O 0 1.2935053028684251e-09
in O 0 4.433174272122642e-09
exon O 0 3.2905640523495094e-07
9 O 0 1.4094237030803924e-06
. O 0 7.879801842136658e-07

We O 0 1.3272078547288402e-07
analyzed O 0 3.7625603965807386e-08
a O 0 7.944060409492693e-10
series O 0 3.052620156651642e-09
of O 0 3.543250137738596e-09
24 O 0 3.310595175776143e-08
patients O 0 3.400159043209783e-10
, O 0 4.83394657635472e-10
10 O 0 2.6912163608727724e-09
with O 0 2.3184607567117155e-09
isolated B-Disease 0 2.6161262667301344e-06
DMS I-Disease 1 0.9998985528945923
( O 0 3.2845693453964486e-07
IDMS B-Disease 0 0.00010590335296001285
) O 0 6.179036837750118e-09
, O 0 2.0594401739515433e-09
10 O 0 7.0576775534902936e-09
with O 0 3.0966023079059823e-09
DDS B-Disease 1 1.0
, O 0 4.697473965364907e-09
and O 0 3.816215787821875e-09
4 O 0 6.263871341616323e-07
with O 0 1.9139582363436602e-08
urogenital B-Disease 1 0.9999653100967407
abnormalities I-Disease 1 0.9999986886978149
and O 0 1.1153120794915594e-05
/ O 1 0.9916166663169861
or O 0 0.00015854049706831574
WT B-Disease 1 1.0
. O 0 2.687466621864587e-05

We O 0 3.871604349114932e-06
report O 0 5.492696573128342e-07
WT1 O 0 1.884119410533458e-05
heterozygous O 0 2.5026133698702324e-07
mutations O 0 3.154909578029219e-08
in O 0 8.065011769531338e-09
16 O 0 9.425180280686618e-08
patients O 0 8.362129877426128e-10
, O 0 8.183158040075966e-10
4 O 0 6.506032690367647e-08
of O 0 2.8524313577804605e-08
whom O 0 7.100184262753828e-08
presented O 0 5.536589355870092e-07
with O 0 1.855175071341364e-07
IDMS B-Disease 0 0.005000058561563492
. O 0 1.2639207852771506e-05

One O 0 2.7948078695771983e-07
male O 0 6.288699694323441e-08
and O 0 1.0484304979740955e-08
two O 0 9.206245543680325e-09
female O 0 4.522751950730708e-08
IDMS B-Disease 0 5.982998482068069e-05
patients O 0 4.3520273607100535e-08
with O 0 9.008368806462386e-08
WT1 O 1 0.9983845949172974
mutations O 0 0.00010030608245870098
underwent O 0 5.0841321353800595e-05
normal O 0 2.597548154881224e-05
puberty O 0 0.00022814357362221926
. O 0 1.4362027513925568e-06

Two O 0 1.2104368352083839e-06
mutations O 0 5.203164619160816e-07
associated O 0 3.259027323565533e-07
with O 0 1.237598379333349e-08
IDMS B-Disease 0 5.536339449463412e-05
are O 0 8.646451332694483e-10
different O 0 8.646979243742692e-10
from O 0 2.5087465438389245e-10
those O 0 2.297181195265452e-10
described O 0 5.8659939128347105e-09
in O 0 2.303193902264411e-08
DDS B-Disease 1 1.0
patients O 0 6.312511686701328e-07
. O 0 1.19337789783458e-06

No O 0 3.4260899610671913e-06
WT1 O 0 0.00011295268632238731
mutations O 0 1.741988313597176e-07
were O 0 1.6644621680939053e-08
detected O 0 7.606232976797855e-09
in O 0 1.6787707890486558e-09
the O 0 7.2913990400991224e-09
six O 0 1.938292903957972e-08
other O 0 4.71034855564767e-09
IDMS B-Disease 0 0.00048261068877764046
patients O 0 1.181436015684767e-08
, O 0 1.7799800522411147e-09
suggesting O 0 2.1093413238304493e-08
genetic O 0 4.6750855631216837e-08
heterogeneity O 0 1.9833508702049585e-07
of O 0 1.4473384624125174e-07
this O 0 4.70735130875255e-08
disease O 0 9.204864909406751e-05
. O 0 1.4807021671003895e-06

We O 0 9.814964414545102e-07
analyzed O 0 1.1877191354869865e-06
genotype O 0 2.5287640710303094e-06
/ O 0 1.0630402584865806e-06
phenotype O 0 6.556409459790302e-08
correlations O 0 3.137387238894007e-08
, O 0 2.2165384805372668e-10
on O 0 1.2308203345412494e-09
the O 0 1.1408325673034625e-10
basis O 0 5.0633242043574e-10
of O 0 1.41781364426663e-10
the O 0 1.4465635633786889e-10
constitution O 0 2.994148262658314e-09
of O 0 7.286699688080489e-09
a O 0 1.2205602750725575e-08
WT1 O 0 3.000332526426064e-06
mutation O 0 2.703761303735064e-08
database O 0 1.818161265987328e-08
of O 0 4.430522437814943e-08
84 O 0 5.680396384377673e-07
germ O 0 1.9225955838919617e-05
- O 0 0.00038425010279752314
line O 0 2.556138497311622e-06
mutations O 0 3.895169342627014e-08
, O 0 4.855643664924969e-10
to O 0 3.6440411799176786e-10
compare O 0 1.8236027132800814e-09
the O 0 5.371366684769896e-10
distribution O 0 4.5793430158980186e-10
and O 0 2.4335278236975455e-10
type O 0 1.101685764837157e-08
of O 0 9.202632611504669e-08
mutations O 0 8.814167173909482e-09
, O 0 2.4518892471903087e-10
according O 0 9.745020762563783e-11
to O 0 1.3318923741678645e-10
the O 0 1.5840290190638484e-09
different O 0 1.0526544969025053e-08
symptoms O 0 5.779323146271054e-06
. O 0 2.563686507528473e-07

This O 0 3.620690236516566e-08
demonstrated O 0 1.4585886276563542e-07
( O 0 3.628382705400668e-09
1 O 0 3.323248165543191e-08
) O 0 3.8103445398895985e-10
the O 0 1.481029632266484e-09
association O 0 2.4526107811340125e-09
between O 0 3.4568823359393264e-09
mutations O 0 2.8377997729478466e-09
in O 0 1.1420459022914997e-09
exons O 0 2.8129955254030392e-08
8 O 0 3.410802307257654e-08
and O 0 1.4110347335005713e-09
9 O 0 9.917223309230394e-08
and O 0 1.3714335445058623e-08
DMS B-Disease 0 4.255457952240249e-06
; O 0 4.049467872135892e-09
( O 0 1.274420902142026e-09
2 O 0 1.271043004180683e-07
) O 0 1.2856148368101117e-09
among O 0 1.4585634922070767e-09
patients O 0 1.4271530623943818e-09
with O 0 1.824507323000546e-09
DMS B-Disease 0 2.6385056116851047e-05
, O 0 1.019419104686392e-09
a O 0 9.792967547994635e-10
higher O 0 5.444064310466956e-09
frequency O 0 1.7054912149205848e-08
of O 0 7.59446194820157e-09
exon O 0 6.931133356147257e-08
8 O 0 5.1999698769122915e-08
mutations O 0 5.1203739026561834e-09
among O 0 1.177648978334389e-09
46 O 0 3.3588065662115696e-08
, O 0 4.871044456677964e-09
XY O 0 2.6442787202540785e-05
patients O 0 2.5630244593344287e-09
with O 0 4.729648339640846e-10
female O 0 4.9761830211991764e-09
phenotype O 0 1.1198910243592763e-08
than O 0 4.5532319581376157e-10
among O 0 9.763239106064248e-10
46 O 0 4.140332521274104e-08
, O 0 1.4198175968260784e-08
XY O 0 0.0028208119329065084
patients O 0 2.9181246308240816e-09
with O 0 5.801554792128627e-10
sexual O 0 2.5617845622605273e-08
ambiguity O 0 1.761376324793673e-07
or O 0 2.7934055069067654e-08
male O 0 3.4820548666658624e-09
phenotype O 0 3.3483276151713426e-09
; O 0 1.0424877627812634e-09
and O 0 6.790643158893772e-09
( O 0 2.342257943155346e-09
3 O 0 1.2660839843192662e-07
) O 0 2.508114826937913e-10
statistically O 0 1.649804320935644e-10
significant O 0 7.63340293752357e-11
evidence O 0 1.2784135972054855e-09
that O 0 2.558821210474349e-11
mutations O 0 2.759463213486413e-10
in O 0 9.346688978340012e-10
exons O 0 6.462239809934545e-08
8 O 0 7.1687679792376e-08
and O 0 4.954154420033774e-09
9 O 0 9.549860635615914e-08
preferentially O 0 4.638119932565132e-08
affect O 0 6.644242489528551e-08
amino O 0 4.421504051776992e-09
acids O 0 2.2323044801542125e-10
with O 0 3.9075381819131394e-11
different O 0 2.9588800853908026e-10
functions O 0 2.2620079143109706e-09
. O 0 2.2869000027014863e-09
. O 0 3.6211805110042405e-08

The O 0 9.246686545338889e-07
185delAG O 0 6.668703463219572e-06
BRCA1 O 0 8.672076035054488e-08
mutation O 0 2.704296342415091e-09
originated O 0 7.3670369804546e-10
before O 0 1.4658985136861702e-09
the O 0 9.057700423031889e-11
dispersion O 0 4.204007364450035e-09
of O 0 5.014032522510092e-10
Jews O 0 1.0092774394010462e-09
in O 0 3.8495795440240954e-10
the O 0 1.1137640809621985e-09
diaspora O 0 6.992393331017865e-10
and O 0 1.266492133389363e-09
is O 0 2.682758737382329e-10
not O 0 5.384394041740848e-10
limited O 0 1.1707784075554173e-08
to O 0 4.4383376973655686e-08
Ashkenazim O 0 0.00024777278304100037
. O 0 4.437627922015963e-06

The O 0 8.071275487964158e-07
185delAG O 0 5.222689651418477e-06
mutation O 0 5.592699281464775e-08
in O 0 1.1447113479334803e-08
BRCA1 O 0 2.3595854159452756e-08
is O 0 7.297391579896839e-10
detected O 0 6.155014276032489e-10
in O 0 3.710828588854298e-10
Ashkenazi O 0 9.923766697284009e-09
Jews O 0 1.631993984396729e-09
both O 0 7.561272163947308e-10
in O 0 4.997412261786849e-09
familial B-Disease 0 0.45903629064559937
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.002201755065470934
in O 0 1.7588853040706454e-07
the O 0 6.037790001300891e-08
general O 0 4.976128309408523e-08
population O 0 2.6556995491588964e-10
. O 0 5.7877336701039894e-08

All O 0 1.554010509607906e-06
tested O 0 1.4455894188358798e-06
Ashkenazi O 0 1.0040008646683418e-06
mutation O 0 5.521322066215362e-09
carriers O 0 7.305706040128257e-10
share O 0 1.1877391292713924e-09
the O 0 1.7799121065920076e-09
same O 0 3.317217833753716e-09
allelic O 0 1.2037738770231954e-06
pattern O 0 2.321112759773314e-07
at O 0 1.1214561368433351e-07
the O 0 1.6646241718376587e-08
BRCA1 O 0 1.3081699989925255e-07
locus O 0 1.082702056010021e-06
. O 0 1.6523811154911527e-06

Our O 0 1.8467812878952827e-06
previous O 0 1.6420212034518045e-07
study O 0 4.149690813193274e-09
showed O 0 1.038748309589721e-09
that O 0 8.332320944326455e-11
this O 0 2.1585701281967573e-10
Ashkenazi O 0 2.552322797555462e-08
mutation O 0 7.82224174322721e-10
also O 0 2.396142173566318e-10
occurs O 0 3.981532326058357e-10
in O 0 1.997295662192755e-10
Iraqi O 0 2.550074640339517e-08
Jews O 0 7.2684742669082425e-09
with O 0 4.01377042713591e-10
a O 0 1.2994920695064138e-09
similar O 0 1.4423057415058338e-08
allelic O 0 2.7550400773179717e-05
pattern O 0 2.780879549391102e-05
. O 0 4.390418325783685e-06

We O 0 3.599558340283693e-07
extended O 0 7.188841522065559e-08
our O 0 6.369589300447842e-09
analysis O 0 1.0297569463801892e-09
to O 0 2.2483370720749463e-10
other O 0 3.3394667586783555e-10
non O 0 2.7362274224174143e-08
- O 0 4.5002582993447504e-08
Ashkenazi O 0 6.710892108685584e-08
subsets O 0 1.3128912179638519e-08
354 O 0 1.3949715160777032e-08
of O 0 1.5406059761247093e-09
Moroccan O 0 1.1604674199361398e-07
origin O 0 5.794004831471966e-09
, O 0 1.9526895655985754e-09
200 O 0 5.138091729861571e-09
Yemenites O 0 1.0614418215482146e-06
and O 0 1.3768275408665431e-08
150 O 0 2.0815086543279904e-08
Iranian O 0 1.9150708396864502e-07
Jews O 0 4.780833933182294e-07
. O 0 1.0545353461566265e-06

Heteroduplex O 0 7.595094939460978e-05
analysis O 0 9.697880898329458e-08
complemented O 0 2.0828588631616185e-08
by O 0 8.539813994845602e-11
direct O 0 8.353298608376747e-10
DNA O 0 3.115334212822063e-09
sequencing O 0 3.859543351580896e-09
of O 0 3.791793545815381e-09
abnormally O 0 2.8682856978434756e-08
migrating O 0 8.114784399992914e-10
bands O 0 1.1672197430812048e-08
were O 0 1.1211669814770175e-08
employed O 0 1.705225542991684e-07
. O 0 4.3093396584481525e-07

Four O 0 3.2372074088016234e-07
of O 0 1.0418049356530901e-07
Moroccan O 0 1.38447830977384e-06
origin O 0 6.719317546810544e-09
( O 0 6.183891176902989e-10
1 O 0 7.899928711196935e-09
. O 0 2.6774016337327566e-10
1 O 0 5.64593172214245e-09
% O 0 9.102157222384832e-11
) O 0 9.388063937354474e-11
and O 0 2.413263755496331e-10
none O 0 5.079170417587875e-09
of O 0 1.0709825915000692e-08
the O 0 2.1242598791104683e-08
Yemenites O 0 4.553819962893613e-06
or O 0 5.063548691452979e-09
Iranians O 0 1.5217318960480952e-08
was O 0 1.2655656078663924e-08
a O 0 7.97842403255089e-10
carrier O 0 1.0287125595809243e-09
of O 0 2.3228084344850686e-08
the O 0 1.0265691230415541e-07
185delAG O 0 6.668995865766192e-06
mutation O 0 1.434755745322036e-06
. O 0 1.8905471961261355e-06

BRCA1 O 0 8.216905371227767e-06
allelic O 0 6.773435416107532e-06
patterns O 0 1.2790172831955715e-07
were O 0 3.831415185118203e-09
determined O 0 4.9724064865586115e-09
for O 0 2.551069078204904e-10
four O 0 6.88094137224482e-10
of O 0 7.334593488117491e-10
these O 0 8.509506294052116e-11
individuals O 0 2.0469534053879634e-11
and O 0 1.4646792112493756e-10
for O 0 1.9836962628083654e-10
12 O 0 1.144460348712073e-08
additional O 0 4.8324184653836255e-09
non O 0 1.5776081454532687e-06
- O 0 3.4478346151445294e-06
Ashkenazi O 0 8.00353234353679e-07
185delAG O 0 2.2102234709109325e-07
mutation O 0 6.351985604169386e-09
carriers O 0 2.1795298899007776e-09
who O 0 5.196043773025849e-08
had O 0 0.00028805856709368527
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.05736909061670303

Six O 0 6.649264378211228e-06
non O 0 2.5899644242599607e-05
- O 0 1.9145973055856302e-06
Ashkenazi O 0 7.589208905756095e-08
individuals O 0 8.980530208368975e-11
shared O 0 1.3182251956678215e-09
the O 0 1.1574468050667974e-09
common O 0 1.074608402262811e-08
Ashkenazi O 0 5.196454821998486e-07
haplotype O 0 9.521451005412018e-08
, O 0 2.3109640867602366e-09
four O 0 7.870225360306904e-09
had O 0 1.0619471524364599e-08
a O 0 6.251110296062734e-09
closely O 0 9.1104164212652e-09
related O 0 6.06578183237616e-08
pattern O 0 1.7052269640771556e-07
, O 0 9.605313211480393e-10
and O 0 1.2145171535138388e-09
the O 0 9.086919661172033e-09
rest O 0 2.3417499050992774e-08
( O 0 4.837601430551786e-09
n O 0 1.6790573909020168e-07
= O 0 4.5478682864086295e-07
6 O 0 1.4393479830232536e-07
) O 0 3.720850016986077e-10
displayed O 0 1.1646577924295798e-08
a O 0 7.956286296462167e-09
distinct O 0 6.465926105647668e-08
BRCA1 O 0 1.248825810762355e-06
allelic O 0 2.0877747374470346e-05
pattern O 0 5.263912953523686e-06
. O 0 1.3632155742016039e-06

We O 0 2.5276426640630234e-07
conclude O 0 3.3853379477477574e-07
that O 0 8.669620576995385e-10
the O 0 4.759023841671706e-09
185delAG O 0 5.653600965160877e-07
BRCA1 O 0 4.27156550131258e-08
mutation O 0 7.640839960743051e-09
occurs O 0 6.857335144161425e-09
in O 0 6.968042809418762e-10
some O 0 5.288313120743737e-10
non O 0 9.931211053526567e-08
- O 0 1.192892682411184e-07
Ashkenazi O 0 1.0628836832893285e-07
populations O 0 9.069598960742553e-10
at O 0 4.933052188960119e-09
rates O 0 1.0124162619362664e-09
comparable O 0 6.695620724528339e-10
with O 0 1.8884342006808552e-11
that O 0 1.310420660871614e-10
of O 0 1.947267946889042e-08
Ashkenazim O 0 1.6594322005403228e-05
. O 0 6.230062012946291e-07

The O 0 1.1068105720823951e-07
majority O 0 4.434172140577175e-09
of O 0 2.0607064499245098e-08
Jewish O 0 8.243257809681381e-08
185delAG O 0 8.652750693727285e-07
mutation O 0 5.401656899550744e-09
carriers O 0 8.082500779771351e-10
have O 0 1.243252167881792e-09
a O 0 3.576090978896218e-09
common O 0 4.5984720031810866e-08
allelic O 0 2.1888245100853965e-05
pattern O 0 1.1947819302804419e-06
, O 0 1.1757591567018721e-09
supporting O 0 2.648815833339313e-09
the O 0 1.879898192669316e-08
founder O 0 1.349888805179944e-07
effect O 0 4.005545406471356e-08
notion O 0 9.08841002456029e-09
, O 0 1.8831981807299059e-10
but O 0 1.0949788992187237e-10
dating O 0 1.6885524090071158e-09
the O 0 2.9510122123710403e-10
mutations O 0 7.1429379078225e-10
origin O 0 9.049520022230695e-10
to O 0 3.2407684869006914e-10
an O 0 7.516434696874796e-11
earlier O 0 3.6432230565708323e-09
date O 0 8.268988693771462e-08
than O 0 1.1477935268899842e-09
currently O 0 2.0008961154616145e-09
estimated O 0 9.984255200379266e-09
. O 0 3.1694213475930155e-07

However O 0 9.801403422216026e-08
, O 0 9.620421126399492e-10
the O 0 6.565614163456246e-10
different O 0 4.366981776193768e-10
allelic O 0 2.09641470405586e-07
pattern O 0 5.4753282796582425e-08
at O 0 7.052943828966818e-08
the O 0 1.1382038422880214e-08
BRCA1 O 0 1.3409554355803266e-08
locus O 0 3.6027998362442304e-08
even O 0 1.1641021480102154e-09
in O 0 3.26654120419434e-10
some O 0 1.0935095884345714e-10
Jewish O 0 3.874656595570514e-09
mutation O 0 2.7344833064546492e-09
carriers O 0 9.198272699073584e-10
, O 0 6.966049403978047e-10
might O 0 1.5662553476403218e-09
suggest O 0 4.474689951905475e-09
that O 0 1.417564815531236e-10
the O 0 6.136212649110462e-10
mutation O 0 8.496293113502418e-10
arose O 0 6.333439550587627e-09
independently O 0 2.825297107378333e-09
. O 0 7.990260897372536e-09
. O 0 1.8741116036835592e-07

Crystal O 0 5.4602292948402464e-05
structure O 0 3.1643101010558894e-06
of O 0 2.2266694941208698e-06
the O 0 3.424241413085838e-06
hemochromatosis B-Disease 1 1.0
protein O 0 5.532298246180289e-07
HFE O 0 5.421815785666695e-06
and O 0 1.627927459502132e-09
characterization O 0 1.2818373917866666e-08
of O 0 7.406885771388261e-09
its O 0 1.6238432820614435e-09
interaction O 0 3.207576426689229e-08
with O 0 5.947617065515942e-09
transferrin O 0 1.5508377373407711e-06
receptor O 0 1.5793724514878704e-06
. O 0 7.126932928258611e-07

HFE O 0 0.0031589081045240164
is O 0 2.327674195612417e-07
an O 0 2.3119969938534268e-08
MHC O 0 7.98589735495625e-06
- O 0 7.791358802933246e-05
related O 0 2.2061497020331444e-06
protein O 0 2.042428626225501e-08
that O 0 1.478150241096543e-10
is O 0 4.7949082204734594e-11
mutated O 0 1.0117636728423918e-09
in O 0 8.034116150135162e-10
the O 0 1.2280234606976137e-08
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.003521377919241786

HFE O 0 0.0001630655606277287
binds O 0 2.5684244064905215e-07
to O 0 5.2724161037076556e-08
transferrin O 0 1.1334116152283968e-06
receptor O 0 3.2730812904446793e-07
( O 0 9.302586256865197e-09
TfR O 0 3.3602970006541e-07
) O 0 5.387927881628229e-10
and O 0 3.904090661865922e-10
reduces O 0 1.483076217390078e-09
its O 0 4.4753364902838655e-10
affinity O 0 2.6525670548949165e-09
for O 0 1.2034578888986402e-09
iron O 0 1.4163213563733734e-05
- O 0 1.5224250091705471e-06
loaded O 0 3.2337698741002896e-08
transferrin O 0 4.147161689616041e-07
, O 0 1.0869852573591743e-08
implicating O 0 3.796546707235393e-06
HFE O 0 0.00011136110697407275
in O 0 4.19882866253829e-07
iron O 1 0.9864525198936462
metabolism O 1 0.9498421549797058
. O 0 5.544685791392112e-06

The O 0 2.981103079946479e-06
2 O 0 1.617943235032726e-05
. O 0 2.310521495019202e-06

6 O 0 0.00023403449449688196
A O 0 2.2656354303762782e-06
crystal O 0 2.3779346520313993e-05
structure O 0 2.9286311473697424e-06
of O 0 6.089848056944902e-07
HFE O 0 9.787645103642717e-05
reveals O 0 4.590488700273454e-08
the O 0 8.276634377857306e-10
locations O 0 3.10474002063188e-09
of O 0 5.395028210841701e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 1.85632143256953e-05
and O 0 3.898986733474885e-07
a O 0 1.5907367867384892e-07
patch O 0 1.324043932982022e-05
of O 0 7.403234121738933e-06
histidines O 0 9.613093425286934e-05
that O 0 1.4983332352613843e-09
could O 0 5.962917271062906e-09
be O 0 3.786763347335409e-09
involved O 0 3.2269289462760753e-09
in O 0 1.3990483438419687e-08
pH O 0 0.00021948618814349174
- O 0 5.225581116974354e-05
dependent O 0 1.3636785070048063e-06
interactions O 0 5.8558016462484375e-06
. O 0 1.6409253476012964e-06

We O 0 2.651031536515802e-07
also O 0 6.36349373195344e-09
demonstrate O 0 6.933960072785794e-09
that O 0 1.7891907955203123e-09
soluble O 0 8.81862689539048e-08
TfR O 0 3.242556090299331e-07
and O 0 7.129820289719646e-09
HFE O 0 1.0524083791096928e-06
bind O 0 1.3485475847119233e-08
tightly O 0 1.7017253384210562e-08
at O 0 2.99525808600265e-08
the O 0 1.5896040039820036e-09
basic O 0 2.4089617411959807e-08
pH O 0 1.4203884290964197e-07
of O 0 1.9166469300557765e-08
the O 0 5.7237725670233885e-09
cell O 0 1.2900886581235227e-08
surface O 0 1.3458161696178195e-08
, O 0 1.8349831376607284e-10
but O 0 3.89328597139027e-10
not O 0 7.666675072570683e-10
at O 0 3.669145698381726e-08
the O 0 1.0055502208672351e-08
acidic O 0 1.8405780792818405e-06
pH O 0 1.1010052730853204e-05
of O 0 3.5957882573711686e-06
intracellular O 0 1.0602575457596686e-05
vesicles O 0 2.905189285229426e-05
. O 0 4.722198355011642e-06

TfR O 0 0.0009224205277860165
HFE O 0 0.0003276692295912653
stoichiometry O 0 4.074828211741988e-06
( O 0 8.339917201283242e-08
2 O 0 6.532213205900916e-07
1 O 0 1.7173364597056207e-07
) O 0 1.2441845331778723e-09
differs O 0 6.9339205488461175e-09
from O 0 1.6083019360735307e-09
TfR O 0 1.561091380608559e-07
transferrin O 0 4.1262524064222816e-08
stoichiometry O 0 1.760183288013195e-08
( O 0 4.1267517181253766e-10
2 O 0 1.343625743999155e-08
2 O 0 1.723305942391562e-08
) O 0 1.9654866623142198e-10
, O 0 5.11111881984494e-11
implying O 0 2.9241181698225205e-10
a O 0 2.1743053191247697e-10
different O 0 1.844893682267923e-10
mode O 0 1.6531986446466362e-08
of O 0 7.838566462581298e-10
binding O 0 6.631567295301011e-09
for O 0 1.1243421749185245e-09
HFE O 0 2.111351477651624e-06
and O 0 5.36778488324785e-09
transferrin O 0 1.4775126544464e-07
to O 0 5.584424034310587e-09
TfR O 0 5.02848990890925e-07
, O 0 8.196670009397167e-10
consistent O 0 1.10866098523843e-08
with O 0 2.6591612245496776e-10
our O 0 4.355629190655463e-09
demonstration O 0 1.1102184060973741e-08
that O 0 4.0593023387103244e-10
HFE O 0 1.6537684359718696e-06
, O 0 2.160836842790559e-09
transferrin O 0 2.551534805661504e-07
, O 0 2.630609730047695e-09
and O 0 5.679208214814935e-09
TfR O 0 3.574661207039753e-07
form O 0 8.655926642120448e-09
a O 0 4.507113615659364e-08
ternary O 0 3.029897243322921e-06
complex O 0 7.062560598569689e-06
. O 0 1.5973175777617143e-06

Identification O 0 2.5719737095641904e-07
of O 0 8.105000404157181e-08
three O 0 5.194118468665465e-09
novel O 0 4.613246229467904e-09
mutations O 0 4.922713348065599e-09
and O 0 6.314775924387561e-10
a O 0 7.941485247187074e-10
high O 0 5.0784755956101435e-08
frequency O 0 8.873648482676799e-08
of O 0 1.3002341425760733e-08
the O 0 9.66323820961179e-09
Arg778Leu O 0 4.2945803215843625e-06
mutation O 0 6.818937414720949e-09
in O 0 2.185265746135201e-09
Korean O 0 1.236792854797386e-07
patients O 0 9.99046534388981e-09
with O 0 4.95502394670666e-09
Wilson B-Disease 0 3.925885903299786e-05
disease I-Disease 0 0.0003253173199482262
. O 0 1.3918574950366747e-06

Four O 0 3.967375960201025e-06
mutations O 0 4.92224160097976e-07
- O 0 7.243247068799974e-07
- O 0 9.194737771167638e-08
R778L O 0 1.5848010548324964e-07
, O 0 1.140472050131791e-09
A874V O 0 1.0389216242856492e-07
, O 0 1.2996953513422227e-09
L1083F O 0 8.511613458495049e-08
, O 0 7.284597924872571e-10
and O 0 1.7613377423231213e-09
2304delC O 0 1.3369948703711998e-07
- O 0 1.8410219126963057e-08
- O 0 2.8963766940393043e-09
in O 0 8.272215135107785e-10
the O 0 2.094139306407783e-09
copper O 0 5.985162232491348e-08
- O 0 7.773643062591873e-08
transporting O 0 3.092106481972223e-08
enzyme O 0 2.2929679488470356e-08
, O 0 1.7301530874647142e-08
P O 0 0.0002903877757489681
- O 0 5.316699571267236e-06
type O 0 9.716210115584545e-06
ATPase O 0 9.576594311511144e-05
( O 0 1.3394242159847636e-08
ATP7B O 0 6.290940291364677e-06
) O 0 6.203998426101975e-10
, O 0 1.2342685207222814e-10
were O 0 8.286285546610372e-10
identified O 0 4.898856431623244e-09
in O 0 9.562830527443111e-10
Korean O 0 1.407384644380727e-07
Patients O 0 6.456695444967409e-08
with O 0 2.2857500781015005e-08
Wilson B-Disease 0 0.015018620528280735
disease I-Disease 1 0.9990206956863403
. O 0 1.63699769473169e-05

Arg778Leu O 0 0.00014205968182068318
, O 0 1.5566218536378074e-08
the O 0 3.7234502148209003e-09
most O 0 1.8548400315676616e-10
frequently O 0 3.3173427893551377e-10
reported O 0 8.596395817406233e-10
mutation O 0 3.8581504657742016e-10
of O 0 2.0767092490103778e-09
this O 0 1.681740718906255e-10
enzyme O 0 6.074842295866745e-10
, O 0 1.7616862135749756e-10
was O 0 1.826045981090374e-09
found O 0 2.999765713607161e-10
in O 0 2.5522617352891075e-10
six O 0 3.780881385750945e-09
of O 0 1.5709565204247156e-08
eight O 0 5.1647507604002385e-08
unrelated O 0 2.623145611835298e-08
patients O 0 3.334699461010615e-10
studied O 0 1.5421148802374773e-08
, O 0 2.1541447792206014e-10
an O 0 8.939855800083052e-11
allele O 0 1.2760317247284547e-08
frequency O 0 1.099349873356914e-07
of O 0 1.1604718253011015e-07
37 O 0 7.982904435266391e-07
. O 0 6.596404205083672e-07

5 O 0 1.4414554243558086e-06
% O 0 3.004605897416468e-09
, O 0 3.113111435304461e-10
which O 0 1.1403800820319887e-10
is O 0 4.2563664398587164e-11
considerably O 0 3.591215380627233e-10
higher O 0 2.2932587773194513e-10
than O 0 6.692689371451399e-12
those O 0 6.01258756324774e-12
in O 0 2.2098677054938065e-11
other O 0 9.86984452500117e-11
Asian O 0 6.0499383280898655e-09
populations O 0 2.00280525497476e-09
. O 0 2.1776028091835542e-08

The O 0 1.3949055244211195e-07
novel O 0 3.1150985790873165e-08
single O 0 1.988099640470864e-08
nucleotide O 0 3.096592138263077e-08
deletion O 0 4.848790879918852e-08
, O 0 2.5202198106200058e-09
2304delC O 0 3.4821570693566173e-07
, O 0 1.80275583350209e-09
was O 0 1.5894986660214272e-08
found O 0 1.5095836802814233e-09
in O 0 3.084729804925246e-09
one O 0 2.063451809419803e-08
patient O 0 2.3078736433035374e-07
. O 0 1.629382609280583e-06

Since O 0 1.4566882100552903e-07
a O 0 1.3367649209783394e-08
mutation O 0 4.211117676788945e-09
at O 0 6.810802943846284e-08
cDNA O 0 2.756179640073242e-07
nucleotide O 0 9.779066658666125e-07
2302 O 0 6.459903670474887e-05
( O 0 1.2208560384863176e-08
2302insC O 0 3.9383868966069713e-07
) O 0 1.4133727521681294e-09
had O 0 2.845398583417591e-09
been O 0 1.5254624230465197e-09
previously O 0 5.738365338459062e-09
described O 0 4.004748976882411e-09
, O 0 3.368214596122243e-10
this O 0 1.6251314183257648e-10
region O 0 2.317514402605525e-09
of O 0 1.4692974836805206e-08
the O 0 4.268584419264698e-08
ATP7B O 0 0.0001331335661234334
gene O 0 9.377193244120008e-09
may O 0 9.076508433736308e-09
be O 0 5.02779640143558e-09
susceptible O 0 1.336217252401184e-07
to O 0 1.1513175302013678e-08
gene O 0 9.139491794485366e-07
rearrangements O 0 0.005984872579574585
causing O 1 0.9628695249557495
Wilson B-Disease 1 0.9984908103942871
disease I-Disease 1 0.9999734163284302
. O 0 9.029525244841352e-06

Disruption O 0 3.66861822840292e-05
of O 0 9.370756970383809e-07
splicing O 0 5.255007522464439e-07
regulated O 0 1.0695148766615148e-08
by O 0 8.435659393235539e-10
a O 0 4.95724528093433e-09
CUG O 0 3.02649823424872e-06
- O 0 1.19876588655643e-07
binding O 0 1.2351674172350613e-07
protein O 0 5.65702578114724e-07
in O 0 1.3969291501325642e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 6.564197974512354e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999632835388184
DM B-Disease 1 1.0
) O 0 5.1321293881301244e-08
is O 0 7.999009232761978e-10
caused O 0 7.070477536785802e-09
by O 0 1.3850551816574352e-09
a O 0 7.735539320208318e-09
CTG O 0 1.3382684755924856e-06
expansion O 0 3.6985795759392204e-08
in O 0 1.4191130492946513e-09
the O 0 2.166565149508415e-09
3 O 0 1.0035616782033685e-07
untranslated O 0 1.0164790182898287e-05
region O 0 1.4769513612122864e-08
of O 0 3.619108923658132e-08
the O 0 5.360728323466901e-07
DM B-Disease 1 1.0
gene O 0 7.496213925151096e-07
. O 0 8.294110784845543e-07

One O 0 1.4912781409748277e-07
model O 0 4.1028934560927155e-07
of O 0 1.9657343273138395e-06
DM B-Disease 1 1.0
pathogenesis O 0 6.995136936893687e-05
suggests O 0 3.5650919993912566e-09
that O 0 1.189223303166287e-10
RNAs O 0 5.9042934985598094e-09
from O 0 8.641439230849812e-10
the O 0 1.4407736115273906e-09
expanded O 0 2.399257681418021e-09
allele O 0 7.72353825340133e-09
create O 0 8.936655304658814e-10
a O 0 1.3574318336040392e-09
gain O 0 2.2863693160957155e-08
- O 0 2.2976216484948964e-08
of O 0 2.2302979019173108e-08
- O 0 1.6094688248813327e-08
function O 0 3.5941774001457816e-09
mutation O 0 1.4477311016669603e-10
by O 0 2.0443235645983826e-11
the O 0 8.130118106519646e-11
inappropriate O 0 2.9638846932300567e-10
binding O 0 1.5991833413053769e-09
of O 0 4.91652007994503e-09
proteins O 0 8.921050703714073e-11
to O 0 4.662880637162914e-10
the O 0 1.1791959408924413e-08
CUG O 0 4.389452806208283e-05
repeats O 0 1.6978516441668035e-06
. O 0 8.269554996331863e-07

Data O 0 1.751626655277505e-06
presented O 0 2.17211947983742e-07
here O 0 1.3206795657083603e-08
indicate O 0 3.436594564476536e-09
that O 0 2.555759492928189e-10
the O 0 2.4078306015695716e-09
conserved O 0 3.482455213088542e-08
heterogeneous O 0 3.978287566042127e-08
nuclear O 0 8.964025823843258e-07
ribonucleoprotein O 0 4.45277510152664e-06
, O 0 2.8738273982753526e-08
CUG O 0 8.351428732567001e-06
- O 0 2.6716864454101596e-07
binding O 0 9.738140249737626e-08
protein O 0 4.9477169028477874e-08
( O 0 2.8141589059060834e-09
CUG O 0 3.926217232219642e-06
- O 0 1.3678095456270967e-07
BP O 0 1.1720400294734645e-07
) O 0 3.747072929716211e-10
, O 0 4.540214870729642e-10
may O 0 1.2642000335461034e-08
mediate O 0 3.355208946231869e-07
the O 0 6.540123109743945e-08
trans O 0 9.323265715011075e-08
- O 0 6.839938038183391e-08
dominant O 0 1.5687623999838252e-07
effect O 0 6.610454050814951e-08
of O 0 7.644191946099e-09
the O 0 4.840536416139685e-09
RNA O 0 3.959559080612962e-08
. O 0 4.354319216304248e-08

CUG O 0 0.15934616327285767
- O 0 0.0002064163563773036
BP O 0 3.394426585145993e-06
was O 0 2.7729573304213773e-08
found O 0 4.0116582278315605e-10
to O 0 8.531511608289577e-11
bind O 0 4.74761618907138e-10
to O 0 1.0107762404842902e-09
the O 0 1.1651000164647485e-08
human O 0 9.067744599633443e-07
cardiac O 0 0.03038967028260231
troponin O 0 0.002028112765401602
T O 0 0.00010341956658521667
( O 0 1.190688525554151e-08
cTNT O 0 2.1640143188506045e-07
) O 0 4.1724193544645516e-10
pre O 0 3.557601147008427e-08
- O 0 1.1419527545797337e-08
messenger O 0 7.902355214639556e-09
RNA O 0 3.344651000602994e-09
and O 0 9.29421095641203e-10
regulate O 0 7.504032950578221e-10
its O 0 3.7637334915352483e-10
alternative O 0 3.591246056089403e-08
splicing O 0 5.532720592782425e-07
. O 0 2.63595097749203e-07

Splicing O 0 5.1925931074947584e-06
of O 0 8.002295430742379e-07
cTNT O 0 1.2601440175785683e-05
was O 0 5.781962499895599e-07
disrupted O 0 5.919591330894036e-06
in O 0 3.2965130003503873e-07
DM B-Disease 1 1.0
striated O 0 9.279565347242169e-06
muscle O 0 2.846467452854995e-07
and O 0 1.4945264581456286e-08
in O 0 2.3034829599311024e-09
normal O 0 1.8863850925754377e-08
cells O 0 4.087382432516051e-09
expressing O 0 2.4996678060773547e-09
transcripts O 0 3.937973502843306e-08
that O 0 1.8222978681592394e-10
contain O 0 1.4164149853002073e-08
CUG O 0 1.5357330994447693e-05
repeats O 0 1.804985004127957e-06
. O 0 4.533509070370201e-07

Altered O 0 1.3361731134864385e-06
expression O 0 9.789838628648795e-08
of O 0 1.39540048849085e-07
genes O 0 1.4917953095050507e-08
regulated O 0 7.361323994814484e-09
posttranscriptionally O 0 3.6085151577935903e-07
by O 0 1.1682709910587619e-08
CUG O 0 0.00015977429575286806
- O 0 3.810686621363857e-06
BP O 0 5.142726990925439e-07
therefore O 0 1.4435277861934992e-08
may O 0 1.0222934498926861e-08
contribute O 0 8.248869143301363e-09
to O 0 5.903530819750813e-08
DM B-Disease 1 1.0
pathogenesis O 0 0.0005040499963797629
. O 0 6.114814254942758e-08
. O 0 2.0446822190933744e-07

Identification O 0 1.2459577192203142e-06
of O 0 7.084654640721055e-08
a O 0 7.230890552989422e-09
novel O 0 3.516294810879117e-08
nonsense O 0 2.433663155443355e-07
mutation O 0 7.428249571006518e-09
and O 0 1.0914930070882178e-09
a O 0 2.313910396622987e-09
missense O 0 7.282437763933558e-08
substitution O 0 1.5260336994060708e-08
in O 0 4.960698074540915e-09
the O 0 1.8975645943442032e-08
vasopressin O 0 2.1864390475911932e-07
- O 0 1.6395583202211128e-07
neurophysin O 0 2.799182254875632e-07
II O 0 8.36590515973512e-06
gene O 0 5.665875546512211e-10
in O 0 3.5753999760856914e-10
two O 0 5.453997253823673e-10
Spanish O 0 2.0184533866540733e-07
kindreds O 0 4.320884727349039e-06
with O 0 2.7638277444452797e-08
familial B-Disease 0 0.10295474529266357
neurohypophyseal I-Disease 1 0.9999997615814209
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.999994158744812
. O 0 0.0003809315094258636

Familial B-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.8573938608169556
FNDI B-Disease 1 1.0
) O 0 3.396543206690694e-07
is O 0 1.2790037917653763e-09
an O 0 2.597662307479709e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 2.182723255828023e-05
by O 0 4.7971198569030093e-08
deficiency O 0 0.09081356972455978
in O 0 1.7094393456318357e-07
the O 0 9.898248208628502e-06
antidiuretic O 0 0.0002393459144514054
hormone O 0 1.6977835457510082e-06
arginine O 0 5.683599738404155e-06
vasopressin O 0 4.895533720628009e-07
( O 0 1.0683996798377393e-08
AVP O 0 5.935737021900422e-07
) O 0 2.8575905530736634e-10
encoded O 0 4.2644132669522605e-10
by O 0 4.141876563945601e-10
the O 0 1.3555490951944194e-08
AVP O 0 6.761875738447998e-06
- O 0 5.079784273220866e-07
neurophysin O 0 3.785566605074564e-06
II O 1 0.999459445476532
( O 0 2.634196789585985e-07
AVP O 0 2.7718429919332266e-05
- O 0 8.919716947275447e-07
NPII O 0 6.342723736452172e-06
) O 0 3.1470528405463938e-09
gene O 0 3.658486846802589e-09
on O 0 8.138476914609782e-08
chromosome O 0 2.503615803561843e-07
20p13 O 0 1.452638753107749e-05
. O 0 3.5638611279864563e-06

In O 0 3.28151301687285e-08
this O 0 5.785961709747767e-10
study O 0 9.03337848967567e-10
, O 0 1.3800574572009339e-10
we O 0 5.133397040779641e-10
analyzed O 0 1.3862736514269614e-09
two O 0 1.478437927637799e-10
families O 0 9.981693249727641e-11
with O 0 2.8552751829558076e-10
FNDI B-Disease 1 0.9999959468841553
using O 0 1.1775731501018072e-08
direct O 0 2.2546002398371456e-08
automated O 0 1.7159923970666568e-07
fluorescent O 0 6.37019965665786e-08
, O 0 7.352802811055881e-10
solid O 0 1.4067171427711855e-08
phase O 0 3.2502555313840276e-08
, O 0 6.317531914268315e-11
single O 0 1.0954719076305963e-10
- O 0 4.4611467298061314e-10
stranded O 0 8.353234215441319e-10
DNA O 0 2.969667844965329e-10
sequencing O 0 6.901656468549788e-10
of O 0 2.6555135868022717e-09
PCR O 0 1.1326256554866632e-07
- O 0 8.100733452920394e-07
amplified O 0 1.4437956679103081e-06
AVP O 0 3.7309288018150255e-05
- O 0 9.749892342370003e-07
NPII O 0 1.44371842907276e-05
DNA O 0 4.324077451656194e-07
. O 0 3.115990239166422e-07

In O 0 4.4819099542792173e-08
one O 0 3.845178397909876e-09
of O 0 4.550768650801729e-09
the O 0 2.4026098888185743e-09
families O 0 1.360661028293464e-10
, O 0 9.459422134483475e-11
affected O 0 4.680005827317757e-10
individuals O 0 6.621499182291046e-11
presented O 0 4.099007355762296e-09
a O 0 1.9622026226073785e-09
novel O 0 1.2031830642911245e-08
nonsense O 0 1.1121941412284286e-07
mutation O 0 3.870394671423583e-09
in O 0 2.0543282630569593e-09
exon O 0 1.0483985235509863e-08
3 O 0 2.5609246279145736e-08
of O 0 4.3673753502559975e-09
the O 0 2.9554465541536956e-09
gene O 0 4.964254562977999e-10
, O 0 1.4455127372858811e-10
consisting O 0 3.8495723275744353e-10
in O 0 4.718798685132697e-10
a O 0 2.589485070814135e-09
G O 0 1.617452340951786e-07
to O 0 3.369586565327154e-08
T O 0 1.2320219866523985e-05
transition O 0 1.6181031696760328e-06
at O 0 5.869460437679663e-07
nucleotide O 0 3.010872262620978e-08
2101 O 0 9.860033287623082e-07
, O 0 6.386885464948477e-10
which O 0 5.200546937533801e-11
produces O 0 1.1988889048186735e-10
a O 0 1.7749006431255765e-10
stop O 0 1.8506250976102478e-09
signal O 0 4.6109086326850957e-08
in O 0 1.2167761020975831e-08
codon O 0 2.2004081756676896e-07
82 O 0 4.826268309443549e-07
( O 0 1.822616013669176e-08
Glu O 0 3.509982707328163e-05
) O 0 9.706834447342771e-09
of O 0 1.762505377200796e-07
NPII O 0 0.00018078745051752776
. O 0 1.6340493402822176e-06

The O 0 1.315706072091416e-06
premature O 0 6.058109192963457e-06
termination O 0 1.2372581750241807e-06
eliminates O 0 3.0088028779573506e-07
part O 0 7.3962977964470156e-09
of O 0 2.1779518633024963e-08
the O 0 9.37923250177164e-09
C O 0 7.90323781529878e-07
- O 0 1.746452227280315e-08
terminal O 0 9.387608024269412e-09
domain O 0 6.705490385172652e-09
of O 0 5.772560651706726e-09
NPII O 0 2.877450469895848e-06
, O 0 6.659982565437872e-10
including O 0 3.1917909981693526e-10
a O 0 1.7265687768386329e-09
cysteine O 0 3.525979508367527e-08
residue O 0 1.716162643106145e-07
in O 0 1.0913764336706322e-09
position O 0 6.350304460056577e-08
85 O 0 1.8962477810191558e-08
, O 0 1.441289587678085e-10
which O 0 6.208683567265894e-11
could O 0 1.8026242998292474e-10
be O 0 2.7634083910044183e-10
involved O 0 2.830986556290327e-10
in O 0 3.003092219344694e-10
the O 0 1.9208801216308302e-09
correct O 0 2.325934644886729e-07
folding O 0 3.9891870073915925e-06
of O 0 1.338311363952016e-07
the O 0 3.757562296868855e-07
prohormone O 0 0.0006175236776471138
. O 0 6.550837042595958e-06

In O 0 7.960176162669086e-08
the O 0 3.497312306421918e-08
second O 0 4.168191836129154e-08
family O 0 1.0170807529519266e-09
, O 0 2.2723244119671193e-10
a O 0 9.40724831366424e-10
G279A O 0 5.7062472080815496e-08
substitution O 0 2.7137378566521875e-08
at O 0 7.847503979974135e-08
position O 0 3.045666119305679e-08
- O 0 7.968010251602209e-09
1 O 0 6.788156703407822e-09
of O 0 9.863846406332755e-10
the O 0 7.968948834147227e-10
signal O 0 1.1187850645910657e-08
peptide O 0 9.83474746085733e-10
was O 0 2.0096930786195344e-09
observed O 0 1.5009475884397716e-09
in O 0 1.3554624089806566e-10
all O 0 6.098594962367088e-10
affected O 0 3.700920236937577e-09
individuals O 0 1.0608128819811213e-09
. O 0 1.0769767300189415e-07

This O 0 1.2630015078229917e-07
missense O 0 7.707934855716303e-06
mutation O 0 1.1634028851403855e-07
, O 0 1.3580877755714482e-08
which O 0 1.2440902530386211e-08
replaces O 0 6.109914829721674e-05
Ala O 0 4.2023119021905586e-05
with O 0 1.2531902626733427e-08
Thr O 0 5.574855549639324e-06
, O 0 2.0099653053051725e-09
is O 0 2.387861297581395e-10
frequent O 0 8.877601986867489e-10
among O 0 2.070631133221923e-08
FNDI B-Disease 1 1.0
patients O 0 1.5406646980409278e-07
and O 0 8.293230990830125e-09
is O 0 5.304193195776463e-10
thought O 0 1.151299500179448e-09
to O 0 1.5580310652740792e-10
reduce O 0 1.0014288287507611e-09
the O 0 1.2169101282211159e-09
efficiency O 0 4.8782524686430406e-08
of O 0 1.0700310859590445e-08
cleavage O 0 2.005826260642607e-08
by O 0 1.7716882405593992e-09
signal O 0 2.051614416131997e-07
peptidases O 0 2.2684914711135207e-06
. O 0 2.1992494936284857e-08
. O 0 1.837505436697029e-07

Genetic O 0 2.915703134931391e-06
heterogeneity O 0 4.029440788144711e-06
of O 0 5.910723302804399e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.5349624621640032e-09
due O 0 1.1687239265256721e-07
to O 0 4.483053483994581e-09
TWIST O 0 7.282851584022865e-06
and O 0 1.6339483011051925e-07
FGFR O 0 0.0007149979937821627
mutations O 0 8.168972271960229e-07
. O 0 9.419723596693075e-07

Thirty O 0 0.0004494599997997284
- O 0 2.1919266146142036e-05
two O 0 1.5725063917670923e-08
unrelated O 0 4.444157042371444e-08
patients O 0 1.2022670636824273e-09
with O 0 1.3582469871042946e-10
features O 0 2.407482746491496e-08
of O 0 2.0210434286127565e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.921616086368431e-09
a O 0 5.401780800440292e-09
common O 0 3.9432276821571577e-07
autosomal B-Disease 1 0.904869794845581
dominant I-Disease 1 0.9999054670333862
condition I-Disease 1 0.5085039138793945
of O 0 0.0004798167501576245
craniosynostosis B-Disease 1 0.9999997615814209
and O 0 0.00014654305414296687
limb B-Disease 1 0.9999985694885254
anomalies I-Disease 0 0.00030549601069651544
, O 0 7.4052044496397684e-09
were O 0 8.252268202113555e-09
screened O 0 3.1582012560704698e-09
for O 0 6.518870443450453e-10
mutations O 0 5.349408027655045e-09
in O 0 6.918055017735014e-09
TWIST O 0 1.7744674551067874e-05
, O 0 2.567762358296477e-08
FGFR2 O 0 4.413558417581953e-05
, O 0 1.7119933914955254e-08
and O 0 1.0023163810046753e-07
FGFR3 O 0 0.00010862777708098292
. O 0 2.6795530629897257e-06

Nine O 0 1.7259330888919067e-06
novel O 0 6.378429873166169e-08
and O 0 5.046877582515208e-09
three O 0 2.966736412091109e-09
recurrent O 0 8.234049886368666e-08
TWIST O 0 3.6520509638648946e-07
mutations O 0 8.557938357967032e-09
were O 0 3.5962621769414227e-09
found O 0 1.0462006816425173e-09
in O 0 2.1307837716477707e-09
12 O 0 1.7266198426568735e-07
families O 0 1.272621652503858e-08
. O 0 7.893422662164085e-07

Seven O 0 6.057122732272546e-07
families O 0 1.131547078259132e-09
were O 0 1.8333679019377769e-09
found O 0 1.0062436994751067e-10
to O 0 2.391608300289505e-10
have O 0 6.369246241533233e-10
the O 0 7.1153651859390266e-09
FGFR3 O 0 1.115935629059095e-05
P250R O 0 6.379592605298967e-07
mutation O 0 6.909641747654405e-09
, O 0 4.761981364787005e-10
and O 0 2.8635541160504374e-10
one O 0 1.1427055135460051e-10
individual O 0 4.496544803167524e-11
was O 0 2.0527812782944466e-09
found O 0 2.4898452744004373e-10
to O 0 1.6662966839664506e-10
have O 0 8.727439881894838e-10
an O 0 1.9338755041786726e-09
FGFR2 O 0 1.0692479918361641e-05
VV269 O 0 6.974383722990751e-06
- O 0 5.949553269601893e-06
270 O 0 2.377033609946011e-07
deletion O 0 7.835551514290273e-07
. O 0 8.911002282729896e-07

To O 0 7.021267123263897e-08
date O 0 9.068445478987996e-07
, O 0 2.041527835672241e-09
our O 0 2.1564190433309705e-09
detection O 0 9.093022335093792e-09
rate O 0 2.2773663510555764e-10
for O 0 3.8592670725812184e-11
TWIST O 0 7.153961689709831e-08
or O 0 1.0513421244695564e-08
FGFR O 0 2.178377144446131e-06
mutations O 0 6.336533076023443e-09
is O 0 3.058388542420687e-10
68 O 0 5.144288994785029e-09
% O 0 3.003974291537759e-10
in O 0 1.7252882456020302e-09
our O 0 1.1070997629758494e-07
Saethre B-Disease 1 0.9999496936798096
- I-Disease 1 0.9999998807907104
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999994039535522
patients O 0 3.585948604722944e-08
, O 0 7.401643187243678e-10
including O 0 1.0619384260834863e-09
our O 0 4.764439509585827e-08
five O 0 8.505978144057735e-09
patients O 0 3.2086011625409583e-10
elsewhere O 0 2.6992461599206763e-09
reported O 0 7.333058604785947e-09
with O 0 5.0501518522594324e-09
TWIST O 0 0.0003090856480412185
mutations O 0 7.51910692997626e-06
. O 0 2.292586714247591e-06

More O 0 1.012007455614139e-08
than O 0 1.0290599483653295e-09
35 O 0 2.7713484840319325e-09
different O 0 3.407170379166047e-10
TWIST O 0 6.452423662040019e-08
mutations O 0 1.2191543330430932e-09
are O 0 4.2182517895339444e-11
now O 0 5.208846201587569e-11
known O 0 1.191280130097283e-10
in O 0 9.315254817510166e-11
the O 0 6.772659655318591e-10
literature O 0 1.067698818246754e-08
. O 0 1.132064113562592e-07

The O 0 2.1218124857114162e-07
most O 0 1.3887984096072614e-09
common O 0 3.487345523467411e-09
phenotypic O 0 2.334294464390041e-07
features O 0 1.2925466919000428e-08
, O 0 8.058364531216e-10
present O 0 5.854120521675554e-10
in O 0 1.3901042816844011e-10
more O 0 1.5189486821109988e-11
than O 0 4.461553002044205e-11
a O 0 1.6414301862166525e-10
third O 0 1.4930384706346445e-09
of O 0 1.7393505524765374e-09
our O 0 4.800650987846211e-09
patients O 0 1.6032351835004732e-10
with O 0 1.3638075391231297e-10
TWIST O 0 1.24215171126707e-06
mutations O 0 3.602531961632849e-08
, O 0 1.7857815226562934e-09
are O 0 1.5626896443521332e-09
coronal B-Disease 0 2.5970724891521968e-05
synostosis I-Disease 0 9.385752491652966e-06
, O 0 1.613910782793937e-08
brachycephaly B-Disease 0 6.623417448281543e-06
, O 0 2.6289459498229917e-08
low B-Disease 0 0.05911701172590256
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 0.3603992164134979
facial B-Disease 1 1.0
asymmetry I-Disease 1 0.9999984502792358
, O 0 8.74289071362e-07
ptosis B-Disease 1 0.9999198913574219
, O 0 1.710171488866763e-07
hypertelorism B-Disease 0 0.0005320071359165013
, O 0 7.890309206004531e-08
broad B-Disease 0 2.4748287614784203e-05
great I-Disease 1 0.9580289721488953
toes I-Disease 1 0.9936189651489258
, O 0 7.782158917279958e-08
and O 0 2.7653021561491187e-07
clinodactyly B-Disease 0 0.00013990222942084074
. O 0 6.260888767428696e-06

Significant O 0 1.629536745895166e-05
intra O 0 0.005686694290488958
- O 0 1.7912043404066935e-05
and O 0 3.115478719450948e-08
interfamilial O 0 6.219517217687098e-06
phenotypic O 0 1.0207045306742657e-05
variability O 0 5.074951445749321e-07
is O 0 1.3087821104651454e-10
present O 0 5.6403933607063195e-11
for O 0 7.252790729106451e-11
either O 0 2.999452464180763e-09
TWIST O 0 1.8670343706617132e-06
mutations O 0 1.0503644887194241e-07
or O 0 4.2303362590701e-08
FGFR O 0 1.1129597623948939e-05
mutations O 0 6.31407090168068e-07
. O 0 1.1334765304127359e-06

The O 0 1.563299178997113e-07
overlap O 0 1.4757010724508746e-08
in O 0 1.4895114031077128e-09
clinical O 0 1.009863215273299e-08
features O 0 1.0760928814690374e-09
and O 0 2.9978841631361774e-10
the O 0 5.358473664784924e-10
presence O 0 1.9328162681464534e-10
, O 0 4.184212004654242e-11
in O 0 3.206617263384892e-11
the O 0 1.215304523682903e-10
same O 0 1.3084451577771716e-10
genes O 0 2.0369685105325885e-10
, O 0 1.1886881756684176e-10
of O 0 1.7953303288464895e-09
mutations O 0 2.1038235598069832e-09
for O 0 3.845499196852842e-10
more O 0 1.3458506531449643e-10
than O 0 1.4795606406714512e-10
one O 0 1.245887060186135e-09
craniosynostotic B-Disease 0 6.629874178543105e-07
condition I-Disease 0 2.1425857710255514e-07
- O 0 1.4200450593193636e-08
such O 0 3.5288891253593135e-10
as O 0 5.0142454632862155e-09
Saethre B-Disease 0 1.0130434930033516e-05
- I-Disease 0 6.237915499696101e-07
Chotzen I-Disease 0 6.563887836819049e-06
, I-Disease 0 7.3827388646918735e-09
Crouzon I-Disease 0 1.6565860278205946e-05
, I-Disease 0 1.4847525875438805e-08
and I-Disease 0 4.367827699525151e-08
Pfeiffer I-Disease 0 0.0005037346272729337
syndromes I-Disease 0 1.2932323443237692e-05
- O 0 2.004897510232695e-07
support O 0 5.49843326425048e-09
the O 0 1.2993887743562027e-08
hypothesis O 0 2.32268000388558e-08
that O 0 9.058011979368175e-11
TWIST O 0 4.487487359483566e-08
and O 0 2.0560806390790276e-09
FGFRs O 0 3.3267082244492485e-07
are O 0 1.220321621531184e-10
components O 0 2.598494752703573e-09
of O 0 2.2023127765891104e-09
the O 0 8.972043108457228e-10
same O 0 3.8036421234899365e-10
molecular O 0 7.626193010423776e-09
pathway O 0 7.533460522068935e-10
involved O 0 1.449717984547405e-10
in O 0 8.760507597127543e-11
the O 0 9.3188845529113e-10
modulation O 0 3.1492555763179553e-07
of O 0 7.002930146882136e-07
craniofacial O 1 1.0
and O 0 7.176843064371496e-05
limb O 1 0.9999990463256836
development O 0 2.245444557047449e-05
in O 0 1.1062782689919004e-08
humans O 0 1.0180633225331803e-08
. O 0 7.3637118624958475e-09
. O 0 2.1662981453118846e-07

Mutation O 0 6.296428409768851e-07
analysis O 0 1.0428068719647854e-07
of O 0 2.391978455307253e-07
UBE3A O 1 0.9979813694953918
in O 0 0.00021408300381153822
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.9807397620752454e-05
. O 0 3.4275772122782655e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00021813763305544853
AS B-Disease 1 1.0
) O 0 4.397617825446787e-09
is O 0 3.2253766324430444e-10
caused O 0 4.306478285087678e-09
by O 0 2.3199291376840847e-09
chromosome O 0 1.385489838412468e-07
15q11 O 0 1.6273032770186546e-06
- O 0 3.0564441999558767e-07
q13 O 0 2.8289824172134104e-07
deletions O 0 1.3744817728422731e-08
of O 0 9.795283473224004e-10
maternal O 0 2.6261379737491097e-09
origin O 0 7.23499815613593e-10
, O 0 3.1499999830764125e-10
by O 0 1.3967972334327783e-09
paternal O 0 3.4695583508437267e-06
uniparental B-Disease 1 0.9981151819229126
disomy I-Disease 1 0.9999270439147949
( O 0 5.364662501960993e-05
UPD B-Disease 1 1.0
) O 0 6.59264998148501e-08
15 O 0 6.257100437778718e-08
, O 0 8.277675767054404e-10
by O 0 2.5205946219131192e-09
imprinting O 0 0.0004501689982134849
defects O 0 0.09878073632717133
, O 0 4.732600977774837e-09
and O 0 2.8095357151869393e-09
by O 0 9.92228521567995e-10
mutations O 0 5.671003222573745e-09
in O 0 6.281084985459984e-09
the O 0 2.0494536556725507e-07
UBE3A O 0 9.43024133448489e-05
gene O 0 5.240063956080121e-07
. O 0 1.9515923668222968e-06

UBE3A O 0 0.001377756241708994
encodes O 0 3.2901230042625684e-06
a O 0 2.79520747881179e-07
ubiquitin O 0 3.3855553738249e-06
- O 0 3.906206075043883e-06
protein O 0 7.976498750394967e-08
ligase O 0 9.821595625680857e-08
and O 0 2.4977008905580078e-08
shows O 0 1.7500275362181128e-07
brain O 0 0.0010355524718761444
- O 0 1.29846910112974e-06
specific O 0 9.075784390688568e-08
imprinting O 0 2.4533439500373788e-05
. O 0 1.7837571704149013e-06

Here O 0 1.7992481389228487e-06
we O 0 1.220181360395145e-07
describe O 0 6.209722300809517e-07
UBE3A O 0 9.165579831460491e-05
coding O 0 8.016710125957616e-06
- O 0 1.1941167485929327e-06
region O 0 4.655064955727539e-08
mutations O 0 2.3596212983534315e-08
detected O 0 3.204724929872782e-09
by O 0 3.76568665139132e-10
SSCP O 0 7.190088240349723e-07
analysis O 0 3.439571516494766e-09
in O 0 6.733837376593499e-10
13 O 0 3.65675880686922e-08
AS B-Disease 1 0.9999921321868896
individuals O 0 5.551160642269792e-10
or O 0 4.274448350827242e-09
families O 0 1.7374539584835702e-09
. O 0 1.3427948886146623e-07

Two O 0 5.382200924941571e-07
identical O 0 1.7495248130217078e-06
de O 0 6.145671795820817e-05
novo O 0 1.1979701412201393e-05
5 O 0 4.125334271520842e-06
- O 0 3.7008379649705603e-07
bp O 0 1.697676879075516e-07
duplications O 0 2.955832769657718e-07
in O 0 1.0055598131941679e-08
exon O 0 1.657686112821466e-07
16 O 0 9.185097127328845e-08
were O 0 3.058134723232797e-08
found O 0 4.73501451381253e-08
. O 0 4.1150215679408575e-07

Among O 0 6.667512764124695e-08
the O 0 5.406047609568532e-09
other O 0 2.2860005555180862e-10
11 O 0 2.949483102199224e-09
unique O 0 2.2816533384872884e-10
mutations O 0 1.97674032698103e-09
, O 0 3.80998121940479e-10
8 O 0 1.703348928572268e-08
were O 0 2.784929620247567e-09
small O 0 2.593038672671355e-09
deletions O 0 5.6027992911822366e-08
or O 0 2.107804952800052e-08
insertions O 0 8.739258561263341e-08
predicted O 0 2.2478745620446716e-07
to O 0 4.651778962028175e-09
cause O 0 2.888181143134716e-07
frameshifts O 0 2.2627875296166167e-05
, O 0 7.6770678703042e-09
1 O 0 2.254527942113782e-07
was O 0 1.4458065855649238e-08
a O 0 6.460951773590295e-10
mutation O 0 3.7287073428871054e-10
to O 0 3.0052063615393365e-10
a O 0 1.2750214217760458e-09
stop O 0 5.7094995398188075e-09
codon O 0 7.959811654245641e-08
, O 0 3.018829186629546e-09
1 O 0 2.974007173861537e-08
was O 0 5.522164947535657e-09
a O 0 1.7000375551745606e-09
missense O 0 6.964912557805292e-08
mutation O 0 2.5347834942124337e-09
, O 0 5.061972507824919e-10
and O 0 1.2794503234658805e-09
1 O 0 6.619134751417732e-08
was O 0 2.3270166238376078e-08
predicted O 0 1.650042058543022e-08
to O 0 2.32295682689454e-10
cause O 0 2.5299002892609224e-09
insertion O 0 7.709806126854346e-09
of O 0 4.236803974322356e-08
an O 0 3.833878992054451e-09
isoleucine O 0 7.160226687119575e-07
in O 0 5.350857090746786e-09
the O 0 3.171785678546257e-08
hect O 0 4.810369205188181e-07
domain O 0 1.9938109829809036e-08
of O 0 1.5470996928002023e-08
the O 0 2.09186463706601e-08
UBE3A O 0 2.690894916668185e-06
protein O 0 8.637983661685666e-09
, O 0 2.7368038391095695e-10
which O 0 1.3350512362286793e-10
functions O 0 1.6164608540591985e-09
in O 0 8.681351748585087e-10
E2 O 0 1.3983819258100993e-07
binding O 0 3.342000098882636e-08
and O 0 2.9591427974651197e-08
ubiquitin O 0 8.542756404494867e-07
transfer O 0 1.0543423059061752e-06
. O 0 1.0845725455510546e-06

Eight O 0 5.275433636597882e-07
of O 0 1.688868778160213e-08
the O 0 1.746477962250026e-09
cases O 0 6.254088358303989e-10
were O 0 8.78975225937495e-10
familial O 0 9.065884931658275e-09
, O 0 9.030088343742193e-10
and O 0 1.408386296475328e-09
five O 0 6.412717912240851e-09
were O 0 7.376771193889908e-09
sporadic O 0 1.0417378462079796e-06
. O 0 4.223936684866203e-06

In O 0 8.880454771542645e-08
two O 0 5.091469912343882e-09
familial O 0 4.164091294001082e-08
cases O 0 1.6877409469984173e-09
and O 0 2.6317928392138867e-10
one O 0 2.2134669097617632e-10
sporadic O 0 9.505914277951888e-09
case O 0 1.6928678903127548e-08
, O 0 3.2220948131822524e-09
mosaicism O 0 7.064703027026553e-07
for O 0 1.679085315231532e-08
UBE3A O 0 1.7205318727064878e-05
mutations O 0 5.527837032559546e-08
was O 0 4.113569218588964e-08
detected O 0 3.6492389110520662e-09
in O 0 3.039210272337556e-10
the O 0 1.0930930605113076e-09
mother O 0 1.7166028598580851e-09
of O 0 2.1398387062276925e-08
three O 0 1.5179171697354832e-08
AS B-Disease 1 1.0
sons O 0 2.583983587101102e-06
, O 0 1.642815439240053e-09
in O 0 7.889474074040947e-10
the O 0 5.708595818276763e-09
maternal O 0 8.525017136662427e-08
grandfather O 0 5.350947276383522e-07
of O 0 4.590200660459232e-06
two O 0 2.860784888980561e-07
AS B-Disease 1 1.0
first O 0 1.6009945511541446e-06
cousins O 0 1.3660118725056236e-07
, O 0 9.51057121945098e-10
and O 0 7.974452764791806e-10
in O 0 1.3725843794887282e-09
the O 0 1.4043473051117417e-08
mother O 0 7.585775563256902e-09
of O 0 1.982991477689211e-07
an O 0 8.803783480004768e-09
AS B-Disease 1 1.0
daughter O 0 0.0026550714392215014
. O 0 0.0001499135687481612

The O 0 2.510624028673192e-07
frequencies O 0 1.0465129918202365e-07
with O 0 2.33923880266218e-10
which O 0 8.138123508416584e-11
we O 0 3.7078567993731326e-10
detected O 0 4.5042125584870973e-10
mutations O 0 1.9075310775384935e-10
were O 0 5.972224936812154e-10
5 O 0 6.75321132348472e-09
( O 0 2.6986218815139296e-10
14 O 0 2.9123250477880447e-09
% O 0 5.0584182675894596e-11
) O 0 6.2888944052375e-11
of O 0 7.494649900685602e-10
35 O 0 3.1221334406694723e-09
in O 0 3.223470101954007e-10
sporadic O 0 1.5427268351686507e-08
cases O 0 2.4134398923791878e-09
and O 0 2.758717476680772e-09
8 O 0 1.812673531276232e-07
( O 0 9.665703792904878e-10
80 O 0 1.7195882495713022e-09
% O 0 8.402543244523386e-11
) O 0 6.973583516201032e-11
of O 0 7.235329557708781e-10
10 O 0 2.4247814867095485e-09
in O 0 8.906909099160032e-10
familial O 0 4.876754999827426e-08
cases O 0 5.146791881571744e-09
. O 0 1.0529596750075143e-08
. O 0 2.691105578378483e-07

The O 0 8.626356429886073e-05
hemochromatosis B-Disease 1 1.0
845 O 0 5.513073847396299e-05
G O 0 1.2042977687087841e-05
- O 0 2.2828583041700767e-06
- O 0 3.717172489814402e-07
> O 0 7.527435030851848e-08
A O 0 7.213589281462873e-09
and O 0 6.795459750463806e-10
187 O 0 1.2855732034466882e-09
C O 0 5.732570684813254e-08
- O 0 3.1496067975922415e-08
- O 0 5.021550464334723e-08
> O 0 1.2502826507443388e-07
G O 0 1.4795826075442164e-07
mutations O 0 1.6716652950776734e-08
: O 0 1.0026367514015533e-09
prevalence O 0 1.2155559225845991e-08
in O 0 7.121199741000339e-10
non O 0 1.2216671052556194e-07
- O 0 1.1201221639112191e-07
Caucasian O 0 4.3357552215184114e-08
populations O 0 1.8522575473411962e-08
. O 0 2.908330998252495e-07

Hemochromatosis B-Disease 1 0.9984186887741089
, O 0 1.6263989266462886e-07
the O 0 2.101997097270214e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9999972581863403
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 2.3307840990582918e-07
leads O 0 1.5023181276774267e-07
, O 0 3.520346458785184e-09
if O 0 1.216228451283996e-08
untreated O 0 5.016916020395001e-06
, O 0 9.93281346062247e-10
to O 0 1.0465624811217822e-08
progressive O 1 0.9999957084655762
iron B-Disease 1 1.0
overload I-Disease 1 0.9999998807907104
and O 0 0.00013407475489657372
premature B-Disease 0 0.11590387672185898
death I-Disease 0 0.004006402567028999
. O 0 6.794947694288567e-06

The O 0 5.0672399083850905e-05
hemochromatosis B-Disease 1 1.0
gene O 0 5.236137212705216e-07
, O 0 3.4748513400018055e-08
HFE O 0 4.6084609493846074e-05
, O 0 1.0030753117007407e-08
recently O 0 1.3689247957415773e-08
has O 0 3.6152145166390426e-10
been O 0 6.036011690468968e-10
identified O 0 1.3640736318265567e-09
, O 0 1.1736457639077713e-10
and O 0 3.5923936048121163e-10
characterization O 0 7.726780104633235e-09
of O 0 2.0976822057150457e-08
this O 0 6.337387281618589e-10
gene O 0 5.938352587442353e-10
has O 0 1.0774231506971432e-10
shown O 0 1.244390285259911e-10
that O 0 1.991671931544925e-11
it O 0 1.680217076582835e-11
contains O 0 3.044615948244456e-11
two O 0 4.374774500992551e-11
mutations O 0 1.706846747273616e-10
that O 0 2.0008251999659166e-11
result O 0 1.525695347837086e-09
in O 0 2.9026425707456838e-09
amino O 0 6.7620278265678735e-09
acid O 0 7.24819226860518e-09
substitutions O 0 7.846472271921812e-08
- O 0 6.258151330484907e-08
cDNA O 0 6.046340672583028e-08
nucleotides O 0 3.384698032959932e-08
845 O 0 1.553457735781194e-07
G O 0 2.3344213673226477e-07
- O 0 2.313526010766509e-07
- O 0 1.2077497046902863e-07
> O 0 6.079216774423912e-08
A O 0 2.8353827730143166e-08
( O 0 7.006171198753464e-10
C282Y O 0 4.4666766285672566e-08
) O 0 2.4246646357362067e-10
and O 0 3.44282546915764e-10
187 O 0 2.1753101542287823e-09
C O 0 8.534355799838522e-08
- O 0 5.626090882060453e-08
- O 0 5.030312166809381e-08
> O 0 8.009978813561247e-08
G O 0 1.1485960982327015e-07
( O 0 3.0079660984227985e-09
H63D O 0 4.960869773640297e-06
) O 0 1.2084590217398272e-08
. O 0 1.557393147777475e-07

Although O 0 2.5484332581982017e-05
hemochromatosis B-Disease 1 1.0
is O 0 1.78908248216203e-08
common O 0 1.1212461181742128e-08
in O 0 4.228510430692722e-09
Caucasians O 0 1.024526952164706e-07
, O 0 7.314703509564424e-09
affecting O 0 7.579530603152307e-08
> O 0 2.0402703171384928e-07
= O 0 2.182666065664307e-07
1 O 0 1.6437446959116642e-07
/ O 0 3.092135969495757e-08
300 O 0 9.585071625295427e-10
individuals O 0 1.79877675254847e-11
of O 0 3.389384883867308e-10
northern O 0 1.541073268995774e-09
European O 0 2.0861191885046537e-08
origin O 0 5.266703961837038e-09
, O 0 1.565699098149409e-10
it O 0 1.5681192455652138e-11
has O 0 5.5989956594670875e-12
not O 0 1.3689984909581732e-11
been O 0 4.21035879771825e-11
recognized O 0 1.0177206299921693e-10
in O 0 1.6052884022066394e-10
other O 0 6.915386596695328e-10
populations O 0 5.6290181404961e-09
. O 0 8.308528265388304e-08

The O 0 1.5251177387654025e-07
present O 0 6.003498587148215e-09
study O 0 4.3652245707015425e-10
used O 0 1.5386611429413222e-10
PCR O 0 2.5334445652447357e-09
and O 0 1.24907073573155e-09
restriction O 0 3.486507749173029e-09
- O 0 5.175240236354739e-09
enzyme O 0 4.984292423237946e-10
digestion O 0 5.026068450320054e-10
to O 0 6.496079368867314e-11
analyze O 0 1.3784506869285451e-09
the O 0 2.818750233224421e-10
frequency O 0 8.358242986616915e-09
of O 0 2.4728512570959538e-09
the O 0 7.471360419231132e-09
845 O 0 8.35263733733882e-08
G O 0 9.531008515750727e-08
- O 0 1.373011144778502e-07
- O 0 7.743218333189361e-08
> O 0 3.180399943403245e-08
A O 0 4.275100717876512e-09
and O 0 3.3820618527968804e-10
187 O 0 6.89861556768534e-10
C O 0 9.346159401957266e-09
- O 0 2.723032910267875e-09
- O 0 4.077369109012352e-09
> O 0 1.6752274234477227e-08
G O 0 2.7549962311468335e-08
mutations O 0 4.104820483519234e-09
in O 0 4.35626024142266e-09
HLA O 0 1.3321812275535194e-07
- O 0 1.8718694150265947e-08
typed O 0 5.2752597845540095e-09
samples O 0 1.7848747480009308e-10
from O 0 9.166637587876281e-11
non O 0 2.0509974163474e-08
- O 0 2.2343215277942363e-08
Caucasian O 0 1.4467112841032304e-08
populations O 0 4.5514605973018263e-10
, O 0 4.908983775031572e-10
comprising O 0 2.7745059583139664e-09
Australian O 0 1.987133657621598e-07
Aboriginal O 0 1.196372068079654e-07
, O 0 1.7642157734698571e-09
Chinese O 0 4.307710188555802e-09
, O 0 3.2666052085517094e-09
and O 0 3.605597598266286e-08
Pacific O 0 1.9385945506655844e-06
Islanders O 0 4.2945310269715264e-05
. O 0 2.5690467282402096e-06

Results O 0 1.819136923586484e-05
showed O 0 2.787514290503168e-07
that O 0 2.3066044629871385e-09
the O 0 1.0201587130609369e-08
845 O 0 1.2724959219667653e-07
G O 0 5.026447524869582e-07
- O 0 9.180899382954522e-07
- O 0 5.44357305898302e-07
> O 0 7.537721558037447e-08
A O 0 4.5622581268389695e-09
mutation O 0 3.5805322595727773e-10
was O 0 5.521130219676706e-10
present O 0 8.358793518459251e-11
in O 0 5.830060045841634e-11
these O 0 4.032753297966707e-11
populations O 0 2.6889251242279144e-11
( O 0 6.344556824355863e-11
allele O 0 1.7961317988479664e-09
frequency O 0 6.535706198462776e-09
0 O 0 3.4244111990489046e-09
. O 0 1.1952105971602123e-10
32 O 0 1.0409836326275013e-09
% O 0 3.603536566365584e-11
) O 0 2.8561507325886026e-11
, O 0 4.252552476824434e-11
and O 0 1.2674002125567796e-10
, O 0 1.0619258250521568e-10
furthermore O 0 6.093920368321903e-10
, O 0 4.969177846980699e-11
it O 0 2.090326002568421e-11
was O 0 1.9002004414403473e-09
always O 0 5.013458537206361e-10
seen O 0 3.3896452311665826e-09
in O 0 5.043026551909691e-10
conjunction O 0 4.602584979807034e-09
with O 0 2.4524096087219505e-09
HLA O 0 2.056593302768306e-06
haplotypes O 0 4.565394107203247e-08
common O 0 7.777184229951217e-09
in O 0 2.4166550982585022e-09
Caucasians O 0 2.7384306378053225e-08
, O 0 9.633916997486835e-10
suggesting O 0 9.38420718910038e-09
that O 0 3.080049992831846e-09
845 O 0 2.0347422946542792e-07
G O 0 1.1280684475423186e-06
- O 0 1.017148133541923e-05
- O 0 7.009063210716704e-06
> O 0 2.0272231893159187e-07
A O 0 7.724598738434452e-09
may O 0 9.248410370865656e-10
have O 0 1.5353278370877632e-10
been O 0 6.50987180828011e-11
introduced O 0 1.100342733595383e-10
into O 0 2.6560375426809557e-11
these O 0 6.68739412804098e-12
populations O 0 1.8465121792710093e-11
by O 0 1.1192919507907462e-10
Caucasian O 0 3.8402404811677116e-08
admixture O 0 1.281381173612317e-06
. O 0 1.1178304930581362e-06

187 O 0 1.8654308178156498e-06
C O 0 3.646288178060786e-06
- O 0 5.996257073093147e-07
- O 0 2.715682967391331e-07
> O 0 1.2453038777948677e-07
G O 0 5.7745680237530905e-08
was O 0 7.98133470425455e-09
present O 0 4.782972351513592e-10
at O 0 1.2597560772320548e-09
an O 0 1.953559362888324e-11
allele O 0 1.1055837356721554e-09
frequency O 0 1.7920809725069375e-08
of O 0 1.6692311533006432e-08
2 O 0 9.32264924813353e-07
. O 0 4.6581251922361844e-07

68 O 0 1.2838936527259648e-06
% O 0 2.478030669550435e-09
in O 0 9.217345775525132e-10
the O 0 1.383178238612004e-09
two O 0 7.103415078368869e-10
populations O 0 2.2606265470681564e-10
analyzed O 0 5.163615313108494e-09
( O 0 1.2233798418748165e-09
Australian O 0 1.018378270600806e-07
Aboriginal O 0 6.741116465036612e-08
and O 0 4.5169392670629804e-09
Chinese O 0 2.201994497852411e-08
) O 0 1.5835556865795297e-08
. O 0 2.0629802577332157e-07

In O 0 7.180015870744683e-08
the O 0 2.184575187413884e-08
Australian O 0 1.0974350317383141e-07
Aboriginal O 0 1.6674237102165534e-08
samples O 0 2.831650747214809e-10
, O 0 2.5375199164123785e-10
187 O 0 1.7421228903913288e-09
C O 0 7.610677243974351e-08
- O 0 4.0216828978145713e-08
- O 0 6.380048489518231e-08
> O 0 5.652345791418156e-08
G O 0 3.1869642924675645e-08
was O 0 1.9382735416684227e-09
found O 0 4.574137943413881e-11
to O 0 2.1888093768018813e-11
be O 0 2.293503581496381e-10
associated O 0 7.477590102666909e-09
with O 0 3.2450753195689686e-09
HLA O 0 7.732605808996595e-06
haplotypes O 0 1.2028600337998796e-07
common O 0 1.116512571286421e-08
in O 0 4.086805560632456e-09
Caucasians O 0 6.265292995522032e-08
, O 0 7.493877740571975e-10
suggesting O 0 2.2923676290531603e-09
that O 0 7.393977097258642e-11
it O 0 6.775330990693718e-11
was O 0 1.0840860431571286e-09
introduced O 0 1.3683550958987212e-09
by O 0 2.3275514848819512e-10
recent O 0 3.81534270843531e-09
admixture O 0 2.8511783511930844e-07
. O 0 4.6979917556200235e-07

In O 0 7.715590299994801e-08
the O 0 1.3202262394429454e-08
Chinese O 0 6.1298517373131745e-09
samples O 0 1.6121225465681732e-09
analyzed O 0 5.568724592563967e-09
, O 0 3.6614591913952665e-10
187 O 0 1.7763442938800722e-09
C O 0 5.2095398217488764e-08
- O 0 2.6081391268917287e-08
- O 0 2.4973912715609003e-08
> O 0 3.646965396342239e-08
G O 0 2.6168891054112464e-08
was O 0 3.126275016640534e-09
present O 0 3.975113016529974e-10
in O 0 3.24439280996458e-10
association O 0 4.863633940033196e-10
with O 0 3.76162191673135e-11
a O 0 7.38941352551592e-10
wide O 0 8.68115801466729e-09
variety O 0 8.205684132178703e-09
of O 0 7.956290204447214e-08
HLA O 0 2.602703261800343e-06
haplotypes O 0 4.132648001586858e-08
, O 0 4.742728432205467e-10
showing O 0 7.058481577004727e-10
this O 0 4.82149459246628e-11
mutation O 0 5.118611437482379e-11
to O 0 3.093576783630425e-11
be O 0 1.1283374928838796e-10
widespread O 0 6.919239625702289e-10
and O 0 6.338088942570153e-10
likely O 0 4.7379389300772345e-09
to O 0 2.2156858570099303e-09
predate O 0 1.8609907215250132e-07
the O 0 8.763207048900767e-09
more O 0 7.191988671273464e-10
genetically O 0 7.47160289193971e-09
restricted O 0 9.87041914868314e-09
845 O 0 2.274744872465817e-07
G O 0 1.6828130355861504e-06
- O 0 3.184948582202196e-06
- O 0 9.384448844684812e-07
> O 0 1.1477003880600023e-07
A O 0 2.140998311972453e-08
mutation O 0 2.700277335065948e-08
. O 0 4.47002612702363e-08

Genotype O 0 7.099109643604606e-05
- O 0 8.029463970160577e-06
phenotype O 0 3.474816026027838e-07
correlations O 0 9.167941357191012e-07
in O 0 1.5433293754085753e-07
attenuated B-Disease 1 0.9787702560424805
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
. O 0 0.0004718514683190733

Germ O 0 0.002024147193878889
- O 0 0.0004358629521448165
line O 0 1.8272754687131965e-06
mutations O 0 7.959113190736389e-08
of O 0 4.552559218495844e-08
the O 0 1.3083241157119119e-08
tumor B-Disease 0 1.983298005825418e-07
suppressor O 0 9.794915740712895e-07
APC O 0 1.6924846590882225e-07
are O 0 1.5767583905201832e-09
implicated O 0 1.5726750746125617e-07
in O 0 1.296492797564497e-07
attenuated B-Disease 1 0.9999949932098389
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9999352693557739
AAPC B-Disease 1 1.0
) O 0 2.7105977906671797e-08
, O 0 5.951779069590657e-10
a O 0 1.0013219142734897e-09
variant O 0 7.422653197863838e-06
of O 1 0.8754247426986694
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.29680554184597e-05
FAP B-Disease 0 2.336612669751048e-05
) O 0 1.134558615945025e-07
. O 0 1.4592746993002947e-06

AAPC B-Disease 1 1.0
is O 0 1.4797850944603397e-08
recognized O 0 3.1969105140916554e-09
by O 0 3.180603003194449e-10
the O 0 1.123058313012848e-09
occurrence O 0 9.559005142989463e-09
of O 0 1.8810748514397346e-08
< O 0 1.1154035064464551e-06
100 O 0 8.975131038369e-08
colonic B-Disease 0 6.333373221423244e-06
adenomas I-Disease 0 2.7704415970219998e-06
and O 0 2.1267032579430634e-09
a O 0 1.6874738273386924e-09
later O 0 9.71750822031936e-08
onset O 1 0.998703122138977
of O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.094973877182383e-08
age O 0 7.793566680902586e-08
> O 0 1.110273899485037e-07
40 O 0 4.059536706790823e-09
years O 0 2.37429276239709e-09
) O 0 2.080420058447885e-09
. O 0 1.148332060552093e-07

The O 0 2.9703684845117095e-07
aim O 0 2.5187847541019437e-07
of O 0 1.5767952277201402e-08
this O 0 2.7372476507636634e-10
study O 0 2.4706767187687717e-10
was O 0 8.668826767532778e-10
to O 0 8.755851599318021e-10
assess O 0 1.8489612330085947e-07
genotype O 0 3.3591031751711853e-06
- O 0 9.11359802557854e-06
phenotype O 0 9.067286441677425e-07
correlations O 0 2.883672550524352e-06
in O 0 2.1141289607840008e-07
AAPC B-Disease 1 1.0
families O 0 1.0876244971314009e-07
. O 0 3.0332429901136493e-07

By O 0 3.079861130572681e-07
protein O 0 4.457638738131209e-07
- O 0 5.208327706895943e-07
truncation O 0 1.1829499726445647e-06
test O 0 9.009148129734967e-07
( O 0 2.8646006455801398e-08
PTT O 0 1.7528482203488238e-06
) O 0 9.833790448610102e-10
assay O 0 8.99392649245101e-09
, O 0 1.4206830156737738e-10
the O 0 8.057780553905047e-10
entire O 0 1.3318683045326907e-08
coding O 0 4.528621744270822e-08
region O 0 5.9675819841231714e-09
of O 0 1.3777523122371349e-08
the O 0 8.696769526750359e-09
APC B-Disease 0 3.494172062801226e-08
gene O 0 1.6073266051463975e-09
was O 0 5.396137314761518e-09
screened O 0 3.912889567914135e-09
in O 0 8.601611090064409e-10
affected O 0 2.1030854835402124e-09
individuals O 0 2.305521190626436e-10
from O 0 1.3361785455856534e-08
11 O 0 3.0634870199719444e-05
AAPC B-Disease 1 1.0
kindreds O 0 2.749562008830253e-05
, O 0 5.541843428602533e-09
and O 0 1.64950320069579e-09
their O 0 5.601941577282332e-09
phenotypic O 0 3.7526524465647526e-06
differences O 0 3.828747139777988e-06
were O 0 6.620535941692651e-07
examined O 0 7.2849629759730306e-06
. O 0 1.0747108944997308e-06

Five O 0 3.0847131711198017e-06
novel O 0 4.3263585780550784e-07
germ O 0 1.611380503163673e-05
- O 0 9.884429346129764e-06
line O 0 5.835163960909995e-07
APC B-Disease 0 2.3918599367789284e-07
mutations O 0 1.4634855993733709e-08
were O 0 5.319048312912855e-09
identified O 0 1.437743701870886e-08
in O 0 9.818239554704178e-09
seven O 0 3.377720645403315e-07
kindreds O 0 3.7778740079374984e-05
. O 0 7.513100172218401e-06

Mutations O 0 4.6473562065330043e-07
were O 0 2.535215060106566e-08
located O 0 3.384102553738444e-09
in O 0 3.7840611200046226e-10
three O 0 3.0705460396518447e-10
different O 0 3.538729864693835e-10
regions O 0 1.4593705133236767e-09
of O 0 2.3306457208605025e-08
the O 0 2.3531494974804446e-08
APC B-Disease 0 2.8386402561864088e-08
gene O 0 1.3812035959404056e-09
( O 0 7.874065288682175e-10
1 O 0 2.5712861173587953e-08
) O 0 4.878424331167253e-10
at O 0 4.902287020769336e-09
the O 0 9.29087917711513e-10
5 O 0 1.2353271294784918e-08
end O 0 1.4834504291627582e-08
spanning O 0 5.255438040308036e-08
exons O 0 2.1754607004709214e-08
4 O 0 1.277419858780604e-08
and O 0 2.463815540476588e-10
5 O 0 5.861117813310557e-09
, O 0 5.415519144236214e-10
( O 0 2.912190211201704e-10
2 O 0 9.19524278941708e-09
) O 0 1.7745080405084934e-10
within O 0 2.1307959841010415e-09
exon O 0 8.617249136477767e-09
9 O 0 3.7339489722398866e-08
, O 0 4.3735504107189627e-10
and O 0 9.482387097747846e-10
( O 0 4.909358475302383e-10
3 O 0 2.4732582204478604e-08
) O 0 8.399407280812454e-10
at O 0 2.1665744753818217e-08
the O 0 3.172056173283977e-09
3 O 0 9.292641323099815e-08
distal O 0 2.791611279917561e-07
end O 0 1.2317585174059786e-07
of O 0 7.762027109947667e-08
the O 0 4.3696442020291215e-08
gene O 0 7.815165048441486e-08
. O 0 5.62959485250758e-07

Variability O 0 8.67578182806028e-06
in O 0 1.0246477444297852e-08
the O 0 5.5110955798909345e-09
number O 0 7.76911956990034e-09
of O 0 0.00010062989895232022
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 2.397457308234152e-07
most O 0 1.1196186339157421e-10
apparent O 0 1.0077654266638092e-09
in O 0 1.4208564880213714e-10
individuals O 0 8.463047103390853e-12
with O 0 5.850567946774632e-11
mutations O 0 1.9874353274218493e-09
in O 0 4.222312721680055e-09
region O 0 5.2354881319160995e-08
1 O 0 0.00020319802570156753
, O 0 5.169403038962628e-08
and O 0 1.030542307489668e-06
upper O 1 1.0
- O 1 1.0
gastrointestinal O 1 0.999893069267273
manifestations O 1 0.9999432563781738
were O 0 2.4701655831904645e-08
more O 0 2.5938784453671815e-10
severe O 0 8.710252785704142e-08
in O 0 5.766662702910708e-09
them O 0 1.696928286776256e-08
. O 0 3.87885563668533e-07

In O 0 2.6929223295724114e-08
individuals O 0 6.161016141703612e-10
with O 0 2.3171685403777786e-10
mutations O 0 8.415667607231114e-10
in O 0 4.134662334731587e-10
either O 0 2.8237669980057944e-09
region O 0 1.167823260317391e-08
2 O 0 7.031532049950329e-07
or O 0 7.047252559289063e-09
region O 0 6.583399159154624e-09
3 O 0 8.49158681148765e-08
, O 0 2.4449167690399065e-10
the O 0 6.615115677455208e-10
average O 0 5.128542590604468e-10
number O 0 2.647824459689474e-10
of O 0 3.6868854635940806e-09
adenomas B-Disease 0 1.5179900856310269e-06
tended O 0 1.4201968490112904e-08
to O 0 6.891645587536743e-10
be O 0 1.2209694366660528e-09
lower O 0 3.1720077675601033e-09
than O 0 4.1167104447570324e-11
those O 0 1.2290572205808648e-11
in O 0 1.0951830588246114e-11
individuals O 0 9.919961987264747e-13
with O 0 5.412395358284083e-12
mutations O 0 1.1558137086309372e-10
in O 0 9.454443478107422e-11
region O 0 6.119568740636794e-10
1 O 0 2.1900238067473765e-08
, O 0 3.114606489384997e-11
although O 0 1.4178407059528553e-10
age O 0 5.555484960950707e-09
at O 0 6.581591271981324e-09
diagnosis O 0 2.251308650613737e-08
was O 0 4.519558949311886e-09
similar O 0 6.445237676899751e-09
. O 0 1.7616383729546214e-07

In O 0 2.735653879426536e-06
all O 0 4.484621968003921e-06
AAPC B-Disease 1 1.0
kindreds O 0 3.934145934181288e-05
, O 0 8.55048210013365e-09
a O 0 4.7466497399284435e-09
predominance O 0 2.7386769829718105e-07
of O 0 3.0163930659909965e-06
right O 1 0.9999978542327881
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9997296929359436
rectal B-Disease 1 1.0
polyp I-Disease 1 0.6752511858940125
sparing O 0 2.2409042230719933e-06
was O 0 5.238959488451655e-07
observed O 0 5.118994863551052e-07
. O 0 8.756141482990643e-07

No O 0 1.8542019461165182e-05
desmoid B-Disease 0 0.4538778066635132
tumors I-Disease 1 1.0
were O 0 7.748684538455564e-08
found O 0 3.6601550679193906e-09
in O 0 2.1173698350196446e-09
these O 0 1.3061724146723463e-08
kindreds O 0 1.150309617514722e-05
. O 0 2.5604447273508413e-06

Our O 0 1.5716180996605544e-06
data O 0 4.030990652381661e-08
suggest O 0 8.027288167511415e-09
that O 0 6.064850843756631e-10
, O 0 1.193222742834621e-09
in O 0 1.820142614405995e-08
AAPC B-Disease 1 1.0
families O 0 3.11418757448223e-09
, O 0 4.404137887714654e-10
the O 0 6.264020968593798e-10
location O 0 8.12169442809818e-09
of O 0 1.9460129507820056e-08
the O 0 1.0275348927279992e-07
APC B-Disease 0 1.4319439287646674e-06
mutation O 0 1.017698707528325e-07
may O 0 1.3017719879826473e-07
partially O 0 6.827945639997779e-07
predict O 0 8.952836338949055e-08
specific O 0 5.256981694401475e-08
phenotypic O 0 2.6877922209678218e-05
expression O 0 2.195248953285045e-06
. O 0 2.438800720483414e-06

This O 0 1.0556200358280421e-08
should O 0 1.8935866208380503e-09
help O 0 4.2356684826216906e-10
in O 0 3.164277451173092e-10
the O 0 7.662815937337086e-10
design O 0 1.0801489480627424e-07
of O 0 4.814720000467787e-08
tailored O 0 2.3543081795196485e-07
clinical O 0 3.6817828004132025e-06
- O 0 6.245815029615187e-07
management O 0 2.7143331138290705e-08
protocols O 0 5.400608671379814e-08
in O 0 1.4101865508653333e-10
this O 0 4.310672999108256e-11
subset O 0 1.2714684860526404e-09
of O 0 5.482930776068429e-10
FAP B-Disease 0 1.8348449870586592e-08
patients O 0 2.8118607442451093e-10
. O 0 1.8261225864790731e-09
. O 0 1.538117686550322e-07

Wilms B-Disease 1 0.9825787544250488
' I-Disease 0 1.4371548786584754e-05
tumor I-Disease 0 6.972222763579339e-07
1 O 0 7.060116331558675e-07
and O 0 2.580685354303114e-08
Dax O 0 1.4130173440207727e-05
- O 0 1.1989546067070478e-07
1 O 0 7.079494679373965e-08
modulate O 0 2.651475838888473e-08
the O 0 5.15015008417663e-09
orphan O 0 8.075971003052018e-09
nuclear O 0 1.529115394305336e-07
receptor O 0 2.1934438620974106e-07
SF O 0 4.7824047214817256e-05
- O 0 1.3392050846050552e-07
1 O 0 2.0181524007512053e-08
in O 0 3.944043147630083e-10
sex O 0 1.8838419713063104e-09
- O 0 1.2080988431861783e-09
specific O 0 3.7550143550113546e-10
gene O 0 2.2264035060004517e-09
expression O 0 4.396027009079262e-08
. O 0 4.692027459896053e-07

Products O 0 1.2700108982244274e-06
of O 0 9.781455219126656e-07
steroidogenic O 0 1.8148588424082845e-05
factor O 0 5.152305107003485e-07
1 O 0 1.3664280231751036e-06
( O 0 1.0640577308151933e-08
SF O 0 1.665634408709593e-05
- O 0 1.7361040249852522e-07
1 O 0 9.894191776993466e-08
) O 0 1.269297444927986e-09
and O 0 9.249403021271974e-09
Wilms B-Disease 0 3.099354944424704e-05
tumor I-Disease 0 5.680195727109094e-07
1 O 0 2.486956191205536e-06
( O 0 1.4857695518344372e-08
WT1 O 0 1.5670503898945753e-06
) O 0 8.47733772069148e-10
genes O 0 2.825414069373977e-10
are O 0 4.221841626295131e-11
essential O 0 1.5883704351793426e-09
for O 0 6.086741666244677e-10
mammalian O 0 1.7932030971223867e-07
gonadogenesis O 0 4.1878274714690633e-07
prior O 0 4.709596623797552e-08
to O 0 6.745834557619901e-09
sexual O 0 7.924334255449139e-08
differentiation O 0 7.793104259690153e-07
. O 0 5.614319888991304e-07

In O 0 3.736079747795884e-07
males O 0 1.223762637891923e-07
, O 0 2.0285801483055366e-08
SF O 0 0.0003100317844655365
- O 0 3.885651949531166e-06
1 O 0 5.730618681809574e-07
participates O 0 7.4336350408543694e-09
in O 0 2.7731605900527256e-10
sexual O 0 1.1049575698862668e-09
development O 0 4.42664904731771e-10
by O 0 4.2105673114800624e-11
regulating O 0 1.3568649537276656e-09
expression O 0 1.1593668247655842e-09
of O 0 6.570929578231244e-09
the O 0 2.2178177516707365e-08
polypeptide O 0 4.416567378484615e-07
hormone O 0 9.219569108154246e-08
Mullerian O 0 2.743494405876845e-06
inhibiting O 0 1.361439103675366e-07
substance O 0 3.361117535405356e-07
( O 0 3.5536068310193514e-08
MIS O 0 2.2205360437510535e-05
) O 0 2.68908824097025e-08
. O 0 4.860661988459469e-07

Here O 0 1.374258545183693e-06
, O 0 8.770999926355216e-09
we O 0 3.438994422566566e-09
show O 0 1.2918188740940195e-09
that O 0 2.605149429513176e-09
WT1 O 0 4.003576759714633e-05
- O 0 1.114259703172138e-05
KTS O 0 0.00014082038251217455
isoforms O 0 2.4625646801723633e-06
associate O 0 6.893373551974946e-07
and O 0 1.2136562865805445e-08
synergize O 0 1.0983403626596555e-06
with O 0 1.4068030296243705e-08
SF O 0 0.0007115670014172792
- O 0 1.9753031210711924e-06
1 O 0 2.5713654849823797e-07
to O 0 9.027044889364788e-09
promote O 0 2.870979187719058e-07
MIS O 0 0.0018133344128727913
expression O 0 8.813966587695177e-07
. O 0 8.329741376655875e-07

In O 0 1.6211863851367525e-07
contrast O 0 2.344172571611125e-07
, O 0 4.7984105577825176e-08
WT1 O 0 8.055898797465488e-05
missense O 0 3.709948259711382e-06
mutations O 0 6.495964299801926e-08
, O 0 2.4730775205483724e-09
associated O 0 1.5969193967180217e-08
with O 0 2.4015560651236e-09
male B-Disease 0 1.7880940106351773e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 8.773737363299006e-07
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.508470740598568e-07
fail O 0 4.572528268909082e-06
to O 0 7.808594659763912e-08
synergize O 0 1.4386002476385329e-05
with O 0 2.2087127149461594e-07
SF O 1 0.9999997615814209
- O 1 0.9961332082748413
1 O 0 0.00014086213195696473
. O 0 1.2320256246312056e-06

Additionally O 0 2.1039327293692622e-06
, O 0 2.4330844894393522e-08
the O 0 1.8908556498331563e-08
X O 0 2.0632687665056437e-05
- O 0 4.2310002754675224e-06
linked O 0 2.485028289811453e-07
, O 0 1.2486229827857187e-09
candidate O 0 1.332803467590793e-08
dosage O 0 5.440261929834378e-07
- O 0 9.316848803564426e-08
sensitive O 0 5.70659572929344e-08
sex O 0 9.720859672768256e-09
- O 0 1.6779583944526166e-08
reversal O 0 2.9800771628174516e-08
gene O 0 5.468875574621279e-09
, O 0 6.077417680216968e-09
Dax O 0 2.071503877232317e-05
- O 0 5.173160957383516e-07
1 O 0 2.2647596154001803e-07
, O 0 4.720322799300902e-09
antagonizes O 0 4.669827546877059e-07
synergy O 0 2.344177119084634e-07
between O 0 1.330180481318166e-07
SF O 0 0.0011367276310920715
- O 0 9.642213854021975e-07
1 O 0 1.5679501075283042e-07
and O 0 5.536064495714754e-09
WT1 O 0 2.1093469513289165e-06
, O 0 6.911772820750173e-10
most O 0 1.0258708466048816e-10
likely O 0 8.487271441204314e-10
through O 0 8.58747656318215e-11
a O 0 2.2741888927590992e-10
direct O 0 1.3672384335805532e-09
interaction O 0 4.095406680448832e-08
with O 0 1.186636922057005e-08
SF O 1 0.9029750227928162
- O 0 0.00012426763714756817
1 O 0 4.645833087124629e-06
. O 0 4.6187997781999e-07

We O 0 4.0702659021008003e-07
propose O 0 2.4652663910273986e-07
that O 0 1.1586910098060343e-08
WT1 O 0 1.4414868019230198e-05
and O 0 2.204680527029268e-07
Dax O 0 0.00010241864947602153
- O 0 1.6870956187631236e-07
1 O 0 2.3893218070725197e-08
functionally O 0 3.032240236677808e-09
oppose O 0 3.0785798910137885e-10
each O 0 1.446693320694692e-10
other O 0 1.236414998162516e-10
in O 0 1.0129763694521898e-09
testis O 0 4.197995906451979e-07
development O 0 2.0479797413486267e-08
by O 0 2.9133861989549814e-09
modulating O 0 6.31820341823186e-07
SF O 0 0.000623682455625385
- O 0 2.891634039769997e-06
1 O 0 2.2387723674910376e-06
- O 0 3.492127405024803e-07
mediated O 0 8.722619782020047e-07
transactivation O 0 2.858869493138627e-06
. O 0 1.956538042691136e-08
. O 0 8.810993534780209e-08

A O 0 6.248649242479587e-06
mouse O 0 7.336936391766358e-07
model O 0 4.577994445753575e-07
for O 0 5.965200671198545e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9998412132263184
centre O 0 8.598810381954536e-05
mutations O 0 3.0119522875793336e-07
. O 0 5.23060236901074e-07

Imprinting O 0 8.679512393428013e-05
in O 0 2.6747915171654313e-07
the O 0 1.0955402984791363e-07
15q11 O 0 3.553394435584778e-06
- O 0 3.922868074823782e-07
q13 O 0 5.173516228751396e-07
region O 0 1.232956847729838e-08
involves O 0 4.732718217326237e-09
an O 0 5.048011453290258e-10
imprinting O 0 6.389639111148426e-07
centre O 0 2.5272662242059596e-05
( O 0 2.0043119164370182e-08
IC O 0 3.6474077660386683e-06
) O 0 1.5336808489863074e-09
, O 0 3.1089103513792793e-10
mapping O 0 9.655531929553263e-10
in O 0 8.899093267844549e-11
part O 0 1.3368528506418897e-10
to O 0 2.9822119773648126e-10
the O 0 2.5376327705828317e-09
promoter O 0 1.5235710293382e-07
and O 0 1.0329717525792148e-08
first O 0 2.8058741108338836e-08
exon O 0 2.863126553620532e-07
of O 0 2.870418143174902e-07
SNRPN O 0 0.0005906766164116561
. O 0 4.962260845786659e-06

Deletion O 0 4.9663326535664964e-06
of O 0 2.6728790203378594e-07
this O 0 1.684959549663745e-08
IC O 0 8.30677254270995e-06
abolishes O 0 1.2497706620706595e-06
local O 0 6.268508911944082e-08
paternally O 0 5.7598718683493644e-08
derived O 0 8.194699918639969e-10
gene O 0 5.640278244456454e-10
expression O 0 1.7662560303222108e-09
and O 0 1.274202188206175e-09
results O 0 3.811373261441986e-08
in O 0 2.6586019430396846e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9933844208717346
PWS B-Disease 1 1.0
) O 0 5.858510121470317e-07
. O 0 2.040407935055555e-06

We O 0 1.245691123585857e-07
have O 0 1.5596641755877272e-09
created O 0 2.7038218330943664e-09
two O 0 7.437006566135551e-10
deletion O 0 9.566993419696246e-09
mutations O 0 6.672039365440696e-09
in O 0 3.0333393574721867e-09
mice O 0 2.3674608939927566e-08
to O 0 9.200909367734766e-09
understand O 0 2.446963890179177e-06
PWS B-Disease 1 1.0
and O 0 1.468185928388266e-07
the O 0 1.476641475761653e-08
mechanism O 0 7.113604283404129e-08
of O 0 1.0468879096947603e-08
this O 0 2.9110422961053928e-09
IC O 0 1.177864305645926e-05
. O 0 5.751862204306235e-07

Mice O 0 4.595208520186134e-05
harbouring O 0 3.1329793273471296e-05
an O 0 2.73030487107917e-08
intragenic O 0 4.1141288420476485e-06
deletion O 0 2.833761527654133e-07
in O 0 2.5885531940161854e-08
Snrpn O 0 8.404346590396017e-05
are O 0 5.510531053687373e-08
phenotypically O 0 1.3135072549630422e-05
normal O 0 2.406014516509458e-07
, O 0 1.0037790598715901e-09
suggesting O 0 2.2318500381146578e-09
that O 0 1.4870410458556194e-10
mutations O 0 2.7457618401172112e-09
of O 0 5.674065217675661e-09
SNRPN O 0 1.3781485677100136e-06
are O 0 1.4124747205190857e-10
not O 0 8.988789573782796e-11
sufficient O 0 1.0761918467494525e-08
to O 0 7.841994609236735e-09
induce O 0 6.2560488913732115e-06
PWS B-Disease 1 1.0
. O 0 3.511686372803524e-05

Mice O 0 2.160561507480452e-06
with O 0 2.402719800898012e-09
a O 0 2.7886608577887273e-09
larger O 0 4.199687264616614e-09
deletion O 0 3.8903280596969125e-08
involving O 0 1.1046104475553875e-08
both O 0 5.256938884201645e-09
Snrpn O 0 2.739172941801371e-06
and O 0 6.3389626880905325e-09
the O 0 2.7946525094080243e-08
putative O 0 1.3114219655108172e-05
PWS O 1 1.0
- O 0 0.0005617677816189826
IC O 0 4.418758908286691e-05
lack O 0 2.4106768137244217e-07
expression O 0 1.4240919554708853e-08
of O 0 1.800615834213204e-08
the O 0 1.1119667853165538e-08
imprinted O 0 7.604524654425404e-08
genes O 0 1.9803714224053692e-08
Zfp127 O 0 3.389412540855119e-06
( O 0 1.6444339223653515e-08
mouse O 0 9.367185072051143e-08
homologue O 0 1.7385242472300888e-06
of O 0 2.1622504675633536e-07
ZNF127 O 0 0.0001927421399159357
) O 0 4.3393622917164976e-08
, O 0 3.926617964111756e-08
Ndn O 0 1.2745264029945247e-05
and O 0 6.184910716910963e-08
Ipw O 0 3.4776800021063536e-05
, O 0 9.672900702639708e-09
and O 0 2.890857331294683e-09
manifest O 0 5.8362658705846115e-08
several O 0 4.082131077609574e-09
phenotypes O 0 1.0395633580628783e-06
common O 0 2.7201465968573757e-07
to O 0 8.727479325898457e-07
PWS B-Disease 1 1.0
infants O 1 0.9999209642410278
. O 0 1.5502268070122227e-05

These O 0 6.351576331553588e-08
data O 0 1.524736070734889e-08
demonstrate O 0 3.3684413036638716e-09
that O 0 7.78193898209878e-11
both O 0 2.388471642689183e-10
the O 0 7.223140419121421e-10
position O 0 1.7873327706752207e-08
of O 0 3.947838500550915e-09
the O 0 2.402133381096405e-09
IC O 0 1.8581603455913864e-07
and O 0 2.4386623276306807e-10
its O 0 1.156550202829898e-10
role O 0 2.1403916139473012e-10
in O 0 1.308287922441309e-10
the O 0 1.7903369065042085e-10
coordinate O 0 6.066400715099007e-10
expression O 0 9.178328652659218e-10
of O 0 3.73202491132929e-09
genes O 0 2.805603527278322e-10
is O 0 3.450469424071123e-11
conserved O 0 7.683803038283088e-10
between O 0 3.1682105827712803e-09
mouse O 0 1.093644197425192e-08
and O 0 1.8881110563917503e-10
human O 0 2.253170844346286e-10
, O 0 2.2691010528874678e-11
and O 0 3.264527884128121e-11
indicate O 0 2.3020235717652326e-10
that O 0 6.433391319671244e-11
the O 0 1.7481875946856462e-09
mouse O 0 5.645985456936842e-09
is O 0 7.012879166268249e-11
a O 0 5.791987722769676e-11
suitable O 0 2.2196533500107307e-09
model O 0 2.90888846343762e-09
system O 0 8.870103540559171e-10
in O 0 1.9373559700941456e-10
which O 0 6.367274762997255e-11
to O 0 2.328510440019471e-10
investigate O 0 2.87525692144186e-09
the O 0 4.809979081699112e-10
molecular O 0 6.191624546403318e-09
mechanisms O 0 7.590363004794654e-09
of O 0 1.890234413437497e-09
imprinting O 0 1.497842561093421e-08
in O 0 1.7400730856209634e-10
this O 0 6.47282713539532e-11
region O 0 9.066589701234307e-10
of O 0 3.4739087162449778e-09
the O 0 2.4010431420862233e-09
genome O 0 1.170483043821946e-09
. O 0 3.1501696806657264e-09
. O 0 7.546194780161386e-08

Mutations O 0 4.1385411009287054e-07
of O 0 1.162600895554533e-07
the O 0 4.885040283397757e-08
ATM O 0 8.494735652675445e-07
gene O 0 1.0053584631464219e-08
detected O 0 1.9363346481782173e-08
in O 0 1.773203806010315e-08
Japanese O 1 0.9999963045120239
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.26656222343444824
: O 0 1.9109223092783623e-09
possible O 0 5.2356452506785445e-09
preponderance O 0 1.0987252352379073e-07
of O 0 6.95748880730207e-09
the O 0 3.1203415407077273e-09
two O 0 2.4004112031406066e-09
founder O 0 6.444625455515052e-08
mutations O 0 2.0198005046268008e-08
4612del165 O 0 1.2754643421430956e-06
and O 0 8.701834275370857e-08
7883del5 O 0 9.63818183663534e-06
. O 0 3.896101134159835e-06

The O 0 2.2908186565473443e-06
ATM O 0 0.0003127139061689377
( O 0 1.0212439747192548e-06
A O 1 1.0
- O 1 1.0
T O 1 1.0
, O 0 5.554234849824979e-09
mutated O 0 1.725676601616044e-09
) O 0 1.651980219286031e-10
gene O 0 5.128806823684329e-10
on O 0 7.643857102834772e-09
human O 0 1.9035605092199148e-08
chromosome O 0 2.3458498787931603e-07
11q22 O 0 6.87482724970323e-06
. O 0 1.8515723922973848e-06

3 O 0 5.056013378634816e-06
has O 0 5.031864258597807e-09
recently O 0 7.501675725052337e-09
been O 0 4.5150938543514485e-10
identified O 0 6.653887996144192e-10
as O 0 1.4557251237778956e-10
the O 0 2.9060034933969803e-10
gene O 0 3.138665161106502e-10
responsible O 0 5.533844493754714e-10
for O 0 1.1582986653158045e-10
the O 0 8.61235172067154e-09
human O 1 0.899193525314331
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.068705028563272e-07
. O 0 1.0157222050111159e-06

In O 0 4.1821039076239686e-08
order O 0 9.051182026098559e-09
to O 0 8.07652111856072e-10
define O 0 9.310325843614464e-09
the O 0 8.736266710052121e-10
types O 0 1.591631360042811e-08
of O 0 2.894346948778548e-07
disease O 0 0.10752008110284805
- O 0 2.220765509264311e-06
causing O 0 3.585070999179152e-06
ATM O 0 0.0001076269181794487
mutations O 0 4.99373697948613e-08
in O 0 2.9020392755541025e-09
Japanese O 0 8.18174157757312e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.5334359559915356e-08
as O 0 2.3869278775734415e-10
well O 0 7.145142116860015e-11
as O 0 2.5798448446967548e-11
to O 0 4.173906012483464e-11
look O 0 7.36706584625324e-10
for O 0 1.1646211772742276e-10
possible O 0 1.0043464726550155e-08
mutational O 0 4.952262884216907e-07
hotspots O 0 1.5151076127040142e-07
, O 0 2.117644504195937e-09
reverse O 0 5.491790844303068e-08
- O 0 2.2960708889741e-08
transcribed O 0 4.26850110812893e-09
RNA O 0 4.908431994188334e-10
derived O 0 1.409186239920146e-10
from O 0 1.0361675406578286e-10
ten O 0 3.918476210174049e-09
patients O 0 1.4762795153000496e-10
belonging O 0 1.6348414844102876e-09
to O 0 7.058145179428266e-10
eight O 0 1.1837117952495646e-08
unrelated O 0 6.393399587523163e-08
Japanese O 0 7.422158432746073e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 1.0697536190207302e-08
was O 0 1.2116071701484543e-08
analyzed O 0 2.075462024464514e-09
for O 0 2.4225139255706907e-11
mutations O 0 8.383589655824863e-11
by O 0 2.6493486224299367e-11
the O 0 3.2880004274815633e-10
restriction O 0 9.61554058598324e-10
endonuclease O 0 1.465421917146159e-07
fingerprinting O 0 4.2318450965694865e-08
method O 0 5.350533172077121e-08
. O 0 1.8099009935212962e-07

As O 0 6.46827018613294e-08
has O 0 7.761146170182087e-10
been O 0 2.629344519888832e-10
reported O 0 1.9581676558022565e-10
by O 0 1.9560575381660783e-11
others O 0 3.0251448568385797e-10
, O 0 1.8539239587944678e-10
mutations O 0 3.723831798474464e-10
that O 0 5.920616080734575e-11
lead O 0 1.3539256382699705e-09
to O 0 3.980160201422223e-09
exon O 0 7.394910994662496e-07
skipping O 0 7.925238492134667e-07
or O 0 6.575972122391249e-08
premature O 0 2.2764616858239606e-07
protein O 0 3.1518901266736066e-08
truncation O 0 9.63372144724417e-07
were O 0 2.6761380667039703e-08
also O 0 1.6951806625087329e-09
predominant O 0 9.989096838580735e-08
in O 0 7.113167388439479e-09
our O 0 5.917588197235091e-08
mutants O 0 1.1831903066195082e-06
. O 0 2.2871046212458168e-07

Six O 0 4.046467267926346e-07
different O 0 5.8324127749642685e-09
mutations O 0 4.845931655950153e-09
were O 0 2.629566564493757e-09
identified O 0 2.037482405015112e-09
on O 0 6.1648162130722994e-09
12 O 0 2.83142131962677e-08
of O 0 9.47246725502282e-09
the O 0 1.592615284096155e-08
16 O 0 5.921088472859992e-07
alleles O 0 1.2166111673650448e-06
examined O 0 7.822106454113964e-06
. O 0 3.5041882711084327e-06

Four O 0 2.9058466566311836e-07
were O 0 1.5632179994895523e-08
deletions O 0 6.332741975256795e-08
involving O 0 2.1399531036081498e-08
a O 0 3.558488836929996e-09
loss O 0 8.396627748652463e-08
of O 0 2.5322870556010457e-07
a O 0 3.279310334391994e-08
single O 0 4.7813536241392285e-08
exon O 0 1.2355815215414623e-06
exon O 0 9.130353078035114e-07
7 O 0 2.601894266263116e-06
, O 0 2.889139061323931e-08
exon O 0 2.1171574360323575e-07
16 O 0 3.2445944952996797e-07
, O 0 1.4363950917584134e-08
exon O 0 3.1270971589947294e-07
33 O 0 2.0113780863084685e-07
or O 0 3.943979365317318e-08
exon O 0 1.272262011298153e-06
35 O 0 1.0105599130838527e-06
. O 0 1.0160661076952238e-06

The O 0 1.2533305948636553e-07
others O 0 1.9307952570102316e-08
were O 0 1.736447607925129e-08
minute O 0 1.2707641872111708e-07
deletions O 0 5.2447230558527735e-08
, O 0 3.727130604147533e-09
4649delA O 0 2.3931536929922004e-07
in O 0 8.37851477086815e-09
exon O 0 1.853120323858093e-07
33 O 0 6.296968990682217e-08
and O 0 8.50649684025484e-09
7883del5 O 0 5.142182430972753e-07
in O 0 3.3838844615274866e-08
exon O 0 1.509006438027427e-06
55 O 0 7.82860638537386e-07
. O 0 1.1794195415859576e-06

The O 0 5.443396275950363e-07
mutations O 0 2.2013043121660303e-07
4612del165 O 0 5.721777256439964e-07
and O 0 4.527582753155457e-09
7883del5 O 0 1.7288277831539745e-07
were O 0 1.9944339513244813e-09
found O 0 3.2346114675618765e-10
in O 0 5.038774258947498e-11
more O 0 2.0631416713934314e-11
than O 0 3.569368065003964e-11
two O 0 9.98927329742827e-11
unrelated O 0 6.474089597752197e-10
families O 0 1.9934467271331968e-11
; O 0 5.609666203776342e-11
44 O 0 5.961459104142364e-10
% O 0 2.492073769566616e-10
( O 0 3.662674330495719e-10
7 O 0 8.00356474428554e-08
of O 0 4.307079493059973e-08
16 O 0 1.464399161932306e-07
) O 0 3.937939141440694e-10
of O 0 1.3164361822859405e-09
the O 0 1.288558260092998e-09
mutant O 0 8.207421409167637e-09
alleles O 0 3.2409677164224604e-09
had O 0 9.22089793409242e-10
one O 0 1.8454990313720998e-10
of O 0 9.420498825463142e-10
the O 0 5.128466984416491e-09
two O 0 1.5861159496921573e-08
mutations O 0 3.5556755051402433e-07
. O 0 1.4221492392607615e-06

The O 0 5.871481221220165e-07
4612del165 O 0 1.0028170436271466e-06
mutations O 0 7.535274626491173e-09
in O 0 2.8697380582975995e-10
three O 0 1.1579187608745656e-10
different O 0 5.3299496760583764e-11
families O 0 2.4483783056528097e-11
were O 0 2.1393713189876706e-10
all O 0 1.3923411035232647e-10
ascribed O 0 6.853229539416361e-09
to O 0 4.3616124600909245e-10
the O 0 2.3878035104729634e-09
same O 0 9.918997179170219e-09
T O 0 8.355384011338174e-07
- O 0 3.7296112509466184e-07
- O 0 9.726333871640236e-08
> O 0 1.729605259015443e-08
A O 0 1.4153663796534488e-09
substitution O 0 1.91981430752719e-09
at O 0 2.6050650525633046e-09
the O 0 3.0450009180782445e-10
splice O 0 4.101689654589791e-09
donor O 0 1.374747815585664e-10
site O 0 2.422239075983157e-09
in O 0 2.4014279453865583e-09
intron O 0 4.402962474614469e-07
33 O 0 2.378782482992392e-06
. O 0 4.020209871669067e-06

Microsatellite O 0 0.00015314185293391347
genotyping O 0 2.5391906092409045e-05
around O 0 2.3957386474648956e-07
the O 0 3.0720485710844514e-08
ATM O 0 5.304897285896004e-07
locus O 0 1.0033971165057665e-07
also O 0 1.4183336727313645e-09
indicated O 0 1.2715558606046784e-09
that O 0 3.467464509965268e-11
a O 0 1.4809781179181414e-10
common O 0 8.510030458097617e-10
haplotype O 0 2.7972710370249843e-08
was O 0 1.0753424817266932e-08
shared O 0 8.272593721159183e-10
by O 0 7.70951913420248e-11
the O 0 5.868608932146913e-10
mutant O 0 1.1688149115229862e-08
alleles O 0 5.534649627492172e-09
in O 0 1.7313603883906126e-09
both O 0 1.1497616192457372e-08
mutations O 0 4.040470855670719e-07
. O 0 9.57228849074454e-07

This O 0 3.166242734664593e-08
suggests O 0 1.369227664582695e-08
that O 0 2.2528957865919352e-10
these O 0 6.407139818698226e-10
two O 0 7.653773725913027e-10
founder O 0 1.0593212529386165e-08
mutations O 0 1.3252638986216425e-09
may O 0 8.326256906165952e-10
be O 0 1.1767148366814695e-09
predominant O 0 1.77394117173435e-08
among O 0 9.384345522889248e-10
Japanese O 0 5.647539680353475e-08
ATM O 0 6.708799560328771e-07
mutant O 0 7.562619543932669e-07
alleles O 0 1.0372777978773229e-06
. O 0 9.522056529931433e-07

W474C O 0 7.926968828542158e-05
amino O 0 9.681724577603745e-07
acid O 0 4.510037143745649e-08
substitution O 0 5.215216347664864e-08
affects O 0 1.0099634017990411e-08
early O 0 9.63916058083214e-09
processing O 0 4.116769591888669e-09
of O 0 1.3269737531018677e-09
the O 0 1.1001691779810585e-09
alpha O 0 1.7324051526657058e-08
- O 0 1.2402111559950413e-09
subunit O 0 4.251875296290564e-09
of O 0 2.263034870608749e-09
beta O 0 8.860794764586899e-08
- O 0 1.3738789661488227e-08
hexosaminidase O 0 5.006631198511968e-08
A O 0 1.9376784621272236e-09
and O 0 1.5504303396696173e-10
is O 0 6.128045293429807e-11
associated O 0 4.172079126618655e-09
with O 0 3.1934002109323956e-09
subacute O 0 0.0001502917002653703
G B-Disease 0 0.00025769666535779834
( I-Disease 0 1.0910527237228962e-07
M2 I-Disease 0 9.129777026828378e-06
) I-Disease 0 9.202738482372297e-08
gangliosidosis I-Disease 0 1.4801805264141876e-05
. O 0 2.9135658223822247e-06

Mutations O 0 7.184618766586937e-07
in O 0 4.092681393785824e-08
the O 0 7.140234004054946e-08
HEXA O 0 1.436341062799329e-05
gene O 0 8.538291851323265e-09
, O 0 2.035035473468838e-09
encoding O 0 6.594232271339706e-09
the O 0 4.653305296642429e-09
alpha O 0 2.023070244661085e-08
- O 0 1.7759919090920562e-09
subunit O 0 2.492707151802165e-09
of O 0 3.269740700417856e-09
beta O 0 1.310362591766534e-07
- O 0 4.8563709498239405e-08
hexosaminidase O 0 3.6634403954849404e-07
A O 0 5.659919111167255e-08
( O 0 1.7856555123429985e-09
Hex O 0 1.0174245517191594e-06
A O 0 2.545598931646964e-08
) O 0 2.5155219574024557e-10
, O 0 1.354426015787169e-10
that O 0 1.472516830691717e-10
abolish O 0 1.268369373974565e-07
Hex O 0 2.8338420179352397e-06
A O 0 5.2557382446138945e-08
enzyme O 0 4.857621860310246e-08
activity O 0 1.4405742376766284e-07
cause O 0 0.0007802072213962674
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.708339929493377e-06
TSD B-Disease 1 0.9763176441192627
) O 0 6.8995276159000696e-09
, O 0 1.214827571871524e-09
the O 0 7.9819590936836e-09
fatal O 0 4.887192972091725e-06
infantile B-Disease 0 2.7031223908124957e-06
form I-Disease 0 7.669607526850086e-08
of I-Disease 0 2.9760847610305063e-05
G I-Disease 0 0.0002269665419589728
( I-Disease 0 2.68306354911374e-08
M2 I-Disease 0 1.1279748832748737e-06
) I-Disease 0 1.3809488663696357e-08
gangliosidosis I-Disease 0 9.455472991248826e-07
, I-Disease 0 4.419986154857725e-09
Type I-Disease 0 3.083564195094368e-07
1 I-Disease 0 3.4333252187934704e-06
. O 0 8.596368843427626e-07

Less O 0 7.364202247117646e-06
severe O 1 0.9994841814041138
, O 0 4.2493402929721924e-07
subacute O 1 0.9999575614929199
( O 0 5.031631644669687e-07
juvenile O 0 0.0016225994331762195
- O 0 3.145844311802648e-05
onset O 1 0.9951943755149841
) O 0 7.022740788897863e-08
and O 0 4.154865393957152e-07
chronic O 1 1.0
( O 0 1.1452123089839006e-06
adult O 0 0.0002187397622037679
- O 0 7.545411790488288e-06
onset O 0 0.0010542233940213919
) O 0 1.9139756446406864e-09
variants O 0 4.648570595122692e-08
are O 0 3.095626255333883e-10
characterized O 0 7.09782232988232e-10
by O 0 8.357693009886091e-11
a O 0 3.7767497462759536e-10
broad O 0 8.22473733563811e-09
spectrum O 0 2.7578980876796777e-08
of O 0 1.1988505743687483e-09
clinical O 0 8.544922991404746e-09
manifestations O 0 1.2945870153657779e-08
and O 0 2.6082061510557253e-10
are O 0 6.659166273959016e-11
associated O 0 7.823554581953829e-10
with O 0 2.0499356379044542e-10
residual O 0 7.191569579845236e-07
levels O 0 8.124081887217471e-07
of O 0 9.101976843339799e-07
Hex O 0 4.181404801784083e-05
A O 0 1.5394500962884194e-07
enzyme O 0 3.993401165303112e-08
activity O 0 1.4499522649202845e-07
. O 0 1.3095205986246583e-07

We O 0 7.950674785206502e-07
identified O 0 2.125301818978187e-07
a O 0 2.890814876366221e-08
1422 O 0 1.485625125496881e-05
G O 0 3.591497716115555e-06
- O 0 3.5718296658160398e-06
- O 0 1.255948859579803e-06
> O 0 4.37056513646894e-07
C O 0 3.2528328119951766e-07
( O 0 1.0280555295949512e-09
amino O 0 1.2708454288912208e-09
acid O 0 3.78624132046923e-10
W474C O 0 3.725624253547721e-09
) O 0 1.88887360613732e-11
substitution O 0 1.0475619677263737e-10
in O 0 4.878719650491803e-11
the O 0 1.377109815070554e-10
first O 0 2.616048211390165e-10
position O 0 3.908473988900596e-09
of O 0 4.145909393571401e-09
exon O 0 2.9437126514153533e-08
13 O 0 3.155674122012897e-08
of O 0 7.913761379541029e-08
HEXA O 0 0.00025878692395053804
of O 0 3.5423471445028554e-07
a O 0 4.7753385246096514e-08
non O 0 2.440685420879163e-06
- O 0 1.6019399708966375e-06
Jewish O 0 1.8459097361755994e-07
proband O 0 2.9409928174572997e-05
who O 0 1.463588894523582e-08
manifested O 0 3.8285648429337016e-07
a O 0 1.949267058876103e-08
subacute O 0 6.165334070828976e-06
variant O 0 6.101862709328998e-06
of O 0 0.41837671399116516
G B-Disease 1 0.9979514479637146
( I-Disease 0 1.8587770966860262e-07
M2 I-Disease 0 6.580641638720408e-06
) I-Disease 0 6.719063350146826e-08
gangliosidosis I-Disease 0 2.2614176486968063e-05
. O 0 1.8330404145672219e-06

On O 0 3.9264118640858214e-06
the O 0 9.335045803027242e-08
second O 0 1.2851280928316555e-07
maternally O 0 1.4514411077470868e-06
inherited O 0 1.2927606576340622e-06
allele O 0 1.0755603341294773e-07
, O 0 2.4615949278938842e-09
we O 0 1.8602867024597458e-09
identified O 0 4.688352817083796e-09
the O 0 4.576219403418236e-09
common O 0 9.063613106263801e-06
infantile O 1 0.9999991655349731
disease O 1 0.9930210709571838
- O 0 0.0003751488111447543
causing O 0 0.00041606847662478685
4 O 1 0.9945969581604004
- O 0 7.888329855632037e-05
bp O 0 4.440395571236877e-07
insertion O 0 4.854852164726253e-08
, O 0 1.608087885074383e-08
+ O 0 5.298824703459104e-07
TATC O 0 2.9129407266736962e-05
1278 O 0 1.3958924682810903e-05
, O 0 1.0814432016559294e-08
in O 0 1.817006811677402e-08
exon O 0 1.3178686231185566e-06
11 O 0 1.3222709185356507e-06
. O 0 1.2233581401233096e-06

Pulse O 0 0.0002478694077581167
- O 0 1.041670111590065e-05
chase O 0 1.2423016926277342e-07
analysis O 0 5.664128277516056e-09
using O 0 8.443809207392405e-09
proband O 0 1.6293281532853143e-06
fibroblasts O 0 2.3416119176999928e-07
revealed O 0 4.24092760908934e-08
that O 0 2.6923138718437656e-10
the O 0 1.4011413140835316e-09
W474C O 0 2.2259206033936607e-08
- O 0 1.366993296336716e-09
containing O 0 5.218096510439807e-10
alpha O 0 9.052252281094297e-09
- O 0 1.194133458781721e-09
subunit O 0 2.889633643476941e-09
precursor O 0 3.685296512401237e-09
was O 0 2.6036941491724974e-09
normally O 0 1.7714103794919112e-10
synthesized O 0 2.0467123829082112e-10
, O 0 2.8732091358896206e-11
but O 0 4.640856102189339e-11
not O 0 1.4085117794326862e-10
phosphorylated O 0 2.557473521846987e-08
or O 0 9.900413822094833e-10
secreted O 0 7.65974672578551e-10
, O 0 3.063070352915531e-10
and O 0 8.6081930472659e-10
the O 0 1.834813367906918e-08
mature O 0 7.550700047431746e-07
lysosomal O 0 1.889478312477877e-06
alpha O 0 6.66877838284563e-07
- O 0 1.1670899624505182e-07
subunit O 0 1.0229219782331711e-07
was O 0 2.4798808340165124e-08
not O 0 2.4090065497972546e-09
detected O 0 1.1193277060783657e-07
. O 0 3.423150189973967e-07

When O 0 2.0069863637672825e-07
the O 0 2.3071248023143198e-08
W474C O 0 1.3071971238787228e-07
- O 0 3.939308435008115e-09
containing O 0 1.6968175753362402e-09
alpha O 0 3.934054504384221e-08
- O 0 7.008687408216474e-09
subunit O 0 3.4289751482674546e-08
was O 0 3.9667252593744706e-08
transiently O 0 3.3432627333240816e-07
co O 0 1.0086047552704258e-07
- O 0 1.123185366935786e-08
expressed O 0 1.0274516792918575e-09
with O 0 2.1520420168119614e-10
the O 0 2.1388257831489454e-09
beta O 0 2.563710488345805e-08
- O 0 1.1592276027982962e-09
subunit O 0 2.125807085917586e-09
to O 0 3.548049909429807e-10
produce O 0 5.981621864492581e-09
Hex O 0 3.2577052024862496e-06
A O 0 1.47921866755496e-07
( O 0 2.7710789218815535e-09
alphabeta O 0 2.5449878648942104e-07
) O 0 1.2094176771171306e-09
in O 0 4.069708126053229e-09
COS O 0 7.85482427545503e-07
- O 0 2.23694897272253e-07
7 O 0 9.351690266612422e-08
cells O 0 1.4273163762013041e-09
, O 0 1.4407701420804386e-10
the O 0 9.060435179897297e-10
mature O 0 8.539920770544995e-09
alpha O 0 1.2134618643244721e-08
- O 0 1.6543713066141663e-09
subunit O 0 3.4269462823033336e-09
was O 0 1.7151007281057673e-09
present O 0 1.622984663329774e-10
, O 0 2.6659802837558644e-11
but O 0 2.213191435673778e-11
its O 0 3.787423846768334e-11
level O 0 1.5621271387544766e-08
was O 0 2.5572233219861573e-09
much O 0 2.272281113269159e-10
lower O 0 8.602907275445659e-10
than O 0 3.115610547332892e-11
that O 0 9.912060755512542e-12
from O 0 4.16106801792715e-11
normal O 0 3.124915659569183e-09
alpha O 0 2.4405585108411287e-08
- O 0 3.611343002418721e-09
subunit O 0 9.02064201113717e-09
transfections O 0 3.3647953756599236e-08
, O 0 4.650337059874943e-11
although O 0 8.965503339730674e-11
higher O 0 5.782399004061745e-10
than O 0 1.6752760637062103e-11
in O 0 4.402212275267381e-11
those O 0 6.877053787546217e-11
cells O 0 3.830514516689476e-10
transfected O 0 4.604297387800216e-09
with O 0 2.3198826540338224e-11
an O 0 3.886317309631515e-11
alpha O 0 1.5586390844646303e-08
- O 0 6.603230850998898e-09
subunit O 0 1.9605613132966937e-08
associated O 0 4.216592941475028e-08
with O 0 2.2207386152217623e-08
infantile O 0 0.06005824729800224
TSD B-Disease 0 0.0029886839911341667
. O 0 2.2455785710917553e-06

Furthermore O 0 3.565961606000201e-07
, O 0 3.408173299135342e-09
the O 0 2.593296022368463e-09
precursor O 0 1.3022072309354371e-08
level O 0 5.176249828764412e-08
of O 0 4.281498267033612e-09
the O 0 2.329808790335619e-09
W474C O 0 6.470960300930528e-08
alpha O 0 7.059686168986445e-08
- O 0 5.582773354717574e-09
subunit O 0 4.837545919400554e-09
was O 0 1.3033445434018631e-09
found O 0 8.710340088091684e-11
to O 0 5.1988607863151515e-11
accumulate O 0 4.53779958053957e-10
in O 0 1.2991493991698633e-10
comparison O 0 4.6174783441266243e-10
to O 0 4.436927769635446e-10
the O 0 5.110226908300319e-09
normal O 0 3.8856043715895794e-08
alpha O 0 1.692889810556153e-07
- O 0 1.3083989891526926e-08
subunit O 0 4.262319919234869e-08
precursor O 0 3.070162435392376e-08
levels O 0 1.00718594353566e-07
. O 0 6.216121306579225e-08

We O 0 5.284476856104448e-07
conclude O 0 7.505871622015547e-07
that O 0 2.6093518457059872e-09
the O 0 1.3821345845599353e-08
1422 O 0 1.134819831349887e-05
G O 0 1.952188085851958e-06
- O 0 1.7546611843499704e-06
- O 0 7.506129691137176e-07
> O 0 1.7443639421799162e-07
C O 0 1.3146433275323943e-07
mutation O 0 8.213196234230224e-10
is O 0 2.619431928307936e-11
the O 0 7.406907032159182e-11
cause O 0 2.403214960366995e-09
of O 0 3.2736487298734573e-08
Hex B-Disease 0 0.022055838257074356
A I-Disease 0 0.0003002754820045084
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.4424875394734045e-08
the O 0 8.460901312901115e-08
proband O 0 5.8093278312298935e-06
. O 0 5.430201213130204e-07

The O 0 2.2344030981003016e-07
resulting O 0 2.1334248856419435e-07
W474C O 0 7.280089562300418e-07
substitution O 0 8.68261835762496e-08
clearly O 0 2.8963116349700613e-08
interferes O 0 5.517048151659765e-09
with O 0 8.455489641789882e-10
alpha O 0 8.555771557894332e-08
- O 0 8.469003276445619e-09
subunit O 0 8.040435872658236e-09
processing O 0 1.8505121879286435e-09
, O 0 1.0364022140496587e-11
but O 0 6.030021967862176e-12
because O 0 9.239690609841311e-12
the O 0 2.2770871993538222e-11
base O 0 3.112624602508163e-10
substitution O 0 3.0105606896313475e-09
falls O 0 1.1299754909543935e-08
at O 0 1.2599297605220272e-08
the O 0 8.818635266472086e-10
first O 0 1.4289072147732895e-09
position O 0 2.0669180145205246e-08
of O 0 2.7166846550130686e-08
exon O 0 2.672460936992138e-07
13 O 0 1.2900584067665477e-07
, O 0 5.087741783427191e-09
aberrant O 0 6.321398160480385e-08
splicing O 0 9.22741492104251e-08
may O 0 2.094675544128677e-08
also O 0 2.1572872377362273e-09
contribute O 0 6.889572468082861e-09
to O 0 8.064703571619702e-09
Hex B-Disease 1 0.5949715971946716
A I-Disease 0 2.4934606699389406e-05
deficiency I-Disease 0 9.7553689556662e-05
in O 0 9.79809122725328e-09
this O 0 3.1145857004588606e-09
proband O 0 4.4413440036805696e-07
. O 0 1.2579462804751529e-08
. O 0 9.998914407560733e-08

Two O 0 2.782953458790871e-07
frequent O 0 2.032058290524219e-07
missense O 0 2.5946017558453605e-05
mutations O 0 1.1356122740835417e-05
in O 0 1.3346600098884664e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0008738671313039958

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.845337571168784e-07
an O 0 4.872910267295083e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 6.820734483881097e-07
by O 0 7.172618610162829e-10
early O 0 8.740316843613982e-06
childhood O 1 0.9999995231628418
deafness B-Disease 1 1.0
and O 1 0.9997887015342712
goiter B-Disease 1 1.0
. O 0 0.02934911660850048

A O 0 4.293702033919544e-07
century O 0 6.824977560881962e-08
after O 0 3.0161817488050247e-09
its O 0 9.155280006334365e-11
recognition O 0 9.557432623097384e-10
as O 0 1.4150154381553648e-09
a O 0 2.8829063580815273e-09
syndrome O 0 1.8583016014872555e-08
by O 0 4.727591651487728e-10
Vaughan O 0 9.478241622673522e-07
Pendred O 0 9.617751857149415e-06
, O 0 1.6986372308736009e-09
the O 0 6.800182639210561e-09
disease O 0 4.596481417706855e-08
gene O 0 6.30120799982592e-09
( O 0 1.5391851349022545e-08
PDS O 0 9.341131772089284e-06
) O 0 1.0074238332435925e-08
was O 0 9.72351443806474e-08
mapped O 0 4.119379326539274e-08
to O 0 1.4689137017853682e-08
chromosome O 0 1.2041275567753473e-06
7q22 O 0 2.7296124244458042e-05
- O 0 8.358438935829327e-05
q31 O 0 5.2309802413219586e-05
. O 0 3.839475539280102e-06

1 O 0 7.706141332164407e-06
and O 0 2.4561558120694826e-08
, O 0 2.8029947252150578e-09
recently O 0 5.975578254435732e-09
, O 0 3.5648659024722917e-10
found O 0 3.407092385998567e-10
to O 0 9.70197922001148e-10
encode O 0 3.6781216294912156e-08
a O 0 3.562578498872426e-08
putative O 0 3.9985752664506435e-06
sulfate O 0 1.1310716217849404e-05
transporter O 0 7.328746869461611e-05
. O 0 3.7640643313352484e-06

We O 0 1.0882884993179687e-07
performed O 0 2.5649953272477433e-09
mutation O 0 5.952539017251013e-10
analysis O 0 1.9472894408067987e-09
of O 0 2.1902106794868814e-09
the O 0 4.5703054674106625e-09
PDS B-Disease 0 6.673046755167888e-07
gene O 0 1.8716828087406157e-09
in O 0 4.768234695973206e-10
patients O 0 2.3871601917413443e-10
from O 0 2.0429603841964905e-10
14 O 0 3.030651640756332e-08
Pendred B-Disease 0 6.834264354438346e-07
families O 0 2.937433352112606e-10
originating O 0 3.186389485598795e-10
from O 0 2.8076271862964575e-10
seven O 0 2.126914200317742e-09
countries O 0 3.2490868329126954e-10
and O 0 1.3440607515846636e-09
identified O 0 2.1910013359160985e-08
all O 0 8.787878869043197e-09
mutations O 0 2.0197165895297076e-07
. O 0 5.355153689379222e-07

The O 0 1.4982830975895922e-07
mutations O 0 2.987498248785414e-08
include O 0 2.0692010327394428e-09
three O 0 2.1112602777151324e-09
single O 0 1.3296542755725227e-09
base O 0 1.951357653240393e-08
deletions O 0 4.8281833642249694e-08
, O 0 4.094311112368132e-09
one O 0 2.745667693204723e-09
splice O 0 1.847940751531496e-07
site O 0 1.1474175387604646e-08
mutation O 0 7.657690481721602e-09
and O 0 1.88790050259513e-08
10 O 0 2.404592578386655e-07
missense O 0 8.949556104198564e-06
mutations O 0 6.55127405480016e-06
. O 0 8.766487553657498e-06

One O 0 1.1068533467550878e-06
missense O 0 6.837381988589186e-06
mutation O 0 8.314933097608446e-08
( O 0 1.0815091044946712e-08
L236P O 0 3.0952637075642997e-07
) O 0 1.1837495428324019e-09
was O 0 2.747338578856784e-09
found O 0 2.202336785162018e-10
in O 0 1.6244154632527597e-10
a O 0 4.742186088257938e-10
homozygous O 0 2.575643698321528e-09
state O 0 7.854355499326005e-10
in O 0 9.370394460361808e-10
two O 0 4.3536356741924465e-09
consanguineous O 0 8.434201390628004e-07
families O 0 1.0002472183856526e-09
and O 0 6.423903631258554e-10
in O 0 7.649789690589159e-10
a O 0 1.2648554426064607e-09
heterozygous O 0 4.89380402868278e-09
state O 0 2.0937398481635228e-09
in O 0 2.6350892579074525e-09
five O 0 4.226938354889853e-09
additional O 0 7.446889771500764e-09
non O 0 2.5170227218040964e-06
- O 0 1.1224828085687477e-05
consanguineous O 0 1.8889788407250308e-05
families O 0 3.9051819555879774e-08
. O 0 3.5502137052390026e-07

Another O 0 1.1284063248240273e-06
missense O 0 8.244181117333937e-06
mutation O 0 1.24117420341463e-07
( O 0 1.2966604678865679e-08
T416P O 0 2.1771673175408068e-07
) O 0 1.6016864501366967e-09
was O 0 5.206606257246449e-09
found O 0 2.0620058438503008e-10
in O 0 2.1767949942574916e-10
a O 0 3.605944987050691e-10
homozygous O 0 1.4034602369150662e-09
state O 0 5.946830805569903e-10
in O 0 1.0572456243806982e-09
one O 0 1.1875170846664673e-09
family O 0 3.8009587144394175e-10
and O 0 5.613361997447441e-10
in O 0 6.207383496104057e-10
a O 0 1.204907174034986e-09
heterozygous O 0 9.78979741717012e-09
state O 0 2.724908521045677e-09
in O 0 1.210491440417627e-08
four O 0 7.630298881622366e-08
families O 0 2.487204042722624e-08
. O 0 7.217830102490552e-07

Pendred B-Disease 0 0.0004918099730275571
patients O 0 1.6276418079996802e-07
in O 0 1.3107994689676161e-08
three O 0 1.198279786507328e-08
non O 0 6.677490205220238e-07
- O 0 1.3860676517651882e-06
consanguineous O 0 1.5194717661870527e-06
families O 0 3.507998058704942e-10
were O 0 5.351610266046691e-10
shown O 0 8.971678955305151e-11
to O 0 1.1959243317871682e-10
be O 0 6.9421612902687e-10
compound O 0 1.5131359276665535e-08
heterozygotes O 0 8.250839300671942e-08
for O 0 6.043133549127333e-09
L236P O 0 1.302813075199083e-06
and O 0 5.5476206739513145e-08
T416P O 0 6.539190053445054e-06
. O 0 1.2475354651542148e-06

In O 0 6.962349630157405e-08
total O 0 5.2807358486006706e-09
, O 0 4.6332521153047423e-10
one O 0 9.851375964986531e-11
or O 0 5.467972602479776e-11
both O 0 3.4151844546803645e-11
of O 0 2.2925721043787206e-10
these O 0 4.8044838940608514e-11
mutations O 0 3.7647673867269305e-10
were O 0 3.509992851924437e-10
found O 0 2.438843571539451e-10
in O 0 3.874617848786954e-10
nine O 0 5.86709036909383e-09
of O 0 7.2524657390715674e-09
the O 0 1.186320108814698e-08
14 O 0 2.7616442821454257e-07
families O 0 9.161158054382668e-09
analyzed O 0 9.30313660774118e-07
. O 0 1.9027729649678804e-06

The O 0 2.5228086286688267e-08
identification O 0 3.062909925688473e-08
of O 0 2.8892713999084663e-08
two O 0 5.324549690044478e-09
frequent O 0 2.222433614917918e-08
PDS B-Disease 0 3.170601121382788e-05
mutations O 0 3.9639115101408606e-08
will O 0 5.461901153580584e-09
facilitate O 0 8.072428947514254e-09
the O 0 4.397919806109485e-09
molecular O 0 1.3721081586481887e-06
diagnosis O 0 0.0018832485657185316
of O 0 0.00011872025788761675
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00018075003754347563

Insertional O 0 3.089687379542738e-05
mutation O 0 5.691475735147833e-08
by O 0 3.6573148953777945e-09
transposable O 0 5.321283538251009e-07
element O 0 1.277150971645824e-07
, O 0 7.283365022203725e-09
L1 O 0 6.685098696834757e-07
, O 0 1.885527955991506e-09
in O 0 1.7220597170464202e-09
the O 0 9.155484548273307e-08
DMD B-Disease 1 1.0
gene O 0 4.798364727776061e-08
results O 0 1.3033532297868078e-07
in O 0 1.4365320488707312e-08
X B-Disease 1 0.9999222755432129
- I-Disease 1 0.9999631643295288
linked I-Disease 0 0.360998272895813
dilated I-Disease 0 0.013089078478515148
cardiomyopathy I-Disease 1 1.0
. O 0 0.00045543332817032933

X B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999998807907104
linked I-Disease 1 0.9998533725738525
dilated I-Disease 1 0.9999285936355591
cardiomyopathy I-Disease 1 1.0
( O 0 1.8353917766944505e-05
XLDCM B-Disease 1 0.9997765421867371
) O 0 5.462161833946766e-09
is O 0 2.3066033805196895e-10
a O 0 5.955866910767327e-10
clinical O 0 4.6918259499761916e-08
phenotype O 0 1.6439925332178973e-07
of O 0 1.5733260738670651e-07
dystrophinopathy B-Disease 0 7.701219146838412e-06
which O 0 1.0029675978628916e-09
is O 0 1.4272530379777493e-10
characterized O 0 2.424123679567458e-10
by O 0 9.589803257048501e-11
preferential O 0 5.266817382221234e-08
myocardial B-Disease 0 0.00016650219913572073
involvement I-Disease 0 1.0268002625934969e-07
without O 0 4.119125929236134e-09
any O 0 1.3048668812132291e-09
overt O 0 1.6034235272854858e-08
clinical O 0 1.7465778512359975e-07
signs O 0 9.531632372272725e-07
of O 0 0.0027534267865121365
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0024457043036818504

To O 0 2.2232136132060987e-08
date O 0 1.8070501539568795e-07
, O 0 1.233873558881271e-09
several O 0 5.29459087683648e-10
mutations O 0 3.845941343172399e-09
in O 0 1.848286412808875e-09
the O 0 7.537009309999121e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.09344426542520523
, O 0 2.9600118978123646e-06
DMD O 1 1.0
, O 0 1.951218964180157e-09
have O 0 2.0090866470479085e-10
been O 0 2.778433871863939e-10
identified O 0 7.654313849414507e-10
in O 0 1.3164706824664307e-10
patients O 0 2.309385321863644e-10
with O 0 5.720015572308057e-10
XLDCM B-Disease 0 0.0004263157316017896
, O 0 5.809319691962855e-09
but O 0 1.922936698761646e-09
a O 0 8.328798761780831e-10
pathogenic O 0 4.693025346114155e-08
correlation O 0 1.0842065911731424e-08
of O 0 3.7079364023639982e-09
these O 0 2.1922041959498983e-09
cardiospecific O 0 4.6534455577784684e-07
mutations O 0 4.088983018846193e-08
in O 0 1.0840989439486748e-08
DMD O 1 1.0
with O 0 3.658012559526469e-09
the O 0 1.757127421342375e-08
XLDCM B-Disease 0 3.250737427151762e-05
phenotype O 0 9.273147583144237e-08
has O 0 4.75057826410108e-10
remained O 0 9.672882939071314e-09
to O 0 8.208153046140865e-10
be O 0 7.698858439653122e-09
elucidated O 0 7.277768872882007e-06
. O 0 5.538390155379602e-07

We O 0 5.987286044728535e-07
report O 0 2.3117411984685532e-08
here O 0 8.258893013923796e-10
the O 0 1.8502077647752913e-10
identification O 0 4.790038365953819e-10
of O 0 7.168747817587473e-10
a O 0 1.1161416235694332e-09
unique O 0 1.2388831294174452e-08
de O 0 1.6635975043755025e-05
novo O 0 5.601074462902034e-06
L1 O 0 6.8048175307922065e-06
insertion O 0 5.699460103869569e-08
in O 0 1.1740656447045694e-08
the O 0 1.334823362952875e-08
muscle O 0 6.905718663574589e-08
exon O 0 3.1587094895257906e-07
1 O 0 3.5729024716602e-07
in O 0 9.754904439773782e-09
DMD O 1 1.0
in O 0 8.395806716521292e-09
three O 0 3.333149756201692e-09
XLDCM B-Disease 0 1.7955474049813347e-06
patients O 0 4.70291361409636e-10
from O 0 2.680252686459994e-10
two O 0 1.0982549314419998e-09
unrelated O 0 2.212523675382272e-08
Japanese O 0 1.6809863723210583e-07
families O 0 3.162151074320718e-08
. O 0 5.439852088784392e-07

The O 0 3.235204530938063e-07
insertion O 0 1.351187108866725e-07
was O 0 1.1702809388225432e-07
a O 0 7.914542798914681e-09
5 O 0 6.186326828583333e-08
- O 0 1.168308916277283e-08
truncated O 0 1.610208855140627e-08
form O 0 4.283507326618974e-09
of O 0 3.034081430541846e-08
human O 0 2.7862167684133965e-08
L1 O 0 1.337601020168222e-06
inversely O 0 9.615659024575507e-08
integrated O 0 3.696054662327697e-08
in O 0 9.629012032164042e-10
the O 0 2.7328566076789684e-09
5 O 0 6.733920798751569e-08
- O 0 8.800429895927664e-08
untranslated O 0 1.1778013686125632e-05
region O 0 8.046787236537511e-09
in O 0 2.416530753279744e-09
the O 0 6.832673093981612e-09
muscle O 0 2.401704080057243e-08
exon O 0 5.9039585664777405e-08
1 O 0 1.589544140756516e-08
, O 0 5.127601121479586e-11
which O 0 1.944867183967247e-11
affected O 0 1.1679045230916785e-10
the O 0 1.3117085195801792e-10
transcription O 0 7.217728081876373e-10
or O 0 1.91359844636807e-10
the O 0 2.6760538229808617e-10
stability O 0 6.817285846949517e-09
of O 0 1.639119062701866e-09
the O 0 8.100125570287275e-10
muscle O 0 2.1488724133433834e-09
form O 0 8.16828471528197e-09
of O 0 1.3231081652520515e-07
dystrophin O 0 2.6817951948032714e-07
transcripts O 0 2.4045915480996882e-08
but O 0 3.723758801310595e-11
not O 0 7.874327925816438e-12
that O 0 1.1327920372561362e-11
of O 0 6.557304699228439e-10
the O 0 4.23885504474697e-09
brain O 0 9.818223588808905e-06
or O 0 6.609017333403244e-08
Purkinje O 0 0.00021511281374841928
cell O 0 2.905191877289326e-06
form O 0 4.0584239968666225e-08
, O 0 1.455978559938842e-09
probably O 0 3.304423623617936e-09
due O 0 1.5018905230590462e-08
to O 0 5.043642170576845e-10
its O 0 2.367752105492116e-10
unique O 0 7.972628113250835e-10
site O 0 9.193927397177504e-09
of O 0 3.4136334647882904e-08
integration O 0 1.0707374258345226e-06
. O 0 1.0952713864753605e-06

We O 0 1.1620510775856019e-07
speculate O 0 1.055587883769249e-08
that O 0 7.740268148648255e-11
this O 0 2.3113849376144024e-11
insertion O 0 3.620796995562614e-10
of O 0 1.2621346190400118e-09
an O 0 1.9256518601906691e-10
L1 O 0 5.321725211615558e-07
sequence O 0 1.591880405271695e-08
in O 0 3.024322836608917e-08
DMD O 1 1.0
is O 0 3.6297256311712545e-09
responsible O 0 1.355545786729806e-09
for O 0 4.812371681706118e-11
some O 0 1.715069405938685e-11
of O 0 1.093374002447689e-10
the O 0 4.244692444754783e-11
population O 0 1.3926027215074854e-12
of O 0 6.091303156319228e-11
Japanese O 0 4.6437471645788264e-09
patients O 0 9.589186111824688e-10
with O 0 1.0755449864063849e-09
XLDCM B-Disease 0 1.760739178280346e-05
. O 0 7.353370534701753e-08
. O 0 2.9226833930806606e-07

Severe O 1 0.9993913173675537
early O 1 0.9999771118164062
- O 1 1.0
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 4.73950058221817e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.13001267611980438
red O 1 0.9746333956718445
hair O 1 0.9870277643203735
pigmentation O 0 0.004411480389535427
caused O 0 2.5906260248120816e-07
by O 0 3.1341574668886096e-08
POMC O 0 7.300372089957818e-05
mutations O 0 1.1303531266548816e-07
in O 0 1.694425044718173e-08
humans O 0 1.1252249976223538e-07
. O 0 5.403364298217639e-07

Sequential O 0 4.052749318361748e-06
cleavage O 0 3.55528896989199e-07
of O 0 1.366251609624669e-07
the O 0 2.3099119061953388e-08
precursor O 0 1.0808903994075081e-08
protein O 0 5.519785073460071e-09
pre O 0 3.119076268376375e-07
- O 0 1.925186126072731e-07
pro O 0 2.8150407160865143e-05
- O 0 9.40251447900664e-06
opiomelanocortin O 0 6.620443400606746e-06
( O 0 1.4675386239559884e-08
POMC O 0 2.4560958991060033e-06
) O 0 2.259032960694185e-09
generates O 0 6.054879264638657e-09
the O 0 2.1490745183427862e-08
melanocortin O 0 2.1202813513809815e-05
peptides O 0 2.2710491975885816e-07
adrenocorticotrophin O 0 3.7166801121202298e-06
( O 0 2.6316349988064758e-08
ACTH O 0 2.1020312033215305e-06
) O 0 2.5231791767055256e-08
, O 0 3.8669508484190374e-08
melanocyte O 0 0.00011533826909726486
- O 0 0.00023360957857221365
stimulating O 0 3.3244425139855593e-05
hormones O 0 6.12697874657897e-08
( O 0 2.7421767079260917e-09
MSH O 0 1.1033976079488639e-06
) O 0 2.9844313131910383e-10
alpha O 0 4.780658091618761e-09
, O 0 8.143651031300436e-11
beta O 0 1.514607883557062e-09
and O 0 1.792609116701982e-10
gamma O 0 2.8121092121580205e-09
as O 0 5.667277758192313e-11
well O 0 3.439627055401573e-11
as O 0 4.138810474896282e-11
the O 0 2.5812141313252823e-10
opioid O 0 1.88200068862443e-08
- O 0 9.054116567597248e-09
receptor O 0 1.8051721895062656e-08
ligand O 0 1.489779890562204e-07
beta O 0 2.7699129532265943e-06
- O 0 1.24740097362519e-06
endorphin O 0 1.1654082300083246e-05
. O 0 3.7626901416842884e-07

While O 0 9.643025578043307e-08
a O 0 5.9023679277458996e-09
few O 0 2.8156728060224623e-09
cases O 0 2.34862818082604e-09
of O 0 2.2917044262271702e-08
isolated O 0 4.736531991511583e-06
ACTH B-Disease 1 0.9984939098358154
deficiency I-Disease 1 0.9999958276748657
have O 0 1.0001947003956957e-07
been O 0 1.0319777032918864e-07
reported O 0 2.580991349532269e-07
( O 0 6.937640506521348e-08
OMIM O 0 0.00014244219346437603
201400 O 0 1.2162121493020095e-05
) O 0 1.3202892112929021e-08
, O 0 2.9594460215776053e-09
an O 0 3.1425662072592786e-09
inherited O 1 0.6565068364143372
POMC O 1 0.9999997615814209
defect O 0 0.20002643764019012
has O 0 9.054151206555616e-09
not O 0 2.956805467135837e-09
been O 0 3.615457488947982e-09
described O 0 5.792943902349634e-09
so O 0 1.9836103870574107e-09
far O 0 1.3517949426500309e-08
. O 0 1.8562441539415886e-07

Recent O 0 1.7792638118407922e-07
studies O 0 5.9400015572919074e-08
in O 0 2.3440098750882044e-09
animal O 0 3.6545815262911674e-09
models O 0 1.7316782674470232e-08
elucidated O 0 2.4085397853923496e-07
a O 0 1.3804819509743993e-09
central O 0 3.914957247275197e-09
role O 0 6.622314696613785e-09
of O 0 5.488314158696994e-08
alpha O 0 1.4912852748238947e-06
- O 0 3.1663699928685674e-07
MSH O 0 9.75037801254075e-06
in O 0 1.82188175656961e-09
the O 0 1.9584673882633297e-09
regulation O 0 5.5071445181908985e-09
of O 0 1.49271095484238e-09
food O 0 1.7477999603165983e-10
intake O 0 2.558334377678051e-10
by O 0 4.1027185121444987e-11
activation O 0 6.92354618081481e-09
of O 0 3.321423136526391e-08
the O 0 9.11728648134158e-08
brain O 0 4.467075086722616e-06
melanocortin O 0 1.658002111071255e-05
- O 0 4.228291174968035e-07
4 O 0 8.335892403010803e-07
- O 0 6.572587096798088e-08
receptor O 0 3.355745903377283e-08
( O 0 6.782332473420638e-09
MC4 O 0 1.1891123904206324e-05
- O 0 2.70397094936925e-07
R O 0 9.856577065647798e-08
; O 0 3.3009717181897713e-09
refs O 0 3.6173014450469054e-07
3 O 0 6.607958624726962e-08
- O 0 5.82903192380968e-09
5 O 0 4.108596129981379e-09
) O 0 3.555940958355208e-11
and O 0 9.525270849852774e-11
the O 0 4.406986442440086e-10
linkage O 0 2.239206509102587e-08
of O 0 1.0626404645108778e-07
human O 0 3.2668676794855855e-06
obesity B-Disease 1 1.0
to O 0 2.3912536395442885e-09
chromosome O 0 8.37445668366854e-09
2 O 0 1.5182506274413754e-07
in O 0 3.4379057378686184e-09
close O 0 4.5692271299913045e-08
proximity O 0 1.9612233614907382e-08
to O 0 3.2216891376890544e-09
the O 0 3.099398782069329e-08
POMC O 0 8.680251085024793e-06
locus O 0 1.444187915922157e-07
, O 0 1.8727754902414517e-09
led O 0 1.1674017308394014e-09
to O 0 1.6908978384133633e-10
the O 0 4.0936609657649115e-10
proposal O 0 1.0955852891569862e-09
of O 0 3.6379039780598532e-09
an O 0 4.739437176048966e-10
association O 0 1.1302534907997597e-08
of O 0 3.700492072766792e-07
POMC O 1 0.999747097492218
with O 0 1.6259164112852886e-06
human O 1 0.9961068034172058
obesity B-Disease 1 1.0
. O 0 1.2574250831676181e-05

The O 0 1.4275804005592363e-07
dual O 0 4.6488810312439455e-07
role O 0 2.0996520788685302e-07
of O 0 1.2771708952641347e-06
alpha O 0 6.669807044090703e-05
- O 0 5.7223867770517245e-05
MSH O 0 0.0008928542374633253
in O 0 1.4634045975014942e-08
regulating O 0 5.173723138796049e-08
food O 0 3.0218363367140455e-09
intake O 0 1.3838254098175184e-08
and O 0 1.2071736499308372e-08
influencing O 0 2.949464033008553e-05
hair O 0 0.17078585922718048
pigmentation O 0 4.5404707634588704e-05
predicts O 0 2.316371094934766e-08
that O 0 9.285789498436614e-11
the O 0 1.1611084316243137e-09
phenotype O 0 1.4946119009096037e-08
associated O 0 1.7226904347467098e-09
with O 0 2.1764628987952506e-10
a O 0 2.9814970492481052e-09
defect O 0 2.025565208896296e-07
in O 0 5.791135038180073e-08
POMC O 0 0.00037191674346104264
function O 0 5.620662477667793e-07
would O 0 1.5413414544696025e-08
include O 0 1.5938648800783994e-07
obesity B-Disease 1 1.0
, O 0 1.321992648684045e-08
alteration O 0 2.6357927254139213e-06
in O 0 3.0613244916821714e-07
pigmentation O 1 0.9999876022338867
and O 0 2.35352181334747e-05
ACTH B-Disease 1 0.9985358715057373
deficiency I-Disease 1 0.9999045133590698
. O 0 1.451480966352392e-05

The O 0 2.0267050615530025e-07
observation O 0 8.398868089898315e-07
of O 0 2.6670880615142778e-08
these O 0 3.3762110884794083e-09
symptoms O 0 6.867639257279734e-08
in O 0 1.5826036037225322e-09
two O 0 5.558643323411161e-09
probands O 0 9.233522177964915e-07
prompted O 0 1.9001070938884368e-08
us O 0 4.2665940225283805e-10
to O 0 1.7818847786177372e-10
search O 0 1.8490655673275569e-09
for O 0 2.1765708679843954e-10
mutations O 0 3.3693985379557034e-09
within O 0 8.069765300433573e-09
their O 0 4.897186656194208e-08
POMC O 0 1.5242005247273482e-05
genes O 0 2.384535378041619e-07
. O 0 5.235108915258024e-07

Patient O 0 3.461619598965626e-06
1 O 0 1.351113951386651e-06
was O 0 3.028623396517105e-08
found O 0 3.038949369926769e-10
to O 0 9.825779079264407e-11
be O 0 2.788521080709927e-10
a O 0 4.86797713250553e-10
compound O 0 2.3344716382212027e-08
heterozygote O 0 8.137545393083201e-08
for O 0 1.3282449584650635e-09
two O 0 1.810191330164912e-09
mutations O 0 2.833397072521393e-09
in O 0 2.8934061813146172e-09
exon O 0 6.705992205979783e-08
3 O 0 2.398006131443253e-07
( O 0 1.6497705424001197e-09
G7013T O 0 5.983928730302068e-08
, O 0 1.6349225306910853e-09
C7133delta O 0 3.058768243136001e-07
) O 0 5.232388411435807e-10
which O 0 1.6915041589626867e-10
interfere O 0 1.9475863144435834e-09
with O 0 9.102174569619592e-11
appropriate O 0 2.6378550455063987e-09
synthesis O 0 1.0717878140553694e-08
of O 0 2.0333953187900988e-08
ACTH O 0 2.002750534302322e-06
and O 0 2.8885696679026296e-07
alpha O 0 5.1787454140139744e-05
- O 0 2.9071183234918863e-05
MSH O 0 0.0006255517364479601
. O 0 1.6483567151226453e-06

Patient O 0 1.8053757457892061e-06
2 O 0 1.4850012348688324e-06
was O 0 4.955007781859422e-08
homozygous O 0 3.3702276525104935e-09
for O 0 3.524093239448689e-10
a O 0 1.3449223956740752e-09
mutation O 0 2.3803776727504555e-09
in O 0 5.591863860843205e-09
exon O 0 1.980453419037076e-07
2 O 0 9.971961389965145e-07
( O 0 6.094341920004354e-09
C3804A O 0 1.3214864225119527e-07
) O 0 1.2196031962119491e-09
which O 0 3.429954320566253e-09
abolishes O 0 4.5008346205577254e-06
POMC O 0 4.3677686335286126e-05
translation O 0 2.1193645807215944e-06
. O 0 2.0611448690033285e-06

These O 0 1.3822848643485486e-08
findings O 0 1.692712991996359e-08
represent O 0 8.193262734934592e-10
the O 0 4.96973018293545e-10
first O 0 2.481979344270968e-10
examples O 0 7.479540875543478e-10
of O 0 1.8938504098287012e-09
a O 0 6.285926446025769e-09
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
within O 0 8.162136566625122e-08
the O 0 4.5133074166869847e-08
POMC O 0 4.892900960840052e-06
gene O 0 4.624002514219683e-09
and O 0 1.2940901683577977e-09
define O 0 1.929576676218403e-08
a O 0 4.573950551645112e-09
new O 0 2.0896779062695714e-07
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.7052066922187805
resulting O 0 1.1567559710101705e-07
in O 0 8.680926200099748e-09
early O 0 0.003971351310610771
- O 1 0.9999997615814209
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.00022725213784724474
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9912164211273193
red O 1 0.9737773537635803
hair O 0 0.015075791627168655
pigmentation O 0 3.787732930504717e-05
. O 0 5.408092818015575e-08
. O 0 5.631559929497598e-07

A O 0 1.467227434659435e-06
European O 0 1.2902211210530368e-06
multicenter O 0 2.6093215637956746e-05
study O 0 1.0389553750655978e-07
of O 0 2.109730485244654e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 9.979365245271765e-08
classification O 0 3.74132049785203e-08
of O 0 2.6903245853304725e-08
105 O 0 4.925608365624612e-08
mutations O 0 3.217783373088423e-09
and O 0 9.296763914257156e-10
a O 0 1.1480495443194627e-09
general O 0 5.210977427339003e-09
system O 0 2.437486879003359e-09
for O 0 5.35798294620804e-10
genotype O 0 4.7779625589328134e-08
- O 0 2.2364064378166404e-08
based O 0 2.428609091609246e-09
prediction O 0 3.3038176638910954e-07
of O 0 8.743043622416735e-08
metabolic O 0 0.4700564444065094
phenotype O 0 3.914984972652746e-06
. O 0 5.136795948601502e-07

Phenylketonuria B-Disease 1 0.9981784820556641
( O 0 2.8492504497990012e-06
PKU B-Disease 0 0.00016466692613903433
) O 0 8.793416128582976e-08
and O 0 2.725609817844088e-07
mild B-Disease 1 0.999993085861206
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.10376828908920288
MHP B-Disease 1 1.0
) O 0 1.7451601053153354e-08
are O 0 6.372105065821643e-09
allelic B-Disease 0 7.579704833915457e-05
disorders I-Disease 0 5.491190677275881e-06
caused O 0 1.0839150021979549e-08
by O 0 6.401276730905181e-10
mutations O 0 9.138571011035879e-10
in O 0 7.479341590510558e-10
the O 0 6.675043628945332e-09
gene O 0 1.1095960594786902e-08
encoding O 0 9.627264034861582e-07
phenylalanine O 0 3.200261926394887e-05
hydroxylase O 0 0.000326440145727247
( O 0 2.0692223756668682e-07
PAH O 0 5.022187178838067e-05
) O 0 3.3127175669278586e-08
. O 0 2.9253325806166686e-07

Previous O 0 4.990585580344487e-07
studies O 0 1.356785439554642e-08
have O 0 2.7422433768187204e-10
suggested O 0 5.980683170925261e-10
that O 0 2.274387275735812e-11
the O 0 3.918249891210479e-10
highly O 0 9.309881754404614e-09
variable O 0 1.6906194559851428e-06
metabolic O 1 0.7275440692901611
phenotypes O 0 5.910942127229646e-05
of O 0 0.00012329791206866503
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9989339709281921
correlate O 0 1.678005332905741e-06
with O 0 6.672028973753186e-08
PAH O 0 0.4315294325351715
genotypes O 0 3.880667281919159e-05
. O 0 8.153530188792502e-07

We O 0 2.521164219615457e-07
identified O 0 4.3114770420515924e-08
both O 0 4.328927438734809e-09
causative O 0 2.6948805498250294e-07
mutations O 0 3.617494215291117e-08
in O 0 6.473920066696337e-09
686 O 0 4.7293011107285565e-07
patients O 0 7.3843442471854814e-09
from O 0 1.0954249063388488e-08
seven O 0 1.1494288543190123e-07
European O 0 1.3104016716170008e-06
centers O 0 6.493870614576736e-07
. O 0 9.06169361769571e-07

On O 0 5.603765771411418e-07
the O 0 6.280677755654551e-09
basis O 0 5.884461362626325e-09
of O 0 8.66385130304792e-10
the O 0 9.718722493445853e-10
phenotypic O 0 5.317544946592534e-07
characteristics O 0 3.155572017021768e-07
of O 0 7.492798914654486e-08
297 O 0 1.835605161204512e-07
functionally O 0 1.7508170913060894e-07
hemizygous O 0 2.0062094563400024e-07
patients O 0 1.3894582151507961e-09
, O 0 3.6134634173734526e-10
105 O 0 7.367237486732847e-09
of O 0 5.725890872554373e-09
the O 0 4.094545147381723e-09
mutations O 0 1.976717456386723e-09
were O 0 1.1287470957910273e-09
assigned O 0 5.902511257538379e-10
to O 0 1.1433660962456571e-10
one O 0 4.4641088048358313e-10
of O 0 4.597461522592994e-09
four O 0 1.1469800220709203e-08
arbitrary O 0 9.43908773365365e-08
phenotype O 0 4.304287699596898e-07
categories O 0 3.585583101539669e-07
. O 0 1.1410456863814034e-06

We O 0 4.419339916239551e-07
proposed O 0 3.92309971175564e-08
and O 0 2.910342633555274e-09
tested O 0 7.788957034904342e-09
a O 0 3.488667688067437e-10
simple O 0 2.1550898565703136e-10
model O 0 1.0251633986158026e-09
for O 0 9.695906577622537e-11
correlation O 0 1.532645677038147e-09
between O 0 1.6968757510227306e-09
genotype O 0 1.712738040282602e-08
and O 0 1.8963552950168605e-09
phenotypic O 0 1.3241145779829822e-06
outcome O 0 1.922385990837938e-06
. O 0 8.759983529671445e-07

The O 0 5.098858082419611e-07
observed O 0 3.093705629453325e-07
phenotype O 0 2.6177733047916263e-07
matched O 0 2.3264929538413526e-08
the O 0 5.7793250185511624e-09
predicted O 0 4.1430734398772984e-08
phenotype O 0 1.2192759690776711e-08
in O 0 7.491391396108327e-10
79 O 0 4.537914488622619e-09
% O 0 5.918471268628878e-11
of O 0 4.988933710592391e-10
the O 0 5.445328077335887e-10
cases O 0 2.624994943634107e-10
, O 0 5.3128779153865935e-11
and O 0 9.166008230199196e-11
in O 0 8.06235703199043e-11
only O 0 1.2990578057703317e-10
5 O 0 8.667359274738828e-09
of O 0 3.2454836595974257e-09
184 O 0 6.110474348730577e-09
patients O 0 2.625135109290966e-10
was O 0 3.49432371926639e-09
the O 0 3.80734599403354e-09
observed O 0 1.5067080028074997e-08
phenotype O 0 7.969378046368547e-09
more O 0 2.8838934712505093e-11
than O 0 3.103825182981801e-11
one O 0 7.406934787734798e-11
category O 0 1.180478048645739e-09
away O 0 1.493639434357874e-09
from O 0 1.2347299571668913e-10
that O 0 2.586951486360789e-10
expected O 0 2.9313582672330085e-08
. O 0 2.397416096755478e-07

Among O 0 2.2286337753030239e-07
the O 0 2.040719060403262e-08
seven O 0 4.788561103197253e-09
contributing O 0 3.515770119477679e-09
centers O 0 1.085981748971676e-09
, O 0 1.215698652856645e-10
the O 0 2.7317920148206554e-10
proportion O 0 4.953019105968792e-10
of O 0 1.0738374633945114e-09
patients O 0 6.710627192818563e-11
for O 0 5.5930954312444214e-11
whom O 0 1.9415555829738196e-09
the O 0 4.6040078416353936e-09
observed O 0 2.0316313964485744e-08
phenotype O 0 1.3014425093160753e-08
did O 0 1.163460661146587e-09
not O 0 4.1707323705786337e-10
match O 0 2.428064647119754e-07
the O 0 9.485484397941946e-09
predicted O 0 8.576292742645819e-08
phenotype O 0 2.428689249711624e-08
was O 0 1.6313629558339926e-08
4 O 0 2.2605512128848204e-08
% O 0 7.598137674591499e-10
- O 0 8.782316207600616e-09
23 O 0 2.0610837481171984e-08
% O 0 1.534526394841862e-09
( O 0 4.506620854272114e-09
P O 0 9.863844752544537e-06
< O 0 4.36777384038578e-07
. O 0 7.558882408886802e-09
0001 O 0 7.666676538065076e-06
) O 0 3.20374560214276e-10
, O 0 4.851003279626731e-11
suggesting O 0 2.7298491245275613e-10
that O 0 1.969234497689598e-11
differences O 0 1.4017106364505594e-09
in O 0 6.76835601454151e-11
methods O 0 2.51127424411024e-10
used O 0 3.893440084223876e-11
for O 0 3.609363155576695e-11
mutation O 0 6.645086148004964e-10
detection O 0 6.833457177890523e-08
or O 0 4.657461083468206e-09
phenotype O 0 1.176143769043847e-07
classification O 0 1.2152824524491734e-08
may O 0 1.945262395608438e-09
account O 0 1.599810978136773e-10
for O 0 4.354296090358645e-11
a O 0 1.11444346806433e-10
considerable O 0 3.2382243553286116e-09
proportion O 0 9.775542153533934e-09
of O 0 3.7456189261320105e-08
genotype O 0 5.212047199165681e-06
- O 0 1.3630436114908662e-05
phenotype O 0 2.669162540769321e-06
inconsistencies O 0 4.440769771463238e-06
. O 0 9.143510624198825e-07

Our O 0 1.455667756999901e-06
data O 0 6.32781578246977e-08
indicate O 0 1.3542207355499158e-08
that O 0 6.719160228207954e-10
the O 0 2.5824579807931514e-08
PAH O 0 5.458604573504999e-05
- O 0 1.0868551214571198e-07
mutation O 0 4.3770822522049e-09
genotype O 0 9.211023943578311e-09
is O 0 7.809238672384922e-11
the O 0 1.457995391085376e-10
main O 0 6.696236898307006e-09
determinant O 0 3.4915680657832127e-07
of O 0 9.132166667313868e-08
metabolic O 0 0.007472003810107708
phenotype O 0 1.2304916197081184e-07
in O 0 1.3445736746220405e-09
most O 0 1.4927025171473929e-09
patients O 0 2.8934847406958397e-08
with O 0 9.216630587616237e-07
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 9.863782179309055e-05

In O 0 4.470520664767719e-08
the O 0 6.009295283604388e-09
present O 0 9.032155579014045e-10
study O 0 3.029151929290208e-10
, O 0 5.939834041290837e-11
the O 0 2.9473895546416884e-10
classification O 0 5.716637385688728e-09
of O 0 2.3203552856898568e-08
105 O 0 6.672448762401473e-07
PAH O 0 0.00015710755542386323
mutations O 0 8.753985092369021e-09
may O 0 1.4434169415267206e-09
allow O 0 3.95375926443009e-10
the O 0 1.0617074996943643e-09
prediction O 0 1.90821349832504e-08
of O 0 7.83288767181034e-10
the O 0 8.805424722702071e-10
biochemical O 0 2.076551908203328e-08
phenotype O 0 2.9836943582495223e-08
in O 0 2.8543130081715162e-09
> O 0 1.323689957644092e-07
10 O 0 1.3544920740571342e-08
, O 0 1.676735528199913e-09
000 O 0 4.174111012389403e-08
genotypes O 0 6.861419876713626e-08
, O 0 2.9087651731707354e-10
which O 0 9.03925129192018e-11
may O 0 2.885281458198108e-10
be O 0 1.034942895272728e-10
useful O 0 6.912405647874209e-10
for O 0 4.4553791211932037e-11
the O 0 2.9856497829605644e-10
management O 0 1.0669944039420898e-08
of O 0 1.8374540999843703e-08
hyperphenylalaninemia B-Disease 1 1.0
in O 0 6.148636799707674e-08
newborns O 0 3.5812291798720253e-07
. O 0 5.089316914563824e-07

Somatic O 0 7.83037394285202e-05
instability O 0 5.844626230100403e-06
of O 0 9.560191074342583e-07
the O 0 1.6588357709679258e-07
CTG O 0 2.6094332497450523e-05
repeat O 0 2.2582892711398017e-07
in O 0 1.270465599390036e-08
mice O 0 5.1042874815721007e-08
transgenic O 0 3.2105141656302294e-08
for O 0 1.704758778586779e-09
the O 0 2.335038743694895e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.4931943951523863e-05
is O 0 2.1563575369754062e-09
age O 0 1.2777748858994187e-09
dependent O 0 2.650310526597366e-10
but O 0 2.4884341115471997e-11
not O 0 1.4486861363294246e-11
correlated O 0 8.658444794473752e-11
to O 0 1.8732845136204546e-11
the O 0 1.7202794744264338e-10
relative O 0 1.8777374322098694e-08
intertissue O 0 7.449413601534616e-07
transcription O 0 8.75649490694741e-08
levels O 0 2.6314449996789335e-07
and O 0 3.939153003784668e-08
proliferative O 0 0.0017605727771297097
capacities O 0 0.00013937361654825509
. O 0 1.2982067119082785e-06

A O 0 2.802301969495602e-05
( O 0 6.416054816327232e-07
CTG O 0 4.3493553675943986e-05
) O 0 2.016713374075607e-08
nexpansion O 0 1.096035248338012e-06
in O 0 5.6584910090862195e-09
the O 0 9.292904223912046e-09
3 O 0 4.2327008031861624e-07
- O 0 3.4489420386307756e-07
untranslated O 0 3.664705218398012e-05
region O 0 6.369336347233912e-08
( O 0 4.685420496031156e-09
UTR O 0 2.6532118226896273e-06
) O 0 1.2159913076459361e-09
of O 0 9.302302927949313e-09
the O 0 1.3123597852882085e-07
DM O 1 1.0
protein O 0 2.5916540380421793e-07
kinase O 0 1.0262050409437506e-07
gene O 0 4.7725952079247236e-09
( O 0 8.689005626116852e-10
DMPK O 0 7.876045629018336e-07
) O 0 4.117521601454399e-10
is O 0 1.066374835656525e-10
responsible O 0 1.983621711332262e-09
for O 0 7.356369291500187e-09
causing O 1 0.9999997615814209
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999957084655762
DM B-Disease 1 1.0
) O 0 3.636401118001231e-07
. O 0 5.221138508204604e-07

Major O 0 6.96347160555888e-06
instability O 0 1.420986245648237e-05
, O 0 5.0603046197750245e-09
with O 0 1.717486153296477e-10
very O 0 4.896201222237551e-10
large O 0 1.827090145845034e-10
expansions O 0 3.0312456988923486e-09
between O 0 1.5942556164105781e-09
generations O 0 3.153295624613861e-09
and O 0 2.105235569205277e-10
high O 0 3.5119633867708444e-09
levels O 0 2.377591679092461e-09
of O 0 6.423735765537231e-09
somatic O 0 8.481873123855621e-07
mosaicism O 0 2.054137212326168e-06
, O 0 3.8143363467746383e-10
is O 0 8.488935249184593e-11
observed O 0 1.7424784948261163e-09
in O 0 1.5396394159594706e-09
patients O 0 7.989712003109162e-09
. O 0 3.2042595421444275e-07

There O 0 1.2896535395157116e-07
is O 0 1.7127632645497215e-09
a O 0 1.8836838755476037e-09
good O 0 7.434769688785536e-09
correlation O 0 8.507129223289667e-09
between O 0 5.2727244792549754e-09
repeat O 0 1.6535453895016872e-08
size O 0 1.6983207729026617e-08
( O 0 5.174862760526366e-10
at O 0 3.821759353428433e-09
least O 0 1.6252801882110646e-10
in O 0 2.0164421521418063e-10
leucocytes O 0 6.071302749433016e-08
) O 0 3.91677024147441e-10
, O 0 1.0990087312423569e-10
clinical O 0 4.9821848868703e-09
severity O 0 2.8086798664617163e-08
and O 0 2.131771648095082e-09
age O 0 5.87479718205941e-08
of O 0 1.0251212501088958e-07
onset O 0 0.0002425813872832805
. O 0 1.5281561900337692e-06

The O 0 5.952561423328007e-06
trinucleotide O 0 0.0002099823614116758
repeat O 0 5.083863015897805e-06
instability O 0 1.0665452464309055e-05
mechanisms O 0 0.00039622338954359293
involved O 0 1.5953035870097665e-07
in O 0 1.0517878479276987e-07
DM B-Disease 1 1.0
and O 0 3.095907175065804e-07
other O 0 1.240841207561516e-08
human O 0 3.8340280298143625e-05
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 4.290193478251325e-10
unknown O 0 6.876302904856857e-08
. O 0 1.4992436092597927e-07

We O 0 7.979692213666567e-07
studied O 0 1.2105003861506702e-06
somatic O 0 2.0751244846906047e-06
instability O 0 1.6327209095834405e-07
by O 0 2.249255892650126e-09
measuring O 0 7.595216970912588e-07
the O 0 2.3222458622740305e-08
CTG O 0 2.2242286377149867e-06
repeat O 0 1.7698349452643924e-08
length O 0 1.6868785257528884e-09
at O 0 2.27449370449051e-09
several O 0 9.068210765628137e-11
ages O 0 9.714682391859242e-10
in O 0 7.444922456301128e-11
various O 0 5.228357746744905e-10
tissues O 0 6.817351128063365e-09
of O 0 2.243276142621653e-08
transgenic O 0 6.419610798502617e-08
mice O 0 4.428357236463398e-09
carrying O 0 3.1547573442480825e-09
a O 0 4.150609189679244e-09
( O 0 3.042122997953811e-09
CTG O 0 3.993442533101188e-06
) O 0 6.869692814603923e-09
55expansion O 0 5.442228712126962e-07
surrounded O 0 2.6379268547316315e-08
by O 0 9.144116019932369e-10
45 O 0 1.3429082734717213e-08
kb O 0 4.628647275239928e-06
of O 0 2.904428129113512e-07
the O 0 4.889370188720932e-07
human O 0 4.819084279006347e-05
DM B-Disease 1 1.0
region O 0 4.2136429101446993e-07
, O 0 3.17521586801206e-09
using O 0 8.962947717350289e-09
small O 0 3.669068959766264e-08
- O 0 5.624769983114675e-07
pool O 0 5.45837281151762e-07
PCR O 0 5.343190991879965e-07
. O 0 3.6264270875108195e-07

These O 0 3.799599923581809e-08
mice O 0 1.6132922553424578e-08
have O 0 1.2131134985438052e-10
been O 0 1.1654345544176437e-10
shown O 0 6.994977513885559e-11
to O 0 5.368639213743087e-11
reproduce O 0 4.932563246740074e-09
the O 0 1.0420225793339455e-09
intergenerational O 0 2.113957009441947e-08
and O 0 1.4455190378015459e-09
somatic O 0 2.9332326789699437e-07
instability O 0 1.0853200649307837e-07
of O 0 5.7996132341031625e-08
the O 0 3.3149298417356476e-08
55 O 0 1.3954456790088443e-07
CTG O 0 3.3756800803530496e-06
repeat O 0 2.430978796041927e-08
suggesting O 0 3.041693785732491e-09
that O 0 1.0500705166505142e-10
surrounding O 0 2.99102054235334e-09
sequences O 0 5.816966908156473e-10
and O 0 4.0083922292488694e-10
the O 0 1.4067969011932746e-09
chromatin O 0 3.712453278126304e-08
environment O 0 3.661050484993211e-08
are O 0 1.910615138323024e-10
involved O 0 2.1537596150977834e-09
in O 0 4.393418073789235e-09
instability O 0 4.134026312385686e-06
mechanisms O 0 0.16223134100437164
. O 0 6.512565050798003e-06

As O 0 9.385033195030701e-08
observed O 0 2.9618361097050183e-08
in O 0 5.398131941447559e-10
some O 0 1.6691723003781078e-10
of O 0 2.560571532583822e-09
the O 0 2.7623716647440233e-09
tissues O 0 4.1814498530357014e-08
of O 0 9.537769756207126e-07
DM B-Disease 1 1.0
patients O 0 7.842413829450834e-09
, O 0 2.2907406527217233e-10
there O 0 1.3027723344549713e-10
is O 0 2.5814494639120333e-11
a O 0 7.727892631370636e-11
tendency O 0 7.805698865048782e-10
for O 0 2.5097515732319664e-10
repeat O 0 1.1815058265085554e-08
length O 0 7.835236459641237e-09
and O 0 3.922079994111982e-09
somatic O 0 2.791872191210132e-07
mosaicism O 0 1.2836484586387087e-07
to O 0 1.2968966178750208e-10
increase O 0 6.977721872525322e-11
with O 0 3.519792096673413e-11
the O 0 8.0581796790824e-10
age O 0 7.40682937205861e-09
of O 0 2.408152122157503e-09
the O 0 6.624158999102292e-09
mouse O 0 2.1831449714682094e-07
. O 0 9.843200388104378e-08

Furthermore O 0 1.3960822116132476e-06
, O 0 7.088031050983545e-09
we O 0 1.8242461985451541e-09
observed O 0 1.159798146410651e-09
no O 0 1.3461383396862203e-10
correlation O 0 4.0702186065999513e-10
between O 0 5.804033365031103e-10
the O 0 1.3975327561865925e-09
somatic O 0 8.985013977280687e-08
mutation O 0 1.031030993914328e-08
rate O 0 5.834682514915812e-09
and O 0 3.745517229702955e-09
tissue O 0 4.448677159984982e-08
proliferation O 0 2.9914190236013383e-07
capacity O 0 1.3310095710039604e-06
. O 0 5.18594958975882e-07

The O 0 1.0846429177036043e-06
somatic O 0 4.5940983000036795e-06
mutation O 0 3.069893494966891e-08
rates O 0 5.176572948073499e-09
in O 0 1.6311248185463256e-10
different O 0 2.1299416397280169e-10
tissues O 0 1.6483426845681493e-09
were O 0 1.0055688504095883e-09
also O 0 8.266895501485294e-11
not O 0 4.9659183015693387e-11
correlated O 0 5.044565876133333e-10
to O 0 6.159309867692642e-11
the O 0 9.638898568198329e-10
relative O 0 2.4768726802903984e-07
inter O 0 0.0001823639904614538
- O 0 2.2809643951404723e-07
tissue O 0 8.560436803861649e-09
difference O 0 5.263681046585589e-09
in O 0 2.9507926657679207e-10
transcriptional O 0 3.856253982803537e-09
levels O 0 2.1028245811294255e-09
of O 0 5.566714866844791e-10
the O 0 4.913911499926371e-10
three O 0 6.102446326039512e-10
genes O 0 7.957299263949835e-10
( O 0 1.3298647738579916e-09
DMAHP O 0 1.843487211772299e-06
, O 0 7.2346706403436656e-09
DMPK O 0 3.460546849964885e-06
and O 0 1.2045010322481176e-08
59 O 0 5.158528892934555e-08
) O 0 8.450765087708589e-10
surrounding O 0 2.0939605605008182e-08
the O 0 1.8646497679242202e-08
repeat O 0 1.6251183865279017e-07
. O 0 5.974828098942453e-08
. O 0 5.957457460681326e-07

A O 0 9.64901119004935e-07
novel O 0 6.884569643261784e-07
missense O 0 4.766857273352798e-06
mutation O 0 7.207320606994472e-08
in O 0 7.220912312533301e-09
patients O 0 3.1154769875030297e-09
from O 0 2.27560459364895e-09
a O 0 1.301804974929155e-08
retinoblastoma B-Disease 0 0.0001998979423660785
pedigree O 0 1.0826565812749323e-06
showing O 0 1.474573423365655e-07
only O 0 3.672945947386097e-09
mild O 0 2.0951574697392061e-07
expression O 0 1.2015730632697341e-08
of O 0 1.030166085769224e-08
the O 0 6.901120119806592e-09
tumor B-Disease 0 1.1234643437774139e-07
phenotype O 0 1.7551118958181178e-07
. O 0 1.286800994648729e-07

We O 0 3.3544850452926767e-08
have O 0 2.3254215220092078e-10
used O 0 3.0433403019891614e-10
single O 0 8.687049968258975e-10
strand O 0 7.083611031077908e-09
conformation O 0 2.9877136320521913e-09
polymorphism O 0 1.0440199815775486e-09
analysis O 0 3.5646824381174724e-10
to O 0 6.213409647903845e-11
study O 0 1.250691217258293e-10
the O 0 4.214578686045911e-10
27 O 0 4.735700898095274e-08
exons O 0 1.725192788626373e-07
of O 0 2.310868119081988e-08
the O 0 1.869215005001479e-08
RB1 O 0 8.989708817352948e-07
gene O 0 9.202870687730069e-10
in O 0 1.173437597090654e-10
individuals O 0 1.7276442429436933e-11
from O 0 6.28236074273758e-11
a O 0 3.8153916137595445e-10
family O 0 1.4426490002605874e-09
showing O 0 2.0969460834407982e-08
mild O 0 1.5565556168439798e-06
expression O 0 1.3307236201853812e-07
of O 0 1.0307280717825051e-06
the O 0 2.6240422812406905e-07
retinoblastoma B-Disease 0 0.0006229071877896786
phenotype O 0 2.4965399916254682e-06
. O 0 6.049248781891947e-07

In O 0 4.026426481118506e-08
this O 0 3.1270621647649932e-09
family O 0 2.478754090873281e-09
affected O 0 1.2555582129536447e-09
individuals O 0 5.6036460194253124e-11
developed O 0 7.536212365266692e-08
unilateral B-Disease 0 0.0015311561292037368
tumors I-Disease 1 1.0
and O 0 1.0026871677837335e-05
, O 0 2.466219228836053e-09
as O 0 2.343083504996457e-10
a O 0 1.6162442217915185e-10
result O 0 1.6827395032947834e-09
of O 0 9.390401345399368e-09
linkage O 0 6.972023669504779e-08
analysis O 0 8.95870932993148e-09
, O 0 5.098016453430887e-10
unaffected O 0 9.876898410254853e-09
mutation O 0 5.367639110964717e-10
carriers O 0 3.5664640685162396e-10
were O 0 2.2089763351829106e-09
also O 0 1.241309277588698e-09
identified O 0 1.0090392521533431e-08
within O 0 9.133139577954807e-09
the O 0 1.7296580168135733e-08
pedigree O 0 1.1137772162328474e-06
. O 0 1.2342059108050307e-06

A O 0 6.387086273207387e-07
single O 0 3.6926795843328364e-08
band O 0 5.389474821981821e-08
shift O 0 5.732778518563464e-08
using O 0 2.9797078582305403e-08
SSCP O 0 1.4052648111828603e-05
was O 0 1.3601544424091117e-07
identified O 0 1.8388178091299778e-08
in O 0 2.40949371566046e-09
exon O 0 2.1487219115101652e-08
21 O 0 1.2134480087411248e-08
which O 0 1.5086330795721636e-10
resulted O 0 7.572273474920621e-09
in O 0 1.1885979978032424e-09
a O 0 8.23830248464219e-09
missense O 0 9.597498547009309e-07
mutation O 0 8.896034842109657e-08
converting O 0 4.5054076736050774e-07
a O 0 1.5087417182257923e-07
cys O 0 0.0002501963172107935
- O 0 2.8734915758832358e-05
- O 0 1.2043367860314902e-05
> O 0 2.0521772512438474e-06
arg O 0 1.6867880958670867e-06
at O 0 8.851166199974614e-08
nucleotide O 0 8.45205860855458e-09
position O 0 1.092695924853615e-07
28 O 0 1.3135367282757215e-07
in O 0 1.0300482244929299e-08
the O 0 9.298864256379602e-08
exon O 0 3.193580596416723e-06
. O 0 1.3897896451453562e-06

The O 0 3.449412417921849e-07
mutation O 0 8.889216474017303e-08
destroyed O 0 6.062716693122638e-07
an O 0 3.1023483781922323e-09
NdeI O 0 1.2293778581806691e-06
restriction O 0 5.993066309883943e-08
enzyme O 0 9.176621773576699e-08
site O 0 2.5890133770190005e-07
. O 0 3.8953703551669605e-07

Analysis O 0 2.980378894790192e-07
of O 0 6.184345124893298e-08
all O 0 3.9894101355741896e-09
family O 0 6.377341432717287e-10
members O 0 1.1168736074873564e-10
demonstrated O 0 1.2703582630280152e-09
that O 0 9.020392072178751e-11
the O 0 6.803347663009163e-09
missense O 0 2.6932568744086893e-06
mutation O 0 9.89809564089228e-07
co O 0 1.707289084151853e-05
- O 0 0.000136064481921494
segregated O 0 1.5777104067637993e-07
with O 0 2.2443533698179863e-09
patients O 0 2.3460909659434037e-08
with O 0 6.68128734560014e-08
tumors B-Disease 1 1.0
or O 0 0.005220646038651466
who O 0 3.620483113309092e-08
, O 0 8.88617401884062e-10
as O 0 4.753306082072584e-10
a O 0 5.782905820872486e-10
result O 0 7.696010051461144e-09
of O 0 7.274427815673334e-08
linkage O 0 2.3632703971543378e-07
analysis O 0 6.350958159373477e-08
had O 0 1.065024246571511e-08
been O 0 2.499195961291889e-09
predicted O 0 8.873373147366692e-09
to O 0 3.374574231163052e-10
carry O 0 1.87704540799416e-09
the O 0 1.3297690948377294e-08
predisposing O 0 4.306403752707411e-06
mutation O 0 5.084635290586448e-07
. O 0 1.7829460148277576e-06

These O 0 4.090051675120776e-08
observations O 0 1.4228177747099835e-07
point O 0 1.4888958510539396e-08
to O 0 3.155556371758905e-10
another O 0 9.601612838139317e-10
region O 0 2.192664050326698e-09
of O 0 1.1971033053725932e-08
the O 0 2.8255085382511425e-08
RB1 O 0 1.2241107469890267e-06
gene O 0 1.4079888366325122e-09
where O 0 1.1365198782087305e-09
mutations O 0 5.657279644744051e-10
only O 0 1.1136572913850173e-10
modify O 0 2.4681672261550602e-09
the O 0 2.920684527563111e-10
function O 0 1.1492545803903909e-09
of O 0 8.320890643176426e-10
the O 0 8.145613628052217e-10
gene O 0 9.338082529453118e-10
and O 0 4.666697583921575e-10
raise O 0 1.1955464396251614e-09
important O 0 3.5916898344368064e-09
questions O 0 5.721906060074389e-09
for O 0 3.176753027300805e-10
genetic O 0 8.043779864408407e-09
counseling O 0 8.226208603190344e-10
in O 0 1.961112799930831e-10
families O 0 4.164419156738042e-11
with O 0 3.105897830590898e-11
these O 0 4.959125332604231e-10
distinctive O 0 2.8745290592269157e-08
phenotypes O 0 3.2764413049335417e-07
. O 0 4.553410448693285e-08
. O 0 7.165322699620447e-07

Maternal B-Disease 0 0.00040432382957078516
disomy I-Disease 1 0.5443283319473267
and O 0 0.3007937967777252
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.6653148531913757
with O 0 1.0607365652504086e-08
gamete O 0 3.046544065909984e-07
complementation O 0 1.4384123687705141e-06
in O 0 4.2912740028100416e-10
a O 0 4.811887555078442e-10
case O 0 4.839641132292627e-09
of O 0 8.865896461429656e-09
familial O 0 4.194550484726278e-08
translocation O 0 2.2393175314050495e-08
( O 0 2.3059709697292874e-09
3 O 0 6.695191956396229e-08
; O 0 1.745192546032115e-09
15 O 0 3.959808125841846e-08
) O 0 2.7472808472595034e-09
( O 0 2.0974051384570203e-09
p25 O 0 1.5813422749033634e-07
; O 0 1.7220794790162586e-09
q11 O 0 7.057222717321565e-08
. O 0 3.3814444577728864e-09
2 O 0 1.1726169191206282e-07
) O 0 7.81247955217168e-09
. O 0 1.9696925335210835e-07

Maternal B-Disease 0 0.005177909508347511
uniparental I-Disease 1 0.9997627139091492
disomy I-Disease 1 0.9997599720954895
( I-Disease 0 2.034571298281662e-05
UPD I-Disease 1 1.0
) I-Disease 0 3.55555940245722e-08
for I-Disease 0 6.45205178173569e-09
chromosome I-Disease 0 9.933579292464856e-08
15 I-Disease 0 7.04460774159088e-08
is O 0 1.4117534918867136e-09
responsible O 0 9.273957601863003e-09
for O 0 3.675649229428757e-10
an O 0 1.0548642515040285e-10
estimated O 0 5.571803018966648e-10
30 O 0 1.8334307405609707e-09
% O 0 9.192620969988852e-11
of O 0 6.499639160217896e-10
cases O 0 3.8609351271645664e-09
of O 0 0.00014480396930593997
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0184351596981287
PWS B-Disease 1 1.0
) O 0 1.262860678252764e-07
. O 0 5.423275979410391e-07

We O 0 1.035931290971348e-06
report O 0 1.8130084100675958e-08
on O 0 4.852109380948377e-09
an O 0 5.683851306281795e-11
unusual O 0 8.252925010054923e-10
case O 0 3.650652224962414e-09
of O 0 9.725217076095305e-09
maternal B-Disease 0 2.828701610724238e-07
disomy I-Disease 0 8.045792128541507e-06
15 I-Disease 0 5.140859116181673e-07
in O 0 7.840951354864956e-08
PWS B-Disease 1 1.0
that O 0 2.65086796957803e-09
is O 0 1.9096242642735461e-10
most O 0 3.860857467063994e-11
consistent O 0 1.4464291986371336e-09
with O 0 1.1405018596200023e-10
adjacent O 0 4.556196753213726e-09
- O 0 1.6050329065819824e-08
1 O 0 6.168782107351944e-08
segregation O 0 2.2223783702202127e-08
of O 0 1.5006355047475495e-09
a O 0 1.3962564437974834e-09
paternal O 0 2.1149007878307202e-08
t O 0 1.1359801987964602e-07
( O 0 1.5691888899382889e-09
3 O 0 2.2934623089554407e-08
; O 0 6.982731060034553e-10
15 O 0 1.3223557360220184e-08
) O 0 6.526260087902358e-10
( O 0 4.580801848952376e-10
p25 O 0 3.4095727130534215e-08
; O 0 2.6938445918389675e-10
q11 O 0 1.4512382406906e-08
. O 0 3.3572147839500133e-10
2 O 0 6.4378169462031565e-09
) O 0 7.257523054748916e-11
with O 0 6.381865175209e-11
simultaneous O 0 2.7010912617697613e-08
maternal O 0 4.962139428243972e-07
meiotic O 0 1.8725691916188225e-05
nondisjunction O 0 1.824157516239211e-05
for O 0 8.351012326102136e-08
chromosome O 0 9.618858030080446e-07
15 O 0 1.4348637478178716e-06
. O 0 1.8778788444251404e-06

The O 0 9.393626783094078e-07
patient O 0 1.8414841918001912e-07
( O 0 7.570569948711636e-09
J O 0 2.903990434788284e-07
. O 0 1.4587748786709653e-09
B O 0 1.54751571557199e-08
. O 0 4.264738839854232e-10
) O 0 9.81281930712008e-11
, O 0 9.992532495894935e-11
a O 0 8.720218436231164e-10
17 O 0 1.3171904456044103e-08
- O 0 1.3774948293132638e-08
year O 0 2.928205011798468e-09
- O 0 4.618187432470222e-08
old O 0 2.658059372606658e-07
white O 0 1.23325314405065e-08
male O 0 4.038746226342482e-09
with O 0 1.7730946710869944e-09
PWS B-Disease 1 1.0
, O 0 1.267565874485399e-08
was O 0 4.6362803374222494e-08
found O 0 7.192263451472058e-10
to O 0 4.939998965447501e-10
have O 0 4.565269939860173e-09
47 O 0 1.4771026712878665e-07
chromosomes O 0 3.3599533821870864e-08
with O 0 2.1742898592691517e-09
a O 0 2.1821016105150193e-08
supernumerary O 0 1.9653311028378084e-05
, O 0 1.4680201054773079e-08
paternal O 0 2.435276655887719e-07
der O 1 0.9363235831260681
( O 0 3.21384732160368e-08
15 O 0 1.0241089398732584e-07
) O 0 8.215295110858278e-10
consisting O 0 3.6637102240888453e-09
of O 0 2.2729164328438856e-08
the O 0 9.557441416063739e-08
short O 0 1.642757467834599e-07
arm O 0 2.8819983981520636e-06
and O 0 1.0460020405389514e-07
the O 0 5.553638402489014e-07
proximal O 1 0.9672186374664307
long O 0 3.885507339873584e-06
arm O 0 1.1325104424031451e-05
of O 0 0.00013507761468645185
chromosome O 0 3.92295351048233e-06
15 O 0 9.617852811061312e-06
, O 0 8.027353715078789e-08
and O 0 9.022354561238899e-07
distal O 1 0.9669869542121887
chromosome O 1 0.7476668953895569
arm O 1 0.8953551054000854
3p O 1 0.9929996728897095
. O 0 6.361700070556253e-05

The O 0 6.6699944909487385e-06
t O 0 1.3213848433224484e-06
( O 0 4.995668323459768e-09
3 O 0 3.263872727643502e-08
; O 0 2.7286048420727127e-10
15 O 0 2.016950828576114e-09
) O 0 8.044814814311962e-11
was O 0 1.3124649145268563e-09
present O 0 2.1704726904658855e-10
in O 0 1.1379509140541089e-10
the O 0 4.213831228394582e-10
balanced O 0 2.3100341639548105e-09
state O 0 1.3053939873497455e-10
in O 0 2.0092551233918954e-10
the O 0 1.0042080500483053e-09
patients O 0 9.158638292205978e-10
father O 0 1.827635998097321e-08
and O 0 1.3938172394034609e-08
a O 0 5.691095950055569e-08
sister O 0 2.7128971851198003e-06
. O 0 1.0036753337772097e-05

Fluorescent O 0 3.6800627185584744e-06
in O 0 3.0707717257882905e-08
situ O 0 2.954927822429454e-07
hybridization O 0 1.0957154294999327e-08
analysis O 0 2.6896973537304802e-09
demonstrated O 0 5.303932848477189e-09
that O 0 3.892343114486607e-10
the O 0 1.8626522546583146e-08
PWS B-Disease 1 1.0
critical O 0 5.17016189860442e-07
region O 0 2.7261629398367404e-08
resided O 0 5.222502608148716e-08
on O 0 1.9436908971215416e-08
the O 0 3.864228048655605e-09
derivative O 0 1.190599885347865e-08
chromosome O 0 4.9548161129564505e-09
3 O 0 1.3663057352175656e-08
and O 0 1.9118036320708853e-10
that O 0 3.839560960838817e-11
there O 0 9.884897761436306e-11
was O 0 7.66074037539255e-10
no O 0 1.3162397560773087e-10
deletion O 0 3.341934284861736e-09
of O 0 6.392763651774658e-09
the O 0 5.449427931125683e-08
PWS B-Disease 1 1.0
region O 0 4.0468606243848626e-07
on O 0 1.1155694892295287e-06
the O 0 3.415672011897186e-08
normal O 0 4.476168768974276e-08
pair O 0 1.8159120429572795e-08
of O 0 2.242044239153529e-08
15s O 0 2.6181530756730353e-06
present O 0 1.5968433686452954e-08
in O 0 4.001513431717285e-08
J O 0 4.77971880172845e-05
. O 0 2.0619470433302922e-06

B O 0 0.0002904537250287831
. O 0 1.6678199244779535e-05

Methylation O 0 8.479126336169429e-06
analysis O 0 6.730992367920408e-07
at O 0 5.727837333324715e-07
exon O 0 2.1237620728697948e-07
alpha O 0 2.8730087819894834e-07
of O 0 2.3479934441184014e-08
the O 0 6.816648578933382e-09
small O 0 2.2119066578341062e-09
nuclear O 0 2.560732355050277e-07
ribonucleoprotein O 0 1.9428684026934206e-05
- O 0 1.9322303614899283e-06
associated O 0 1.843121708589024e-07
polypeptide O 0 7.485841138077376e-07
N O 0 2.2757328679290367e-06
( O 0 4.442705758833654e-09
SNRPN O 0 1.3249785979496664e-06
) O 0 9.95098003997441e-10
gene O 0 9.866047978590586e-10
showed O 0 4.386978780246409e-09
a O 0 1.360814905204677e-09
pattern O 0 2.6808994135762987e-08
characteristic O 0 4.674033604601391e-08
of O 0 8.932552475471311e-09
only O 0 8.160946918245315e-10
the O 0 2.9534179546431005e-09
maternal O 0 1.7973526666992257e-08
chromosome O 0 2.4312244661928162e-08
15 O 0 1.42579935413778e-07
in O 0 8.102666981812945e-08
J O 0 0.0007510443683713675
. O 0 1.8708486095420085e-05

B O 0 0.0002673010458238423
. O 0 1.1321572856104467e-05

Maternal B-Disease 0 4.1369825339643285e-05
disomy I-Disease 0 1.7433958419132978e-05
was O 0 1.2291839368572255e-07
confirmed O 0 1.018354645054842e-08
by O 0 5.016050907968861e-10
polymerase O 0 2.6627562377257163e-09
chain O 0 2.2516510878034524e-09
reaction O 0 1.2162487683653467e-09
analysis O 0 1.5375919204529964e-08
of O 0 2.28207337471531e-08
microsatellite O 0 6.959972438380646e-07
repeats O 0 1.3035931090144004e-07
at O 0 1.2828786566387862e-07
the O 0 1.1128514998404171e-08
gamma O 0 5.185108875593869e-07
- O 0 1.4792313152156567e-07
aminobutyric O 0 6.867487627459923e-07
acid O 0 4.281957544094439e-08
receptor O 0 1.4593273078844504e-07
beta3 O 0 1.7285027524849284e-06
subunit O 0 1.2774106039614708e-07
( O 0 2.970071300012478e-09
GABRB3 O 0 1.411975858900405e-06
) O 0 4.69601335595371e-09
locus O 0 3.6393430491443723e-07
. O 0 5.618192631118291e-07

A O 0 1.1770962373702787e-05
niece O 0 1.3457564818963874e-05
( O 0 3.816363403075229e-08
B O 0 8.794874872819491e-08
. O 0 8.478114321697205e-10
B O 0 5.2995643429198935e-09
. O 0 1.1801036536862597e-10
) O 0 2.7614625863758846e-11
with O 0 3.300804768402443e-11
45 O 0 4.320115931655266e-10
chromosomes O 0 5.897222155049064e-10
and O 0 1.8578816263215003e-10
the O 0 5.860935070600704e-10
derivative O 0 2.7959998760707094e-09
3 O 0 6.996826229510589e-09
but O 0 1.2038935126579275e-10
without O 0 4.950412302306972e-10
the O 0 2.667188470084625e-09
der O 0 2.2936581444810145e-05
( O 0 4.6345975945882856e-09
15 O 0 2.4456470626432747e-08
) O 0 7.721177586184069e-10
demonstrated O 0 1.8979228855187102e-08
a O 0 5.532834190802305e-09
phenotype O 0 1.1056458504299371e-07
consistent O 0 9.842333170695383e-09
with O 0 1.5447068624219185e-10
that O 0 1.5431755873152042e-10
reported O 0 4.622573879231595e-09
for O 0 1.281902695104975e-09
haploinsufficiency O 0 1.252186393685406e-06
of O 0 3.085644095790485e-07
distal O 0 3.5262339224573225e-05
3 O 0 0.00010055451275547966
p O 0 0.00011851416638819501
. O 0 3.4904799122159602e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 2.458716153341811e-06
with O 0 1.0787156057290304e-08
unbalanced O 0 1.2806011909560766e-05
segregation O 0 5.018462729822204e-07
of O 0 4.74029171471102e-08
non O 0 2.4720329747651704e-06
- O 0 9.129412887887156e-07
Robertsonian O 0 1.8356317013967782e-05
translocations O 0 1.115325972023129e-06
has O 0 1.8208637930783311e-09
been O 0 1.3829065670378782e-09
reported O 0 1.3989995828467272e-09
previously O 0 3.322650821147022e-09
but O 0 5.148241832841904e-10
has O 0 7.143316493873897e-11
not O 0 8.497617887126552e-11
, O 0 4.9827499765120464e-11
to O 0 1.096224361285536e-10
our O 0 1.4238685785983307e-09
knowledge O 0 5.745769193765682e-09
, O 0 2.368104323746678e-10
been O 0 3.576245966030456e-10
observed O 0 2.757844175249602e-09
in O 0 3.895120614938463e-10
a O 0 2.0652304311141734e-09
case O 0 9.813001611291838e-08
of O 0 3.128456000922597e-06
PWS B-Disease 1 1.0
. O 0 6.242583185667172e-05

Furthermore O 0 6.9690991040261e-06
, O 0 2.3902515522422618e-08
our O 0 1.827402229537256e-08
findings O 0 5.966762639530998e-09
are O 0 7.540011670581492e-11
best O 0 3.8450154171698614e-10
interpreted O 0 1.0938939754012722e-09
as O 0 7.461672946185161e-10
true O 0 2.720563330171899e-08
gamete O 0 8.189674645109335e-07
complementation O 0 4.5681558731303085e-06
resulting O 0 1.106875942014085e-07
in O 0 6.001508978670245e-08
maternal B-Disease 0 0.0002092498616548255
UPD I-Disease 1 1.0
15 I-Disease 0 0.00039087003096938133
and O 0 8.185692422557622e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.999738872051239
- I-Disease 1 0.9999995231628418
Jampel I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9939974546432495
type I-Disease 0 6.13512602285482e-05
2 I-Disease 0 9.996690641855821e-05
and O 0 2.361882422974304e-07
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 5.466310071255975e-09
a O 0 9.131131406547865e-10
case O 0 1.7850390054974241e-09
for O 0 2.261126841318628e-10
" O 0 9.965114955434728e-09
lumping O 0 3.599667408593632e-08
" O 0 1.5286241250578314e-07
. O 0 5.686537747351395e-07

Recent O 0 1.1975970437561045e-07
studies O 0 1.863497800513869e-08
demonstrated O 0 3.7378111272801107e-08
the O 0 6.3298166708136705e-09
existence O 0 2.5994825847419634e-08
of O 0 7.357576325972559e-09
a O 0 2.4870414616628977e-09
genetically O 0 1.0956735962963648e-08
distinct O 0 4.066775360911379e-09
, O 0 3.705445950075159e-10
usually O 0 2.096623985536894e-10
lethal O 0 3.963410932783518e-09
form O 0 6.206025915389546e-09
of O 0 1.1715583525528928e-07
the O 0 1.30015166632802e-07
Schwartz B-Disease 1 0.8243257999420166
- I-Disease 1 0.9999780654907227
Jampel I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999914169311523
( O 0 4.7326487617738167e-08
SJS B-Disease 0 0.0009388474863953888
) O 0 2.7301851446281944e-08
of O 0 9.031419949678821e-07
myotonia B-Disease 1 0.9999994039535522
and O 0 0.0018462640000507236
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 0.9999997615814209
, O 0 3.445791918466057e-08
which O 0 5.6314877205920766e-09
we O 0 2.5259140556954662e-08
called O 0 6.579787026339545e-08
SJS B-Disease 0 0.00013439424219541252
type I-Disease 0 6.413799383153673e-06
2 I-Disease 0 2.5731224013725296e-05
. O 0 1.0376735417594318e-06

This O 0 4.1870686118272715e-07
disorder O 0 0.19443553686141968
is O 0 1.1515696174413392e-09
reminiscent O 0 2.252137498715001e-08
of O 0 9.391333044561634e-09
another O 0 1.7855839029579101e-09
rare O 0 6.09820238750558e-09
condition O 0 9.865002681408441e-08
, O 0 3.7065082114651204e-09
the O 0 5.213008691384857e-08
Stuve B-Disease 1 0.999997615814209
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.116392564261332e-06
SWS B-Disease 0 0.003098650835454464
) O 0 4.306346390592353e-09
, O 0 5.956912185745011e-10
which O 0 1.0710474729336283e-09
comprises O 0 9.32514776508242e-09
campomelia B-Disease 0 1.0742763834059588e-06
at O 0 1.775875091425405e-07
birth O 0 3.1945262435328914e-07
with O 0 9.242457821301286e-08
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.0375904366810573e-06
contractures B-Disease 1 0.7107319235801697
, O 0 1.958845707861201e-08
and O 0 7.494281639708333e-09
early B-Disease 0 9.218142054123746e-07
death I-Disease 0 4.966521828464465e-06
. O 0 1.7192223822348751e-06

To O 0 2.982590530109519e-08
test O 0 3.21209441267456e-08
for O 0 3.3832681101131357e-10
possible O 0 6.8143868325876156e-09
nosologic O 0 5.28272380506678e-07
identity O 0 7.581942185197477e-09
between O 0 2.413128363798478e-08
these O 0 6.659389040208907e-09
disorders O 0 1.4623951472003682e-07
, O 0 1.588924269935177e-10
we O 0 3.568028927869449e-10
reviewed O 0 2.6724029655866843e-09
the O 0 1.6748392950294289e-10
literature O 0 1.0233308644913564e-09
and O 0 1.5033535527564368e-10
obtained O 0 1.5336983905100965e-09
a O 0 4.495158412165523e-10
follow O 0 1.1033444158314865e-09
- O 0 1.5945841314035647e-09
up O 0 1.331724591713268e-10
of O 0 2.020222461540655e-10
the O 0 9.010418799970665e-11
only O 0 6.299964022682403e-11
two O 0 1.7093944315593745e-10
surviving O 0 7.1767551901302795e-09
patients O 0 1.5743864545392228e-10
, O 0 4.0938560874614893e-10
one O 0 1.523078441145742e-09
with O 0 4.68733363234719e-09
SJS B-Disease 0 0.00017862401728052646
type I-Disease 0 0.0017305053770542145
2 I-Disease 0 0.00096878781914711
at O 0 2.2371473562543542e-07
age O 0 5.715078188472944e-09
10 O 0 7.80266184996492e-10
years O 0 1.2285751582741256e-10
and O 0 6.791374407288941e-11
another O 0 3.6020955662685594e-10
with O 0 8.489716707416051e-10
SWS B-Disease 0 1.8703759678828646e-06
at O 0 2.0310425341563132e-08
age O 0 1.6659486234971155e-08
7 O 0 1.576254646806774e-07
years O 0 2.588089209609734e-08
. O 0 1.8368677956459578e-07

Patients O 0 7.385149842775718e-07
reported O 0 4.58226594446387e-08
as O 0 3.066374487659118e-09
having O 0 2.039194058056637e-08
either O 0 4.0616305341245607e-07
neonatal O 1 0.9999994039535522
SJS B-Disease 1 1.0
or O 0 0.000257939042057842
SWS B-Disease 0 0.0013614492490887642
presented O 0 3.967481632116687e-08
a O 0 1.2259026016536723e-09
combination O 0 6.756896375748056e-09
of O 0 1.583528508319887e-08
a O 0 7.821172154365286e-09
severe O 0 0.00011560186976566911
, O 0 5.776980671612364e-08
prenatal O 0 0.3521808683872223
- O 1 0.9676262140274048
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 1.118581167247612e-06
with O 0 1.0872945495066233e-05
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999998807907104
respiratory O 1 1.0
and O 1 0.9840552806854248
feeding O 0 0.05791384354233742
difficulties O 1 0.9519161581993103
, O 0 4.559546340487941e-08
tendency O 0 1.1569865421279246e-07
to O 0 1.4020669958370036e-08
hyperthermia B-Disease 1 0.9989621639251709
, O 0 5.715056428101661e-09
and O 0 1.5975584188865355e-09
frequent O 0 8.333343459732134e-10
death O 0 3.210202521586325e-07
in O 0 9.483277274568991e-09
infancy O 0 1.3351387906368473e-06
) O 0 3.9511208194120684e-10
with O 0 9.925346655670353e-11
a O 0 3.0088096458769087e-09
distinct O 0 2.84335555988946e-07
campomelic B-Disease 1 0.8970116376876831
- I-Disease 1 0.9999978542327881
metaphyseal I-Disease 1 0.9999505281448364
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 0.9999996423721313
. O 0 7.196552905952558e-05

The O 0 1.9036644971492933e-07
similarity O 0 1.2555844364214863e-07
of O 0 6.89937209585878e-08
the O 0 8.867317546901177e-09
clinical O 0 5.425967586347724e-08
and O 0 2.2950363831597542e-09
radiographic O 0 4.984734005120117e-06
findings O 0 3.8681022829223366e-07
is O 0 8.070854540243033e-10
so O 0 2.1125602656102416e-10
extensive O 0 1.129005333666555e-09
that O 0 3.899640332871712e-10
these O 0 1.4614102816778995e-08
disorders O 0 7.722738700977061e-06
appear O 0 2.867277526519274e-09
to O 0 2.3676979821196653e-10
be O 0 7.080973585260608e-10
a O 0 7.955963665651211e-10
single O 0 4.7303361228046015e-09
entity O 0 2.9830061976099387e-07
. O 0 2.0309630599513184e-06

The O 0 2.093730245178449e-06
follow O 0 4.170295824224013e-07
- O 0 2.6638096528586175e-07
up O 0 2.9989151162368444e-09
observation O 0 1.3891144234889907e-08
of O 0 7.026713100266591e-10
an O 0 2.7559798193577123e-11
identical O 0 2.1116750570371323e-09
and O 0 7.062037066241089e-10
unique O 0 4.979942236360557e-09
pattern O 0 1.1071247172367293e-06
of O 0 0.00014883534458931535
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 2.3778679292263405e-07
the O 0 2.782152250802028e-07
two O 0 1.3920531394262525e-08
patients O 0 1.211643452236899e-09
( O 0 3.39321404307924e-10
one O 0 6.017194520424596e-10
with O 0 1.222255630040081e-09
SJS B-Disease 0 2.7807947844848968e-05
type I-Disease 0 9.889520697470289e-06
2 I-Disease 0 6.7142091211280786e-06
, O 0 7.331334983540216e-10
one O 0 1.0243560444322952e-09
with O 0 2.2052297765640105e-09
SWS B-Disease 0 3.4278157272638055e-06
) O 0 2.5316089224958205e-09
surviving O 0 7.987399186504263e-08
beyond O 0 2.0264731404040504e-07
infancy O 0 3.7791392060171347e-07
adds O 0 1.026443463558735e-08
to O 0 2.6619420556706075e-10
the O 0 3.020710903633983e-10
evidence O 0 1.1830250112865315e-09
in O 0 2.3009041894006543e-10
favor O 0 9.375690446233875e-09
of O 0 1.2713575969769408e-08
identity O 0 8.58822630789291e-08
. O 0 4.969512588104408e-07

The O 0 5.533300964088994e-07
hypothesis O 0 1.2407841722961166e-06
that O 0 2.0602074712883223e-08
SWS B-Disease 0 2.139094431186095e-05
and O 0 1.7768356030956056e-07
SJS B-Disease 0 0.00020198590937070549
type I-Disease 0 2.1188623577472754e-05
2 I-Disease 0 1.749523107719142e-05
are O 0 7.256281131517994e-10
the O 0 1.4570620265885736e-09
same O 0 4.991096869133571e-09
disorder O 0 1.4435366324505594e-07
should O 0 2.365603268827954e-10
be O 0 5.310763495636195e-10
testable O 0 3.828809269634803e-08
by O 0 1.663901932902334e-10
molecular O 0 1.173640207241533e-08
methods O 0 3.870197318178725e-08
. O 0 8.35425861822614e-09
. O 0 1.1252786435989037e-07

A O 0 5.452356163004879e-06
mouse O 0 4.2613731920937425e-07
model O 0 6.553683817855926e-08
of O 0 5.466135633014346e-08
severe O 1 0.9999992847442627
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9999277591705322
defects O 1 0.9999994039535522
in O 0 5.733411967412394e-07
hemostasis O 1 0.6050219535827637
and O 0 4.903743501927238e-06
thrombosis B-Disease 0 0.03236573934555054
. O 0 3.492589894449338e-05

von B-Disease 1 0.9998834133148193
Willebrand I-Disease 1 0.9999727010726929
factor I-Disease 0 0.055604416877031326
( I-Disease 0 4.795350378117291e-06
vWf I-Disease 1 0.8420969843864441
) I-Disease 0 1.3761229638475925e-05
deficiency I-Disease 1 0.9999998807907104
causes O 1 0.9999909400939941
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.1391180455684662
humans O 0 1.6359566870960407e-05
. O 0 6.651514468103414e-07

We O 0 3.600482045840181e-07
generated O 0 3.231858158869727e-08
a O 0 8.778715532287151e-09
mouse O 0 1.4354201383071086e-08
model O 0 4.196941016942901e-09
for O 0 6.876607616668196e-11
this O 0 3.909707627092196e-11
disease O 0 2.1722161569481813e-10
by O 0 9.62048409686167e-12
using O 0 7.383467170996028e-10
gene O 0 5.274555459067187e-09
targeting O 0 9.29581460695772e-08
. O 0 4.058977935983421e-07

vWf B-Disease 0 0.003276075003668666
- I-Disease 1 0.9975180625915527
deficient I-Disease 0 0.0011071586050093174
mice O 0 3.218163442397781e-07
appeared O 0 5.3863406179743833e-08
normal O 0 2.307837654313971e-08
at O 0 7.110915412056329e-09
birth O 0 3.501821055351684e-10
; O 0 4.5236165507889226e-11
they O 0 1.4299096628977992e-10
were O 0 1.3611186622242144e-09
viable O 0 5.3097355845466154e-08
and O 0 1.5282530796412175e-08
fertile O 0 1.608217417015112e-06
. O 0 1.8148942899642861e-06

Neither O 0 6.453211972257122e-05
vWf O 0 0.00041717514977790415
nor O 0 3.9725742681184784e-05
vWf O 0 0.00020057092478964478
propolypeptide O 0 9.607712854631245e-05
( O 0 3.3879703664752014e-07
von B-Disease 0 0.0004564559494610876
Willebrand I-Disease 0 0.00010506225225981325
antigen O 0 9.87897124105075e-07
II O 1 0.8335350155830383
) O 0 7.822932523993131e-09
were O 0 6.108027417184303e-09
detectable O 0 1.9158939323915547e-08
in O 0 4.234505524003396e-10
plasma O 0 6.937307173160434e-09
, O 0 2.0446523640860192e-10
platelets O 0 1.533133953124377e-09
, O 0 1.0162057306750683e-10
or O 0 1.0368673974969767e-10
endothelial O 0 3.166680528909893e-10
cells O 0 1.478246136610295e-10
of O 0 4.423205690606835e-10
the O 0 1.9018575603269028e-09
homozygous O 0 1.1477069250531713e-07
mutant O 0 1.9330707345943665e-06
mice O 0 2.391165025983355e-06
. O 0 1.0274736723658862e-06

The O 0 1.4256745544116711e-06
mutant O 0 2.7300733563606627e-05
mice O 0 4.876708317169687e-06
exhibited O 0 3.429045136726927e-06
defects O 0 0.00022137605992611498
in O 0 3.613784116396346e-08
hemostasis O 0 0.0001913560990942642
with O 0 2.9821622948844606e-09
a O 0 1.6667305757778195e-08
highly O 0 1.6911693592192023e-06
prolonged O 1 0.752888560295105
bleeding O 1 0.9996956586837769
time O 0 1.2290847735130228e-06
and O 0 4.125347530248291e-08
spontaneous O 0 1.3670467069459846e-07
bleeding O 0 7.904903327471402e-07
events O 0 3.2965674634510833e-09
in O 0 3.844076723602541e-10
approximately O 0 3.8910735744579483e-10
10 O 0 1.5654251228625071e-09
% O 0 2.441123969632031e-10
of O 0 8.128668405049666e-09
neonates O 0 1.4081729204917792e-06
. O 0 1.2666180282394635e-06

As O 0 6.223737614163838e-08
in O 0 6.877270308791594e-09
the O 0 6.962014964528862e-09
human O 0 2.2955452649853214e-08
disease O 0 1.1725662218964317e-08
, O 0 8.396775635910458e-11
the O 0 3.551279270652685e-10
factor O 0 6.385037387701686e-09
VIII O 0 1.096551841328619e-05
level O 0 8.697766702425724e-07
in O 0 1.0301655084532513e-09
these O 0 4.572360823296151e-10
mice O 0 3.2258951065955443e-09
was O 0 1.0565077701585324e-09
reduced O 0 1.3458024694656956e-09
strongly O 0 1.4427556371821026e-10
as O 0 3.0897024522191785e-11
a O 0 2.3281630096017025e-11
result O 0 1.5373557982201191e-10
of O 0 3.5319933089361655e-10
the O 0 1.4938979220335824e-10
lack O 0 2.892468042858809e-09
of O 0 8.321732192229092e-10
protection O 0 1.1204095429206973e-09
provided O 0 7.141848779035342e-10
by O 0 2.1494792612486435e-09
vWf O 0 2.8964282137167174e-06
. O 0 1.4281974927143892e-06

Defective O 0 0.0027417305391281843
thrombosis B-Disease 0 0.00023058826627675444
in O 0 1.8350695540902962e-07
mutant O 0 6.521898399114434e-07
mice O 0 7.538297097653412e-08
was O 0 1.2959929129863212e-08
also O 0 2.925200359715774e-10
evident O 0 2.9968680870240405e-09
in O 0 1.4456395802664446e-10
an O 0 1.7592946197075854e-11
in O 0 1.6845819184041488e-10
vivo O 0 1.300261409653558e-08
model O 0 5.5148099420421204e-08
of O 0 4.1811017581494525e-06
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 0.0022699469700455666

In O 0 3.436124274003305e-08
this O 0 1.2439448360268557e-09
model O 0 1.0704393815785807e-08
, O 0 7.399864054846716e-10
the O 0 7.0110939276446516e-09
exteriorized O 0 1.3598084933619248e-06
mesentery O 0 4.009615167888114e-06
was O 0 1.9182841981546517e-07
superfused O 0 1.7436017287764116e-06
with O 0 7.87207188324146e-09
ferric O 0 1.5574970575471525e-06
chloride O 0 7.66182921552172e-08
and O 0 1.3248606478555303e-07
the O 0 5.8894045196211664e-08
accumulation O 0 3.7384285178632126e-07
of O 0 3.424880787861184e-07
fluorescently O 0 7.618583595103701e-07
labeled O 0 2.8046756028743403e-08
platelets O 0 4.86102322838633e-08
was O 0 3.073877508086298e-08
observed O 0 1.3263367293347983e-08
by O 0 5.3556972190449414e-09
intravital O 0 3.847873358608922e-06
microscopy O 0 1.8582273696665652e-05
. O 0 2.4820208182063652e-06

We O 0 4.538968596534687e-07
conclude O 0 4.000972353424004e-07
that O 0 6.86387446879877e-10
these O 0 1.2604266519389284e-09
mice O 0 1.7280786579476626e-08
very O 0 2.7424120752073122e-09
closely O 0 2.6476453029999902e-08
mimic O 0 7.610837656102376e-06
severe O 0 0.41064396500587463
human O 1 0.9990257024765015
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 5.9336678532417864e-05
will O 0 2.8704747023766686e-08
be O 0 1.878141198119465e-09
very O 0 3.4290370543033077e-10
useful O 0 9.674372414281152e-10
for O 0 5.2191487243113954e-11
investigating O 0 9.839062897754047e-10
the O 0 1.601517668481378e-10
role O 0 1.3866836567899554e-09
of O 0 6.022640164360382e-09
vWf O 0 4.34499838775082e-07
in O 0 2.3409461036294488e-08
normal O 0 1.2057339517923538e-06
physiology O 0 6.231908173504053e-06
and O 0 1.390407966539442e-08
in O 0 7.260715140233742e-09
disease O 0 5.0437336085451534e-08
models O 0 2.5346059473463356e-08
. O 0 1.3010429178450522e-08
. O 0 2.1935903760095243e-07

Oral O 0 2.1898580598644912e-05
contraceptives O 0 1.2067429224771331e-06
and O 0 5.524471990980828e-09
the O 0 4.217001414730248e-09
risk O 0 3.647213020485651e-07
of O 0 0.4809933006763458
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.1701703667640686

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999963045120239
Clinical O 0 0.0006352727068588138
Study O 0 3.8506306054841843e-07
Group O 0 7.800853296657806e-08
. O 0 1.0508879313420039e-06

BACKGROUND O 0 1.075716227205703e-05
Women O 0 7.216729613901407e-08
with O 0 7.968827264726031e-10
mutations O 0 2.0765507091624613e-09
in O 0 3.1626784524618756e-10
either O 0 1.540314986669955e-09
the O 0 8.771333881441024e-09
BRCA1 O 0 8.326006550873899e-09
or O 0 1.7927159756681021e-09
the O 0 4.951131948871534e-09
BRCA2 O 0 2.4153662181447544e-08
gene O 0 4.189207203353362e-09
have O 0 5.704283156937606e-10
a O 0 1.3804609677592339e-09
high O 0 7.921598665916463e-08
lifetime O 0 3.2937228411356045e-07
risk O 0 2.5900879336404614e-05
of O 1 0.9999978542327881
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.2916586697101593

Oral O 0 0.00012079872249159962
contraceptives O 0 0.00011295925651211292
protect O 0 7.607811312482227e-06
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.253553250535333e-06
general O 0 3.856698072013387e-07
, O 0 8.513212357286193e-10
but O 0 1.8782692068342044e-10
it O 0 3.406330773003674e-11
is O 0 9.9596468225438e-12
not O 0 1.1152382836665531e-11
known O 0 5.837259148266938e-11
whether O 0 1.9474886980841433e-10
they O 0 1.7426038390055965e-10
also O 0 1.0197491462360375e-10
protect O 0 5.375199729762414e-10
against O 0 5.855086726569425e-08
hereditary B-Disease 1 1.0
forms I-Disease 1 0.9999992847442627
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0033388773445039988

METHODS O 0 1.8499187035558862e-06
We O 0 4.5503192325213604e-08
enrolled O 0 2.3283085681669036e-08
207 O 0 4.5000181359000635e-08
women O 0 5.071871367334779e-09
with O 0 1.2667199733584766e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.859419000993512e-07
161 O 0 2.6614880965780685e-08
of O 0 1.8876088248021006e-08
their O 0 4.32846718467772e-08
sisters O 0 6.881392664581654e-07
as O 0 9.869515871230305e-09
controls O 0 1.451483910841489e-07
in O 0 1.6766531274470253e-08
a O 0 2.4956294808475832e-08
case O 0 6.847214422123216e-07
- O 0 5.331148145160114e-07
control O 0 2.1109215708747797e-07
study O 0 7.51620135019948e-08
. O 0 2.1520077098102774e-07

All O 0 1.0667709915423984e-07
the O 0 6.0732689988185484e-09
patients O 0 3.0047536681010456e-10
carried O 0 3.767094691742301e-10
a O 0 3.8895375809033794e-10
pathogenic O 0 4.046373547339499e-08
mutation O 0 4.383189811107968e-09
in O 0 3.909920387457078e-09
either O 0 5.5751684158167336e-08
BRCA1 O 0 6.769979421505923e-08
( O 0 4.952605436869817e-09
179 O 0 2.3788267355939752e-08
women O 0 2.276498989317588e-09
) O 0 9.072764761697272e-10
or O 0 1.1217680118136286e-08
BRCA2 O 0 9.320580574012638e-08
( O 0 1.2829136863956592e-08
28 O 0 8.200357797250035e-07
women O 0 7.378829280924037e-08
) O 0 2.8636829796369057e-08
. O 0 8.734940024623938e-07

The O 0 8.138862881423847e-07
control O 0 1.1957018841712852e-06
women O 0 1.1049770876070397e-08
were O 0 4.855090551814101e-09
enrolled O 0 2.0222630237043404e-09
regardless O 0 2.5206092768570443e-09
of O 0 2.144151967087282e-09
whether O 0 6.054436951785647e-10
or O 0 2.6642379968855323e-10
not O 0 1.5478714143757344e-10
they O 0 3.679149485069644e-10
had O 0 1.9214629887187584e-09
either O 0 1.9380083315923002e-08
mutation O 0 1.7460199330798787e-07
. O 0 9.177100537272054e-07

Lifetime O 0 9.98592258838471e-06
histories O 0 1.1763921747842687e-06
of O 0 6.059000270397519e-07
oral O 0 1.8080687596011558e-06
- O 0 6.033587851561606e-08
contraceptive O 0 7.1302279636142885e-09
use O 0 5.037565919963072e-10
were O 0 8.312483479322452e-10
obtained O 0 2.3248638569839386e-09
by O 0 1.7941211016836434e-10
interview O 0 6.401963403845912e-09
or O 0 2.1830776075759672e-10
by O 0 4.258688887648354e-11
written O 0 1.1204924488250612e-10
questionnaire O 0 1.4650815283179242e-10
and O 0 7.365881515841721e-11
were O 0 3.123269420868269e-10
compared O 0 4.2861039717401184e-10
between O 0 3.4723719455342916e-09
patients O 0 4.71514605138168e-10
and O 0 1.0583109943951285e-09
control O 0 4.079412519786274e-06
women O 0 2.1304760622342656e-08
, O 0 9.190906924416709e-10
after O 0 7.4352519696674335e-09
adjustment O 0 9.798427846874347e-09
for O 0 2.153023315187852e-10
year O 0 4.4172282498422533e-10
of O 0 2.210713168082634e-09
birth O 0 1.3742982751807631e-08
and O 0 3.377165924689507e-08
parity O 0 3.828791250271024e-06
. O 0 1.1372933386155637e-06

RESULTS O 0 2.608577415230684e-05
The O 0 2.3174366958755854e-07
adjusted O 0 2.711136346533749e-07
odds O 0 2.4176299007194757e-07
ratio O 0 2.712289699502435e-07
for O 0 6.599783546334947e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.2229190815560287e-07
with O 0 1.3505255247459047e-10
any O 0 3.0594035638209505e-10
past O 0 6.757485682129527e-10
use O 0 1.0724123672423147e-10
of O 0 7.009485769593482e-10
oral O 0 1.2462205489782718e-08
contraceptives O 0 2.733535708898671e-08
was O 0 2.2962197476772417e-08
0 O 0 1.778349343339869e-07
. O 0 1.8568920268080547e-07

5 O 0 4.1811176743067335e-06
( O 0 2.5161961403341593e-08
95 O 0 1.0556667717764867e-07
percent O 0 7.323316619789466e-09
confidence O 0 7.471235363709638e-08
interval O 0 1.5671826503194097e-08
, O 0 1.1660970800075887e-10
0 O 0 8.4577311820766e-10
. O 0 3.34367845911121e-11
3 O 0 5.335750730139921e-10
to O 0 5.147532747273864e-11
0 O 0 4.212170168216289e-09
. O 0 4.709313494721812e-10
8 O 0 4.046937007728957e-08
) O 0 4.290146904395442e-09
. O 0 1.1047941939068551e-07

The O 0 5.895788035559235e-07
risk O 0 1.3609795246338763e-07
decreased O 0 2.7756824394487012e-08
with O 0 1.8095830389697198e-10
increasing O 0 1.0213302426009818e-09
duration O 0 6.292236509608529e-09
of O 0 6.742062463871434e-10
use O 0 7.359116094285412e-10
( O 0 1.0287753982041181e-09
P O 0 1.806726146469373e-07
for O 0 2.8626859216451805e-10
trend O 0 4.315901414031487e-09
, O 0 1.6654959356099397e-10
< O 0 3.6124039315410528e-09
0 O 0 1.6334825714281465e-09
. O 0 1.5174234091475114e-10
001 O 0 8.040497156969195e-09
) O 0 8.495571433841942e-12
; O 0 2.6239913020198458e-12
use O 0 3.0546207924198043e-11
for O 0 1.610391542339329e-10
six O 0 9.58477963663995e-10
or O 0 1.0635980984829985e-10
more O 0 1.3911856909520903e-11
years O 0 1.7097759319462114e-10
was O 0 6.500097682327066e-10
associated O 0 3.7177358414020034e-10
with O 0 5.13695926074309e-11
a O 0 3.223113720363102e-10
60 O 0 2.114826980204043e-09
percent O 0 1.5716090651096692e-09
reduction O 0 2.4180398128237357e-08
in O 0 1.2306965224695432e-08
risk O 0 1.124059622270579e-06
. O 0 2.3361926650977693e-06

Oral O 0 0.0001546889980090782
- O 0 2.618163080114755e-06
contraceptive O 0 1.5124585672765534e-07
use O 0 4.7498103228349464e-09
protected O 0 3.195643330400344e-06
against O 1 0.9999992847442627
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 8.783690219615892e-09
for O 0 5.800758207108458e-10
carriers O 0 1.620899664489528e-10
of O 0 2.1452903453678118e-08
the O 0 8.484236957428948e-08
BRCA1 O 0 8.878897261865859e-08
mutation O 0 8.477536894702098e-09
( O 0 8.149839691995453e-10
odds O 0 5.031214200812428e-08
ratio O 0 3.5446288126905756e-09
, O 0 2.0293444702446095e-10
0 O 0 3.524780911590142e-09
. O 0 1.0154519586302868e-10
5 O 0 1.1138873157179319e-09
; O 0 1.0913592252137505e-10
95 O 0 4.563354583098089e-09
percent O 0 1.3631112905088116e-09
confidence O 0 3.732254683086467e-08
interval O 0 1.150360517954141e-08
, O 0 8.924352229433552e-11
0 O 0 6.035919541957924e-10
. O 0 2.2753243733575346e-11
3 O 0 3.3689276368598087e-10
to O 0 3.840425200074549e-11
0 O 0 1.3075477367507915e-09
. O 0 1.4943424275770667e-10
9 O 0 6.450033840366132e-09
) O 0 7.232373033794204e-11
and O 0 7.248890376843065e-11
for O 0 4.068927486611251e-11
carriers O 0 2.336398297053677e-10
of O 0 8.607589307985108e-09
the O 0 7.353089870321128e-08
BRCA2 O 0 2.0704699466023158e-07
mutation O 0 1.8044355343249663e-08
( O 0 1.082352540926479e-09
odds O 0 4.096414585319508e-08
ratio O 0 4.176545775891327e-09
, O 0 3.141701621078852e-10
0 O 0 4.219125049331751e-09
. O 0 1.7573402455450804e-10
4 O 0 5.695457883092558e-09
; O 0 1.5419486520951153e-10
95 O 0 8.852125255032206e-09
percent O 0 2.4405477638822504e-09
confidence O 0 3.512005264383333e-08
interval O 0 1.2153265060987906e-08
, O 0 1.2192467868654688e-10
0 O 0 6.954778419832053e-10
. O 0 2.7392935142422914e-11
2 O 0 4.761754324178469e-10
to O 0 6.35939842452693e-11
1 O 0 2.263967457949434e-09
. O 0 5.824916660124302e-10
1 O 0 2.94744868511998e-08
) O 0 3.3090723494666463e-09
. O 0 6.901188953634119e-08

CONCLUSIONS O 0 0.00045603522448800504
Oral O 0 0.0005834752810187638
- O 0 5.748068815591978e-06
contraceptive O 0 1.9465555567421688e-07
use O 0 3.1394926658379063e-09
may O 0 8.166680665055992e-09
reduce O 0 2.0163209768497836e-08
the O 0 1.5091814020706806e-08
risk O 0 2.475453811712214e-06
of O 1 0.9987347722053528
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.5806320991250686e-07
women O 0 6.657379092445126e-10
with O 0 1.0592635796280447e-10
pathogenic O 0 6.048163214700253e-08
mutations O 0 1.1244107867014463e-09
in O 0 1.3872337722986572e-09
the O 0 2.1118937709729835e-08
BRCA1 O 0 3.5220043059780437e-07
or O 0 5.521514481188206e-07
BRCA2 O 0 1.6726942703826353e-05
gene O 0 1.833243550208863e-05

A O 0 1.2680212648774614e-06
Japanese O 0 1.3267640497360844e-06
family O 0 6.005402042319474e-08
with O 0 2.4030601508684413e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.3803036047477235e-08
a O 0 3.152918637283619e-08
codon O 0 3.0515570870193187e-07
291 O 0 1.4946952830996452e-07
deletion O 0 1.0138624872979562e-07
: O 0 3.3767522111816106e-09
a O 0 2.9787117217239256e-09
clinical O 0 6.158553844670678e-08
, O 0 1.8352850350566996e-09
biochemical O 0 3.020288374955271e-07
, O 0 1.1765943774832976e-08
pathological O 0 5.051717744208872e-05
, O 0 8.481030100426779e-09
and O 0 1.3481591842889884e-08
genetic O 0 1.8820909986061451e-07
report O 0 1.0415028839361185e-07
. O 0 1.4930897123122122e-06

We O 0 3.015343850165664e-07
report O 0 7.738845120286442e-09
a O 0 1.5566061772886997e-09
Japanese O 0 5.4843379615476806e-08
family O 0 3.72780810664608e-08
with O 0 4.2437838487785484e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.2814096510410309
ALD B-Disease 1 1.0
) O 0 6.378294337139323e-09
with O 0 4.876182235769022e-10
a O 0 3.072644805257596e-09
three O 0 2.8866700141350066e-09
base O 0 3.4403608850652745e-08
pair O 0 1.9992535271740053e-07
deletion O 0 4.209959456602519e-07
( O 0 3.066978493393435e-08
delGAG O 0 2.3980799142009346e-06
291 O 0 1.0535144667755958e-07
) O 0 2.5857094243519896e-09
in O 0 1.0392958493810056e-08
the O 0 9.027846203935042e-07
ALD B-Disease 1 1.0
gene O 0 4.475666628422914e-06
. O 0 6.3469537963101175e-06

A O 0 3.9677848917563097e-07
variety O 0 2.2923076770098305e-08
of O 0 1.4016285909690396e-08
phenotypes O 0 5.1490918195895574e-08
were O 0 3.829931927157304e-09
observed O 0 5.341883380083345e-09
within O 0 1.4322086849816174e-09
this O 0 7.754266118098485e-10
family O 0 7.3976100800621225e-09
. O 0 1.1535380650684601e-07

While O 0 1.0877448630708386e-07
the O 0 5.5460866121848085e-08
proband O 0 5.191954187466763e-06
( O 0 2.81636025611931e-09
patient O 0 7.585775563256902e-09
1 O 0 9.163976244508376e-08
) O 0 7.608550456339458e-10
was O 0 5.247842604916286e-09
classified O 0 8.785562277680015e-10
as O 0 1.2678547101074855e-10
having O 0 6.358249482474321e-10
a O 0 2.834098233872595e-10
rare O 0 7.446289695955954e-10
intermediate O 0 4.616206084051555e-08
type O 0 7.614220010054851e-08
of O 0 1.992454485844064e-07
adult O 0 7.142432991713576e-07
cerebral O 0 0.0001783163461368531
and O 0 2.7531740443009767e-07
cerebello O 1 0.5147320628166199
- O 0 0.003145044669508934
brain O 0 3.034653673239518e-05
stem O 0 2.8612804570116168e-08
forms O 0 1.674511085347774e-09
, O 0 1.114356384945836e-10
his O 0 1.5422788601782145e-09
younger O 0 5.816529480284771e-08
brother O 0 2.7889635134670243e-07
( O 0 4.1257939287220324e-09
patient O 0 5.3044186820727646e-09
2 O 0 3.8727677065253374e-07
) O 0 8.802003570451689e-09
and O 0 5.167618510881766e-08
nephew O 0 0.0025780750438570976
( O 0 8.626297187674936e-08
patient O 0 4.573137459829013e-07
3 O 0 2.877978295146022e-05
) O 0 1.692790618790241e-08
had O 0 6.150302311880296e-08
a O 0 1.6061362373420707e-07
childhood O 0 0.06693989783525467
ALD B-Disease 1 1.0
type O 0 0.33382168412208557
. O 0 2.046644476649817e-05

Another O 0 3.365468273841543e-06
nephew O 0 6.143756763776764e-05
( O 0 3.6601640829303506e-08
patient O 0 3.422088568072468e-08
4 O 0 4.1691149021971796e-07
) O 0 1.4996512920362193e-09
of O 0 9.815842361149407e-09
patient O 0 2.113811881088168e-08
1 O 0 1.5793136753927683e-06
was O 0 1.2890239986518282e-07
classified O 0 3.3537925769877575e-09
as O 0 6.903920768408511e-10
having O 0 2.1799038130154713e-09
an O 0 4.340706960537233e-10
adolescent O 0 3.1670520428406235e-08
form O 0 3.376019463985358e-08
. O 0 1.0580550906524877e-06

The O 0 2.280743274241104e-06
tau O 0 1.1568465197342448e-05
level O 0 7.434871349687455e-07
in O 0 4.766054662042052e-09
the O 0 1.7982921818315845e-08
cerebrospinal O 0 2.5825424927461427e-06
fluid O 0 1.0658939118002309e-06
( O 0 2.175124613756907e-08
CSF O 0 1.3868569794794894e-06
) O 0 1.324147125281172e-09
in O 0 1.228847579248793e-09
patient O 0 7.511139266114242e-09
1 O 0 2.2997575399585912e-07
was O 0 4.613319148916162e-08
as O 0 8.591461986284799e-10
high O 0 1.0943536743468485e-08
as O 0 7.271462598712475e-11
that O 0 2.8188350958968655e-11
of O 0 7.151090275492322e-10
patients O 0 1.879080002709088e-09
with O 0 1.2648126990200126e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.5591122508049011
( O 0 4.960130528530726e-09
AD B-Disease 0 1.5757407254568534e-06
) O 0 1.9979262688707422e-08
. O 0 2.0782901799520914e-07

His O 0 2.3888218493084423e-05
brain O 0 7.888570507930126e-06
magnetic O 0 9.90998728411796e-07
resonance O 0 6.927227218511689e-07
image O 0 4.556090402729751e-07
( O 0 6.756303516652906e-09
MRI O 0 3.974203536927234e-06
) O 0 3.291139361039086e-09
showed O 0 4.368377304331261e-08
abnormalities B-Disease 0 7.704890663262631e-07
in I-Disease 0 2.209996408097936e-09
the I-Disease 0 1.685599215761613e-08
bilateral I-Disease 0 0.0004093711613677442
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9999992847442627
and O 0 0.07470231503248215
brain O 1 0.9992196559906006
stem O 0 1.8619120112361998e-07
, O 0 1.8883775099176603e-10
but O 0 9.98666357943101e-11
not O 0 9.172724385608788e-11
in O 0 7.788209521741862e-10
the O 0 1.0436203012886835e-08
cerebral O 0 0.00012108853115933016
white O 0 4.292563460239762e-08
matter O 0 1.8320578831776402e-08
, O 0 1.1735808158608307e-10
where O 0 1.88756371644061e-10
marked O 0 1.0474926481762736e-09
reductions O 0 5.856803930726073e-09
of O 0 1.62466502473535e-08
the O 0 2.277120891847062e-08
cerebral O 0 2.787088760669576e-06
blood O 0 6.962399989873802e-09
flow O 0 8.752316205118404e-09
and O 0 1.2863391241069166e-08
oxygen O 0 4.677047726886485e-08
metabolism O 0 4.505021479417337e-06
were O 0 4.060140668116219e-09
clearly O 0 4.238790207722332e-09
demonstrated O 0 1.3140536658795554e-08
by O 0 2.0251540444604643e-09
positron O 0 9.924564636776267e-08
emission O 0 1.1328709348390475e-07
tomography O 0 4.831655928683176e-07
( O 0 6.895317206101481e-09
PET O 0 6.805998253867074e-08
) O 0 8.227216241607493e-09
. O 0 1.2544271044134803e-07

In O 0 1.327128131833888e-07
patients O 0 1.2323455145235584e-08
2 O 0 1.3138962629000162e-07
and O 0 3.275820503745308e-09
3 O 0 8.907105097932799e-08
, O 0 2.890911121600226e-10
the O 0 5.847290984739573e-10
autopsy O 0 4.111184992439121e-08
findings O 0 2.082525263347179e-08
showed O 0 4.529114150386704e-08
massive O 0 2.233226041425951e-06
demyelination B-Disease 1 1.0
of I-Disease 1 0.9712232947349548
the I-Disease 0 0.00013804818445350975
cerebral I-Disease 1 0.9999775886535645
white I-Disease 0 2.046598126526078e-07
matter I-Disease 0 3.240883117427984e-08
with O 0 1.560696155644692e-10
sparing O 0 6.208120684192409e-09
of O 0 2.082620476073771e-08
the O 0 9.933920352978021e-08
U O 1 0.8496374487876892
- O 0 0.4001184105873108
fibers O 0 2.455608864693204e-06
, O 0 1.971175445092399e-09
compatible O 0 4.599489855650063e-08
with O 0 1.8900135623223235e-10
the O 0 2.2965733759150453e-09
findings O 0 1.8375242660795266e-08
of O 0 5.568388061760743e-08
childhood O 0 9.123341442318633e-05
ALD B-Disease 1 1.0
. O 0 1.3876037883164827e-05

Oleic O 0 0.0007786860805936158
and O 0 7.99733697931515e-06
erucic O 0 0.002614035736769438
acids O 0 8.922124834498391e-07
( O 0 3.747669907738782e-08
Lorenzos O 0 3.0414396405831212e-06
Oil O 0 7.029534998537201e-08
) O 0 6.627138282588874e-10
were O 0 2.0646385989753213e-10
administered O 0 8.987555838446681e-11
to O 0 4.685576926455326e-11
patients O 0 7.51313733449166e-11
1 O 0 7.042737504292518e-09
and O 0 8.345160673606244e-10
4 O 0 1.586603026737521e-08
, O 0 7.087699177565909e-11
but O 0 4.127474056980773e-11
sufficient O 0 9.770727560365344e-10
effectiveness O 0 3.8802996371600784e-09
was O 0 1.7258706686007486e-09
not O 0 2.630066719966351e-10
obtained O 0 4.4177884461760186e-08
. O 0 1.4882901666624093e-07

The O 0 3.1358862884189875e-07
findings O 0 5.752373510858888e-08
in O 0 1.3153017563993785e-09
this O 0 2.547160260490955e-10
family O 0 3.916561241990024e-10
suggest O 0 4.746257831200751e-10
that O 0 8.406663559723526e-11
delGAG291 O 0 2.1204828115628516e-08
is O 0 1.1055345527921645e-10
part O 0 2.668215093315496e-10
of O 0 1.4863612562976414e-09
the O 0 2.391627784703587e-09
cause O 0 5.6717414764762e-08
of O 0 3.1262530342246464e-07
Japanese O 0 0.0002670605608727783
ALD B-Disease 1 1.0
with O 0 4.6937955744397186e-08
phenotypic O 0 3.554309660103172e-05
variations O 0 5.109823632665211e-06
. O 0 2.412068852208904e-06

Moreover O 0 2.337326066026435e-07
, O 0 1.9651353877492284e-09
although O 0 3.7413169784450417e-10
the O 0 4.1468722900006583e-10
scale O 0 9.002697254345549e-09
of O 0 1.1790198817251962e-09
the O 0 5.779983713871673e-10
study O 0 3.286658722956304e-10
is O 0 3.276542231978041e-11
limited O 0 5.399985458787171e-10
, O 0 2.798175302576311e-10
there O 0 4.0501299536366275e-10
is O 0 1.2828683948473696e-10
a O 0 1.0570117003894097e-09
possibility O 0 5.597736318918578e-08
that O 0 7.017863623559606e-09
PET O 0 5.415167834144086e-07
can O 0 3.350782407096631e-08
detect O 0 7.8532889347116e-07
an O 0 4.505787298825226e-09
insidious B-Disease 0 3.94712060369784e-06
lesion I-Disease 0 9.955043788067997e-05
which O 0 6.149033282554228e-09
is O 0 8.937234285966156e-10
undetectable O 0 1.988425779586578e-08
by O 0 4.2112438536356933e-10
computed O 0 3.8731290175064714e-08
tomogram O 0 9.718663704916253e-07
( O 0 3.4978711038746724e-09
CT O 0 1.1856221817652113e-06
) O 0 5.972315975100173e-10
or O 0 2.47161485722458e-10
MRI O 0 5.632973198999025e-08
analysis O 0 3.0104788106832814e-10
, O 0 3.3418802447560125e-11
and O 0 1.8728378223253905e-11
that O 0 9.161301925408871e-12
the O 0 2.0103975428842347e-10
higher O 0 4.9461763573788176e-09
level O 0 2.0086977414734974e-08
of O 0 1.9523880290250872e-09
tau O 0 5.685963344603806e-08
reflects O 0 5.717386564185745e-10
the O 0 2.2556476131363468e-10
process O 0 4.304539835686683e-09
of O 0 1.3160377676513235e-08
neuronal B-Disease 0 2.4787661459413357e-05
degeneration I-Disease 1 0.9999895095825195
in O 0 1.3431001661956543e-06
ALD B-Disease 1 1.0
. O 0 1.2328811862971634e-05

Lorenzos O 0 7.926332909846678e-05
Oil O 0 1.3050821223714593e-07
should O 0 1.1905493257913236e-09
be O 0 1.0956766743897006e-10
given O 0 6.118503620422544e-11
in O 0 2.141289055790363e-11
the O 0 7.499936782728867e-11
early O 0 1.2787647607481745e-09
stage O 0 2.074270755159091e-09
. O 0 2.074508120841756e-09
. O 0 5.8176389927666605e-08

Nonsense O 0 1.2927106581628323e-05
mutation O 0 7.9793288421115e-08
in O 0 9.807851419907365e-09
exon O 0 7.259790635316676e-08
4 O 0 1.5616123505424184e-07
of O 0 1.0519078053050634e-08
human O 0 1.574595209774543e-08
complement O 0 4.518371454764747e-08
C9 O 0 0.00023312807024922222
gene O 0 5.140473380293997e-09
is O 0 1.2711769137307982e-10
the O 0 3.9382400118803673e-10
major O 0 1.6974972538719157e-09
cause O 0 4.98722627639836e-08
of O 0 1.4674832016225992e-07
Japanese O 0 1.7165606550406665e-05
complement B-Disease 0 0.007536822464317083
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999879598617554
. O 0 1.002801855065627e-05

Deficiency B-Disease 1 0.9156530499458313
of I-Disease 0 8.684462227392942e-05
the I-Disease 0 1.8415016711514909e-06
ninth I-Disease 0 8.717888135834073e-07
component I-Disease 0 3.6200340503000916e-08
of I-Disease 0 4.139455711538176e-08
human I-Disease 0 3.010745786014013e-08
complement I-Disease 0 5.159532534548816e-08
( O 0 3.6176942330712336e-08
C9 O 0 0.3749309778213501
) O 0 1.8072314755812613e-09
is O 0 1.7694450071825685e-10
the O 0 5.737345043499431e-10
most O 0 2.5947791137959086e-10
common O 0 4.027325530842063e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.008232660865588e-09
Japan O 0 8.488797220707056e-09
but O 0 4.100717543309429e-10
is O 0 3.375087362367246e-11
rare O 0 8.294898795613292e-11
in O 0 3.9103938836992924e-11
other O 0 7.683652325507495e-11
countries O 0 1.2976345553639135e-09
. O 0 7.016474512511195e-08

We O 0 2.1017436324655137e-07
studied O 0 6.914153516390797e-08
the O 0 1.4340620912989266e-09
molecular O 0 1.2471454979845475e-08
basis O 0 1.7694738119189424e-08
of O 0 1.1647427555772083e-07
C9 B-Disease 1 0.9999985694885254
deficiency I-Disease 0 0.004303146153688431
in O 0 3.1243928333424265e-08
four O 0 8.027414821754064e-08
Japanese O 0 8.847679964674171e-06
C9 B-Disease 1 1.0
- I-Disease 0 0.27582159638404846
deficient I-Disease 0 1.853537469287403e-05
patients O 0 1.175118580221124e-08
who O 0 7.431731341434045e-10
had O 0 1.4293221717309734e-08
suffered O 0 1.7583497537998483e-05
from O 0 5.134105776960496e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 6.409134221030399e-05

Direct O 0 1.05544131656643e-07
sequencing O 0 5.328118746206201e-08
of O 0 5.5814243893337334e-08
amplified O 0 2.4115919927680807e-07
C9 O 0 1.0582332834019326e-05
cDNA O 0 3.548235838479741e-08
and O 0 3.905269441162318e-09
DNA O 0 1.8629433995442923e-08
revealed O 0 3.0685292529142316e-08
a O 0 4.394079766711911e-09
nonsense O 0 2.4048193836279097e-07
substitution O 0 1.6509149247667665e-07
( O 0 1.906060198564319e-08
CGA O 0 2.571605818957323e-06
- O 0 8.652561405142478e-07
- O 0 4.17284525155992e-07
> O 0 2.1933476546109887e-07
TGA O 0 5.408329002420942e-07
) O 0 2.2584987213747354e-09
at O 0 2.3967617224229798e-08
codon O 0 1.6666097835127403e-08
95 O 0 1.257140347377117e-08
in O 0 2.2130883792215172e-09
exon O 0 3.50000846083276e-08
4 O 0 8.374012594458691e-08
in O 0 2.8037647759049378e-09
the O 0 2.455813863377898e-08
four O 0 1.69386197512722e-07
C9 B-Disease 1 0.990913987159729
- I-Disease 0 1.545230406918563e-05
deficient I-Disease 0 2.6826110115507618e-06
individuals O 0 1.3219018768495516e-08
. O 0 5.833477985106583e-07

An O 0 2.1353666568302287e-07
allele O 0 8.740215093894221e-07
- O 0 2.5238679768335714e-07
specific O 0 1.0350110102308463e-08
polymerase O 0 3.111012958356696e-08
chain O 0 9.422516988877305e-09
reaction O 0 2.4725916869527964e-09
system O 0 4.758442972985222e-09
designed O 0 6.995064971704323e-09
to O 0 3.5887090521491416e-10
detect O 0 1.992145115536914e-09
exclusively O 0 4.59495191895698e-10
only O 0 7.655682338070235e-11
one O 0 5.3362154972536047e-11
of O 0 8.96849677856082e-11
the O 0 1.6988405127094097e-10
normal O 0 6.067129576514674e-10
and O 0 4.92458643308602e-11
mutant O 0 1.459749099375074e-09
alleles O 0 7.978347427162191e-10
indicated O 0 4.771454897856131e-10
that O 0 2.3805298010604048e-11
all O 0 4.396649017079923e-11
the O 0 5.432970046070906e-11
four O 0 3.4143639304762274e-11
patients O 0 5.73878358028912e-12
were O 0 3.9298189702385855e-11
homozygous O 0 1.5781806417258792e-10
for O 0 1.3574052992737506e-10
the O 0 1.2976394403452218e-09
mutation O 0 1.2166873064600736e-09
in O 0 3.0675912920941073e-09
exon O 0 4.922640428617342e-08
4 O 0 7.276120328469915e-08
and O 0 3.433186235302088e-10
that O 0 6.889368242557481e-11
the O 0 5.513668965839713e-10
parents O 0 1.5405199338403008e-10
of O 0 1.6889968312838732e-09
patient O 0 3.974432782882786e-09
2 O 0 2.099778129149854e-07
were O 0 5.6535210291031035e-08
heterozygous O 0 3.4432432016728853e-07
. O 0 2.384146910117124e-06

The O 0 2.70525532641841e-07
common O 0 8.914582849683939e-08
mutation O 0 4.140126819152101e-08
at O 0 1.0012444562335077e-07
codon O 0 3.0996528010973634e-08
95 O 0 4.728480007543112e-08
in O 0 3.261761527539875e-09
exon O 0 3.0839192532994275e-08
4 O 0 3.1113870591070736e-08
might O 0 9.207664075638888e-10
be O 0 2.785432717811176e-10
responsible O 0 5.280028636533984e-10
for O 0 8.283041613710296e-11
most O 0 4.510738449425844e-10
Japanese O 0 1.400887526870065e-06
C9 B-Disease 1 0.9999997615814209
deficiency I-Disease 0 0.021579205989837646
. O 0 6.416684783516757e-08
. O 0 3.2391528748121345e-07

BRCA1 O 0 6.846052542641701e-07
required O 0 7.249619926597006e-08
for O 0 1.3286205913232152e-08
transcription O 0 3.394447958271485e-07
- O 0 1.2381347858081426e-07
coupled O 0 1.500903152873434e-07
repair O 0 1.6570206753385719e-06
of O 0 3.9169503907032777e-07
oxidative O 0 8.235104178311303e-05
DNA O 0 2.7896230676560663e-06
damage O 0 7.350997475441545e-05
. O 0 6.7109249357599765e-06

The O 0 8.717483069631271e-06
breast B-Disease 1 0.9999830722808838
and I-Disease 1 0.9998564720153809
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0004036283353343606
gene O 0 4.189624860373442e-07
BRCA1 O 0 3.015734932887426e-07
encodes O 0 6.751101722102248e-08
a O 0 1.814319539050757e-08
zinc O 0 2.4140402388184157e-07
finger O 0 3.642912815848831e-07
protein O 0 1.928373727366761e-08
of O 0 2.389531417179569e-08
unknown O 0 1.2451400266400015e-07
function O 0 2.519090003261226e-07
. O 0 3.1879798711997864e-07

Association O 0 4.173235765847494e-07
of O 0 2.1177066855671e-07
the O 0 2.9822835756476707e-08
BRCA1 O 0 3.779259127867363e-09
protein O 0 3.824228989035561e-10
with O 0 5.3120879223156336e-11
the O 0 6.402350871681506e-10
DNA O 0 9.372472575819302e-09
repair O 0 4.058779978777238e-08
protein O 0 1.5514849849296297e-08
Rad51 O 0 5.790416821582767e-07
and O 0 7.579755156861268e-10
changes O 0 6.262253493538594e-10
in O 0 2.009270527736362e-10
the O 0 2.879717297954443e-10
phosphorylation O 0 4.694455491005556e-09
and O 0 2.084229011600769e-09
cellular O 0 2.6075920089851934e-08
localization O 0 1.9814035567833344e-07
of O 0 1.319599363114321e-08
the O 0 9.508852372164256e-09
protein O 0 6.496581494985776e-09
after O 0 7.518535127815085e-09
exposure O 0 1.597218002302725e-08
to O 0 2.465250448224765e-09
DNA O 0 2.2175180447447929e-07
- O 0 4.297249631690647e-07
damaging O 0 1.6043331925175153e-05
agents O 0 5.270714087401984e-09
are O 0 2.656119768573717e-10
consistent O 0 4.3959662576753544e-09
with O 0 4.925582164361231e-11
a O 0 2.7153454484896145e-10
role O 0 2.733722137548966e-09
for O 0 1.913979197354365e-09
BRCA1 O 0 4.06540436870273e-08
in O 0 2.534518905861205e-08
DNA O 0 4.833195248465927e-07
repair O 0 9.760482498677447e-06
. O 0 4.3051022657891735e-06

Here O 0 8.151703241310315e-07
, O 0 1.092101076238805e-09
it O 0 8.202077211860725e-11
is O 0 3.5189063468665793e-11
shown O 0 3.1734706529285006e-10
that O 0 7.234915999632108e-10
mouse O 0 4.8039140665423474e-08
embryonic O 0 5.1292328606677984e-08
stem O 0 4.821189492076883e-08
cells O 0 2.2258358711724213e-08
deficient B-Disease 0 8.728047617978518e-08
in I-Disease 0 1.5637837691429013e-09
BRCA1 I-Disease 0 1.1473497707470415e-08
are O 0 4.1927783467343716e-10
defective O 0 1.6041973083247285e-08
in O 0 5.200747610345502e-10
the O 0 3.8454259221332165e-10
ability O 0 2.4662932807117954e-10
to O 0 1.0048550880270568e-10
carry O 0 4.0377429177951285e-10
out O 0 7.432383597461012e-10
transcription O 0 4.625239569122641e-08
- O 0 6.717397837974204e-08
coupled O 0 1.4122234404112533e-07
repair O 0 1.4779087678107317e-06
of O 0 2.238331546777772e-07
oxidative O 0 1.1561196515685879e-05
DNA O 0 3.7765559568470053e-07
damage O 0 3.3537220588186756e-05
, O 0 1.5717088075462016e-08
and O 0 3.2214696688015465e-08
are O 0 6.896449189497389e-09
hypersensitive O 0 1.7622746781853493e-06
to O 0 2.9389665812118437e-08
ionizing O 0 7.204735084087588e-06
radiation O 0 1.7128091712947935e-05
and O 0 2.7794332169150948e-08
hydrogen O 0 4.321167068610521e-08
peroxide O 0 9.77243144006934e-06
. O 0 1.7972313344216673e-06

These O 0 4.5007734428281765e-08
results O 0 1.0642022374440785e-07
suggest O 0 7.980847982480554e-09
that O 0 5.134904723647082e-10
BRCA1 O 0 1.149575279413284e-08
participates O 0 1.1116841891478657e-09
, O 0 9.513305421204876e-11
directly O 0 2.4624577377174717e-10
or O 0 5.112155143649488e-10
indirectly O 0 2.0808090805957136e-09
, O 0 4.887430460343012e-10
in O 0 3.096472411812101e-09
transcription O 0 3.323337693927897e-07
- O 0 4.3452183717818116e-07
coupled O 0 1.204897102979885e-06
repair O 0 5.385017175285611e-06
of O 0 1.05729452570813e-06
oxidative O 0 7.423718489008024e-05
DNA O 0 3.541873923040839e-07
damage O 0 3.1841439067648025e-06
. O 0 8.342924218140979e-08
. O 0 9.711974371384713e-07

Truncation O 0 6.704300176352262e-05
mutations O 0 3.158293679916824e-07
in O 0 1.2196481158355255e-08
the O 0 3.087409439217481e-08
transactivation O 0 1.1046789040847216e-05
region O 0 1.1252249976223538e-07
of O 0 3.111713908765523e-07
PAX6 O 0 0.00020513887284323573
result O 0 5.552669790631626e-07
in O 0 5.397365043791069e-08
dominant O 0 1.2259857612662017e-05
- O 0 4.901494889963942e-07
negative O 0 2.8074373048525558e-08
mutants O 0 2.1097071112308186e-06
. O 0 3.5549024346437363e-07

PAX6 O 0 0.00028355472022667527
is O 0 2.031220702747305e-08
a O 0 9.709648196576381e-09
transcription O 0 7.921308942115957e-09
factor O 0 7.945277324949984e-09
with O 0 3.1892957719215076e-10
two O 0 1.1111541686759097e-09
DNA O 0 6.788985373873402e-09
- O 0 1.279475458915158e-08
binding O 0 3.8375606692397923e-08
domains O 0 2.886303320792649e-07
( O 0 3.8884269137895444e-09
paired O 0 1.6448636230848024e-08
box O 0 4.0612579965682016e-08
and O 0 1.1044271275295614e-08
homeobox O 0 2.9175092208788556e-07
) O 0 3.402691239884348e-09
and O 0 7.060101392397655e-09
a O 0 3.165228434909295e-08
proline O 0 3.6546712181007024e-06
- O 0 1.2990627510589547e-05
serine O 0 1.4684042071166914e-05
- O 0 1.8349752281210385e-05
threonine O 0 2.489490361767821e-05
( O 0 5.180289619488576e-08
PST O 0 0.005538808647543192
) O 0 2.6857513546474365e-08
- O 0 1.716483382097067e-07
rich O 0 7.884487018827713e-08
transactivation O 0 3.5976288927486166e-05
domain O 0 2.924157115558046e-06
. O 0 1.8093159042109619e-06

PAX6 O 1 0.9927501678466797
regulates O 0 2.2345648176269606e-05
eye O 0 0.003639707574620843
development O 0 5.011872303839482e-07
in O 0 2.4899178274750966e-09
animals O 0 6.824060205801175e-10
ranging O 0 9.497433062222171e-09
from O 0 7.113841737904636e-10
jellyfish O 0 8.220373826084426e-10
to O 0 6.662943530244547e-10
Drosophila O 0 3.4653471203682784e-08
to O 0 2.764849016401172e-09
humans O 0 1.0614979117917756e-07
. O 0 1.9632038572581223e-07

Heterozygous O 0 5.623375614050019e-07
mutations O 0 2.1802708971563334e-08
in O 0 3.168996176583505e-09
the O 0 4.708336387437839e-09
human O 0 1.6370389488429282e-08
PAX6 O 0 1.7852395330919535e-06
gene O 0 2.5151680738133564e-09
result O 0 4.227341143803187e-09
in O 0 1.0725724752802535e-09
various O 0 7.979690685999685e-09
phenotypes O 0 5.571728820541466e-07
, O 0 3.808537485383567e-09
including O 0 1.068332355913526e-08
aniridia B-Disease 1 1.0
, O 0 3.17679155159567e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.644112662153475e-08
autosomal B-Disease 0 0.00017759925685822964
dominant I-Disease 1 0.7214413285255432
keratitis I-Disease 1 0.999998927116394
, O 0 9.853062010733993e-08
and O 0 4.677868616909109e-07
familial B-Disease 1 0.9093909859657288
foveal I-Disease 1 0.9999997615814209
dysplasia I-Disease 1 1.0
. O 0 0.002371987560763955

It O 0 1.4565348038786397e-08
is O 0 8.239603443982446e-10
believed O 0 3.321510400056127e-09
that O 0 1.2605197441395433e-10
the O 0 1.1394740706549555e-09
mutated O 0 1.563811480309596e-08
allele O 0 1.2687056027971266e-07
of O 0 1.2234463042659627e-07
PAX6 O 0 1.202725343318889e-05
produces O 0 1.6160917937213526e-08
an O 0 5.026796756624208e-10
inactive O 0 1.645089575674774e-08
protein O 0 4.220994753723062e-08
and O 0 2.6981252787550147e-08
aniridia B-Disease 1 1.0
is O 0 3.015318661425681e-09
caused O 0 1.335368349231203e-08
due O 0 3.869761755481704e-08
to O 0 7.290731129927508e-09
genetic O 0 2.2330334559228504e-07
haploinsufficiency O 0 8.731485650059767e-06
. O 0 1.3482474514603382e-06

However O 0 1.7975862931507436e-07
, O 0 3.717900654010009e-09
several O 0 2.0771686592979677e-09
truncation O 0 1.448399018499913e-07
mutations O 0 6.563163790218596e-09
have O 0 2.704563240030211e-10
been O 0 2.2823234968605277e-10
found O 0 1.7971657495507998e-10
to O 0 2.54941068256187e-10
occur O 0 1.5672715347747612e-09
in O 0 7.24483029124201e-10
the O 0 6.459538237635343e-09
C O 0 5.319352112564957e-06
- O 0 1.9053153721415583e-07
terminal O 0 4.03609874410904e-08
half O 0 2.39561792625409e-09
of O 0 4.1116687832243315e-09
PAX6 O 0 1.4267722008298733e-06
in O 0 9.955345436907237e-10
patients O 0 3.9533068485475553e-10
with O 0 4.720644430911136e-10
Aniridia B-Disease 1 1.0
resulting O 0 1.5748987891583965e-08
in O 0 1.0796907812249401e-09
mutant O 0 2.7676139158216984e-09
proteins O 0 9.669128692157969e-11
that O 0 3.853324256897217e-11
retain O 0 5.4023163720273715e-09
the O 0 3.801555514826305e-09
DNA O 0 6.098225924233702e-09
- O 0 1.852694775372754e-09
binding O 0 4.0271768142474684e-09
domains O 0 1.3890772088132053e-08
but O 0 3.677823323666729e-10
have O 0 3.9924605288454984e-10
lost O 0 1.2631780954563965e-08
most O 0 1.3178826085979978e-10
of O 0 1.5746184356402182e-09
the O 0 9.09468678145231e-09
transactivation O 0 5.232730927673401e-06
domain O 0 1.1655133675958496e-06
. O 0 2.088083192575141e-06

It O 0 2.0352306506765672e-08
is O 0 2.986686453709808e-10
not O 0 5.643740336180869e-11
clear O 0 5.024505811412894e-10
whether O 0 1.5563440813881613e-10
such O 0 1.1086640633317657e-10
mutants O 0 2.3729792530957639e-07
really O 0 3.1055943594537894e-08
behave O 0 5.111815859493163e-09
as O 0 1.4060511643876339e-09
loss O 0 2.5813942983177185e-08
- O 0 1.4131929404470611e-08
of O 0 1.3179548830066778e-07
- O 0 1.6016453230349725e-07
function O 0 4.871753134239043e-08
mutants O 0 7.508822363888612e-08
as O 0 1.7949537411965366e-09
predicted O 0 2.8399888662988815e-08
by O 0 8.011258323392667e-09
haploinsufficiency O 0 1.1320493285893463e-05
. O 0 2.5999297577072866e-06

Contrary O 0 2.5171064521600783e-07
to O 0 6.076954051081884e-09
this O 0 8.61188731438034e-10
theory O 0 5.258586455170189e-08
, O 0 1.2111812663917476e-09
our O 0 3.752081312313749e-09
data O 0 2.8337159285740654e-09
showed O 0 1.49363654777801e-09
that O 0 4.340531406521464e-11
these O 0 1.8462031903254683e-10
mutants O 0 1.0667237759776071e-08
are O 0 4.856199331548794e-10
dominant O 0 1.4367322442865316e-08
- O 0 2.896288320286544e-09
negative O 0 2.091105733015297e-09
in O 0 1.1707688152284845e-09
transient O 0 1.8510355914713728e-08
transfection O 0 1.9780006965675057e-08
assays O 0 1.8711152627304273e-09
when O 0 3.343845478287477e-10
they O 0 2.73877226453223e-10
are O 0 3.30020205607795e-10
coexpressed O 0 1.698033145203226e-07
with O 0 3.6340344067298247e-09
wild O 0 1.0905451119924692e-07
- O 0 7.939998454276065e-07
type O 0 2.7848760510096326e-05
PAX6 O 0 0.37926623225212097
. O 0 8.253243322542403e-06

We O 0 2.1531759841764142e-07
found O 0 3.663249037444416e-09
that O 0 1.5473193559767395e-10
the O 0 1.9568506814948705e-09
dominant O 0 1.486723988364247e-07
- O 0 9.091530195348696e-09
negative O 0 2.3674822102748294e-09
effects O 0 2.2174541314257112e-08
result O 0 4.693622823737087e-09
from O 0 3.883777743851624e-10
the O 0 5.456640139733793e-10
enhanced O 0 4.576464096572863e-09
DNA O 0 1.482510669781334e-09
binding O 0 1.3447608582239923e-09
ability O 0 1.1087577522772563e-09
of O 0 2.9976112703167246e-09
these O 0 9.043998328017722e-10
mutants O 0 2.844139146418456e-07
. O 0 6.188864176692732e-08

Kinetic O 0 4.399543286126573e-06
studies O 0 4.5401417736457006e-08
of O 0 5.973298744521571e-09
binding O 0 3.346784183122509e-08
and O 0 6.702958188498087e-09
dissociation O 0 4.189456959124982e-08
revealed O 0 1.6197269303575013e-08
that O 0 1.714547115394538e-10
various O 0 1.3922170083446872e-09
truncation O 0 1.531513191821432e-07
mutants O 0 1.3802620912883867e-07
have O 0 6.358324977639995e-09
3 O 0 7.420166525662353e-08
- O 0 1.4691742933337082e-08
5 O 0 2.8554797637525553e-08
- O 0 5.254432888790461e-09
fold O 0 5.992012663824653e-09
higher O 0 2.9652091892984345e-09
affinity O 0 2.623943839985543e-10
to O 0 1.1153281770370782e-10
various O 0 3.4120478664689813e-10
DNA O 0 9.46435374515886e-10
- O 0 1.4143590465476308e-10
binding O 0 2.484641103972507e-10
sites O 0 2.6179849954566237e-10
when O 0 2.0294102509588186e-10
compared O 0 1.3331935555527252e-10
with O 0 2.4431349304743222e-11
the O 0 9.023511382544314e-10
wild O 0 1.7985119171726183e-08
- O 0 9.052773464190977e-08
type O 0 1.704620331111073e-06
PAX6 O 0 0.0009997354354709387
. O 0 5.629022325592814e-06

These O 0 1.35465526795997e-07
results O 0 1.5117836937861284e-07
provide O 0 1.375850322560268e-09
a O 0 3.8420389092408413e-10
new O 0 1.888356804258251e-09
insight O 0 5.640883316004874e-09
into O 0 1.8530402212668662e-10
the O 0 2.1343987688382526e-10
role O 0 3.759959565918791e-10
of O 0 3.199692288902156e-09
mutant O 0 2.080132190940276e-07
PAX6 O 0 1.796880860638339e-05
in O 0 5.460092111775339e-08
causing O 0 3.3902401810337324e-06
aniridia B-Disease 1 1.0
. O 0 5.293475737744302e-07
. O 0 1.9314049950480694e-06

Reversal O 0 1.281767890759511e-05
of O 0 1.1015113159373868e-06
severe O 1 0.999992847442627
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.0008641975582577288
excellent O 0 0.00013212424528319389
neuropsychologic O 0 0.00013533548917621374
outcome O 0 6.124131323304027e-05
in O 0 1.0862292754154623e-07
very B-Disease 0 4.5401159809443925e-07
- I-Disease 0 4.494430868362542e-06
long I-Disease 0 1.891896317829378e-06
- I-Disease 0 0.0036990088410675526
chain I-Disease 0 6.0549111367436126e-05
acyl I-Disease 0 0.00028054139693267643
- I-Disease 1 0.9999983310699463
coenzyme I-Disease 1 0.9999275207519531
A I-Disease 0 0.30834341049194336
dehydrogenase I-Disease 0 0.0013318368000909686
deficiency I-Disease 0 0.1886501908302307
. O 0 1.4642612313764403e-06

Very B-Disease 0 3.6098430427955464e-05
- I-Disease 0 2.1873724108445458e-05
long I-Disease 0 1.0612220648908988e-06
- I-Disease 0 1.0199610187555663e-05
chain I-Disease 0 8.411372505179315e-07
acyl I-Disease 0 1.0408749631096725e-06
- I-Disease 0 0.00010342193127144128
coenzyme I-Disease 0 1.1299362995487172e-05
A I-Disease 0 1.2975247045687865e-06
dehydrogenase I-Disease 0 4.643838451556803e-07
( I-Disease 0 8.126901818172882e-09
VLCAD I-Disease 0 0.0002788831770885736
) I-Disease 0 1.570612084833556e-08
deficiency I-Disease 0 7.244688276841771e-06
is O 0 1.4743752885237882e-09
a O 0 1.4245892465680754e-08
disorder O 0 2.233412305940874e-05
of O 0 2.081514367091586e-06
fatty O 0 5.7928364327608506e-08
acid O 0 5.4491572143433586e-08
beta O 0 9.890739249840408e-08
oxidation O 0 6.912937333680702e-09
that O 0 8.741634083264671e-10
reportedly O 0 1.3931820141976914e-08
has O 0 3.1057570404335877e-10
high O 0 2.8572557653205877e-08
rates O 0 7.039930860486265e-09
of O 0 2.432619439218797e-09
morbidity O 0 7.113386573109892e-07
and O 0 1.0667502436945142e-08
mortality O 0 9.384170880366582e-07
. O 0 2.648403665261867e-07

We O 0 3.234948451336095e-07
describe O 0 6.71044375621932e-08
the O 0 7.977210891851882e-09
outcome O 0 1.955807391595954e-07
of O 0 1.628785462060023e-08
a O 0 5.5117470587617845e-09
5 O 0 4.86423239465239e-08
- O 0 1.3207828608585714e-08
year O 0 2.73117861659955e-09
- O 0 5.4135210092454145e-08
old O 0 9.089294508157764e-07
girl O 0 1.9039150345179223e-07
with O 0 2.0276557322063127e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.0313716813925566e-07
was O 0 2.02462842935347e-07
first O 0 5.698576721613335e-09
seen O 0 9.323227523339028e-09
at O 0 2.952783084708699e-08
5 O 0 1.186867848446127e-08
months O 0 1.5959259469511267e-09
of O 0 1.5191907731804122e-09
age O 0 1.944217231653056e-08
with O 0 9.505728426617566e-10
severe O 1 0.6894456148147583
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 1.0
hepatomegaly B-Disease 1 1.0
, O 1 0.9999998807907104
encephalopathy B-Disease 1 0.9999901056289673
, O 0 1.3261059450542234e-07
and O 0 7.731086952844635e-07
hypotonia B-Disease 1 0.5005026459693909
. O 0 1.8813541828421876e-05

Biochemical O 0 1.1457551408966538e-05
studies O 0 1.9732281089090975e-06
indicated O 0 0.002134301932528615
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 5.945108932792209e-05
by O 0 3.3864917536874373e-09
a O 0 3.1744651352028086e-09
stable O 0 8.768461157160345e-08
yet O 0 2.491572459462077e-08
inactive O 0 1.1215673367814816e-07
enzyme O 0 1.544396752706234e-07
. O 0 3.8643855759801227e-07

Molecular O 0 4.786368208442582e-06
genetic O 0 7.363897225332039e-08
analysis O 0 2.4046833857482852e-08
of O 0 3.2793792570373625e-08
her O 0 2.5248640511676967e-08
VLCAD O 0 0.00030659156618639827
gene O 0 1.3089984918224218e-07
revealed O 0 4.5551738026006205e-07
a O 0 2.83799064249024e-08
T1372C O 0 1.2878643929070677e-06
( O 0 2.8179735878097745e-08
F458L O 0 1.7089059838326648e-06
) O 0 3.559671313269064e-08
missense O 0 3.5140669751854148e-06
mutation O 0 1.9729073130747565e-07
and O 0 5.932358959626072e-08
a O 0 1.7657104933732626e-07
1668 O 0 0.0001905947719933465
ACAG O 0 0.0013684993609786034
1669 O 0 0.00034937262535095215
splice O 0 4.104488107259385e-05
site O 0 2.1795824522996554e-06
mutation O 0 1.0657679467840353e-06
. O 0 2.556045728852041e-06

After O 0 2.3685069550083426e-07
initial O 0 4.2995942806101084e-08
treatment O 0 1.864208876156681e-08
with O 0 2.0247445942089826e-09
intravenous O 0 3.394919900756577e-08
glucose O 0 3.204854010618874e-06
and O 0 3.5925342700693363e-08
carnitine O 0 1.285276766793686e-06
, O 0 9.489117269723124e-10
the O 0 1.3851819691268474e-09
patient O 0 1.9095451886386172e-09
has O 0 2.437099966279277e-10
thrived O 0 1.1429464485956942e-08
on O 0 5.2872670686099354e-09
a O 0 2.27459784341022e-09
low O 0 3.2152703965948604e-07
- O 0 2.2249724906941992e-07
fat O 0 2.5574573214726115e-07
diet O 0 6.226444781987084e-08
supplemented O 0 7.82338016591666e-09
with O 0 4.4591902392809857e-10
medium O 0 3.0010278351255693e-06
- O 0 2.463837347477238e-07
chain O 0 1.2261277326786058e-08
triglyceride O 0 9.277783163952336e-08
oil O 0 4.2858061988226837e-08
and O 0 1.2056410092498027e-08
carnitine O 0 3.0807572670710215e-07
and O 0 2.095681628233592e-09
avoidance O 0 2.3790745729002083e-07
of O 0 4.685181664854099e-08
fasting O 0 7.724247552687302e-07
. O 0 1.9597077027810883e-07

Her O 0 7.0310820774466265e-06
ventricular O 0 0.017254287376999855
hypertrophy O 0 0.0014437770005315542
resolved O 0 9.007472726807464e-06
significantly O 0 2.1501486813235715e-08
over O 0 3.3570626278844884e-09
1 O 0 1.612237099379854e-08
year O 0 2.56531212938782e-10
, O 0 1.17340179239811e-10
and O 0 5.190708418645329e-10
cognitively O 0 4.584906321269955e-07
, O 0 1.7681023312121624e-10
she O 0 9.961646785239253e-11
is O 0 2.7654791651121613e-11
in O 0 8.591753003495128e-11
the O 0 9.253491861649366e-10
superior O 0 2.8316600264588487e-07
range O 0 9.228999431343254e-08
for O 0 3.6366207822879915e-09
age O 0 8.309731356348493e-07
. O 0 7.747139534330927e-07

Clinical O 0 6.998629942245316e-06
recognition O 0 1.6044688209149172e-06
of O 1 0.9999758005142212
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.755486067622769e-08
important O 0 2.305764246202102e-09
because O 0 1.0469827088632755e-10
it O 0 1.6608572156462387e-11
is O 0 1.1688175600987893e-11
one O 0 2.4870105974628132e-11
of O 0 1.9199342116138496e-10
the O 0 5.453477114336636e-10
few O 0 4.017418397950223e-09
directly O 0 1.7555430886773138e-08
treatable O 0 0.32315561175346375
causes O 0 5.018127922085114e-07
of O 0 8.270561920653563e-06
cardiomyopathy B-Disease 1 1.0
in O 0 1.1468460797914304e-05
children O 0 4.740165238104055e-08
. O 0 5.356189802796507e-08
. O 0 1.099026690098981e-06

Cloning O 0 3.8644370192741917e-07
of O 0 4.212999726860289e-08
a O 0 2.1530695004656764e-09
novel O 0 4.747745308009144e-09
member O 0 1.3897610173785324e-08
of O 0 1.8086357300717282e-08
the O 0 2.3158190032290804e-08
low O 0 1.2223958947288338e-06
- O 0 3.567437829588016e-07
density O 0 5.462289465185677e-08
lipoprotein O 0 1.3126456906320527e-05
receptor O 0 7.927280421426985e-06
family O 0 5.222064487497846e-07
. O 0 1.1413461606935016e-06

A O 0 6.25613381544099e-07
gene O 0 1.421844775251202e-08
encoding O 0 4.569000466858597e-08
a O 0 4.975176715049656e-09
novel O 0 1.553225992267926e-08
transmembrane O 0 1.4883313781410834e-07
protein O 0 7.88451348654462e-09
was O 0 3.002600834633995e-09
identified O 0 4.6552206534045126e-10
by O 0 3.315171401285788e-11
DNA O 0 1.0613775414114457e-09
sequence O 0 4.4348549832484707e-10
analysis O 0 6.813083985868218e-10
within O 0 1.328751775275805e-09
the O 0 4.4454346870281825e-09
insulin B-Disease 0 2.293190118507482e-05
- I-Disease 1 0.9948471784591675
dependent I-Disease 1 0.9999234676361084
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.3692156244360376e-06
IDDM B-Disease 0 3.549221946741454e-05
) O 0 2.3435002827199014e-09
locus O 0 9.18432547791781e-08
IDDM4 O 0 4.960287697031163e-06
on O 0 6.220693649083842e-07
chromosome O 0 8.374346407435951e-07
11q13 O 0 1.150603566202335e-05
. O 0 3.3784081097110175e-06

Based O 0 1.302972947314629e-07
on O 0 5.549917148073291e-08
its O 0 4.339690828913945e-09
chromosomal O 0 3.3463504678366007e-07
position O 0 8.050527071645774e-07
, O 0 1.1710747926940712e-09
this O 0 1.4254276925473874e-10
gene O 0 3.8486472342391664e-10
is O 0 4.2859549242990624e-11
a O 0 6.6760430517121e-11
candidate O 0 3.911486690100219e-09
for O 0 2.2160322465936133e-09
conferring O 0 7.913713488960639e-07
susceptibility O 0 1.2623933798749931e-05
to O 0 6.734209136993741e-07
diabetes B-Disease 1 0.9996707439422607
. O 0 2.47459265665384e-05

The O 0 5.092132937534188e-07
gene O 0 6.249753425890958e-08
, O 0 1.3261900022598638e-08
termed O 0 1.9736674516934727e-07
low O 0 1.7122633835242596e-06
- O 0 3.1875330819275405e-07
density O 0 1.2175840780059843e-08
lipoprotein O 0 2.7503739374878933e-07
receptor O 0 7.397853352131278e-08
related O 0 2.0341757078767841e-07
protein O 0 1.8850615290944006e-08
5 O 0 4.13902938589672e-08
( O 0 3.2553329476492365e-10
LRP5 O 0 1.9873685630500404e-07
) O 0 1.872331595320631e-10
, O 0 1.392513881981472e-10
encodes O 0 5.510661926777516e-10
a O 0 6.698686605410842e-10
protein O 0 2.4587560876199177e-09
of O 0 3.3974139057590946e-08
1615 O 0 2.0988220057915896e-05
amino O 0 6.713504063782239e-08
acids O 0 2.0742312312194144e-09
that O 0 1.8124292344712245e-10
contains O 0 4.1597530975323593e-10
conserved O 0 6.774084404526093e-09
modules O 0 5.093140131862128e-09
which O 0 7.385604627874187e-11
are O 0 3.9827304648687445e-11
characteristic O 0 3.729249797856937e-09
of O 0 3.088191258271422e-09
the O 0 4.989887614215149e-09
low O 0 3.2238736480394437e-07
- O 0 2.0450366733371084e-08
density O 0 2.9641009646752536e-09
lipoprotein O 0 5.442602173388877e-07
( O 0 5.752820442239681e-09
LDL O 0 2.557450216045254e-06
) O 0 2.083526418061865e-08
receptor O 0 3.7919119222351583e-07
family O 0 7.896933595930022e-08
. O 0 2.6694706889429654e-07

These O 0 8.897137604435557e-08
modules O 0 2.126084410747353e-07
include O 0 4.895895688861174e-09
a O 0 4.836420597342794e-09
putative O 0 1.5126316554869845e-07
signal O 0 1.7843258603988943e-07
peptide O 0 1.3483134608804903e-08
for O 0 1.5280892107227828e-09
protein O 0 2.236140828060229e-09
export O 0 6.852105105537021e-09
, O 0 5.517182266601139e-10
four O 0 1.7161642107410557e-09
epidermal O 0 3.93764274519981e-08
growth O 0 1.9690411523498597e-09
factor O 0 3.407204740568659e-09
( O 0 5.547837189645577e-10
EGF O 0 2.9104718635153404e-08
) O 0 1.2664867765632692e-10
repeats O 0 1.4794485636571153e-09
with O 0 1.7729247236975e-10
associated O 0 2.000435372906395e-08
spacer O 0 1.8059510864532058e-07
domains O 0 1.2338300336978136e-07
, O 0 3.3356872819467753e-09
three O 0 3.693980676899855e-09
LDL O 0 6.831867693790628e-08
- O 0 1.102794087159964e-07
receptor O 0 1.85383388640048e-08
( O 0 1.9740500345477585e-09
LDLR O 0 1.7610752820473863e-06
) O 0 8.746604551745918e-10
repeats O 0 6.806813335202833e-09
, O 0 1.5847231860099953e-10
a O 0 7.8276740644867e-10
single O 0 5.175082140596032e-09
transmembrane O 0 5.633246473735198e-07
spanning O 0 2.5856621732600615e-07
domain O 0 5.43002549591165e-08
, O 0 1.7066716928582082e-09
and O 0 3.23864446372113e-09
a O 0 7.1588450722970265e-09
cytoplasmic O 0 4.548636240997439e-07
domain O 0 1.6115565131258336e-06
. O 0 9.531568707643601e-07

The O 0 6.018922249495517e-07
encoded O 0 6.18609092839506e-08
protein O 0 1.1557576229392907e-08
has O 0 2.2431327628691378e-10
a O 0 1.7827415932369917e-10
unique O 0 5.920167689410505e-10
organization O 0 2.5235964429271007e-09
of O 0 9.309633064447098e-09
EGF O 0 8.053652322814742e-07
and O 0 1.3036685508893697e-08
LDLR O 0 5.1547749535529874e-06
repeats O 0 8.84464856909517e-09
; O 0 1.150284797968304e-10
therefore O 0 2.4675836929333173e-09
, O 0 1.1088845397466685e-09
LRP5 O 0 1.162897547146713e-06
likely O 0 1.4207793164189297e-08
represents O 0 8.913708104962836e-10
a O 0 4.373767459320277e-10
new O 0 8.558342368125693e-10
category O 0 5.927854207499195e-09
of O 0 7.619185282692342e-09
the O 0 4.0012462676486393e-08
LDLR O 0 3.58939723810181e-05
family O 0 6.343113767570685e-08
. O 0 3.6123648783359386e-07

Both O 0 3.6641321798924764e-07
human O 0 2.8105321803195693e-07
and O 0 4.41585932264843e-08
mouse O 0 5.401102498581167e-07
LRP5 O 0 1.0546888915996533e-05
cDNAs O 0 3.215607762285799e-07
have O 0 6.858456580438599e-10
been O 0 6.738000157824331e-10
isolated O 0 1.0762570834543794e-09
and O 0 5.347987608317339e-10
the O 0 2.41278175217019e-09
encoded O 0 4.349618443200143e-09
mature O 0 6.971635713171054e-09
proteins O 0 4.8583741196761565e-11
are O 0 3.000640014239053e-11
95 O 0 8.044327981515664e-10
% O 0 4.4062444665149414e-11
identical O 0 1.2130401128018775e-09
, O 0 1.0950498841033607e-10
indicating O 0 2.1751318524110275e-09
a O 0 7.141112701170016e-10
high O 0 2.4406515919395133e-08
degree O 0 1.7544357433507685e-07
of O 0 6.410516562027624e-09
evolutionary O 0 7.835568993641573e-08
conservation O 0 6.123915596845109e-09
. O 0 3.4508873536509554e-09
. O 0 1.2047358666222863e-07

The O 0 9.602634918337571e-07
APC B-Disease 0 7.090913527463272e-07
variants O 0 7.266010015882785e-08
I1307K O 0 2.4605594717286294e-07
and O 0 2.6387507734426663e-09
E1317Q O 0 1.5043681855786417e-07
are O 0 1.1799468069284558e-09
associated O 0 6.877417035866529e-07
with O 0 0.10522203147411346
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.9030937532279495e-08
but O 0 4.2809242262187297e-10
not O 0 1.1845553704592504e-10
always O 0 1.9292288599981333e-10
with O 0 4.866563749206243e-11
a O 0 1.2401922822036227e-09
family O 0 2.2519002218501782e-09
history O 0 8.270502860341367e-08
. O 0 3.7679325259887264e-07

Classical O 0 0.04094398021697998
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0006840862915851176
FAP B-Disease 0 0.00022440351312980056
) O 0 3.178816854187971e-08
is O 0 2.548468769347778e-09
a O 0 1.3964624123730118e-08
high O 1 0.9797663688659668
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.8340017199516296
that O 0 2.5659288582779993e-10
predisposes O 0 4.36837499506737e-09
to O 0 1.662997656248777e-10
hundreds O 0 6.491115422946336e-10
or O 0 6.096769200603092e-10
thousands O 0 2.5187156804662436e-09
of O 0 3.280618693679571e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
carcinoma I-Disease 1 1.0
and O 0 1.5232426164857316e-07
that O 0 1.3691251465886012e-09
results O 0 3.4406628657279725e-08
from O 0 1.5612804382669765e-09
truncating O 0 1.0274369088847379e-07
mutations O 0 3.229662981496517e-09
in O 0 1.8219269426467122e-09
the O 0 1.1615211015225668e-08
APC B-Disease 0 1.8244496402530785e-07
gene O 0 7.63685079618881e-08
. O 0 7.066771559038898e-07

A O 0 4.229142405165476e-07
variant O 0 6.54726875382039e-07
of O 0 1.4951800153539807e-07
FAP B-Disease 0 3.1068084354046732e-06
is O 0 1.5154956400920128e-08
attenuated B-Disease 0 0.0007242505671456456
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999622106552124
coli I-Disease 1 0.9999992847442627
, O 0 4.213417525988916e-08
which O 0 3.541790638550424e-09
results O 0 4.825918153983366e-08
from O 0 2.392576581300432e-09
germ O 0 8.433919447270455e-07
- O 0 6.269387426982576e-07
line O 0 4.167094402873772e-08
mutations O 0 1.5241973239099593e-09
in O 0 2.893393580283288e-10
the O 0 3.5935998621283716e-10
5 O 0 3.497457656820302e-09
and O 0 2.1219292989371752e-10
3 O 0 8.07498601318457e-09
regions O 0 1.4157822691984734e-09
of O 0 1.5175725565086395e-08
the O 0 5.66623796771637e-08
APC B-Disease 0 4.1297411712548637e-07
gene O 0 8.46509848884125e-08
. O 0 6.831013479313697e-07

Attenuated B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 7.39711879305105e-07
have O 0 4.795178476513229e-09
" O 0 7.764752041339307e-08
multiple O 0 2.859940104826819e-05
" O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 5.445874151632779e-08
typically O 0 3.2772204949793604e-09
fewer O 0 5.723769236354315e-10
than O 0 1.3354689576416945e-10
100 O 0 5.482000409173793e-10
) O 0 3.5954628163636926e-11
without O 0 2.947243282758194e-10
the O 0 6.706100674769289e-10
florid O 0 1.5057347013680555e-07
phenotype O 0 1.1961401646942704e-08
of O 0 5.568236538522342e-09
classical O 0 5.2576634601564365e-08
FAP B-Disease 0 1.0186138297285652e-06
. O 0 3.1952910717336636e-07

Another O 0 6.98188443948311e-07
group O 0 2.5523325675180786e-08
of O 0 2.0463005512283416e-08
patients O 0 1.6818956227737658e-09
with O 0 4.769435402174338e-10
multiple O 0 5.17547050549183e-07
adenomas B-Disease 0 0.0016117992345243692
has O 0 6.058783696971659e-09
no O 0 3.918999347263252e-09
mutations O 0 3.267458970057646e-09
in O 0 1.2757292999765468e-09
the O 0 4.6208814552528565e-09
APC B-Disease 0 1.1652667275541262e-08
gene O 0 3.42170680678322e-10
, O 0 7.144160957262002e-11
and O 0 1.608580213474653e-10
their O 0 6.983303380003747e-10
phenotype O 0 5.1049275917591785e-09
probably O 0 1.748310940463682e-09
results O 0 5.3870570226877135e-09
from O 0 8.41024416775582e-10
variation O 0 1.7841616184455233e-08
at O 0 4.0308524518195554e-08
a O 0 5.86748982733809e-10
locus O 0 9.637450837374217e-09
, O 0 5.373005929065755e-10
or O 0 5.494676935668963e-10
loci O 0 6.346087655373367e-09
, O 0 5.083355403279199e-10
elsewhere O 0 5.975737682462068e-09
in O 0 2.12096740170864e-09
the O 0 2.640413399035424e-08
genome O 0 4.791368368728399e-08
. O 0 3.7580207390419673e-07

Recently O 0 1.813100311665039e-06
, O 0 3.6571823347486543e-09
however O 0 2.461317816226938e-09
, O 0 4.328495895045137e-10
a O 0 1.5655355900534573e-09
missense O 0 1.1309364822409407e-07
variant O 0 3.8956079606577987e-07
of O 0 3.238694489482441e-06
APC B-Disease 0 1.9690851331688464e-06
( O 0 3.3452270287170904e-08
I1307K O 0 6.447760938499414e-07
) O 0 2.319433756170497e-09
was O 0 8.102045256919155e-09
described O 0 2.485988748190948e-09
that O 0 1.0370097835998848e-10
confers O 0 1.1405726141333616e-08
an O 0 1.464506016457534e-10
increased O 0 4.621313109964831e-09
risk O 0 1.311857090513513e-06
of O 1 1.0
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.9517439088522224e-06
including O 0 1.312570763190024e-08
multiple O 0 1.1327579159114975e-06
adenomas B-Disease 0 0.00010941400978481397
, O 0 3.704636952761575e-08
in O 0 1.6049602891143877e-07
Ashkenazim O 0 0.00041177269304171205
. O 0 4.817815806745784e-06

We O 0 1.5184360790954088e-07
have O 0 1.314604536339914e-09
studied O 0 1.765064894243551e-08
a O 0 3.640623080780614e-10
set O 0 2.1491390889138984e-09
of O 0 1.260669457714414e-09
164 O 0 1.234100199809518e-08
patients O 0 1.4457920416433012e-09
with O 0 3.070723231246575e-09
multiple O 1 0.9999972581863403
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999415874481201
/ I-Disease 1 1.0
or I-Disease 1 0.9997473359107971
carcinoma I-Disease 1 1.0
and O 0 6.867068691462919e-07
analyzed O 0 8.435021641162166e-07
codons O 0 3.9634471704630414e-07
1263 O 0 8.751318091526628e-06
- O 0 1.0860702559511992e-06
1377 O 0 1.053382129612146e-05
( O 0 2.8040123112305082e-08
exon O 0 3.722465464761626e-07
15G O 0 8.999813871923834e-07
) O 0 2.4323967284800574e-09
of O 0 1.4579913276691059e-08
the O 0 2.4090907047025212e-08
APC B-Disease 0 1.886921836558031e-07
gene O 0 5.2855728682743575e-09
for O 0 4.9198223273094754e-09
germ O 0 4.98458166475757e-06
- O 0 1.1028379049093928e-05
line O 0 1.0249497108816286e-06
variants O 0 3.215774540876737e-06
. O 0 1.162057060355437e-06

Three O 0 1.471584027967765e-07
patients O 0 2.6718423029592486e-09
with O 0 1.8226975484481045e-10
the O 0 3.7202416702797336e-09
I1307K O 0 4.910899420451642e-08
allele O 0 2.5574980355713706e-08
were O 0 2.3017086014931465e-09
detected O 0 1.8444724636523802e-09
, O 0 1.0241992670634303e-10
each O 0 1.47157064311898e-10
of O 0 1.1839737190655342e-08
Ashkenazi O 0 1.0880577292482485e-06
descent O 0 1.144942643804825e-06
. O 0 2.8969197956030257e-06

Four O 0 1.60869603860192e-06
patients O 0 1.0650063586581382e-07
had O 0 1.8349570751752253e-08
a O 0 8.454315469919038e-09
germ O 0 2.184841378038982e-06
- O 0 3.2568198093940737e-06
line O 0 3.486001673991268e-07
E1317Q O 0 2.178559952881187e-06
missense O 0 9.33173168959911e-07
variant O 0 2.263956417891677e-07
of O 0 8.770300752303228e-08
APC O 0 2.429995937802687e-08
that O 0 1.280650863133559e-10
was O 0 1.030275642577294e-09
not O 0 6.68433711159544e-11
present O 0 1.3841196244701592e-10
in O 0 1.3921844232989145e-10
controls O 0 1.6673402658540226e-09
; O 0 2.545601229808625e-10
one O 0 1.916363456810899e-10
of O 0 7.423769932124458e-10
these O 0 2.8101931892621224e-10
individuals O 0 5.83692538747016e-11
had O 0 4.887831250854902e-10
an O 0 7.752576358655006e-11
unusually O 0 1.0669511940619714e-09
large O 0 1.2264405047091032e-09
number O 0 7.790055711609511e-09
of O 0 5.487560201800079e-07
metaplastic B-Disease 0 0.001387116964906454
polyps I-Disease 0 4.073324362252606e-06
of I-Disease 0 3.1307044423556363e-07
the I-Disease 0 2.225772561814665e-07
colorectum I-Disease 0 1.9569302821764722e-05
. O 0 2.0561776636895956e-06

There O 0 5.6384983793122956e-08
is O 0 5.250442858262261e-10
increasing O 0 6.258121798552452e-10
evidence O 0 3.4529283876594263e-09
that O 0 8.89257764646878e-11
there O 0 2.138277888086293e-10
exist O 0 1.1686092094009837e-09
germ O 0 7.28630027424515e-08
- O 0 2.1957287543727944e-08
line O 0 5.310603956587556e-09
variants O 0 8.75363426189324e-09
of O 0 9.077633755794068e-09
the O 0 5.230454735993817e-09
APC B-Disease 0 1.2394030690643376e-08
gene O 0 3.183862340438992e-10
that O 0 5.363992583440336e-11
predispose O 0 6.035416166838559e-09
to O 0 3.2253891224520714e-10
the O 0 6.093130444639883e-10
development O 0 1.0073085476847154e-08
of O 0 3.659375025222289e-08
multiple O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 2.3754306965884098e-08
but O 0 1.1512928388413002e-09
without O 0 1.7418404496538642e-09
the O 0 1.95396387958624e-09
florid O 0 5.476623599065533e-08
phenotype O 0 1.1243812991779123e-08
of O 0 2.9328333095435255e-09
classical O 0 3.8942406632713755e-08
FAP B-Disease 0 1.5791584928592783e-07
, O 0 5.544875114615877e-10
and O 0 3.8203942787085055e-10
possibly O 0 6.828438703365691e-09
with O 0 4.2373413111640446e-10
importance O 0 2.8579017907759408e-06
for O 1 0.997805655002594
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 5.591455760622921e-07
in O 0 1.992373155346172e-09
the O 0 1.2547777261673332e-09
general O 0 1.5258116992100668e-09
population O 0 1.6868799759817144e-11
. O 0 8.496147674286192e-10
. O 0 1.0561219454530146e-07

Genomic O 0 3.3851827652142674e-07
structure O 0 1.0232205482907375e-07
of O 0 4.1523055216430294e-08
the O 0 2.6066427949444915e-07
human O 1 0.99998939037323
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9998167157173157
CLD B-Disease 1 0.9999998807907104
) O 0 3.752512611754355e-07
gene O 0 2.8363731985336926e-07
. O 0 1.621178626010078e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999916553497314
CLD B-Disease 1 1.0
) O 0 2.2039820635200158e-08
is O 0 2.8049937372820466e-10
caused O 0 1.7822561204638987e-09
by O 0 1.9335574807932687e-10
mutations O 0 8.133565487788985e-10
in O 0 4.756625648916213e-10
a O 0 9.116565280464783e-10
gene O 0 1.704973384697439e-09
which O 0 1.7920459560727409e-09
encodes O 0 1.9414528651395813e-08
an O 0 3.959715666468355e-09
intestinal O 0 2.46456625063729e-06
anion O 0 2.2623037239100086e-06
transporter O 0 6.117214797995985e-05
. O 0 2.555061200837372e-06

We O 0 2.917921051448502e-07
report O 0 7.113411193415686e-09
here O 0 8.768519799140506e-10
the O 0 1.3318822433827648e-10
complete O 0 4.195970237930169e-10
genomic O 0 3.0490823199613715e-09
organization O 0 5.47732859068617e-10
of O 0 3.4627158917999168e-09
the O 0 1.0954980922406321e-08
human O 0 6.855493950297387e-08
CLD B-Disease 0 1.0797593859024346e-05
gene O 0 9.112850030135178e-09
which O 0 1.4947252324759575e-09
spans O 0 1.067979926716589e-08
approximately O 0 2.6230844163421807e-09
39kb O 0 3.1200966077449266e-07
, O 0 2.0623687202458996e-09
and O 0 6.708176236713825e-09
comprises O 0 2.671527710162991e-08
21 O 0 3.2177337061511935e-07
exons O 0 4.145175353187369e-06
. O 0 1.2225988257341669e-06

All O 0 3.2001569252315676e-06
exon O 0 8.238962436735164e-06
/ O 0 2.935282964244834e-06
intron O 0 5.591674039351346e-07
boundaries O 0 6.648591011071403e-08
conform O 0 4.925232843788763e-08
to O 0 7.829499715228394e-09
the O 0 5.621424747914716e-08
GT O 0 0.0065271551720798016
/ O 0 0.00011610796354943886
AG O 0 9.145640069618821e-05
rule O 0 1.4153382608128595e-06
. O 0 1.0598324706734275e-06

An O 0 6.732402191289566e-09
analysis O 0 2.901895168605506e-09
of O 0 2.617766448054226e-09
the O 0 3.898169786964445e-09
putative O 0 6.91056669666068e-08
promoter O 0 3.366372141044849e-07
region O 0 2.8243880123568488e-08
sequence O 0 1.1803390265185953e-08
shows O 0 1.479802147485998e-08
a O 0 2.3478412103372648e-08
putative O 0 2.8435554213501746e-06
TATA O 0 6.992115959292278e-05
box O 0 5.120327841723338e-07
and O 0 1.957370443506079e-08
predicts O 0 1.0852559739760181e-07
multiple O 0 1.1952415057692178e-08
transcription O 0 2.9731564765711482e-08
factor O 0 2.2799500953851748e-08
binding O 0 4.733371028464717e-08
sites O 0 1.6686095705154003e-07
. O 0 4.87719717057189e-07

The O 0 2.8502350346570893e-07
genomic O 0 5.875447328662631e-08
structure O 0 4.897373884205081e-08
was O 0 8.246918703491701e-09
determined O 0 3.4146017124925265e-09
using O 0 4.676124487623667e-10
DNA O 0 3.5755656213609655e-09
from O 0 2.271197951930759e-10
several O 0 2.988030933792629e-10
sources O 0 4.302602718553317e-09
including O 0 5.629530175355058e-10
multiple O 0 6.436097876871827e-09
large O 0 3.536837311912677e-08
- O 0 2.0215311451465823e-06
insert O 0 2.1927891680206812e-07
libaries O 0 3.4605634482431924e-06
and O 0 7.184013828265279e-09
genomic O 0 1.5044996359847573e-08
DNA O 0 2.337403515184633e-08
from O 0 6.230041815769027e-09
Finnish O 0 1.4820364413026255e-05
CLD B-Disease 1 0.998843789100647
patients O 0 1.602323607130529e-07
and O 0 5.2983949672125163e-08
controls O 0 2.731943823164329e-06
. O 0 4.254301529726945e-06

Exon O 0 3.0161487302393652e-05
- O 0 6.01573162839486e-07
specific O 0 3.261369618812182e-09
primers O 0 2.867049531118937e-08
developed O 0 3.4292872985730583e-09
in O 0 9.470110112763663e-11
this O 0 3.500169945547249e-11
study O 0 1.1031502100689039e-10
will O 0 7.584465694376874e-11
facilitate O 0 3.9631364856518303e-10
mutation O 0 2.087605782685742e-10
screening O 0 1.9018164820749917e-10
studies O 0 4.3464404297921533e-10
of O 0 6.435039168195544e-10
patients O 0 2.896584916367573e-10
with O 0 2.888728700689569e-10
the O 0 2.7549223347023144e-08
disease O 0 3.886293143295916e-06
. O 0 3.2684147299733013e-07

Genomic O 0 3.7501695260289125e-07
sequencing O 0 9.378877763310811e-08
of O 0 7.541518698417349e-08
a O 0 1.372559523815653e-07
BAC O 0 0.0004327667411416769
clone O 0 8.738908036320936e-06
H O 1 1.0
_ O 0 4.4764423279275434e-08
RG364P16 O 0 2.6125385943487345e-07
revealed O 0 2.337394633400436e-08
the O 0 5.631227151248197e-10
presence O 0 2.6715760159667923e-10
of O 0 1.4957290961348235e-09
another O 0 4.338430725780995e-10
, O 0 2.7628549448266426e-10
highly O 0 1.7423654741222094e-09
homologous O 0 1.5051044854885731e-09
gene O 0 2.3866151277474046e-09
3 O 0 7.965825687961114e-08
of O 0 3.7891133786160935e-08
the O 0 1.520470505056437e-07
CLD B-Disease 0 0.0026352056302130222
gene O 0 1.336555843778342e-08
, O 0 6.399933361045385e-10
with O 0 7.384266809129514e-11
a O 0 3.456563923975864e-10
similar O 0 6.239647687422689e-10
genomic O 0 1.7362092208372815e-08
structure O 0 3.6301608474786917e-07
, O 0 1.654797299188715e-09
recently O 0 8.80247341683571e-09
identified O 0 5.1307664783450946e-09
as O 0 3.055416364361463e-09
the O 0 1.763642103469465e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 4.0426101577395457e-07
( O 0 3.61128975612246e-08
PDS B-Disease 0 4.105295374756679e-06
) O 0 5.620392595773183e-09
. O 0 3.7006259390182095e-08
. O 0 6.071870757295983e-07

The O 0 1.6577982933085877e-06
APCI1307K O 0 0.0003767317975871265
allele O 0 2.0591919565049466e-06
and O 0 5.2200629596654835e-08
cancer B-Disease 0 2.6354356919000566e-07
risk O 0 8.765414172273722e-09
in O 0 2.6123894159013616e-09
a O 0 3.6177685291960415e-09
community O 0 1.7609547153796257e-09
- O 0 4.0361509690001185e-09
based O 0 4.184597113265909e-10
study O 0 4.178687118550073e-10
of O 0 4.060899616575853e-09
Ashkenazi O 0 3.0096094860709854e-07
Jews O 0 1.7133073981767666e-07
. O 0 7.980750069691567e-07

Mutations O 0 1.6588832068009651e-06
in O 0 3.6382736823270534e-08
APC O 0 3.1569808811582334e-07
are O 0 1.6120026424815137e-09
classically O 0 2.6024699195659196e-07
associated O 0 3.2383562142968003e-07
with O 0 2.1587736682704417e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9003115892410278
FAP B-Disease 0 0.0009077679715119302
) O 0 2.5150157512143778e-08
, O 0 1.7335478608160315e-09
a O 0 1.3915752994364539e-08
highly O 1 0.5654784440994263
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 8.410929149249569e-05
by O 0 1.0471175926340948e-08
multiple O 0 1.6364932662327192e-06
intestinal O 0 0.0002502759743947536
polyps B-Disease 0 2.0980899080313975e-06
and O 0 4.813689447047409e-09
, O 0 5.144845660609576e-10
without O 0 9.98783056260777e-10
surgical O 0 8.427867470572892e-08
intervention O 0 3.518468716379175e-08
, O 0 2.0658843524756776e-09
the O 0 7.434741267076106e-09
development O 0 3.115550134680234e-05
of O 1 0.9999990463256836
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.2138426427554805e-05
CRC B-Disease 0 0.0004520027432590723
) O 0 9.153721691745886e-08
. O 0 8.283391252916772e-07

APC B-Disease 0 2.1872701836400665e-05
is O 0 3.297260775525501e-08
a O 0 8.741275792090164e-08
tumour O 1 1.0
- O 0 8.316181265399791e-06
suppressor O 0 3.084487616433762e-07
gene O 0 1.8678241175962285e-09
, O 0 6.482911985017381e-10
and O 0 3.953014804380928e-09
somatic O 0 2.5568990622559795e-06
loss O 0 7.569185527245281e-07
occurs O 0 2.7043810746363306e-07
in O 0 2.0144919687936635e-07
tumours B-Disease 1 1.0
. O 0 5.695959771401249e-05

The O 0 1.5410836567752995e-05
germline O 0 0.00017358899640385062
T O 0 1.085487656382611e-05
- O 0 9.090251040788644e-08
to O 0 1.5793528707064297e-09
- O 0 8.980504340172502e-09
A O 0 5.3981756842347295e-09
transversion O 0 2.3415047678554402e-07
responsible O 0 7.651661526608677e-09
for O 0 6.772001293064989e-10
the O 0 5.968629590569208e-09
APC O 0 7.529832402042302e-08
I1307K O 0 2.853362559562811e-07
allele O 0 3.373457602151575e-08
converts O 0 3.020904415507175e-08
the O 0 6.48697273675225e-09
wild O 0 6.917844075360335e-09
- O 0 2.020978939754059e-09
type O 0 8.037119858528285e-10
sequence O 0 5.069489272813144e-10
to O 0 2.2058596615970316e-10
a O 0 6.160467247440238e-09
homopolymer O 0 8.231971150962636e-05
tract O 0 6.755075901310192e-06
( O 0 4.123608476902518e-08
A8 O 0 7.3260616773040965e-06
) O 0 1.044119457560555e-09
that O 0 4.139475429099093e-10
is O 0 1.1931954313482152e-09
genetically O 0 5.014199899733285e-08
unstable O 0 1.4059096429264173e-05
and O 0 2.8772669224963465e-07
prone O 0 3.2454379834234715e-05
to O 0 2.834664485362737e-07
somatic O 1 0.6064556837081909
mutation O 0 4.913138127449201e-06
. O 0 1.6424831983385957e-06

The O 0 6.322899253063952e-07
I1307K O 0 1.5671162145736162e-06
allele O 0 9.175396797900248e-08
was O 0 2.1122401605566665e-08
found O 0 1.082775979988071e-09
in O 0 2.6677380304818143e-09
6 O 0 8.300749527734297e-07
. O 0 7.105101644810929e-07

1 O 0 3.1855047382123303e-06
% O 0 1.8123687439697278e-08
of O 0 3.9912080751491885e-08
unselected O 0 1.2979247912880965e-05
Ashkenazi O 0 5.00047121931857e-07
Jews O 0 2.107218044500314e-08
and O 0 1.5086482063608742e-09
higher O 0 1.334281307663332e-08
proportions O 0 1.4581943652558493e-08
of O 0 3.6158937177788175e-08
Ashkenazim O 0 4.9707864491210785e-06
with O 0 1.758719281319543e-09
family O 0 1.004125671499878e-09
or O 0 8.963900732794627e-10
personal O 0 1.0613902645673079e-08
histories O 0 1.1945890321385377e-07
of O 0 4.443256329977885e-06
CRC B-Disease 0 0.0562247633934021
( O 0 8.356939673603847e-08
ref O 0 3.195527369825868e-06
. O 0 1.950152217489176e-08
2 O 0 4.83610961055092e-07
) O 0 2.0349512297457295e-08
. O 0 4.948887522004952e-07

To O 0 9.111045784493399e-08
evaluate O 0 2.2589441073250782e-07
the O 0 3.474651233403847e-09
role O 0 4.824130428460194e-09
of O 0 7.000297230774777e-09
I1307K O 0 1.1163512425582667e-07
in O 0 3.0490356905943372e-09
cancer B-Disease 0 1.7700545029697423e-08
, O 0 1.3427541301069823e-09
we O 0 9.052528504582824e-09
genotyped O 0 5.403308023232967e-07
5 O 0 1.1328902616014602e-07
, O 0 1.0716814102806893e-08
081 O 0 5.3339927035267465e-06
Ashkenazi O 0 3.9184411093629024e-07
volunteers O 0 1.3643839835708604e-08
in O 0 2.430801337993671e-09
a O 0 9.442144843774258e-09
community O 0 1.6731519281165674e-08
survey O 0 1.3452623193188629e-07
. O 0 1.9339136088092346e-06

Risk O 0 2.1963331164442934e-05
of O 0 0.00027133486582897604
developing O 1 1.0
colorectal B-Disease 1 1.0
, I-Disease 0 0.02336227148771286
breast I-Disease 0 0.018835093826055527
and I-Disease 0 3.222895941235038e-07
other I-Disease 0 9.800487532629631e-08
cancers I-Disease 0 0.016097314655780792
were O 0 8.321533329080921e-08
compared O 0 2.448223312967457e-08
between O 0 1.4407528681203985e-07
genotyped O 0 9.79683409241261e-06
I1307K O 0 9.279575579057564e-07
carriers O 0 3.943939841377642e-09
and O 0 5.7574962575301925e-09
non O 0 1.0500779978883656e-07
- O 0 1.3047481317585152e-08
carriers O 0 1.5623997928759792e-10
and O 0 4.019961308276976e-10
their O 0 4.805210673808347e-10
first O 0 1.2874380450611511e-09
- O 0 3.6622709309597212e-09
degree O 0 6.844766886615616e-08
relatives O 0 4.1230425296134854e-08
. O 0 1.3607525772840745e-07

Sperm O 0 1.4040479356935975e-07
DNA O 0 6.030953159097407e-08
analysis O 0 1.3283925959228782e-08
in O 0 3.6662266555964607e-09
a O 0 7.344792152252921e-08
Friedreich B-Disease 1 0.9867666363716125
ataxia I-Disease 1 0.9999997615814209
premutation O 0 0.43188393115997314
carrier O 0 2.1663291249751637e-07
suggests O 0 1.673082294928463e-07
both O 0 4.0207705609418554e-08
meiotic O 0 1.709702337393537e-05
and O 0 6.653030482084432e-08
mitotic O 0 4.1571641418158833e-07
expansion O 0 3.6253684498888106e-08
in O 0 5.58965673747025e-09
the O 0 2.6044405743164134e-08
FRDA B-Disease 0 1.5473879102501087e-05
gene O 0 1.9488439306769578e-07
. O 0 7.690700272178219e-07

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 1.1489415783216828e-06
usually O 0 4.1766273994880976e-08
caused O 0 1.663986104460946e-08
by O 0 2.1900800617480343e-10
an O 0 7.64272672926225e-11
expansion O 0 5.1555160140992484e-09
of O 0 5.263804325750243e-08
a O 0 1.3174948776395468e-07
GAA O 0 3.7422782042995095e-05
trinucleotide O 0 9.890810588331078e-07
repeat O 0 1.267788860559449e-07
in O 0 7.529958878649268e-09
intron O 0 2.2724133685869674e-08
1 O 0 7.640696964017479e-08
of O 0 1.586037257084172e-08
the O 0 3.238936585603369e-08
FRDA B-Disease 0 2.1556899810093455e-05
gene O 0 1.7032068910793896e-07
. O 0 6.684046525151643e-07

Occasionally O 0 1.2406268297127099e-06
, O 0 1.1999469862189471e-08
a O 0 3.3297564705492277e-09
fully O 0 9.797568090164077e-09
expanded O 0 3.3617981731737245e-09
allele O 0 1.6153551385400533e-08
has O 0 8.134833084927351e-11
been O 0 7.401625146119528e-11
found O 0 2.1718961698558026e-11
to O 0 2.726148300158382e-11
arise O 0 9.083344632010437e-10
from O 0 8.741195961503578e-11
a O 0 4.851644641590269e-10
premutation O 0 8.312569832469308e-08
of O 0 9.331944106349965e-09
100 O 0 1.196016885529616e-08
or O 0 4.336547121397416e-09
less O 0 3.4254188818749753e-08
triplet O 0 1.0626951734593604e-05
repeats O 0 1.1727606761269271e-06
. O 0 4.644582531909691e-07

We O 0 1.212787879012467e-07
have O 0 8.50594095158641e-10
examined O 0 1.118588777160312e-08
the O 0 6.392418261391697e-10
sperm O 0 4.092607086558786e-10
DNA O 0 4.261577757347368e-09
of O 0 6.335856284067631e-09
a O 0 1.3753210126310478e-08
premutation O 0 3.7703516682086047e-06
carrier O 0 4.234998414176516e-07
. O 0 8.94556342245778e-06

This O 0 2.487821575414273e-07
mans O 0 3.095030479016714e-05
leucocyte O 0 3.01778254652163e-06
DNA O 0 6.394533613729436e-08
showed O 0 9.526715416541265e-09
one O 0 1.3188891090365473e-09
normal O 0 3.679452964533425e-09
allele O 0 4.3073566935447616e-09
and O 0 6.552553499794556e-10
one O 0 1.4475931564561506e-10
allele O 0 2.2617059336482725e-09
of O 0 4.2100252173327135e-09
approximately O 0 2.4295729872392258e-09
100 O 0 9.990007932003664e-09
repeats O 0 1.7712997646412987e-07
. O 0 3.894846258845064e-07

His O 0 1.822027115849778e-06
sperm O 0 6.636707183815815e-08
showed O 0 3.897636347005573e-08
an O 0 5.068425679155553e-10
expanded O 0 6.262889318264797e-09
allele O 0 3.1927928745290046e-08
in O 0 6.908824623508281e-09
a O 0 1.492037071670893e-08
tight O 0 2.5661472591309575e-07
range O 0 2.853150249393366e-07
centering O 0 9.037108128495674e-08
on O 0 1.0102581882165396e-08
a O 0 6.573458444236735e-10
size O 0 6.0798988066324e-09
of O 0 8.236606063860563e-09
approximately O 0 1.5947613007938344e-08
320 O 0 1.8129640011466108e-07
trinucleotide O 0 5.901835265831323e-06
repeats O 0 2.233664645245881e-06
. O 0 1.3440700286082574e-06

His O 0 1.2876549590146169e-05
affected O 0 2.5126721538981656e-06
son O 0 1.033549960993696e-05
has O 0 8.773308302068017e-09
repeat O 0 4.134902553687425e-08
sizes O 0 1.471575501454936e-07
of O 0 1.8020921288552927e-07
1040 O 0 5.2576315283658914e-06
and O 0 4.266533082386559e-08
540 O 0 7.301561026906711e-07
. O 0 2.548592306084174e-07

These O 0 2.0890935203965455e-08
data O 0 7.73716202218111e-09
suggest O 0 4.874415315825331e-10
that O 0 1.9945307558333347e-11
expansion O 0 5.349833909207291e-10
occurs O 0 1.2291376250139763e-10
in O 0 4.160116001683534e-11
two O 0 4.529824432220053e-11
stages O 0 1.1763513496632072e-09
, O 0 4.3073440647578565e-11
the O 0 9.080152602036762e-11
first O 0 5.718073792237988e-10
during O 0 1.0459891841563262e-09
meiosis O 0 6.198584312500088e-09
followed O 0 9.345548779293722e-10
by O 0 2.3430521411960115e-10
a O 0 3.117093694271489e-09
second O 0 4.5538794068988864e-08
mitotic O 0 2.457037680869689e-06
expansion O 0 1.8977276567966328e-06
. O 0 4.01283978135325e-06

We O 0 2.2336999450089934e-07
also O 0 1.4734671260896448e-09
show O 0 4.3936923543874684e-10
that O 0 2.8852524536215896e-11
in O 0 1.0584557535997519e-10
all O 0 2.0895538077603248e-10
informative O 0 2.101774088103525e-09
carrier O 0 4.840091105684508e-10
father O 0 3.625200806212092e-09
to O 0 9.343694706842598e-10
affected O 0 1.0117950921539887e-08
child O 0 2.595524151161044e-08
transmissions O 0 2.07383735073563e-07
, O 0 4.5060086217851847e-10
with O 0 7.681806579729056e-11
the O 0 1.053386933236311e-09
notable O 0 1.5943529829698377e-09
exception O 0 2.36487363025617e-09
of O 0 9.327531635960895e-09
the O 0 1.0468759192860944e-08
premutation O 0 5.422634785645641e-07
carrier O 0 5.900983257589587e-09
, O 0 4.21131041150602e-09
the O 0 1.1679925471241859e-08
expansion O 0 3.91687891010406e-08
size O 0 3.013974847476675e-08
decreases O 0 1.8759511277721685e-08
. O 0 9.468998918293892e-09
. O 0 1.7277942276905378e-07

The O 0 4.674960791817284e-07
R496H O 0 4.047566108056344e-06
mutation O 0 1.272954648356972e-07
of O 0 5.5150312761043097e-08
arylsulfatase O 0 5.183935627428582e-06
A O 0 3.17113837411398e-08
does O 0 1.4845705775812235e-09
not O 0 5.803705072082721e-09
cause O 0 1.1108359103673138e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 1.1695601642713882e-05

Deficiency B-Disease 1 0.998440682888031
of I-Disease 0 0.0007600243552587926
arylsulfatase I-Disease 1 0.9867652654647827
A I-Disease 0 6.69583969283849e-05
( O 0 1.6174399775081838e-07
ARSA O 0 2.5760638891370036e-05
) O 0 5.4772266722125096e-09
enzyme O 0 5.248035606086887e-08
activity O 0 1.7160169818453141e-07
causes O 0 1.412257734045852e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 3.6515637020784197e-06
MLD B-Disease 1 1.0
) O 0 9.484981688956395e-08
. O 0 4.572396221647068e-07

A O 0 1.6066570651673828e-07
number O 0 1.2824585837734048e-08
of O 0 1.4545670978804992e-07
ARSA O 0 5.8865964092547074e-05
gene O 0 7.38894101459664e-08
mutations O 0 3.950310656364309e-08
responsible O 0 4.949245990815143e-08
for O 0 1.7240456173794882e-08
MLD B-Disease 1 1.0
have O 0 1.7592736156757383e-08
been O 0 2.1826259910540102e-08
identified O 0 1.6036794647789065e-07
. O 0 4.352152132014453e-07

Recently O 0 1.10759572180541e-06
, O 0 9.802577416451186e-09
the O 0 7.919239486398055e-09
R496H O 0 3.8918798850318126e-07
mutation O 0 2.8662512363553105e-08
of O 0 7.736973373084766e-08
ARSA O 0 2.9269302103784867e-05
was O 0 3.6568145844739774e-08
proposed O 0 1.1988940951113136e-09
to O 0 3.055700137366557e-10
be O 0 4.4853776248743316e-10
a O 0 8.554295050089422e-10
cause O 0 6.847587741276584e-08
of O 0 6.5059166445280425e-06
MLD B-Disease 1 1.0
( O 0 2.656437345649465e-07
Draghia O 0 2.6331565095460974e-05
et O 0 2.0801371647394262e-05
al O 0 1.06232175767218e-06
. O 0 4.23796597814885e-09
, O 0 8.232675097197273e-10
1997 O 0 5.641034306336223e-09
) O 0 7.112217481619609e-09
. O 0 4.0896819086810865e-07

We O 0 2.558391543061589e-07
have O 0 4.112312268489404e-09
investigated O 0 3.182384133992855e-08
the O 0 1.8860601969095114e-09
R496H O 0 4.931116848183592e-08
mutation O 0 8.983412902452415e-10
and O 0 2.6980712108937155e-10
found O 0 4.936570041635946e-10
this O 0 1.1146646106130476e-10
mutation O 0 2.3889012989997127e-09
at O 0 1.2969078255764543e-08
a O 0 3.661543013233626e-10
relatively O 0 4.249700868985684e-10
high O 0 5.548379533593106e-09
frequency O 0 7.793667045064012e-09
in O 0 8.840962684164566e-11
an O 0 3.190529437868683e-11
African O 0 6.350346914985039e-10
American O 0 1.163764015710278e-10
population O 0 2.642897185822779e-12
( O 0 3.703472598037827e-11
f O 0 1.4884244947666048e-08
= O 0 2.3966656215179682e-08
0 O 0 1.0588363963393022e-08
. O 0 5.4967524976135e-10
09 O 0 3.176943863536508e-08
, O 0 2.035446922121764e-09
n O 0 5.1763290542794493e-08
= O 0 1.6583422279836668e-07
61 O 0 2.6401416164389957e-08
subjects O 0 7.22485538062756e-08
) O 0 1.269467642117661e-08
. O 0 2.527707749777619e-07

The O 0 5.602394139714306e-06
ARSA O 0 0.00015406780585180968
enzyme O 0 1.333444714646248e-07
activity O 0 2.913976793195161e-08
in O 0 1.1732501636885218e-09
subjects O 0 8.43514857962191e-09
with O 0 4.834552549959348e-11
and O 0 1.8409111735007144e-10
without O 0 5.24219723185837e-10
the O 0 1.0838668851320676e-09
R496H O 0 4.2700907698645096e-08
mutation O 0 2.6058653013194544e-09
was O 0 1.936895088761048e-09
determined O 0 3.0927360672450277e-09
and O 0 6.039305167071518e-10
found O 0 5.62154711669649e-10
to O 0 4.398689468221306e-10
be O 0 9.704778314301166e-09
normal O 0 4.343825992236816e-07
. O 0 5.028446707910916e-07

It O 0 1.1092616603036731e-08
is O 0 5.362031374467335e-10
therefore O 0 1.3763069572902964e-09
concluded O 0 3.6674925318891383e-09
that O 0 6.03739003235404e-11
the O 0 8.775413173900404e-10
R496H O 0 7.492312903423226e-08
mutation O 0 4.805094100390761e-09
of O 0 2.624967621045471e-08
ARSA O 0 3.5461057450447697e-06
does O 0 1.3804555276664132e-09
not O 0 1.1086308537855416e-09
negatively O 0 2.706618484893397e-09
influence O 0 6.170910005209862e-09
the O 0 4.822548138605498e-09
activity O 0 1.4389343050424941e-08
of O 0 1.7554759423887845e-08
ARSA O 0 1.775178316165693e-05
and O 0 2.885365502081072e-09
is O 0 1.4973840223309054e-10
not O 0 2.6870142222357174e-10
a O 0 2.76769829277157e-09
cause O 0 7.480431349904393e-07
of O 0 0.00017922215920407325
MLD B-Disease 1 1.0

Down O 0 1.1458807421149686e-05
- O 0 9.71557710727211e-07
regulation O 0 9.28688237422648e-08
of O 0 7.797521561769827e-08
transmembrane O 0 7.980963346199133e-06
carbonic O 0 0.0011004750849679112
anhydrases O 0 0.0003166391106788069
in O 0 1.2585170452439343e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.8188780546188354
lines O 0 2.1870188504635735e-07
by O 0 2.512790864273029e-08
wild O 0 4.1400883787900966e-07
- O 0 1.1748617225748603e-06
type O 0 7.551784801762551e-05
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 0.9999980926513672
transgenes O 0 0.0031793704256415367
. O 0 1.0431652299303096e-05

To O 0 3.1361162200482795e-07
discover O 0 7.535967938565591e-07
genes O 0 3.458644926013221e-08
involved O 0 4.184114388294802e-08
in O 0 5.342477393810441e-08
von B-Disease 1 0.9999980926513672
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( O 0 1.5917390555841848e-05
VHL B-Disease 1 0.9972142577171326
) O 0 1.786607555231967e-07
- O 0 4.490815172175644e-06
mediated O 0 2.193590989918448e-05
carcinogenesis O 0 0.0022161416709423065
, O 0 3.3586766701176884e-09
we O 0 7.796016276984119e-09
used O 0 7.730660200877537e-08
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999783039093018
lines O 0 1.0882468814088497e-05
stably O 0 7.220061525003985e-05
transfected O 0 3.7440875075844815e-06
with O 0 3.119307834253959e-08
wild O 0 6.163572834338993e-07
- O 0 4.066842848260421e-06
type O 0 0.0012836207170039415
VHL O 1 0.9999991655349731
- O 0 0.076187364757061
expressing O 0 1.2687277148870635e-06
transgenes O 0 3.909920997102745e-05
. O 0 1.4567162907042075e-06

Large O 0 1.4417756801776704e-06
- O 0 3.784509317483753e-06
scale O 0 2.2035992515156977e-06
RNA O 0 1.6556226967168186e-07
differential O 0 4.4675718413600407e-07
display O 0 2.7208020725311144e-08
technology O 0 2.4437072809746496e-08
applied O 0 2.2619992545713785e-09
to O 0 9.145977725166787e-11
these O 0 8.703498338702431e-11
cell O 0 2.84069168188239e-09
lines O 0 5.062146257728273e-10
identified O 0 1.174324859576359e-09
several O 0 6.050788758926728e-10
differentially O 0 5.9085884629439533e-08
expressed O 0 1.9240669058007143e-09
genes O 0 1.0183152099330073e-09
, O 0 1.1870794625057357e-10
including O 0 7.549422892383362e-11
an O 0 2.2949390998672214e-10
alpha O 0 2.648605743615917e-07
carbonic O 0 1.0526058758841828e-05
anhydrase O 0 2.9088821975165047e-05
gene O 0 1.3175854007840826e-07
, O 0 3.6969147743093345e-08
termed O 0 2.6750210508907912e-06
CA12 O 0 0.00027348168077878654
. O 0 4.455608632270014e-06

The O 0 6.285797553573502e-07
deduced O 0 3.976148832407489e-07
protein O 0 1.0037183528766036e-08
sequence O 0 6.1840359499854e-09
was O 0 8.23104695513166e-09
classified O 0 1.4910007672952474e-09
as O 0 4.909883055681519e-10
a O 0 1.652781689287508e-09
one O 0 4.359219651917101e-09
- O 0 4.854259714193176e-07
pass O 0 4.104721256226185e-07
transmembrane O 0 0.00013572952593676746
CA O 0 1.8425047528580762e-05
possessing O 0 6.246166321943747e-07
an O 0 3.493823674816099e-09
apparently O 0 4.4347835626012966e-08
intact O 0 1.4129508940641244e-07
catalytic O 0 8.821133690162242e-08
domain O 0 1.1297527890974379e-07
in O 0 2.433813506286242e-08
the O 0 1.2823160489006113e-07
extracellular O 0 3.984343493357301e-06
CA O 0 2.8639986339840107e-05
module O 0 2.97867718472844e-05
. O 0 4.7019411795190535e-06

Reintroduced O 0 3.504643973428756e-05
wild O 0 1.530873646515829e-06
- O 0 7.998671662790002e-07
type O 0 6.320174179563764e-07
VHL B-Disease 0 0.00011150051432196051
strongly O 0 8.82123458723072e-08
inhibited O 0 5.3458609983181304e-08
the O 0 2.7403730396002857e-09
overexpression O 0 1.8737267737378716e-08
of O 0 4.833137445814373e-09
the O 0 4.2595056370942075e-09
CA12 O 0 8.426587214671599e-07
gene O 0 1.2888334843808025e-09
in O 0 5.211968634455388e-10
the O 0 4.569468803339305e-09
parental O 0 3.0005642202013405e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9998133778572083
lines O 0 1.1701637049554847e-05
. O 0 9.982979463529773e-06

Similar O 0 4.995966307319577e-08
results O 0 5.5660731135276365e-08
were O 0 3.719049734840496e-09
obtained O 0 3.822371308359607e-09
with O 0 1.0693613772261301e-09
CA9 O 0 1.4177768207446206e-05
, O 0 6.9877312824928595e-09
encoding O 0 1.3004158461171755e-07
another O 0 4.2409435963008946e-08
transmembrane O 0 1.180452613880334e-06
CA O 0 4.159444699780579e-07
with O 0 1.1635116203834173e-09
an O 0 1.0175696951719715e-09
intact O 0 9.834098335659291e-08
catalytic O 0 1.987956181892514e-07
domain O 0 1.093246851269214e-06
. O 0 1.5659508108001319e-06

Although O 0 5.440205796958253e-08
both O 0 1.2395638293583033e-08
domains O 0 5.221785670528334e-08
of O 0 2.0278605461498955e-08
the O 0 1.0192096056016453e-08
VHL B-Disease 0 1.0753669812402222e-06
protein O 0 4.885466697857055e-09
contribute O 0 4.3176284769685935e-10
to O 0 3.948182614177398e-10
regulation O 0 1.2529033810437795e-08
of O 0 1.6900223442917195e-08
CA12 O 0 2.2081529095885344e-05
expression O 0 7.195779527791046e-09
, O 0 3.557482364247022e-10
the O 0 4.4190989756387467e-10
elongin O 0 3.546470139781377e-08
binding O 0 1.5096016880988827e-08
domain O 0 4.80519730672313e-08
alone O 0 4.224383509665586e-09
could O 0 8.746741997356366e-09
effectively O 0 1.921999484011394e-07
regulate O 0 2.9982135174577706e-07
CA9 O 0 0.00029635519604198635
expression O 0 2.154649791918928e-06
. O 0 2.0680656689364696e-06

We O 0 4.660605100070825e-06
mapped O 0 5.109677204018226e-06
CA12 O 0 4.3794971134047955e-05
and O 0 3.2487372436662554e-07
CA9 O 0 9.952102118404582e-05
loci O 0 4.0841666759661166e-07
to O 0 2.2695113344184392e-08
chromosome O 0 6.411571007447492e-08
bands O 0 1.8285167868725694e-07
15q22 O 0 2.4113169274642132e-06
and O 0 7.517405009593858e-08
17q21 O 0 5.642377800540999e-06
. O 0 1.014533381749061e-06

2 O 0 1.1475714927655645e-05
respectively O 0 6.195159585331567e-07
, O 0 9.207720808035447e-09
regions O 0 1.722579767715615e-08
prone O 0 1.2580260033701052e-07
to O 0 1.873461386026065e-09
amplification O 0 9.25491221437369e-08
in O 0 5.562567739758606e-09
some O 0 9.22533605063336e-09
human O 0 2.7098926693724934e-06
cancers B-Disease 0 0.0005902447155676782
. O 0 5.315795306159998e-07

Additional O 0 8.29969053484092e-08
experiments O 0 2.762926420984968e-08
are O 0 1.7936042928656803e-10
needed O 0 1.4070277165600942e-09
to O 0 1.8536198964635986e-10
define O 0 3.808769299951109e-09
the O 0 1.5258232455295229e-09
role O 0 4.5037769069722344e-09
of O 0 2.2410436173458947e-08
CA O 0 3.0008851581442286e-07
IX O 0 3.3642870675976155e-06
and O 0 4.3018332007704885e-08
CA O 0 5.187557121644204e-07
XII O 0 4.383352461445611e-06
enzymes O 0 3.0271321005415075e-09
in O 0 5.122374191479651e-10
the O 0 1.6044719997054813e-09
regulation O 0 5.881566789156523e-09
of O 0 7.5418311595854e-09
pH O 0 3.769884244775312e-07
in O 0 6.0296172499363365e-09
the O 0 1.2787312542172913e-08
extracellular O 0 9.656756105869135e-08
microenvironment O 0 2.5958169658224506e-07
and O 0 1.1829076607128286e-09
its O 0 4.3822429018902653e-10
potential O 0 2.0536045752805876e-08
impact O 0 1.9314343262522016e-06
on O 0 2.8827138521592133e-05
cancer B-Disease 0 0.00018456214456818998
cell O 0 2.820710687956307e-05
growth O 0 5.024827487432049e-07
. O 0 5.83842052037653e-07

A O 0 2.233914074167842e-06
gene O 0 1.523786039570041e-07
encoding O 0 1.0410059303467278e-06
a O 0 7.735158646937634e-08
transmembrane O 0 5.37559401436738e-07
protein O 0 2.5323252828002296e-08
is O 0 3.1778074616184426e-10
mutated O 0 3.7256948637320875e-09
in O 0 2.94545637880006e-10
patients O 0 3.716192020775111e-09
with O 0 7.067621510259414e-08
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9964235424995422
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.2396222359711828e-07
. O 0 5.689803401764948e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00024179325555451214
WFS B-Disease 1 0.997977077960968
; O 0 3.3926875175893656e-07
OMIM O 0 0.0007774418918415904
222300 O 0 5.281532594381133e-06
) O 0 3.824508265637405e-09
is O 0 4.238666917455447e-10
an O 0 4.561214073106612e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999957084655762
defined O 0 5.545261316797223e-08
by O 0 2.401121079742552e-09
young O 0 1.844910144654932e-07
- O 0 3.5116818253300153e-06
onset O 1 0.9999927282333374
non O 1 0.9999997615814209
- O 1 0.9999992847442627
immune O 1 1.0
insulin B-Disease 1 1.0
- I-Disease 1 1.0
dependent I-Disease 1 1.0
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999997615814209
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999994039535522
. O 0 4.4155367504572496e-05

Linkage O 0 2.831543042702833e-06
to O 0 1.7671062835233897e-08
markers O 0 8.052194999663698e-08
on O 0 2.2740313454505667e-07
chromosome O 0 5.8750322295964e-07
4p O 0 3.531628681230359e-05
was O 0 2.477170255588135e-07
confirmed O 0 6.683657716166636e-08
in O 0 6.46478914845261e-09
five O 0 2.3446819596983914e-08
families O 0 1.1439758473841266e-08
. O 0 4.97752409955865e-07

On O 0 4.709955874204752e-07
the O 0 1.1807173017075456e-08
basis O 0 5.0747285484931126e-08
of O 0 7.125159839915796e-08
meiotic O 0 9.206225513480604e-05
recombinants O 0 0.013530823402106762
and O 0 1.9886306290572975e-06
disease O 0 0.0031870838720351458
- O 0 1.5892703686404275e-06
associated O 0 4.587863315919094e-07
haplotypes O 0 4.200659020625608e-07
, O 0 5.938718405928967e-09
the O 0 5.4147914596569535e-08
WFS B-Disease 0 5.8351994084659964e-05
gene O 0 1.0889192658680713e-08
was O 0 1.0840989439486748e-08
localized O 0 1.5398692099211075e-08
to O 0 4.26548130150195e-09
a O 0 1.018712438849434e-07
BAC O 0 0.07030967622995377
/ O 0 0.0002743680961430073
P1 O 0 0.00022764422465115786
contig O 0 9.749615855980664e-06
of O 0 3.591301123151425e-08
less O 0 6.171757327422256e-09
than O 0 1.575189201297178e-09
250 O 0 2.3887205102823827e-08
kb O 0 1.3124579709256068e-05
. O 0 8.320690199070668e-07

Mutations O 0 2.5150453097921854e-07
in O 0 6.805242591667593e-09
a O 0 2.304805679642641e-09
novel O 0 4.217837634712396e-09
gene O 0 2.7102553534774643e-09
( O 0 2.6006663489397397e-09
WFS1 O 0 1.427068809789489e-06
) O 0 3.2134961358565306e-09
encoding O 0 7.011524161271154e-08
a O 0 1.1754907269789783e-08
putative O 0 3.2382573067479825e-07
transmembrane O 0 2.2333250626616064e-07
protein O 0 5.054584750752156e-09
were O 0 8.567161424721803e-10
found O 0 3.016375760278578e-10
in O 0 2.2241784802812248e-10
all O 0 5.148241832841904e-10
affected O 0 2.069552307304434e-09
individuals O 0 1.3475254245776114e-10
in O 0 4.163168032533804e-09
six O 0 1.972226328916804e-07
WFS B-Disease 0 0.0005246984073892236
families O 0 1.5952473786384758e-09
, O 0 4.3414771777605665e-10
and O 0 2.4815344223938496e-10
these O 0 3.357336630926966e-10
mutations O 0 4.181870405517429e-09
were O 0 3.768361622746852e-09
associated O 0 1.6706676930766662e-08
with O 0 3.4995326636533264e-09
the O 0 4.111242560611572e-06
disease O 1 0.9541352987289429
phenotype O 0 1.1446891221567057e-05
. O 0 3.7348152090999065e-06

WFS1 O 0 0.00011715459550032392
appears O 0 1.828935296543932e-07
to O 0 3.918730229202083e-09
function O 0 7.4431691921006404e-09
in O 0 1.8648764754658487e-09
survival O 0 1.706710861526517e-07
of O 0 3.330736220163999e-08
islet O 0 3.283805085629865e-07
beta O 0 1.2194849432489718e-06
- O 0 2.426134244615241e-07
cells O 0 1.1173946212750252e-08
and O 0 4.276454301788135e-09
neurons O 0 7.068430818435445e-08
. O 0 9.976316661663986e-09
. O 0 2.4845542156981537e-07

Stable O 0 3.963277049479075e-05
interaction O 0 1.696052294164474e-07
between O 0 1.5923905749559708e-08
the O 0 2.502721141439679e-09
products O 0 2.1877262224023752e-09
of O 0 5.083376830583575e-09
the O 0 5.792933244208598e-09
BRCA1 O 0 9.879535411982943e-09
and O 0 8.059244827052225e-09
BRCA2 O 0 3.647535962159054e-08
tumor B-Disease 0 7.14346271024624e-08
suppressor O 0 2.3046624164635432e-07
genes O 0 1.1336108052262261e-08
in O 0 9.043968240973754e-09
mitotic O 0 9.097307156480383e-07
and O 0 3.048988332920999e-07
meiotic O 0 1.870884261734318e-05
cells O 0 1.8917575062005199e-06
. O 0 2.3447971670975676e-06

BRCA1 O 0 2.1316247512004338e-05
and O 0 4.383024929666135e-07
BRCA2 O 0 2.754931074377964e-07
account O 0 2.35595942754685e-09
for O 0 2.3652241276650443e-10
most O 0 7.939390811451119e-11
cases O 0 1.5563085542513733e-10
of O 0 1.1167314850624166e-09
familial O 0 2.447485769607738e-08
, O 0 1.5103209793920769e-09
early O 0 1.5982838021955104e-06
onset O 1 0.9999819993972778
breast B-Disease 1 0.9952189326286316
and I-Disease 1 0.9996346235275269
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.0282714103814214e-05
encode O 0 1.9564037501140774e-08
products O 0 3.882424604029211e-09
that O 0 1.4446363549858177e-10
each O 0 1.6136013358813983e-10
interact O 0 5.198050323507175e-10
with O 0 8.44828318413704e-10
hRAD51 O 0 1.1228971743548755e-06
. O 0 1.8101013665727805e-07

Results O 0 7.560885023849551e-06
presented O 0 7.208295755845029e-07
here O 0 2.4099453099779566e-08
show O 0 2.1528971938522545e-09
that O 0 3.173240559206647e-10
BRCA1 O 0 1.3504444673628768e-08
and O 0 1.4720521690492205e-08
BRCA2 O 0 2.1685966089535214e-07
coexist O 0 8.230594517044665e-08
in O 0 1.368271496104967e-09
a O 0 9.322760341490266e-10
biochemical O 0 2.689129452448924e-08
complex O 0 1.9008199103609513e-07
and O 0 5.7410698417470485e-09
colocalize O 0 5.529165036932682e-07
in O 0 9.48443545922828e-09
subnuclear O 0 1.6652440990583273e-06
foci O 0 1.2118264294258552e-06
in O 0 9.132859801752602e-09
somatic O 0 4.334299674724207e-08
cells O 0 2.19972262627266e-09
and O 0 4.858293212173237e-10
on O 0 4.596391711686465e-09
the O 0 6.157573895215762e-10
axial O 0 5.610667042077466e-09
elements O 0 1.8896260556289235e-08
of O 0 1.0362005298247823e-07
developing O 0 9.156652822639444e-07
synaptonemal O 0 2.4500401195837185e-05
complexes O 0 1.1057929896196583e-06
. O 0 9.675724186308798e-07

Like O 0 1.6357271306333132e-06
BRCA1 O 0 2.341532308491878e-06
and O 0 4.5123002223590447e-07
RAD51 O 0 4.986277053831145e-05
, O 0 5.208009667967417e-08
BRCA2 O 0 3.0892948643668205e-07
relocates O 0 2.1215231527094147e-07
to O 0 1.3556576305973067e-08
PCNA O 0 2.378814315306954e-06
+ O 0 5.796151825165907e-08
replication O 0 6.32863361715863e-09
sites O 0 1.6098947730469604e-09
following O 0 1.864819632046988e-09
exposure O 0 1.0638771641424682e-08
of O 0 1.5242040518614886e-08
S O 0 3.8451884165624506e-07
phase O 0 2.9524842375394655e-06
cells O 0 1.569231677933658e-08
to O 0 2.752190031429791e-09
hydroxyurea O 0 6.903464964125305e-07
or O 0 7.477237318198604e-08
UV O 0 4.1171431803377345e-05
irradiation O 0 1.4906780734236236e-06
. O 0 3.207885868050653e-07

Thus O 0 3.8435899796240847e-07
, O 0 3.14776862353483e-08
BRCA1 O 0 2.312049929287241e-08
and O 0 6.67137767251802e-09
BRCA2 O 0 1.832662377410088e-08
participate O 0 5.6659756886290324e-09
, O 0 8.976596133081216e-10
together O 0 3.133437120883542e-10
, O 0 9.037028070313369e-11
in O 0 1.7220916359583782e-10
a O 0 1.0979219755569147e-09
pathway O 0 5.652623258356471e-09
( O 0 8.816751773110809e-10
s O 0 1.914527736346372e-08
) O 0 8.302500908996535e-10
associated O 0 3.4259790560042802e-09
with O 0 2.825732148270532e-10
the O 0 6.112934158863936e-09
activation O 0 3.0280112639502477e-08
of O 0 8.142591667592569e-08
double O 0 2.7756824394487012e-08
- O 0 5.447441822070687e-07
strand O 0 4.175886658686068e-08
break O 0 1.0479990919520787e-07
repair O 0 8.666013968650077e-07
and O 0 8.513740112903179e-08
/ O 0 1.7107355461121188e-06
or O 0 2.5585372043224197e-08
homologous O 0 8.742409107753701e-08
recombination O 0 2.885774961214338e-07
. O 0 1.2297882676648442e-06

Dysfunction O 0 0.0012237547198310494
of O 0 1.7807946051107137e-06
this O 0 5.386923351835549e-09
pathway O 0 1.3185980307639511e-08
may O 0 2.255244435644954e-09
be O 0 7.072901708760071e-10
a O 0 6.309539002380404e-10
general O 0 4.32457003540776e-09
phenomenon O 0 5.324245044846521e-09
in O 0 2.739044269173263e-10
the O 0 2.3049320785339944e-10
majority O 0 1.7369163052283199e-10
of O 0 1.304008456770589e-09
cases O 0 2.8867086498962635e-09
of O 0 1.0349719303803795e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.326910028699785e-05
. O 0 1.465189598093275e-05

A O 0 8.13554152045981e-07
novel O 0 4.649164679904061e-07
Arg362Ser O 0 7.159589586080983e-06
mutation O 0 3.875841159128868e-08
in O 0 4.202684422693892e-09
the O 0 1.4081775745466985e-08
sterol O 0 1.1823285603895783e-06
27 O 0 3.544601213434362e-06
- O 0 8.601325134804938e-06
hydroxylase O 0 1.1684318451443687e-05
gene O 0 1.8622401398715738e-08
( O 0 3.231271250569989e-09
CYP27 O 0 1.947065811691573e-06
) O 0 7.615170716235298e-10
: O 0 1.438806573883511e-10
its O 0 1.1252233866887451e-10
effects O 0 4.826228749976735e-09
on O 0 2.4428963740774634e-08
pre O 0 1.692943101261335e-07
- O 0 1.0813482553828635e-08
mRNA O 0 8.175626398099212e-09
splicing O 0 1.1130510735313237e-08
and O 0 1.5852772428104345e-09
enzyme O 0 6.24034113272387e-09
activity O 0 3.5494476691155796e-08
. O 0 1.1058251203621694e-07

A O 0 4.499546264469245e-07
novel O 0 3.950664861918085e-08
C O 0 1.703799910046655e-07
to O 0 4.784341256502955e-10
A O 0 5.146634673991457e-09
mutation O 0 7.578743188574322e-10
in O 0 5.708505890211768e-10
the O 0 2.6933835162168407e-09
sterol O 0 2.5177570250889403e-07
27 O 0 5.155076792107138e-07
- O 0 6.890284112159861e-07
hydroxylase O 0 2.4894429770938586e-06
gene O 0 6.451436718180048e-09
( O 0 1.6979571082487155e-09
CYP27 O 0 6.579239766324463e-07
) O 0 5.731897734229108e-10
was O 0 3.675609150377568e-09
identified O 0 1.1140699474054827e-09
by O 0 4.3933567894782755e-10
sequencing O 0 2.6243467843301005e-08
amplified O 0 5.077299647382461e-07
CYP27 O 0 1.4765993000764865e-05
gene O 0 1.6912672151647712e-08
products O 0 5.368931521587683e-09
from O 0 1.9893655611724625e-09
a O 0 2.3319608466465525e-09
patient O 0 2.31506831482875e-08
with O 0 2.2418644718413816e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 6.888668053761648e-07
CTX B-Disease 0 0.00016272367793135345
) O 0 1.0838678576874372e-07
. O 0 1.1382405773474602e-06

The O 0 4.456010458397941e-07
mutation O 0 1.262564381931952e-07
changed O 0 3.7744346315093935e-08
the O 0 1.2674981952898179e-08
adrenodoxin O 0 7.011710749793565e-07
cofactor O 0 1.0093899760477143e-07
binding O 0 7.724734985004034e-08
residue O 0 1.4064670494917664e-06
362Arg O 0 8.261876587312145e-07
to O 0 1.4419949678767807e-08
362Ser O 0 3.1314561965700705e-06
( O 0 4.460614988488487e-08
CGT O 0 4.009003077953821e-06
362Arg O 0 9.329141903435811e-07
to O 0 1.6840566274822777e-08
AGT O 0 1.5996645743143745e-05
362Ser O 0 6.367909577420505e-07
) O 0 8.986566490953862e-10
, O 0 2.448538316546234e-10
and O 0 4.976265510769906e-10
was O 0 1.2821406158991522e-08
responsible O 0 8.227185155362804e-09
for O 0 3.664024639249419e-09
deficiency O 0 6.349714112729998e-06
in O 0 4.072117576470191e-08
the O 0 4.7653665546931734e-07
sterol O 0 7.454498245351715e-06
27 O 0 2.8563774321810342e-05
- O 0 1.721710395941045e-05
hydroxylase O 0 4.483573775360128e-06
activity O 0 6.474166980297014e-09
, O 0 4.0058831252132165e-11
as O 0 3.001968118532261e-11
confirmed O 0 4.0370806697609396e-10
by O 0 5.1176642784644955e-11
expression O 0 1.2433897245145431e-09
of O 0 4.120131791296444e-09
mutant O 0 1.2194201204351884e-08
cDNA O 0 2.963299827740684e-08
into O 0 3.132280923523467e-08
COS O 0 3.253733893870958e-06
- O 0 4.510243911681755e-07
1 O 0 3.8533491419912025e-07
cells O 0 1.2735861787405156e-07
. O 0 2.080425787198692e-07

Quantitative O 0 7.669664796594589e-07
analysis O 0 2.8665738227573456e-08
showed O 0 2.4674378096278815e-09
that O 0 4.0823452257532367e-11
the O 0 1.5331010072561213e-10
expression O 0 5.164016991798803e-10
of O 0 2.245680974510833e-09
CYP27 O 0 1.4207013521172485e-07
gene O 0 2.446899627361887e-10
mRNA O 0 1.0080306589443921e-09
in O 0 5.384229173621691e-10
the O 0 1.140598282489691e-09
patient O 0 4.710726031476042e-09
represented O 0 8.927101724509612e-09
52 O 0 5.347483238438144e-07
. O 0 1.3600355259768548e-06

5 O 0 1.0855131904463633e-06
% O 0 9.576268666933174e-09
of O 0 1.7412999042676347e-08
the O 0 3.709444840183096e-08
normal O 0 3.530819014940789e-07
level O 0 1.0448746252222918e-05
. O 0 4.501082742081053e-07

As O 0 4.741159642662751e-08
the O 0 6.431263077644189e-09
mutation O 0 3.1319566939913557e-09
occurred O 0 3.104256052210985e-08
at O 0 8.017709163254949e-09
the O 0 1.5488763605020495e-09
penultimate O 0 1.6251492240826337e-07
nucleotide O 0 1.2992351194895946e-08
of O 0 2.9628138165094242e-08
exon O 0 9.955126500926781e-08
6 O 0 1.2540900797830545e-06
( O 0 3.763678257939773e-09
- O 0 3.2239285019386443e-08
2 O 0 8.89449083274485e-08
position O 0 2.0406477574397286e-07
of O 0 2.2406020150356198e-07
exon O 0 2.120972766306295e-07
6 O 0 1.1986543313469156e-06
- O 0 1.550987036580409e-07
intron O 0 1.1952077727528376e-07
6 O 0 6.453974492615089e-07
splice O 0 2.571375148363586e-07
site O 0 2.6443245815244154e-08
) O 0 5.191589935726881e-10
of O 0 3.6535916514424116e-09
the O 0 8.533277195965638e-09
gene O 0 5.213094844691568e-09
, O 0 2.1210158074325136e-09
we O 0 2.428669487741786e-09
hypothesized O 0 5.042624984241684e-09
that O 0 1.5389312046920622e-10
the O 0 8.522212380235317e-10
mutation O 0 3.859764063918192e-09
may O 0 6.679424124911293e-09
partially O 0 7.931229362156955e-08
affect O 0 3.5417652810565414e-08
the O 0 1.1598363158782377e-08
normal O 0 3.009741078585648e-08
splicing O 0 3.440807105903332e-08
efficiency O 0 2.1580206066573737e-08
in O 0 1.091157941779386e-09
exon O 0 2.613427518838307e-08
6 O 0 1.2802199300665507e-08
and O 0 2.4301141654525793e-10
cause O 0 5.577076578333617e-10
alternative O 0 1.5366616867851235e-09
splicing O 0 4.29400248691536e-09
elsewhere O 0 5.445847661711412e-10
, O 0 1.5201574374290594e-11
which O 0 6.906231662939799e-12
resulted O 0 8.832000686354036e-10
in O 0 3.065273868063656e-10
decreased O 0 1.0755271340201489e-08
transcript O 0 2.059032766510427e-08
in O 0 5.149675685878208e-10
the O 0 4.748976767388058e-09
patient O 0 4.7582275897184445e-08
. O 0 2.109502759140014e-07

Transfection O 0 3.3833686757134274e-05
of O 0 5.355664143280592e-07
constructed O 0 1.8721819969869102e-06
minigenes O 0 3.929621925635729e-06
, O 0 1.6353591814066704e-09
with O 0 1.0304539166394733e-10
or O 0 4.807190756572766e-10
without O 0 1.015216244404371e-09
the O 0 2.063379911376728e-09
mutation O 0 7.843606320001584e-10
, O 0 3.375192070276256e-10
into O 0 2.987975422641398e-09
COS O 0 9.521920105726167e-07
- O 0 2.92932185175232e-07
1 O 0 9.052289584587925e-08
cells O 0 1.037661179204008e-09
confirmed O 0 5.625837573575154e-10
that O 0 2.4637248838277337e-11
the O 0 2.9677652002568777e-10
mutant O 0 1.8716336924740062e-08
minigene O 0 2.3713006669368042e-07
was O 0 6.2024638758373385e-09
responsible O 0 7.074089092284908e-10
for O 0 1.6497508914525838e-10
a O 0 1.0716175724567734e-09
mRNA O 0 1.469734733916539e-08
species O 0 1.7345765934706492e-09
alternatively O 0 4.6592134594902745e-08
spliced O 0 3.600656839353178e-07
at O 0 1.6593580198787095e-07
an O 0 9.909576492717065e-10
activated O 0 1.3943987653419754e-07
cryptic O 0 2.540998593758559e-07
5 O 0 1.7803654372983146e-07
splice O 0 8.00102895937016e-07
site O 0 1.5949720477692608e-07
88 O 0 3.3924220588232856e-07
bp O 0 2.0130842415255756e-07
upstream O 0 1.2675852367749485e-08
from O 0 8.265748641100856e-10
the O 0 1.9457968569724926e-09
3 O 0 6.744139113834535e-08
end O 0 4.046805912594209e-08
of O 0 3.2167726260468044e-08
exon O 0 4.29917207611652e-07
6 O 0 1.9056931250815978e-06
. O 0 3.957230489959329e-07

Our O 0 9.989037152990932e-07
data O 0 3.2731804822105914e-08
suggest O 0 1.466687216122864e-09
that O 0 4.748482856919978e-11
the O 0 3.7285013965160374e-10
C O 0 1.0262516170200797e-08
to O 0 9.474481615923125e-11
A O 0 1.383808845289991e-09
mutation O 0 1.1106668917904017e-09
at O 0 5.674054115445415e-09
the O 0 1.913935454567195e-09
penultimate O 0 1.9490371983010846e-07
nucleotide O 0 5.367027711145056e-09
of O 0 6.841109456701133e-09
exon O 0 1.9592192757045268e-08
6 O 0 4.9724565798214826e-08
of O 0 3.1188540638993345e-09
the O 0 6.938405405776393e-09
CYP27 O 0 2.2147080471768277e-06
gene O 0 1.0429332952810455e-09
not O 0 2.321441927577439e-10
only O 0 8.775044579856228e-10
causes O 0 2.7284725589993286e-08
the O 0 2.4484053895434954e-08
deficiency B-Disease 0 1.4593985042665736e-06
in I-Disease 0 1.1428025636917027e-08
the I-Disease 0 3.879258159145138e-08
sterol I-Disease 0 9.74771751316439e-07
27 I-Disease 0 5.0957360144820996e-06
- I-Disease 0 5.668622179655358e-06
hydroxylase I-Disease 0 8.278161658381578e-06
activity I-Disease 0 8.23468937483085e-09
, O 0 1.1860135096242175e-10
but O 0 8.741363188846663e-11
also O 0 1.1048769538168912e-10
partially O 0 3.1004909750720344e-09
leads O 0 2.136374271932695e-10
to O 0 7.274666979917299e-11
alternative O 0 2.887787786676199e-09
pre O 0 4.086948024450976e-08
- O 0 4.791246954738426e-09
mRNA O 0 4.684026944090647e-09
splicing O 0 1.066833732465966e-08
of O 0 3.3875899863033965e-09
the O 0 4.8052495316142085e-09
gene O 0 1.5815693643617124e-08
. O 0 2.0130437405896373e-07

To O 0 6.29622434189514e-08
our O 0 1.9348357582771314e-08
knowledge O 0 1.2540414928707833e-08
, O 0 6.117791689908003e-11
this O 0 7.224014789142252e-12
is O 0 1.127614061152693e-11
the O 0 5.743922351642006e-11
first O 0 2.4825569377995294e-10
report O 0 3.822128724628726e-10
regarding O 0 2.51138110307636e-09
effects O 0 1.5937578368152572e-08
on O 0 2.5070081122180454e-08
pre O 0 1.6161848748197372e-07
- O 0 1.3504960705290614e-08
mRNA O 0 8.036802334743243e-09
splicing O 0 1.1347313311205198e-08
of O 0 2.7554254433681535e-09
a O 0 9.662975974933374e-10
mutation O 0 1.3810533827651739e-09
at O 0 1.1862884008451147e-08
the O 0 1.5637837691429013e-09
- O 0 9.161735370355473e-09
2 O 0 4.073445580843327e-08
position O 0 1.3172788726478757e-07
of O 0 2.7914827782637985e-08
a O 0 1.4606578169207296e-08
5 O 0 3.7845094880140095e-07
splice O 0 5.138881988386856e-06
site O 0 7.327720368266455e-07
. O 0 2.2692270249535795e-06

ATM O 0 0.00010552411549724638
germline O 0 5.106030948809348e-05
mutations O 0 1.3984379165776772e-07
in O 0 2.735449733393125e-08
classical O 1 0.9950799942016602
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 1.5115461792447604e-05
in O 0 1.0240928993709986e-08
the O 0 1.3899942530315457e-08
Dutch O 0 3.277090172559838e-06
population O 0 1.0341106859712568e-09
. O 0 1.178891650965852e-07

Germline O 0 8.163172606145963e-05
mutations O 0 1.5791736984738236e-07
in O 0 7.903771859218978e-09
the O 0 8.599122303110107e-09
ATM O 0 3.989161427853105e-07
gene O 0 1.7996879542181432e-09
are O 0 1.1204027289268836e-10
responsible O 0 6.082436221355181e-10
for O 0 2.949256672213352e-10
the O 0 9.697418863652274e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.941621558733459e-07
. O 0 1.2664706900977762e-06

In O 0 3.3039279401236854e-07
our O 0 7.597913764811892e-08
study O 0 2.1981831910267147e-09
, O 0 1.7798060247820047e-10
we O 0 1.2113400560398446e-10
have O 0 1.9673799048214313e-11
determined O 0 2.336662419111235e-09
the O 0 2.2355437501175857e-09
ATM O 0 8.975268173117001e-08
mutation O 0 3.281098281959771e-09
spectrum O 0 1.5309897349879975e-08
in O 0 1.206786226504164e-09
19 O 0 5.679146042325556e-08
classical O 0 2.0900636172882514e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.675897251147035e-09
, O 0 8.667152412433765e-11
including O 0 2.962803613559828e-11
some O 0 2.202928117700509e-11
immigrant O 0 1.9590605526698113e-10
populations O 0 2.444663915746048e-11
, O 0 3.008399085402402e-11
as O 0 7.205138569110758e-11
well O 0 7.614586045034955e-11
as O 0 1.024873449995134e-10
12 O 0 1.0071985467874356e-09
of O 0 9.529400601948623e-10
Dutch O 0 1.7507520055914938e-07
ethnic O 0 4.668560649179199e-09
origin O 0 1.1382390141534415e-07
. O 0 1.2859659364039544e-06

Both O 0 1.1367788488314545e-07
the O 0 5.061997043753763e-08
protein O 0 1.860464848846277e-08
truncation O 0 4.1898167069120973e-07
test O 0 2.322631900142369e-07
( O 0 1.4299712525200903e-08
PTT O 0 7.559656296507455e-07
) O 0 3.665700520905091e-10
and O 0 2.1084944901161862e-10
the O 0 4.016075805246544e-10
restriction O 0 2.747889027432393e-09
endonuclease O 0 1.989076992003902e-07
fingerprinting O 0 5.667156699473708e-08
( O 0 3.6152989491000653e-09
REF O 0 2.826832883329189e-07
) O 0 6.919974315788835e-11
method O 0 3.4642336221857306e-10
were O 0 2.0528896638172256e-10
used O 0 1.353909345747084e-10
and O 0 2.6984725565171175e-10
compared O 0 4.3131423432818394e-10
for O 0 7.520249006853774e-11
their O 0 4.445992185519998e-10
detection O 0 1.3969311929429296e-08
efficiency O 0 2.5547288728944295e-08
, O 0 3.971823980819522e-10
identifying O 0 5.263279589939884e-09
76 O 0 3.821387650759789e-09
% O 0 4.824705218675618e-11
and O 0 1.7695868381739643e-10
60 O 0 5.93635973711315e-10
% O 0 5.455523879871471e-11
of O 0 1.611443201099405e-09
the O 0 6.90808654724151e-09
mutations O 0 2.9970870230044966e-08
, O 0 7.784887401385276e-09
respectively O 0 2.7992680884381116e-07
. O 0 6.527586151605647e-07

Most O 0 5.3861864302007234e-08
patients O 0 8.075232038606828e-09
were O 0 2.372554375185132e-09
found O 0 4.891673732743129e-10
to O 0 1.839040447704221e-10
be O 0 1.9700781006548596e-09
compound O 0 3.0968524811214593e-07
heterozygote O 0 1.9324797904118896e-05
. O 0 3.023913222932606e-06

Seventeen O 0 2.5138608634733828e-06
mutations O 0 2.767784046397992e-08
were O 0 9.724884009187917e-09
distinct O 0 1.4398395808967734e-09
, O 0 1.9603313416993728e-10
of O 0 7.464320272987379e-10
which O 0 2.0548798773667443e-10
10 O 0 1.2739542754047761e-09
were O 0 9.204064177481541e-10
not O 0 1.2004638394458311e-09
reported O 0 3.6061202024484373e-08
previously O 0 3.701445336901088e-07
. O 0 1.34754429836903e-06

Mutations O 0 4.86059207105427e-07
are O 0 4.0322651884139304e-09
small O 0 2.8551294661838256e-09
deletions O 0 4.453644208979313e-08
or O 0 3.495305023193396e-08
point O 0 5.649575314237154e-07
mutations O 0 2.1811658257320232e-07
frequently O 0 1.4738269271674653e-07
affecting O 0 6.215048529156775e-07
splice O 0 5.2738719205081e-06
sites O 0 3.9517433947366953e-07
. O 0 1.1538223816387472e-06

Moreover O 0 7.799047125445213e-06
, O 0 8.397589112973947e-08
a O 0 8.37366087580449e-08
16 O 0 1.31486808641057e-06
. O 0 9.720378102429095e-07

7 O 0 3.684880357468501e-05
- O 0 3.4066590615111636e-06
kb O 0 1.3416020010481589e-05
genomic O 0 7.22700548294597e-08
deletion O 0 4.058818703356337e-08
of O 0 8.328294498483046e-09
the O 0 2.843917101813531e-09
3 O 0 5.3875222505439524e-08
end O 0 1.19625420680336e-08
of O 0 8.790762784371964e-09
the O 0 2.3970849749588297e-09
gene O 0 3.059986986020391e-10
, O 0 9.112110371800597e-11
most O 0 4.317247254137513e-11
likely O 0 9.558270841480976e-10
a O 0 5.120723289842033e-10
result O 0 4.46108083806962e-09
of O 0 1.5205916525928842e-08
recombination O 0 1.6729956087147002e-08
between O 0 3.689096317316398e-08
two O 0 3.6878982090371437e-09
LINE O 0 6.221423376473467e-08
elements O 0 3.190795894170151e-08
, O 0 2.7394322366092183e-09
was O 0 3.458790232002684e-08
identified O 0 1.1644029740409678e-07
. O 0 4.7424077820323873e-07

The O 0 1.6092607779683021e-07
most O 0 1.1162055724156517e-09
frequently O 0 4.96222896106957e-10
found O 0 4.89075946408235e-10
mutation O 0 2.3346255484391065e-10
, O 0 2.1051511922554056e-10
identified O 0 1.6000620828293677e-09
in O 0 8.678901486369739e-10
three O 0 2.677402966000386e-09
unrelated O 0 6.145354092268462e-08
Turkish O 0 8.115943273878656e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.905980084870862e-08
, O 0 4.2156824697769935e-09
was O 0 2.62508255133298e-08
previously O 0 7.958076864156283e-09
described O 0 3.6806604430950074e-09
to O 0 4.3895459489462496e-10
be O 0 1.3750475202911616e-09
a O 0 2.87570101065171e-09
Turkish O 0 2.868707042580354e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 0.15205255150794983
mutation O 0 1.1990247230642126e-06
. O 0 6.313125595625024e-07

The O 0 1.470022823468753e-07
presence O 0 1.3696716649747032e-08
of O 0 3.59288385709533e-08
a O 0 7.836492343926693e-09
founder O 0 1.4034922912742331e-07
mutation O 0 4.355230398545018e-09
among O 0 6.254923801130019e-10
relatively O 0 1.5139253739526737e-10
small O 0 6.056674606291779e-11
ethnic O 0 7.395584838976177e-11
population O 0 5.904182958510473e-12
groups O 0 1.5670966260761254e-11
in O 0 1.512499708811177e-10
Western O 0 4.771150585725081e-08
Europe O 0 2.55375994129281e-07
could O 0 2.5324556673922416e-08
indicate O 0 1.3454465985773822e-08
a O 0 2.7181810136056583e-09
high O 0 2.4171729506861084e-08
carrier O 0 1.019302420246504e-09
frequency O 0 3.2847818687287145e-08
in O 0 7.692483872112632e-10
such O 0 1.235182733871909e-09
communities O 0 2.1203737432529124e-08
. O 0 1.2351544853572705e-07

In O 0 6.666240892627684e-08
patients O 0 4.593201374802902e-09
of O 0 6.710992206393485e-09
Dutch O 0 2.0984900857001776e-06
ethnic O 0 1.108626634938048e-09
origin O 0 3.937881132287657e-09
, O 0 6.120549067567538e-10
however O 0 1.1489784679241666e-09
, O 0 1.5153293897451903e-10
no O 0 1.1116369630359557e-10
significant O 0 8.260626627176748e-10
founder O 0 3.746405141669129e-08
effect O 0 4.7490701149399683e-08
could O 0 1.3681104249485543e-08
be O 0 1.184981357482684e-08
identified O 0 2.962859753097291e-07
. O 0 3.9204073232212977e-07

The O 0 1.1716522863025602e-07
observed O 0 2.5522934876676118e-08
genetic O 0 5.501370470284428e-09
heterogeneity O 0 1.3470076609678472e-08
including O 0 1.0421815632710718e-09
the O 0 2.957708078454857e-09
relative O 0 1.9894982017376606e-07
high O 0 4.184332738077501e-06
percentage O 0 4.02634192653295e-08
of O 0 1.1257004928211245e-07
splice O 0 1.0220506737823598e-05
- O 0 5.367402877709537e-07
site O 0 1.1190348203626854e-08
mutations O 0 4.0890668628890126e-09
had O 0 1.6427933458018629e-09
no O 0 1.1679474054560046e-09
reflection O 0 2.194740567063036e-08
on O 0 3.327954800624866e-08
the O 0 1.9526234851241497e-08
phenotype O 0 6.042479867574002e-07
. O 0 6.100730161051615e-07

All O 0 3.962808037272225e-08
patients O 0 4.753380800082141e-09
manifested O 0 1.4863138275700294e-08
classical O 0 1.7070541957764362e-07
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9990918636322021
T I-Disease 1 0.9999998807907104
and O 0 1.022652362792087e-08
increased O 0 8.741271706469433e-09
cellular O 0 1.837478613708754e-08
radioresistant O 0 5.87883270952716e-08
DNA O 0 6.949928188504373e-09
synthesis O 0 3.7082848791669676e-08
. O 0 4.579312928854051e-08

Determination O 0 1.910396804305492e-06
of O 0 1.573410060018432e-07
the O 0 9.413571255834086e-09
genomic O 0 5.42364686495489e-09
structure O 0 8.603961987319053e-09
of O 0 4.160754851767479e-09
the O 0 2.918742358914983e-09
COL4A4 O 0 1.0368011089667561e-06
gene O 0 9.57816381763621e-10
and O 0 2.1498101909767087e-10
of O 0 2.0345076734429313e-09
novel O 0 6.410738961903917e-08
mutations O 0 0.0006145466468296945
causing O 1 0.9565237164497375
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.5223914980888367

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 8.622503173683072e-07
a O 0 2.2854737835587002e-07
progressive O 1 0.9999834299087524
hematuric B-Disease 1 0.9999998807907104
glomerulonephritis I-Disease 1 1.0
characterized O 0 9.052530367625877e-05
by O 0 1.0366314739940208e-07
glomerular B-Disease 0 0.000629571673925966
basement I-Disease 1 0.926884651184082
membrane I-Disease 0 2.1459678464452736e-05
abnormalities I-Disease 0 0.07304571568965912
and O 0 1.0097245706219837e-08
associated O 0 4.3352756051717733e-08
with O 0 1.7043556566065377e-09
mutations O 0 5.553026927174187e-09
in O 0 1.056640885899185e-09
either O 0 8.482695434963716e-09
the O 0 1.660061599295659e-08
COL4A3 O 0 3.1322237191488966e-05
or O 0 3.8151388714879886e-09
the O 0 7.093575948857733e-09
COL4A4 O 0 5.99193526795716e-07
gene O 0 7.445863370314498e-10
, O 0 1.5723189417116146e-10
which O 0 1.0151073037700797e-10
encode O 0 1.422934658990016e-09
the O 0 3.954870209099681e-09
alpha3 O 0 3.32084113097153e-07
and O 0 1.0720535570385437e-08
alpha4 O 0 1.4355180155689595e-06
type O 0 8.031532274799247e-07
IV O 1 0.9999986886978149
collagen O 0 0.00036301653017289937
chains O 0 1.8159902310799225e-06
, O 0 6.017510401079562e-08
respectively O 0 5.399609221967694e-07
. O 0 5.24142819813278e-07

To O 0 2.906183915740712e-08
date O 0 3.0073428547439107e-07
, O 0 8.551260255451609e-10
mutation O 0 1.3835600720657482e-10
screening O 0 1.9835752484986813e-10
in O 0 9.849045884413599e-11
the O 0 4.2865780369716333e-10
two O 0 4.632271233262486e-10
genes O 0 1.054597187355455e-09
has O 0 1.0777026493435926e-10
been O 0 3.278644300497291e-10
hampered O 0 1.481934575053856e-08
by O 0 2.1075374778689593e-10
the O 0 9.89875181822697e-10
lack O 0 2.4421650479666823e-08
of O 0 2.128644283061476e-08
genomic O 0 6.275530495258863e-08
structure O 0 1.9696248898526392e-07
information O 0 4.855519009083764e-08
. O 0 2.1508054715013714e-07

We O 0 3.3773596896935487e-07
report O 0 1.349502198877417e-08
here O 0 1.4248574542463643e-09
the O 0 1.8352211417216324e-10
complete O 0 6.571815869271802e-10
characterization O 0 1.4535589398789739e-09
of O 0 2.1658130844315338e-09
the O 0 3.1823095270056e-09
48 O 0 3.1857972260240786e-08
exons O 0 1.2034256258175446e-07
of O 0 3.87875509488822e-08
the O 0 4.453074708976601e-08
COL4A4 O 0 2.439301897538826e-05
gene O 0 5.019038962217337e-09
, O 0 8.548325935997525e-10
a O 0 9.70790337007088e-10
comprehensive O 0 2.0669890687941006e-08
gene O 0 1.854993159078333e-09
screen O 0 3.725021713307797e-08
, O 0 1.0922406312730004e-09
and O 0 5.302747130286889e-10
the O 0 4.861037128378598e-10
subsequent O 0 1.167829388748487e-09
detection O 0 1.4207820697720308e-08
of O 0 2.2887240991309454e-09
10 O 0 3.9022611808547936e-09
novel O 0 4.306937917419873e-09
mutations O 0 1.555740247738413e-08
in O 0 2.1991226617501525e-09
eight O 0 6.61885692920805e-08
patients O 0 8.097257477857056e-07
diagnosed O 1 0.9955046772956848
with O 0 1.0919142368948087e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0022821309976279736

Furthermore O 0 6.231470024431474e-07
, O 0 1.0208672129863317e-08
we O 0 6.228687343678985e-09
identified O 0 8.262379225243421e-09
a O 0 1.6063245178443708e-09
glycine O 0 2.37887203269338e-08
to O 0 3.727955721899434e-09
alanine O 0 8.674111029449705e-08
substitution O 0 8.378805205211393e-08
in O 0 1.2297743268163686e-08
the O 0 3.058659814314524e-08
collagenous O 0 2.1964633560855873e-06
domain O 0 8.61084092917963e-09
that O 0 5.15051820637602e-11
is O 0 7.07113118059155e-11
apparently O 0 1.1963333657050157e-09
silent O 0 7.452033656818458e-09
in O 0 8.610507862272243e-10
the O 0 2.228013551430763e-09
heterozygous O 0 4.51335635531791e-09
carriers O 0 1.3367233986372185e-09
, O 0 1.4401388970242124e-09
in O 0 6.4485088380195066e-09
11 O 0 5.058324745732534e-07
. O 0 9.476615332459914e-07

5 O 0 6.589563668057963e-07
% O 0 3.1374396414207695e-09
of O 0 3.0476403622969883e-09
all O 0 2.3154721195961514e-10
control O 0 2.2955530809554148e-09
individuals O 0 4.3512818348467874e-11
, O 0 5.618886259051159e-11
and O 0 8.431182835222373e-11
in O 0 1.3008405463921235e-10
one O 0 1.0096253694191759e-10
control O 0 1.7595178647411558e-09
individual O 0 4.5005116300345094e-10
homozygous O 0 3.992805197583493e-09
for O 0 8.038653631636805e-10
this O 0 2.3018447148359655e-09
glycine O 0 3.98480409558033e-07
substitution O 0 5.905664579586301e-07
. O 0 7.704178415224305e-07

There O 0 2.656892839070224e-08
has O 0 4.726762314888333e-10
been O 0 2.1123144899881652e-10
no O 0 1.151929246434591e-10
previous O 0 7.485120856465244e-10
finding O 0 2.361799644745588e-09
of O 0 1.8633192766515094e-09
a O 0 2.133419219063626e-09
glycine O 0 1.828898277267399e-08
substitution O 0 1.1106505048985582e-08
that O 0 2.620512695727939e-10
is O 0 7.609968905031295e-11
not O 0 4.686702761991235e-11
associated O 0 5.324689578145581e-10
with O 0 1.3918678709590182e-11
any O 0 1.5967929756222077e-10
obvious O 0 1.8403959467505615e-09
phenotype O 0 6.784648842739216e-09
in O 0 6.794837470458504e-10
homozygous O 0 2.7408761482661248e-08
individuals O 0 4.68552796561994e-09
. O 0 2.3072045962635457e-07

Founder O 0 0.0003456974809523672
BRCA1 O 0 2.732311259023845e-06
and O 0 1.1529903787277362e-07
BRCA2 O 0 1.1225368723444262e-07
mutations O 0 1.3441434631999982e-08
in O 0 4.548555754269046e-09
French O 0 2.185326775361318e-05
Canadian O 0 0.05023613199591637
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.445704012643546e-06
. O 0 6.220680006663315e-06

We O 0 4.2206405481692855e-08
have O 0 8.445770194320801e-10
identified O 0 4.631655503573029e-09
four O 0 6.754431458588783e-10
mutations O 0 6.70121624857245e-10
in O 0 2.845245150595588e-10
each O 0 3.6205277664791424e-10
of O 0 5.183363427363474e-08
the O 0 1.872853431450494e-06
breast B-Disease 0 0.01378108561038971
cancer I-Disease 0 0.010416366159915924
- O 1 0.990356981754303
susceptibility O 0 2.7801661417470314e-05
genes O 0 5.472826956065546e-07
, O 0 5.3925184317904495e-08
BRCA1 O 0 4.7135777947460156e-08
and O 0 4.766220840224378e-08
BRCA2 O 0 4.5365755596549207e-08
, O 0 1.9666688277908406e-09
in O 0 2.733106851948719e-09
French O 0 4.3490814277902246e-05
Canadian O 0 0.0002342041552765295
breast B-Disease 1 0.9999943971633911
cancer I-Disease 1 0.9999924898147583
and O 1 0.999994158744812
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.4170100826049747e-07
from O 0 5.806376179862127e-08
Quebec O 0 5.299741587805329e-06
. O 0 5.049902938480955e-06

To O 0 3.327628519400605e-07
identify O 0 1.631721374906192e-06
founder O 0 5.29473527421942e-06
effects O 0 1.549765693198424e-05
, O 0 1.081521538992547e-08
we O 0 5.737424313423389e-09
examined O 0 3.282790217440379e-08
independently O 0 3.4338296650560096e-09
ascertained O 0 1.6812028036383708e-07
French O 0 3.3344616667818627e-07
Canadian O 0 1.4699834594011918e-07
cancer B-Disease 0 4.916372731145202e-08
families O 0 2.0293676461502486e-10
for O 0 6.423410414679864e-11
the O 0 1.383966552470639e-10
distribution O 0 2.7737531715921193e-10
of O 0 1.9634083248121215e-09
these O 0 1.228050883206322e-09
eight O 0 1.629018520077352e-08
mutations O 0 2.1684641637875757e-07
. O 0 7.011363436504325e-07

Mutations O 0 1.1654182685560954e-07
were O 0 1.1378305408982214e-08
found O 0 1.685701245257576e-09
in O 0 1.3214045413434405e-09
41 O 0 4.440284939732919e-08
of O 0 5.406751668601828e-08
97 O 0 1.6849166968313511e-06
families O 0 6.119737605558839e-08
. O 0 7.700373316765763e-07

Six O 0 3.2105759828482405e-07
of O 0 4.061691782908383e-08
eight O 0 2.2395225229843163e-08
mutations O 0 4.517215046462297e-09
were O 0 5.219442655857165e-09
observed O 0 2.640952345700498e-08
at O 0 5.3187569903911935e-08
least O 0 6.321708934109438e-09
twice O 0 1.766759822885433e-07
. O 0 4.5346072852225916e-07

The O 0 2.328794153072522e-06
BRCA1 O 0 7.020905172794301e-07
C4446T O 0 1.2137394378441968e-06
mutation O 0 1.4261035019558221e-08
was O 0 5.15968734404737e-09
the O 0 1.4983553286995743e-10
most O 0 1.5788845925124306e-11
common O 0 6.301501681571509e-11
mutation O 0 1.0814935752501142e-10
found O 0 1.363903850970516e-10
, O 0 1.083130599099924e-10
followed O 0 3.0557295582767097e-10
by O 0 2.1591549381749786e-10
the O 0 9.098001463314631e-09
BRCA2 O 0 6.480352681137447e-07
8765delAG O 0 5.073110969533445e-06
mutation O 0 7.121830662981665e-07
. O 0 1.4923010667189374e-06

Together O 0 2.3712436458822594e-08
, O 0 6.784295902839688e-10
these O 0 6.044384437409178e-11
mutations O 0 2.337561810783484e-10
were O 0 2.1640653158350176e-10
found O 0 1.3253012576264211e-10
in O 0 2.691102063412387e-10
28 O 0 1.8856118444432468e-08
of O 0 1.6063006924582623e-08
41 O 0 4.3840952201890104e-08
families O 0 5.73272873616304e-10
identified O 0 3.758756861316215e-09
to O 0 1.4322579788839107e-09
have O 0 3.6372729272926563e-09
a O 0 3.558897532229821e-08
mutation O 0 1.1185096582266851e-06
. O 0 5.940368737356039e-06

The O 0 1.6941301339556958e-07
odds O 0 1.4883443100188742e-06
of O 0 2.4956342770110496e-08
detection O 0 6.865295176794461e-08
of O 0 2.637995821785921e-09
any O 0 5.351221687988073e-10
of O 0 6.412669062427767e-09
the O 0 6.375800776226015e-09
four O 0 2.910322116633779e-08
BRCA1 O 0 4.9686452285868654e-08
mutations O 0 3.871097931096301e-08
was O 0 1.7323728229712287e-07
18 O 0 3.2315381304215407e-07
. O 0 8.285746275760175e-07

7x O 0 0.0012036440894007683
greater O 0 4.336102676916198e-07
if O 0 2.6172886080644275e-08
one O 0 8.174687038398076e-10
or O 0 1.5856091439836462e-10
more O 0 1.5719042387174476e-11
cases O 0 2.2841874225409953e-10
of O 0 8.974104304115826e-08
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.2538889393454156e-07
also O 0 4.292338151579145e-10
present O 0 8.337222023868662e-10
in O 0 1.2117151726442899e-09
the O 0 2.171596946709542e-08
family O 0 3.3705504165482125e-08
. O 0 3.266972044002614e-07

The O 0 1.4516486146476382e-07
odds O 0 7.843678986318992e-07
of O 0 1.318080045109582e-08
detection O 0 3.410854176877365e-08
of O 0 2.381308705778906e-09
any O 0 4.460916636084278e-10
of O 0 7.426549597511212e-09
the O 0 8.027288167511415e-09
four O 0 2.2459991200207696e-08
BRCA2 O 0 8.896018499626734e-08
mutations O 0 3.8206749763958214e-08
was O 0 2.0924160537560965e-07
5 O 0 9.837510788202053e-07
. O 0 1.0076199714603717e-06

3x O 0 2.6332667403039522e-05
greater O 0 8.78898944733919e-08
if O 0 3.867398845613934e-09
there O 0 1.0615172074679435e-09
were O 0 1.031435714615725e-09
at O 0 2.106558039116635e-09
least O 0 1.221868162204487e-10
five O 0 1.2336047461314337e-10
cases O 0 2.790787601014699e-10
of O 0 4.711193213324805e-09
breast B-Disease 0 1.1415960443628137e-07
cancer I-Disease 0 6.902439508849056e-08
in O 0 2.5146320581370674e-08
the O 0 7.19741592547507e-07
family O 0 2.4040900825639255e-07
. O 0 1.1271210951235844e-06

Interestingly O 0 2.164626494050026e-06
, O 0 8.470941281757405e-09
the O 0 1.6204615427284352e-09
presence O 0 1.2156573525601289e-09
of O 0 5.776242772981277e-08
a O 0 5.496443833408193e-08
breast B-Disease 0 5.419749982138455e-07
cancer I-Disease 0 3.5467820680423756e-07
case O 0 3.4665180237425375e-07
< O 0 1.0842189794857404e-06
36 O 0 4.674051368169785e-08
years O 0 1.7541764707473817e-09
of O 0 1.7731285328892454e-09
age O 0 5.814152714833654e-09
was O 0 2.941325849548093e-09
strongly O 0 4.010235199469747e-10
predictive O 0 1.776965241617745e-08
of O 0 1.6897832022522152e-09
the O 0 2.102406582160654e-10
presence O 0 7.892766301642595e-11
of O 0 9.292013269934785e-10
any O 0 5.933676883174144e-10
of O 0 3.774130341582804e-09
the O 0 3.9526453221583324e-09
eight O 0 2.3987144714965325e-08
mutations O 0 9.416375945647815e-08
screened O 0 2.4281987975882657e-07
. O 0 1.0288248404322076e-06

Carriers O 0 1.3396214626482106e-07
of O 0 8.222623648634908e-08
the O 0 6.160984167280503e-09
same O 0 1.2437645358076566e-09
mutation O 0 4.3147302397628096e-10
, O 0 5.4367742946537234e-11
from O 0 2.1182968573674188e-11
different O 0 1.7975222699195825e-10
families O 0 5.567296276764999e-11
, O 0 8.634877535218521e-11
shared O 0 5.890566923127949e-10
similar O 0 1.187143494618681e-09
haplotypes O 0 2.402986964966658e-08
, O 0 6.200213120699516e-10
indicating O 0 1.9493033853734687e-09
that O 0 1.2361156542795015e-10
the O 0 5.989313489607184e-10
mutant O 0 6.787328032942241e-09
alleles O 0 3.1876068451452966e-09
were O 0 7.264839285703317e-10
likely O 0 5.473401176736559e-10
to O 0 1.2766024348742633e-10
be O 0 2.558705469724032e-10
identical O 0 2.0754422624946756e-09
by O 0 2.3413188054988154e-10
descent O 0 6.291900334076672e-09
for O 0 3.2748817546668363e-10
a O 0 1.2503245105932592e-09
mutation O 0 4.2123948773564734e-09
in O 0 2.5207005371896685e-09
the O 0 2.0927108934643002e-08
founder O 0 5.635444608742546e-07
population O 0 1.3475003335372548e-09
. O 0 2.06927367685239e-07

The O 0 1.2664398418849032e-08
identification O 0 1.4010404392195142e-08
of O 0 2.2274708300074053e-08
common O 0 1.8874347063047026e-07
BRCA1 O 0 3.0592437383347715e-07
and O 0 3.5860858815794927e-07
BRCA2 O 0 5.644975544782938e-07
mutations O 0 6.148977149678103e-08
will O 0 7.902325016573286e-09
facilitate O 0 3.993475328201157e-09
carrier O 0 9.72419256228818e-10
detection O 0 5.8670597269383507e-08
in O 0 5.978998629529997e-09
French O 0 0.48193904757499695
Canadian O 1 0.8336064219474792
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
and O 1 0.9999988079071045
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.36002904077759e-06
. O 0 3.0362987217813497e-06

Are O 0 1.275732870453794e-07
Dp71 O 0 8.086430170806125e-06
and O 0 4.948132215076839e-08
Dp140 O 0 2.949979489130783e-06
brain O 0 2.6129546313313767e-05
dystrophin O 0 2.2747415187041042e-06
isoforms O 0 5.919598038417462e-07
related O 0 2.7070639063708768e-08
to O 0 2.9560893732849536e-09
cognitive B-Disease 0 0.0010249920887872577
impairment I-Disease 1 0.9929782748222351
in O 0 9.951907486538403e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999759197235107

Molecular O 0 1.4135670198811567e-06
study O 0 8.843265675295697e-09
and O 0 9.959865154840486e-10
neuropsychological O 0 1.0193421928761381e-07
analysis O 0 1.8483532482349574e-09
were O 0 8.45018444106671e-10
performed O 0 1.8469392681907948e-10
concurrently O 0 8.951155372471931e-10
on O 0 3.205660403793331e-09
49 O 0 9.23353837833929e-09
patients O 0 5.191909568935671e-09
with O 0 1.795544193328169e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999982118606567
DMD B-Disease 1 1.0
) O 0 3.151287453206919e-09
in O 0 1.8349900765546323e-10
order O 0 4.736454561893311e-10
to O 0 9.213262791574195e-11
find O 0 6.910718663988291e-10
a O 0 1.9844227650001045e-10
molecular O 0 5.868052710411575e-09
explanation O 0 2.0505193099040753e-09
for O 0 2.1534872496342672e-10
the O 0 3.4026781392526573e-09
cognitive B-Disease 0 0.021135913208127022
impairment I-Disease 0 1.00840525192325e-05
observed O 0 1.1890521456336955e-08
in O 0 1.8055913431069825e-09
most O 0 8.049105382212929e-09
DMD B-Disease 1 1.0
patients O 0 1.9910602588879556e-07
. O 0 5.119107413520396e-07

Complete O 0 3.663597283320996e-07
analysis O 0 3.439442153307937e-08
of O 0 1.1474022620916458e-08
the O 0 1.1966466928470254e-08
dystrophin O 0 1.8326910833366128e-07
gene O 0 2.1557489127133067e-09
was O 0 5.5715081437313074e-09
performed O 0 1.954421208205659e-10
to O 0 1.0201148953337125e-10
define O 0 7.131710777485978e-09
the O 0 5.279104708932891e-09
localization O 0 1.0860236443477334e-06
of O 0 2.99620666055489e-08
deletions O 0 4.414259535678866e-08
and O 0 7.093683862535727e-09
duplications O 0 1.7221123016497586e-07
in O 0 2.948914890055221e-09
relation O 0 2.2983668301890248e-08
to O 0 1.7402265184429666e-09
the O 0 1.4349081922659934e-08
different O 0 2.82567668818956e-07
DMD B-Disease 1 1.0
promoters O 0 3.303710400359705e-05
. O 0 1.769563596099033e-06

Qualitative O 0 1.063454988070589e-06
analysis O 0 5.5269410381697526e-08
of O 0 1.7921459871672596e-08
the O 0 2.0434612224562443e-08
Dp71 O 0 3.96852237827261e-06
transcript O 0 2.4668537434990867e-07
and O 0 8.21413603802057e-10
testing O 0 1.334883870107717e-09
for O 0 7.776004840032158e-11
the O 0 2.623663508671825e-10
specific O 0 2.963025380608997e-10
first O 0 1.6573780126094562e-09
exon O 0 8.546992447122648e-09
of O 0 3.742296694753122e-09
Dp140 O 0 1.2254652403953514e-07
were O 0 5.550316650726472e-09
also O 0 8.061623590904787e-10
carried O 0 9.931682143360376e-09
out O 0 1.2532333393266981e-08
. O 0 8.963327502442553e-08

Neuropsychological O 0 0.00015404901932924986
analysis O 0 1.1246247595408931e-06
assessed O 0 1.7659120885582524e-06
verbal O 0 2.6666486974136205e-06
and O 0 1.5703685107837373e-07
visuospatial O 0 5.509200491360389e-05
intelligence O 0 5.835686920363514e-07
, O 0 6.550669784388674e-09
verbal O 0 6.55785413528065e-07
memory O 0 0.02281845547258854
, O 0 2.0055814786701376e-08
and O 0 3.688420946446058e-08
reading O 0 5.9862745729333255e-06
skills O 0 9.56680960371159e-05
. O 0 1.566348146297969e-06

Comparison O 0 7.953624958645378e-07
of O 0 2.1574986419636843e-07
molecular O 0 4.366486621165677e-07
and O 0 6.205658653613e-09
psychometric O 0 1.1090828593296465e-06
findings O 0 3.273542503734461e-08
demonstrated O 0 7.486939068712672e-09
that O 0 5.447062800811864e-10
deletions O 0 1.998989773710491e-08
and O 0 1.9110171223246653e-09
duplications O 0 3.486383093331824e-08
that O 0 2.629805817555564e-10
were O 0 1.765121160346439e-09
localized O 0 1.4751663890422151e-08
in O 0 3.716043250889811e-09
the O 0 1.914403569003298e-08
distal O 0 5.022336040383379e-07
part O 0 8.484022373522748e-09
of O 0 4.3313497144481516e-07
the O 0 5.9060081269990405e-08
gene O 0 2.3874802135281925e-09
seemed O 0 7.246492295109874e-09
to O 0 2.40772818349555e-10
be O 0 6.509204286686554e-10
preferentially O 0 1.1789171416864974e-08
associated O 0 1.013715547060201e-07
with O 0 9.392626765247769e-08
cognitive B-Disease 1 0.9999998807907104
impairment I-Disease 1 0.9999876022338867
. O 0 9.553497875458561e-06

Two O 0 4.86357350837352e-07
altered O 0 8.175051107173203e-07
Dp71 O 0 5.62793275094009e-06
transcripts O 0 1.486768042013864e-07
and O 0 1.0682768003533738e-09
two O 0 6.18964990373172e-10
deleted O 0 3.518050739614864e-09
Dp140 O 0 1.2358433387760215e-08
DNA O 0 2.05340766612494e-09
sequences O 0 3.34924588063501e-10
were O 0 5.121426616128133e-10
found O 0 1.9376848736651908e-10
in O 0 2.7891222664777615e-10
four O 0 1.7966182985773571e-09
patients O 0 2.903035811741006e-09
with O 0 2.090066075766117e-08
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.09231693297624588

These O 0 4.8119108697619595e-08
findings O 0 3.155475170046884e-08
suggest O 0 1.2307662666799501e-09
that O 0 4.70604250013551e-11
some O 0 3.965614642220672e-11
sequences O 0 2.966101253498721e-10
located O 0 5.428425486897481e-10
in O 0 2.6507754324889277e-10
the O 0 1.4024139627366594e-09
distal O 0 4.226231098414246e-08
part O 0 1.2007110861134151e-09
of O 0 1.7947902719583908e-08
the O 0 6.992637135994073e-09
gene O 0 1.0744153344788288e-09
and O 0 5.032533834103958e-10
, O 0 1.4821677218890272e-10
in O 0 1.4634086997755702e-10
particular O 0 1.0302264596973032e-09
, O 0 8.867464540429637e-10
some O 0 5.1292885494547136e-09
DMD B-Disease 1 1.0
isoforms O 0 3.6926167013007216e-06
expressed O 0 1.3505218277032327e-08
in O 0 3.048675312200544e-09
the O 0 1.2399421045472536e-08
brain O 0 8.868172471920843e-07
may O 0 1.4150101090848466e-09
be O 0 2.94802487976753e-10
related O 0 7.189054351819379e-10
to O 0 2.6824875654085645e-10
the O 0 6.581967859631277e-09
cognitive B-Disease 1 0.9978203773498535
impairment I-Disease 1 0.6136060357093811
associated O 0 7.02231830018718e-07
with O 0 9.029183445363742e-08
DMD B-Disease 1 1.0
. O 0 2.1240840908376413e-07
. O 0 6.484686423391395e-07

I1307K O 0 5.0588099838932976e-05
APC O 0 5.628286999126431e-06
and O 0 7.497945375689596e-08
hMLH1 O 0 1.859221697486646e-06
mutations O 0 2.2841636138082322e-08
in O 0 1.6132976066174365e-09
a O 0 2.033196500050849e-09
non O 0 1.0196727373568137e-07
- O 0 4.882729953692433e-08
Jewish O 0 6.469945468268179e-09
family O 0 1.3161047807130899e-09
with O 0 1.2789940218027596e-09
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9989345669746399

We O 0 3.462645565832645e-07
describe O 0 9.238580389592244e-08
a O 0 8.847703014680519e-09
French O 0 7.888034474490269e-07
Canadian O 0 2.050807779596653e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.89960686233826e-05
HNPCC B-Disease 0 0.18368157744407654
) O 0 2.7111616063280053e-08
kindred O 0 4.751452706841519e-07
which O 0 1.678886030198612e-09
carries O 0 4.7620929422009795e-09
a O 0 2.0013961599119057e-09
novel O 0 2.277177379994555e-08
truncating O 0 1.3257925957077532e-06
mutation O 0 4.211039339452327e-08
in O 0 2.7853984008174848e-08
hMLH1 O 0 1.2522112228907645e-05
. O 0 4.379066012916155e-06

Interestingly O 0 2.219861244157073e-06
, O 0 1.2412861849497858e-08
the O 0 1.18105969448834e-08
I1307K O 0 5.83788562380505e-07
APC O 0 1.677930328014554e-07
polymorphism O 0 8.493660885733334e-08
, O 0 6.396004281761236e-10
associated O 0 3.1202462835722145e-09
with O 0 4.702318742721978e-11
an O 0 2.995504885805467e-11
increased O 0 6.413228281765271e-10
risk O 0 2.6399866328574717e-06
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.3484622058967943e-06
is O 0 3.386683433692639e-10
also O 0 1.1043523040488168e-10
present O 0 1.9610942036951684e-10
in O 0 2.153602435273072e-10
this O 0 4.4338652194220174e-10
family O 0 8.479493551760697e-09
. O 0 1.6815154424421053e-07

The O 0 3.5990746027891873e-07
I1307K O 0 1.7228938986590947e-06
polymorphism O 0 1.1799467358741822e-07
has O 0 3.3902511353822717e-10
previously O 0 6.70112743073048e-10
only O 0 9.966074493439336e-11
been O 0 1.8597427764444063e-10
identified O 0 9.721188298783545e-10
in O 0 3.121566338748494e-10
individuals O 0 1.3996875880550874e-10
of O 0 1.2781851133070177e-08
self O 0 1.046686065819813e-06
- O 0 3.692193058668636e-05
reported O 0 6.30657268629875e-07
Ashkenazi O 0 1.3011231203563511e-06
Jewish O 0 1.5541571940502763e-07
origins O 0 2.0786696950381156e-06
. O 0 4.995965355192311e-06

In O 0 8.069876855643088e-08
addition O 0 4.474613568561381e-09
, O 0 4.5266998482951237e-10
in O 0 2.053813924485226e-10
this O 0 1.4663061043140857e-10
family O 0 3.988540608901303e-10
, O 0 9.11433567507558e-11
there O 0 7.860616324517622e-11
appears O 0 4.604286396592272e-10
to O 0 1.0408044565091146e-10
be O 0 4.794718511114127e-10
no O 0 1.0727484456296565e-09
relationship O 0 3.4569613838186797e-09
between O 0 4.319154367493638e-09
the O 0 2.5474626852428628e-09
I1307K O 0 3.0274222240223025e-08
polymorphism O 0 5.475043529656887e-09
and O 0 1.8685429592490976e-10
the O 0 1.5553291987657758e-10
presence O 0 2.1533723415512185e-10
or O 0 1.197082100112823e-09
absence O 0 4.6061881420200734e-08
of O 0 3.9028364540172333e-08
cancer B-Disease 0 5.5508273533178e-08
. O 0 2.5967622718781058e-08
. O 0 7.609971817146288e-07

Identification O 0 4.1486256918688014e-07
of O 0 3.736072073934338e-08
a O 0 1.7121034590061868e-09
novel O 0 2.637442486630448e-09
mutation O 0 3.6689551397017794e-09
of O 0 1.0964722463313592e-08
the O 0 2.428198264681214e-08
CPO O 0 1.1665118790915585e-06
gene O 0 4.642525031073319e-09
in O 0 2.4487778471637967e-09
a O 0 1.022196016720045e-08
Japanese O 0 2.7082676297141006e-06
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9992577433586121
family O 0 2.2075132619647775e-06
. O 0 5.065289315098198e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 0.001369682839140296
HCP B-Disease 1 0.9999994039535522
) O 0 6.062924029492933e-08
is O 0 3.482639732155235e-09
an O 0 6.178872080653264e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 5.617838496618788e-07
by O 0 9.641808240701266e-09
a O 0 1.198653905021274e-07
deficiency B-Disease 0 0.001941908267326653
of I-Disease 0 0.017873220145702362
coproporphyrinogen I-Disease 1 0.9862144589424133
oxidase I-Disease 0 1.9193339539924636e-06
( O 0 9.193892758219135e-09
CPO O 0 4.5690265437769995e-07
) O 0 3.7330624702569537e-10
caused O 0 2.5348463328356274e-09
by O 0 3.0925279004279105e-10
a O 0 1.2735850152267858e-09
mutation O 0 5.2203885658741456e-09
in O 0 3.762831379816589e-09
the O 0 5.665189917181124e-08
CPO O 0 9.320132448920049e-06
gene O 0 3.7182505252530973e-07
. O 0 9.845591648627305e-07

Only O 0 6.593002410681947e-08
11 O 0 1.0403751815601936e-07
mutations O 0 4.10690370600264e-09
of O 0 5.022429583334542e-09
the O 0 3.2138334216114117e-09
gene O 0 1.9746713153523388e-09
have O 0 5.22441978567656e-10
been O 0 3.246690916114403e-09
reported O 0 2.654846298355551e-08
in O 0 6.451352874137228e-08
HCP B-Disease 1 0.9862146973609924
patients O 0 5.36330560407805e-07
. O 0 3.7308211631170707e-06

We O 0 5.444704811452539e-07
report O 0 1.632137802687339e-08
another O 0 1.6785401957264412e-09
mutation O 0 3.4095450907045688e-09
in O 0 1.3426362244217671e-09
a O 0 4.290752197988468e-09
Japanese O 0 5.038176595917321e-07
family O 0 2.978023871946789e-07
. O 0 1.508354671386769e-06

Polymerase O 0 7.138080491131404e-06
chain O 0 2.124819502569153e-07
reaction O 0 2.541005095224591e-08
- O 0 7.886637831688859e-08
single O 0 3.3827860512758434e-09
strand O 0 1.0810348172185513e-08
conformational O 0 2.0265073175096404e-08
polymorphism O 0 6.40347819214071e-09
and O 0 2.977403879000917e-10
direct O 0 1.1090834917126813e-09
sequence O 0 3.065696141391072e-09
analyses O 0 5.5469513426942285e-09
demonstrated O 0 2.2305828295543506e-08
a O 0 5.616427323218431e-09
C O 0 9.072894613382232e-08
to O 0 2.5009985193946704e-09
T O 0 2.641763607869052e-08
substitution O 0 2.7864066609595284e-09
in O 0 4.089376892668639e-10
exon O 0 2.2416368761213334e-09
1 O 0 5.091644439403353e-09
of O 0 1.8224481923567737e-09
the O 0 1.867870302874053e-09
CPO O 0 1.8143218483146484e-07
gene O 0 2.2576545077868104e-09
at O 0 3.228863931781234e-08
nucleotide O 0 3.91980670144676e-09
position O 0 7.873742191577549e-08
85 O 0 3.306480778064724e-08
, O 0 7.539195934214149e-10
which O 0 5.604930963798438e-10
lies O 0 2.1954022599857126e-08
in O 0 1.213023903545718e-09
the O 0 9.58244417148535e-09
putative O 0 2.9930941991551663e-07
presequence O 0 5.504610953721567e-07
for O 0 2.439449531266291e-09
targeting O 0 3.927606684328566e-08
to O 0 2.949512811767363e-08
mitochondria O 0 1.6335275176970754e-06
. O 0 1.3752863878835342e-06

This O 0 8.449640986896156e-09
mutation O 0 4.357075145122735e-09
changes O 0 1.953591066694571e-09
the O 0 8.502145099065217e-10
codon O 0 6.240912675536947e-09
for O 0 2.3106719315713065e-10
glutamine O 0 3.6314222739974866e-09
to O 0 2.7470281604990987e-10
a O 0 1.7137208319084607e-09
termination O 0 1.9394954620111093e-07
codon O 0 5.517208592209499e-07
at O 0 1.199411258312466e-06
amino O 0 1.218359386712109e-07
acid O 0 5.541465242231425e-08
position O 0 1.2112301419620053e-06
29 O 0 2.5762351469893474e-06
. O 0 1.087997475224256e-06

MaeI O 0 7.255842501763254e-05
restriction O 0 1.9965821707046416e-07
analysis O 0 1.2464967369396618e-07
showed O 0 2.5805968917325117e-08
two O 0 6.992793566418243e-10
other O 0 5.153357948706194e-11
carriers O 0 7.593527195925986e-11
in O 0 7.680110436503185e-10
the O 0 1.3648186580894617e-08
family O 0 4.741376713468526e-08
. O 0 3.853742214232625e-07

The O 0 2.606886710054823e-06
C O 0 0.0005740317283198237
- O 0 9.108997619478032e-05
T O 0 5.393814035414835e-07
mutation O 0 1.3473667737073924e-09
is O 0 1.0496139374316371e-10
located O 0 3.4504843426930165e-10
within O 0 3.05316605331285e-10
a O 0 3.190074593373282e-10
recently O 0 1.1626242191198344e-09
proposed O 0 2.5288195981687522e-09
putative O 0 2.5901437439301844e-08
alternative O 0 3.060539199850609e-08
translation O 0 4.218837545977294e-08
initiation O 0 2.541538179912095e-08
codon O 0 1.3628967110435042e-07
( O 0 8.853644928308313e-09
TIC O 0 1.2704285268227977e-07
- O 0 3.291392047799491e-08
1 O 0 5.2487457935512793e-08
) O 0 3.3517508213343206e-10
, O 0 1.6344757491904005e-10
supporting O 0 2.6138946562781484e-09
that O 0 3.2302664987327034e-09
TIC O 0 1.6418317727584508e-07
- O 0 5.540134040415978e-08
1 O 0 6.913256100915532e-08
is O 0 2.839303236967794e-10
the O 0 3.0429063713199866e-09
real O 0 5.916273835282482e-07
TIC O 0 3.0974490528024035e-07
rather O 0 5.703023830960774e-09
than O 0 3.217366151275769e-09
TIC O 0 1.48590899584633e-07
- O 0 2.9091953734905474e-08
2 O 0 6.570832056240761e-08
. O 0 7.889764397361887e-09
. O 0 1.2340170485458657e-07

Human B-Disease 0 1.1846851748487097e-06
complement I-Disease 0 1.930369990077452e-06
factor I-Disease 0 0.00030590020469389856
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.07306502759456635
with O 0 0.018897198140621185
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9994723200798035

This O 0 1.2568526663869761e-08
study O 0 4.1805785500059756e-09
reports O 0 2.9793254530119384e-09
on O 0 5.106933542720071e-09
six O 0 3.343573196090688e-09
cases O 0 1.3563397072147154e-09
of O 0 1.9457532474120853e-08
deficiency B-Disease 0 3.5536588711693184e-06
in I-Disease 0 2.1981046316454922e-08
the I-Disease 0 1.172293835338678e-07
human I-Disease 0 3.933199366201734e-08
complement I-Disease 0 2.6954301901582767e-08
regulatory I-Disease 0 7.952072422767742e-08
protein I-Disease 0 2.1860756760361255e-08
Factor I-Disease 0 2.2402109323138575e-07
H I-Disease 1 1.0
( O 0 2.4208535176484247e-09
FH O 0 1.743716921964733e-07
) O 0 3.619614330485632e-11
in O 0 1.795383286484764e-11
the O 0 6.155480986036466e-11
context O 0 8.802502615701258e-10
of O 0 7.095750653718369e-10
an O 0 1.3731500381197748e-09
acute B-Disease 1 0.9999980926513672
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.02421468496322632

Five O 0 2.8165075605102174e-07
of O 0 1.3762184281063128e-08
the O 0 8.610409607534564e-10
cases O 0 2.0072288275940764e-10
were O 0 2.42960429552852e-10
observed O 0 6.734633961613667e-10
in O 0 2.4147833732612867e-10
children O 0 7.296612203333552e-10
presenting O 0 1.1425153445543401e-07
with O 0 1.7931276943272678e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.999994158744812
HUS B-Disease 1 1.0
) O 0 8.580167923355475e-05
. O 0 7.186568109318614e-05

Two O 0 6.951017894607503e-08
of O 0 3.015366445424661e-08
the O 0 5.019556326146812e-09
children O 0 4.634631012301327e-10
exhibited O 0 1.9906799764157768e-08
a O 0 1.6814825087863028e-08
homozygous O 0 6.18453213974135e-06
deficiency O 0 0.000356469041435048
characterized O 0 2.575404245419577e-08
by O 0 1.1404176492035845e-09
the O 0 5.529542601578896e-09
absence O 0 8.72402026175223e-08
of O 0 5.0742638535439255e-08
the O 0 5.3919912978983575e-09
150 O 0 3.870564757590955e-09
- O 0 7.022576742343745e-09
kD O 0 4.961476207654414e-08
form O 0 6.012525477494535e-10
of O 0 1.1295530732979842e-08
Factor O 0 2.627279798161908e-07
H O 1 1.0
and O 0 1.2801192328382172e-09
the O 0 2.993884307134209e-10
presence O 0 9.899482622532929e-11
, O 0 6.223385001780102e-11
upon O 0 1.5949948029003735e-09
immunoblotting O 0 8.437887544232581e-08
, O 0 4.374317852384735e-10
of O 0 2.603535165235371e-09
the O 0 7.102050947338512e-09
42 O 0 4.7892761756429536e-08
- O 0 5.7739072190088336e-08
kD O 0 9.796840458875522e-07
Factor O 0 5.230438091530232e-07
H O 1 0.9999966621398926
- O 0 1.7219216488228994e-06
like O 0 5.7496829519720904e-09
protein O 0 1.5757219529177746e-08
1 O 0 1.6888003528947593e-07
( O 0 1.1706482450080102e-09
FHL O 0 3.9810169027987286e-07
- O 0 1.0995507615518818e-08
1 O 0 1.0488426127608363e-08
) O 0 1.9277390794769644e-10
and O 0 4.924175511789031e-10
other O 0 2.296017154179708e-09
FH O 0 6.087233941798331e-06
- O 0 7.205451169056687e-08
related O 0 3.656919034256134e-08
protein O 0 1.5543699660724997e-08
( O 0 1.6050289985969357e-09
FHR O 0 2.1366104192566127e-06
) O 0 6.369589300447842e-09
bands O 0 4.0846768456503924e-07
. O 0 8.34265222238173e-07

Southern O 0 1.1577034229048877e-06
blot O 0 1.8218448758489103e-06
and O 0 3.516735791464498e-09
PCR O 0 5.21999021785291e-09
analysis O 0 3.525787439784267e-10
of O 0 3.406059323474153e-10
DNA O 0 9.174268567058164e-10
of O 0 8.414448027238564e-10
one O 0 2.768156259769228e-10
patient O 0 1.176373887190607e-09
with O 0 5.461054941591215e-10
homozygous O 0 9.941272764990572e-07
deficiency O 0 2.1342731997719966e-05
ruled O 0 7.217947199933405e-07
out O 0 2.124716624862799e-09
the O 0 3.399264481007691e-10
presence O 0 1.6757051302107584e-10
of O 0 2.05068362291172e-09
a O 0 4.3377690328583185e-10
large O 0 7.629505915929258e-10
deletion O 0 2.2606718275142157e-08
of O 0 9.652042365360103e-08
the O 0 4.099322836736974e-07
FH O 0 0.006370385643094778
gene O 0 2.5016818838707877e-08
as O 0 3.606098086805787e-09
the O 0 7.9608097891537e-09
underlying O 0 1.2967593647772446e-05
defect O 0 4.036856807942968e-06
for O 0 5.303045469418066e-08
the O 0 3.5629639114631573e-06
deficiency O 1 0.9998725652694702
. O 0 6.079651939217001e-05

The O 0 1.8837646109659545e-07
other O 0 4.6917523199851985e-09
four O 0 3.238706192121299e-09
children O 0 3.628678746370184e-10
presented O 0 8.34110736036564e-09
with O 0 1.6624182030966494e-09
heterozygous O 0 3.7320913293115154e-07
deficiency O 0 3.969654062530026e-05
and O 0 1.5761397520464016e-08
exhibited O 0 9.45323037626622e-08
a O 0 1.3617815319832971e-08
normal O 0 1.5440963352375547e-07
immunoblotting O 0 1.1467544709375943e-06
pattern O 0 5.0736154832975444e-08
of O 0 1.3444998891998239e-08
proteins O 0 5.984859274832388e-10
of O 0 1.1941318156516445e-08
the O 0 3.958947303317473e-08
FH O 0 3.715111597557552e-05
family O 0 6.879293579231671e-08
. O 0 3.1410641554430185e-07

Factor B-Disease 1 0.9996967315673828
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
is O 0 5.228599775364273e-09
the O 0 4.208379422721009e-09
only O 0 5.5745910110260866e-09
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
associated O 0 4.1110598658633535e-07
with O 0 5.050905826919916e-08
HUS B-Disease 1 1.0
. O 0 1.162040098279249e-05

These O 0 6.402869701105374e-08
observations O 0 1.5288952681657975e-07
suggest O 0 6.279216258064935e-09
a O 0 1.3801711995498067e-09
role O 0 6.433348520573645e-09
for O 0 4.476150117227462e-09
FH O 0 3.248134453315288e-05
and O 0 2.059430102008264e-07
/ O 0 3.783285501413047e-05
or O 0 2.2991896742041718e-07
FH O 0 9.399134796694852e-06
receptors O 0 1.4263211056686487e-08
in O 0 1.1948328992872348e-09
the O 0 2.5852064933218344e-09
pathogenesis O 0 9.475196520725149e-07
of O 0 2.6898423044485753e-08
idiopathic O 0 8.491729386150837e-05
HUS B-Disease 1 0.999997615814209
. O 0 3.5228910633122723e-07
. O 0 2.0989543827454327e-06

Further O 0 7.424895187568836e-08
evidence O 0 2.5185968866026087e-08
for O 0 1.2437734175918536e-10
a O 0 1.304256563861017e-10
major O 0 5.320344165227198e-10
ancient O 0 5.283761339569537e-08
mutation O 0 4.402145350468345e-06
underlying O 1 0.9952331185340881
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 3.405319830562803e-07
linkage O 0 1.7170349337902735e-06
disequilibrium O 0 1.0209059837507084e-06
studies O 0 3.0279059259896712e-09
in O 0 2.5848551077345405e-10
the O 0 6.713267719504756e-10
Japanese O 0 1.905849345007482e-08
population O 0 1.9875213974618333e-10
. O 0 7.613087404934049e-08

The O 1 0.8009397983551025
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9817422032356262
DM B-Disease 1 1.0
) O 0 4.5226137501686026e-08
mutation O 0 9.270313405806974e-09
is O 0 4.3708650587781506e-10
an O 0 6.051111833826894e-10
unstable O 0 6.594177648366895e-07
( O 0 3.1526958821359585e-08
CTG O 0 8.517786227457691e-06
) O 0 1.0772557956784112e-08
n O 0 1.2188765197151952e-07
repeat O 0 2.7759472942534558e-08
, O 0 7.495021270287339e-10
present O 0 1.0948750794881335e-09
at O 0 3.899910172577847e-09
a O 0 1.1821672807332817e-10
copy O 0 1.4572260065293108e-09
number O 0 3.786198299327026e-10
of O 0 1.5952655862960796e-09
5 O 0 2.0351762941572815e-08
- O 0 1.351557710194129e-08
37 O 0 1.5973521172440996e-08
repeats O 0 7.444305172299437e-09
on O 0 2.6717723144997763e-08
normal O 0 1.131549876021154e-08
chromosomes O 0 2.747731819852106e-09
but O 0 6.874316671456882e-10
amplified O 0 3.1801676847464933e-09
to O 0 3.6617803234051394e-10
50 O 0 1.6607005770552519e-09
- O 0 5.684041237685733e-09
3000 O 0 9.285178848017495e-09
copies O 0 7.823245162796866e-09
on O 0 3.8270792401817744e-07
DM B-Disease 1 0.9999994039535522
chromosomes O 0 8.115316063594946e-07
. O 0 4.669907980314747e-07

Previous O 0 1.4116244528850075e-06
findings O 0 1.332816594867836e-07
in O 0 2.6153610388490733e-09
Caucasian O 0 2.839089674466777e-08
populations O 0 2.4676307663895614e-09
of O 0 6.305285893404289e-08
a O 0 3.4808731470548082e-06
DM B-Disease 1 1.0
founder O 1 0.9999185800552368
chromosome O 0 6.591870373995334e-07
raise O 0 1.3262659415147482e-08
a O 0 2.855347513985862e-09
question O 0 6.741024183298805e-09
about O 0 2.0919703469512996e-10
the O 0 2.1149310081014505e-10
molecular O 0 4.672756848123072e-09
events O 0 3.7458150470293106e-10
involved O 0 1.7250503803190043e-10
in O 0 1.7008344732616365e-10
the O 0 9.440428438978188e-10
expansion O 0 3.57806442252695e-08
mutation O 0 2.0509239107013855e-07
. O 0 6.66425762574363e-07

To O 0 3.6372023259900743e-07
investigate O 0 4.922340508528578e-07
whether O 0 2.2103684216290276e-08
a O 0 2.326231118843225e-08
founder O 0 5.298400083120214e-07
chromosome O 0 3.494951883453723e-08
for O 0 6.49028963906062e-09
the O 0 1.2842178875871468e-07
DM B-Disease 1 1.0
mutation O 0 4.683910592717666e-09
exists O 0 4.854754931393757e-10
in O 0 1.3225259776206144e-10
the O 0 2.3540897009510786e-10
Japanese O 0 2.5561506244997645e-09
population O 0 6.055458651871293e-12
, O 0 8.439743348631623e-11
we O 0 8.406490503709563e-10
genotyped O 0 4.9347111286124345e-08
families O 0 9.643748299925647e-11
using O 0 7.680096003603865e-10
polymorphic O 0 2.1883451495341433e-08
markers O 0 4.564897793102318e-08
near O 0 2.8815699693041097e-07
the O 0 1.1787320630674003e-07
( O 0 3.862535535859024e-08
CTG O 0 6.4070932239701506e-06
) O 0 8.874525114777043e-09
n O 0 1.6389000734307047e-07
repeat O 0 5.450779028137731e-08
region O 0 1.9552695462721204e-08
and O 0 1.8547392954815223e-08
constructed O 0 8.319183280036668e-07
haplotypes O 0 3.536109716151259e-06
. O 0 1.9893191165465396e-06

Six O 0 2.8012601660520886e-07
different O 0 3.959753858140402e-09
haplotypes O 0 2.558278566766603e-08
were O 0 1.7699725018971435e-09
found O 0 3.362791822780764e-09
and O 0 1.6076249664820352e-08
DM B-Disease 1 1.0
alleles O 0 1.431718459343756e-07
were O 0 2.6501615124630007e-08
always O 0 3.998736275434567e-08
haplotype O 0 5.726433869313041e-07
A O 0 5.840230414833059e-07
. O 0 1.5382231595140183e-06

To O 0 2.3765954537680045e-08
find O 0 5.790999679788911e-09
an O 0 7.990877404218111e-11
origin O 0 9.77352310194135e-10
of O 0 8.748327395835531e-09
the O 0 1.0563069530178382e-08
( O 0 1.249762515698194e-08
CTG O 0 3.236801603634376e-06
) O 0 5.870224306647742e-09
n O 0 1.5038847323012305e-07
repeat O 0 6.27536351771596e-08
mutation O 0 4.753988758210426e-09
and O 0 8.055044964372371e-10
to O 0 3.935791970111069e-10
investigate O 0 1.1023099766305222e-08
the O 0 1.2830475570879685e-09
mechanism O 0 1.3749092531156748e-08
of O 0 4.3520418380182946e-09
the O 0 5.965428706566911e-10
expansion O 0 1.812513028554008e-09
mutation O 0 1.068349575472638e-10
in O 0 4.393338123853674e-11
the O 0 8.936276024718026e-11
Japanese O 0 2.1077355416565524e-09
population O 0 3.8457154127868876e-12
we O 0 8.444863558443316e-11
have O 0 7.127257117822694e-11
studied O 0 7.060451334695017e-09
90 O 0 5.402542857524395e-09
Japanese O 0 1.8551043012848822e-07
DM B-Disease 1 1.0
families O 0 8.065380363575514e-09
comprising O 0 5.0920911931484625e-09
190 O 0 1.2573561747331041e-08
affected O 0 2.4719741809065e-09
and O 0 2.2601878146844e-09
130 O 0 2.8776284466403013e-08
unaffected O 0 1.6886151854578202e-07
members O 0 2.3224538736599243e-08
. O 0 3.9230516790667025e-07

The O 0 6.367071705426497e-07
results O 0 3.529580112626718e-07
suggest O 0 4.957311894315808e-09
that O 0 8.039676563376119e-11
a O 0 2.120108810732546e-10
few O 0 5.745569020554342e-10
common O 0 1.4696135419711709e-09
ancestral O 0 1.8325192030488324e-08
mutations O 0 2.2480763917087643e-09
in O 0 5.013296444644766e-10
both O 0 1.5703296440960912e-09
Caucasian O 0 2.4400650389111433e-08
and O 0 1.7316246214704734e-09
Japanese O 0 2.6962013066622603e-08
populations O 0 2.0983442761135507e-10
have O 0 8.239535442822188e-11
originated O 0 3.315457630659324e-10
by O 0 6.038104044536752e-11
expansion O 0 1.581098030278838e-09
of O 0 1.244234382191678e-09
an O 0 1.5779519357828065e-10
ancestral O 0 8.365803161325402e-09
n O 0 3.393903469373072e-08
= O 0 8.38971203620531e-08
5 O 0 2.9552623459494498e-08
repeat O 0 1.2735662302532091e-08
to O 0 5.816637393962765e-09
n O 0 2.796548983496905e-07
= O 0 7.010053195699584e-07
19 O 0 2.721646410464018e-07
- O 0 5.108670819709005e-08
37 O 0 1.6186213258606585e-08
copies O 0 2.049566205641895e-08
. O 0 3.320334371892386e-07

These O 0 2.9721187289055706e-08
data O 0 1.5405802855639195e-08
support O 0 1.0051010024270113e-09
multistep O 0 2.2182668146797369e-07
models O 0 3.786664706240117e-07
of O 0 1.5037716138976975e-07
triplet O 0 5.607557795883622e-06
repeat O 0 8.149878993890525e-08
expansion O 0 5.445975226336941e-09
that O 0 4.6851744706088994e-11
have O 0 2.2501719237899565e-11
been O 0 4.920961901855314e-11
proposed O 0 1.499993879106043e-10
for O 0 1.3182697988778358e-10
both O 0 8.994150313412774e-09
DM B-Disease 1 1.0
and O 0 2.039865734104751e-07
Friedreichs B-Disease 0 0.00020864440011791885
ataxia I-Disease 0 0.003678898559883237
. O 0 1.2791208803264453e-07
. O 0 1.0938715604424942e-06

The O 0 1.0056464816443622e-07
molecular O 0 4.553901078452327e-07
basis O 0 5.954293555987533e-07
of O 0 3.511519025778398e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.568974106191945e-08
the O 0 4.331099479060185e-09
western O 0 2.318983760574156e-08
Cape O 0 1.4621233503930853e-06
, O 0 1.938772919984899e-09
South O 0 3.8490696852022666e-08
Africa O 0 2.9247800625853415e-07
. O 0 3.8364265719792456e-07

Deficiency B-Disease 1 0.5169704556465149
of I-Disease 0 2.0628182028303854e-05
the I-Disease 0 1.9847510657200473e-07
sixth I-Disease 0 2.0803028633054055e-07
component I-Disease 0 5.525061741451509e-09
of I-Disease 0 1.1367502494863402e-08
human I-Disease 0 1.1287217382971448e-08
complement I-Disease 0 1.4923502433816793e-08
( O 0 2.0817626733560246e-08
C6 O 0 0.0021282234229147434
) O 0 2.716538105573818e-09
has O 0 2.615838656794267e-10
been O 0 3.318254004902599e-10
reported O 0 3.371350976166809e-10
in O 0 3.2357515972192274e-11
a O 0 1.1173978409217966e-10
number O 0 1.6167836514036082e-10
of O 0 6.30502761111984e-10
families O 0 2.8894763318132455e-11
from O 0 5.99673991019678e-11
the O 0 1.2688811112937515e-09
western O 0 4.131449671262999e-08
Cape O 0 4.835555955651216e-06
, O 0 2.076033034370539e-08
South O 0 3.562630297437863e-07
Africa O 0 1.913301275635604e-06
. O 0 1.378919023409253e-06

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9959561228752136
is O 0 4.95789809207281e-09
endemic O 0 4.596303782022915e-09
in O 0 4.952451782003209e-10
the O 0 3.354054589621569e-09
Cape O 0 6.907614533702144e-07
and O 0 6.769612093115995e-10
almost O 0 5.587894591485565e-10
all O 0 9.077382595590322e-11
pedigrees O 0 4.606818482244535e-09
of O 0 5.109272116499142e-09
total O 0 8.386693934880896e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.0504076303495822e-07
C6Q0 O 0 5.5141932534752414e-05
) O 0 3.348185340090737e-10
have O 0 6.881567538030708e-11
been O 0 1.7657902917633805e-10
ascertained O 0 1.659884318883087e-08
because O 0 9.111106868964214e-10
of O 0 1.9610661539104512e-08
recurrent O 0 4.254266605130397e-05
disease O 0 0.0004928400740027428
. O 0 3.943407136830501e-06

We O 0 9.803029854538181e-08
have O 0 9.384094612485683e-10
sequenced O 0 4.897183991658949e-09
the O 0 4.811914755542546e-10
expressed O 0 2.487387851246581e-09
exons O 0 1.1605581562434963e-07
of O 0 3.6411201165265084e-08
the O 0 3.164980810765883e-08
C6 O 0 2.503250834706705e-05
gene O 0 1.9283579177908905e-09
from O 0 2.2071137972812238e-10
selected O 0 6.427838261657826e-10
cases O 0 7.017722514213176e-11
and O 0 1.0382724541235788e-10
have O 0 1.000865015865493e-10
found O 0 1.1176563008419294e-09
three O 0 1.8154608927289928e-09
molecular O 0 0.00023953722848091274
defects O 1 0.8665446639060974
leading O 0 1.6975228618321125e-06
to O 0 4.301062261902189e-08
total O 0 2.2875265131006017e-06
deficiency O 1 0.9999998807907104
879delG O 1 0.9996448755264282
, O 0 3.0857080446367036e-08
which O 0 2.362475326478375e-09
is O 0 4.098950623365738e-10
the O 0 9.090589392357629e-10
common O 0 7.76218733733458e-09
defect O 0 3.561749650771162e-08
in O 0 3.2590314891223215e-09
the O 0 1.8024747916456363e-08
Cape O 0 1.3848996331944363e-06
and O 0 3.5438918466468294e-09
hitherto O 0 4.1305831643967394e-08
unreported O 0 6.246200001669422e-09
, O 0 7.578753596915178e-11
and O 0 6.511936545550157e-10
1195delC O 0 1.0645960912825103e-07
and O 0 2.333028659151637e-09
1936delG O 0 2.2064831739498914e-07
, O 0 3.073346854787218e-10
which O 0 9.090723313009974e-11
have O 0 1.794418780232121e-10
been O 0 3.4279709626439114e-10
previously O 0 2.325458048346718e-09
reported O 0 2.5299051742422307e-09
in O 0 4.166949452155677e-09
African O 0 5.642984319820243e-07
- O 0 5.921619390392152e-07
Americans O 0 5.536933045391379e-08
. O 0 1.2624899454749539e-06

We O 0 3.4080585464835167e-07
also O 0 2.7337532237936557e-09
show O 0 1.1049154924336335e-09
that O 0 6.823262788113738e-11
the O 0 5.599438690495617e-10
879delG O 0 9.963446956362532e-08
and O 0 6.286862141990923e-09
1195delC O 0 2.2649267066299217e-06
defects O 0 5.114382020110497e-06
are O 0 1.72522240937667e-09
associated O 0 8.166637144313427e-08
with O 0 3.3663297926977975e-08
characteristic O 1 0.9999998807907104
C6 O 1 1.0
/ O 1 0.9999998807907104
C7 O 1 0.9608473777770996
region O 0 6.455131540406e-08
DNA O 0 2.2010203437616838e-08
marker O 0 2.088834527569361e-08
haplotypes O 0 4.700817068936658e-09
, O 0 3.729772740657111e-11
although O 0 5.871629571441161e-11
small O 0 2.16927656393473e-10
variations O 0 2.9557960523618476e-09
were O 0 6.953866815706533e-09
observed O 0 1.181240349978907e-07
. O 0 1.9228153291805938e-07

The O 0 9.628034831621335e-07
1936delG O 0 2.0135279555688612e-05
defect O 0 2.634134034451563e-06
was O 0 1.6612659692327725e-07
observed O 0 1.3600501169719337e-08
only O 0 5.860644747279764e-10
once O 0 1.6009167325137241e-09
in O 0 3.6498981614840886e-10
the O 0 1.0776661785172337e-09
Cape O 0 3.2149208095688664e-07
, O 0 1.4035907158760352e-10
but O 0 1.0863230454072337e-10
its O 0 1.8563088566292407e-10
associated O 0 6.61607790775065e-09
haplotype O 0 7.494685405617929e-08
could O 0 1.5398574859659675e-08
be O 0 2.137053023432145e-08
deduced O 0 8.464434699817502e-07
. O 0 4.7275696601900563e-07

The O 0 2.5683533522169455e-07
data O 0 1.0511055137385483e-08
from O 0 2.0837549741248296e-10
the O 0 2.4300630951934465e-10
haplotypes O 0 3.4794658265724365e-09
indicate O 0 6.564374599449252e-10
that O 0 5.259460922335535e-11
these O 0 2.8506719207399556e-10
three O 0 1.1029657187577868e-09
molecular O 0 2.962734470202122e-06
defects O 0 4.55859981229878e-06
account O 0 1.4339526233086985e-09
for O 0 2.7588753503948737e-09
the O 0 1.0579122999843094e-07
defects O 0 0.0008786056423559785
in O 0 1.1604492478056727e-08
all O 0 4.463770242324472e-09
the O 0 1.3485141003855006e-08
38 O 0 6.901846916207433e-08
unrelated O 0 3.548093729932589e-08
C6Q0 O 0 2.2835138224763796e-06
individuals O 0 3.4575400875702655e-10
we O 0 2.1223673929426923e-09
have O 0 3.11378811623797e-10
studied O 0 2.065708137877209e-08
from O 0 5.079071607738683e-10
the O 0 1.8690153424927303e-08
Cape O 0 4.926862402498955e-06
. O 0 7.692094072808686e-07

We O 0 1.8754506925233727e-07
have O 0 2.286987266231222e-09
also O 0 5.873357356023234e-10
observed O 0 4.200849001989582e-09
the O 0 1.7271715169187019e-09
879delG O 0 1.0182306908745886e-07
defect O 0 2.7055669704623142e-08
in O 0 3.616333232869806e-09
two O 0 4.3658619830466705e-08
Dutch O 1 1.0
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.00034553208388388157
, O 0 1.4988649210678773e-09
but O 0 9.718426063898278e-10
the O 0 4.115246365898884e-09
879delG O 0 6.034618991179741e-07
defect O 0 1.1637590091595484e-07
in O 0 4.733603287121468e-09
the O 0 2.1952514472900475e-08
Cape O 0 3.4889492326328764e-06
probably O 0 1.505599200868346e-08
did O 0 1.6879083686305307e-09
not O 0 2.9917948674018646e-10
come O 0 9.162412495378192e-10
from O 0 3.1773952913205505e-10
The O 0 4.4908925467268546e-09
Netherlands O 0 1.1612147687856123e-07
. O 0 1.6713210371221976e-08
. O 0 2.330744166556542e-07

Complement B-Disease 1 1.0
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 8.006157941053971e-07
seven O 0 6.904242866312416e-08
further O 0 3.6439686823541706e-08
molecular O 0 1.1967232239840087e-05
defects O 0 8.508384780725464e-06
and O 0 3.689263117223618e-09
their O 0 5.999537755485562e-09
associated O 0 1.6020699433738628e-07
marker O 0 1.4514204167426215e-06
haplotypes O 0 2.7350824893801473e-06
. O 0 2.5077908958337503e-06

Seven O 0 6.804582994845987e-07
further O 0 4.1376559067884955e-08
molecular O 0 4.428608804118994e-07
bases O 0 1.3810389987156668e-07
of O 0 0.018054302781820297
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.26142731460277e-06
described O 0 9.886275620374363e-07
. O 0 8.239578050961427e-07

All O 0 3.9090796377649895e-08
these O 0 9.185509575182493e-10
new O 0 4.478011295105944e-09
molecular O 0 2.713992159897316e-07
defects O 0 2.0875447148682724e-07
involve O 0 6.0313887217944284e-09
single O 0 5.827275106895513e-09
- O 0 1.2479597444325918e-07
nucleotide O 0 1.6662220048146992e-08
events O 0 2.2512216535375273e-09
, O 0 4.675098641548914e-10
deletions O 0 3.097192946555083e-09
and O 0 8.82826201031861e-10
substitutions O 0 6.624790493958699e-09
, O 0 1.8885576436034057e-10
some O 0 6.196711199724092e-11
of O 0 7.063882256908016e-10
which O 0 8.068853918352659e-10
alter O 0 1.0050136722838943e-07
splice O 0 3.1732139404994086e-07
sites O 0 1.1106080499700965e-08
, O 0 2.1062123156667667e-09
and O 0 3.3349492056800045e-09
others O 0 2.0747782158991868e-08
codons O 0 6.852780529698066e-07
. O 0 1.7405333210263052e-06

They O 0 2.810073063130858e-08
are O 0 4.6445422507979117e-10
distributed O 0 6.203667024529125e-10
along O 0 1.7286612141731439e-09
the O 0 9.206983619947096e-09
C7 O 0 8.0778509072843e-06
gene O 0 1.51903423173394e-09
, O 0 7.916346744796243e-11
but O 0 1.1475739802868645e-10
predominantly O 0 1.6659566781651591e-10
towards O 0 4.0761714004133864e-09
the O 0 3.5186682456611607e-09
3 O 0 1.7068687441224029e-07
end O 0 3.6613934639717627e-07
. O 0 4.724649045328988e-07

All O 0 5.376907452614432e-08
were O 0 1.0777140069251345e-08
found O 0 7.329140072620532e-10
in O 0 3.97796490192448e-10
compound O 0 1.592369258673898e-08
heterozygous O 0 1.4628715128139902e-08
individuals O 0 1.2062483456531936e-08
. O 0 7.582536909467308e-07

The O 0 0.00015171080303844064
C6 O 1 1.0
/ O 1 0.9996328353881836
C7 O 0 0.053206827491521835
marker O 0 4.29837018600665e-06
haplotypes O 0 4.554778740839538e-07
associated O 0 9.148851631834987e-08
with O 0 1.42730627317178e-08
most O 0 2.4746674398556934e-07
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999972581863403
are O 0 7.645333255368314e-08
tabulated O 0 1.2580202337630908e-06
. O 0 4.869495739967533e-08
. O 0 5.010882659917115e-07

A O 0 7.785714842611924e-06
genome O 0 1.082487841586044e-07
- O 0 9.372190135081837e-08
wide O 0 9.351972529714203e-09
search O 0 5.216586274059409e-09
for O 0 9.176701065705117e-10
chromosomal O 0 4.379788606456714e-06
loci O 0 1.1175426152476575e-05
linked O 0 1.3016161574341822e-05
to O 0 1.3243352725567092e-07
mental O 1 0.999756395816803
health O 0 8.055833973230619e-07
wellness O 0 2.1879293399251765e-06
in O 0 1.313201813957221e-08
relatives O 0 2.09837445197536e-08
at O 0 5.161176375167997e-08
high O 0 4.894142762168485e-07
risk O 0 2.3388624015296955e-07
for O 0 2.3405766569339903e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 2.1818435058662544e-08
the O 0 1.473383548500351e-08
Old O 0 6.620434760407079e-07
Order O 0 1.9463736578018143e-07
Amish O 0 1.49660513670824e-06
. O 0 4.62147880853081e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.000707275525201112
BPAD B-Disease 1 1.0
; O 1 0.9999052286148071
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 7.342634944507154e-08
is O 0 3.4078465049880435e-10
characterized O 0 5.417616355529731e-10
by O 0 1.0170259079345101e-10
episodes O 0 7.739346052915153e-09
of O 0 3.3734060878032324e-08
mania B-Disease 0 2.576183817382116e-07
and O 0 2.5764656186311186e-08
/ O 0 7.580637611681595e-05
or O 0 2.838689852069365e-07
hypomania B-Disease 0 0.00038176545058377087
interspersed O 0 1.9998363853801493e-08
with O 0 5.824449811342447e-10
periods O 0 8.727914035944195e-08
of O 0 1.619247171902316e-07
depression B-Disease 0 2.1346906578401104e-05
. O 0 9.977783292924869e-07

Compelling O 0 1.8148546132579213e-06
evidence O 0 1.573935435317253e-07
supports O 0 7.512858779534781e-09
a O 0 1.2188289266745755e-09
significant O 0 4.505383177644262e-09
genetic O 0 1.2103805957508484e-08
component O 0 1.2772980007014212e-08
in O 0 1.4258960678859012e-09
the O 0 4.505615436301014e-09
susceptibility O 0 8.152490948987179e-08
to O 0 1.527081927577001e-08
develop O 0 1.0945292160613462e-05
BPAD B-Disease 1 1.0
. O 0 3.10755567625165e-05

To O 0 1.4726306396539712e-08
date O 0 2.300091068718757e-07
, O 0 7.353742614846226e-10
however O 0 1.0403881089970923e-09
, O 0 2.49396614471209e-10
linkage O 0 4.090908056753051e-09
studies O 0 1.31425359484183e-09
have O 0 1.1045524911379445e-10
attempted O 0 6.0395155543346846e-09
only O 0 1.8449711203238905e-10
to O 0 6.146028130871173e-10
identify O 0 5.375389733330849e-08
chromosomal O 0 3.1995894005376613e-06
loci O 0 7.343446668528486e-07
that O 0 2.833121515166681e-09
cause O 0 1.2893363532384683e-07
or O 0 4.758932803383686e-09
increase O 0 7.89409537738095e-10
the O 0 2.291471457027683e-09
risk O 0 1.7133654495182782e-08
of O 0 3.749114512174856e-07
developing O 1 0.9828810691833496
BPAD B-Disease 1 1.0
. O 0 3.0400009563891217e-05

To O 0 3.814180260519606e-08
determine O 0 7.60327694138141e-08
whether O 0 5.833669547428144e-09
there O 0 8.327352696291257e-10
could O 0 7.502644616685927e-10
be O 0 9.118965582644023e-10
protective O 0 1.3293151468474207e-08
alleles O 0 1.3351646011017237e-08
that O 0 2.956149769417493e-10
prevent O 0 2.240734930936128e-09
or O 0 1.801319204908225e-09
reduce O 0 8.400244055906114e-09
the O 0 2.4415069965755265e-09
risk O 0 2.4381810348472754e-08
of O 0 2.6402329922348144e-07
developing O 1 0.8831340670585632
BPAD B-Disease 1 1.0
, O 0 1.4177278240268265e-09
similar O 0 4.756786284310088e-11
to O 0 2.801276398345376e-11
what O 0 3.4682378496908584e-11
is O 0 1.2482287772841438e-11
observed O 0 3.3182728786940174e-10
in O 0 1.6317688866784863e-10
other O 0 7.888440123338114e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.0331919764183795e-09
we O 0 1.1132840205263506e-09
used O 0 6.4590945925147025e-09
mental O 0 0.00931036937981844
health O 0 1.1153594670076927e-07
wellness O 0 8.541233569303586e-07
( O 0 8.058333444971311e-10
absence O 0 2.3454466813177532e-08
of O 0 1.561432938501639e-08
any O 0 4.322593127881191e-08
psychiatric B-Disease 0 0.0030234509613364935
disorder I-Disease 0 1.0294667163179838e-06
) O 0 1.2069749644183503e-09
as O 0 1.2602127119620832e-09
the O 0 5.393235635864357e-09
phenotype O 0 7.1231212928069e-08
in O 0 7.592376505272114e-09
our O 0 9.227239416986777e-08
genome O 0 1.2007437710792601e-08
- O 0 1.0376166414971522e-07
wide O 0 1.1908205976851605e-07
linkage O 0 2.0689303426024708e-07
scan O 0 9.139517942458042e-07
of O 0 2.9666137990602692e-08
several O 0 1.5018180032910777e-09
large O 0 2.817746480587857e-09
multigeneration O 0 5.137996481607843e-07
Old O 0 3.973995887918136e-07
Order O 0 7.135754742648714e-08
Amish O 0 5.658849886458484e-07
pedigrees O 0 1.1733966687188513e-07
exhibiting O 0 2.7764448518041718e-08
an O 0 1.9901171821601338e-09
extremely O 0 2.2572579894131195e-07
high O 0 0.0001090860678232275
incidence O 0 0.3328407108783722
of O 1 0.9594519138336182
BPAD B-Disease 1 1.0
. O 0 0.0025696870870888233

We O 0 1.3458667069699004e-07
have O 0 9.735383610376402e-10
found O 0 5.463388630388977e-10
strong O 0 3.4901653789276565e-10
evidence O 0 2.727440939764847e-09
for O 0 1.4696407979464254e-10
a O 0 1.3481611382815117e-09
locus O 0 1.0096190550257234e-07
on O 0 1.0128881058335537e-06
chromosome O 0 2.352764568058774e-06
4p O 0 7.32565822545439e-05
at O 0 2.12619283956883e-06
D4S2949 O 0 1.2648340543819359e-06
( O 0 7.823245162796866e-09
maximum O 0 2.4106356022457476e-07
GENEHUNTER O 0 8.959650585893542e-06
- O 0 2.0570158199006983e-07
PLUS O 0 1.1143770706212308e-07
nonparametric O 0 1.1734363170035067e-06
linkage O 0 4.8698208132691434e-08
score O 0 2.995349390744195e-08
= O 0 5.839160976961466e-08
4 O 0 2.8394470774628644e-08
. O 0 1.1411291911400667e-09
05 O 0 3.009956799360225e-07
, O 0 6.924496975813099e-09
P O 0 7.177933980528906e-07
= O 0 3.390487179899537e-08
5 O 0 6.71174715805023e-09
. O 0 3.5822536603724586e-10
22 O 0 4.633819994381838e-09
x O 0 2.68737050390655e-08
10 O 0 1.4281940075022703e-08
( O 0 1.1148841849717428e-09
- O 0 5.950715031843856e-09
4 O 0 1.7756338621666146e-08
) O 0 4.353500615561501e-10
; O 0 1.1384638787248491e-09
SIBPAL O 0 1.7694943608148606e-06
Pempirical O 0 7.240864192681329e-07
value O 0 3.255777514254987e-08
< O 0 1.5438607192663767e-07
3 O 0 3.855682706443986e-08
x O 0 4.597051628252302e-08
10 O 0 1.4377711465840548e-08
( O 0 1.11215281428656e-09
- O 0 8.210803592589855e-09
5 O 0 1.2608047050832738e-08
) O 0 3.496708478323285e-10
) O 0 2.069772270241188e-10
and O 0 7.53754225701897e-10
suggestive O 0 1.7571174737440742e-08
evidence O 0 6.208712655109139e-09
for O 0 3.1700342351115296e-10
a O 0 1.5460399627187371e-09
locus O 0 8.666933837275792e-08
on O 0 1.543798930470075e-06
chromosome O 0 4.0025165617407765e-06
4q O 0 0.00011922282283194363
at O 0 3.0455030355369672e-06
D4S397 O 0 1.003980742098065e-06
( O 0 9.169934145347725e-09
maximum O 0 3.233054712836747e-07
GENEHUNTER O 0 9.20115508051822e-06
- O 0 1.794426225387724e-07
PLUS O 0 8.023220487984872e-08
nonparametric O 0 4.915791578241624e-07
linkage O 0 1.513066649749817e-08
score O 0 9.048350513296555e-09
= O 0 1.2567903162619132e-08
3 O 0 4.2963863577938355e-09
. O 0 2.3997323572721996e-10
29 O 0 7.372804144978318e-09
, O 0 1.0164136199364293e-09
P O 0 2.5355859634146327e-07
= O 0 2.635854734478471e-08
2 O 0 1.920320791271024e-08
. O 0 5.884222553653728e-10
57 O 0 3.5848117807546487e-09
x O 0 2.0942760414754957e-08
10 O 0 1.832879092944495e-08
( O 0 2.0617905160946748e-09
- O 0 1.8685234692839003e-08
3 O 0 3.6310016326979166e-08
) O 0 7.390879019908425e-10
; O 0 1.43248202189028e-09
SIBPAL O 0 2.0388010852911975e-06
Pempirical O 0 1.4259885574574582e-06
value O 0 5.371781952590027e-08
< O 0 1.737899708587065e-07
1 O 0 3.9761861359011164e-08
x O 0 5.051137108580406e-08
10 O 0 1.65760631887224e-08
( O 0 7.952004055233886e-10
- O 0 5.578951967066814e-09
3 O 0 9.636274889146534e-09
) O 0 5.703224698061504e-11
) O 0 1.7807456897944718e-11
that O 0 2.6106833708738897e-11
are O 0 3.0554381247327456e-10
linked O 0 9.690946711771176e-08
to O 0 2.790051034651242e-08
mental O 1 0.9999446868896484
health O 0 1.565197999298107e-05
wellness O 0 2.944256630144082e-05
. O 0 2.2393403469322948e-06

These O 0 3.389484959370748e-08
findings O 0 7.660717926682992e-08
are O 0 3.083716337837217e-10
consistent O 0 3.869664144673379e-09
with O 0 8.613854768357854e-11
the O 0 4.687519261636908e-10
hypothesis O 0 1.8879677821104224e-09
that O 0 1.1015012686688141e-11
certain O 0 2.7381874545540086e-10
alleles O 0 3.856195363027837e-09
could O 0 7.612585561922458e-10
prevent O 0 1.5393047947398486e-09
or O 0 4.50509768379348e-10
modify O 0 4.431424560635833e-09
the O 0 4.054327151781223e-10
clinical O 0 6.123226370391421e-09
manifestations O 0 1.104731026657646e-07
of O 0 7.796569434503908e-08
BPAD B-Disease 1 1.0
and O 0 1.2575864793973324e-08
perhaps O 0 3.5327094582982e-09
other O 0 3.90404819583523e-09
related O 0 3.1216524803312495e-05
affective B-Disease 1 0.9999872446060181
disorders I-Disease 1 0.9998409748077393
. O 0 4.489149432629347e-06

Segregation O 0 0.00024047886836342514
distortion O 1 0.5439035296440125
in O 0 1.0654046491254121e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0005028044688515365

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999998807907104
DM B-Disease 1 1.0
) O 0 4.233552886034886e-07
is O 0 1.507834190839219e-09
an O 0 1.448765107880945e-09
autosomal B-Disease 1 0.9992380142211914
dominant I-Disease 1 0.9999990463256836
disease I-Disease 0 0.3437967300415039
which O 0 7.074520969041487e-10
, O 0 7.357400799712366e-11
in O 0 1.084352260760646e-10
the O 0 6.343906511219188e-10
typical O 0 2.130954523948958e-09
pedigree O 0 5.593677521176232e-09
, O 0 2.2612131611587927e-10
shows O 0 8.868140666251634e-10
a O 0 1.4732929320970811e-09
three O 0 3.248790791943179e-09
generation O 0 1.7591688106222136e-07
anticipation O 0 3.91683101952367e-07
cascade O 0 1.8734821196630946e-06
. O 0 1.1618952839853591e-06

This O 0 1.0192912291984157e-08
results O 0 6.701656474206175e-08
in O 0 1.0213774714884494e-08
infertility B-Disease 0 0.0011226293863728642
and O 0 0.029728814959526062
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0022065844386816025
CDM B-Disease 0 0.0003299314994364977
) O 0 5.231290400864452e-10
with O 0 1.6308790429242492e-10
the O 0 7.867373419401247e-09
disappearance O 0 3.9873509649623884e-07
of O 0 4.7633764665988565e-07
DM B-Disease 1 1.0
in O 0 2.4353365546403438e-08
that O 0 3.913158241886094e-09
pedigree O 0 5.801438192065689e-07
. O 0 7.711426519563247e-07

The O 0 7.233183652033404e-08
concept O 0 8.561681141827648e-08
of O 0 3.963042161103658e-08
segregation O 0 2.491870247922634e-07
distortion O 0 4.5646629587281495e-07
, O 0 2.0960003177528108e-10
where O 0 1.323075954351438e-10
there O 0 6.242691780178333e-11
is O 0 2.6937197264431667e-11
preferential O 0 1.5843432121798173e-09
transmission O 0 1.259876825088213e-08
of O 0 1.6749647224756359e-09
the O 0 1.4593287689379508e-09
larger O 0 1.841617858211464e-09
allele O 0 1.996970055984093e-08
at O 0 5.741598485542454e-08
the O 0 7.552944936151107e-09
DM B-Disease 1 1.0
locus O 0 8.101213921918315e-08
, O 0 5.271173497689574e-10
has O 0 1.1377208897211943e-10
been O 0 4.831973710039961e-10
put O 0 4.1210430623550565e-09
forward O 0 2.7511733335927602e-08
to O 0 3.043423069115647e-09
explain O 0 3.549873994757036e-08
partially O 0 8.769514892037478e-08
the O 0 9.20765064194029e-09
maintenance O 0 1.0126024818646329e-07
of O 0 2.970600689877756e-07
DM B-Disease 1 1.0
in O 0 3.379408397563566e-08
the O 0 1.0584082943410067e-08
population O 0 2.0082321916525814e-10
. O 0 4.200170167223405e-08

In O 0 3.0311466048260627e-07
a O 0 6.32870893468862e-08
survey O 0 3.855814867392837e-08
of O 0 1.1744042183181591e-07
DM B-Disease 1 1.0
in O 0 3.319054542316735e-08
Northern O 0 1.610218731684654e-07
Ireland O 0 3.217313349068718e-07
, O 0 1.0478648171385885e-08
59 O 0 4.973509248884511e-08
pedigrees O 0 2.4565267153775494e-07
were O 0 4.1045016274665613e-08
ascertained O 0 3.851625933748437e-06
. O 0 9.190439413941931e-07

Sibships O 0 1.4150401511869859e-05
where O 0 1.49680872141289e-08
the O 0 6.226807403031387e-10
status O 0 1.3346802552050008e-09
of O 0 1.122563597633075e-09
all O 0 6.906182570265429e-11
the O 0 1.3920092856167798e-10
members O 0 7.01119370893899e-11
had O 0 3.417141014594449e-10
been O 0 2.3540805416111255e-10
identified O 0 2.1700308217020847e-09
were O 0 2.144667332615313e-09
examined O 0 2.2460033832771842e-08
to O 0 8.864098899330486e-10
determine O 0 2.7030342408806973e-08
the O 0 1.3069698212575531e-08
transmission O 0 5.972229701001197e-06
of O 0 1.2902702337669325e-06
the O 0 1.1362362783984281e-05
DM B-Disease 1 1.0
expansion O 0 1.3549307595894788e-06
from O 0 5.771724431724579e-09
affected O 0 2.582298819220341e-09
parents O 0 1.7840033617044782e-10
to O 0 4.2774309094717466e-10
their O 0 2.672234655776151e-09
offspring O 0 3.7448046441568295e-08
. O 0 1.8923317668395612e-07

Where O 0 2.1450493647989788e-07
the O 0 4.650495100122498e-08
transmitting O 0 1.6622151406409102e-06
parent O 0 5.1515087307052454e-08
was O 0 9.815602908247456e-08
male O 0 2.0290832125624547e-08
, O 0 1.167616137109917e-08
58 O 0 4.568381939407118e-07
. O 0 1.0900070037678233e-06

3 O 0 9.567615961714182e-07
% O 0 2.112988450875264e-09
of O 0 2.1912176517702164e-09
the O 0 9.142999135569596e-10
offspring O 0 1.3287821953866796e-09
were O 0 1.2013868788685045e-09
affected O 0 9.007330437071914e-10
, O 0 1.4650676505301163e-10
and O 0 1.4484879962139985e-10
in O 0 2.1217916312821217e-10
the O 0 5.987782492056226e-10
case O 0 2.437086976669889e-09
of O 0 1.7280677999664817e-09
a O 0 2.8729270074023816e-09
female O 0 2.9537405410451356e-08
transmitting O 0 2.399477580183884e-06
parent O 0 3.789063498516043e-07
, O 0 2.0846601955781807e-07
68 O 0 6.417225904442603e-06
. O 0 7.342575372604188e-06

7 O 0 4.538108896667836e-06
% O 0 3.6393632996123415e-08
were O 0 8.348336422159264e-08
affected O 0 1.1849309800027186e-07
. O 0 4.275387937013875e-07

Studies O 0 1.4444208318309393e-06
on O 0 8.439914722657704e-07
meiotic O 0 1.2292134670133237e-05
drive O 0 6.551140927513188e-07
in O 0 6.354957093890334e-08
DM B-Disease 1 1.0
have O 0 1.9312731414089512e-09
shown O 0 3.932542624873747e-10
increased O 0 5.232168587276931e-10
transmission O 0 7.295836823573154e-09
of O 0 8.54314230469555e-10
the O 0 4.895986394082286e-10
larger O 0 8.830349784716418e-10
allele O 0 1.0171588016305577e-08
at O 0 3.0245939086626095e-08
the O 0 1.179211750468312e-08
DM B-Disease 1 0.9999982118606567
locus O 0 1.4221355115751066e-07
in O 0 8.874727619456735e-09
non O 0 2.9783379886794137e-06
- O 0 4.8016110667958856e-05
DM O 1 1.0
heterozygotes O 0 8.360206038560136e-07
for O 0 1.277858441284252e-08
CTGn O 0 1.505834370618686e-05
. O 0 8.305888172799314e-07

This O 0 1.8135756008064163e-08
study O 0 1.8040698934740362e-09
provides O 0 1.942128680099131e-10
further O 0 2.370635077131311e-10
evidence O 0 3.5517619956237922e-09
that O 0 2.2590661286070457e-10
the O 0 1.04075184026442e-08
DM B-Disease 1 1.0
expansion O 0 1.0768494007606932e-07
tends O 0 1.338578936582735e-08
to O 0 7.559469716866829e-10
be O 0 3.455695729570607e-09
transmitted O 0 3.542441007198249e-08
preferentially O 0 5.188843488213024e-08
. O 0 1.3965920686587197e-07

Diagnosis O 1 0.9999703168869019
of O 0 0.010841342620551586
hemochromatosis B-Disease 1 1.0
. O 0 0.000511917460244149

If O 0 7.157262189139146e-06
untreated O 1 0.9998292922973633
, O 0 7.992456403371762e-07
hemochromatosis B-Disease 1 1.0
can O 0 1.4902459497534437e-06
cause O 0 8.929984323913231e-05
serious O 0 0.051683951169252396
illness O 0 0.00047433626605197787
and O 0 2.461515213880716e-09
early B-Disease 0 9.860713845455393e-08
death I-Disease 0 2.456500851621968e-07
, O 0 3.0890084934398487e-10
but O 0 6.614408465388522e-10
the O 0 5.7005875575555365e-09
disease O 0 1.3362860329380055e-07
is O 0 2.8963750842159186e-10
still O 0 1.113216185899546e-09
substantially O 0 2.590059544615997e-08
under O 0 3.569775799405761e-07
- O 0 0.001485003624111414
diagnosed O 0 0.00014331589045468718
. O 0 9.345098987978417e-07

The O 0 3.1648184517507616e-07
cornerstone O 0 5.878994670638349e-06
of O 0 9.132337552841818e-09
screening O 0 1.610183431033363e-09
and O 0 3.6346353704530543e-10
case O 0 1.3812799792844999e-09
detection O 0 1.0362120050899648e-08
is O 0 1.2527683057594885e-10
the O 0 5.425299653971649e-10
measurement O 0 1.7144344610642293e-08
of O 0 2.9201414619706156e-08
serum O 0 3.349638788563425e-08
transferrin O 0 2.7075395792053314e-07
saturation O 0 2.7281819825475395e-07
and O 0 5.619620768726463e-09
the O 0 1.754016842880901e-08
serum O 0 1.0460580313065293e-07
ferritin O 0 2.3717061594652478e-06
level O 0 3.6507976801658515e-06
. O 0 2.1040479225575837e-07

Once O 0 7.61304193019896e-07
the O 0 2.2016838130411998e-08
diagnosis O 0 3.0500809771183413e-06
is O 0 5.763118871016104e-10
suspected O 0 1.176670583191708e-08
, O 0 7.151935710325574e-10
physicians O 0 3.382218505265655e-09
must O 0 4.985416524050379e-09
use O 0 2.265925580502426e-08
serum O 0 5.814659971292713e-07
ferritin O 0 0.00013654277427121997
levels O 0 9.480191511102021e-05
and O 0 1.0305718660674756e-06
hepatic O 1 0.9996021389961243
iron O 0 0.14561377465724945
stores O 0 1.1769134289352223e-07
on O 0 3.922692428659502e-07
liver O 0 7.473131091728646e-08
biopsy O 0 1.1197800020568138e-08
specimens O 0 1.035093455392655e-09
to O 0 1.3245077257195703e-10
assess O 0 1.1554952550341113e-08
patients O 0 2.0384531562722685e-10
for O 0 1.9890611380191103e-10
the O 0 1.6809430514186374e-09
presence O 0 8.176484378452642e-09
of O 0 2.4528699782422336e-07
iron B-Disease 1 0.998955488204956
overload I-Disease 0 0.13159802556037903
. O 0 5.718586635339307e-06

Liver O 0 0.000658117700368166
biopsy O 0 0.00035182261490263045
is O 0 7.744190178016197e-09
also O 0 4.5410900040288027e-10
used O 0 1.6730608565218574e-10
to O 0 1.8463229556342498e-10
establish O 0 1.1122631704552077e-09
the O 0 2.6874549807764936e-10
presence O 0 3.4081323874168845e-10
or O 0 2.038912816360039e-09
absence O 0 1.0768042102426989e-07
of O 0 7.952830571866798e-08
cirrhosis B-Disease 1 0.9972665309906006
, O 0 1.36340516654343e-09
which O 0 2.1957013984774676e-10
can O 0 2.52256171506815e-09
affect O 0 9.789315669195275e-08
prognosis O 0 2.888527887989767e-06
and O 0 3.728625586063572e-08
management O 0 5.427006612990226e-07
. O 0 3.4468573062440555e-07

A O 0 1.2341658930381527e-06
DNA O 0 1.3882608129733853e-07
- O 0 2.2198577198651037e-08
based O 0 5.192303254020203e-10
test O 0 3.781148283366065e-09
for O 0 3.656350500147454e-10
the O 0 4.321988988920111e-09
HFE O 0 3.6077624372410355e-06
gene O 0 3.638389811655429e-09
is O 0 1.4942740100831742e-10
commercially O 0 6.964003818055176e-10
available O 0 3.1000399469682804e-10
, O 0 5.202174108154267e-11
but O 0 3.5494964606419543e-11
its O 0 2.8066137955362613e-11
place O 0 1.2618434075406526e-09
in O 0 3.3796094395244225e-11
the O 0 1.0826514684758592e-10
diagnosis O 0 1.710362340645588e-07
of O 0 4.728083524696558e-08
hemochromatosis B-Disease 1 1.0
is O 0 1.2831265827628613e-08
still O 0 7.93782461983028e-09
being O 0 3.087474098606435e-08
evaluated O 0 3.298254966921377e-07
. O 0 3.0267932515926077e-07

Currently O 0 4.200787202535139e-07
, O 0 3.993155583970065e-09
the O 0 1.4513843460406406e-09
most O 0 7.042985639138521e-11
useful O 0 6.356345449987089e-10
role O 0 1.7436678489968216e-10
for O 0 3.377715121488656e-11
this O 0 1.9953906582603764e-11
test O 0 1.7532799656549969e-09
is O 0 4.7875151759635415e-11
in O 0 3.3903078261454667e-11
the O 0 2.1746288103585698e-10
detection O 0 5.6616034527223746e-08
of O 0 1.0897799285203291e-07
hemochromatosis B-Disease 1 1.0
in O 0 7.482672970127169e-08
the O 0 4.2160461788398607e-08
family O 0 1.7920597228382462e-09
members O 0 2.966293877193493e-10
of O 0 1.1206895411675077e-09
patients O 0 3.6044114914979275e-10
with O 0 1.5097095795724158e-10
a O 0 2.79978884520915e-09
proven O 0 1.78881839474343e-06
case O 0 5.406725449574878e-07
of O 0 1.5991878399290727e-06
the O 0 4.600455213221721e-06
disease O 0 0.0011491221375763416
. O 0 1.9977412648586323e-06

It O 0 2.097634066444698e-08
is O 0 2.2027832891069465e-09
crucial O 0 8.142637852870394e-08
to O 0 3.5819155641547695e-08
diagnose O 1 0.9999986886978149
hemochromatosis B-Disease 1 1.0
before O 1 0.9999755620956421
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.0008852661121636629
because O 0 1.0635407221570858e-07
phlebotomy O 0 0.17067740857601166
therapy O 0 3.3187920053023845e-05
can O 0 1.5275945841608518e-08
avert O 0 1.1259542588959448e-05
serious O 1 0.9999861717224121
chronic O 1 1.0
disease O 1 0.9999998807907104
and O 0 2.490582851066847e-09
can O 0 7.204372654001645e-10
even O 0 2.654884090347309e-10
lead O 0 6.515713524279931e-10
to O 0 2.6692431598362987e-10
normal O 0 1.394705506641003e-08
life O 0 3.356166677903616e-09
expectancy O 0 2.665611953389657e-09
. O 0 1.1774557995281043e-09
. O 0 4.2937507771512173e-08

Prevalence O 0 4.994460141460877e-06
of O 0 1.238127680380785e-07
the O 0 5.022335969329106e-08
I1307K O 0 1.0524386198085267e-06
APC B-Disease 0 7.473245489109104e-08
gene O 0 5.719469897691454e-10
variant O 0 4.78421569027887e-09
in O 0 3.252844382739539e-10
Israeli O 0 6.896053950100622e-09
Jews O 0 1.089918155727787e-09
of O 0 3.2177205344652293e-10
differing O 0 6.842907351867211e-10
ethnic O 0 2.780151386883034e-10
origin O 0 3.2383724590800966e-09
and O 0 8.954643249126093e-09
risk O 0 1.3626423651658115e-06
for O 0 0.11010302603244781
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.998988926410675

BACKGROUND O 0 5.627256541629322e-06
& O 0 2.2875572085467866e-06
AIMS O 0 3.3094656259891053e-07
Israeli O 0 1.7855889211659814e-07
Jews O 0 1.681938144315609e-08
of O 0 1.9455008271052066e-08
European O 0 4.808570963632519e-08
birth O 0 2.1339857880775526e-08
, O 0 1.0322661614381445e-09
i O 0 8.923033867347385e-09
. O 0 9.276447388018028e-10
e O 0 6.9268746294426364e-09
. O 0 2.122658937508959e-09
, O 0 3.706373874479141e-09
Ashkenazim O 0 1.5092439298314275e-06
, O 0 1.7259926821111549e-09
have O 0 8.887021119008409e-10
the O 0 2.2175216329856084e-08
highest O 1 0.9999241828918457
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 6.52613744023256e-05
of O 0 5.495657617871075e-08
any O 0 4.873553560713617e-09
Israeli O 0 6.518448003589583e-07
ethnic O 0 2.967553136556944e-08
group O 0 3.0396307693081326e-08
. O 0 6.025796892572544e-07

The O 0 1.2688401511695702e-06
I1307K O 0 9.033090464072302e-06
APC B-Disease 0 8.202063099815859e-07
gene O 0 1.5233990069418724e-08
variant O 0 1.2802081528207054e-07
was O 0 5.7537672404350815e-08
found O 0 5.961165783219258e-09
in O 0 8.038886889494279e-09
6 O 0 2.002234850806417e-06
. O 0 9.73927967606869e-07

1 O 0 3.970086481785984e-07
% O 0 1.3808031384954234e-09
of O 0 1.1074008376965594e-09
American O 0 6.479030645323292e-10
Jews O 0 1.4993308816713125e-09
, O 0 2.174545821187479e-10
28 O 0 3.905991974306744e-09
% O 0 1.6961369808665694e-10
of O 0 2.2532922194784533e-09
their O 0 1.8974092199641746e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.5572364140534773e-05
, O 0 1.1064634763968684e-09
but O 0 4.898770278316533e-10
not O 0 2.944877675048474e-10
in O 0 7.669366253182375e-10
non O 0 3.68005146356154e-08
- O 0 5.168416805645393e-08
Jews O 0 5.8858560691987805e-08
. O 0 2.781056593903486e-07

We O 0 5.514273198059527e-07
assessed O 0 1.0174235285376199e-06
the O 0 1.4312263374449685e-08
I1307K O 0 1.5543379561222537e-07
prevalence O 0 8.05810707049659e-09
in O 0 6.892576093209257e-11
Israeli O 0 2.2259365461962943e-09
Jews O 0 3.2842148445233477e-10
of O 0 1.2923628833760858e-10
differing O 0 1.4434216322189997e-10
ethnic O 0 6.87443088565054e-11
origin O 0 1.1214122963565387e-09
and O 0 4.360450223117596e-09
risk O 0 1.1030672339984449e-06
for O 0 0.0009268231224268675
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.8532247543334961

METHODS O 0 5.7701964806256e-07
DNA O 0 2.1969102093066795e-08
samples O 0 5.87299875398628e-10
from O 0 2.7612903630291896e-10
500 O 0 1.0296528074604794e-09
unrelated O 0 1.7982674238581353e-09
Jews O 0 3.459593278520856e-09
of O 0 9.942143996966024e-09
European O 0 8.706067688990515e-08
or O 0 1.3431670886632219e-08
non O 0 2.8615568226086907e-07
- O 0 1.88781754673073e-08
European O 0 1.0523453219946077e-08
origin O 0 2.974567037128395e-09
, O 0 1.77740752671518e-10
with O 0 3.834108724953822e-11
or O 0 2.1984421227916329e-10
without O 0 3.95333682456922e-10
a O 0 3.194860764832441e-10
personal O 0 4.74511985260051e-09
and O 0 2.3755530875746445e-08
/ O 0 3.333359563839622e-05
or O 0 1.0630175495407457e-07
family O 0 5.330118124646788e-09
history O 0 2.0797902067215546e-08
of O 0 5.761871690879161e-08
neoplasia B-Disease 0 6.305662100203335e-05
, O 0 1.571612884276874e-08
were O 0 3.736699483170014e-08
examined O 0 1.5715400536464585e-07
for O 0 1.7508271499266925e-09
the O 0 8.729541534080454e-09
I1307K O 0 1.5108324191714928e-07
variant O 0 4.6318344715245985e-08
by O 0 1.1367236041337492e-09
the O 0 9.329417238745918e-09
allele O 0 9.834717928924874e-08
- O 0 3.642308143980699e-08
specific O 0 4.661228736324574e-09
oligonucleotide O 0 4.126189878661535e-07
( O 0 7.373619936856812e-09
ASO O 0 3.944486707041506e-06
) O 0 4.3765484569746604e-09
method O 0 1.2395169335377432e-07
. O 0 1.7019127085404762e-07

RESULTS O 0 5.135731498739915e-06
In O 0 4.286607335757253e-08
persons O 0 1.2702765062044818e-08
at O 0 2.0493160945989075e-08
average O 0 1.9608108470237084e-09
risk O 0 9.823110325157813e-09
for O 0 1.527748281660024e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.131422919797842e-07
I1307K O 0 2.2859816795062216e-07
was O 0 2.503949581011966e-08
found O 0 9.022633751243347e-10
in O 0 1.4891421429297225e-09
5 O 0 1.8621872754920332e-07
. O 0 3.9207063196045056e-07

0 O 0 1.500509711149789e-06
% O 0 5.298917749030352e-09
of O 0 1.1581342107547243e-08
120 O 0 1.918058600836048e-08
European O 0 4.387943164374519e-08
and O 0 2.4574445589564675e-08
1 O 0 9.958447435565176e-07
. O 0 2.1760465074294189e-07

6 O 0 4.705256287707016e-06
% O 0 6.082276460261937e-09
of O 0 1.3279821686751347e-08
188 O 0 2.5219089039296705e-08
non O 0 9.385910715309365e-08
- O 0 3.457174102550198e-08
European O 0 1.8577416938114766e-08
Jews O 0 1.75040053562725e-08
( O 0 1.3499854567555758e-09
P O 0 1.9679876572809007e-07
= O 0 1.5966453048577023e-08
0 O 0 9.444522497403796e-09
. O 0 1.2510616986816103e-09
08 O 0 1.4974646944665437e-07
) O 0 4.479822290903712e-09
. O 0 9.645490450793659e-08

It O 0 1.9204525969485076e-08
occurred O 0 3.1714805004412483e-07
in O 0 6.823074549799912e-09
15 O 0 1.638889131072574e-07
. O 0 4.394912025418307e-07

4 O 0 3.444702542765299e-06
% O 0 9.822079150012542e-09
of O 0 2.8802642049186034e-08
52 O 0 1.3735127879499487e-07
Ashkenazi O 0 2.0654096033467795e-07
Israelis O 0 9.258938149514506e-08
with O 0 8.364749781719638e-09
familial O 0 3.5315866853125044e-07
cancer B-Disease 0 1.3843978194927331e-06
( O 0 8.684208552267592e-08
P O 0 0.00020973484788555652
= O 0 7.895922635725583e-07
0 O 0 7.64020242627339e-08
. O 0 9.207892226470449e-10
02 O 0 5.9452496259382315e-08
) O 0 1.1237156344323651e-10
and O 0 1.565878399167886e-10
was O 0 1.0467875455333342e-09
not O 0 9.190621874655136e-11
detected O 0 7.059962614519577e-10
in O 0 5.304841010911332e-10
51 O 0 2.9210607266350053e-08
non O 0 7.702664674980042e-07
- O 0 5.921348247284186e-07
European O 0 1.9062005662817683e-07
Jews O 0 4.169304901324722e-08
at O 0 6.896924986676822e-08
increased O 0 8.140367491193956e-09
cancer B-Disease 0 1.3608537585696467e-07
risk O 0 1.0213583578888574e-07
. O 0 7.863361588533735e-07

Colorectal B-Disease 1 0.999988317489624
neoplasia I-Disease 1 0.999430239200592
occurred O 0 0.000750112347304821
personally O 0 2.315664886509694e-07
or O 0 2.537202004049277e-09
in O 0 5.655596546638719e-10
the O 0 4.836215317105541e-10
families O 0 7.66611565894415e-11
of O 0 2.1542443384703347e-09
13 O 0 4.328648728346707e-08
of O 0 8.289833886010456e-08
20 O 0 5.167101448932954e-07
Ashkenazi O 0 3.7666359276045114e-07
I1307K O 0 3.5850806057169393e-07
carriers O 0 3.033356676951371e-09
, O 0 2.9191709050024883e-09
8 O 0 9.19463190030001e-08
of O 0 2.262587273094141e-08
whom O 0 7.589078165892715e-08
also O 0 6.697693066826105e-09
had O 0 5.9534506213765326e-09
a O 0 9.557413749305965e-10
personal O 0 1.8959148917474522e-08
or O 0 1.3877584414956345e-08
family O 0 2.129479703683046e-09
history O 0 2.5880201093286814e-08
of O 0 2.0862968597157305e-07
noncolonic O 0 0.00019308904302306473
neoplasia B-Disease 1 0.8381494879722595
. O 0 0.00019066566892433912

CONCLUSIONS O 0 3.3105348848039284e-05
The O 0 6.776916734452243e-07
I1307K O 0 6.6102552409574855e-06
APC O 0 6.553671596520871e-07
variant O 0 2.6483556325729296e-07
may O 0 1.8624461972649442e-08
represent O 0 5.168433681035367e-09
a O 0 4.6945451970259455e-09
susceptibility O 0 9.31631518596987e-08
gene O 0 2.4175463408937503e-08
for O 0 2.3439037377670502e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.8159437331632944e-07
or I-Disease 0 3.876639809163862e-08
other I-Disease 0 1.305207941726394e-09
, I-Disease 0 7.264991941369203e-10
cancers I-Disease 0 2.3011962113628215e-08
in O 0 1.2768782697847314e-09
Ashkenazi O 0 7.005228042089584e-08
Jews O 0 1.466500521019043e-08
, O 0 1.4098269218720816e-09
and O 0 2.428192313885802e-09
partially O 0 8.035380005821935e-08
explains O 0 7.143009739252193e-09
the O 0 1.7876216062973072e-09
higher O 0 8.262247206403117e-07
incidence O 1 0.99982088804245
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.542929112474667e-06
European O 0 7.842138984415215e-06
Israelis O 0 6.703870440105675e-06
. O 0 4.4212791294739873e-07

Systematic O 0 1.8396954715171887e-07
analysis O 0 4.1643534842705776e-08
of O 0 7.103218280235524e-08
coproporphyrinogen O 0 1.8820128389052115e-05
oxidase O 0 2.198009951825952e-06
gene O 0 2.987396499065653e-07
defects O 0 6.628788923990214e-06
in O 0 2.7429889470909075e-08
hereditary B-Disease 1 0.9999911785125732
coproporphyria I-Disease 1 0.6395423412322998
and O 0 4.242173758939316e-07
mutation O 0 4.17379681039165e-07
update O 0 5.998195319989463e-06
. O 0 1.8546882074588211e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999998807907104
( O 0 3.054863555007614e-05
HC B-Disease 1 1.0
) O 0 1.4728713892964151e-07
is O 0 1.6107762901285128e-09
an O 0 1.1302313529526486e-09
acute O 1 0.9999986886978149
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9034714102745056
autosomal O 1 1.0
dominant O 1 0.9998130202293396
inheritance O 0 1.07687401396106e-05
caused O 0 1.8487462227767537e-07
by O 0 7.687878111894975e-10
deficient B-Disease 0 3.306341866959883e-08
activity I-Disease 0 1.2639807422942795e-08
of I-Disease 0 3.743376097986584e-08
coproporphyrinogen I-Disease 0 1.245720113729476e-06
III I-Disease 0 0.023942692205309868
oxidase I-Disease 0 1.0070723419630667e-06
( O 0 3.695081929322441e-08
CPO O 0 2.945352434835513e-06
) O 0 2.4208963722571752e-08
. O 0 3.9676677943134564e-07

Clinical O 0 0.00042740421486087143
manifestations O 0 0.01122046448290348
of O 0 5.659186172124464e-06
the O 0 9.191000458486087e-07
disease O 0 0.0003515196731314063
are O 0 2.4187754577020826e-10
characterized O 0 1.0449842102744356e-09
by O 0 2.0363935537837108e-10
acute O 0 5.5257161875488237e-05
attacks O 0 8.594581686338643e-07
of O 1 0.9999997615814209
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.102726869817161e-07
precipitated O 0 5.17696072677154e-08
by O 0 3.775093293523213e-10
drugs O 0 3.2811358074980035e-09
, O 0 3.476129162294228e-09
fasting O 0 9.648891818869743e-07
, O 0 1.9009554819149344e-08
cyclical O 0 5.5537839216412976e-05
hormonal O 0 5.345440513337962e-06
changes O 0 8.101304729279946e-07
, O 0 8.67377991653484e-08
or O 0 9.172023965220433e-06
infectious B-Disease 0 0.0916900485754013
diseases I-Disease 0 0.008585607632994652
. O 0 2.021382670136518e-06

Skin O 1 1.0
photosensitivity O 1 0.9999566078186035
may O 0 9.634818525228184e-06
also O 0 1.5615135851021478e-08
be O 0 5.4571636098899035e-09
present O 0 1.2876842703235525e-08
. O 0 1.287733937260782e-07

The O 0 3.6726893881677825e-07
seven O 0 2.505536258468055e-07
exons O 0 2.3734658327612124e-07
, O 0 2.7099762434090735e-09
the O 0 9.544102397285315e-09
exon O 0 1.8226269560273067e-07
/ O 0 2.2901669183283957e-07
intron O 0 9.62292503459139e-08
boundaries O 0 7.993904205250146e-09
and O 0 5.57705548409615e-10
part O 0 2.42109721160233e-10
of O 0 4.985549750813334e-09
3 O 0 1.009956136499568e-07
noncoding O 0 4.3724373455233945e-08
sequence O 0 2.0841295356177625e-09
of O 0 4.13575262925292e-09
the O 0 4.923276897272899e-09
CPO O 0 2.2349593109538546e-07
gene O 0 3.2825631102184616e-09
were O 0 2.7307931471654e-09
systematically O 0 9.769967945771896e-09
analyzed O 0 3.728780395562126e-09
by O 0 2.6806104558296795e-10
an O 0 4.5567941087121255e-10
exon O 0 2.8275895402885e-08
- O 0 6.963305310137002e-08
by O 0 1.3692120326425083e-08
- O 0 3.937680503440788e-06
exon O 0 1.791327917999297e-06
denaturing O 0 2.4700118956388906e-05
gradient O 0 3.851835117529845e-06
gel O 0 4.807159257325111e-07
electrophoresis O 0 7.898108123072234e-08
( O 0 4.221693217232314e-09
DGGE O 0 1.1457400432846043e-06
) O 0 3.708549856096255e-10
strategy O 0 4.001190934133092e-09
followed O 0 4.4631892626156855e-10
by O 0 4.3377669511901473e-11
direct O 0 2.561156287050892e-10
sequencing O 0 1.2712551011873074e-09
in O 0 6.1220667424422e-10
seven O 0 9.281867718868853e-09
unrelated O 0 6.524462037305057e-08
heterozygous O 0 2.131647249825619e-07
HC B-Disease 0 0.19482147693634033
patients O 0 2.026383683073618e-08
from O 0 6.914862460405402e-09
France O 0 1.5272995597115369e-06
, O 0 1.4962036942733903e-08
Holland O 0 1.0143302233700524e-06
, O 0 3.0730435973680414e-09
and O 0 2.4675836929333173e-09
Czech O 0 1.0086217798743746e-06
Republic O 0 9.976384717447218e-06
. O 0 1.1682659533107653e-05

Seven O 0 3.7204353020570124e-07
novel O 0 3.218816502226218e-08
mutations O 0 1.304076402419696e-08
and O 0 1.559750550939043e-09
two O 0 1.2423182482734774e-09
new O 0 8.813090701664805e-09
polymorphisms O 0 3.645157420351097e-08
were O 0 4.3122501125480994e-08
detected O 0 3.340907426263584e-07
. O 0 6.994159775786102e-07

Among O 0 7.090874021287163e-08
these O 0 3.776909895947256e-09
mutations O 0 4.940491127314317e-09
two O 0 1.1742262717717722e-09
are O 0 7.676141944301662e-10
missense O 0 1.953037696011961e-07
( O 0 4.172739931362912e-09
G197W O 0 3.3720817782523227e-07
, O 0 4.610845039110245e-09
W427R O 0 1.9129367956338683e-07
) O 0 2.1186705723152954e-09
, O 0 6.852219347486255e-10
two O 0 9.65549529219345e-10
are O 0 7.554669667619862e-10
nonsense O 0 1.2335628696291678e-07
( O 0 2.284850975087238e-09
Q306X O 0 1.6966151861197432e-07
, O 0 2.2219492912256555e-09
Q385X O 0 1.097079262990519e-07
) O 0 1.3011587363109811e-09
, O 0 3.095661782470671e-10
two O 0 3.4868516407549066e-10
are O 0 1.55577731253409e-10
small O 0 1.0766841862519527e-09
deletions O 0 1.8776729504565992e-08
( O 0 3.410989268815001e-09
662de14bp O 0 1.4020835692463152e-07
; O 0 5.600894414925506e-09
1168del3bp O 0 8.090465257737378e-07
removing O 0 2.969844388189813e-07
a O 0 4.7214324894184756e-08
glycine O 0 1.0217169688075955e-07
at O 0 1.6233880728577788e-07
position O 0 1.398124567231207e-07
390 O 0 2.986882918776246e-08
) O 0 1.9118255589756217e-10
, O 0 1.0045829446081456e-10
and O 0 2.2058849191708418e-10
one O 0 3.1914074161143446e-10
is O 0 1.8838160198431098e-10
a O 0 2.9676874291340027e-09
splicing O 0 1.3186640046569664e-07
mutation O 0 7.745300933947874e-08
( O 0 1.9785291627272272e-08
IVS1 O 0 1.5504130715271458e-05
- O 0 1.1046863619412761e-06
15c O 0 1.4318784451461397e-06
- O 0 4.136603592996835e-07
- O 0 2.455371941323392e-07
> O 0 1.0486709101087399e-07
g O 0 1.5197944236433614e-08
) O 0 1.7624422754547453e-10
which O 0 1.4580121832086235e-10
creates O 0 7.694128112412102e-10
a O 0 3.727882447179809e-10
new O 0 7.404678536993003e-10
acceptor O 0 1.7811959684976841e-09
splice O 0 7.891970312812191e-07
site O 0 1.8243224531033775e-07
. O 0 2.887561549869133e-07

The O 0 2.2875083516282757e-07
pathological O 0 4.321975097809627e-07
significance O 0 5.127589375319985e-08
of O 0 2.022229139697629e-08
the O 0 3.6923182289427814e-09
point O 0 2.9850948379817055e-08
mutations O 0 1.1046588532792612e-08
G197W O 0 1.0157981478187139e-07
, O 0 1.975828167743998e-09
W427R O 0 1.1866928417703093e-07
, O 0 8.578231458500341e-10
and O 0 1.4043278762088107e-09
the O 0 2.1546264772354107e-09
in O 0 3.733213738144059e-09
- O 0 4.086932392510789e-08
frame O 0 6.145917268440826e-07
deletion O 0 4.90706035805033e-08
390delGly O 0 1.0662949989637127e-07
were O 0 3.382553792619092e-09
assessed O 0 1.4226531064309711e-08
by O 0 1.8272436341781884e-10
their O 0 1.178084851893857e-09
respective O 0 2.32318946302712e-08
expression O 0 6.40054764744491e-09
in O 0 2.089080686218381e-09
a O 0 6.958041920412938e-10
prokaryotic O 0 1.924852277568334e-09
system O 0 1.093772961091588e-09
using O 0 5.931493074484706e-10
site O 0 1.3881158444917219e-08
- O 0 1.87803816942278e-08
directed O 0 1.1115935727445958e-08
mutagenesis O 0 3.8082596347521758e-06
. O 0 1.7395642544215661e-06

These O 0 8.251532079839308e-08
mutations O 0 6.453741008272118e-08
resulted O 0 3.463443931650545e-08
in O 0 1.2046773578688885e-09
the O 0 2.277914967763195e-09
absence O 0 4.549763943373364e-08
or O 0 1.882107358852636e-09
a O 0 7.436921634074167e-10
dramatic O 0 1.0678251172180353e-08
decrease O 0 3.4010511740234506e-08
of O 0 6.37174252915429e-07
CPO O 0 5.278272874420509e-05
activity O 0 6.684392701572506e-06
. O 0 2.5083911623369204e-06

The O 0 1.5412039999773697e-07
two O 0 9.946487189438358e-09
polymorphisms O 0 1.2314690600589984e-08
were O 0 3.4756386657619487e-09
localized O 0 2.0794768573750844e-08
in O 0 5.0420863040301356e-09
noncoding O 0 8.189504541178394e-08
part O 0 4.293421174139667e-09
of O 0 1.756537670871694e-08
the O 0 3.606483112150727e-09
gene O 0 4.1143341511507003e-10
1 O 0 1.6137754244027747e-08
) O 0 2.8828775477940383e-10
a O 0 3.7093301763491127e-09
C O 0 4.4941342025595077e-07
/ O 0 2.6230915750602435e-07
G O 0 1.7404256880126923e-07
polymorphism O 0 3.289892092084301e-08
in O 0 1.44209322261446e-09
the O 0 5.365287769620863e-09
promotor O 0 1.933677367560449e-06
region O 0 3.9188066125461773e-08
, O 0 8.547449859008793e-09
142 O 0 3.3910822594407364e-08
bp O 0 5.177316353410788e-08
upstream O 0 4.728306191026377e-09
from O 0 6.090527526758649e-10
the O 0 3.191074293695806e-09
transcriptional O 0 1.8884657393414273e-08
initiation O 0 7.417064740167234e-09
site O 0 7.558204728752571e-09
( O 0 7.177654026691016e-10
- O 0 2.0298033476251476e-08
142C O 0 4.804244326805929e-07
/ O 0 6.229236646504432e-07
G O 0 3.902014213963412e-07
) O 0 1.9315751220716493e-09
, O 0 5.086633336759405e-10
and O 0 1.030348362185407e-09
2 O 0 8.584378008436033e-08
) O 0 1.2054749420897792e-09
a O 0 4.817877652385505e-09
6 O 0 2.569247499195626e-07
bp O 0 8.630279779708872e-08
deletion O 0 2.5201442710454103e-08
polymorphism O 0 4.386393026578617e-09
in O 0 4.670303588305558e-10
the O 0 1.6964906146554881e-09
3 O 0 4.749649562540981e-08
noncoding O 0 7.508936050726334e-08
part O 0 4.1835139796830845e-09
of O 0 1.7515160877223934e-08
the O 0 2.1016550277863644e-08
CPO O 0 1.9494736989145167e-06
gene O 0 2.7672246716292648e-08
, O 0 1.1187082371577617e-08
574 O 0 3.0131965900181967e-07
bp O 0 8.651738170328827e-08
downstream O 0 2.0265847666678383e-08
of O 0 1.9679081475487692e-08
the O 0 6.747854719435509e-09
last O 0 8.800241424467004e-09
base O 0 2.899881224038836e-09
of O 0 2.478952376705479e-09
the O 0 7.735568630096168e-09
normal O 0 1.0805548811276822e-07
termination O 0 1.5525972685281886e-07
codon O 0 2.4287894007102295e-07
( O 0 1.9615862711930276e-08
+ O 0 7.04911656157492e-07
574 O 0 1.322766593148117e-06
delATTCTT O 0 2.24411633098498e-06
) O 0 3.6027792305048933e-08
. O 0 5.68974940051703e-07

Five O 0 7.102207291609375e-06
intragenic O 0 6.812313222326338e-05
dimorphisms O 0 1.2071435776306316e-05
are O 0 3.802099080019161e-09
now O 0 1.1070988570338613e-09
well O 0 4.2607387062965074e-10
characterized O 0 9.644028908795121e-10
and O 0 2.4783461394228823e-10
the O 0 6.102469085611517e-10
high O 0 1.2503060808910504e-08
degree O 0 4.436830991494389e-08
of O 0 1.0798436811398915e-08
allelic O 0 7.817146752131521e-07
heterogeneity O 0 4.6746535531383415e-07
in O 0 3.374152868218516e-08
HC B-Disease 1 0.9996640682220459
is O 0 8.917469429547964e-09
demonstrated O 0 2.288070533040809e-08
with O 0 2.831386236579192e-10
seven O 0 6.425521226205433e-10
new O 0 1.3383656682908196e-10
different O 0 3.742185381017116e-11
mutations O 0 7.913628780054083e-11
making O 0 6.042343708712039e-11
a O 0 5.2988516352492354e-11
total O 0 1.8343007668342182e-10
of O 0 4.446418344628e-09
nineteen O 0 2.11607653000101e-06
CPO O 0 0.0001354688429273665
gene B-Disease 0 1.5239969798130915e-05
defects I-Disease 0 0.0006974037387408316
reported O 0 1.9905570525224903e-07
so O 0 8.817966801188959e-09
far O 0 1.7928604378880664e-08
. O 0 2.0617088480889834e-08
. O 0 3.208871248716605e-07

Coincidence O 0 5.04891067976132e-06
of O 0 1.0689137042163566e-07
two O 0 3.287688565833946e-09
novel O 0 1.203045396636071e-08
arylsulfatase O 0 6.487767336693651e-07
A O 0 4.907023054556703e-08
alleles O 0 7.356820930226604e-08
and O 0 1.7214627945350003e-08
mutation O 0 7.699214421563738e-08
459 O 0 4.295184510283434e-07
+ O 0 1.0797137974805082e-06
1G O 0 9.30210626393091e-06
> O 0 5.835619845129258e-07
A O 0 2.9904114740020304e-08
within O 0 8.163721254561551e-09
a O 0 4.070585646331892e-09
family O 0 3.891691857660362e-09
with O 0 1.0396804306367358e-08
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 5.3808340005900845e-09
molecular O 0 8.143100416191373e-09
basis O 0 6.3981548947822375e-09
of O 0 6.393714446772947e-09
phenotypic O 0 4.79216396342963e-06
heterogeneity O 0 1.633163083170075e-05
. O 0 5.953741947450908e-06

In O 0 1.1241373698567259e-07
a O 0 2.482843619588948e-08
family O 0 1.8625729847343564e-09
with O 0 1.9056364819469707e-10
three O 0 9.532490352626155e-10
siblings O 0 4.55411175437348e-09
, O 0 1.5123091667845756e-10
one O 0 8.129993900318766e-11
developed O 0 3.955028748947598e-09
classical O 0 4.372862747459294e-07
late O 1 0.9789380431175232
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.0801752523548203e-06
MLD B-Disease 1 1.0
) O 0 7.648655042657992e-09
, O 0 2.624425565755928e-09
fatal O 0 5.116135071148165e-07
at O 0 2.249560253630989e-07
age O 0 1.0744530953843423e-07
5 O 0 1.5166617117756687e-07
years O 0 4.454431934419745e-09
, O 0 6.134118213374506e-10
with O 0 9.513055898580092e-10
deficient O 0 2.755188461378566e-06
arylsulfatase O 0 2.9002427254454233e-05
A O 0 3.2491818728885846e-06
( O 0 3.1726266058740293e-08
ARSA O 0 3.415311766730156e-06
) O 0 7.568227156085072e-10
activity O 0 2.930797604605573e-09
and O 0 5.198426689112523e-10
increased O 0 6.355900250554214e-09
galactosylsulfatide O 0 5.459661224449519e-06
( O 0 8.858260258648443e-08
GS O 1 0.9999996423721313
) O 0 1.4336306364270968e-08
excretion O 0 1.9025738140499016e-07
. O 0 9.198666361953656e-08

The O 0 1.7721801270909054e-07
two O 0 7.073256202971834e-09
other O 0 1.6895511656400686e-09
siblings O 0 3.7954279719087936e-08
, O 0 1.4936650805097429e-09
apparently O 0 4.803969133604369e-08
healthy O 0 1.1278775247092199e-07
at O 0 4.99978909829224e-07
12 O 0 1.7245611161342822e-07
( O 0 4.118379415274376e-09
1 O 0 6.872172093608242e-07
/ O 0 3.9062479118001647e-07
2 O 0 1.8673232204946544e-07
) O 0 5.847737294395472e-10
and O 0 4.469620784597339e-10
15 O 0 4.647149776104698e-09
years O 0 1.1510096209477183e-09
, O 0 1.3114884178655473e-10
respectively O 0 2.3150490413570424e-09
, O 0 1.1828890644771661e-10
and O 0 1.7504121763156633e-10
their O 0 7.470359331129828e-10
father O 0 5.105553313455857e-08
, O 0 1.083904188625695e-09
apparently O 0 1.7237759664112673e-08
healthy O 0 4.880437387555503e-09
as O 0 8.082562397149218e-10
well O 0 1.0393528260266294e-09
, O 0 1.892474399411981e-09
presented O 0 2.203028657277173e-07
ARSA O 0 8.186754712369293e-05
and O 0 2.581788862698886e-07
GS O 1 1.0
values O 0 2.5312242968311693e-08
within O 0 2.806150867229462e-09
the O 0 1.1703982227828647e-09
range O 0 2.936640974837701e-08
of O 0 1.7567127486017853e-07
MLD B-Disease 1 1.0
patients O 0 3.7157016663513787e-07
. O 0 6.838998842795263e-07

Mutation O 0 1.5682925891269406e-07
screening O 0 4.619949578454907e-08
and O 0 4.5583958829809035e-09
sequence O 0 1.0503841352260679e-08
analysis O 0 4.117248320056888e-09
disclosed O 0 2.4941542164924613e-08
the O 0 1.1284500001096376e-09
involvement O 0 6.059500012867147e-09
of O 0 1.1074541284017414e-08
three O 0 3.664276215786799e-09
different O 0 1.9671313467028995e-08
ARSA O 0 9.231055628333706e-06
mutations O 0 2.3571248064513384e-08
being O 0 3.1359137508957247e-09
the O 0 5.736972563674669e-10
molecular O 0 1.193683196731854e-08
basis O 0 9.965305913794964e-09
of O 0 2.0873052619663213e-08
intrafamilial O 0 1.0281961294822395e-05
phenotypic O 0 3.647046469268389e-05
heterogeneity O 0 2.4494423996657133e-05
. O 0 5.23571588928462e-06

The O 0 6.67885331040452e-07
late O 0 5.037224036641419e-05
infantile O 0 0.0005209441296756268
patient O 0 6.667614371735908e-08
inherited O 0 2.064702471216151e-07
from O 0 6.755310977268891e-09
his O 0 3.054130104374053e-08
mother O 0 6.547871578277409e-09
the O 0 6.6271668153206065e-09
frequent O 0 4.7109596224004235e-09
0 O 0 1.552622393319325e-06
- O 0 7.377856832135876e-07
type O 0 2.6011548470705748e-06
mutation O 0 1.824679145556729e-07
459 O 0 3.032184565654461e-07
+ O 0 3.3587943448765145e-07
1G O 0 1.9340002381795784e-06
> O 0 1.0119112658912854e-07
A O 0 5.71864378073883e-09
, O 0 1.460238457928753e-10
and O 0 1.1928671939109847e-10
from O 0 1.2643362745645703e-10
his O 0 1.892236367595501e-09
father O 0 1.1962382195918053e-08
a O 0 2.566457324437721e-10
novel O 0 1.0337360967227482e-09
, O 0 4.224905147953706e-10
single O 0 1.8102052079527198e-09
basepair O 0 4.74226794722199e-07
microdeletion O 0 1.0415193401058787e-06
of O 0 1.7541347574479005e-07
guanine O 0 1.8669119583591964e-07
at O 0 4.3344158484615036e-07
nucleotide O 0 1.1857546056148749e-08
7 O 0 7.404643298514202e-08
in O 0 6.490029846872858e-09
exon O 0 1.2980862607037125e-07
1 O 0 3.8738389207537693e-07
( O 0 6.032297328317782e-09
7delG O 0 6.599902917514555e-07
) O 0 1.633776136600318e-08
. O 0 3.522814040479716e-07

The O 0 2.3001524596111267e-07
two O 0 4.061831049284592e-08
clinically O 0 1.3730947102885693e-05
unaffected O 0 2.847170605946303e-07
siblings O 0 7.92161429785665e-08
carried O 0 1.7573889010691346e-08
the O 0 2.6546842946117977e-08
maternal O 0 4.31043304160994e-07
mutation O 0 1.5948670295529155e-07
459 O 0 6.504668021989346e-07
+ O 0 2.2766535039409064e-06
1G O 0 1.6751586372265592e-05
> O 0 9.054220981852268e-07
A O 0 4.652038398944569e-08
and O 0 2.265306608961737e-09
, O 0 2.2115975717440506e-10
on O 0 2.440184942997803e-09
their O 0 5.208312114923785e-10
paternal O 0 5.021490778744919e-09
allele O 0 8.14011880123644e-09
, O 0 4.172275858138619e-10
a O 0 2.1580062736781258e-10
novel O 0 1.2928861314875917e-09
cytosine O 0 2.301463908338519e-08
to O 0 2.193099257752351e-09
thymidine O 0 7.821740837243851e-07
transition O 0 4.3914891989516036e-07
at O 0 4.620231663921004e-07
nucleotide O 0 1.0542904504973194e-07
2435 O 0 8.3248551163706e-06
in O 0 3.08589633846168e-08
exon O 0 1.7395844054135523e-07
8 O 0 9.715209614569176e-08
, O 0 4.662738528615762e-10
resulting O 0 2.44602826882101e-09
in O 0 1.3514822594373754e-09
substitution O 0 3.1456202975732594e-08
of O 0 4.673248810149744e-08
alanine O 0 3.779030919304205e-07
464 O 0 1.528341329048999e-07
by O 0 3.033537510077622e-08
valine O 0 2.5083552827709354e-05
( O 0 5.751660481223553e-08
A464V O 0 4.922236712445738e-06
) O 0 6.906192595579341e-08
. O 0 8.515970648659277e-07

The O 0 6.486016559392738e-07
fathers O 0 1.0342246241634712e-06
genotype O 0 3.7175769307395967e-07
thus O 0 1.1123935905743565e-07
was O 0 5.826166784572706e-07
7delG O 0 9.057433999259956e-06
/ O 0 5.923917342443019e-06
A464V O 0 2.3735958166071214e-05
. O 0 3.199366574335727e-06

Mutation O 0 1.6331006236214307e-06
A464V O 0 1.8775853050101432e-06
was O 0 2.6305961853267945e-08
not O 0 1.8922390043751847e-10
found O 0 2.2965590540380276e-10
in O 0 1.0904691594149085e-09
18 O 0 1.2282102090921398e-07
unrelated O 0 2.7092285108665237e-06
MLD B-Disease 1 1.0
patients O 0 9.843651582741586e-08
and O 0 2.282108191309362e-08
50 O 0 1.0689054619206217e-07
controls O 0 1.1881156751769595e-06
. O 0 3.890264906658558e-06

A464V O 0 8.968875590653624e-06
, O 0 8.387499583761837e-09
although O 0 2.1831672469829755e-08
clearly O 0 1.2842434671256342e-07
modifying O 0 2.0068191588507034e-06
ARSA O 0 0.0005930300103500485
and O 0 4.830471880268306e-07
GS O 1 1.0
levels O 0 1.896273573720464e-07
, O 0 2.5396265646016047e-10
apparently O 0 1.964134854759436e-09
bears O 0 4.3594523546630626e-09
little O 0 6.635840210655886e-10
significance O 0 1.6602350605410265e-09
for O 0 5.6636900030992976e-11
clinical O 0 5.259847668526163e-09
manifestation O 0 6.70431674620886e-08
of O 0 4.1542475059941353e-07
MLD B-Disease 1 1.0
, O 0 5.9493785897757334e-08
mimicking O 0 3.846369338589284e-07
the O 0 4.8189278345489583e-08
frequent O 0 3.8373855204554275e-07
ARSA O 0 0.00033611655817367136
pseudodeficiency O 0 6.482768367277458e-05
allele O 0 1.1012731192749925e-05
. O 0 4.762572643812746e-06

Our O 0 1.1875652035087114e-06
results O 0 3.349197896795886e-08
demonstrate O 0 2.8566440324340192e-09
that O 0 4.129852015921642e-11
in O 0 3.401896125909687e-11
certain O 0 7.059168249945458e-10
genetic O 0 3.453298802469362e-08
conditions O 0 5.579092885454884e-07
MLD B-Disease 1 1.0
- O 0 0.005204830318689346
like O 0 8.98885446076747e-08
ARSA O 0 0.0015982243930920959
and O 0 3.032404265468358e-07
GS O 1 1.0
values O 0 4.513046381049435e-09
need O 0 4.699093891780137e-10
not O 0 2.4989075045334097e-11
be O 0 3.772614859398615e-11
paralleled O 0 8.30307100851968e-10
by O 0 8.662127959357946e-11
clinical O 0 5.907427294005174e-07
disease O 0 2.1664551752564876e-07
, O 0 2.210939625824082e-10
a O 0 5.499489197369201e-10
finding O 0 1.5781251860857992e-08
with O 0 1.4514147661515153e-09
serious O 0 8.494840813000337e-07
diagnostic O 0 8.01111582404701e-06
and O 0 1.096740405159835e-07
prognostic O 0 0.07736112177371979
implications O 0 2.8622947866097093e-05
. O 0 1.8952442815134418e-06

Moreover O 0 2.2811325379734626e-06
, O 0 4.628611094403823e-08
further O 0 1.2396387205626525e-07
ARSA O 0 0.0001015296729747206
alleles O 0 2.4797537889753585e-07
functionally O 0 3.761649125522126e-08
similar O 0 4.568002365257229e-10
to O 0 8.558636022115707e-10
A464V O 0 3.76463482609779e-08
might O 0 6.397187779505487e-10
exist O 0 1.8231922638278775e-09
which O 0 1.6114300172009877e-10
, O 0 7.42807135245549e-11
together O 0 3.0549587165529246e-11
with O 0 3.8278977210204346e-11
0 O 0 4.147999277392955e-08
- O 0 7.778920618761731e-09
type O 0 1.7879909108842185e-08
mutations O 0 4.871936631900553e-09
, O 0 1.7819765107951469e-10
may O 0 9.719802740448813e-09
cause O 0 1.581529318173125e-06
pathological O 0 0.27235957980155945
ARSA O 0 0.28976064920425415
and O 0 4.251368864061078e-06
GS O 1 1.0
levels O 0 1.7233199400834565e-07
, O 0 8.584070260164722e-11
but O 0 4.7263633978777975e-11
not O 0 2.2225997084457383e-11
clinical O 0 3.799699666018341e-09
outbreak O 0 4.693271327127491e-10
of O 0 2.3928139469830967e-09
the O 0 1.711813979454746e-08
disease O 0 1.3518804564682796e-07
. O 0 2.3215594779912863e-08
. O 0 5.144890451447282e-07

Human O 1 0.9970388412475586
MLH1 O 1 1.0
deficiency O 1 0.9999994039535522
predisposes O 0 1.6099951608339325e-05
to O 0 2.6798676344697014e-07
hematological B-Disease 1 0.9998527765274048
malignancy I-Disease 1 0.9729766845703125
and O 0 7.534947030762851e-07
neurofibromatosis B-Disease 1 0.974572479724884
type I-Disease 1 0.7076117396354675
1 I-Disease 1 0.9761745929718018
. O 0 6.196180038386956e-06

Heterozygous O 0 8.330747732543387e-06
germ O 0 1.3452380699163768e-05
- O 0 1.6632521919746068e-06
line O 0 3.7237217753727236e-08
mutations O 0 2.194429749025062e-09
in O 0 4.6033030165482103e-10
the O 0 3.625719280364592e-09
DNA O 0 4.945453113691656e-08
mismatch O 0 9.74692011368461e-06
repair O 0 2.0360923826956423e-06
genes O 0 3.1021905044781306e-08
lead O 0 6.127773843900286e-08
to O 0 1.0736664535215823e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.8981232643127441

The O 0 1.0042201665783068e-06
disease O 0 1.8845636304831714e-06
susceptibility O 0 1.0916355819290402e-07
of O 0 1.5556369703517703e-07
individuals O 0 1.4867440611965321e-09
who O 0 1.0256488991444712e-08
constitutionally O 0 1.480505744666516e-07
lack O 0 1.3189725223128335e-06
both O 0 2.0178298143491702e-07
wild O 0 1.3484272187724855e-07
- O 0 3.3804397503445216e-08
type O 0 1.0595354815734481e-08
alleles O 0 3.127743752884271e-08
is O 0 8.003679385915063e-10
unknown O 0 1.2749215727581031e-07
. O 0 4.3692941176232125e-07

We O 0 1.0416857065820295e-07
have O 0 2.3412751737339477e-09
identified O 0 4.8408685948686525e-09
three O 0 2.0779564180450905e-10
offspring O 0 6.212831915597405e-10
in O 0 2.119829728419731e-10
a O 0 1.007869698810282e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.6630645404802635e-05
who O 0 3.5078546289923906e-08
developed O 0 3.2171578823181335e-06
hematological B-Disease 1 0.9999790191650391
malignancy I-Disease 1 0.999147891998291
at O 0 8.532761057722382e-06
a O 0 2.6801212360538784e-09
very O 0 7.638882859595242e-10
early O 0 6.4070939664873094e-09
age O 0 3.386285030160252e-09
, O 0 1.3673107090994563e-10
and O 0 1.6298559724070572e-10
at O 0 2.6777400297106624e-09
least O 0 1.4031811823578266e-10
two O 0 6.062985530297382e-11
of O 0 2.0836000980128944e-10
them O 0 2.301746987454223e-10
displayed O 0 1.7871043311856738e-08
signs O 0 1.431546365893155e-07
of O 0 5.460695433612273e-07
neurofibromatosis B-Disease 0 0.04315211623907089
type I-Disease 0 0.001271177432499826
1 I-Disease 0 0.0005538170225918293
( O 0 3.9949551222662194e-08
NF1 B-Disease 0 2.2285465092863888e-05
) O 0 3.624469613328074e-08
. O 0 3.7644056760655076e-07

DNA O 0 2.1018718143750448e-07
sequence O 0 1.760411549867058e-08
analysis O 0 7.420347447606446e-09
and O 0 1.7877784808106867e-09
allele O 0 1.2485640965564926e-08
- O 0 2.2736694749170283e-09
specific O 0 3.8841480032303366e-10
amplification O 0 3.0951261553724407e-09
in O 0 5.669442693090332e-10
two O 0 2.334559656702595e-09
siblings O 0 3.969328332686928e-08
revealed O 0 1.000328211375745e-07
a O 0 3.100871026617824e-08
homozygous O 0 1.014531335385982e-06
MLH1 O 0 0.00036051784991286695
mutation O 0 5.815087433802546e-07
( O 0 7.953543956773501e-08
C676T O 0 8.583682756579947e-06
- O 0 1.9213217456126586e-05
- O 0 8.359453204320744e-06
> O 0 1.4021867400515475e-06
Arg226Stop O 0 1.1495089893287513e-05
) O 0 2.356068584674631e-08
. O 0 2.397759146788303e-07

Thus O 0 1.4882903087709565e-06
, O 0 3.594179176502621e-08
a O 0 2.5984565610315258e-08
homozygous O 0 3.070019545248215e-07
germ O 0 1.307788807025645e-05
- O 0 3.417600237298757e-05
line O 0 5.600903932645451e-06
MLH1 O 1 0.9784567356109619
mutation O 0 4.374289233055606e-07
and O 0 2.1396836302756128e-08
consequent O 0 0.0024120754096657038
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 1 0.9911041259765625
in O 0 3.3045205327653093e-07
a O 0 2.1709867326080712e-07
mutator O 0 0.29621046781539917
phenotype O 0 9.874148645394598e-07
characterized O 0 8.077234880943251e-09
by O 0 1.0650176296422842e-09
leukemia B-Disease 1 0.9998624324798584
and O 0 0.0010027092648670077
/ O 1 1.0
or O 1 0.999997615814209
lymphoma B-Disease 1 1.0
associated O 1 0.9867576360702515
with O 0 2.2979949676482647e-07
neurofibromatosis B-Disease 1 0.9960625767707825
type I-Disease 0 0.06709454208612442
1 I-Disease 0 0.0050079007633030415
. O 0 1.0596267685514249e-07
. O 0 3.0257368166530796e-07

Missense O 0 0.00012501535820774734
mutations O 0 7.017049483692972e-07
in O 0 1.4339478937586136e-08
the O 0 5.087839038964148e-09
most O 0 2.2034332691767133e-10
ancient O 0 6.4782930131457306e-09
residues O 0 6.56336638371613e-08
of O 0 1.1085087514572933e-08
the O 0 6.211416092583022e-08
PAX6 O 0 0.00032347103115171194
paired O 0 5.494749757417594e-07
domain O 0 2.6354834403718996e-07
underlie O 0 2.282592731717159e-06
a O 0 3.758226174710444e-09
spectrum O 0 2.798242917378957e-07
of O 0 1.2637090094358427e-06
human O 1 0.9999920129776001
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 0.9999994039535522
. O 0 0.0004232275823596865

Mutations O 0 5.492680656971061e-07
of O 0 1.1274849498477124e-07
the O 0 4.265605468845024e-08
human O 0 1.3402731724454497e-07
PAX6 O 0 0.0005207417998462915
gene O 0 4.0110758163791616e-06
underlie O 1 0.999823272228241
aniridia B-Disease 1 1.0
( O 1 0.6260031461715698
congenital B-Disease 1 1.0
absence I-Disease 0 0.007349248975515366
of I-Disease 0 0.04752081260085106
the I-Disease 0 1.840748700487893e-05
iris I-Disease 0 0.0001160859246738255
) O 0 4.58002658021428e-09
, O 0 1.433044904963765e-09
a O 0 1.0334230360342644e-08
rare O 0 8.149650057021063e-06
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 0.9999984502792358
the I-Disease 1 0.9981131553649902
eye I-Disease 1 0.9999979734420776
. O 0 3.0974224500823766e-05

The O 0 4.764848426930257e-07
spectrum O 0 8.901209298528556e-07
of O 0 5.260031343823357e-07
PAX6 O 0 0.00035630998900160193
mutations O 0 6.08719460615248e-07
in O 0 7.26443047938119e-08
aniridia B-Disease 1 1.0
patients O 0 3.480675303535463e-08
is O 0 4.753687443681542e-10
highly O 0 1.9021875186098214e-09
biased O 0 1.7916368832970875e-08
, O 0 2.128187348571231e-10
with O 0 4.417301940895513e-11
92 O 0 4.664670871790122e-09
% O 0 5.6318474189742673e-11
of O 0 5.313336992607276e-10
all O 0 4.5831002881691063e-10
reported O 0 3.6186240670588177e-09
mutations O 0 5.1782418353241155e-09
leading O 0 6.4856857662221046e-09
to O 0 2.201220761222089e-09
premature O 0 1.2629244849904353e-07
truncation O 0 1.2477996733650798e-06
of O 0 1.3682260942005087e-06
the O 0 1.476553421753124e-07
protein O 0 4.006936293876606e-08
( O 0 1.4117481628161954e-09
nonsense O 0 3.598830033979539e-08
, O 0 7.734767826228506e-10
splicing O 0 6.472364422194232e-09
, O 0 2.177268365599616e-10
insertions O 0 1.719499653773937e-09
and O 0 9.603811079728075e-10
deletions O 0 6.4531593402250564e-09
) O 0 7.765425524830505e-10
and O 0 1.2232957979918524e-09
just O 0 6.144155850762445e-09
2 O 0 3.447113172683203e-08
% O 0 1.9688672914242034e-10
leading O 0 7.210916863620298e-10
to O 0 7.546198388386216e-11
substitution O 0 2.4596988890124294e-09
of O 0 3.819159744011813e-08
one O 0 1.0889607438002713e-08
amino O 0 6.778879679814054e-09
acid O 0 1.232622226510216e-09
by O 0 4.1295075692282524e-10
another O 0 5.639657185696478e-09
( O 0 5.789309920345431e-09
missense O 0 1.111288270294608e-06
) O 0 4.366944494904601e-08
. O 0 6.946166877241922e-07

The O 0 2.511823709028249e-07
extraordinary O 0 1.392401571820301e-07
conservation O 0 1.0059530985984111e-08
of O 0 4.312511237003491e-09
the O 0 1.0536869154975648e-08
PAX6 O 0 2.943945219158195e-06
protein O 0 5.518587542496789e-08
at O 0 9.511013843166438e-08
the O 0 2.380823893588513e-08
amino O 0 4.628363825531778e-08
acid O 0 7.1275522373071e-08
level O 0 1.3442581803246867e-05
amongst O 0 5.436486389953643e-07
vertebrates O 0 1.1801171240222175e-06
predicts O 0 3.2230307311920114e-08
that O 0 5.083519716286844e-10
pathological O 0 6.0384400057955645e-06
missense O 0 2.0725574358948506e-06
mutations O 0 2.3475276833551106e-08
should O 0 2.0172279402430604e-09
in O 0 3.114584146146626e-10
fact O 0 3.487942434876601e-10
be O 0 1.2735940080332853e-10
common O 0 1.5813354792282297e-10
even O 0 3.174098484048926e-11
though O 0 4.836222047832628e-11
they O 0 9.892234947850298e-11
are O 0 6.595306939471968e-11
hardly O 0 7.552944936151107e-09
ever O 0 1.2480283473337295e-08
seen O 0 2.6556262966437316e-08
in O 0 1.7587133527285914e-08
aniridia B-Disease 1 1.0
patients O 0 2.000434022875197e-07
. O 0 5.212069140725362e-07

This O 0 1.5597096947317368e-08
indicates O 0 8.0584907635739e-09
that O 0 1.788435927130294e-10
there O 0 1.981491776215094e-10
is O 0 4.723560431685314e-11
a O 0 2.8935975837640626e-10
heavy O 0 1.6836560234878561e-07
ascertainment O 0 5.488121314556338e-05
bias O 0 5.162314096196496e-07
in O 0 2.6980726541836475e-09
the O 0 1.3244451091409815e-09
selection O 0 8.156156638960965e-09
of O 0 2.1687314166740634e-09
patients O 0 3.302015327832919e-10
for O 0 1.2046015296363066e-09
PAX6 O 0 3.9948704397829715e-06
mutation O 0 6.652876471946456e-09
analysis O 0 4.428577060622274e-09
and O 0 6.513401484831149e-10
that O 0 1.0011819845390235e-10
the O 0 2.241504315492193e-09
missing O 0 3.376983102043596e-07
PAX6 O 0 0.00030352501198649406
missense O 0 1.632889143365901e-05
mutations O 0 5.556101996262441e-07
frequently O 0 4.9378655830878415e-08
may O 0 8.941589868527444e-08
underlie O 0 2.2594475012738258e-05
phenotypes O 0 1.7197355646203505e-06
distinct O 0 2.8486907055480515e-08
from O 0 1.0717223553058375e-08
textbook O 0 9.489262993156444e-06
aniridia B-Disease 1 1.0
. O 0 8.649559276818763e-06

Here O 0 7.742611956018663e-07
we O 0 6.232680149764747e-09
present O 0 1.0769203306892905e-09
four O 0 1.0138848649532406e-09
novel O 0 2.0437575187770562e-08
PAX6 O 0 1.4682109394925646e-05
missense O 0 2.0760071492986754e-06
mutations O 0 7.139907154396496e-08
, O 0 4.754269422591051e-09
two O 0 3.662564473927432e-09
in O 0 4.598882163975304e-09
association O 0 1.2457785025787871e-08
with O 0 4.50005899210737e-09
atypical O 0 4.3244999687885866e-06
phenotypes O 0 3.274386472185142e-05
ectopia B-Disease 0 0.00010583772382233292
pupillae I-Disease 0 2.859686173906084e-05
( O 0 4.904569195218755e-09
displaced B-Disease 0 2.3528127002236943e-08
pupils I-Disease 0 1.3280661903536384e-07
) O 0 1.6224355192662188e-08
and O 0 1.8949329387396574e-05
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999997615814209
( O 0 2.727104799760127e-07
searching B-Disease 0 7.602325808875321e-07
gaze I-Disease 0 1.1883505976584274e-05
) O 0 4.349875570852646e-09
, O 0 8.031358356141993e-10
and O 0 3.1501696806657264e-09
two O 0 4.588219137957594e-09
in O 0 1.2559181250537677e-08
association O 0 3.408564808182746e-08
with O 0 2.9125750700131903e-09
more O 0 9.932286992864192e-09
recognizable O 0 2.886215406761039e-05
aniridia B-Disease 1 1.0
phenotypes O 0 5.4006239224690944e-05
. O 0 1.3183588407628122e-06

Strikingly O 0 8.76878675626358e-06
, O 0 1.0227888758151948e-08
all O 0 1.8270772672579483e-09
four O 0 5.774518085921443e-10
mutations O 0 3.4801275750062644e-10
are O 0 8.214695590424981e-11
located O 0 1.5376380169129789e-09
within O 0 5.614799736264331e-09
the O 0 4.928634567136214e-08
PAX6 O 0 2.3279581000679173e-05
paired O 0 1.468166317408759e-07
domain O 0 7.580138117191382e-08
and O 0 1.7071803526391705e-08
affect O 0 1.621591536604683e-07
amino O 0 1.8961211267765066e-08
acids O 0 9.112358645424479e-10
which O 0 1.4409047566221744e-10
are O 0 4.291026561853428e-11
highly O 0 2.9637603482512986e-10
conserved O 0 3.6023790617178975e-09
in O 0 5.64363555888292e-10
all O 0 6.399298868586811e-10
known O 0 2.057006120992355e-09
paired O 0 1.5512009454710096e-08
domain O 0 2.8695332332517864e-08
proteins O 0 1.3254187969380382e-08
. O 0 1.104602489476747e-07

Our O 0 1.4029945987203973e-06
results O 0 9.463224870387421e-08
support O 0 3.881017729412406e-09
the O 0 2.2990847003967474e-09
hypothesis O 0 1.5509544759595428e-09
that O 0 1.4066237757903721e-11
the O 0 5.0251643124443746e-11
under O 0 6.593524060072298e-10
- O 0 1.2060729082108423e-09
representation O 0 5.4623909839790485e-09
of O 0 1.032455720917369e-08
missense O 0 3.7102840906300116e-06
mutations O 0 1.9875638201938273e-07
is O 0 9.183354632291696e-10
caused O 0 1.7279894848343247e-08
by O 0 4.616485416164551e-09
ascertainment O 0 0.00017763466166798025
bias O 0 2.774780568870483e-06
and O 0 8.47886205690429e-09
suggest O 0 8.163409503936236e-09
that O 0 9.206903989200654e-11
a O 0 3.804193349221663e-10
substantial O 0 5.912249356754273e-09
burden O 0 1.194940296045388e-06
of O 0 0.45631858706474304
PAX6 B-Disease 1 1.0
- I-Disease 1 1.0
related I-Disease 1 0.9591770768165588
disease I-Disease 0 0.00024271047732327133
remains O 0 6.4112994913045895e-09
to O 0 4.122786556592928e-10
be O 0 1.4355013844280506e-09
uncovered O 0 7.480717556518357e-08
. O 0 9.977020987150809e-09
. O 0 1.6872775177034782e-07

The O 0 2.3968539153429447e-07
chromosomal O 0 6.458481607296562e-07
order O 0 1.6734462349177193e-07
of O 0 2.9946815516268543e-07
genes O 0 7.527750511826525e-08
controlling O 0 8.861696301210031e-07
the O 0 2.939236480870022e-07
major O 0 3.2090777040139074e-06
histocompatibility O 1 0.6565072536468506
complex O 0 7.551856833742931e-05
, O 0 3.599830877831778e-09
properdin O 0 3.535027133239055e-07
factor O 0 2.2105075103695526e-08
B O 0 1.88781456245124e-07
, O 0 1.1510052910779223e-09
and O 0 3.836351236685687e-09
deficiency B-Disease 0 1.1582224033190869e-06
of I-Disease 0 8.493245786667103e-07
the I-Disease 0 1.0306852971098124e-07
second I-Disease 0 3.7371982841705176e-08
component I-Disease 0 3.206365306596126e-08
of I-Disease 0 5.676655234765349e-08
complement I-Disease 0 2.392380054061505e-07
. O 0 1.6159519873326644e-06

The O 0 4.550284771198676e-08
relationship O 0 5.444832584799997e-09
of O 0 6.398594099010779e-09
the O 0 1.979622910042167e-09
genes O 0 5.164410565861033e-10
coding O 0 3.943879889334312e-09
for O 0 4.869332714818597e-10
HLA O 0 1.2769472590434816e-08
to O 0 1.4181786300859756e-10
those O 0 7.604832735763623e-11
coding O 0 3.905194834175063e-09
for O 0 1.4134125814191378e-10
properdin O 0 3.579948426590818e-08
Factor O 0 1.7442216559970802e-08
B O 0 4.031267408777239e-08
allotypes O 0 7.385644096302713e-08
and O 0 4.940545195175616e-10
for O 0 3.365671352728583e-10
deficiency B-Disease 0 9.725147265271517e-08
of I-Disease 0 3.630585965197497e-08
the I-Disease 0 1.0820869533745281e-08
second I-Disease 0 1.002363791968719e-08
component I-Disease 0 1.1587948378632973e-08
of I-Disease 0 3.808117909898101e-08
complement I-Disease 0 6.393339191390623e-08
( O 0 9.42226563438453e-09
C2 O 0 5.6783178479236085e-06
) O 0 1.6175897288306373e-09
was O 0 8.499426051855608e-09
studied O 0 1.0043024190053984e-08
in O 0 1.4635259670825462e-10
families O 0 8.242193039187384e-11
of O 0 1.7095843629633123e-09
patients O 0 1.29121611180949e-08
with O 0 2.1967555596802413e-07
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.000243062007939443

Patients O 0 1.6670570346377644e-07
were O 0 5.9110316641408645e-09
selected O 0 6.58467669278906e-10
because O 0 1.484031925125251e-10
they O 0 1.7588124012757334e-10
were O 0 4.073651416192092e-10
heterozygous O 0 2.9935545153847443e-09
or O 0 1.0868339117564574e-08
homozygous O 0 5.357513259696134e-07
for O 0 1.9182161850039847e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00015114394773263484

12 O 0 5.268211680231616e-06
families O 0 1.0852616583179042e-08
with O 0 3.486294808396906e-09
15 O 0 2.038092361544841e-07
matings O 0 3.234947507735342e-05
informative O 0 1.865741978690494e-05
for O 0 1.8405869468551828e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 8.5225360635377e-07
found O 0 4.4578509772463804e-08
. O 0 1.8833243586868775e-07

Of O 0 5.090664672025014e-06
57 O 0 1.2820986512451782e-06
informative O 0 3.219885229555075e-07
meioses O 0 9.344734053229331e-07
, O 0 7.623541797840971e-10
two O 0 2.501941986920997e-10
crossovers O 0 3.192498931881005e-09
were O 0 2.8757232151122025e-09
noted O 0 2.9971882753443424e-09
between O 0 3.5985760149515045e-08
the O 0 2.8336635296000168e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 5.325606178274711e-09
and O 0 1.9691237529428918e-09
the O 0 9.47380396354447e-09
HLA O 0 9.850224813590103e-08
- O 0 3.444129248464378e-08
B O 0 2.636216756002341e-08
gene O 0 2.64744060007871e-10
, O 0 4.29056790096638e-11
with O 0 1.952099419610942e-11
a O 0 2.2694743306850285e-10
recombinant O 0 5.790289359097756e-10
fraction O 0 1.072625654963133e-09
of O 0 2.0137690626143012e-08
0 O 0 9.71316808318079e-07
. O 0 5.168091661289509e-07

035 O 0 0.011977778747677803
. O 0 6.587940151803195e-05

A O 0 9.981304174289107e-07
lod O 0 7.8594193837489e-06
score O 0 7.824696268698972e-08
of O 0 1.843108776711233e-08
13 O 0 2.214377303744186e-08
was O 0 7.773047094872254e-09
calculated O 0 5.190641694241549e-09
for O 0 1.2734416854343067e-09
linkage O 0 2.6827492547454312e-06
between O 0 0.4683958888053894
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.156164103122137e-06
HLA O 0 1.6278992234219913e-06
- O 0 9.336755368849481e-08
B O 0 2.111386088188283e-08
at O 0 1.2507204161238406e-09
a O 0 2.785829726625888e-11
maximum O 0 3.6812763948290694e-10
likelihood O 0 4.3102474367451293e-10
value O 0 3.671053183662565e-10
of O 0 3.434194595364204e-10
the O 0 1.3989348568443916e-10
recombinant O 0 1.2610296140636024e-10
fraction O 0 2.133776072499316e-10
of O 0 2.426456369164498e-09
0 O 0 1.562559930334828e-07
. O 0 1.0251251580939424e-07

04 O 0 0.006884611211717129
. O 0 6.040821608621627e-05

18 O 0 2.979511464218376e-06
families O 0 5.763330257479993e-09
with O 0 1.7266577057029053e-09
21 O 0 1.178430792947438e-07
informative O 0 7.389955669623305e-08
matings O 0 1.0544553674662893e-07
for O 0 8.134496409795133e-10
both O 0 3.84327192293199e-09
properdin O 0 4.401871365189436e-07
Factor O 0 8.437421428197922e-08
B O 0 1.902649842122628e-07
allotype O 0 1.9752229718505987e-07
and O 0 4.476064408009961e-09
HLA O 0 1.457013354411174e-07
- O 0 1.2040462848972311e-08
B O 0 2.155667644387904e-08
were O 0 2.5124160529799155e-09
found O 0 4.529344899140142e-09
. O 0 7.550384140131428e-08

Of O 0 8.568723387725186e-06
72 O 0 2.892935981435585e-06
informative O 0 4.800461397280742e-07
meioses O 0 1.0343893563913298e-06
, O 0 2.3743920163354915e-09
three O 0 1.1295008262024453e-09
recombinants O 0 1.8303661875052057e-07
were O 0 3.162414774493527e-09
found O 0 6.727315926546851e-10
, O 0 2.4097038253678704e-10
giving O 0 6.493356963233055e-10
a O 0 4.751856130802423e-10
recombinant O 0 8.51993753325786e-10
fraction O 0 1.4068237685904705e-09
of O 0 1.7395702656131107e-08
0 O 0 8.733682079764549e-07
. O 0 3.971813384850975e-07

042 O 0 0.0020745471119880676
. O 0 5.008948210161179e-05

A O 0 1.1647255178104388e-06
lod O 0 7.73310057411436e-06
score O 0 1.4477360821274488e-07
of O 0 5.517367185348121e-08
16 O 0 1.8982801464062504e-07
between O 0 1.0051229537566542e-07
HLA O 0 5.48713103398768e-07
- O 0 2.732680570716184e-08
B O 0 7.078438724050784e-09
and O 0 9.697238151362697e-11
Factor O 0 1.7791043083192903e-09
B O 0 8.311250354609001e-09
allotypes O 0 2.0924314725334625e-08
was O 0 1.3387851938162498e-09
calculated O 0 9.735456885096028e-10
at O 0 1.4924690372453142e-09
a O 0 1.1449438619415275e-10
maximum O 0 3.2052569487461824e-09
likelihood O 0 4.732980229960049e-09
value O 0 1.4030079320548339e-09
of O 0 1.2790086767466846e-09
the O 0 8.156900155320557e-10
recombinant O 0 7.769248022704289e-10
fraction O 0 3.0952895802016656e-10
of O 0 3.1504159281325883e-09
0 O 0 1.3929088993336336e-07
. O 0 9.99348017671764e-08

04 O 0 0.008696630597114563
. O 0 6.057458449504338e-05

A O 0 1.6799542379430932e-07
crossover O 0 5.642166911457025e-08
was O 0 1.407103589201597e-08
shown O 0 1.702957358462598e-10
to O 0 7.582006550377329e-11
have O 0 1.677668698407686e-10
occurred O 0 1.113503422800477e-08
between O 0 6.080591585799766e-10
genes O 0 6.339645475250677e-11
for O 0 5.637629599264393e-11
Factor O 0 1.522308834545072e-09
B O 0 1.3058635062179746e-08
and O 0 3.131060966055088e-09
HLA O 0 6.835086452383621e-08
- O 0 1.4901543110568127e-08
D O 0 2.041661417706564e-08
, O 0 2.5286880922514854e-10
in O 0 2.581554137126574e-10
which O 0 6.246839712176211e-10
HLA O 0 1.1894597662376327e-07
- O 0 6.827933418662724e-08
D O 0 1.31827661675743e-07
segregared O 0 8.773627655500604e-07
with O 0 5.7574962575301925e-09
HLA O 0 1.1196175364602823e-06
- O 0 4.3957584239251446e-08
A O 0 9.295562541922209e-09
and O 0 6.791653461846181e-09
B O 0 8.583916724091978e-07
. O 0 2.0522543309198227e-07

These O 0 1.7865863455313047e-08
studies O 0 5.047147588754797e-09
suggest O 0 7.140676938632851e-10
that O 0 5.058611168839988e-11
the O 0 2.4036034274033113e-10
genes O 0 1.1044092029788288e-10
for O 0 8.948231738914458e-11
Factor O 0 8.224301950576773e-08
B O 0 3.003387428179849e-05
and O 0 1.435273043171037e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.2136557314690322e-09
located O 0 2.596046155822762e-10
outside O 0 7.756129627445318e-10
those O 0 6.712111422224609e-11
for O 0 1.0965547914132401e-10
HLA O 0 8.795760564339616e-09
, O 0 2.5963767594228138e-11
that O 0 5.278069648007033e-12
the O 0 3.0169609865904334e-11
order O 0 4.796822383745791e-10
of O 0 2.5493145372479376e-09
genese O 0 2.663372811184672e-07
is O 0 4.4936174781184945e-09
HLA O 0 3.4653083957891795e-07
- O 0 6.004233199519149e-08
A O 0 6.356278703378848e-08
, O 0 2.893273620685477e-09
- O 0 1.4335978626434098e-08
B O 0 5.4878331212648845e-08
, O 0 1.243835701103535e-09
- O 0 4.1923966520585054e-09
D O 0 7.334989060581165e-09
, O 0 2.560687495378744e-10
Factor O 0 2.1759753110472957e-08
B O 0 6.76315153214091e-07
allotype O 0 2.5374765755259432e-05
, O 0 6.24678591520933e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 6.037105260148223e-10
that O 0 4.674837947304944e-11
the O 0 9.834296710309332e-10
genes O 0 1.1798348964475736e-08
coding O 0 9.113381338465842e-07
for O 0 2.3035923391034885e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.1683646938820402e-08
Factor O 0 4.346917137354467e-08
B O 0 4.4995204007136635e-08
allotypes O 0 4.117007179615939e-08
are O 0 7.922600075982444e-11
approximately O 0 1.3338904980564337e-10
3 O 0 3.6930438707116764e-09
- O 0 2.9299369597168834e-09
- O 0 3.032379014555886e-09
5 O 0 8.86555806545175e-09
centimorgans O 0 1.2721658038117312e-07
from O 0 1.9348274093999862e-09
the O 0 7.1592003436649065e-09
HLA O 0 1.666837761149509e-07
- O 0 1.1616496209398974e-08
A O 0 5.849681183889288e-09
and O 0 2.9098208287337e-09
HLA O 0 1.5042549250665616e-07
- O 0 3.6369346645415135e-08
B O 0 1.7104529348443975e-08
loci O 0 2.386706166035424e-09
, O 0 3.934483641665487e-11
and O 0 2.6062254784853245e-11
that O 0 5.0937930089201e-12
the O 0 6.44727188303662e-11
apparent O 0 3.971848627770669e-09
lack O 0 3.854234265077139e-08
of O 0 4.46876420312492e-08
recombinants O 0 3.33043203681882e-07
between O 0 3.723634733887593e-09
the O 0 4.767309214059878e-09
Factor O 0 1.4363845934894925e-07
B O 0 7.993547114892863e-06
gene O 0 1.9781193714152323e-06
and O 0 0.00013993638276588172
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.896149903757305e-08
suggests O 0 2.149688427266483e-09
that O 0 3.82719689273614e-11
these O 0 4.7815106041237954e-11
two O 0 1.6936543834056295e-10
genes O 0 5.438166583715542e-10
lie O 0 9.10176733981416e-09
in O 0 5.835436023282625e-10
close O 0 1.1639383679096227e-08
proximity O 0 7.596779205698567e-09
to O 0 3.150854910316525e-09
one O 0 3.88672161122372e-09
another O 0 2.681932542714094e-08
. O 0 5.471146664604021e-07

Distribution O 0 4.607629477959563e-07
of O 0 2.935804843673395e-07
emerin O 0 1.1563722182472702e-05
and O 0 1.999310050848635e-08
lamins O 0 5.281210178509355e-06
in O 0 1.092284929171683e-08
the O 0 2.0176598169996396e-08
heart O 0 2.4235441742348485e-07
and O 0 1.1904682573060654e-08
implications O 0 8.683775831741514e-07
for O 0 4.847856871492695e-08
Emery B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0005821207887493074

Emerin O 0 0.0009043929749168456
is O 0 4.941586695395017e-08
a O 0 1.691964079952868e-08
nuclear O 0 3.070204002142418e-07
membrane O 0 2.2606207039643778e-07
protein O 0 3.804647619176649e-08
which O 0 6.126494311864406e-10
is O 0 2.3905774582111405e-10
missing O 0 1.4724395924758937e-08
or O 0 1.3969091439136605e-09
defective O 0 2.1318383858215384e-07
in O 0 5.4053906239914795e-08
Emery B-Disease 1 1.0
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00017574388766661286
EDMD B-Disease 1 1.0
) O 0 3.909799488610588e-07
. O 0 9.457700116399792e-07

It O 0 1.3874303483873973e-08
is O 0 7.623570663639612e-10
one O 0 8.986737465299655e-10
member O 0 4.381802032327187e-09
of O 0 9.732528560846276e-09
a O 0 9.99774751875293e-09
family O 0 7.911132193783033e-09
of O 0 1.8702014870086714e-07
lamina O 1 0.9999253749847412
- O 1 0.9941914677619934
associated O 0 2.1031362393841846e-06
proteins O 0 3.4570535323297236e-09
which O 0 1.8678383284509437e-09
includes O 0 5.308345762955469e-09
LAP1 O 0 1.3300488717504777e-05
, O 0 1.9306957810272252e-08
LAP2 O 0 1.7721355106914416e-05
and O 0 1.4588208330224006e-07
lamin O 0 2.8103760996600613e-05
B O 0 3.5317859783390304e-06
receptor O 0 4.0173060256165627e-07
( O 0 2.657947284490092e-08
LBR O 0 3.044396862605936e-06
) O 0 3.514564994588909e-08
. O 0 5.078011326986598e-07

A O 0 5.039300049247686e-06
panel O 0 1.4922127320460277e-06
of O 0 1.1161213109289747e-07
16 O 0 1.0547148576733889e-07
monoclonal O 0 7.0664061269098966e-09
antibodies O 0 1.3097940509965156e-09
( O 0 2.6904873884348035e-09
mAbs O 0 1.7628315163165098e-07
) O 0 1.1726819515445186e-09
has O 0 2.643494589893436e-10
been O 0 5.900507860090443e-10
mapped O 0 8.854805777502861e-10
to O 0 1.4699183537025817e-10
six O 0 3.9057143630394364e-10
specific O 0 6.716619621593978e-11
sites O 0 8.227117875847512e-10
throughout O 0 1.2399651305727843e-09
the O 0 3.1388223131756376e-09
emerin O 0 1.2355809531072737e-07
molecule O 0 6.120339235415884e-10
using O 0 2.030142720599315e-09
phage O 0 3.909847379190978e-08
- O 0 7.70526309423758e-09
displayed O 0 4.298566835814199e-09
peptide O 0 6.017160103510832e-10
libraries O 0 4.1865449995626136e-10
and O 0 1.6926079982049202e-10
has O 0 1.2857630758700278e-11
been O 0 2.1422653581626427e-11
used O 0 4.5869898157580025e-11
to O 0 3.1964880742307855e-10
localize O 0 1.6845314121383126e-07
emerin O 0 1.797041136342159e-06
in O 0 8.224360747988158e-09
human O 0 1.1302819302727585e-07
and O 0 9.203878903463192e-08
rabbit O 0 9.98692257780931e-07
heart O 0 4.261289632268017e-06
. O 0 5.0734347496472765e-06

Several O 0 7.214513289000024e-07
mAbs O 0 5.865549155714689e-06
against O 0 2.8303369958848634e-07
different O 0 7.027885828847502e-08
emerin O 0 3.7980244087520987e-06
epitopes O 0 4.902930186290178e-07
did O 0 8.677400131773538e-09
not O 0 1.2840857266382955e-09
recognize O 0 1.0915851333948012e-08
intercalated O 0 1.7823121822857502e-07
discs O 0 1.5941081699111237e-07
in O 0 2.0504333786419693e-09
the O 0 4.497407335435355e-09
heart O 0 5.914505329940312e-09
, O 0 1.3831115419637996e-10
though O 0 8.848487220713963e-11
they O 0 2.420842970529691e-10
recognized O 0 1.6860035589871813e-09
cardiomyocyte O 0 1.481565021776987e-07
nuclei O 0 2.9947553770171e-08
strongly O 0 1.537172522603214e-08
, O 0 3.6244123258200034e-09
both O 0 8.589270628078793e-09
at O 0 1.5872892618062906e-06
the O 0 3.781366331168101e-08
rim O 0 4.518790035490383e-07
and O 0 5.0635775572516195e-09
in O 0 5.500572886063537e-09
intranuclear O 0 2.751042529780534e-06
spots O 0 6.654616413470649e-07
or O 0 3.982615126574274e-08
channels O 0 2.937286183168908e-07
. O 0 2.9241891752462834e-07

A O 0 4.528277713689022e-06
polyclonal O 0 1.3573721844295505e-05
rabbit O 0 6.953225124561868e-07
antiserum O 0 3.2677028229954885e-06
against O 0 5.608588367067568e-07
emerin O 0 6.47743945592083e-06
did O 0 2.0475891204796426e-08
recognize O 0 1.4967117323294588e-08
both O 0 2.6413391474022774e-09
nuclear O 0 1.0392585636509466e-07
membrane O 0 4.190943414528192e-08
and O 0 2.0362547203944814e-09
intercalated O 0 6.275243435993616e-08
discs O 0 1.7555596087959202e-08
but O 0 1.519671055660865e-10
, O 0 1.360385328691427e-11
after O 0 8.831659709107598e-11
affinity O 0 1.905120367018398e-10
purification O 0 9.065136974406585e-10
against O 0 1.7739404389871538e-09
a O 0 1.7516221806346266e-09
pure O 0 4.974258871470738e-08
- O 0 1.3645691865349363e-07
emerin O 0 1.203924284709501e-06
band O 0 2.3898140355527175e-08
on O 0 2.0231395225778215e-08
a O 0 1.3364684914307645e-09
western O 0 8.242547089309937e-09
blot O 0 1.786445295692829e-06
, O 0 2.2918125175408477e-09
it O 0 5.502186484207527e-10
stained O 0 6.973206723159819e-07
only O 0 1.5907929418190747e-09
the O 0 4.459430158476607e-09
nuclear O 0 2.98805730380991e-07
membrane O 0 1.8488268551664078e-06
. O 0 7.119739393601776e-07

These O 0 8.252870031810744e-08
results O 0 6.783240991126149e-08
would O 0 3.28196025911609e-10
not O 0 1.0656225901684024e-10
be O 0 1.1305262281879891e-10
expected O 0 1.2517371583697923e-09
if O 0 7.971290294506161e-10
immunostaining O 0 2.359351896075168e-07
at O 0 2.0628929675581276e-08
intercalated O 0 9.771891740228966e-08
discs O 0 1.450057425245177e-07
were O 0 3.544953219858371e-09
due O 0 1.1010681255640975e-08
to O 0 3.351188215816592e-10
a O 0 3.8954250936029666e-10
product O 0 1.099906943302642e-09
of O 0 1.4103790135777672e-08
the O 0 1.3906996443324715e-08
emerin O 0 1.390125021316635e-06
gene O 0 2.5708581929961838e-09
and O 0 5.584996909391293e-10
, O 0 1.3425126288435507e-10
therefore O 0 6.014016507016606e-10
, O 0 5.7488659666038444e-11
cast O 0 6.840519262141243e-10
some O 0 6.679060776670909e-11
doubt O 0 4.1398089400956906e-09
upon O 0 5.342708941924457e-09
the O 0 1.250372250183318e-09
hypothesis O 0 1.6098772093187108e-08
that O 0 9.850704696390267e-10
cardiac B-Disease 0 2.1470732463058084e-05
defects I-Disease 0 0.00014806051331106573
in O 0 3.463018742877466e-07
EDMD B-Disease 1 1.0
are O 0 2.2852532310935203e-08
caused O 0 8.0689531500866e-08
by O 0 1.3106138396778988e-09
absence O 0 3.584902685815905e-07
of O 0 1.2147456800448708e-06
emerin O 0 1.1150472346344031e-05
from O 0 4.177360679591402e-08
intercalated O 0 8.503209755872376e-06
discs O 0 2.5842255126917735e-05
. O 0 3.1131050945987226e-06

Although O 0 9.102193416765658e-07
emerin O 0 2.9725366402999498e-05
was O 0 1.7811365182751615e-07
abundant O 0 1.7242166805431225e-08
in O 0 1.4165736361704262e-09
the O 0 3.784770274961602e-09
membranes O 0 1.1607725447504436e-08
of O 0 1.3973469492611912e-08
cardiomyocyte O 0 7.67382175581588e-08
nuclei O 0 1.346655764677962e-08
, O 0 3.6328542951657994e-10
it O 0 8.6310736335804e-11
was O 0 4.887423354915654e-09
absent O 0 1.1982523417941593e-08
from O 0 3.2545197092836986e-10
many O 0 2.890172545733094e-10
non O 0 1.4684184179714066e-07
- O 0 2.255250421967503e-07
myocyte O 0 1.983762558666058e-06
cells O 0 9.350403118446593e-09
in O 0 1.4459381469933419e-09
the O 0 1.960303208647929e-08
heart O 0 9.160740432889725e-07
. O 0 1.7248273707082262e-06

This O 0 1.1283773915238271e-08
distribution O 0 1.0718204990212143e-08
of O 0 1.9859621502860136e-08
emerin O 0 9.340751034869754e-07
was O 0 5.897180521685641e-09
similar O 0 2.2015639311590007e-10
to O 0 9.460180555587172e-11
that O 0 9.336742490262395e-11
of O 0 1.3701002110622085e-08
lamin O 0 1.0213656423729844e-05
A O 0 8.206031765212174e-08
, O 0 1.0789495963337004e-09
a O 0 9.83099601725712e-10
candidate O 0 7.682854352708546e-09
gene O 0 2.588670389158665e-09
for O 0 4.851181678589e-10
an O 0 2.7878296893213417e-10
autosomal O 0 1.691925355373769e-08
form O 0 1.5482603998862032e-07
of O 0 0.00450491439551115
EDMD B-Disease 1 1.0
. O 0 7.829739479348063e-05

In O 0 3.164561803714605e-07
contrast O 0 2.0826649915761664e-07
, O 0 5.878563413830307e-08
lamin O 0 5.529226837097667e-05
B1 O 0 3.080878377659246e-05
was O 0 2.830585117408191e-07
absent O 0 1.656189567711408e-07
from O 0 4.123763996943808e-09
cardiomyocyte O 0 3.057464539324428e-07
nuclei O 0 1.2599890908404632e-07
, O 0 3.885491040023226e-09
showing O 0 1.7336676094714676e-08
that O 0 4.748315518554591e-09
lamin O 0 4.362515392131172e-05
B1 O 0 3.359554966664291e-06
is O 0 2.552553723944584e-10
not O 0 1.5241645445751573e-10
essential O 0 1.79372172670611e-09
for O 0 5.32269950337394e-10
localization O 0 4.844339400733588e-07
of O 0 3.606443499393208e-08
emerin O 0 5.97252096667944e-07
to O 0 4.7244390621870025e-09
the O 0 1.834498597474976e-08
nuclear O 0 7.080006525939098e-06
lamina O 1 0.9999972581863403
. O 0 2.1713336536777206e-05

Lamin O 1 0.9993444085121155
B1 O 1 0.8332974314689636
is O 0 2.1056511201322792e-08
also O 0 1.7818890807319576e-09
almost O 0 1.6090444532324e-09
completely O 0 4.5204579635083064e-08
absent O 0 2.0141153811437107e-07
from O 0 1.4080835164520522e-08
skeletal O 0 1.1991610335826408e-05
muscle O 0 8.756090892347856e-07
nuclei O 0 7.929221465019509e-05
. O 0 5.8829095905821305e-06

In O 0 3.8089463032520143e-06
EDMD B-Disease 1 1.0
, O 0 9.841638615171178e-09
the O 0 1.3844688728781307e-09
additional O 0 1.5696707267309762e-09
absence O 0 3.785003244161089e-08
of O 0 1.7334470214791509e-07
lamin O 0 0.00010964043758576736
B1 O 0 6.143633800093085e-05
from O 0 8.170407994612106e-08
heart O 0 9.213636803906411e-05
and O 0 6.866144394734874e-05
skeletal O 1 0.9999979734420776
muscle O 0 0.00021464771998580545
nuclei O 0 0.2145637422800064
which O 0 1.2815299044177664e-07
already O 0 8.468683176943159e-08
lack O 0 6.728279004164506e-06
emerin O 0 9.21156388358213e-05
may O 0 4.249816054624489e-09
offer O 0 5.749274389899028e-10
an O 0 9.8072756513079e-12
alternative O 0 4.810997156212693e-10
explanation O 0 1.9973918075066877e-09
of O 0 3.9271230711790395e-10
why O 0 6.493580118061004e-10
these O 0 9.571547721076712e-11
tissues O 0 2.1876804812137607e-09
are O 0 1.0031125236009686e-10
particularly O 0 5.727919805131876e-10
affected O 0 1.4149075244773712e-09
. O 0 4.210643833602035e-09
. O 0 1.0693459273625194e-07

Genetic O 0 2.036521664194879e-06
mapping O 0 3.984659429079329e-07
of O 0 8.519052130395721e-08
the O 0 5.339838438089828e-08
copper B-Disease 0 2.1013017885707086e-06
toxicosis I-Disease 0 0.00016524498641956598
locus O 0 2.4030020995269297e-06
in O 0 3.195154079094209e-07
Bedlington O 0 0.0001211525232065469
terriers O 0 3.9737183215038385e-06
to O 0 8.51407744306698e-09
dog O 0 1.9576466669946058e-08
chromosome O 0 2.979338376007945e-08
10 O 0 9.416983637322573e-09
, O 0 3.707573692501853e-10
in O 0 5.36784394711276e-10
a O 0 2.9225026842993884e-09
region O 0 2.6299840527599372e-08
syntenic O 0 2.2360047751135426e-06
to O 0 3.0094945202563395e-08
human O 0 1.5063106673096627e-07
chromosome O 0 3.9571665411131107e-07
region O 0 2.9230068321339786e-07
2p13 O 0 2.0063211195520125e-05
- O 0 1.0846949408005457e-05
p16 O 0 2.7621788376563927e-06
. O 0 7.744997105874063e-07

Abnormal O 1 0.9999996423721313
hepatic B-Disease 1 1.0
copper I-Disease 0 0.00028584557003341615
accumulation I-Disease 0 4.46536359959282e-05
is O 0 3.899077061220169e-09
recognized O 0 2.2598343196733595e-09
as O 0 1.397159610228016e-09
an O 0 1.4313621399253407e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 8.065289307523926e-07
man O 0 2.0271381799830124e-05
, O 0 1.1004781974577327e-08
mouse O 0 4.93550146529742e-07
, O 0 4.6892317584479315e-08
rat O 0 6.126348353063804e-07
and O 0 8.37683984400428e-08
dog O 0 4.5864117055316456e-06
. O 0 4.739129963127198e-06

The O 0 1.5614158144217072e-07
major O 0 1.0456111709800098e-07
cause O 0 3.6392323181644315e-06
of O 0 0.00023475410125683993
hepatic B-Disease 1 1.0
copper I-Disease 0 0.00322140334174037
accumulation I-Disease 0 0.023287814110517502
in O 0 2.069638185275835e-06
man O 0 0.0005396509077399969
is O 0 2.457677616973797e-09
a O 0 9.783413190689316e-09
dysfunctional O 0 8.608493544670637e-07
ATP7B O 0 0.0034935290459543467
gene O 0 4.820030952146226e-08
, O 0 2.9195608153287367e-09
causing O 0 6.462622081926384e-07
Wilson B-Disease 0 0.00010782907338580117
disease I-Disease 0 0.0007867365493439138
( O 0 8.214205848844358e-08
WD B-Disease 0 0.00022836250718683004
) O 0 2.635196665323747e-07
. O 0 1.8253299458592664e-06

Mutations O 0 2.962837299946841e-07
in O 0 1.0357693369655863e-08
the O 0 2.176996538594267e-08
ATP7B O 0 2.7168016458745115e-06
genes O 0 1.268193994263811e-09
have O 0 9.622765084760232e-11
also O 0 4.492464733552026e-11
been O 0 1.0887354212618661e-10
demonstrated O 0 7.296059312267289e-09
in O 0 8.094939829561554e-09
mouse O 0 9.379992889080313e-07
and O 0 2.554953653088887e-07
rat O 0 2.5753117824933724e-06
. O 0 6.765990292478818e-07

The O 0 6.445744702432421e-07
ATP7B O 0 5.7285673392470926e-05
gene O 0 8.018933073117296e-09
has O 0 2.5478841259030105e-10
been O 0 2.3211498001440845e-10
excluded O 0 1.2298370100083389e-09
in O 0 1.4894850630664536e-10
the O 0 2.951074107304663e-10
much O 0 1.059953236293154e-09
rarer O 0 2.1177722828724654e-06
human O 0 6.726756964781089e-07
copper B-Disease 0 9.102059993892908e-05
overload I-Disease 1 0.9962826371192932
disease O 1 0.9979696869850159
non B-Disease 0 7.403951894957572e-05
- I-Disease 0 2.279186446685344e-06
Indian I-Disease 0 5.880108400191375e-09
childhood I-Disease 0 3.676333619750949e-07
cirrhosis I-Disease 0 0.054792217910289764
, O 0 1.2579456365457986e-09
indicating O 0 2.1778269854166865e-08
genetic O 0 9.357774644058736e-08
heterogeneity O 0 6.180666218824626e-07
. O 0 1.3791136552754324e-06

By O 0 8.507798554546753e-08
investigating O 0 5.04872957662883e-07
the O 0 3.4299564077855393e-08
common O 0 6.063085493224207e-06
autosomal O 1 0.9999909400939941
recessive O 1 0.9989050626754761
copper B-Disease 1 0.5419806838035583
toxicosis I-Disease 1 0.9988372921943665
( O 0 4.786344902640849e-07
CT B-Disease 0 0.0009783247951418161
) O 0 2.4936737119674035e-08
in O 0 5.574679207143163e-08
Bedlington O 0 0.009601564146578312
terriers O 0 2.635980308696162e-05
, O 0 2.0550925405871112e-09
we O 0 5.898740940146752e-10
have O 0 3.74851504003626e-11
identified O 0 3.237592693938751e-10
a O 0 4.130151429193596e-11
new O 0 2.0390521215940538e-10
locus O 0 1.9565939979315772e-08
involved O 0 3.027293749013893e-09
in O 0 3.691320316079327e-08
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0003294405760243535

We O 0 1.2256698767032503e-07
examined O 0 7.73594024394697e-08
whether O 0 1.1366195762363418e-09
the O 0 3.339118315182077e-09
WD B-Disease 0 1.9673768747452414e-06
gene O 0 8.364179393538507e-08
ATP7B O 0 1.7017362551996484e-05
was O 0 1.1924662146611809e-07
also O 0 4.029843125863408e-09
causative O 0 1.2156789352957276e-08
for O 0 9.138710344025469e-10
CT B-Disease 0 2.0728855361085152e-06
by O 0 3.849405239009229e-09
investigating O 0 9.772190168177985e-08
the O 0 3.311075502665517e-08
chromosomal O 0 1.0376110367360525e-05
co O 0 1.2996166333323345e-05
- O 0 2.7082443921244703e-05
localization O 0 0.000477777561172843
of O 0 6.194005891302368e-06
ATP7B O 0 0.0004924261593259871
and O 0 1.468798682680017e-08
C04107 O 0 1.1411965772367694e-07
, O 0 4.985499790777226e-10
using O 0 7.052533557150298e-10
fluorescence O 0 3.329135722651699e-08
in O 0 1.4147888416360388e-09
situ O 0 1.1208852157551519e-07
hybridization O 0 2.2787371989352323e-08
( O 0 4.730480451797803e-09
FISH O 0 1.9767587389196706e-07
) O 0 1.110879299659473e-08
. O 0 3.084722948187846e-07

C04107 O 0 3.7770922062918544e-05
is O 0 9.192208771935384e-09
an O 0 4.794371011307419e-10
anonymous O 0 6.849727007818274e-09
microsatellite O 0 8.858781370690849e-07
marker O 0 1.5807753470653552e-06
closely O 0 2.018018392391241e-07
linked O 0 5.273602710076375e-07
to O 0 1.4719545049501903e-07
CT B-Disease 1 0.8284803032875061
. O 0 1.090370278689079e-05

However O 0 9.11617178189772e-07
, O 0 1.3918493380060681e-07
BAC O 0 1.3451264749164693e-05
clones O 0 1.4720500018938765e-07
containing O 0 4.204426318210608e-08
ATP7B O 0 1.1166019248776138e-05
and O 0 2.7423194381981375e-08
C04107 O 0 5.729366989726259e-07
mapped O 0 1.6325364171621004e-08
to O 0 1.6733744390151628e-09
the O 0 8.603158185849225e-09
canine O 0 1.2711520014363487e-07
chromosome O 0 1.1073131389593982e-07
regions O 0 4.811387555037072e-08
CFA22q11 O 0 1.801943471946288e-05
and O 0 4.323714364318221e-08
CFA10q26 O 0 1.4137681318970863e-05
, O 0 3.5974971890340157e-09
respectively O 0 8.023951281188602e-09
, O 0 1.886746731072364e-10
demonstrating O 0 2.994490877483713e-09
that O 0 3.165834816520885e-10
WD B-Disease 0 2.6186623358626093e-07
cannot O 0 1.618738565412059e-08
be O 0 4.354449689714102e-09
homologous O 0 1.3207275273430241e-08
to O 0 2.1941044536788468e-08
CT B-Disease 0 0.00010179558739764616
. O 0 9.964679748009075e-07

The O 0 1.459727059227589e-06
copper O 0 1.059816327142471e-06
transport O 0 2.95551132012406e-07
genes O 0 2.0545760648360556e-08
CTR1 O 0 2.03787385544274e-06
and O 0 9.753118312971765e-09
CTR2 O 0 1.5088472537172493e-05
were O 0 3.773000134543736e-09
also O 0 3.6410538473141685e-10
excluded O 0 1.3178782509726261e-09
as O 0 1.896853368821283e-10
candidate O 0 8.193949407875323e-10
genes O 0 2.7192634255435166e-10
for O 0 3.329062581158837e-10
CT B-Disease 0 9.096075359593669e-07
since O 0 7.103961419119287e-09
they O 0 1.5384828966347186e-09
both O 0 2.9314684013570513e-09
mapped O 0 3.894485800515213e-08
to O 0 4.757970906155151e-09
canine O 0 6.084902111069823e-07
chromosome O 0 1.2887576303910464e-06
region O 0 8.892665164239588e-07
CFA11q22 O 0 0.0003393425140529871
. O 0 7.956652552820742e-06

2 O 0 8.506308950018138e-05
- O 0 1.0799942174344324e-05
22 O 0 1.3400232319327188e-06
. O 0 7.039738534331264e-07

5 O 0 6.821647548349574e-05
. O 0 1.1425678167142905e-05

A O 0 2.4704233965167077e-06
transcribed O 0 2.6914469231087423e-07
sequence O 0 1.170957020235619e-08
identified O 0 1.4539756065801157e-08
from O 0 1.025147633448853e-09
the O 0 5.23939158725284e-09
C04107 O 0 1.2471757315779541e-07
- O 0 1.5200813052729245e-08
containing O 0 7.273134094987199e-09
BAC O 0 2.8819295039284043e-06
was O 0 4.539411957438233e-09
found O 0 8.04767016915342e-11
to O 0 2.427268455673648e-11
be O 0 8.45053471643098e-11
homologous O 0 1.4586017116346994e-10
to O 0 8.934196438215025e-11
a O 0 6.0666438539414e-10
gene O 0 1.1865005644651205e-09
expressed O 0 3.6190932473090243e-09
from O 0 9.317805194086759e-09
human O 0 4.495419858585592e-08
chromosome O 0 1.2964333961917873e-07
2p13 O 0 1.2569806813189643e-06
- O 0 2.572998880623345e-07
p16 O 0 5.880043829620263e-08
, O 0 6.224575299640378e-10
a O 0 6.307806499350477e-10
region O 0 3.719858421291633e-09
devoid O 0 1.1181157333339797e-07
of O 0 2.4431188183626773e-09
any O 0 1.1362641938461593e-09
positional O 0 3.7914924178039655e-07
candidate O 0 2.769627940324426e-07
genes O 0 1.779964833303893e-07
. O 0 4.292244568659953e-07

Molecular O 0 1.2126217825425556e-06
analysis O 0 8.84539517187477e-08
of O 0 2.3351308442443042e-08
the O 0 2.6059513658083233e-08
APC B-Disease 0 4.175990042654121e-08
gene O 0 2.0194068639511897e-09
in O 0 2.0077697282516738e-09
205 O 0 1.4925609193028322e-08
families O 0 6.129661778153661e-10
: O 0 1.8585701866413729e-09
extended O 0 3.897517686368701e-08
genotype O 0 8.644708486826858e-07
- O 0 6.265998422350094e-07
phenotype O 0 7.974004034849713e-08
correlations O 0 8.72533405527065e-08
in O 0 1.087988699133291e-09
FAP B-Disease 0 1.1341989569757516e-08
and O 0 9.431102426793458e-11
evidence O 0 1.0710106135292108e-09
for O 0 5.088959809107507e-11
the O 0 3.6618780230313064e-10
role O 0 3.209753574040519e-09
of O 0 7.609661167862214e-08
APC B-Disease 0 5.768677624473639e-07
amino O 0 8.856671485091283e-08
acid O 0 3.8577425698349543e-08
changes O 0 2.3539180347142974e-06
in O 1 0.9403288960456848
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9863344430923462
. O 0 2.3645025066798553e-05

BACKGROUND O 0 0.00015207534306682646
/ O 0 4.373900083010085e-05
AIMS O 0 3.8626867535640486e-06
The O 0 1.61461343850533e-07
development O 0 1.6078683984233066e-05
of O 1 0.9910646677017212
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.5065823194836412e-08
a O 0 9.18177867070824e-10
variable O 0 9.19847042979427e-09
range O 0 6.118930251375332e-09
of O 0 9.274063295094948e-09
extracolonic O 0 3.598704324758728e-06
manifestations O 0 0.00013504375237971544
in O 0 1.4194826007951633e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.8555887183756568e-06
FAP B-Disease 0 1.6382061858166708e-06
) O 0 1.6504819733142995e-09
is O 0 1.1360034440910383e-10
the O 0 1.802809984630116e-10
result O 0 4.719449719914337e-09
of O 0 1.2147308936505397e-08
the O 0 8.781244176248038e-09
dominant O 0 3.029923391295597e-06
inheritance O 0 3.1363188099930994e-06
of O 0 0.0003639628703240305
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 1.0
( O 0 1.118680415856943e-06
APC B-Disease 0 1.1709635145962238e-06
) O 0 4.586629387404173e-08
gene O 0 1.3642829799209721e-07
mutations O 0 5.998007281959872e-07
. O 0 2.6387681373307714e-06

In O 0 4.792876850956418e-08
this O 0 7.975928251191533e-10
study O 0 2.954092803708619e-10
, O 0 3.967127668036419e-11
direct O 0 1.7462072066098955e-10
mutation O 0 2.963861933658052e-10
analysis O 0 8.44018188672635e-10
of O 0 1.5445338341635306e-09
the O 0 4.352971316734511e-09
APC B-Disease 0 2.0689531865514255e-08
gene O 0 1.8579711102972851e-09
was O 0 6.899475213373307e-09
performed O 0 3.9358069581219013e-10
to O 0 4.210159720852147e-10
determine O 0 3.861644159997013e-08
genotype O 0 1.2804124480680912e-06
- O 0 2.90983916784171e-06
phenotype O 0 1.746093261090209e-07
correlations O 0 1.5059602276323858e-07
for O 0 3.5418716848312215e-09
nine O 0 4.9324903272918164e-08
extracolonic O 0 4.323714506426768e-07
manifestations O 0 4.559154831440537e-07
and O 0 1.2575378516288538e-09
to O 0 6.731281643190812e-10
investigate O 0 1.3234862983324547e-08
the O 0 2.5384268020900436e-09
incidence O 0 5.103012767904147e-07
of O 0 4.841780878450663e-07
APC B-Disease 0 7.974352342898783e-07
mutations O 0 1.797716606688482e-07
in O 0 1.1912795372381879e-07
non O 1 0.9999998807907104
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.3965781514998525e-05

METHODS O 0 2.7480534754431574e-06
The O 0 3.035138433915563e-07
APC B-Disease 0 1.725954632547655e-07
gene O 0 4.1592711497173696e-09
was O 0 1.6654086110179378e-08
analysed O 0 4.247419482794612e-08
in O 0 1.8239435517486413e-09
190 O 0 2.2148670453248087e-08
unrelated O 0 2.229319839841537e-08
FAP B-Disease 0 2.0809378042940807e-07
and O 0 1.4088706201675905e-08
15 O 0 1.875332372947014e-06
non O 1 0.9999773502349854
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 9.294059566400392e-08
using O 0 3.903826595319515e-08
denaturing O 0 7.130970061552944e-06
gradient O 0 6.012760422891006e-07
gel O 0 9.867656558526505e-08
electrophoresis O 0 2.1865469435056184e-08
, O 0 1.436608054738997e-09
the O 0 4.091071481582276e-09
protein O 0 2.5024060601452902e-09
truncation O 0 4.6926405872227406e-08
test O 0 1.9949903062865815e-08
, O 0 1.7572497623685734e-10
and O 0 3.127251513301843e-10
direct O 0 3.4642615442948e-09
sequencing O 0 6.941161956319775e-08
. O 0 2.3957545636221766e-07

RESULTS O 0 6.391563510987908e-05
Chain O 0 1.0336260629628669e-06
terminating O 0 4.216681759316998e-07
signals O 0 7.098126530991067e-08
were O 0 2.3465149823209686e-09
only O 0 3.055286301734128e-10
identified O 0 8.934303297181145e-10
in O 0 2.375623031625196e-10
patients O 0 3.0847338572392857e-10
belonging O 0 3.474518450730102e-09
to O 0 3.854533581204578e-09
the O 0 5.14483140534594e-08
FAP B-Disease 0 2.0202976429573027e-06
group O 0 2.736504001177309e-08
( O 0 1.2206394117697528e-08
105 O 0 3.593089843434427e-07
patients O 0 1.3533480114347185e-08
) O 0 1.0755291768305142e-08
. O 0 5.279102879285347e-07

Amino O 0 2.8330935037956806e-06
acid O 0 3.9196592638290895e-08
changes O 0 4.740406733816371e-09
were O 0 1.5806578268495741e-09
identified O 0 1.2019805151197716e-09
in O 0 1.95476052011756e-10
four O 0 4.5963718942054754e-10
patients O 0 8.551941793610851e-11
, O 0 8.990436173306193e-11
three O 0 3.1460251070924983e-10
of O 0 5.820610660123293e-09
whom O 0 4.0826162006624145e-08
belonged O 0 5.615241605028132e-08
to O 0 6.132646834799971e-09
the O 0 7.512230837392053e-08
non O 0 0.1299927532672882
- O 1 0.9990847110748291
FAP O 0 0.4564243257045746
group O 0 1.0733489943959285e-05
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0009544520289637148
. O 0 1.0279509297106415e-05

Genotype O 0 0.0004942782688885927
- O 0 0.00010026783274952322
phenotype O 0 1.4786559177082381e-06
correlations O 0 4.146983769715007e-07
identified O 0 2.1609450229220784e-08
significant O 0 5.477770237405366e-09
differences O 0 5.3842757807842645e-08
in O 0 2.0638522002514037e-09
the O 0 1.5267490605097578e-09
nature O 0 1.4559868866115266e-09
of O 0 1.4780610069209388e-09
certain O 0 5.938809444216986e-09
extracolonic O 0 7.344202685999335e-07
manifestations O 0 3.602882827635767e-07
in O 0 2.282734001823883e-09
FAP B-Disease 0 6.292958687481587e-08
patients O 0 1.012821826407162e-09
belonging O 0 3.1164280045459236e-09
to O 0 2.512947849808711e-09
three O 0 2.19664197942393e-08
mutation O 0 3.728725630480767e-07
subgroups O 0 2.2669298687105766e-06
. O 0 2.882182343455497e-06

CONCLUSIONS O 0 3.417685002204962e-05
Extended O 0 4.4910934775543865e-06
genotype O 0 1.4402557098947e-05
- O 0 1.426954440830741e-06
phenotype O 0 8.128765216497413e-08
correlations O 0 4.9124917467224805e-08
made O 0 1.0980621967249249e-09
in O 0 1.570271968009962e-10
this O 0 4.6330907860214765e-11
study O 0 1.5858722668404823e-10
may O 0 3.983750551661558e-10
have O 0 9.241175880081443e-11
the O 0 1.2099107826735178e-10
potential O 0 1.8326956618963663e-10
to O 0 8.170052828715413e-11
determine O 0 3.750821875314614e-09
the O 0 5.482648779420174e-10
most O 0 4.3072784922104645e-11
appropriate O 0 9.83643499985476e-10
surveillance O 0 2.041130819918635e-09
and O 0 4.176089474228206e-10
prophylactic O 0 3.971381374867633e-07
treatment O 0 1.1454779347275235e-08
regimens O 0 1.128810112049905e-08
for O 0 6.574934346970096e-11
those O 0 2.9958188707546185e-11
patients O 0 1.3467179628412485e-11
with O 0 1.2960601342149047e-11
mutations O 0 2.8799056472905704e-09
associated O 0 4.9990331874028016e-09
with O 0 7.086297104663686e-10
life O 0 1.4147517823914768e-08
threatening O 0 4.089311289590114e-07
conditions O 0 4.812911811313825e-06
. O 0 1.2533763538158382e-06

This O 0 2.289249323439435e-08
study O 0 3.4802623005703026e-09
also O 0 1.0058253535616402e-10
provided O 0 1.4252753144372576e-10
evidence O 0 8.699983511384346e-10
for O 0 1.1481038342253669e-10
the O 0 7.583485506224008e-10
pathological O 0 1.4721777574777661e-07
nature O 0 1.6555368631543388e-08
of O 0 6.159599763577717e-08
amino O 0 2.5759151256465884e-08
acid O 0 3.6316092355548335e-09
changes O 0 6.967953325442977e-09
in O 0 7.426691261969154e-09
APC O 0 1.0630175495407457e-07
associated O 0 3.1533211597434274e-08
with O 0 8.613366131449141e-10
both O 0 8.250757410621645e-09
FAP B-Disease 0 1.5499815617658896e-06
and O 0 1.221707890408652e-07
non O 1 0.999994158744812
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.1251498222009104e-07
. O 0 3.1575826398011486e-08
. O 0 3.7250933360155614e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 0.0016032676212489605
cancer B-Disease 0 0.004633738659322262
risk O 0 5.503439979293034e-07
of O 0 2.764018063317053e-06
the O 0 7.3177335480068e-07
APC O 0 1.6721761539884028e-06
I1307K O 0 3.4827589843189344e-06
polymorphism O 0 1.4664832406197092e-06
. O 0 5.514777967619011e-07

Germ O 0 0.0002874851634260267
- O 0 4.722504672827199e-05
line O 0 2.6416836362841423e-07
and O 0 1.1255615106620098e-08
somatic O 0 2.1092090207730507e-07
truncating O 0 1.4670200698674307e-07
mutations O 0 3.038249651865499e-09
of O 0 6.98124269504774e-09
the O 0 6.878949854183247e-09
APC B-Disease 0 3.491607003525132e-08
gene O 0 2.4276785026700054e-09
are O 0 7.40582262181988e-10
thought O 0 3.293864736519936e-09
to O 0 4.245538143266003e-09
initiate O 0 1.2864024938608054e-06
colorectal B-Disease 1 1.0
tumor I-Disease 0 1.447377053409582e-05
formation O 0 4.128679847781314e-06
in O 0 9.527075235382654e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9048214554786682
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.9206470369681483e-06
respectively O 0 6.3323582253360655e-06
. O 0 4.3000595724151935e-06

Recently O 0 3.4782017337420257e-06
, O 0 3.443433271854701e-08
an O 0 7.0152674780388224e-09
isoleucine O 0 2.8656663744186517e-06
- O 0 4.710818757303059e-06
- O 0 1.938598506967537e-05
> O 0 4.755913778353715e-06
lysine O 0 2.1238968201942043e-06
polymorphism O 0 6.221482351520535e-08
at O 0 6.0358210873801e-08
codon O 0 8.138135143553882e-08
1307 O 0 4.409498615132179e-06
( O 0 1.4511378765291738e-09
I1307K O 0 4.806737052831522e-08
) O 0 4.163261402290175e-10
of O 0 3.0026581221420656e-09
the O 0 9.975384074323301e-09
APC B-Disease 0 4.496328998015997e-08
gene O 0 1.217776213202626e-09
has O 0 2.0153348434526208e-10
been O 0 7.559830539349832e-10
identified O 0 1.2205456645375534e-09
in O 0 6.156881116048396e-10
6 O 0 5.67775941817672e-08
% O 0 9.925767985308198e-10
- O 0 1.750320421933793e-08
7 O 0 6.557097265158518e-08
% O 0 5.355132448592315e-10
of O 0 7.835535775768676e-09
the O 0 2.4979676993552857e-08
Ashkenazi O 0 1.0626688151660346e-07
Jewish O 0 1.9103401527331698e-08
population O 0 7.187134776209803e-10
. O 0 1.935356834792401e-07

To O 0 1.858559102174695e-07
assess O 0 6.821579745519557e-07
the O 0 8.142199803273797e-09
risk O 0 7.35443350663445e-09
of O 0 2.4665247622124298e-09
this O 0 4.846631429522574e-10
common O 0 8.446949806284465e-09
APC B-Disease 0 2.6917678042082116e-07
allelic O 0 2.978272959808237e-06
variant O 0 5.592565503320657e-05
in O 0 2.0871036667813314e-06
colorectal O 1 1.0
carcinogenesis O 1 0.9998880624771118
, O 0 1.8128528012084644e-08
we O 0 3.4397684700593345e-09
have O 0 1.208762118176665e-10
analyzed O 0 7.046912497976621e-10
a O 0 6.721592032965518e-11
large O 0 1.5473371195451335e-10
cohort O 0 8.510018467688951e-09
of O 0 1.2869820764649376e-08
unselected O 0 5.336557023838395e-06
Ashkenazi O 0 5.877879516447138e-07
Jewish O 0 5.0205542834191874e-08
subjects O 0 4.991546802557423e-07
with O 0 8.971260179180263e-09
adenomatous B-Disease 0 5.746940132667078e-06
polyps I-Disease 0 5.384421911003301e-06
and O 0 3.4552886774008584e-08
. O 0 9.611559335098718e-07
or O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.267211212687471e-08
for O 0 3.938669834724351e-09
the O 0 3.817746829781754e-08
APC O 0 3.456264892065519e-07
I1307K O 0 1.4487900443782564e-06
polymorphism O 0 1.040125766849087e-06
. O 0 5.008842549614201e-07

The O 0 2.239878540422069e-06
APC O 0 2.460134965076577e-06
I1307K O 0 1.1840617162306444e-06
allele O 0 8.676807539131914e-08
was O 0 4.55041480051932e-08
identified O 0 4.640984485604349e-09
in O 0 1.1459319049222927e-09
48 O 0 1.626575141244757e-08
( O 0 7.950017311131319e-10
10 O 0 1.7703979393601799e-09
. O 0 3.8468270235902935e-10
1 O 0 1.522748149795916e-08
% O 0 2.251641512129865e-10
) O 0 4.4849671199109764e-10
of O 0 9.275407109043954e-09
476 O 0 1.1832969448732911e-07
patients O 0 2.7980128436411178e-08
. O 0 3.7142527276046167e-07

Compared O 0 9.472705642110668e-08
with O 0 4.2810466283071946e-10
the O 0 7.640369448225215e-10
frequency O 0 5.614627873740119e-09
in O 0 1.0819083129387508e-10
two O 0 2.689468960037633e-11
separate O 0 3.412319385387441e-11
population O 0 2.4537581168326827e-12
control O 0 4.5407433368893635e-10
groups O 0 1.4820009108795773e-10
, O 0 4.0090497588352036e-10
the O 0 5.8534088687167696e-09
APC O 0 7.619420472337879e-08
I1307K O 0 2.201130087087222e-07
allele O 0 6.260754048525996e-08
is O 0 6.092735205243116e-10
associated O 0 5.677201486697925e-10
with O 0 2.0176336296140462e-11
an O 0 1.4201187101270385e-11
estimated O 0 6.524764062376676e-11
relative O 0 6.185226997246218e-09
risk O 0 9.484742768961496e-09
of O 0 2.1040177955455874e-07
1 O 0 2.4783690605545416e-05
. O 0 2.9311008802324068e-06

5 O 0 2.425398452032823e-05
- O 0 4.603892193699721e-06
1 O 0 2.299008428963134e-06
. O 0 6.24883568889345e-07

7 O 0 0.00013850018149241805
for O 0 1.7306995232502231e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.6657001972198486
( O 0 1.2299531704229594e-07
both O 0 1.9006296270163148e-07
P O 0 0.000497923232614994
= O 0 6.849089118077245e-07
. O 0 1.2209888211600628e-08
01 O 0 8.572586125410453e-07
) O 0 7.993583572840635e-09
. O 0 1.5925431284813385e-07

Furthermore O 0 2.149902229575673e-06
, O 0 2.133001153481473e-08
compared O 0 1.0152787055517365e-08
with O 0 3.202415221892352e-09
noncarriers O 0 1.137438630394172e-06
, O 0 7.10806791204277e-09
APC O 0 6.382409623029162e-08
I1307K O 0 9.903386199994202e-08
carriers O 0 1.0804818151299855e-09
had O 0 1.26687882406884e-09
increased O 0 1.1439708069715948e-09
numbers O 0 2.627961848133964e-09
of O 0 5.5146735178368544e-08
adenomas B-Disease 1 0.9987475872039795
and O 0 0.028037874028086662
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9991949200630188
per O 0 5.745498299347673e-08
patient O 0 3.731315345589792e-08
( O 0 8.030305309603136e-09
P O 0 3.458055289229378e-05
= O 0 2.4754771743573656e-07
. O 0 2.2424277990040764e-09
03 O 0 7.345744990061576e-08
) O 0 1.280423683747145e-10
, O 0 2.803537436923964e-11
as O 0 6.466262247872834e-11
well O 0 8.890542468886764e-11
as O 0 5.5798723280764406e-11
a O 0 1.878398131482939e-10
younger O 0 1.7867499479962135e-08
age O 0 4.4976840030130916e-08
at O 0 1.5078067860940791e-07
diagnosis O 0 1.1286872450000374e-06
. O 0 3.4538729209998564e-07

We O 0 3.586243337849737e-07
conclude O 0 3.729273601038585e-07
that O 0 6.888898895773821e-10
the O 0 2.8633317938897562e-09
APC O 0 6.271378794053817e-08
I1307K O 0 1.800838020926676e-07
variant O 0 2.55810107319121e-07
leads O 0 2.2386128506468594e-08
to O 0 3.809569104618049e-09
increased O 0 2.3845058194638113e-07
adenoma B-Disease 1 1.0
formation O 0 3.830416517303092e-06
and O 0 1.1088216567145537e-08
directly O 0 2.101333107518144e-09
contributes O 0 1.6457155083138275e-10
to O 0 1.034784966047475e-10
3 O 0 5.147419823714472e-09
% O 0 5.061342317480566e-11
- O 0 3.067642528886694e-10
4 O 0 9.932510369736747e-10
% O 0 1.2453299676196128e-11
of O 0 2.401174814536944e-10
all O 0 1.1972807190119283e-09
Ashkenazi O 0 1.1312260994600365e-06
Jewish O 0 1.1781677130784374e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.372409072559094e-06

The O 0 1.8993756611962453e-07
estimated O 0 1.629351054077688e-08
relative O 0 8.023618391916898e-08
risk O 0 5.280273107644007e-09
for O 0 7.406854019009756e-10
carriers O 0 1.0994055665847213e-09
may O 0 2.391888820341137e-08
justify O 0 3.520253955002772e-08
specific O 0 2.582574820664263e-09
clinical O 0 5.093509169995514e-09
screening O 0 4.3232814550542287e-10
for O 0 6.816875536275191e-11
the O 0 5.672644576293351e-10
360 O 0 7.619286535032188e-09
, O 0 2.396046139274688e-10
000 O 0 2.3558426320846593e-09
Americans O 0 8.226016395829205e-11
expected O 0 9.793901245558345e-10
to O 0 3.0262703454297935e-10
harbor O 0 8.26948998167154e-09
this O 0 2.7509813871340327e-10
allele O 0 7.1256875955327814e-09
, O 0 5.116837509255845e-10
and O 0 2.725234760081463e-10
genetic O 0 4.5989059782591823e-10
testing O 0 9.3536089984525e-10
in O 0 3.34978239591166e-10
the O 0 1.2594677523125597e-09
setting O 0 1.3295890610720562e-08
of O 0 1.1641337671619567e-08
long O 0 6.184519563134927e-09
- O 0 3.649331148380952e-08
term O 0 7.614045216541854e-08
- O 0 3.2438020269864865e-08
outcome O 0 5.9436736421503156e-08
studies O 0 2.7735960195229836e-09
may O 0 2.4542157195384107e-09
impact O 0 6.548585673726848e-08
significantly O 0 7.651969440303219e-07
on O 1 0.9999707937240601
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 2.085048890876351e-06
in O 0 2.7264410173977183e-10
this O 0 1.3776720042546486e-10
population O 0 7.128915513465728e-11
. O 0 2.6796111995963656e-08

Localization O 0 0.00010484577069291845
of O 0 1.728908046061406e-06
human O 0 4.328174441070587e-07
BRCA1 O 0 1.145232744192981e-07
and O 0 9.31931509740025e-09
its O 0 3.811873039438751e-09
loss O 0 3.260239793689834e-07
in O 0 1.2042483454877129e-08
high O 0 0.00017969477630686015
- O 0 1.5394487490993924e-05
grade O 1 0.9985430240631104
, O 0 1.3732444585912162e-06
non B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.12028554826974869

Although O 0 2.317718994504503e-08
the O 0 9.30003185573014e-09
link O 0 2.009578992101524e-08
between O 0 2.367456453100658e-08
the O 0 2.5313592999509638e-08
BRCA1 O 0 2.62363414549327e-07
tumour B-Disease 1 1.0
- O 0 1.6995281839626841e-06
suppressor O 0 4.069873966727755e-07
gene O 0 1.124115467376896e-08
and O 0 4.0844700066600126e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.4442856866025977e-07
established O 0 1.9009082308230063e-08
, O 0 4.461248870324397e-10
the O 0 5.994799101571857e-10
role O 0 1.0974215980397162e-09
, O 0 8.6844947899678e-11
if O 0 8.049419464306595e-11
any O 0 3.72602726450566e-10
, O 0 5.131654545742492e-10
of O 0 9.538861256430664e-09
BRCA1 O 0 5.785625489806989e-08
in O 0 4.799408159783525e-08
non B-Disease 1 0.999984622001648
- I-Disease 1 0.9999996423721313
familial I-Disease 1 0.9996134638786316
cancers I-Disease 1 0.9999972581863403
is O 0 4.920631724303348e-08
unclear O 0 1.946304564626189e-06
. O 0 3.4782283364620525e-06

BRCA1 O 0 1.7160657534986967e-06
mutations O 0 4.8562228016635345e-08
are O 0 6.155014276032489e-10
rare O 0 3.040295792899883e-09
in O 0 1.3993411984714044e-09
sporadic B-Disease 0 2.0961917925887974e-06
cancers I-Disease 0 0.22902712225914001
, O 0 5.377745804224787e-09
but O 0 5.1892956598464934e-09
loss O 0 1.6326430340996012e-07
of O 0 9.07753374690401e-08
BRCA1 O 0 8.66359073370404e-09
resulting O 0 6.9222125809176305e-09
from O 0 7.280014369115406e-10
reduced O 0 2.6958518972719503e-08
expression O 0 1.5565802868877654e-08
or O 0 8.549993602002814e-09
incorrect O 0 5.1475602447226265e-08
subcellular O 0 5.219684453550144e-07
localization O 0 9.719014997244813e-07
is O 0 4.893652150173011e-10
postulated O 0 1.3846808144535316e-08
to O 0 1.6589837836811228e-10
be O 0 3.748909793710453e-10
important O 0 1.0825941254566374e-09
in O 0 1.320424547479604e-09
non B-Disease 0 2.9481141609721817e-05
- I-Disease 1 0.655745804309845
familial I-Disease 1 0.9999986886978149
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9999910593032837

Epigenetic O 0 0.0008542112191207707
loss O 0 3.0331380912684835e-05
, O 0 8.54076720457897e-09
however O 0 7.397708667866709e-09
, O 0 1.517035663756161e-10
has O 0 1.3458088810036628e-11
not O 0 1.5671594230659558e-11
received O 0 1.2362617873851178e-10
general O 0 1.0816447737482804e-09
acceptance O 0 1.8823660408173737e-09
due O 0 1.1273275646317416e-08
to O 0 1.1915488595803936e-09
controversy O 0 9.23649778883373e-09
regarding O 0 1.6461347840390772e-08
the O 0 6.896449189497389e-09
subcellular O 0 7.541719355685927e-07
localization O 0 2.3020490971248364e-06
of O 0 1.0343483580754764e-07
BRCA1 O 0 1.2655800851746335e-08
proteins O 0 3.2282754247603407e-10
, O 0 1.469066257531182e-10
reports O 0 5.588982054938185e-10
of O 0 5.623906340623819e-10
which O 0 1.9997047073783136e-10
have O 0 3.510869928113891e-10
ranged O 0 3.147564697769667e-08
from O 0 7.004380409014743e-10
exclusively O 0 6.096175786396429e-10
nuclear O 0 3.404458581712788e-08
, O 0 7.337896401615751e-10
to O 0 5.410893400004113e-10
conditionally O 0 2.661406739434824e-08
nuclear O 0 4.364238392895459e-08
, O 0 5.428880678337578e-10
to O 0 5.367331579186896e-10
the O 0 1.3158595102424897e-08
ER O 0 9.134175343206152e-06
/ O 0 7.864389317546738e-07
golgi O 0 3.881530972194014e-07
, O 0 4.584612689484402e-10
to O 0 5.555948479063488e-10
cytoplasmic O 0 1.2712611408005614e-07
invaginations O 0 8.80286961546517e-07
into O 0 8.412445851035955e-09
the O 0 3.081320798514753e-08
nucleus O 0 5.596619416792237e-07
. O 0 3.4775709423229273e-07

In O 0 6.38801225250063e-08
an O 0 8.881141377869994e-10
attempt O 0 6.4081571160556905e-09
to O 0 1.617315059654345e-09
resolve O 0 1.3792961794933944e-07
this O 0 2.5539381720562915e-09
issue O 0 1.6972553140703894e-08
, O 0 1.3496430639747814e-09
we O 0 2.845333302303743e-09
have O 0 1.876923727550661e-09
comprehensively O 0 1.733448357299494e-06
characterized O 0 6.497636917401906e-08
19 O 0 2.693930127861677e-07
anti O 0 2.573612619016785e-06
- O 0 3.1439216400031e-05
BRCA1 O 0 2.6731697744253324e-07
antibodies O 0 8.416028407509657e-08
. O 0 1.033787725646107e-06

These O 0 2.449050668928976e-07
reagents O 0 7.228521781144082e-07
detect O 0 1.6091826182673685e-07
a O 0 1.9245007365498168e-08
220 O 0 1.3318216929292248e-07
- O 0 6.853297236375511e-07
kD O 0 2.3848292585171293e-06
protein O 0 7.764407783383831e-09
localized O 0 2.8554252295975857e-08
in O 0 1.5056902391563654e-09
discrete O 0 2.8746827140935238e-08
nuclear O 0 4.84066831063501e-08
foci O 0 6.99456052188907e-07
in O 0 1.7135147745150903e-09
all O 0 1.760568579811661e-09
epithelial O 0 2.2678584343793773e-08
cell O 0 3.5897262051776124e-08
lines O 0 9.912297649350421e-10
, O 0 1.0220468915633774e-10
including O 0 5.70327916837865e-11
those O 0 1.6921754275589507e-10
derived O 0 3.7264769048306334e-09
from O 0 2.10548254386822e-08
breast B-Disease 0 2.803686584229581e-06
malignancies I-Disease 0 2.278428291901946e-05
. O 0 6.479607691289857e-06

Immunohistochemical O 0 0.0004737951676361263
staining O 0 0.00011260993778705597
of O 0 5.67312736166059e-06
human O 0 8.147816856762802e-07
breast O 0 7.030365622995305e-07
specimens O 0 1.455757825397086e-07
also O 0 4.487846538836493e-08
revealed O 0 1.8267179484610097e-06
BRCA1 O 0 3.6092379218644055e-07
nuclear O 0 4.0755899135547224e-06
foci O 0 0.001587852369993925
in O 0 4.25143213078627e-07
benign O 1 0.9999998807907104
breast O 1 0.9999967813491821
, O 0 2.6435236577526666e-06
invasive B-Disease 1 0.9999840259552002
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 0.0048704301007092
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0005251396214589477

Conversely O 0 3.926115823560394e-06
, O 0 5.394287683202492e-08
BRCA1 O 0 4.75688430867649e-08
expression O 0 2.052422054532599e-08
was O 0 1.3328263825940212e-08
reduced O 0 4.421740307236632e-09
or O 0 1.4104287182625797e-10
undetectable O 0 2.410992294699099e-09
in O 0 3.3536545068768575e-11
the O 0 6.235647415087087e-11
majority O 0 7.335513446671271e-11
of O 0 3.5236382700531976e-09
high O 0 1.7919242054631468e-06
- O 0 7.562273367511807e-07
grade O 0 0.000799850735347718
, O 0 8.648617608741915e-07
ductal B-Disease 1 0.9999992847442627
carcinomas I-Disease 1 1.0
, O 0 1.4169986073397922e-08
suggesting O 0 1.5243697859546046e-08
that O 0 8.360184211575472e-10
absence O 0 1.405601892656705e-07
of O 0 1.925961043980351e-07
BRCA1 O 0 1.4119104996268561e-08
may O 0 2.9494606756941266e-09
contribute O 0 6.215902237372006e-10
to O 0 4.125650099329192e-10
the O 0 1.2506536917200606e-09
pathogenesis O 0 2.6973850708600366e-07
of O 0 2.608864013708967e-09
a O 0 3.152325900313002e-10
significant O 0 2.369885843123143e-09
percentage O 0 1.224136791933006e-08
of O 0 1.0069996392303437e-07
sporadic B-Disease 0 0.24712033569812775
breast I-Disease 1 0.9737306833267212
cancers I-Disease 0 0.1067272275686264
. O 0 5.039560164732393e-07
. O 0 3.5771067814494018e-06

